ArticleId,PMCid,TableName,SpecPragmatics,CellContent,Header,Stub,SuperRow,rowN,columnN,function,hasGender,actual,predicted,error,prediction
352,1764757,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
352,1764757,Table 1,BaselineCharacteristic,,,,None,0,1,1,no,1:no,1:no,,0.735
352,1764757,Table 1,BaselineCharacteristic,Cilengitide + Gemcitabine n = xx,,,None,0,2,1,no,1:no,1:no,,0.605
352,1764757,Table 1,BaselineCharacteristic,Gemcitabine n = xx,,,None,0,3,1,no,1:no,1:no,,0.616
352,1764757,Table 1,BaselineCharacteristic,Total n = xx,,,None,0,4,1,no,1:no,1:no,,0.573
352,1764757,Table 1,BaselineCharacteristic,"Age, years", ; ,"Age, years",,1,0,24,no,1:no,1:no,,0.772
352,1764757,Table 1,BaselineCharacteristic,Median, ; ,"Age, years",,1,1,43,no,1:no,1:no,,0.769
352,1764757,Table 1,BaselineCharacteristic,xx,Cilengitide + Gemcitabine n = xx ; ,"Age, years",,1,2,43,no,1:no,1:no,,0.573
352,1764757,Table 1,BaselineCharacteristic,xx,Gemcitabine n = xx ; ,"Age, years",,1,3,43,no,1:no,1:no,,0.587
352,1764757,Table 1,BaselineCharacteristic,xx,Total n = xx ; ,"Age, years",,1,4,43,no,1:no,1:no,,0.544
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,2,0,2,no,1:no,1:no,,0.831
352,1764757,Table 1,BaselineCharacteristic,Range, ; ,,,2,1,3,no,1:no,1:no,,0.644
352,1764757,Table 1,BaselineCharacteristic,"Gender (n, %)", ; ,"Gender (n, %)",,3,0,24,no,1:no,1:no,,0.589
352,1764757,Table 1,BaselineCharacteristic,Male, ; ,"Gender (n, %)",,3,1,43,no,1:no,2:yes,+,0.637
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,"Gender (n, %)",,3,2,43,yes,2:yes,2:yes,,0.683
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,"Gender (n, %)",,3,3,43,yes,2:yes,2:yes,,0.664
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,"Gender (n, %)",,3,4,43,yes,2:yes,2:yes,,0.67
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,4,0,2,no,1:no,1:no,,0.826
352,1764757,Table 1,BaselineCharacteristic,Female, ; ,,,4,1,3,no,1:no,1:no,,0.532
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,,,4,2,3,no,1:no,2:yes,+,0.53
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,,,4,3,3,no,1:no,2:yes,+,0.511
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,4,4,3,no,1:no,2:yes,+,0.561
352,1764757,Table 1,BaselineCharacteristic,Stage, ; ,Stage,,5,0,24,no,1:no,1:no,,0.813
352,1764757,Table 1,BaselineCharacteristic,III, ; ,Stage,,5,1,43,no,1:no,1:no,,0.768
352,1764757,Table 1,BaselineCharacteristic,x (x%),Cilengitide + Gemcitabine n = xx ; ,Stage,,5,2,43,no,1:no,1:no,,0.579
352,1764757,Table 1,BaselineCharacteristic,x (x%),Gemcitabine n = xx ; ,Stage,,5,3,43,no,1:no,1:no,,0.577
352,1764757,Table 1,BaselineCharacteristic,x (x%),Total n = xx ; ,Stage,,5,4,43,no,1:no,1:no,,0.522
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,6,0,2,no,1:no,1:no,,0.826
352,1764757,Table 1,BaselineCharacteristic,IV, ; ,,,6,1,3,no,1:no,1:no,,0.721
352,1764757,Table 1,BaselineCharacteristic,x (x%),Cilengitide + Gemcitabine n = xx ; ,,,6,2,3,no,1:no,1:no,,0.525
352,1764757,Table 1,BaselineCharacteristic,x (x%),Gemcitabine n = xx ; ,,,6,3,3,no,1:no,1:no,,0.519
352,1764757,Table 1,BaselineCharacteristic,x (x%),Total n = xx ; ,,,6,4,3,no,1:no,2:yes,+,0.532
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,7,0,2,no,1:no,1:no,,0.836
352,1764757,Table 1,BaselineCharacteristic,IVa, ; ,,,7,1,3,no,1:no,1:no,,0.705
352,1764757,Table 1,BaselineCharacteristic,x (x%),Cilengitide + Gemcitabine n = xx ; ,,,7,2,3,no,1:no,1:no,,0.541
352,1764757,Table 1,BaselineCharacteristic,x (x%),Gemcitabine n = xx ; ,,,7,3,3,no,1:no,1:no,,0.534
352,1764757,Table 1,BaselineCharacteristic,x (x%),Total n = xx ; ,,,7,4,3,no,1:no,2:yes,+,0.518
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,8,0,2,no,1:no,1:no,,0.837
352,1764757,Table 1,BaselineCharacteristic,IVb, ; ,,,8,1,3,no,1:no,1:no,,0.729
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,,,8,2,3,no,1:no,1:no,,0.558
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,,,8,3,3,no,1:no,1:no,,0.577
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,8,4,3,no,1:no,1:no,,0.527
352,1764757,Table 1,BaselineCharacteristic,KP score at screening, ; ,KP score at screening,,9,0,24,no,1:no,1:no,,0.856
352,1764757,Table 1,BaselineCharacteristic,xx, ; ,KP score at screening,,9,1,43,no,1:no,1:no,,0.693
352,1764757,Table 1,BaselineCharacteristic,x (x%),Cilengitide + Gemcitabine n = xx ; ,KP score at screening,,9,2,43,no,1:no,1:no,,0.663
352,1764757,Table 1,BaselineCharacteristic,x (x%),Gemcitabine n = xx ; ,KP score at screening,,9,3,43,no,1:no,1:no,,0.658
352,1764757,Table 1,BaselineCharacteristic,x (x%),Total n = xx ; ,KP score at screening,,9,4,43,no,1:no,1:no,,0.603
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,10,0,2,no,1:no,1:no,,0.863
352,1764757,Table 1,BaselineCharacteristic,xx, ; ,,,10,1,3,no,1:no,1:no,,0.655
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,,,10,2,3,no,1:no,1:no,,0.596
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,,,10,3,3,no,1:no,1:no,,0.61
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,10,4,3,no,1:no,1:no,,0.57
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,11,0,2,no,1:no,1:no,,0.867
352,1764757,Table 1,BaselineCharacteristic,xx, ; ,,,11,1,3,no,1:no,1:no,,0.687
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,,,11,2,3,no,1:no,1:no,,0.626
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,,,11,3,3,no,1:no,1:no,,0.633
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,11,4,3,no,1:no,1:no,,0.588
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,12,0,2,no,1:no,1:no,,0.873
352,1764757,Table 1,BaselineCharacteristic,xxx, ; ,,,12,1,3,no,1:no,1:no,,0.654
352,1764757,Table 1,BaselineCharacteristic,x (xx%),Cilengitide + Gemcitabine n = xx ; ,,,12,2,3,no,1:no,1:no,,0.639
352,1764757,Table 1,BaselineCharacteristic,x (xx%),Gemcitabine n = xx ; ,,,12,3,3,no,1:no,1:no,,0.645
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,12,4,3,no,1:no,1:no,,0.592
1134,2217514,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
1134,2217514,Table 1,BaselineCharacteristic,N = xx,,Characteristics,None,0,1,1,no,1:no,1:no,,0.555
1134,2217514,Table 1,BaselineCharacteristic,"Mean (range) age, years",Characteristics ; ,"Mean (range) age, years",,1,0,2,no,1:no,1:no,,0.809
1134,2217514,Table 1,BaselineCharacteristic,"Performance status*, n (%)",Characteristics ; ,None,None,2,0,24,no,1:no,1:no,,0.708
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,"Performance status*, n (%)",None,2,1,43,no,1:no,2:yes,+,0.536
1134,2217514,Table 1,BaselineCharacteristic,?xx%,Characteristics ; ,?xx%," Performance status*, n (%)",3,0,2,no,1:no,1:no,,0.685
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?xx%," Performance status*, n (%)",3,1,3,no,1:no,2:yes,+,0.609
1134,2217514,Table 1,BaselineCharacteristic,?xx%,Characteristics ; ,?xx%," Performance status*, n (%)",4,0,2,no,1:no,1:no,,0.685
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?xx%," Performance status*, n (%)",4,1,3,no,1:no,2:yes,+,0.609
1134,2217514,Table 1,BaselineCharacteristic,?xxx%,Characteristics ; ,?xxx%," Performance status*, n (%)",5,0,2,no,1:no,1:no,,0.726
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?xxx%," Performance status*, n (%)",5,1,3,no,1:no,2:yes,+,0.553
1134,2217514,Table 1,BaselineCharacteristic,"Sex, n (%)",Characteristics ; ,None,None,6,0,24,no,1:no,1:no,,0.531
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,"Sex, n (%)",None,6,1,43,no,1:no,2:yes,+,0.677
1134,2217514,Table 1,BaselineCharacteristic,?Male,Characteristics ; ,?Male," Sex, n (%)",7,0,2,no,1:no,2:yes,+,0.575
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Male," Sex, n (%)",7,1,3,yes,2:yes,2:yes,,0.797
1134,2217514,Table 1,BaselineCharacteristic,?Female,Characteristics ; ,?Female," Sex, n (%)",8,0,2,no,1:no,1:no,,0.501
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Female," Sex, n (%)",8,1,3,yes,2:yes,2:yes,,0.787
1134,2217514,Table 1,BaselineCharacteristic,"Race, n (%)",Characteristics ; ,None,None,9,0,24,no,1:no,1:no,,0.721
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,"Race, n (%)",None,9,1,43,no,1:no,1:no,,0.515
1134,2217514,Table 1,BaselineCharacteristic,?Caucasian,Characteristics ; ,?Caucasian," Race, n (%)",10,0,2,no,1:no,1:no,,0.717
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Caucasian," Race, n (%)",10,1,3,no,1:no,2:yes,+,0.539
1134,2217514,Table 1,BaselineCharacteristic,?Blacks/Asians,Characteristics ; ,?Blacks/Asians," Race, n (%)",11,0,2,no,1:no,1:no,,0.733
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Blacks/Asians," Race, n (%)",11,1,3,no,1:no,2:yes,+,0.5
1134,2217514,Table 1,BaselineCharacteristic,"Prior therapy, n (%)",Characteristics ; ,None,None,12,0,24,no,1:no,1:no,,0.79
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,"Prior therapy, n (%)",None,12,1,43,no,1:no,1:no,,0.682
1134,2217514,Table 1,BaselineCharacteristic,?Chemotherapy,Characteristics ; ,None,None,13,0,24,no,1:no,1:no,,0.851
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,?Chemotherapy,None,13,1,43,no,1:no,1:no,,0.706
1134,2217514,Table 1,BaselineCharacteristic,??x prior regimen,Characteristics ; ,??x prior regimen," Prior therapy, n (%) Prior therapy, n (%) ?Chemotherapy",14,0,2,no,1:no,1:no,,0.727
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,??x prior regimen," Prior therapy, n (%) Prior therapy, n (%) ?Chemotherapy",14,1,3,no,1:no,1:no,,0.646
1134,2217514,Table 1,BaselineCharacteristic,???x prior regimens,Characteristics ; ,???x prior regimens," Prior therapy, n (%) Prior therapy, n (%) ?Chemotherapy",15,0,2,no,1:no,1:no,,0.728
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,???x prior regimens," Prior therapy, n (%) Prior therapy, n (%) ?Chemotherapy",15,1,3,no,1:no,1:no,,0.647
1134,2217514,Table 1,BaselineCharacteristic,?Radiotherapy,Characteristics ; ,?Radiotherapy," Prior therapy, n (%) Prior therapy, n (%)",16,0,2,no,1:no,1:no,,0.779
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Radiotherapy," Prior therapy, n (%) Prior therapy, n (%)",16,1,3,no,1:no,1:no,,0.63
1134,2217514,Table 1,BaselineCharacteristic,?Immunotherapy,Characteristics ; ,?Immunotherapy," Prior therapy, n (%) Prior therapy, n (%)",17,0,2,no,1:no,1:no,,0.804
1134,2217514,Table 1,BaselineCharacteristic,x (x),N = xx ; ,?Immunotherapy," Prior therapy, n (%) Prior therapy, n (%)",17,1,3,no,1:no,1:no,,0.676
1134,2217514,Table 1,BaselineCharacteristic,?Other,Characteristics ; ,?Other," Prior therapy, n (%) Prior therapy, n (%)",18,0,2,no,1:no,1:no,,0.808
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Other," Prior therapy, n (%) Prior therapy, n (%)",18,1,3,no,1:no,1:no,,0.698
1176,2228375,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
1176,2228375,Table 1,BaselineCharacteristic,Budesonide pMDI (n = xxx),,Characteristic,None,0,1,1,no,1:no,1:no,,0.711
1176,2228375,Table 1,BaselineCharacteristic,Budesonide/formoterol DPI (n = xxx),,Characteristic,None,0,2,1,no,1:no,1:no,,0.71
1176,2228375,Table 1,BaselineCharacteristic,Budesonide/formoterol pMDI (n = xxx),,Characteristic,None,0,3,1,no,1:no,1:no,,0.712
1176,2228375,Table 1,BaselineCharacteristic,"Males/females, n",Characteristic ; ,"Males/females, n",,1,0,2,no,1:no,1:no,,0.791
1176,2228375,Table 1,BaselineCharacteristic,xx/xxx,Budesonide pMDI (n = xxx) ; ,"Males/females, n",,1,1,3,yes,2:yes,1:no,+,0.544
1176,2228375,Table 1,BaselineCharacteristic,xx/xxx,Budesonide/formoterol DPI (n = xxx) ; ,"Males/females, n",,1,2,3,yes,2:yes,1:no,+,0.545
1176,2228375,Table 1,BaselineCharacteristic,xx/xxx,Budesonide/formoterol pMDI (n = xxx) ; ,"Males/females, n",,1,3,3,yes,2:yes,1:no,+,0.563
1176,2228375,Table 1,BaselineCharacteristic,"Mean age (range), years",Characteristic ; ,"Mean age (range), years",,2,0,2,no,1:no,1:no,,0.846
1176,2228375,Table 1,BaselineCharacteristic,"Smokers, n (%)",Characteristic ; ,"Smokers, n (%)",,3,0,2,no,1:no,1:no,,0.738
1176,2228375,Table 1,BaselineCharacteristic,xx (x),Budesonide pMDI (n = xxx) ; ,"Smokers, n (%)",,3,1,3,no,1:no,2:yes,+,0.678
1176,2228375,Table 1,BaselineCharacteristic,xx (x),Budesonide/formoterol DPI (n = xxx) ; ,"Smokers, n (%)",,3,2,3,no,1:no,2:yes,+,0.654
1176,2228375,Table 1,BaselineCharacteristic,xx (x),Budesonide/formoterol pMDI (n = xxx) ; ,"Smokers, n (%)",,3,3,3,no,1:no,2:yes,+,0.645
1176,2228375,Table 1,BaselineCharacteristic,"Mean morning PEF (range), l/min",Characteristic ; ,"Mean morning PEF (range), l/min",,5,0,2,no,1:no,1:no,,0.837
1176,2228375,Table 1,BaselineCharacteristic,Mean FEVx(range),Characteristic ; ,None,None,6,0,24,no,1:no,1:no,,0.833
1176,2228375,Table 1,BaselineCharacteristic,Mean FEVx(range),Budesonide pMDI (n = xxx) ; ,Mean FEVx(range),None,6,1,43,no,1:no,1:no,,0.647
1176,2228375,Table 1,BaselineCharacteristic,Mean FEVx(range),Budesonide/formoterol DPI (n = xxx) ; ,Mean FEVx(range),None,6,2,43,no,1:no,1:no,,0.658
1176,2228375,Table 1,BaselineCharacteristic,Mean FEVx(range),Budesonide/formoterol pMDI (n = xxx) ; ,Mean FEVx(range),None,6,3,43,no,1:no,1:no,,0.679
1176,2228375,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Mean FEVx(range),8,0,2,no,1:no,1:no,,0.849
1176,2228375,Table 1,BaselineCharacteristic,"LABA use at entry, n (%)",Characteristic ; ,"LABA use at entry, n (%)",,10,0,2,no,1:no,1:no,,0.78
1176,2228375,Table 1,BaselineCharacteristic,xx (xx),Budesonide pMDI (n = xxx) ; ,"LABA use at entry, n (%)",,10,1,3,no,1:no,2:yes,+,0.533
1176,2228375,Table 1,BaselineCharacteristic,xx (xx),Budesonide/formoterol DPI (n = xxx) ; ,"LABA use at entry, n (%)",,10,2,3,no,1:no,2:yes,+,0.52
1176,2228375,Table 1,BaselineCharacteristic,xx (xx),Budesonide/formoterol pMDI (n = xxx) ; ,"LABA use at entry, n (%)",,10,3,3,no,1:no,1:no,,0.5
1176,2228375,Table 1,BaselineCharacteristic,"Reliever medication use (range), inhalations/day",Characteristic ; ,"Reliever medication use (range), inhalations/day",,11,0,2,no,1:no,1:no,,0.897
1176,2228375,Table 1,BaselineCharacteristic,"Reliever medication-free days (range), %",Characteristic ; ,"Reliever medication-free days (range), %",,12,0,2,no,1:no,1:no,,0.855
1176,2228375,Table 1,BaselineCharacteristic,"Nights with awakenings (range), %",Characteristic ; ,"Nights with awakenings (range), %",,14,0,2,no,1:no,1:no,,0.847
1176,2228375,Table 1,BaselineCharacteristic,"Symptom-free days (range), %",Characteristic ; ,"Symptom-free days (range), %",,15,0,2,no,1:no,1:no,,0.85
1176,2228375,Table 1,BaselineCharacteristic,"Asthma-control days (range), %",Characteristic ; ,"Asthma-control days (range), %",,16,0,2,no,1:no,1:no,,0.85
1269,2359662,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1269,2359662,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,no,1:no,1:no,,0.76
1269,2359662,Table 1,BaselineCharacteristic,(%),,,None,0,2,1,no,1:no,1:no,,0.757
1269,2359662,Table 1,BaselineCharacteristic,Patients enrolled, ; ,Patients enrolled,,1,0,2,no,1:no,1:no,,0.773
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Patients enrolled,,1,1,3,no,1:no,2:yes,+,0.535
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,Patients enrolled,,1,2,3,no,1:no,1:no,,0.631
1269,2359662,Table 1,BaselineCharacteristic,Evaluable for toxicity, ; ,Evaluable for toxicity,,2,0,2,no,1:no,1:no,,0.833
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Evaluable for toxicity,,2,1,3,no,1:no,2:yes,+,0.531
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,Evaluable for toxicity,,2,2,3,no,1:no,1:no,,0.672
1269,2359662,Table 1,BaselineCharacteristic,Evaluable for response, ; ,Evaluable for response,,3,0,2,no,1:no,1:no,,0.83
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Evaluable for response,,3,1,3,no,1:no,2:yes,+,0.541
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,Evaluable for response,,3,2,3,no,1:no,1:no,,0.668
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no,1:no,1:no,,0.858
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,4,1,3,no,1:no,1:no,,0.723
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,4,2,3,no,1:no,1:no,,0.701
1269,2359662,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,5,0,24,no,1:no,1:no,,0.853
1269,2359662,Table 1,BaselineCharacteristic,Age (years),No. of patients ; ,Age (years),None,5,1,43,no,1:no,1:no,,0.794
1269,2359662,Table 1,BaselineCharacteristic,Age (years),(%) ; ,Age (years),None,5,2,43,no,1:no,1:no,,0.785
1269,2359662,Table 1,BaselineCharacteristic,?Median (range), ; ,?Median (range), Age (years),6,0,2,no,1:no,1:no,,0.839
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,?Median (range), Age (years),6,2,3,no,1:no,1:no,,0.759
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,7,0,2,no,1:no,1:no,,0.869
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,7,1,3,no,1:no,1:no,,0.794
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,7,2,3,no,1:no,1:no,,0.711
1269,2359662,Table 1,BaselineCharacteristic,Gender, ; ,None,None,8,0,24,no,1:no,1:no,,0.746
1269,2359662,Table 1,BaselineCharacteristic,Gender,No. of patients ; ,Gender,None,8,1,43,no,1:no,1:no,,0.701
1269,2359662,Table 1,BaselineCharacteristic,Gender,(%) ; ,Gender,None,8,2,43,no,1:no,1:no,,0.65
1269,2359662,Table 1,BaselineCharacteristic,?Male/female, ; ,?Male/female, Gender,9,0,2,no,1:no,1:no,,0.807
1269,2359662,Table 1,BaselineCharacteristic,x/xx,No. of patients ; ,?Male/female, Gender,9,1,3,yes,2:yes,1:no,+,0.597
1269,2359662,Table 1,BaselineCharacteristic,xx/xx,(%) ; ,?Male/female, Gender,9,2,3,yes,2:yes,1:no,+,0.629
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,2,no,1:no,1:no,,0.888
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,10,1,3,no,1:no,1:no,,0.825
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,10,2,3,no,1:no,1:no,,0.749
1269,2359662,Table 1,BaselineCharacteristic,Performance status (WHO), ; ,None,None,11,0,24,no,1:no,1:no,,0.894
1269,2359662,Table 1,BaselineCharacteristic,Performance status (WHO),No. of patients ; ,Performance status (WHO),None,11,1,43,no,1:no,1:no,,0.87
1269,2359662,Table 1,BaselineCharacteristic,Performance status (WHO),(%) ; ,Performance status (WHO),None,11,2,43,no,1:no,1:no,,0.806
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (WHO),12,0,2,no,1:no,1:no,,0.866
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Performance status (WHO),12,1,3,no,1:no,1:no,,0.774
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Performance status (WHO),12,2,3,no,1:no,1:no,,0.66
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (WHO),13,0,2,no,1:no,1:no,,0.866
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Performance status (WHO),13,1,3,no,1:no,1:no,,0.72
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Performance status (WHO),13,2,3,no,1:no,1:no,,0.649
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (WHO),14,0,2,no,1:no,1:no,,0.854
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Performance status (WHO),14,1,3,no,1:no,1:no,,0.772
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?x, Performance status (WHO),14,2,3,no,1:no,1:no,,0.729
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,15,0,2,no,1:no,1:no,,0.892
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,15,1,3,no,1:no,1:no,,0.849
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,15,2,3,no,1:no,1:no,,0.749
1269,2359662,Table 1,BaselineCharacteristic,Previous chemotherapy regimens, ; ,None,None,16,0,24,no,1:no,1:no,,0.883
1269,2359662,Table 1,BaselineCharacteristic,Previous chemotherapy regimens,No. of patients ; ,Previous chemotherapy regimens,None,16,1,43,no,1:no,1:no,,0.875
1269,2359662,Table 1,BaselineCharacteristic,Previous chemotherapy regimens,(%) ; ,Previous chemotherapy regimens,None,16,2,43,no,1:no,1:no,,0.803
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Previous chemotherapy regimens,17,0,2,no,1:no,1:no,,0.874
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous chemotherapy regimens,17,1,3,no,1:no,1:no,,0.774
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Previous chemotherapy regimens,17,2,3,no,1:no,1:no,,0.673
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Previous chemotherapy regimens,18,0,2,no,1:no,1:no,,0.878
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous chemotherapy regimens,18,1,3,no,1:no,1:no,,0.777
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Previous chemotherapy regimens,18,2,3,no,1:no,1:no,,0.69
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Previous chemotherapy regimens,19,0,2,no,1:no,1:no,,0.878
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Previous chemotherapy regimens,19,1,3,no,1:no,1:no,,0.731
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Previous chemotherapy regimens,19,2,3,no,1:no,1:no,,0.69
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,20,0,2,no,1:no,1:no,,0.902
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,20,1,3,no,1:no,1:no,,0.862
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,20,2,3,no,1:no,1:no,,0.777
1269,2359662,Table 1,BaselineCharacteristic,Previous treatment, ; ,None,None,21,0,24,no,1:no,1:no,,0.885
1269,2359662,Table 1,BaselineCharacteristic,Previous treatment,No. of patients ; ,Previous treatment,None,21,1,43,no,1:no,1:no,,0.876
1269,2359662,Table 1,BaselineCharacteristic,Previous treatment,(%) ; ,Previous treatment,None,21,2,43,no,1:no,1:no,,0.793
1269,2359662,Table 1,BaselineCharacteristic,?Surgery, ; ,?Surgery, Previous treatment,22,0,2,no,1:no,1:no,,0.9
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Surgery, Previous treatment,22,1,3,no,1:no,1:no,,0.745
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Surgery, Previous treatment,22,2,3,no,1:no,1:no,,0.72
1269,2359662,Table 1,BaselineCharacteristic,?Adjuvant chemotherapy, ; ,?Adjuvant chemotherapy, Previous treatment,23,0,2,no,1:no,1:no,,0.904
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Adjuvant chemotherapy, Previous treatment,23,1,3,no,1:no,1:no,,0.783
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Adjuvant chemotherapy, Previous treatment,23,2,3,no,1:no,1:no,,0.742
1269,2359662,Table 1,BaselineCharacteristic,?Neo-adjuvant chemotherapy, ; ,?Neo-adjuvant chemotherapy, Previous treatment,24,0,2,no,1:no,1:no,,0.904
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Neo-adjuvant chemotherapy, Previous treatment,24,1,3,no,1:no,1:no,,0.783
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?Neo-adjuvant chemotherapy, Previous treatment,24,2,3,no,1:no,1:no,,0.769
1269,2359662,Table 1,BaselineCharacteristic,?Chemotherapy for metastatic disease, ; ,?Chemotherapy for metastatic disease, Previous treatment,25,0,2,no,1:no,1:no,,0.896
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Chemotherapy for metastatic disease, Previous treatment,25,1,3,no,1:no,1:no,,0.757
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Chemotherapy for metastatic disease, Previous treatment,25,2,3,no,1:no,1:no,,0.774
1269,2359662,Table 1,BaselineCharacteristic,?Adjuvant radiotherapy, ; ,?Adjuvant radiotherapy, Previous treatment,26,0,2,no,1:no,1:no,,0.898
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Adjuvant radiotherapy, Previous treatment,26,1,3,no,1:no,1:no,,0.773
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Adjuvant radiotherapy, Previous treatment,26,2,3,no,1:no,1:no,,0.711
1269,2359662,Table 1,BaselineCharacteristic,?Radiotherapy for metastatic disease, ; ,?Radiotherapy for metastatic disease, Previous treatment,27,0,2,no,1:no,1:no,,0.893
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Radiotherapy for metastatic disease, Previous treatment,27,1,3,no,1:no,1:no,,0.8
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Radiotherapy for metastatic disease, Previous treatment,27,2,3,no,1:no,1:no,,0.742
1269,2359662,Table 1,BaselineCharacteristic,?None, ; ,?None, Previous treatment,28,0,2,no,1:no,1:no,,0.901
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?None, Previous treatment,28,1,3,no,1:no,1:no,,0.869
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?None, Previous treatment,28,2,3,no,1:no,1:no,,0.766
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,29,0,2,no,1:no,1:no,,0.905
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,29,1,3,no,1:no,1:no,,0.865
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,29,2,3,no,1:no,1:no,,0.792
1269,2359662,Table 1,BaselineCharacteristic,Type of tumour, ; ,None,None,30,0,24,no,1:no,1:no,,0.788
1269,2359662,Table 1,BaselineCharacteristic,Type of tumour,No. of patients ; ,Type of tumour,None,30,1,43,no,1:no,1:no,,0.769
1269,2359662,Table 1,BaselineCharacteristic,Type of tumour,(%) ; ,Type of tumour,None,30,2,43,no,1:no,1:no,,0.718
1269,2359662,Table 1,BaselineCharacteristic,?Breast cancer, ; ,?Breast cancer, Type of tumour,31,0,2,no,1:no,1:no,,0.793
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Breast cancer, Type of tumour,31,1,3,no,1:no,1:no,,0.7
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Breast cancer, Type of tumour,31,2,3,no,1:no,1:no,,0.635
1269,2359662,Table 1,BaselineCharacteristic,?Lung cancer, ; ,?Lung cancer, Type of tumour,32,0,2,no,1:no,1:no,,0.793
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Lung cancer, Type of tumour,32,1,3,no,1:no,1:no,,0.7
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?Lung cancer, Type of tumour,32,2,3,no,1:no,1:no,,0.695
1269,2359662,Table 1,BaselineCharacteristic,?Bladder cancer, ; ,?Bladder cancer, Type of tumour,33,0,2,no,1:no,1:no,,0.793
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Bladder cancer, Type of tumour,33,1,3,no,1:no,1:no,,0.7
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Bladder cancer, Type of tumour,33,2,3,no,1:no,1:no,,0.635
1269,2359662,Table 1,BaselineCharacteristic,?Ovarian cancer, ; ,?Ovarian cancer, Type of tumour,34,0,2,no,1:no,1:no,,0.793
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Ovarian cancer, Type of tumour,34,1,3,no,1:no,1:no,,0.7
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?Ovarian cancer, Type of tumour,34,2,3,no,1:no,1:no,,0.695
1269,2359662,Table 1,BaselineCharacteristic,?Cancer of unknown primary, ; ,?Cancer of unknown primary, Type of tumour,35,0,2,no,1:no,1:no,,0.796
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Cancer of unknown primary, Type of tumour,35,1,3,no,1:no,1:no,,0.71
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?Cancer of unknown primary, Type of tumour,35,2,3,no,1:no,1:no,,0.699
1269,2359662,Table 1,BaselineCharacteristic,?Other, ; ,?Other, Type of tumour,36,0,2,no,1:no,1:no,,0.79
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Other, Type of tumour,36,1,3,no,1:no,1:no,,0.693
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Other, Type of tumour,36,2,3,no,1:no,1:no,,0.631
1318,2360329,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1318,2360329,Table 1,BaselineCharacteristic,VIN/CARBO,,,None,0,1,1,no,1:no,1:no,,0.735
1318,2360329,Table 1,BaselineCharacteristic,VIN/CARBO,,,None,0,2,1,no,1:no,1:no,,0.775
1318,2360329,Table 1,BaselineCharacteristic,GEM/CARBO,,,None,0,3,1,no,1:no,1:no,,0.79
1318,2360329,Table 1,BaselineCharacteristic,GEM/CARBO,,,None,0,4,1,no,1:no,1:no,,0.802
1318,2360329,Table 1,BaselineCharacteristic,,,,None,0,5,1,no,1:no,1:no,,0.795
1318,2360329,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no,1:no,1:no,,0.792
1318,2360329,Table 1,BaselineCharacteristic,(n=xxx),VIN/CARBO ; ,,None,1,1,1,no,1:no,1:no,,0.716
1318,2360329,Table 1,BaselineCharacteristic,(n=xxx),VIN/CARBO ; ,,None,1,2,1,no,1:no,1:no,,0.756
1318,2360329,Table 1,BaselineCharacteristic,(n=xxx),GEM/CARBO ; ,,None,1,3,1,no,1:no,1:no,,0.77
1318,2360329,Table 1,BaselineCharacteristic,(n=xxx),GEM/CARBO ; ,,None,1,4,1,no,1:no,1:no,,0.782
1318,2360329,Table 1,BaselineCharacteristic,, ; ,,None,1,5,1,no,1:no,1:no,,0.776
1318,2360329,Table 1,BaselineCharacteristic,Characteristics, ;  ; ,None,None,2,0,12,no,1:no,1:no,,0.791
1318,2360329,Table 1,BaselineCharacteristic,n,VIN/CARBO ; (n=xxx) ; ,Characteristics,None,2,1,1,no,1:no,1:no,,0.65
1318,2360329,Table 1,BaselineCharacteristic,%,VIN/CARBO ; (n=xxx) ; ,Characteristics,None,2,2,1,no,1:no,1:no,,0.73
1318,2360329,Table 1,BaselineCharacteristic,n,GEM/CARBO ; (n=xxx) ; ,Characteristics,None,2,3,1,no,1:no,1:no,,0.668
1318,2360329,Table 1,BaselineCharacteristic,%,GEM/CARBO ; (n=xxx) ; ,Characteristics,None,2,4,1,no,1:no,1:no,,0.736
1318,2360329,Table 1,BaselineCharacteristic,P, ;  ; ,Characteristics,None,2,5,1,no,1:no,1:no,,0.788
1318,2360329,Table 1,BaselineCharacteristic,Age (years), ;  ; Characteristics ; ,None,None,3,0,24,no,1:no,1:no,,0.823
1318,2360329,Table 1,BaselineCharacteristic,Age (years),VIN/CARBO ; (n=xxx) ; n ; ,Age (years),None,3,1,43,no,1:no,1:no,,0.729
1318,2360329,Table 1,BaselineCharacteristic,Age (years),VIN/CARBO ; (n=xxx) ; % ; ,Age (years),None,3,2,43,no,1:no,1:no,,0.777
1318,2360329,Table 1,BaselineCharacteristic,Age (years),GEM/CARBO ; (n=xxx) ; n ; ,Age (years),None,3,3,43,no,1:no,1:no,,0.753
1318,2360329,Table 1,BaselineCharacteristic,Age (years),GEM/CARBO ; (n=xxx) ; % ; ,Age (years),None,3,4,43,no,1:no,1:no,,0.789
1318,2360329,Table 1,BaselineCharacteristic,Age (years), ;  ; P ; ,Age (years),None,3,5,43,no,1:no,1:no,,0.848
1318,2360329,Table 1,BaselineCharacteristic,?Median, ;  ; Characteristics ; ,?Median, Age (years),4,0,2,no,1:no,1:no,,0.83
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Median, Age (years),4,1,3,no,1:no,1:no,,0.641
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Median, Age (years),4,2,3,no,1:no,1:no,,0.598
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Median, Age (years),4,3,3,no,1:no,1:no,,0.659
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Median, Age (years),4,4,3,no,1:no,1:no,,0.612
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?Median, Age (years),4,5,3,no,1:no,1:no,,0.72
1318,2360329,Table 1,BaselineCharacteristic,?Range, ;  ; Characteristics ; ,?Range, Age (years),5,0,2,no,1:no,1:no,,0.817
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Range, Age (years),5,5,3,no,1:no,1:no,,0.788
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; Characteristics ; ,None,None,6,0,2,no,1:no,1:no,,0.843
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; n ; ,None,None,6,1,3,no,1:no,1:no,,0.669
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; % ; ,None,None,6,2,3,no,1:no,1:no,,0.711
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; n ; ,None,None,6,3,3,no,1:no,1:no,,0.701
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; % ; ,None,None,6,4,3,no,1:no,1:no,,0.732
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,None,None,6,5,3,no,1:no,1:no,,0.82
1318,2360329,Table 1,BaselineCharacteristic,Sex, ;  ; Characteristics ; ,None,None,7,0,24,no,1:no,1:no,,0.58
1318,2360329,Table 1,BaselineCharacteristic,Sex,VIN/CARBO ; (n=xxx) ; n ; ,Sex,None,7,1,43,no,1:no,2:yes,+,0.521
1318,2360329,Table 1,BaselineCharacteristic,Sex,VIN/CARBO ; (n=xxx) ; % ; ,Sex,None,7,2,43,no,1:no,1:no,,0.541
1318,2360329,Table 1,BaselineCharacteristic,Sex,GEM/CARBO ; (n=xxx) ; n ; ,Sex,None,7,3,43,no,1:no,1:no,,0.513
1318,2360329,Table 1,BaselineCharacteristic,Sex,GEM/CARBO ; (n=xxx) ; % ; ,Sex,None,7,4,43,no,1:no,1:no,,0.562
1318,2360329,Table 1,BaselineCharacteristic,Sex, ;  ; P ; ,Sex,None,7,5,43,no,1:no,1:no,,0.618
1318,2360329,Table 1,BaselineCharacteristic,?Female, ;  ; Characteristics ; ,?Female, Sex,8,0,2,no,1:no,1:no,,0.515
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Female, Sex,8,1,3,yes,2:yes,2:yes,,0.79
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Female, Sex,8,2,3,yes,2:yes,2:yes,,0.818
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Female, Sex,8,3,3,yes,2:yes,2:yes,,0.771
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Female, Sex,8,4,3,yes,2:yes,2:yes,,0.801
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?Female, Sex,8,5,3,no,1:no,2:yes,+,0.642
1318,2360329,Table 1,BaselineCharacteristic,?Male, ;  ; Characteristics ; ,?Male, Sex,9,0,2,no,1:no,2:yes,+,0.507
1318,2360329,Table 1,BaselineCharacteristic,xxx,VIN/CARBO ; (n=xxx) ; n ; ,?Male, Sex,9,1,3,yes,2:yes,2:yes,,0.722
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Male, Sex,9,2,3,yes,2:yes,2:yes,,0.764
1318,2360329,Table 1,BaselineCharacteristic,xxx,GEM/CARBO ; (n=xxx) ; n ; ,?Male, Sex,9,3,3,yes,2:yes,2:yes,,0.706
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Male, Sex,9,4,3,yes,2:yes,2:yes,,0.757
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Male, Sex,9,5,3,no,1:no,2:yes,+,0.546
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; Characteristics ; ,None,None,10,0,2,no,1:no,1:no,,0.862
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; n ; ,None,None,10,1,3,no,1:no,1:no,,0.738
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; % ; ,None,None,10,2,3,no,1:no,1:no,,0.749
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; n ; ,None,None,10,3,3,no,1:no,1:no,,0.757
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; % ; ,None,None,10,4,3,no,1:no,1:no,,0.768
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,None,None,10,5,3,no,1:no,1:no,,0.852
1318,2360329,Table 1,BaselineCharacteristic,Performance status, ;  ; Characteristics ; ,None,None,11,0,24,no,1:no,1:no,,0.87
1318,2360329,Table 1,BaselineCharacteristic,Performance status,VIN/CARBO ; (n=xxx) ; n ; ,Performance status,None,11,1,43,no,1:no,1:no,,0.777
1318,2360329,Table 1,BaselineCharacteristic,Performance status,VIN/CARBO ; (n=xxx) ; % ; ,Performance status,None,11,2,43,no,1:no,1:no,,0.806
1318,2360329,Table 1,BaselineCharacteristic,Performance status,GEM/CARBO ; (n=xxx) ; n ; ,Performance status,None,11,3,43,no,1:no,1:no,,0.795
1318,2360329,Table 1,BaselineCharacteristic,Performance status,GEM/CARBO ; (n=xxx) ; % ; ,Performance status,None,11,4,43,no,1:no,1:no,,0.821
1318,2360329,Table 1,BaselineCharacteristic,Performance status, ;  ; P ; ,Performance status,None,11,5,43,no,1:no,1:no,,0.881
1318,2360329,Table 1,BaselineCharacteristic,?x/x, ;  ; Characteristics ; ,?x/x, Performance status,12,0,2,no,1:no,1:no,,0.867
1318,2360329,Table 1,BaselineCharacteristic,xxx,VIN/CARBO ; (n=xxx) ; n ; ,?x/x, Performance status,12,1,3,no,1:no,1:no,,0.649
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?x/x, Performance status,12,2,3,no,1:no,1:no,,0.66
1318,2360329,Table 1,BaselineCharacteristic,xxx,GEM/CARBO ; (n=xxx) ; n ; ,?x/x, Performance status,12,3,3,no,1:no,1:no,,0.673
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?x/x, Performance status,12,4,3,no,1:no,1:no,,0.669
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?x/x, Performance status,12,5,3,no,1:no,1:no,,0.818
1318,2360329,Table 1,BaselineCharacteristic,?x, ;  ; Characteristics ; ,?x, Performance status,13,0,2,no,1:no,1:no,,0.837
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?x, Performance status,13,1,3,no,1:no,1:no,,0.678
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?x, Performance status,13,2,3,no,1:no,1:no,,0.649
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?x, Performance status,13,3,3,no,1:no,1:no,,0.705
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?x, Performance status,13,4,3,no,1:no,1:no,,0.671
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?x, Performance status,13,5,3,no,1:no,1:no,,0.855
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; Characteristics ; ,None,None,14,0,2,no,1:no,1:no,,0.866
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; n ; ,None,None,14,1,3,no,1:no,1:no,,0.745
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; % ; ,None,None,14,2,3,no,1:no,1:no,,0.758
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; n ; ,None,None,14,3,3,no,1:no,1:no,,0.759
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; % ; ,None,None,14,4,3,no,1:no,1:no,,0.772
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,None,None,14,5,3,no,1:no,1:no,,0.854
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease, ;  ; Characteristics ; ,None,None,15,0,24,no,1:no,1:no,,0.844
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease,VIN/CARBO ; (n=xxx) ; n ; ,Extent of disease,None,15,1,43,no,1:no,1:no,,0.765
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease,VIN/CARBO ; (n=xxx) ; % ; ,Extent of disease,None,15,2,43,no,1:no,1:no,,0.814
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease,GEM/CARBO ; (n=xxx) ; n ; ,Extent of disease,None,15,3,43,no,1:no,1:no,,0.767
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease,GEM/CARBO ; (n=xxx) ; % ; ,Extent of disease,None,15,4,43,no,1:no,1:no,,0.821
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease, ;  ; P ; ,Extent of disease,None,15,5,43,no,1:no,1:no,,0.874
1318,2360329,Table 1,BaselineCharacteristic,?Stage IIIB, ;  ; Characteristics ; ,?Stage IIIB, Extent of disease,16,0,2,no,1:no,1:no,,0.853
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Stage IIIB, Extent of disease,16,1,3,no,1:no,1:no,,0.722
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Stage IIIB, Extent of disease,16,2,3,no,1:no,1:no,,0.713
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Stage IIIB, Extent of disease,16,3,3,no,1:no,1:no,,0.728
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Stage IIIB, Extent of disease,16,4,3,no,1:no,1:no,,0.715
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?Stage IIIB, Extent of disease,16,5,3,no,1:no,1:no,,0.822
1318,2360329,Table 1,BaselineCharacteristic,?Stage IV, ;  ; Characteristics ; ,?Stage IV, Extent of disease,17,0,2,no,1:no,1:no,,0.873
1318,2360329,Table 1,BaselineCharacteristic,xxx,VIN/CARBO ; (n=xxx) ; n ; ,?Stage IV, Extent of disease,17,1,3,no,1:no,1:no,,0.783
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Stage IV, Extent of disease,17,2,3,no,1:no,1:no,,0.753
1318,2360329,Table 1,BaselineCharacteristic,xxx,GEM/CARBO ; (n=xxx) ; n ; ,?Stage IV, Extent of disease,17,3,3,no,1:no,1:no,,0.783
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Stage IV, Extent of disease,17,4,3,no,1:no,1:no,,0.753
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Stage IV, Extent of disease,17,5,3,no,1:no,1:no,,0.887
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; Characteristics ; ,None,None,18,0,2,no,1:no,1:no,,0.875
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; n ; ,None,None,18,1,3,no,1:no,1:no,,0.769
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; % ; ,None,None,18,2,3,no,1:no,1:no,,0.777
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; n ; ,None,None,18,3,3,no,1:no,1:no,,0.775
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; % ; ,None,None,18,4,3,no,1:no,1:no,,0.785
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,None,None,18,5,3,no,1:no,1:no,,0.865
1318,2360329,Table 1,BaselineCharacteristic,Histology, ;  ; Characteristics ; ,None,None,19,0,24,no,1:no,1:no,,0.867
1318,2360329,Table 1,BaselineCharacteristic,Histology,VIN/CARBO ; (n=xxx) ; n ; ,Histology,None,19,1,43,no,1:no,1:no,,0.785
1318,2360329,Table 1,BaselineCharacteristic,Histology,VIN/CARBO ; (n=xxx) ; % ; ,Histology,None,19,2,43,no,1:no,1:no,,0.801
1318,2360329,Table 1,BaselineCharacteristic,Histology,GEM/CARBO ; (n=xxx) ; n ; ,Histology,None,19,3,43,no,1:no,1:no,,0.794
1318,2360329,Table 1,BaselineCharacteristic,Histology,GEM/CARBO ; (n=xxx) ; % ; ,Histology,None,19,4,43,no,1:no,1:no,,0.812
1318,2360329,Table 1,BaselineCharacteristic,Histology, ;  ; P ; ,Histology,None,19,5,43,no,1:no,1:no,,0.882
1318,2360329,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ;  ; Characteristics ; ,?Squamous cell carcinoma, Histology,20,0,2,no,1:no,1:no,,0.885
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Squamous cell carcinoma, Histology,20,1,3,no,1:no,1:no,,0.746
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Squamous cell carcinoma, Histology,20,2,3,no,1:no,1:no,,0.717
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Squamous cell carcinoma, Histology,20,3,3,no,1:no,1:no,,0.763
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Squamous cell carcinoma, Histology,20,4,3,no,1:no,1:no,,0.723
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?Squamous cell carcinoma, Histology,20,5,3,no,1:no,1:no,,0.848
1318,2360329,Table 1,BaselineCharacteristic,?Adenocarcinoma, ;  ; Characteristics ; ,?Adenocarcinoma, Histology,21,0,2,no,1:no,1:no,,0.871
1318,2360329,Table 1,BaselineCharacteristic,xxx,VIN/CARBO ; (n=xxx) ; n ; ,?Adenocarcinoma, Histology,21,1,3,no,1:no,1:no,,0.697
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Adenocarcinoma, Histology,21,2,3,no,1:no,1:no,,0.667
1318,2360329,Table 1,BaselineCharacteristic,xxx,GEM/CARBO ; (n=xxx) ; n ; ,?Adenocarcinoma, Histology,21,3,3,no,1:no,1:no,,0.703
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Adenocarcinoma, Histology,21,4,3,no,1:no,1:no,,0.675
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Adenocarcinoma, Histology,21,5,3,no,1:no,1:no,,0.876
1318,2360329,Table 1,BaselineCharacteristic,?Large cell carcinoma, ;  ; Characteristics ; ,?Large cell carcinoma, Histology,22,0,2,no,1:no,1:no,,0.885
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Large cell carcinoma, Histology,22,1,3,no,1:no,1:no,,0.747
1318,2360329,Table 1,BaselineCharacteristic,x,VIN/CARBO ; (n=xxx) ; % ; ,?Large cell carcinoma, Histology,22,2,3,no,1:no,1:no,,0.811
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Large cell carcinoma, Histology,22,3,3,no,1:no,1:no,,0.763
1318,2360329,Table 1,BaselineCharacteristic,x,GEM/CARBO ; (n=xxx) ; % ; ,?Large cell carcinoma, Histology,22,4,3,no,1:no,1:no,,0.817
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Large cell carcinoma, Histology,22,5,3,no,1:no,1:no,,0.894
1318,2360329,Table 1,BaselineCharacteristic,?Other, ;  ; Characteristics ; ,?Other, Histology,23,0,2,no,1:no,1:no,,0.876
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Other, Histology,23,1,3,no,1:no,1:no,,0.733
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Other, Histology,23,2,3,no,1:no,1:no,,0.68
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Other, Histology,23,3,3,no,1:no,1:no,,0.749
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Other, Histology,23,4,3,no,1:no,1:no,,0.688
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Other, Histology,23,5,3,no,1:no,1:no,,0.883
1345,2360517,Table 2,BaselineCharacteristic,N=xx,,None,None,0,0,12,no,1:no,1:no,,0.77
1345,2360517,Table 2,BaselineCharacteristic,,,N=xx,None,0,1,1,no,1:no,1:no,,0.709
1345,2360517,Table 2,BaselineCharacteristic,Age in years (mean),N=xx ; ,Age in years (mean),,1,0,2,no,1:no,1:no,,0.812
1345,2360517,Table 2,BaselineCharacteristic,xx.x?yrs (xx.x?yrs), ; ,Age in years (mean),,1,1,3,no,1:no,1:no,,0.662
1345,2360517,Table 2,BaselineCharacteristic,Sex ratio,N=xx ; ,Sex ratio,,2,0,2,no,1:no,1:no,,0.563
1345,2360517,Table 2,BaselineCharacteristic,xx males/x females, ; ,Sex ratio,,2,1,3,yes,2:yes,2:yes,,0.693
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,3,0,2,no,1:no,1:no,,0.816
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,3,1,3,no,1:no,1:no,,0.711
1345,2360517,Table 2,BaselineCharacteristic,Histology n (%),N=xx ; ,None,None,4,0,24,no,1:no,1:no,,0.725
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Histology n (%),None,4,1,43,no,1:no,1:no,,0.66
1345,2360517,Table 2,BaselineCharacteristic,?Squamous cell carcinoma,N=xx ; ,?Squamous cell carcinoma, Histology n (%),5,0,2,no,1:no,1:no,,0.746
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Squamous cell carcinoma, Histology n (%),5,1,3,no,1:no,2:yes,+,0.513
1345,2360517,Table 2,BaselineCharacteristic,?Adenocarcinoma,N=xx ; ,?Adenocarcinoma, Histology n (%),6,0,2,no,1:no,1:no,,0.698
1345,2360517,Table 2,BaselineCharacteristic,x (x.x%), ; ,?Adenocarcinoma, Histology n (%),6,1,3,no,1:no,1:no,,0.513
1345,2360517,Table 2,BaselineCharacteristic,?Poor differenced,N=xx ; ,?Poor differenced, Histology n (%),7,0,2,no,1:no,1:no,,0.698
1345,2360517,Table 2,BaselineCharacteristic,x (x.x%), ; ,?Poor differenced, Histology n (%),7,1,3,no,1:no,1:no,,0.513
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,8,0,2,no,1:no,1:no,,0.849
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,8,1,3,no,1:no,1:no,,0.774
1345,2360517,Table 2,BaselineCharacteristic,Tumour n (%),N=xx ; ,None,None,9,0,24,no,1:no,1:no,,0.77
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Tumour n (%),None,9,1,43,no,1:no,1:no,,0.719
1345,2360517,Table 2,BaselineCharacteristic,?Proximal,N=xx ; ,?Proximal, Tumour n (%),10,0,2,no,1:no,1:no,,0.758
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Proximal, Tumour n (%),10,1,3,no,1:no,1:no,,0.531
1345,2360517,Table 2,BaselineCharacteristic,?Middle,N=xx ; ,?Middle, Tumour n (%),11,0,2,no,1:no,1:no,,0.758
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Middle, Tumour n (%),11,1,3,no,1:no,1:no,,0.546
1345,2360517,Table 2,BaselineCharacteristic,?Distal,N=xx ; ,?Distal, Tumour n (%),12,0,2,no,1:no,1:no,,0.758
1345,2360517,Table 2,BaselineCharacteristic,x (xx.x%), ; ,?Distal, Tumour n (%),12,1,3,no,1:no,1:no,,0.553
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,13,0,2,no,1:no,1:no,,0.869
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,13,1,3,no,1:no,1:no,,0.813
1345,2360517,Table 2,BaselineCharacteristic,Dysphagia (Atkinson score): n (%),N=xx ; ,None,None,14,0,24,no,1:no,1:no,,0.791
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Dysphagia (Atkinson score): n (%),None,14,1,43,no,1:no,1:no,,0.732
1345,2360517,Table 2,BaselineCharacteristic,?Grade>x,N=xx ; ,?Grade>x, Dysphagia (Atkinson score): n (%),15,0,2,no,1:no,1:no,,0.745
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Grade>x, Dysphagia (Atkinson score): n (%),15,1,3,no,1:no,1:no,,0.541
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,16,0,2,no,1:no,1:no,,0.869
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,16,1,3,no,1:no,1:no,,0.808
1345,2360517,Table 2,BaselineCharacteristic,Performance status ECOG: n (%),N=xx ; ,None,None,17,0,24,no,1:no,1:no,,0.815
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Performance status ECOG: n (%),None,17,1,43,no,1:no,1:no,,0.75
1345,2360517,Table 2,BaselineCharacteristic,?x,N=xx ; ,?x, Performance status ECOG: n (%),18,0,2,no,1:no,1:no,,0.755
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?x, Performance status ECOG: n (%),18,1,3,no,1:no,1:no,,0.621
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,20,0,2,no,1:no,1:no,,0.879
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,20,1,3,no,1:no,1:no,,0.832
1345,2360517,Table 2,BaselineCharacteristic,Weight loss n (%),N=xx ; ,None,None,21,0,24,no,1:no,1:no,,0.792
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Weight loss n (%),None,21,1,43,no,1:no,1:no,,0.741
1345,2360517,Table 2,BaselineCharacteristic,?<xx%,N=xx ; ,?<xx%, Weight loss n (%),22,0,2,no,1:no,1:no,,0.783
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?<xx%, Weight loss n (%),22,1,3,no,1:no,1:no,,0.596
1345,2360517,Table 2,BaselineCharacteristic,?>xx%,N=xx ; ,?>xx%, Weight loss n (%),23,0,2,no,1:no,1:no,,0.785
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?>xx%, Weight loss n (%),23,1,3,no,1:no,1:no,,0.599
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,24,0,2,no,1:no,1:no,,0.881
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,24,1,3,no,1:no,1:no,,0.838
1345,2360517,Table 2,BaselineCharacteristic,"Tumour stage, UICC xxxx: n (%)",N=xx ; ,None,None,25,0,24,no,1:no,1:no,,0.822
1345,2360517,Table 2,BaselineCharacteristic,, ; ,"Tumour stage, UICC xxxx: n (%)",None,25,1,43,no,1:no,1:no,,0.803
1345,2360517,Table 2,BaselineCharacteristic,?Stage I,N=xx ; ,?Stage I," Tumour stage, UICC xxxx: n (%)",26,0,2,no,1:no,1:no,,0.827
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Stage I," Tumour stage, UICC xxxx: n (%)",26,1,3,no,1:no,1:no,,0.7
1345,2360517,Table 2,BaselineCharacteristic,?Stage II,N=xx ; ,?Stage II," Tumour stage, UICC xxxx: n (%)",27,0,2,no,1:no,1:no,,0.826
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Stage II," Tumour stage, UICC xxxx: n (%)",27,1,3,no,1:no,1:no,,0.684
1345,2360517,Table 2,BaselineCharacteristic,?Stage III,N=xx ; ,?Stage III," Tumour stage, UICC xxxx: n (%)",28,0,2,no,1:no,1:no,,0.825
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Stage III," Tumour stage, UICC xxxx: n (%)",28,1,3,no,1:no,1:no,,0.683
1345,2360517,Table 2,BaselineCharacteristic,?Serum albumin (mean in g?l?x),N=xx ; ,?Serum albumin (mean in g?l?x)," Tumour stage, UICC xxxx: n (%)",29,0,2,no,1:no,1:no,,0.827
1345,2360517,Table 2,BaselineCharacteristic,xx.x?g?l?x, ; ,?Serum albumin (mean in g?l?x)," Tumour stage, UICC xxxx: n (%)",29,1,3,no,1:no,1:no,,0.728
1345,2360517,Table 2,BaselineCharacteristic,"?Tumour diameter (CT scan, median in mm)",N=xx ; ,"?Tumour diameter (CT scan, median in mm)"," Tumour stage, UICC xxxx: n (%)",30,0,2,no,1:no,1:no,,0.854
1345,2360517,Table 2,BaselineCharacteristic,xx.x?mm, ; ,"?Tumour diameter (CT scan, median in mm)"," Tumour stage, UICC xxxx: n (%)",30,1,3,no,1:no,1:no,,0.759
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,31,0,2,no,1:no,1:no,,0.881
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,31,1,3,no,1:no,1:no,,0.838
1345,2360517,Table 2,BaselineCharacteristic,Endoscopic Ultrasonography (n=xx),N=xx ; ,None,None,32,0,24,no,1:no,1:no,,0.867
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Endoscopic Ultrasonography (n=xx),None,32,1,43,no,1:no,1:no,,0.812
1345,2360517,Table 2,BaselineCharacteristic,?Tx,N=xx ; ,?Tx, Endoscopic Ultrasonography (n=xx),33,0,2,no,1:no,1:no,,0.872
1345,2360517,Table 2,BaselineCharacteristic,x (xx%), ; ,?Tx, Endoscopic Ultrasonography (n=xx),33,1,3,no,1:no,1:no,,0.719
1345,2360517,Table 2,BaselineCharacteristic,?N+,N=xx ; ,?N+, Endoscopic Ultrasonography (n=xx),34,0,2,no,1:no,1:no,,0.872
1345,2360517,Table 2,BaselineCharacteristic,x (xx%), ; ,?N+, Endoscopic Ultrasonography (n=xx),34,1,3,no,1:no,1:no,,0.713
1345,2360517,Table 2,BaselineCharacteristic,?Mxa (celiac node),N=xx ; ,?Mxa (celiac node), Endoscopic Ultrasonography (n=xx),35,0,2,no,1:no,1:no,,0.872
1345,2360517,Table 2,BaselineCharacteristic,x (x.x%), ; ,?Mxa (celiac node), Endoscopic Ultrasonography (n=xx),35,1,3,no,1:no,1:no,,0.77
1347,2360530,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
1347,2360530,Table 1,BaselineCharacteristic,N,,Characteristic,None,0,1,1,no,1:no,1:no,,0.72
1347,2360530,Table 1,BaselineCharacteristic,(%),,Characteristic,None,0,2,1,no,1:no,1:no,,0.776
1347,2360530,Table 1,BaselineCharacteristic,Included,Characteristic ; ,Included,,1,0,2,no,1:no,1:no,,0.834
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,Included,,1,1,3,no,1:no,1:no,,0.501
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,Included,,1,2,3,no,1:no,1:no,,0.642
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,0,2,no,1:no,1:no,,0.852
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,2,1,3,no,1:no,1:no,,0.646
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,2,2,3,no,1:no,1:no,,0.686
1347,2360530,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,3,0,24,no,1:no,1:no,,0.845
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,Age (years),None,3,1,43,no,1:no,1:no,,0.729
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,Age (years),None,3,2,43,no,1:no,1:no,,0.777
1347,2360530,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),4,0,2,no,1:no,1:no,,0.85
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Median, Age (years),4,1,3,no,1:no,1:no,,0.641
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,?Median, Age (years),4,2,3,no,1:no,1:no,,0.731
1347,2360530,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),5,0,2,no,1:no,1:no,,0.836
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,?Range, Age (years),5,2,3,no,1:no,1:no,,0.734
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,0,2,no,1:no,1:no,,0.876
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,6,1,3,no,1:no,1:no,,0.669
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,6,2,3,no,1:no,1:no,,0.711
1347,2360530,Table 1,BaselineCharacteristic,KPS ?xx%,Characteristic ; ,KPS ?xx%,,7,0,2,no,1:no,1:no,,0.813
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,KPS ?xx%,,7,1,3,no,1:no,2:yes,+,0.516
1347,2360530,Table 1,BaselineCharacteristic,xxx,(%) ; ,KPS ?xx%,,7,2,3,no,1:no,1:no,,0.547
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,8,0,2,no,1:no,1:no,,0.883
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,8,1,3,no,1:no,1:no,,0.704
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,8,2,3,no,1:no,1:no,,0.726
1347,2360530,Table 1,BaselineCharacteristic,HER x testing,Characteristic ; ,None,None,9,0,24,no,1:no,1:no,,0.855
1347,2360530,Table 1,BaselineCharacteristic,HER x testing,N ; ,HER x testing,None,9,1,43,no,1:no,1:no,,0.714
1347,2360530,Table 1,BaselineCharacteristic,HER x testing,(%) ; ,HER x testing,None,9,2,43,no,1:no,1:no,,0.737
1347,2360530,Table 1,BaselineCharacteristic,?IHC x+,Characteristic ; ,?IHC x+, HER x testing,10,0,2,no,1:no,1:no,,0.856
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?IHC x+, HER x testing,10,1,3,no,1:no,1:no,,0.619
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?IHC x+, HER x testing,10,2,3,no,1:no,1:no,,0.57
1347,2360530,Table 1,BaselineCharacteristic,?IHC x+/FISH+,Characteristic ; ,?IHC x+/FISH+, HER x testing,11,0,2,no,1:no,1:no,,0.857
1347,2360530,Table 1,BaselineCharacteristic,x,N ; ,?IHC x+/FISH+, HER x testing,11,1,3,no,1:no,1:no,,0.655
1347,2360530,Table 1,BaselineCharacteristic,x.x,(%) ; ,?IHC x+/FISH+, HER x testing,11,2,3,no,1:no,1:no,,0.694
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,12,0,2,no,1:no,1:no,,0.902
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,12,1,3,no,1:no,1:no,,0.751
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,12,2,3,no,1:no,1:no,,0.76
1347,2360530,Table 1,BaselineCharacteristic,Prior hormonotherapy,Characteristic ; ,Prior hormonotherapy,,13,0,2,no,1:no,1:no,,0.894
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,Prior hormonotherapy,,13,1,3,no,1:no,1:no,,0.69
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,Prior hormonotherapy,,13,2,3,no,1:no,1:no,,0.625
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,14,0,2,no,1:no,1:no,,0.902
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,14,1,3,no,1:no,1:no,,0.745
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,14,2,3,no,1:no,1:no,,0.758
1347,2360530,Table 1,BaselineCharacteristic,Prior chemotherapy,Characteristic ; ,Prior chemotherapy,,15,0,24,no,1:no,1:no,,0.866
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,Prior chemotherapy,,15,1,43,no,1:no,1:no,,0.715
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,Prior chemotherapy,,15,2,43,no,1:no,1:no,,0.651
1347,2360530,Table 1,BaselineCharacteristic,?Neoadjuvant,Characteristic ; ,?Neoadjuvant, Prior chemotherapy,16,0,2,no,1:no,1:no,,0.899
1347,2360530,Table 1,BaselineCharacteristic,x,N ; ,?Neoadjuvant, Prior chemotherapy,16,1,3,no,1:no,1:no,,0.692
1347,2360530,Table 1,BaselineCharacteristic,x.x,(%) ; ,?Neoadjuvant, Prior chemotherapy,16,2,3,no,1:no,1:no,,0.717
1347,2360530,Table 1,BaselineCharacteristic,?Adjuvant,Characteristic ; ,?Adjuvant, Prior chemotherapy,17,0,2,no,1:no,1:no,,0.911
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Adjuvant, Prior chemotherapy,17,1,3,no,1:no,1:no,,0.747
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Adjuvant, Prior chemotherapy,17,2,3,no,1:no,1:no,,0.693
1347,2360530,Table 1,BaselineCharacteristic,?Both,Characteristic ; ,?Both, Prior chemotherapy,18,0,2,no,1:no,1:no,,0.914
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Both, Prior chemotherapy,18,1,3,no,1:no,1:no,,0.755
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Both, Prior chemotherapy,18,2,3,no,1:no,1:no,,0.708
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,19,0,2,no,1:no,1:no,,0.911
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,19,1,3,no,1:no,1:no,,0.769
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,19,2,3,no,1:no,1:no,,0.777
1347,2360530,Table 1,BaselineCharacteristic,Chemotherapy regimen,Characteristic ; ,None,None,20,0,24,no,1:no,1:no,,0.902
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,Chemotherapy regimen,None,20,1,43,no,1:no,1:no,,0.791
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,Chemotherapy regimen,None,20,2,43,no,1:no,1:no,,0.811
1347,2360530,Table 1,BaselineCharacteristic,?Anthracycline based,Characteristic ; ,?Anthracycline based, Chemotherapy regimen,21,0,2,no,1:no,1:no,,0.91
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Anthracycline based, Chemotherapy regimen,21,1,3,no,1:no,1:no,,0.723
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Anthracycline based, Chemotherapy regimen,21,2,3,no,1:no,1:no,,0.678
1347,2360530,Table 1,BaselineCharacteristic,?Anthracycline+taxane,Characteristic ; ,?Anthracycline+taxane, Chemotherapy regimen,22,0,2,no,1:no,1:no,,0.912
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Anthracycline+taxane, Chemotherapy regimen,22,1,3,no,1:no,1:no,,0.729
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Anthracycline+taxane, Chemotherapy regimen,22,2,3,no,1:no,1:no,,0.686
1347,2360530,Table 1,BaselineCharacteristic,?CMF,Characteristic ; ,?CMF, Chemotherapy regimen,23,0,2,no,1:no,1:no,,0.912
1347,2360530,Table 1,BaselineCharacteristic,x,N ; ,?CMF, Chemotherapy regimen,23,1,3,no,1:no,1:no,,0.738
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?CMF, Chemotherapy regimen,23,2,3,no,1:no,1:no,,0.692
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,24,0,2,no,1:no,1:no,,0.913
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,24,1,3,no,1:no,1:no,,0.778
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,24,2,3,no,1:no,1:no,,0.79
1347,2360530,Table 1,BaselineCharacteristic,Metastatic sites ?x,Characteristic ; ,Metastatic sites ?x,,25,0,24,no,1:no,1:no,,0.883
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,Metastatic sites ?x,,25,1,43,no,1:no,1:no,,0.751
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,Metastatic sites ?x,,25,2,43,no,1:no,1:no,,0.742
1347,2360530,Table 1,BaselineCharacteristic,?Lymph nodes,Characteristic ; ,?Lymph nodes, Metastatic sites ?x,26,0,2,no,1:no,1:no,,0.899
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Lymph nodes, Metastatic sites ?x,26,1,3,no,1:no,1:no,,0.749
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Lymph nodes, Metastatic sites ?x,26,2,3,no,1:no,1:no,,0.736
1347,2360530,Table 1,BaselineCharacteristic,?Visceral (lung/liver),Characteristic ; ,?Visceral (lung/liver), Metastatic sites ?x,27,0,2,no,1:no,1:no,,0.899
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Visceral (lung/liver), Metastatic sites ?x,27,1,3,no,1:no,1:no,,0.749
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Visceral (lung/liver), Metastatic sites ?x,27,2,3,no,1:no,1:no,,0.736
1347,2360530,Table 1,BaselineCharacteristic,?Liver,Characteristic ; ,?Liver, Metastatic sites ?x,28,0,2,no,1:no,1:no,,0.91
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Liver, Metastatic sites ?x,28,1,3,no,1:no,1:no,,0.771
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Liver, Metastatic sites ?x,28,2,3,no,1:no,1:no,,0.754
1347,2360530,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?Lung, Metastatic sites ?x,29,0,2,no,1:no,1:no,,0.899
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Lung, Metastatic sites ?x,29,1,3,no,1:no,1:no,,0.749
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Lung, Metastatic sites ?x,29,2,3,no,1:no,1:no,,0.736
1347,2360530,Table 1,BaselineCharacteristic,?Bone,Characteristic ; ,?Bone, Metastatic sites ?x,30,0,2,no,1:no,1:no,,0.902
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Bone, Metastatic sites ?x,30,1,3,no,1:no,1:no,,0.749
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Bone, Metastatic sites ?x,30,2,3,no,1:no,1:no,,0.736
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,31,0,2,no,1:no,1:no,,0.913
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,31,1,3,no,1:no,1:no,,0.778
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,31,2,3,no,1:no,1:no,,0.792
1347,2360530,Table 1,BaselineCharacteristic,Disease-free interval from diagnosis to first relapse (months),Characteristic ; ,None,None,32,0,24,no,1:no,1:no,,0.916
1347,2360530,Table 1,BaselineCharacteristic,Disease-free interval from diagnosis to first relapse (months),N ; ,Disease-free interval from diagnosis to first relapse (months),None,32,1,43,no,1:no,1:no,,0.815
1347,2360530,Table 1,BaselineCharacteristic,Disease-free interval from diagnosis to first relapse (months),(%) ; ,Disease-free interval from diagnosis to first relapse (months),None,32,2,43,no,1:no,1:no,,0.838
1347,2360530,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Disease-free interval from diagnosis to first relapse (months),33,0,2,no,1:no,1:no,,0.927
1347,2360530,Table 1,BaselineCharacteristic,xx.x,N ; ,?Median, Disease-free interval from diagnosis to first relapse (months),33,1,3,no,1:no,1:no,,0.766
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,?Median, Disease-free interval from diagnosis to first relapse (months),33,2,3,no,1:no,1:no,,0.829
1347,2360530,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Disease-free interval from diagnosis to first relapse (months),34,0,2,no,1:no,1:no,,0.926
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,?Range, Disease-free interval from diagnosis to first relapse (months),34,2,3,no,1:no,1:no,,0.832
1348,2360532,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
1348,2360532,Table 1,BaselineCharacteristic,n,,Characteristic,None,0,1,1,no,1:no,1:no,,0.72
1348,2360532,Table 1,BaselineCharacteristic,%,,Characteristic,None,0,2,1,no,1:no,1:no,,0.776
1348,2360532,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,1,0,24,no,1:no,1:no,,0.597
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,Sex,None,1,1,43,no,1:no,2:yes,+,0.544
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,Sex,None,1,2,43,no,1:no,1:no,,0.529
1348,2360532,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Sex,2,0,2,no,1:no,1:no,,0.526
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Male, Sex,2,1,3,yes,2:yes,2:yes,,0.808
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Male, Sex,2,2,3,yes,2:yes,2:yes,,0.828
1348,2360532,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Sex,3,0,2,no,1:no,1:no,,0.549
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Female, Sex,3,1,3,yes,2:yes,2:yes,,0.797
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Female, Sex,3,2,3,yes,2:yes,2:yes,,0.845
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,no,1:no,1:no,,0.869
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,4,1,3,no,1:no,1:no,,0.668
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,4,2,3,no,1:no,1:no,,0.701
1348,2360532,Table 1,BaselineCharacteristic,WHO performance status,Characteristic ; ,None,None,5,0,24,no,1:no,1:no,,0.877
1348,2360532,Table 1,BaselineCharacteristic,WHO performance status,n ; ,WHO performance status,None,5,1,43,no,1:no,1:no,,0.713
1348,2360532,Table 1,BaselineCharacteristic,WHO performance status,% ; ,WHO performance status,None,5,2,43,no,1:no,1:no,,0.767
1348,2360532,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO performance status,6,0,2,no,1:no,1:no,,0.847
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?x, WHO performance status,6,1,3,no,1:no,1:no,,0.611
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?x, WHO performance status,6,2,3,no,1:no,1:no,,0.555
1348,2360532,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO performance status,7,0,2,no,1:no,1:no,,0.854
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?x, WHO performance status,7,1,3,no,1:no,1:no,,0.609
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?x, WHO performance status,7,2,3,no,1:no,1:no,,0.562
1348,2360532,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO performance status,8,0,2,no,1:no,1:no,,0.857
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?x, WHO performance status,8,1,3,no,1:no,1:no,,0.632
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?x, WHO performance status,8,2,3,no,1:no,1:no,,0.592
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,9,0,2,no,1:no,1:no,,0.891
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,9,1,3,no,1:no,1:no,,0.717
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,9,2,3,no,1:no,1:no,,0.742
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,13,0,2,no,1:no,1:no,,0.902
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,13,1,3,no,1:no,1:no,,0.751
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,13,2,3,no,1:no,1:no,,0.76
1348,2360532,Table 1,BaselineCharacteristic,Raised AFP,Characteristic ; ,Raised AFP,,14,0,2,no,1:no,1:no,,0.885
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,Raised AFP,,14,1,3,no,1:no,1:no,,0.619
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,Raised AFP,,14,2,3,no,1:no,1:no,,0.582
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,15,0,2,no,1:no,1:no,,0.902
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,15,1,3,no,1:no,1:no,,0.739
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,15,2,3,no,1:no,1:no,,0.749
1348,2360532,Table 1,BaselineCharacteristic,Race,Characteristic ; ,None,None,16,0,24,no,1:no,1:no,,0.883
1348,2360532,Table 1,BaselineCharacteristic,Race,n ; ,Race,None,16,1,43,no,1:no,1:no,,0.746
1348,2360532,Table 1,BaselineCharacteristic,Race,% ; ,Race,None,16,2,43,no,1:no,1:no,,0.771
1348,2360532,Table 1,BaselineCharacteristic,?Caucasian,Characteristic ; ,?Caucasian, Race,17,0,2,no,1:no,1:no,,0.903
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Caucasian, Race,17,1,3,no,1:no,1:no,,0.663
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Caucasian, Race,17,2,3,no,1:no,1:no,,0.639
1348,2360532,Table 1,BaselineCharacteristic,?Asian,Characteristic ; ,?Asian, Race,18,0,2,no,1:no,1:no,,0.906
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Asian, Race,18,1,3,no,1:no,1:no,,0.678
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Asian, Race,18,2,3,no,1:no,1:no,,0.651
1348,2360532,Table 1,BaselineCharacteristic,?African,Characteristic ; ,?African, Race,19,0,2,no,1:no,1:no,,0.906
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?African, Race,19,1,3,no,1:no,1:no,,0.714
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?African, Race,19,2,3,no,1:no,1:no,,0.743
1348,2360532,Table 1,BaselineCharacteristic,?Polynesian or Melanesian,Characteristic ; ,?Polynesian or Melanesian, Race,20,0,2,no,1:no,1:no,,0.907
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Polynesian or Melanesian, Race,20,1,3,no,1:no,1:no,,0.73
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Polynesian or Melanesian, Race,20,2,3,no,1:no,1:no,,0.761
1348,2360532,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other, Race,21,0,2,no,1:no,1:no,,0.91
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Other, Race,21,1,3,no,1:no,1:no,,0.732
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Other, Race,21,2,3,no,1:no,1:no,,0.747
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,22,0,2,no,1:no,1:no,,0.913
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,22,1,3,no,1:no,1:no,,0.776
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,22,2,3,no,1:no,1:no,,0.787
1348,2360532,Table 1,BaselineCharacteristic,Possible causes of HCCa,Characteristic ; ,None,None,23,0,24,no,1:no,1:no,,0.909
1348,2360532,Table 1,BaselineCharacteristic,Possible causes of HCCa,n ; ,Possible causes of HCCa,None,23,1,43,no,1:no,1:no,,0.807
1348,2360532,Table 1,BaselineCharacteristic,Possible causes of HCCa,% ; ,Possible causes of HCCa,None,23,2,43,no,1:no,1:no,,0.842
1348,2360532,Table 1,BaselineCharacteristic,?Alcoholic liver disease,Characteristic ; ,?Alcoholic liver disease, Possible causes of HCCa,24,0,2,no,1:no,1:no,,0.902
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Alcoholic liver disease, Possible causes of HCCa,24,1,3,no,1:no,1:no,,0.746
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Alcoholic liver disease, Possible causes of HCCa,24,2,3,no,1:no,1:no,,0.741
1348,2360532,Table 1,BaselineCharacteristic,?Hepatitis,Characteristic ; ,?Hepatitis, Possible causes of HCCa,25,0,24,no,1:no,1:no,,0.882
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Hepatitis, Possible causes of HCCa,25,1,43,no,1:no,1:no,,0.713
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Hepatitis, Possible causes of HCCa,25,2,43,no,1:no,1:no,,0.708
1348,2360532,Table 1,BaselineCharacteristic,??HBsAg and no antibody to HCV,Characteristic ; ,??HBsAg and no antibody to HCV, Possible causes of HCCa ?Hepatitis,26,0,2,no,1:no,1:no,,0.879
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,??HBsAg and no antibody to HCV, Possible causes of HCCa ?Hepatitis,26,1,3,no,1:no,1:no,,0.684
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,??HBsAg and no antibody to HCV, Possible causes of HCCa ?Hepatitis,26,2,3,no,1:no,1:no,,0.68
1348,2360532,Table 1,BaselineCharacteristic,??Antibody to HCV and no HBsAg,Characteristic ; ,??Antibody to HCV and no HBsAg, Possible causes of HCCa ?Hepatitis,27,0,2,no,1:no,1:no,,0.879
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,??Antibody to HCV and no HBsAg, Possible causes of HCCa ?Hepatitis,27,1,3,no,1:no,1:no,,0.71
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,??Antibody to HCV and no HBsAg, Possible causes of HCCa ?Hepatitis,27,2,3,no,1:no,1:no,,0.68
1348,2360532,Table 1,BaselineCharacteristic,??HBsAg and antibody to HCV,Characteristic ; ,??HBsAg and antibody to HCV, Possible causes of HCCa ?Hepatitis,28,0,2,no,1:no,1:no,,0.908
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,??HBsAg and antibody to HCV, Possible causes of HCCa ?Hepatitis,28,1,3,no,1:no,1:no,,0.775
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,??HBsAg and antibody to HCV, Possible causes of HCCa ?Hepatitis,28,2,3,no,1:no,1:no,,0.811
1348,2360532,Table 1,BaselineCharacteristic,??No HBsAg or antibody to HCV,Characteristic ; ,??No HBsAg or antibody to HCV, Possible causes of HCCa ?Hepatitis,29,0,2,no,1:no,1:no,,0.873
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,??No HBsAg or antibody to HCV, Possible causes of HCCa ?Hepatitis,29,1,3,no,1:no,1:no,,0.701
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,??No HBsAg or antibody to HCV, Possible causes of HCCa ?Hepatitis,29,2,3,no,1:no,1:no,,0.687
1348,2360532,Table 1,BaselineCharacteristic,??Unclassified,Characteristic ; ,??Unclassified, Possible causes of HCCa ?Hepatitis,30,0,2,no,1:no,1:no,,0.901
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,??Unclassified, Possible causes of HCCa ?Hepatitis,30,1,3,no,1:no,1:no,,0.748
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,??Unclassified, Possible causes of HCCa ?Hepatitis,30,2,3,no,1:no,1:no,,0.711
1348,2360532,Table 1,BaselineCharacteristic,?Haemochromatosis,Characteristic ; ,?Haemochromatosis, Possible causes of HCCa,31,0,2,no,1:no,1:no,,0.901
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Haemochromatosis, Possible causes of HCCa,31,1,3,no,1:no,1:no,,0.748
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Haemochromatosis, Possible causes of HCCa,31,2,3,no,1:no,1:no,,0.789
1348,2360532,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other, Possible causes of HCCa,32,0,2,no,1:no,1:no,,0.905
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Other, Possible causes of HCCa,32,1,3,no,1:no,1:no,,0.758
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Other, Possible causes of HCCa,32,2,3,no,1:no,1:no,,0.712
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,33,0,2,no,1:no,1:no,,0.913
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,33,1,3,no,1:no,1:no,,0.778
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,33,2,3,no,1:no,1:no,,0.792
1348,2360532,Table 1,BaselineCharacteristic,Most recent treatment for HCC,Characteristic ; ,None,None,34,0,24,no,1:no,1:no,,0.893
1348,2360532,Table 1,BaselineCharacteristic,Most recent treatment for HCC,n ; ,Most recent treatment for HCC,None,34,1,43,no,1:no,1:no,,0.796
1348,2360532,Table 1,BaselineCharacteristic,Most recent treatment for HCC,% ; ,Most recent treatment for HCC,None,34,2,43,no,1:no,1:no,,0.8
1348,2360532,Table 1,BaselineCharacteristic,?No previous therapy,Characteristic ; ,?No previous therapy, Most recent treatment for HCC,35,0,2,no,1:no,1:no,,0.888
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?No previous therapy, Most recent treatment for HCC,35,1,3,no,1:no,1:no,,0.697
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?No previous therapy, Most recent treatment for HCC,35,2,3,no,1:no,1:no,,0.724
1348,2360532,Table 1,BaselineCharacteristic,?Surgery,Characteristic ; ,?Surgery, Most recent treatment for HCC,36,0,2,no,1:no,1:no,,0.912
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Surgery, Most recent treatment for HCC,36,1,3,no,1:no,1:no,,0.758
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Surgery, Most recent treatment for HCC,36,2,3,no,1:no,1:no,,0.771
1348,2360532,Table 1,BaselineCharacteristic,?Chemotherapy,Characteristic ; ,?Chemotherapy, Most recent treatment for HCC,37,0,2,no,1:no,1:no,,0.91
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Chemotherapy, Most recent treatment for HCC,37,1,3,no,1:no,1:no,,0.747
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Chemotherapy, Most recent treatment for HCC,37,2,3,no,1:no,1:no,,0.772
1348,2360532,Table 1,BaselineCharacteristic,?Local ablation,Characteristic ; ,?Local ablation, Most recent treatment for HCC,38,0,2,no,1:no,1:no,,0.907
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Local ablation, Most recent treatment for HCC,38,1,3,no,1:no,1:no,,0.737
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Local ablation, Most recent treatment for HCC,38,2,3,no,1:no,1:no,,0.697
1348,2360532,Table 1,BaselineCharacteristic,?Chemoembolisation,Characteristic ; ,?Chemoembolisation, Most recent treatment for HCC,39,0,2,no,1:no,1:no,,0.907
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Chemoembolisation, Most recent treatment for HCC,39,1,3,no,1:no,1:no,,0.737
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Chemoembolisation, Most recent treatment for HCC,39,2,3,no,1:no,1:no,,0.762
1348,2360532,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other, Most recent treatment for HCC,40,0,2,no,1:no,1:no,,0.911
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Other, Most recent treatment for HCC,40,1,3,no,1:no,1:no,,0.756
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Other, Most recent treatment for HCC,40,2,3,no,1:no,1:no,,0.701
1351,2360546,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1351,2360546,Table 1,BaselineCharacteristic,No.,,,None,0,1,1,no,1:no,1:no,,0.761
1351,2360546,Table 1,BaselineCharacteristic,%,,,None,0,2,1,no,1:no,1:no,,0.757
1351,2360546,Table 1,BaselineCharacteristic,Total, ; ,Total,,1,0,2,no,1:no,1:no,,0.721
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,Total,,1,1,3,no,1:no,2:yes,+,0.635
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,Total,,1,2,3,no,1:no,1:no,,0.534
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,2,0,2,no,1:no,1:no,,0.842
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,2,1,3,no,1:no,1:no,,0.7
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,2,2,3,no,1:no,1:no,,0.686
1351,2360546,Table 1,BaselineCharacteristic,Sex, ; ,None,None,3,0,24,no,1:no,1:no,,0.573
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,Sex,None,3,1,43,no,1:no,2:yes,+,0.513
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,Sex,None,3,2,43,no,1:no,1:no,,0.524
1351,2360546,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Sex,4,0,2,no,1:no,2:yes,+,0.515
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?Male, Sex,4,1,3,yes,2:yes,2:yes,,0.816
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?Male, Sex,4,2,3,yes,2:yes,2:yes,,0.851
1351,2360546,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Sex,5,0,2,no,1:no,1:no,,0.519
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?Female, Sex,5,1,3,yes,2:yes,2:yes,,0.788
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?Female, Sex,5,2,3,yes,2:yes,2:yes,,0.851
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,6,0,2,no,1:no,1:no,,0.866
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,6,1,3,no,1:no,1:no,,0.735
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,6,2,3,no,1:no,1:no,,0.711
1351,2360546,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,7,0,24,no,1:no,1:no,,0.853
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,Age (years),None,7,1,43,no,1:no,1:no,,0.776
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,Age (years),None,7,2,43,no,1:no,1:no,,0.787
1351,2360546,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),8,0,2,no,1:no,1:no,,0.851
1351,2360546,Table 1,BaselineCharacteristic,xx.x,No. ; ,?Median, Age (years),8,1,3,no,1:no,1:no,,0.634
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,?Median, Age (years),8,2,3,no,1:no,1:no,,0.754
1351,2360546,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),9,0,2,no,1:no,1:no,,0.862
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,?Range, Age (years),9,2,3,no,1:no,1:no,,0.786
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,2,no,1:no,1:no,,0.888
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,10,1,3,no,1:no,1:no,,0.773
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,10,2,3,no,1:no,1:no,,0.749
1351,2360546,Table 1,BaselineCharacteristic,Histology, ; ,None,None,11,0,24,no,1:no,1:no,,0.878
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,Histology,None,11,1,43,no,1:no,1:no,,0.826
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,Histology,None,11,2,43,no,1:no,1:no,,0.786
1351,2360546,Table 1,BaselineCharacteristic,?Adeno, ; ,?Adeno, Histology,12,0,2,no,1:no,1:no,,0.882
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?Adeno, Histology,12,1,3,no,1:no,1:no,,0.718
1351,2360546,Table 1,BaselineCharacteristic,xx,% ; ,?Adeno, Histology,12,2,3,no,1:no,1:no,,0.616
1351,2360546,Table 1,BaselineCharacteristic,?Squamous, ; ,?Squamous, Histology,13,0,2,no,1:no,1:no,,0.887
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?Squamous, Histology,13,1,3,no,1:no,1:no,,0.722
1351,2360546,Table 1,BaselineCharacteristic,xx,% ; ,?Squamous, Histology,13,2,3,no,1:no,1:no,,0.626
1351,2360546,Table 1,BaselineCharacteristic,?Large, ; ,?Large, Histology,14,0,2,no,1:no,1:no,,0.878
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?Large, Histology,14,1,3,no,1:no,1:no,,0.723
1351,2360546,Table 1,BaselineCharacteristic,xx,% ; ,?Large, Histology,14,2,3,no,1:no,1:no,,0.601
1351,2360546,Table 1,BaselineCharacteristic,?Other, ; ,?Other, Histology,15,0,2,no,1:no,1:no,,0.887
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?Other, Histology,15,1,3,no,1:no,1:no,,0.725
1351,2360546,Table 1,BaselineCharacteristic,xx,% ; ,?Other, Histology,15,2,3,no,1:no,1:no,,0.612
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,16,0,2,no,1:no,1:no,,0.893
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,16,1,3,no,1:no,1:no,,0.79
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,16,2,3,no,1:no,1:no,,0.749
1351,2360546,Table 1,BaselineCharacteristic,Performance status (ECOG), ; ,None,None,17,0,24,no,1:no,1:no,,0.906
1351,2360546,Table 1,BaselineCharacteristic,Performance status (ECOG),No. ; ,Performance status (ECOG),None,17,1,43,no,1:no,1:no,,0.841
1351,2360546,Table 1,BaselineCharacteristic,Performance status (ECOG),% ; ,Performance status (ECOG),None,17,2,43,no,1:no,1:no,,0.816
1351,2360546,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (ECOG),18,0,2,no,1:no,1:no,,0.889
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?x, Performance status (ECOG),18,1,3,no,1:no,1:no,,0.761
1351,2360546,Table 1,BaselineCharacteristic,x,% ; ,?x, Performance status (ECOG),18,2,3,no,1:no,1:no,,0.793
1351,2360546,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (ECOG),19,0,2,no,1:no,1:no,,0.889
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?x, Performance status (ECOG),19,1,3,no,1:no,1:no,,0.729
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Performance status (ECOG),19,2,3,no,1:no,1:no,,0.701
1351,2360546,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (ECOG),20,0,2,no,1:no,1:no,,0.89
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?x, Performance status (ECOG),20,1,3,no,1:no,1:no,,0.761
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Performance status (ECOG),20,2,3,no,1:no,1:no,,0.706
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,21,0,2,no,1:no,1:no,,0.902
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,21,1,3,no,1:no,1:no,,0.816
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,21,2,3,no,1:no,1:no,,0.777
1351,2360546,Table 1,BaselineCharacteristic,Disease stage, ; ,None,None,22,0,24,no,1:no,1:no,,0.887
1351,2360546,Table 1,BaselineCharacteristic,Disease stage,No. ; ,Disease stage,None,22,1,43,no,1:no,1:no,,0.843
1351,2360546,Table 1,BaselineCharacteristic,Disease stage,% ; ,Disease stage,None,22,2,43,no,1:no,1:no,,0.832
1351,2360546,Table 1,BaselineCharacteristic,?IIIA, ; ,?IIIA, Disease stage,23,0,2,no,1:no,1:no,,0.907
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?IIIA, Disease stage,23,1,3,no,1:no,1:no,,0.779
1351,2360546,Table 1,BaselineCharacteristic,x.x,% ; ,?IIIA, Disease stage,23,2,3,no,1:no,1:no,,0.8
1351,2360546,Table 1,BaselineCharacteristic,?IIIB, ; ,?IIIB, Disease stage,24,0,2,no,1:no,1:no,,0.907
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?IIIB, Disease stage,24,1,3,no,1:no,1:no,,0.771
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?IIIB, Disease stage,24,2,3,no,1:no,1:no,,0.724
1351,2360546,Table 1,BaselineCharacteristic,?IV, ; ,?IV, Disease stage,25,0,2,no,1:no,1:no,,0.913
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?IV, Disease stage,25,1,3,no,1:no,1:no,,0.799
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?IV, Disease stage,25,2,3,no,1:no,1:no,,0.735
1355,2360560,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1355,2360560,Table 1,BaselineCharacteristic,No. of patients (%),,,None,0,1,1,no,1:no,1:no,,0.758
1355,2360560,Table 1,BaselineCharacteristic,Gender, ; ,None,None,1,0,24,no,1:no,1:no,,0.703
1355,2360560,Table 1,BaselineCharacteristic,Gender,No. of patients (%) ; ,Gender,None,1,1,43,no,1:no,1:no,,0.633
1355,2360560,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Gender,2,0,2,no,1:no,1:no,,0.703
1355,2360560,Table 1,BaselineCharacteristic,xx (xx),No. of patients (%) ; ,?Female, Gender,2,1,3,no,1:no,2:yes,+,0.747
1355,2360560,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Gender,3,0,2,no,1:no,1:no,,0.692
1355,2360560,Table 1,BaselineCharacteristic,xx (xx),No. of patients (%) ; ,?Male, Gender,3,1,3,no,1:no,2:yes,+,0.81
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no,1:no,1:no,,0.858
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,4,1,3,no,1:no,1:no,,0.711
1355,2360560,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,5,0,24,no,1:no,1:no,,0.853
1355,2360560,Table 1,BaselineCharacteristic,Age (years),No. of patients (%) ; ,Age (years),None,5,1,43,no,1:no,1:no,,0.77
1355,2360560,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),6,0,2,no,1:no,1:no,,0.843
1355,2360560,Table 1,BaselineCharacteristic,xx,No. of patients (%) ; ,?Median, Age (years),6,1,3,no,1:no,1:no,,0.572
1355,2360560,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),7,0,2,no,1:no,1:no,,0.831
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,8,0,2,no,1:no,1:no,,0.873
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,8,1,3,no,1:no,1:no,,0.755
1355,2360560,Table 1,BaselineCharacteristic,KPS, ; ,None,None,9,0,24,no,1:no,1:no,,0.861
1355,2360560,Table 1,BaselineCharacteristic,KPS,No. of patients (%) ; ,KPS,None,9,1,43,no,1:no,1:no,,0.778
1355,2360560,Table 1,BaselineCharacteristic,?Median, ; ,?Median, KPS,10,0,2,no,1:no,1:no,,0.873
1355,2360560,Table 1,BaselineCharacteristic,xx,No. of patients (%) ; ,?Median, KPS,10,1,3,no,1:no,1:no,,0.57
1355,2360560,Table 1,BaselineCharacteristic,?Range, ; ,?Range, KPS,11,0,2,no,1:no,1:no,,0.881
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,12,0,2,no,1:no,1:no,,0.892
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,12,1,3,no,1:no,1:no,,0.792
1355,2360560,Table 1,BaselineCharacteristic,Extent of resection, ; ,None,None,13,0,24,no,1:no,1:no,,0.891
1355,2360560,Table 1,BaselineCharacteristic,Extent of resection,No. of patients (%) ; ,Extent of resection,None,13,1,43,no,1:no,1:no,,0.815
1355,2360560,Table 1,BaselineCharacteristic,?Gross total resection, ; ,?Gross total resection, Extent of resection,14,0,2,no,1:no,1:no,,0.797
1355,2360560,Table 1,BaselineCharacteristic,xx (xx),No. of patients (%) ; ,?Gross total resection, Extent of resection,14,1,3,no,1:no,1:no,,0.512
1355,2360560,Table 1,BaselineCharacteristic,?Partial resection or biopsy, ; ,?Partial resection or biopsy, Extent of resection,15,0,2,no,1:no,1:no,,0.871
1355,2360560,Table 1,BaselineCharacteristic,xx (xx),No. of patients (%) ; ,?Partial resection or biopsy, Extent of resection,15,1,3,no,1:no,1:no,,0.612
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,16,0,2,no,1:no,1:no,,0.893
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,16,1,3,no,1:no,1:no,,0.791
1355,2360560,Table 1,BaselineCharacteristic,Previous treatment, ; ,None,None,17,0,24,no,1:no,1:no,,0.883
1355,2360560,Table 1,BaselineCharacteristic,Previous treatment,No. of patients (%) ; ,Previous treatment,None,17,1,43,no,1:no,1:no,,0.831
1355,2360560,Table 1,BaselineCharacteristic,?Primary resection, ; ,?Primary resection, Previous treatment,18,0,2,no,1:no,1:no,,0.897
1355,2360560,Table 1,BaselineCharacteristic,xx (xxx),No. of patients (%) ; ,?Primary resection, Previous treatment,18,1,3,no,1:no,1:no,,0.631
1355,2360560,Table 1,BaselineCharacteristic,?Radiotherapy, ; ,?Radiotherapy, Previous treatment,19,0,2,no,1:no,1:no,,0.894
1355,2360560,Table 1,BaselineCharacteristic,xx (xxx),No. of patients (%) ; ,?Radiotherapy, Previous treatment,19,1,3,no,1:no,1:no,,0.633
1355,2360560,Table 1,BaselineCharacteristic,?Chemotherapy, ; ,?Chemotherapy, Previous treatment,20,0,2,no,1:no,1:no,,0.901
1355,2360560,Table 1,BaselineCharacteristic,x,No. of patients (%) ; ,?Chemotherapy, Previous treatment,20,1,3,no,1:no,1:no,,0.746
1355,2360560,Table 1,BaselineCharacteristic,?Repeat surgery for recurrence, ; ,?Repeat surgery for recurrence, Previous treatment,21,0,2,no,1:no,1:no,,0.899
1355,2360560,Table 1,BaselineCharacteristic,x,No. of patients (%) ; ,?Repeat surgery for recurrence, Previous treatment,21,1,3,no,1:no,1:no,,0.751
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,22,0,2,no,1:no,1:no,,0.904
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,22,1,3,no,1:no,1:no,,0.811
1355,2360560,Table 1,BaselineCharacteristic,Cycles of temozolomide, ; ,None,None,23,0,24,no,1:no,1:no,,0.9
1355,2360560,Table 1,BaselineCharacteristic,Cycles of temozolomide,No. of patients (%) ; ,Cycles of temozolomide,None,23,1,43,no,1:no,1:no,,0.826
1355,2360560,Table 1,BaselineCharacteristic,??x, ; ,??x, Cycles of temozolomide,24,0,2,no,1:no,1:no,,0.881
1355,2360560,Table 1,BaselineCharacteristic,xx,No. of patients (%) ; ,??x, Cycles of temozolomide,24,1,3,no,1:no,1:no,,0.659
1355,2360560,Table 1,BaselineCharacteristic,?>xx, ; ,?>xx, Cycles of temozolomide,27,0,2,no,1:no,1:no,,0.889
1355,2360560,Table 1,BaselineCharacteristic,x,No. of patients (%) ; ,?>xx, Cycles of temozolomide,27,1,3,no,1:no,1:no,,0.722
1377,2360766,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1377,2360766,Table 1,BaselineCharacteristic,Phase I (n=xx),,,None,0,1,1,no,1:no,1:no,,0.676
1377,2360766,Table 1,BaselineCharacteristic,Phase II (n=xx),,,None,0,2,1,no,1:no,1:no,,0.7
1377,2360766,Table 1,BaselineCharacteristic,"Median age, years (range)", ; ,"Median age, years (range)",,1,0,2,no,1:no,1:no,,0.835
1377,2360766,Table 1,BaselineCharacteristic,Male/female, ; ,Male/female,,2,0,2,no,1:no,1:no,,0.831
1377,2360766,Table 1,BaselineCharacteristic,xx/x,Phase I (n=xx) ; ,Male/female,,2,1,3,yes,2:yes,1:no,+,0.622
1377,2360766,Table 1,BaselineCharacteristic,xx/x,Phase II (n=xx) ; ,Male/female,,2,2,3,yes,2:yes,1:no,+,0.63
1377,2360766,Table 1,BaselineCharacteristic,, ; ,None,None,3,0,2,no,1:no,1:no,,0.84
1377,2360766,Table 1,BaselineCharacteristic,,Phase I (n=xx) ; ,None,None,3,1,3,no,1:no,1:no,,0.651
1377,2360766,Table 1,BaselineCharacteristic,,Phase II (n=xx) ; ,None,None,3,2,3,no,1:no,1:no,,0.68
1377,2360766,Table 1,BaselineCharacteristic,Performance status, ; ,None,None,4,0,24,no,1:no,1:no,,0.851
1377,2360766,Table 1,BaselineCharacteristic,Performance status,Phase I (n=xx) ; ,Performance status,None,4,1,43,no,1:no,1:no,,0.723
1377,2360766,Table 1,BaselineCharacteristic,Performance status,Phase II (n=xx) ; ,Performance status,None,4,2,43,no,1:no,1:no,,0.751
1377,2360766,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status,5,0,2,no,1:no,1:no,,0.837
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase I (n=xx) ; ,?x, Performance status,5,1,3,no,1:no,1:no,,0.552
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase II (n=xx) ; ,?x, Performance status,5,2,3,no,1:no,1:no,,0.573
1377,2360766,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status,6,0,2,no,1:no,1:no,,0.837
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?x, Performance status,6,1,3,no,1:no,1:no,,0.641
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?x, Performance status,6,2,3,no,1:no,1:no,,0.654
1377,2360766,Table 1,BaselineCharacteristic,, ; ,None,None,7,0,2,no,1:no,1:no,,0.869
1377,2360766,Table 1,BaselineCharacteristic,,Phase I (n=xx) ; ,None,None,7,1,3,no,1:no,1:no,,0.68
1377,2360766,Table 1,BaselineCharacteristic,,Phase II (n=xx) ; ,None,None,7,2,3,no,1:no,1:no,,0.702
1377,2360766,Table 1,BaselineCharacteristic,Histological type, ; ,None,None,8,0,24,no,1:no,1:no,,0.744
1377,2360766,Table 1,BaselineCharacteristic,Histological type,Phase I (n=xx) ; ,Histological type,None,8,1,43,no,1:no,1:no,,0.633
1377,2360766,Table 1,BaselineCharacteristic,Histological type,Phase II (n=xx) ; ,Histological type,None,8,2,43,no,1:no,1:no,,0.638
1377,2360766,Table 1,BaselineCharacteristic,?Intestinal, ; ,?Intestinal, Histological type,9,0,2,no,1:no,1:no,,0.758
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase I (n=xx) ; ,?Intestinal, Histological type,9,1,3,no,1:no,1:no,,0.523
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase II (n=xx) ; ,?Intestinal, Histological type,9,2,3,no,1:no,1:no,,0.518
1377,2360766,Table 1,BaselineCharacteristic,?Diffuse, ; ,?Diffuse, Histological type,10,0,2,no,1:no,1:no,,0.765
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Diffuse, Histological type,10,1,3,no,1:no,1:no,,0.585
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Diffuse, Histological type,10,2,3,no,1:no,1:no,,0.595
1377,2360766,Table 1,BaselineCharacteristic,, ; ,None,None,11,0,2,no,1:no,1:no,,0.892
1377,2360766,Table 1,BaselineCharacteristic,,Phase I (n=xx) ; ,None,None,11,1,3,no,1:no,1:no,,0.734
1377,2360766,Table 1,BaselineCharacteristic,,Phase II (n=xx) ; ,None,None,11,2,3,no,1:no,1:no,,0.739
1377,2360766,Table 1,BaselineCharacteristic,Prior therapy, ; ,None,None,12,0,24,no,1:no,1:no,,0.887
1377,2360766,Table 1,BaselineCharacteristic,Prior therapy,Phase I (n=xx) ; ,Prior therapy,None,12,1,43,no,1:no,1:no,,0.757
1377,2360766,Table 1,BaselineCharacteristic,Prior therapy,Phase II (n=xx) ; ,Prior therapy,None,12,2,43,no,1:no,1:no,,0.766
1377,2360766,Table 1,BaselineCharacteristic,?None, ; ,?None, Prior therapy,13,0,2,no,1:no,1:no,,0.905
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase I (n=xx) ; ,?None, Prior therapy,13,1,3,no,1:no,1:no,,0.7
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase II (n=xx) ; ,?None, Prior therapy,13,2,3,no,1:no,1:no,,0.715
1377,2360766,Table 1,BaselineCharacteristic,?Gastrectomy, ; ,?Gastrectomy, Prior therapy,14,0,2,no,1:no,1:no,,0.882
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Gastrectomy, Prior therapy,14,1,3,no,1:no,1:no,,0.665
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Gastrectomy, Prior therapy,14,2,3,no,1:no,1:no,,0.681
1377,2360766,Table 1,BaselineCharacteristic,?Gastrectomy+chemotherapy, ; ,?Gastrectomy+chemotherapy, Prior therapy,15,0,2,no,1:no,1:no,,0.884
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Gastrectomy+chemotherapy, Prior therapy,15,1,3,no,1:no,1:no,,0.667
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Gastrectomy+chemotherapy, Prior therapy,15,2,3,no,1:no,1:no,,0.683
1377,2360766,Table 1,BaselineCharacteristic,, ; ,None,None,16,0,2,no,1:no,1:no,,0.893
1377,2360766,Table 1,BaselineCharacteristic,,Phase I (n=xx) ; ,None,None,16,1,3,no,1:no,1:no,,0.729
1377,2360766,Table 1,BaselineCharacteristic,,Phase II (n=xx) ; ,None,None,16,2,3,no,1:no,1:no,,0.734
1377,2360766,Table 1,BaselineCharacteristic,Site of metastasis, ; ,None,None,17,0,24,no,1:no,1:no,,0.897
1377,2360766,Table 1,BaselineCharacteristic,Site of metastasis,Phase I (n=xx) ; ,Site of metastasis,None,17,1,43,no,1:no,1:no,,0.797
1377,2360766,Table 1,BaselineCharacteristic,Site of metastasis,Phase II (n=xx) ; ,Site of metastasis,None,17,2,43,no,1:no,1:no,,0.79
1377,2360766,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver, Site of metastasis,18,0,2,no,1:no,1:no,,0.906
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Liver, Site of metastasis,18,1,3,no,1:no,1:no,,0.776
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Liver, Site of metastasis,18,2,3,no,1:no,1:no,,0.768
1377,2360766,Table 1,BaselineCharacteristic,?Lymph nodes, ; ,?Lymph nodes, Site of metastasis,19,0,2,no,1:no,1:no,,0.887
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase I (n=xx) ; ,?Lymph nodes, Site of metastasis,19,1,3,no,1:no,1:no,,0.722
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase II (n=xx) ; ,?Lymph nodes, Site of metastasis,19,2,3,no,1:no,1:no,,0.709
1377,2360766,Table 1,BaselineCharacteristic,?Peritoneum, ; ,?Peritoneum, Site of metastasis,20,0,2,no,1:no,1:no,,0.887
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Peritoneum, Site of metastasis,20,1,3,no,1:no,1:no,,0.749
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Peritoneum, Site of metastasis,20,2,3,no,1:no,1:no,,0.741
1386,2361170,Table 2,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
1386,2361170,Table 2,BaselineCharacteristic,n,,Characteristics,None,0,1,1,no,1:no,1:no,,0.665
1386,2361170,Table 2,BaselineCharacteristic,Men/women,Characteristics ; ,Men/women,,1,0,2,no,1:no,1:no,,0.785
1386,2361170,Table 2,BaselineCharacteristic,xx/xx,n ; ,Men/women,,1,1,3,yes,2:yes,1:no,+,0.619
1386,2361170,Table 2,BaselineCharacteristic,PS x/x/x,Characteristics ; ,PS x/x/x,,2,0,2,no,1:no,1:no,,0.826
1386,2361170,Table 2,BaselineCharacteristic,xx/xx/x,n ; ,PS x/x/x,,2,1,3,no,1:no,1:no,,0.694
1386,2361170,Table 2,BaselineCharacteristic,LAD/MET,Characteristics ; ,LAD/MET,,3,0,2,no,1:no,1:no,,0.801
1386,2361170,Table 2,BaselineCharacteristic,xx/xx,n ; ,LAD/MET,,3,1,3,no,1:no,1:no,,0.633
1386,2361170,Table 2,BaselineCharacteristic,Adjuvant RT-CT,Characteristics ; ,Adjuvant RT-CT,,4,0,2,no,1:no,1:no,,0.803
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,Adjuvant RT-CT,,4,1,3,no,1:no,1:no,,0.565
1386,2361170,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,5,0,2,no,1:no,1:no,,0.843
1386,2361170,Table 2,BaselineCharacteristic,,n ; ,None,None,5,1,3,no,1:no,1:no,,0.666
1386,2361170,Table 2,BaselineCharacteristic,Prior therapy,Characteristics ; ,None,None,6,0,24,no,1:no,1:no,,0.837
1386,2361170,Table 2,BaselineCharacteristic,Prior therapy,n ; ,Prior therapy,None,6,1,43,no,1:no,1:no,,0.73
1386,2361170,Table 2,BaselineCharacteristic,?RT-CT,Characteristics ; ,?RT-CT, Prior therapy,7,0,2,no,1:no,1:no,,0.826
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,?RT-CT, Prior therapy,7,1,3,no,1:no,1:no,,0.648
1386,2361170,Table 2,BaselineCharacteristic,?GEM,Characteristics ; ,?GEM, Prior therapy,8,0,2,no,1:no,1:no,,0.823
1386,2361170,Table 2,BaselineCharacteristic,xx,n ; ,?GEM, Prior therapy,8,1,3,no,1:no,1:no,,0.646
1386,2361170,Table 2,BaselineCharacteristic,?GEM-PX,Characteristics ; ,?GEM-PX, Prior therapy,9,0,2,no,1:no,1:no,,0.842
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,?GEM-PX, Prior therapy,9,1,3,no,1:no,1:no,,0.676
1386,2361170,Table 2,BaselineCharacteristic,?GEM-CDDP,Characteristics ; ,?GEM-CDDP, Prior therapy,10,0,2,no,1:no,1:no,,0.845
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,?GEM-CDDP, Prior therapy,10,1,3,no,1:no,1:no,,0.691
1386,2361170,Table 2,BaselineCharacteristic,?Ralitrexed-GEM,Characteristics ; ,?Ralitrexed-GEM, Prior therapy,11,0,2,no,1:no,1:no,,0.85
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,?Ralitrexed-GEM, Prior therapy,11,1,3,no,1:no,1:no,,0.692
1388,2361202,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1388,2361202,Table 1,BaselineCharacteristic,Patients,,,None,0,1,1,no,1:no,1:no,,0.723
1388,2361202,Table 1,BaselineCharacteristic,Patients,,,None,0,2,1,no,1:no,1:no,,0.758
1388,2361202,Table 1,BaselineCharacteristic,Characteristic, ; ,None,None,1,0,12,no,1:no,1:no,,0.805
1388,2361202,Table 1,BaselineCharacteristic,No.,Patients ; ,Characteristic,None,1,1,1,no,1:no,1:no,,0.72
1388,2361202,Table 1,BaselineCharacteristic,%,Patients ; ,Characteristic,None,1,2,1,no,1:no,1:no,,0.767
1388,2361202,Table 1,BaselineCharacteristic,Total, ; Characteristic ; ,Total,,2,0,2,no,1:no,1:no,,0.755
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,Total,,2,1,3,no,1:no,2:yes,+,0.653
1388,2361202,Table 1,BaselineCharacteristic,xxx,Patients ; % ; ,Total,,2,2,3,no,1:no,2:yes,+,0.508
1388,2361202,Table 1,BaselineCharacteristic,Male, ; Characteristic ; ,Male,,3,0,2,no,1:no,1:no,,0.737
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,Male,,3,1,3,yes,2:yes,2:yes,,0.736
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,Male,,3,2,3,yes,2:yes,2:yes,,0.737
1388,2361202,Table 1,BaselineCharacteristic,Female, ; Characteristic ; ,Female,,4,0,2,no,1:no,1:no,,0.751
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,Female,,4,1,3,yes,2:yes,2:yes,,0.674
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,Female,,4,2,3,yes,2:yes,2:yes,,0.73
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,5,0,2,no,1:no,1:no,,0.876
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,5,1,3,no,1:no,1:no,,0.712
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,5,2,3,no,1:no,1:no,,0.711
1388,2361202,Table 1,BaselineCharacteristic,Age (years), ; Characteristic ; ,None,None,6,0,24,no,1:no,1:no,,0.862
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,Age (years),None,6,1,43,no,1:no,1:no,,0.79
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,Age (years),None,6,2,43,no,1:no,1:no,,0.795
1388,2361202,Table 1,BaselineCharacteristic,?Median, ; Characteristic ; ,?Median, Age (years),7,0,2,no,1:no,1:no,,0.853
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Median, Age (years),7,1,3,no,1:no,1:no,,0.616
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Median, Age (years),7,2,3,no,1:no,1:no,,0.593
1388,2361202,Table 1,BaselineCharacteristic,?Range, ; Characteristic ; ,?Range, Age (years),8,0,2,no,1:no,1:no,,0.86
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,9,0,2,no,1:no,1:no,,0.891
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,9,1,3,no,1:no,1:no,,0.756
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,9,2,3,no,1:no,1:no,,0.746
1388,2361202,Table 1,BaselineCharacteristic,Disease at time of commencing IRESSA, ; Characteristic ; ,None,None,10,0,24,no,1:no,1:no,,0.872
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,Disease at time of commencing IRESSA,None,10,1,43,no,1:no,1:no,,0.816
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,Disease at time of commencing IRESSA,None,10,2,43,no,1:no,1:no,,0.808
1388,2361202,Table 1,BaselineCharacteristic,?Locally recurrent, ; Characteristic ; ,?Locally recurrent, Disease at time of commencing IRESSA,11,0,2,no,1:no,1:no,,0.866
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Locally recurrent, Disease at time of commencing IRESSA,11,1,3,no,1:no,1:no,,0.636
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Locally recurrent, Disease at time of commencing IRESSA,11,2,3,no,1:no,1:no,,0.64
1388,2361202,Table 1,BaselineCharacteristic,?Metastatica, ; Characteristic ; ,?Metastatica, Disease at time of commencing IRESSA,12,0,2,no,1:no,1:no,,0.872
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Metastatica, Disease at time of commencing IRESSA,12,1,3,no,1:no,1:no,,0.674
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Metastatica, Disease at time of commencing IRESSA,12,2,3,no,1:no,1:no,,0.658
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,13,0,2,no,1:no,1:no,,0.902
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,13,1,3,no,1:no,1:no,,0.788
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,13,2,3,no,1:no,1:no,,0.764
1388,2361202,Table 1,BaselineCharacteristic,Histology, ; Characteristic ; ,None,None,14,0,24,no,1:no,1:no,,0.888
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,Histology,None,14,1,43,no,1:no,1:no,,0.814
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,Histology,None,14,2,43,no,1:no,1:no,,0.788
1388,2361202,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ; Characteristic ; ,?Squamous cell carcinoma, Histology,15,0,2,no,1:no,1:no,,0.911
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Squamous cell carcinoma, Histology,15,1,3,no,1:no,1:no,,0.715
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Squamous cell carcinoma, Histology,15,2,3,no,1:no,1:no,,0.658
1388,2361202,Table 1,BaselineCharacteristic,?UCNTb, ; Characteristic ; ,?UCNTb, Histology,16,0,2,no,1:no,1:no,,0.895
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,?UCNTb, Histology,16,1,3,no,1:no,1:no,,0.723
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; % ; ,?UCNTb, Histology,16,2,3,no,1:no,1:no,,0.708
1388,2361202,Table 1,BaselineCharacteristic,?Carcinosarcoma, ; Characteristic ; ,?Carcinosarcoma, Histology,17,0,2,no,1:no,1:no,,0.907
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,?Carcinosarcoma, Histology,17,1,3,no,1:no,1:no,,0.756
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; % ; ,?Carcinosarcoma, Histology,17,2,3,no,1:no,1:no,,0.751
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,18,0,2,no,1:no,1:no,,0.911
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,18,1,3,no,1:no,1:no,,0.8
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,18,2,3,no,1:no,1:no,,0.784
1388,2361202,Table 1,BaselineCharacteristic,ECOG performance status, ; Characteristic ; ,None,None,19,0,24,no,1:no,1:no,,0.915
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,ECOG performance status,None,19,1,43,no,1:no,1:no,,0.845
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,ECOG performance status,None,19,2,43,no,1:no,1:no,,0.835
1388,2361202,Table 1,BaselineCharacteristic,?x, ; Characteristic ; ,?x, ECOG performance status,20,0,2,no,1:no,1:no,,0.896
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,?x, ECOG performance status,20,1,3,no,1:no,1:no,,0.771
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; % ; ,?x, ECOG performance status,20,2,3,no,1:no,1:no,,0.796
1388,2361202,Table 1,BaselineCharacteristic,?x, ; Characteristic ; ,?x, ECOG performance status,21,0,2,no,1:no,1:no,,0.896
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?x, ECOG performance status,21,1,3,no,1:no,1:no,,0.696
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?x, ECOG performance status,21,2,3,no,1:no,1:no,,0.682
1388,2361202,Table 1,BaselineCharacteristic,?x, ; Characteristic ; ,?x, ECOG performance status,22,0,2,no,1:no,1:no,,0.898
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?x, ECOG performance status,22,1,3,no,1:no,1:no,,0.703
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?x, ECOG performance status,22,2,3,no,1:no,1:no,,0.69
1388,2361202,Table 1,BaselineCharacteristic,?x, ; Characteristic ; ,?x, ECOG performance status,23,0,2,no,1:no,1:no,,0.899
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,?x, ECOG performance status,23,1,3,no,1:no,1:no,,0.779
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; % ; ,?x, ECOG performance status,23,2,3,no,1:no,1:no,,0.806
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,24,0,2,no,1:no,1:no,,0.913
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,24,1,3,no,1:no,1:no,,0.805
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,24,2,3,no,1:no,1:no,,0.792
1388,2361202,Table 1,BaselineCharacteristic,Prior therapy (n=xx), ; Characteristic ; ,None,None,25,0,24,no,1:no,1:no,,0.896
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,Prior therapy (n=xx),None,25,1,43,no,1:no,1:no,,0.809
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,Prior therapy (n=xx),None,25,2,43,no,1:no,1:no,,0.805
1388,2361202,Table 1,BaselineCharacteristic,?Surgery, ; Characteristic ; ,?Surgery, Prior therapy (n=xx),26,0,2,no,1:no,1:no,,0.904
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Surgery, Prior therapy (n=xx),26,1,3,no,1:no,1:no,,0.687
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Surgery, Prior therapy (n=xx),26,2,3,no,1:no,1:no,,0.669
1388,2361202,Table 1,BaselineCharacteristic,?Radiotherapy, ; Characteristic ; ,?Radiotherapy, Prior therapy (n=xx),27,0,24,no,1:no,1:no,,0.874
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Radiotherapy, Prior therapy (n=xx),27,1,43,no,1:no,1:no,,0.646
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Radiotherapy, Prior therapy (n=xx),27,2,43,no,1:no,1:no,,0.658
1388,2361202,Table 1,BaselineCharacteristic,??With chemotherapy, ; Characteristic ; ,??With chemotherapy, Prior therapy (n=xx) ?Radiotherapy,28,0,2,no,1:no,1:no,,0.903
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,??With chemotherapy, Prior therapy (n=xx) ?Radiotherapy,28,1,3,no,1:no,1:no,,0.699
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??With chemotherapy, Prior therapy (n=xx) ?Radiotherapy,28,2,3,no,1:no,1:no,,0.711
1388,2361202,Table 1,BaselineCharacteristic,??Alone (radical or palliative), ; Characteristic ; ,??Alone (radical or palliative), Prior therapy (n=xx) ?Radiotherapy,29,0,2,no,1:no,1:no,,0.9
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,??Alone (radical or palliative), Prior therapy (n=xx) ?Radiotherapy,29,1,3,no,1:no,1:no,,0.678
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??Alone (radical or palliative), Prior therapy (n=xx) ?Radiotherapy,29,2,3,no,1:no,1:no,,0.676
1388,2361202,Table 1,BaselineCharacteristic,?Chemotherapy, ; Characteristic ; ,?Chemotherapy, Prior therapy (n=xx),30,0,24,no,1:no,1:no,,0.879
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Chemotherapy, Prior therapy (n=xx),30,1,43,no,1:no,1:no,,0.679
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Chemotherapy, Prior therapy (n=xx),30,2,43,no,1:no,1:no,,0.705
1388,2361202,Table 1,BaselineCharacteristic,??Radical chemoradiation only, ; Characteristic ; ,??Radical chemoradiation only, Prior therapy (n=xx) ?Chemotherapy,31,0,2,no,1:no,1:no,,0.903
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,??Radical chemoradiation only, Prior therapy (n=xx) ?Chemotherapy,31,1,3,no,1:no,1:no,,0.699
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??Radical chemoradiation only, Prior therapy (n=xx) ?Chemotherapy,31,2,3,no,1:no,1:no,,0.711
1388,2361202,Table 1,BaselineCharacteristic,??Radical chemoradiation and then for recurrence or metastases, ; Characteristic ; ,??Radical chemoradiation and then for recurrence or metastases, Prior therapy (n=xx) ?Chemotherapy,32,0,2,no,1:no,1:no,,0.915
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,??Radical chemoradiation and then for recurrence or metastases, Prior therapy (n=xx) ?Chemotherapy,32,1,3,no,1:no,1:no,,0.769
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??Radical chemoradiation and then for recurrence or metastases, Prior therapy (n=xx) ?Chemotherapy,32,2,3,no,1:no,1:no,,0.741
1388,2361202,Table 1,BaselineCharacteristic,??Only for recurrent disease or metastases, ; Characteristic ; ,??Only for recurrent disease or metastases, Prior therapy (n=xx) ?Chemotherapy,33,0,2,no,1:no,1:no,,0.902
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,??Only for recurrent disease or metastases, Prior therapy (n=xx) ?Chemotherapy,33,1,3,no,1:no,1:no,,0.755
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??Only for recurrent disease or metastases, Prior therapy (n=xx) ?Chemotherapy,33,2,3,no,1:no,1:no,,0.725
1424,2361402,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1424,2361402,Table 2,BaselineCharacteristic,Phase I,,,None,0,1,1,no,1:no,1:no,,0.702
1424,2361402,Table 2,BaselineCharacteristic,Phase II,,,None,0,2,1,no,1:no,1:no,,0.725
1424,2361402,Table 2,BaselineCharacteristic,Total,,,None,0,3,1,no,1:no,1:no,,0.691
1424,2361402,Table 2,BaselineCharacteristic,No. patients entered, ; ,No. patients entered,,1,0,2,no,1:no,1:no,,0.705
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase I ; ,No. patients entered,,1,1,3,no,1:no,2:yes,+,0.592
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,No. patients entered,,1,2,3,no,1:no,2:yes,+,0.6
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,No. patients entered,,1,3,3,no,1:no,2:yes,+,0.645
1424,2361402,Table 2,BaselineCharacteristic,Median age (years) (range), ; ,Median age (years) (range),,2,0,2,no,1:no,1:no,,0.847
1424,2361402,Table 2,BaselineCharacteristic,, ; ,None,None,3,0,2,no,1:no,1:no,,0.84
1424,2361402,Table 2,BaselineCharacteristic,,Phase I ; ,None,None,3,1,3,no,1:no,1:no,,0.679
1424,2361402,Table 2,BaselineCharacteristic,,Phase II ; ,None,None,3,2,3,no,1:no,1:no,,0.703
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,None,None,3,3,3,no,1:no,1:no,,0.669
1424,2361402,Table 2,BaselineCharacteristic,Gender, ; ,None,None,4,0,24,no,1:no,1:no,,0.72
1424,2361402,Table 2,BaselineCharacteristic,Gender,Phase I ; ,Gender,None,4,1,43,no,1:no,1:no,,0.608
1424,2361402,Table 2,BaselineCharacteristic,Gender,Phase II ; ,Gender,None,4,2,43,no,1:no,1:no,,0.625
1424,2361402,Table 2,BaselineCharacteristic,Gender,Total ; ,Gender,None,4,3,43,no,1:no,1:no,,0.594
1424,2361402,Table 2,BaselineCharacteristic,?Male, ; ,?Male, Gender,5,0,2,no,1:no,1:no,,0.694
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase I ; ,?Male, Gender,5,1,3,yes,2:yes,2:yes,,0.701
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,?Male, Gender,5,2,3,yes,2:yes,2:yes,,0.711
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,?Male, Gender,5,3,3,yes,2:yes,2:yes,,0.727
1424,2361402,Table 2,BaselineCharacteristic,?Female, ; ,?Female, Gender,6,0,2,no,1:no,1:no,,0.705
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?Female, Gender,6,1,3,yes,2:yes,2:yes,,0.539
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?Female, Gender,6,2,3,yes,2:yes,2:yes,,0.537
1424,2361402,Table 2,BaselineCharacteristic,x,Total ; ,?Female, Gender,6,3,3,yes,2:yes,2:yes,,0.552
1424,2361402,Table 2,BaselineCharacteristic,, ; ,None,None,7,0,2,no,1:no,1:no,,0.869
1424,2361402,Table 2,BaselineCharacteristic,,Phase I ; ,None,None,7,1,3,no,1:no,1:no,,0.708
1424,2361402,Table 2,BaselineCharacteristic,,Phase II ; ,None,None,7,2,3,no,1:no,1:no,,0.726
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,None,None,7,3,3,no,1:no,1:no,,0.689
1424,2361402,Table 2,BaselineCharacteristic,ECOG PS, ; ,None,None,8,0,24,no,1:no,1:no,,0.871
1424,2361402,Table 2,BaselineCharacteristic,ECOG PS,Phase I ; ,ECOG PS,None,8,1,43,no,1:no,1:no,,0.764
1424,2361402,Table 2,BaselineCharacteristic,ECOG PS,Phase II ; ,ECOG PS,None,8,2,43,no,1:no,1:no,,0.77
1424,2361402,Table 2,BaselineCharacteristic,ECOG PS,Total ; ,ECOG PS,None,8,3,43,no,1:no,1:no,,0.734
1424,2361402,Table 2,BaselineCharacteristic,?x, ; ,?x, ECOG PS,9,0,2,no,1:no,1:no,,0.858
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?x, ECOG PS,9,1,3,no,1:no,1:no,,0.708
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,?x, ECOG PS,9,2,3,no,1:no,1:no,,0.67
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,?x, ECOG PS,9,3,3,no,1:no,1:no,,0.641
1424,2361402,Table 2,BaselineCharacteristic,?x, ; ,?x, ECOG PS,10,0,2,no,1:no,1:no,,0.868
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?x, ECOG PS,10,1,3,no,1:no,1:no,,0.728
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?x, ECOG PS,10,2,3,no,1:no,1:no,,0.73
1424,2361402,Table 2,BaselineCharacteristic,x,Total ; ,?x, ECOG PS,10,3,3,no,1:no,1:no,,0.729
1424,2361402,Table 2,BaselineCharacteristic,?x, ; ,?x, ECOG PS,11,0,2,no,1:no,1:no,,0.869
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?x, ECOG PS,11,1,3,no,1:no,1:no,,0.733
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?x, ECOG PS,11,2,3,no,1:no,1:no,,0.735
1424,2361402,Table 2,BaselineCharacteristic,x,Total ; ,?x, ECOG PS,11,3,3,no,1:no,1:no,,0.738
1424,2361402,Table 2,BaselineCharacteristic,Baseline LVEF (median), ; ,Baseline LVEF (median),,12,0,2,no,1:no,1:no,,0.878
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,Baseline LVEF (median),,12,3,3,no,1:no,1:no,,0.74
1424,2361402,Table 2,BaselineCharacteristic,, ; ,None,None,13,0,2,no,1:no,1:no,,0.892
1424,2361402,Table 2,BaselineCharacteristic,,Phase I ; ,None,None,13,1,3,no,1:no,1:no,,0.762
1424,2361402,Table 2,BaselineCharacteristic,,Phase II ; ,None,None,13,2,3,no,1:no,1:no,,0.762
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,None,None,13,3,3,no,1:no,1:no,,0.724
1424,2361402,Table 2,BaselineCharacteristic,Dominant site of disease, ; ,None,None,14,0,24,no,1:no,1:no,,0.871
1424,2361402,Table 2,BaselineCharacteristic,Dominant site of disease,Phase I ; ,Dominant site of disease,None,14,1,43,no,1:no,1:no,,0.793
1424,2361402,Table 2,BaselineCharacteristic,Dominant site of disease,Phase II ; ,Dominant site of disease,None,14,2,43,no,1:no,1:no,,0.78
1424,2361402,Table 2,BaselineCharacteristic,Dominant site of disease,Total ; ,Dominant site of disease,None,14,3,43,no,1:no,1:no,,0.747
1424,2361402,Table 2,BaselineCharacteristic,?Viscera, ; ,?Viscera, Dominant site of disease,15,0,2,no,1:no,1:no,,0.86
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase I ; ,?Viscera, Dominant site of disease,15,1,3,no,1:no,1:no,,0.695
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?Viscera, Dominant site of disease,15,2,3,no,1:no,1:no,,0.735
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,?Viscera, Dominant site of disease,15,3,3,no,1:no,1:no,,0.631
1424,2361402,Table 2,BaselineCharacteristic,?Soft tissue/bone, ; ,?Soft tissue/bone, Dominant site of disease,16,0,2,no,1:no,1:no,,0.861
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?Soft tissue/bone, Dominant site of disease,16,1,3,no,1:no,1:no,,0.739
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,?Soft tissue/bone, Dominant site of disease,16,2,3,no,1:no,1:no,,0.675
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,?Soft tissue/bone, Dominant site of disease,16,3,3,no,1:no,1:no,,0.631
1424,2361402,Table 2,BaselineCharacteristic,, ; ,None,None,17,0,2,no,1:no,1:no,,0.9
1424,2361402,Table 2,BaselineCharacteristic,,Phase I ; ,None,None,17,1,3,no,1:no,1:no,,0.776
1424,2361402,Table 2,BaselineCharacteristic,,Phase II ; ,None,None,17,2,3,no,1:no,1:no,,0.773
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,None,None,17,3,3,no,1:no,1:no,,0.735
1424,2361402,Table 2,BaselineCharacteristic,Number of metastatic sites, ; ,None,None,18,0,24,no,1:no,1:no,,0.903
1424,2361402,Table 2,BaselineCharacteristic,Number of metastatic sites,Phase I ; ,Number of metastatic sites,None,18,1,43,no,1:no,1:no,,0.834
1424,2361402,Table 2,BaselineCharacteristic,Number of metastatic sites,Phase II ; ,Number of metastatic sites,None,18,2,43,no,1:no,1:no,,0.824
1424,2361402,Table 2,BaselineCharacteristic,Number of metastatic sites,Total ; ,Number of metastatic sites,None,18,3,43,no,1:no,1:no,,0.807
1424,2361402,Table 2,BaselineCharacteristic,?x, ; ,?x, Number of metastatic sites,19,0,2,no,1:no,1:no,,0.867
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?x, Number of metastatic sites,19,1,3,no,1:no,1:no,,0.799
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?x, Number of metastatic sites,19,2,3,no,1:no,1:no,,0.787
1424,2361402,Table 2,BaselineCharacteristic,x,Total ; ,?x, Number of metastatic sites,19,3,3,no,1:no,1:no,,0.79
1424,2361402,Table 2,BaselineCharacteristic,??x, ; ,??x, Number of metastatic sites,20,0,2,no,1:no,1:no,,0.868
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,??x, Number of metastatic sites,20,1,3,no,1:no,1:no,,0.8
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,??x, Number of metastatic sites,20,2,3,no,1:no,1:no,,0.764
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,??x, Number of metastatic sites,20,3,3,no,1:no,1:no,,0.752
1433,2361449,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
1433,2361449,Table 1,BaselineCharacteristic,No.,,Characteristic,None,0,1,1,no,1:no,1:no,,0.777
1433,2361449,Table 1,BaselineCharacteristic,%,,Characteristic,None,0,2,1,no,1:no,1:no,,0.776
1433,2361449,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,1,0,24,no,1:no,1:no,,0.845
1433,2361449,Table 1,BaselineCharacteristic,Age (years),No. ; ,Age (years),None,1,1,43,no,1:no,1:no,,0.766
1433,2361449,Table 1,BaselineCharacteristic,Age (years),% ; ,Age (years),None,1,2,43,no,1:no,1:no,,0.783
1433,2361449,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),2,0,2,no,1:no,1:no,,0.858
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Median, Age (years),2,1,3,no,1:no,1:no,,0.621
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,?Median, Age (years),2,2,3,no,1:no,1:no,,0.738
1433,2361449,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),3,0,2,no,1:no,1:no,,0.837
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,?Range, Age (years),3,2,3,no,1:no,1:no,,0.722
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,no,1:no,1:no,,0.869
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,4,1,3,no,1:no,1:no,,0.685
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,4,2,3,no,1:no,1:no,,0.701
1433,2361449,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,5,0,24,no,1:no,1:no,,0.633
1433,2361449,Table 1,BaselineCharacteristic,Sex,No. ; ,Sex,None,5,1,43,no,1:no,1:no,,0.527
1433,2361449,Table 1,BaselineCharacteristic,Sex,% ; ,Sex,None,5,2,43,no,1:no,1:no,,0.532
1433,2361449,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Sex,6,0,2,no,1:no,1:no,,0.53
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Male, Sex,6,1,3,yes,2:yes,2:yes,,0.812
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Male, Sex,6,2,3,yes,2:yes,2:yes,,0.84
1433,2361449,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Sex,7,0,2,no,1:no,1:no,,0.556
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Female, Sex,7,1,3,yes,2:yes,2:yes,,0.778
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Female, Sex,7,2,3,yes,2:yes,2:yes,,0.838
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,8,0,2,no,1:no,1:no,,0.883
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,8,1,3,no,1:no,1:no,,0.755
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,8,2,3,no,1:no,1:no,,0.726
1433,2361449,Table 1,BaselineCharacteristic,ECOG performance status,Characteristic ; ,None,None,9,0,24,no,1:no,1:no,,0.895
1433,2361449,Table 1,BaselineCharacteristic,ECOG performance status,No. ; ,ECOG performance status,None,9,1,43,no,1:no,1:no,,0.803
1433,2361449,Table 1,BaselineCharacteristic,ECOG performance status,% ; ,ECOG performance status,None,9,2,43,no,1:no,1:no,,0.791
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,10,0,2,no,1:no,1:no,,0.875
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?x, ECOG performance status,10,1,3,no,1:no,1:no,,0.705
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,10,2,3,no,1:no,1:no,,0.643
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,11,0,2,no,1:no,1:no,,0.876
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?x, ECOG performance status,11,1,3,no,1:no,1:no,,0.682
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,11,2,3,no,1:no,1:no,,0.656
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,12,0,2,no,1:no,1:no,,0.876
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?x, ECOG performance status,12,1,3,no,1:no,1:no,,0.725
1433,2361449,Table 1,BaselineCharacteristic,x.x,% ; ,?x, ECOG performance status,12,2,3,no,1:no,1:no,,0.752
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,13,0,2,no,1:no,1:no,,0.902
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,13,1,3,no,1:no,1:no,,0.795
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,13,2,3,no,1:no,1:no,,0.76
1433,2361449,Table 1,BaselineCharacteristic,Extent of disease,Characteristic ; ,None,None,14,0,24,no,1:no,1:no,,0.88
1433,2361449,Table 1,BaselineCharacteristic,Extent of disease,No. ; ,Extent of disease,None,14,1,43,no,1:no,1:no,,0.824
1433,2361449,Table 1,BaselineCharacteristic,Extent of disease,% ; ,Extent of disease,None,14,2,43,no,1:no,1:no,,0.817
1433,2361449,Table 1,BaselineCharacteristic,?Relapsed,Characteristic ; ,?Relapsed, Extent of disease,15,0,2,no,1:no,1:no,,0.87
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Relapsed, Extent of disease,15,1,3,no,1:no,1:no,,0.69
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Relapsed, Extent of disease,15,2,3,no,1:no,1:no,,0.646
1433,2361449,Table 1,BaselineCharacteristic,?Initially metastatic,Characteristic ; ,?Initially metastatic, Extent of disease,16,0,2,no,1:no,1:no,,0.879
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Initially metastatic, Extent of disease,16,1,3,no,1:no,1:no,,0.727
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Initially metastatic, Extent of disease,16,2,3,no,1:no,1:no,,0.681
1433,2361449,Table 1,BaselineCharacteristic,?Initially locally advanced,Characteristic ; ,?Initially locally advanced, Extent of disease,17,0,2,no,1:no,1:no,,0.883
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Initially locally advanced, Extent of disease,17,1,3,no,1:no,1:no,,0.769
1433,2361449,Table 1,BaselineCharacteristic,x.x,% ; ,?Initially locally advanced, Extent of disease,17,2,3,no,1:no,1:no,,0.763
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,18,0,2,no,1:no,1:no,,0.911
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,18,1,3,no,1:no,1:no,,0.815
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,18,2,3,no,1:no,1:no,,0.777
1433,2361449,Table 1,BaselineCharacteristic,Prior adjuvant chemotherapy,Characteristic ; ,None,None,19,0,24,no,1:no,1:no,,0.909
1433,2361449,Table 1,BaselineCharacteristic,Prior adjuvant chemotherapy,No. ; ,Prior adjuvant chemotherapy,None,19,1,43,no,1:no,1:no,,0.842
1433,2361449,Table 1,BaselineCharacteristic,Prior adjuvant chemotherapy,% ; ,Prior adjuvant chemotherapy,None,19,2,43,no,1:no,1:no,,0.831
1433,2361449,Table 1,BaselineCharacteristic,?Yes,Characteristic ; ,?Yes, Prior adjuvant chemotherapy,20,0,24,no,1:no,1:no,,0.895
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Yes, Prior adjuvant chemotherapy,20,1,43,no,1:no,1:no,,0.734
1433,2361449,Table 1,BaselineCharacteristic,xx,% ; ,?Yes, Prior adjuvant chemotherapy,20,2,43,no,1:no,1:no,,0.73
1433,2361449,Table 1,BaselineCharacteristic,??x-FU+doxorubicin+mitomycin-C,Characteristic ; ,??x-FU+doxorubicin+mitomycin-C, Prior adjuvant chemotherapy ?Yes,21,0,2,no,1:no,1:no,,0.916
1433,2361449,Table 1,BaselineCharacteristic,?x,No. ; ,??x-FU+doxorubicin+mitomycin-C, Prior adjuvant chemotherapy ?Yes,21,1,3,no,1:no,1:no,,0.743
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,??x-FU+doxorubicin+mitomycin-C, Prior adjuvant chemotherapy ?Yes,21,2,3,no,1:no,1:no,,0.818
1433,2361449,Table 1,BaselineCharacteristic,??x-FU or doxifluridine+cisplatin,Characteristic ; ,??x-FU or doxifluridine+cisplatin, Prior adjuvant chemotherapy ?Yes,22,0,2,no,1:no,1:no,,0.918
1433,2361449,Table 1,BaselineCharacteristic,?x,No. ; ,??x-FU or doxifluridine+cisplatin, Prior adjuvant chemotherapy ?Yes,22,1,3,no,1:no,1:no,,0.765
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,??x-FU or doxifluridine+cisplatin, Prior adjuvant chemotherapy ?Yes,22,2,3,no,1:no,1:no,,0.821
1433,2361449,Table 1,BaselineCharacteristic,??Doxifluridine+mitomycin-C,Characteristic ; ,??Doxifluridine+mitomycin-C, Prior adjuvant chemotherapy ?Yes,23,0,2,no,1:no,1:no,,0.919
1433,2361449,Table 1,BaselineCharacteristic,?x,No. ; ,??Doxifluridine+mitomycin-C, Prior adjuvant chemotherapy ?Yes,23,1,3,no,1:no,1:no,,0.751
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,??Doxifluridine+mitomycin-C, Prior adjuvant chemotherapy ?Yes,23,2,3,no,1:no,1:no,,0.823
1433,2361449,Table 1,BaselineCharacteristic,?No,Characteristic ; ,?No, Prior adjuvant chemotherapy,24,0,2,no,1:no,1:no,,0.889
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?No, Prior adjuvant chemotherapy,24,1,3,no,1:no,1:no,,0.752
1433,2361449,Table 1,BaselineCharacteristic,xx,% ; ,?No, Prior adjuvant chemotherapy,24,2,3,no,1:no,1:no,,0.713
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,25,0,2,no,1:no,1:no,,0.913
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,25,1,3,no,1:no,1:no,,0.82
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,25,2,3,no,1:no,1:no,,0.792
1433,2361449,Table 1,BaselineCharacteristic,Metastatic sites,Characteristic ; ,None,None,26,0,24,no,1:no,1:no,,0.917
1433,2361449,Table 1,BaselineCharacteristic,Metastatic sites,No. ; ,Metastatic sites,None,26,1,43,no,1:no,1:no,,0.874
1433,2361449,Table 1,BaselineCharacteristic,Metastatic sites,% ; ,Metastatic sites,None,26,2,43,no,1:no,1:no,,0.856
1433,2361449,Table 1,BaselineCharacteristic,?Abdominal lymph node,Characteristic ; ,?Abdominal lymph node, Metastatic sites,27,0,2,no,1:no,1:no,,0.919
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Abdominal lymph node, Metastatic sites,27,1,3,no,1:no,1:no,,0.762
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Abdominal lymph node, Metastatic sites,27,2,3,no,1:no,1:no,,0.736
1433,2361449,Table 1,BaselineCharacteristic,?Liver,Characteristic ; ,?Liver, Metastatic sites,28,0,2,no,1:no,1:no,,0.925
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Liver, Metastatic sites,28,1,3,no,1:no,1:no,,0.785
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Liver, Metastatic sites,28,2,3,no,1:no,1:no,,0.754
1433,2361449,Table 1,BaselineCharacteristic,?Peritoneum,Characteristic ; ,?Peritoneum, Metastatic sites,29,0,2,no,1:no,1:no,,0.919
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Peritoneum, Metastatic sites,29,1,3,no,1:no,1:no,,0.762
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Peritoneum, Metastatic sites,29,2,3,no,1:no,1:no,,0.736
1433,2361449,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?Lung, Metastatic sites,30,0,2,no,1:no,1:no,,0.919
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Lung, Metastatic sites,30,1,3,no,1:no,1:no,,0.797
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Lung, Metastatic sites,30,2,3,no,1:no,1:no,,0.736
1433,2361449,Table 1,BaselineCharacteristic,?Cervical lymph node,Characteristic ; ,?Cervical lymph node, Metastatic sites,31,0,2,no,1:no,1:no,,0.919
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Cervical lymph node, Metastatic sites,31,1,3,no,1:no,1:no,,0.797
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Cervical lymph node, Metastatic sites,31,2,3,no,1:no,1:no,,0.736
1433,2361449,Table 1,BaselineCharacteristic,?Ovary,Characteristic ; ,?Ovary, Metastatic sites,32,0,2,no,1:no,1:no,,0.919
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Ovary, Metastatic sites,32,1,3,no,1:no,1:no,,0.797
1433,2361449,Table 1,BaselineCharacteristic,x.x,% ; ,?Ovary, Metastatic sites,32,2,3,no,1:no,1:no,,0.816
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,33,0,2,no,1:no,1:no,,0.913
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,33,1,3,no,1:no,1:no,,0.82
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,33,2,3,no,1:no,1:no,,0.792
1433,2361449,Table 1,BaselineCharacteristic,No. of metastases,Characteristic ; ,None,None,34,0,24,no,1:no,1:no,,0.907
1433,2361449,Table 1,BaselineCharacteristic,No. of metastases,No. ; ,No. of metastases,None,34,1,43,no,1:no,1:no,,0.865
1433,2361449,Table 1,BaselineCharacteristic,No. of metastases,% ; ,No. of metastases,None,34,2,43,no,1:no,1:no,,0.823
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, No. of metastases,35,0,2,no,1:no,1:no,,0.841
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?x, No. of metastases,35,1,3,no,1:no,1:no,,0.759
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, No. of metastases,35,2,3,no,1:no,1:no,,0.683
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, No. of metastases,36,0,2,no,1:no,1:no,,0.841
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?x, No. of metastases,36,1,3,no,1:no,1:no,,0.759
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, No. of metastases,36,2,3,no,1:no,1:no,,0.683
1433,2361449,Table 1,BaselineCharacteristic,??x,Characteristic ; ,??x, No. of metastases,37,0,2,no,1:no,1:no,,0.841
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,??x, No. of metastases,37,1,3,no,1:no,1:no,,0.759
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,??x, No. of metastases,37,2,3,no,1:no,1:no,,0.683
1437,2361475,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
1437,2361475,Table 1,BaselineCharacteristic,No. of patients,,Characteristics,None,0,1,1,no,1:no,1:no,,0.767
1437,2361475,Table 1,BaselineCharacteristic,"Median age (range), years",Characteristics ; ,"Median age (range), years",,1,0,2,no,1:no,1:no,,0.823
1437,2361475,Table 1,BaselineCharacteristic,Male/female (%),Characteristics ; ,Male/female (%),,2,0,2,no,1:no,1:no,,0.739
1437,2361475,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x),No. of patients ; ,Male/female (%),,2,1,3,yes,2:yes,2:yes,,0.554
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,3,0,2,no,1:no,1:no,,0.831
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,3,1,3,no,1:no,1:no,,0.718
1437,2361475,Table 1,BaselineCharacteristic,KPS (%),Characteristics ; ,None,None,4,0,24,no,1:no,1:no,,0.756
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,KPS (%),None,4,1,43,no,1:no,1:no,,0.733
1437,2361475,Table 1,BaselineCharacteristic,?xxx,Characteristics ; ,?xxx, KPS (%),5,0,2,no,1:no,1:no,,0.662
1437,2361475,Table 1,BaselineCharacteristic,xx (xx.x),No. of patients ; ,?xxx, KPS (%),5,1,3,no,1:no,2:yes,+,0.58
1437,2361475,Table 1,BaselineCharacteristic,?xx,Characteristics ; ,?xx, KPS (%),7,0,2,no,1:no,1:no,,0.591
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?xx, KPS (%),7,1,3,no,1:no,2:yes,+,0.536
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,8,0,2,no,1:no,1:no,,0.847
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,8,1,3,no,1:no,1:no,,0.813
1437,2361475,Table 1,BaselineCharacteristic,Stage IIIB/IV (%),Characteristics ; ,Stage IIIB/IV (%),,9,0,2,no,1:no,1:no,,0.794
1437,2361475,Table 1,BaselineCharacteristic,x (xx.x)/xx (xx.x),No. of patients ; ,Stage IIIB/IV (%),,9,1,3,no,1:no,1:no,,0.607
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,10,0,2,no,1:no,1:no,,0.862
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,10,1,3,no,1:no,1:no,,0.825
1437,2361475,Table 1,BaselineCharacteristic,Sites of metastasis,Characteristics ; ,None,None,11,0,24,no,1:no,1:no,,0.872
1437,2361475,Table 1,BaselineCharacteristic,Sites of metastasis,No. of patients ; ,Sites of metastasis,None,11,1,43,no,1:no,1:no,,0.876
1437,2361475,Table 1,BaselineCharacteristic,?Liver,Characteristics ; ,?Liver, Sites of metastasis,12,0,2,no,1:no,1:no,,0.871
1437,2361475,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Liver, Sites of metastasis,12,1,3,no,1:no,1:no,,0.789
1437,2361475,Table 1,BaselineCharacteristic,?Brain,Characteristics ; ,?Brain, Sites of metastasis,13,0,2,no,1:no,1:no,,0.847
1437,2361475,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Brain, Sites of metastasis,13,1,3,no,1:no,1:no,,0.782
1437,2361475,Table 1,BaselineCharacteristic,?Bone,Characteristics ; ,?Bone, Sites of metastasis,14,0,2,no,1:no,1:no,,0.843
1437,2361475,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Bone, Sites of metastasis,14,1,3,no,1:no,1:no,,0.787
1437,2361475,Table 1,BaselineCharacteristic,?Nodes,Characteristics ; ,?Nodes, Sites of metastasis,15,0,2,no,1:no,1:no,,0.848
1437,2361475,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Nodes, Sites of metastasis,15,1,3,no,1:no,1:no,,0.706
1437,2361475,Table 1,BaselineCharacteristic,?Others,Characteristics ; ,?Others, Sites of metastasis,16,0,2,no,1:no,1:no,,0.849
1437,2361475,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Others, Sites of metastasis,16,1,3,no,1:no,1:no,,0.706
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,17,0,2,no,1:no,1:no,,0.873
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,17,1,3,no,1:no,1:no,,0.86
1437,2361475,Table 1,BaselineCharacteristic,No. of metastatic sites,Characteristics ; ,None,None,18,0,24,no,1:no,1:no,,0.897
1437,2361475,Table 1,BaselineCharacteristic,No. of metastatic sites,No. of patients ; ,No. of metastatic sites,None,18,1,43,no,1:no,1:no,,0.914
1437,2361475,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, No. of metastatic sites,19,0,2,no,1:no,1:no,,0.832
1437,2361475,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, No. of metastatic sites,19,1,3,no,1:no,1:no,,0.749
1437,2361475,Table 1,BaselineCharacteristic,??x,Characteristics ; ,??x, No. of metastatic sites,20,0,2,no,1:no,1:no,,0.832
1437,2361475,Table 1,BaselineCharacteristic,xx,No. of patients ; ,??x, No. of metastatic sites,20,1,3,no,1:no,1:no,,0.749
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,21,0,2,no,1:no,1:no,,0.875
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,21,1,3,no,1:no,1:no,,0.862
1437,2361475,Table 1,BaselineCharacteristic,Histology (%),Characteristics ; ,None,None,22,0,24,no,1:no,1:no,,0.82
1437,2361475,Table 1,BaselineCharacteristic,Histology (%),No. of patients ; ,Histology (%),None,22,1,43,no,1:no,1:no,,0.834
1437,2361475,Table 1,BaselineCharacteristic,?Adenocarcinoma,Characteristics ; ,?Adenocarcinoma, Histology (%),23,0,2,no,1:no,1:no,,0.831
1437,2361475,Table 1,BaselineCharacteristic,xx (xx.x),No. of patients ; ,?Adenocarcinoma, Histology (%),23,1,3,no,1:no,1:no,,0.679
1437,2361475,Table 1,BaselineCharacteristic,?Squamous,Characteristics ; ,?Squamous, Histology (%),24,0,2,no,1:no,1:no,,0.834
1437,2361475,Table 1,BaselineCharacteristic,xx (xx.x),No. of patients ; ,?Squamous, Histology (%),24,1,3,no,1:no,1:no,,0.694
1437,2361475,Table 1,BaselineCharacteristic,?Bronchioloalveolar,Characteristics ; ,?Bronchioloalveolar, Histology (%),25,0,2,no,1:no,1:no,,0.832
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?Bronchioloalveolar, Histology (%),25,1,3,no,1:no,1:no,,0.753
1437,2361475,Table 1,BaselineCharacteristic,?Undifferentiated,Characteristics ; ,?Undifferentiated, Histology (%),26,0,2,no,1:no,1:no,,0.832
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?Undifferentiated, Histology (%),26,1,3,no,1:no,1:no,,0.753
1437,2361475,Table 1,BaselineCharacteristic,?Other NSCLC,Characteristics ; ,?Other NSCLC, Histology (%),27,0,2,no,1:no,1:no,,0.833
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?Other NSCLC, Histology (%),27,1,3,no,1:no,1:no,,0.753
1437,2361475,Table 1,BaselineCharacteristic,?Unknown,Characteristics ; ,?Unknown, Histology (%),28,0,2,no,1:no,1:no,,0.832
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?Unknown, Histology (%),28,1,3,no,1:no,1:no,,0.753
1443,2361496,Table 2,BaselineCharacteristic,Median age (range),,None,None,0,0,12,no,1:no,1:no,,0.833
1443,2361496,Table 2,BaselineCharacteristic,Male?:?female,,None,None,1,0,12,no,1:no,1:no,,0.573
1443,2361496,Table 2,BaselineCharacteristic,xx?:?x,,Male?:?female,None,1,1,1,yes,2:yes,2:yes,,0.658
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,2,0,2,no,1:no,1:no,,0.842
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,2,1,3,no,1:no,1:no,,0.719
1443,2361496,Table 2,BaselineCharacteristic,Performance status,,None,None,3,0,24,no,1:no,1:no,,0.832
1443,2361496,Table 2,BaselineCharacteristic,Performance status,,Performance status,None,3,1,43,no,1:no,1:no,,0.76
1443,2361496,Table 2,BaselineCharacteristic,?x,,?x, Performance status,4,0,2,no,1:no,1:no,,0.827
1443,2361496,Table 2,BaselineCharacteristic,xx,,?x, Performance status,4,1,3,no,1:no,1:no,,0.627
1443,2361496,Table 2,BaselineCharacteristic,?x,,?x, Performance status,5,0,2,no,1:no,1:no,,0.837
1443,2361496,Table 2,BaselineCharacteristic,xx,,?x, Performance status,5,1,3,no,1:no,1:no,,0.654
1443,2361496,Table 2,BaselineCharacteristic,?x,,?x, Performance status,6,0,2,no,1:no,1:no,,0.837
1443,2361496,Table 2,BaselineCharacteristic,x,,?x, Performance status,6,1,3,no,1:no,1:no,,0.755
1443,2361496,Table 2,BaselineCharacteristic,?Unrecorded,,?Unrecorded, Performance status,7,0,2,no,1:no,1:no,,0.875
1443,2361496,Table 2,BaselineCharacteristic,x,,?Unrecorded, Performance status,7,1,3,no,1:no,1:no,,0.757
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,8,0,2,no,1:no,1:no,,0.873
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,8,1,3,no,1:no,1:no,,0.774
1443,2361496,Table 2,BaselineCharacteristic,Histology,,None,None,9,0,24,no,1:no,1:no,,0.867
1443,2361496,Table 2,BaselineCharacteristic,Histology,,Histology,None,9,1,43,no,1:no,1:no,,0.802
1443,2361496,Table 2,BaselineCharacteristic,?Squamous,,?Squamous, Histology,10,0,2,no,1:no,1:no,,0.877
1443,2361496,Table 2,BaselineCharacteristic,xx,,?Squamous, Histology,10,1,3,no,1:no,1:no,,0.691
1443,2361496,Table 2,BaselineCharacteristic,?Adeno,,?Adeno, Histology,11,0,2,no,1:no,1:no,,0.876
1443,2361496,Table 2,BaselineCharacteristic,xx,,?Adeno, Histology,11,1,3,no,1:no,1:no,,0.707
1443,2361496,Table 2,BaselineCharacteristic,?Mixed,,?Mixed, Histology,12,0,2,no,1:no,1:no,,0.882
1443,2361496,Table 2,BaselineCharacteristic,x,,?Mixed, Histology,12,1,3,no,1:no,1:no,,0.779
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,13,0,2,no,1:no,1:no,,0.892
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,13,1,3,no,1:no,1:no,,0.813
1443,2361496,Table 2,BaselineCharacteristic,Stage,,None,None,14,0,24,no,1:no,1:no,,0.885
1443,2361496,Table 2,BaselineCharacteristic,Stage,,Stage,None,14,1,43,no,1:no,1:no,,0.846
1443,2361496,Table 2,BaselineCharacteristic,?Locally advanced,,?Locally advanced, Stage,15,0,2,no,1:no,1:no,,0.892
1443,2361496,Table 2,BaselineCharacteristic,x,,?Locally advanced, Stage,15,1,3,no,1:no,1:no,,0.776
1443,2361496,Table 2,BaselineCharacteristic,?Metastatic,,?Metastatic, Stage,16,0,2,no,1:no,1:no,,0.897
1443,2361496,Table 2,BaselineCharacteristic,xx,,?Metastatic, Stage,16,1,3,no,1:no,1:no,,0.783
1762,2364769,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1762,2364769,Table 1,BaselineCharacteristic,Interferon,,,None,0,1,1,no,1:no,1:no,,0.735
1762,2364769,Table 1,BaselineCharacteristic,Observation,,,None,0,2,1,no,1:no,1:no,,0.775
1762,2364769,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no,1:no,1:no,,0.792
1762,2364769,Table 1,BaselineCharacteristic,(n=xxx),Interferon ; ,,None,1,1,1,no,1:no,1:no,,0.716
1762,2364769,Table 1,BaselineCharacteristic,(n=xxx),Observation ; ,,None,1,2,1,no,1:no,1:no,,0.756
1762,2364769,Table 1,BaselineCharacteristic,Median (range) age at diagnosis (years), ;  ; ,Median (range) age at diagnosis (years),,2,0,2,no,1:no,1:no,,0.873
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,3,0,2,no,1:no,1:no,,0.84
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,3,1,3,no,1:no,1:no,,0.711
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,3,2,3,no,1:no,1:no,,0.753
1762,2364769,Table 1,BaselineCharacteristic,FIGO stage at diagnosis, ;  ; ,None,None,4,0,24,no,1:no,1:no,,0.897
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,FIGO stage at diagnosis,None,4,1,43,no,1:no,1:no,,0.858
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,FIGO stage at diagnosis,None,4,2,43,no,1:no,1:no,,0.879
1762,2364769,Table 1,BaselineCharacteristic,?I, ;  ; ,?I, FIGO stage at diagnosis,5,0,2,no,1:no,1:no,,0.896
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Interferon ; (n=xxx) ; ,?I, FIGO stage at diagnosis,5,1,3,no,1:no,1:no,,0.727
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Observation ; (n=xxx) ; ,?I, FIGO stage at diagnosis,5,2,3,no,1:no,1:no,,0.735
1762,2364769,Table 1,BaselineCharacteristic,?II, ;  ; ,?II, FIGO stage at diagnosis,6,0,2,no,1:no,1:no,,0.897
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?II, FIGO stage at diagnosis,6,1,3,no,1:no,1:no,,0.719
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?II, FIGO stage at diagnosis,6,2,3,no,1:no,1:no,,0.726
1762,2364769,Table 1,BaselineCharacteristic,?III, ;  ; ,?III, FIGO stage at diagnosis,7,0,2,no,1:no,1:no,,0.897
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?III, FIGO stage at diagnosis,7,1,3,no,1:no,1:no,,0.722
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?III, FIGO stage at diagnosis,7,2,3,no,1:no,1:no,,0.729
1762,2364769,Table 1,BaselineCharacteristic,?IV, ;  ; ,?IV, FIGO stage at diagnosis,8,0,2,no,1:no,1:no,,0.899
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?IV, FIGO stage at diagnosis,8,1,3,no,1:no,1:no,,0.765
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?IV, FIGO stage at diagnosis,8,2,3,no,1:no,1:no,,0.768
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,9,0,2,no,1:no,1:no,,0.881
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,9,1,3,no,1:no,1:no,,0.788
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,9,2,3,no,1:no,1:no,,0.801
1762,2364769,Table 1,BaselineCharacteristic,Residual disease following surgery (cm), ;  ; ,None,None,10,0,24,no,1:no,1:no,,0.853
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Residual disease following surgery (cm),None,10,1,43,no,1:no,1:no,,0.806
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Residual disease following surgery (cm),None,10,2,43,no,1:no,1:no,,0.814
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, Residual disease following surgery (cm),11,0,2,no,1:no,1:no,,0.84
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, Residual disease following surgery (cm),11,1,3,no,1:no,1:no,,0.671
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, Residual disease following surgery (cm),11,2,3,no,1:no,1:no,,0.685
1762,2364769,Table 1,BaselineCharacteristic,?<x, ;  ; ,?<x, Residual disease following surgery (cm),12,0,2,no,1:no,1:no,,0.87
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?<x, Residual disease following surgery (cm),12,1,3,no,1:no,1:no,,0.676
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?<x, Residual disease following surgery (cm),12,2,3,no,1:no,1:no,,0.685
1762,2364769,Table 1,BaselineCharacteristic,?>x, ;  ; ,?>x, Residual disease following surgery (cm),14,0,2,no,1:no,1:no,,0.869
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?>x, Residual disease following surgery (cm),14,1,3,no,1:no,1:no,,0.671
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?>x, Residual disease following surgery (cm),14,2,3,no,1:no,1:no,,0.68
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,15,0,2,no,1:no,1:no,,0.892
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,15,1,3,no,1:no,1:no,,0.807
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,15,2,3,no,1:no,1:no,,0.82
1762,2364769,Table 1,BaselineCharacteristic,Histology, ;  ; ,None,None,16,0,24,no,1:no,1:no,,0.879
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Histology,None,16,1,43,no,1:no,1:no,,0.823
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Histology,None,16,2,43,no,1:no,1:no,,0.834
1762,2364769,Table 1,BaselineCharacteristic,?Serous, ;  ; ,?Serous, Histology,17,0,2,no,1:no,1:no,,0.896
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Serous, Histology,17,1,3,no,1:no,1:no,,0.705
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Serous, Histology,17,2,3,no,1:no,1:no,,0.714
1762,2364769,Table 1,BaselineCharacteristic,?Mucinous, ;  ; ,?Mucinous, Histology,18,0,2,no,1:no,1:no,,0.9
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Interferon ; (n=xxx) ; ,?Mucinous, Histology,18,1,3,no,1:no,1:no,,0.719
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Observation ; (n=xxx) ; ,?Mucinous, Histology,18,2,3,no,1:no,1:no,,0.729
1762,2364769,Table 1,BaselineCharacteristic,?Endometrioid, ;  ; ,?Endometrioid, Histology,19,0,2,no,1:no,1:no,,0.9
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Endometrioid, Histology,19,1,3,no,1:no,1:no,,0.72
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Endometrioid, Histology,19,2,3,no,1:no,1:no,,0.729
1762,2364769,Table 1,BaselineCharacteristic,?Clear cell, ;  ; ,?Clear cell, Histology,20,0,2,no,1:no,1:no,,0.906
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?Clear cell, Histology,20,1,3,no,1:no,1:no,,0.816
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?Clear cell, Histology,20,2,3,no,1:no,1:no,,0.822
1762,2364769,Table 1,BaselineCharacteristic,?Other, ;  ; ,?Other, Histology,21,0,2,no,1:no,1:no,,0.904
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Other, Histology,21,1,3,no,1:no,1:no,,0.727
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Observation ; (n=xxx) ; ,?Other, Histology,21,2,3,no,1:no,1:no,,0.736
1762,2364769,Table 1,BaselineCharacteristic,?Undifferentiated, ;  ; ,?Undifferentiated, Histology,22,0,2,no,1:no,1:no,,0.902
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?Undifferentiated, Histology,22,1,3,no,1:no,1:no,,0.806
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?Undifferentiated, Histology,22,2,3,no,1:no,1:no,,0.812
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, Histology,23,0,2,no,1:no,1:no,,0.904
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Not stated, Histology,23,1,3,no,1:no,1:no,,0.735
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Not stated, Histology,23,2,3,no,1:no,1:no,,0.744
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,24,0,2,no,1:no,1:no,,0.905
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,24,1,3,no,1:no,1:no,,0.838
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,24,2,3,no,1:no,1:no,,0.848
1762,2364769,Table 1,BaselineCharacteristic,Tumour grade, ;  ; ,None,None,25,0,24,no,1:no,1:no,,0.905
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Tumour grade,None,25,1,43,no,1:no,1:no,,0.865
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Tumour grade,None,25,2,43,no,1:no,1:no,,0.872
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, Tumour grade,26,0,2,no,1:no,1:no,,0.891
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Interferon ; (n=xxx) ; ,?x, Tumour grade,26,1,3,no,1:no,1:no,,0.757
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, Tumour grade,26,2,3,no,1:no,1:no,,0.769
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, Tumour grade,27,0,2,no,1:no,1:no,,0.891
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, Tumour grade,27,1,3,no,1:no,1:no,,0.756
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, Tumour grade,27,2,3,no,1:no,1:no,,0.769
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, Tumour grade,28,0,2,no,1:no,1:no,,0.891
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, Tumour grade,28,1,3,no,1:no,1:no,,0.756
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, Tumour grade,28,2,3,no,1:no,1:no,,0.769
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, Tumour grade,29,0,2,no,1:no,1:no,,0.911
1762,2364769,Table 1,BaselineCharacteristic,xx,Interferon ; (n=xxx) ; ,?Not stated, Tumour grade,29,1,3,no,1:no,1:no,,0.793
1762,2364769,Table 1,BaselineCharacteristic,xx,Observation ; (n=xxx) ; ,?Not stated, Tumour grade,29,2,3,no,1:no,1:no,,0.803
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,30,0,2,no,1:no,1:no,,0.905
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,30,1,3,no,1:no,1:no,,0.838
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,30,2,3,no,1:no,1:no,,0.848
1762,2364769,Table 1,BaselineCharacteristic,WHO performance status pre-chemotherapy, ;  ; ,None,None,31,0,24,no,1:no,1:no,,0.91
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,WHO performance status pre-chemotherapy,None,31,1,43,no,1:no,1:no,,0.867
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,WHO performance status pre-chemotherapy,None,31,2,43,no,1:no,1:no,,0.877
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,32,0,2,no,1:no,1:no,,0.898
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,32,1,3,no,1:no,1:no,,0.76
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,32,2,3,no,1:no,1:no,,0.774
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,33,0,2,no,1:no,1:no,,0.898
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,33,1,3,no,1:no,1:no,,0.76
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,33,2,3,no,1:no,1:no,,0.774
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,34,0,2,no,1:no,1:no,,0.898
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,34,1,3,no,1:no,1:no,,0.837
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,34,2,3,no,1:no,1:no,,0.774
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,35,0,2,no,1:no,1:no,,0.898
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,35,1,3,no,1:no,1:no,,0.837
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,35,2,3,no,1:no,1:no,,0.843
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,36,0,2,no,1:no,1:no,,0.898
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,36,1,3,no,1:no,1:no,,0.837
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,36,2,3,no,1:no,1:no,,0.858
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, WHO performance status pre-chemotherapy,37,0,2,no,1:no,1:no,,0.919
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?Not stated, WHO performance status pre-chemotherapy,37,1,3,no,1:no,1:no,,0.854
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?Not stated, WHO performance status pre-chemotherapy,37,2,3,no,1:no,1:no,,0.86
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,38,0,2,no,1:no,1:no,,0.905
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,38,1,3,no,1:no,1:no,,0.838
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,38,2,3,no,1:no,1:no,,0.848
1762,2364769,Table 1,BaselineCharacteristic,Chemotherapy regimen, ;  ; ,None,None,39,0,24,no,1:no,1:no,,0.896
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Chemotherapy regimen,None,39,1,43,no,1:no,1:no,,0.851
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Chemotherapy regimen,None,39,2,43,no,1:no,1:no,,0.861
1762,2364769,Table 1,BaselineCharacteristic,?Platinum single agent, ;  ; ,?Platinum single agent, Chemotherapy regimen,40,0,2,no,1:no,1:no,,0.902
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Platinum single agent, Chemotherapy regimen,40,1,3,no,1:no,1:no,,0.752
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Platinum single agent, Chemotherapy regimen,40,2,3,no,1:no,1:no,,0.761
1762,2364769,Table 1,BaselineCharacteristic,?Platinum combination, ;  ; ,?Platinum combination, Chemotherapy regimen,41,0,2,no,1:no,1:no,,0.902
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Platinum combination, Chemotherapy regimen,41,1,3,no,1:no,1:no,,0.752
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Platinum combination, Chemotherapy regimen,41,2,3,no,1:no,1:no,,0.761
1762,2364769,Table 1,BaselineCharacteristic,?Platinum/taxane, ;  ; ,?Platinum/taxane, Chemotherapy regimen,42,0,2,no,1:no,1:no,,0.902
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Platinum/taxane, Chemotherapy regimen,42,1,3,no,1:no,1:no,,0.752
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Platinum/taxane, Chemotherapy regimen,42,2,3,no,1:no,1:no,,0.761
1762,2364769,Table 1,BaselineCharacteristic,?Taxane single agent, ;  ; ,?Taxane single agent, Chemotherapy regimen,43,0,2,no,1:no,1:no,,0.902
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?Taxane single agent, Chemotherapy regimen,43,1,3,no,1:no,1:no,,0.825
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?Taxane single agent, Chemotherapy regimen,43,2,3,no,1:no,1:no,,0.816
1762,2364769,Table 1,BaselineCharacteristic,?Other single agent, ;  ; ,?Other single agent, Chemotherapy regimen,44,0,2,no,1:no,1:no,,0.905
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?Other single agent, Chemotherapy regimen,44,1,3,no,1:no,1:no,,0.811
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?Other single agent, Chemotherapy regimen,44,2,3,no,1:no,1:no,,0.817
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,45,0,2,no,1:no,1:no,,0.905
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,45,1,3,no,1:no,1:no,,0.838
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,45,2,3,no,1:no,1:no,,0.848
1762,2364769,Table 1,BaselineCharacteristic,Response to surgery and/or chemotherapy, ;  ; ,None,None,46,0,24,no,1:no,1:no,,0.904
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Response to surgery and/or chemotherapy,None,46,1,43,no,1:no,1:no,,0.86
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Response to surgery and/or chemotherapy,None,46,2,43,no,1:no,1:no,,0.87
1762,2364769,Table 1,BaselineCharacteristic,?Disease free, ;  ; ,?Disease free, Response to surgery and/or chemotherapy,47,0,2,no,1:no,1:no,,0.897
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Disease free, Response to surgery and/or chemotherapy,47,1,3,no,1:no,1:no,,0.761
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Disease free, Response to surgery and/or chemotherapy,47,2,3,no,1:no,1:no,,0.77
1762,2364769,Table 1,BaselineCharacteristic,?Disease present, ;  ; ,?Disease present, Response to surgery and/or chemotherapy,48,0,2,no,1:no,1:no,,0.897
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Disease present, Response to surgery and/or chemotherapy,48,1,3,no,1:no,1:no,,0.761
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Disease present, Response to surgery and/or chemotherapy,48,2,3,no,1:no,1:no,,0.77
1762,2364769,Table 1,BaselineCharacteristic,?Not evaluable, ;  ; ,?Not evaluable, Response to surgery and/or chemotherapy,49,0,2,no,1:no,1:no,,0.909
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?Not evaluable, Response to surgery and/or chemotherapy,49,1,3,no,1:no,1:no,,0.838
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?Not evaluable, Response to surgery and/or chemotherapy,49,2,3,no,1:no,1:no,,0.844
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,50,0,2,no,1:no,1:no,,0.905
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,50,1,3,no,1:no,1:no,,0.838
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,50,2,3,no,1:no,1:no,,0.848
1762,2364769,Table 1,BaselineCharacteristic,CAxxx after surgery and/or chemotherapy, ;  ; ,None,None,51,0,24,no,1:no,1:no,,0.904
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,CAxxx after surgery and/or chemotherapy,None,51,1,43,no,1:no,1:no,,0.86
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,CAxxx after surgery and/or chemotherapy,None,51,2,43,no,1:no,1:no,,0.87
1762,2364769,Table 1,BaselineCharacteristic,?<xx?U?ml?x, ;  ; ,?<xx?U?ml?x, CAxxx after surgery and/or chemotherapy,52,0,2,no,1:no,1:no,,0.887
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?<xx?U?ml?x, CAxxx after surgery and/or chemotherapy,52,1,3,no,1:no,1:no,,0.757
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?<xx?U?ml?x, CAxxx after surgery and/or chemotherapy,52,2,3,no,1:no,1:no,,0.77
1762,2364769,Table 1,BaselineCharacteristic,?>xxx, ;  ; ,?>xxx, CAxxx after surgery and/or chemotherapy,55,0,2,no,1:no,1:no,,0.906
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?>xxx, CAxxx after surgery and/or chemotherapy,55,1,3,no,1:no,1:no,,0.814
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?>xxx, CAxxx after surgery and/or chemotherapy,55,2,3,no,1:no,1:no,,0.821
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, CAxxx after surgery and/or chemotherapy,56,0,2,no,1:no,1:no,,0.909
1762,2364769,Table 1,BaselineCharacteristic,xx,Interferon ; (n=xxx) ; ,?Not stated, CAxxx after surgery and/or chemotherapy,56,1,3,no,1:no,1:no,,0.805
1762,2364769,Table 1,BaselineCharacteristic,xx,Observation ; (n=xxx) ; ,?Not stated, CAxxx after surgery and/or chemotherapy,56,2,3,no,1:no,1:no,,0.815
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,57,0,2,no,1:no,1:no,,0.905
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,57,1,3,no,1:no,1:no,,0.838
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,57,2,3,no,1:no,1:no,,0.848
1762,2364769,Table 1,BaselineCharacteristic,WHO performance status at randomisation, ;  ; ,None,None,58,0,24,no,1:no,1:no,,0.913
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,WHO performance status at randomisation,None,58,1,43,no,1:no,1:no,,0.878
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,WHO performance status at randomisation,None,58,2,43,no,1:no,1:no,,0.889
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,59,0,2,no,1:no,1:no,,0.908
1762,2364769,Table 1,BaselineCharacteristic,xxx (xx%),Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,59,1,3,no,1:no,1:no,,0.771
1762,2364769,Table 1,BaselineCharacteristic,xxx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,59,2,3,no,1:no,1:no,,0.775
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,60,0,2,no,1:no,1:no,,0.908
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,60,1,3,no,1:no,1:no,,0.783
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,60,2,3,no,1:no,1:no,,0.796
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,61,0,2,no,1:no,1:no,,0.908
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,61,1,3,no,1:no,1:no,,0.848
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,61,2,3,no,1:no,1:no,,0.854
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,62,0,2,no,1:no,1:no,,0.908
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,62,1,3,no,1:no,1:no,,0.861
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,62,2,3,no,1:no,1:no,,0.871
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,63,0,2,no,1:no,1:no,,0.908
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,63,1,3,no,1:no,1:no,,0.861
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,63,2,3,no,1:no,1:no,,0.871
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, WHO performance status at randomisation,64,0,2,no,1:no,1:no,,0.923
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?Not stated, WHO performance status at randomisation,64,1,3,no,1:no,1:no,,0.867
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?Not stated, WHO performance status at randomisation,64,2,3,no,1:no,1:no,,0.873
1769,2364792,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1769,2364792,Table 1,BaselineCharacteristic,No. (%),,,None,0,1,1,no,1:no,1:no,,0.773
1769,2364792,Table 1,BaselineCharacteristic,Number of patients, ; ,Number of patients,,1,0,2,no,1:no,1:no,,0.728
1769,2364792,Table 1,BaselineCharacteristic,xx (xxx),No. (%) ; ,Number of patients,,1,1,3,no,1:no,2:yes,+,0.61
1769,2364792,Table 1,BaselineCharacteristic,Median age (years), ; ,Median age (years),,2,0,24,no,1:no,1:no,,0.814
1769,2364792,Table 1,BaselineCharacteristic,xx,No. (%) ; ,Median age (years),,2,1,43,no,1:no,1:no,,0.588
1769,2364792,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Median age (years),3,0,2,no,1:no,1:no,,0.838
1769,2364792,Table 1,BaselineCharacteristic,WHOa performance status, ; ,None,None,4,0,24,no,1:no,1:no,,0.851
1769,2364792,Table 1,BaselineCharacteristic,WHOa performance status,No. (%) ; ,WHOa performance status,None,4,1,43,no,1:no,1:no,,0.73
1769,2364792,Table 1,BaselineCharacteristic,?x, ; ,?x, WHOa performance status,5,0,2,no,1:no,1:no,,0.837
1769,2364792,Table 1,BaselineCharacteristic,xx (xx),No. (%) ; ,?x, WHOa performance status,5,1,3,no,1:no,1:no,,0.523
1769,2364792,Table 1,BaselineCharacteristic,??x, ; ,??x, WHOa performance status,6,0,2,no,1:no,1:no,,0.837
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,??x, WHOa performance status,6,1,3,no,1:no,1:no,,0.529
1769,2364792,Table 1,BaselineCharacteristic,Adjuvant therapy, ; ,None,None,7,0,24,no,1:no,1:no,,0.849
1769,2364792,Table 1,BaselineCharacteristic,Adjuvant therapy,No. (%) ; ,Adjuvant therapy,None,7,1,43,no,1:no,1:no,,0.745
1769,2364792,Table 1,BaselineCharacteristic,?Chemotherapy with anthracyclines, ; ,?Chemotherapy with anthracyclines, Adjuvant therapy,8,0,2,no,1:no,1:no,,0.848
1769,2364792,Table 1,BaselineCharacteristic,xx (xx),No. (%) ; ,?Chemotherapy with anthracyclines, Adjuvant therapy,8,1,3,no,1:no,1:no,,0.564
1769,2364792,Table 1,BaselineCharacteristic,?Chemotherapy without anthracyclines, ; ,?Chemotherapy without anthracyclines, Adjuvant therapy,9,0,2,no,1:no,1:no,,0.867
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Chemotherapy without anthracyclines, Adjuvant therapy,9,1,3,no,1:no,1:no,,0.617
1769,2364792,Table 1,BaselineCharacteristic,?Hormonal therapy, ; ,?Hormonal therapy, Adjuvant therapy,10,0,2,no,1:no,1:no,,0.866
1769,2364792,Table 1,BaselineCharacteristic,xx (xx),No. (%) ; ,?Hormonal therapy, Adjuvant therapy,10,1,3,no,1:no,1:no,,0.58
1769,2364792,Table 1,BaselineCharacteristic,Previous metastatic breast cancer therapy, ; ,None,None,11,0,24,no,1:no,1:no,,0.897
1769,2364792,Table 1,BaselineCharacteristic,Previous metastatic breast cancer therapy,No. (%) ; ,Previous metastatic breast cancer therapy,None,11,1,43,no,1:no,1:no,,0.828
1769,2364792,Table 1,BaselineCharacteristic,?Hormonal therapy, ; ,?Hormonal therapy, Previous metastatic breast cancer therapy,12,0,2,no,1:no,1:no,,0.894
1769,2364792,Table 1,BaselineCharacteristic,x (x),No. (%) ; ,?Hormonal therapy, Previous metastatic breast cancer therapy,12,1,3,no,1:no,1:no,,0.741
1769,2364792,Table 1,BaselineCharacteristic,Disease sites, ; ,None,None,13,0,24,no,1:no,1:no,,0.861
1769,2364792,Table 1,BaselineCharacteristic,Disease sites,No. (%) ; ,Disease sites,None,13,1,43,no,1:no,1:no,,0.772
1769,2364792,Table 1,BaselineCharacteristic,?Soft tissue and skin, ; ,?Soft tissue and skin, Disease sites,14,0,2,no,1:no,1:no,,0.882
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Soft tissue and skin, Disease sites,14,1,3,no,1:no,1:no,,0.656
1769,2364792,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver, Disease sites,15,0,2,no,1:no,1:no,,0.885
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Liver, Disease sites,15,1,3,no,1:no,1:no,,0.65
1769,2364792,Table 1,BaselineCharacteristic,?Lung and pleura, ; ,?Lung and pleura, Disease sites,16,0,2,no,1:no,1:no,,0.888
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Lung and pleura, Disease sites,16,1,3,no,1:no,1:no,,0.667
1769,2364792,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone, Disease sites,17,0,2,no,1:no,1:no,,0.885
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Bone, Disease sites,17,1,3,no,1:no,1:no,,0.68
1769,2364792,Table 1,BaselineCharacteristic,?Brain, ; ,?Brain, Disease sites,18,0,2,no,1:no,1:no,,0.888
1769,2364792,Table 1,BaselineCharacteristic,x (x),No. (%) ; ,?Brain, Disease sites,18,1,3,no,1:no,1:no,,0.743
1769,2364792,Table 1,BaselineCharacteristic,Number of organs involved, ; ,None,None,19,0,24,no,1:no,1:no,,0.898
1769,2364792,Table 1,BaselineCharacteristic,Number of organs involved,No. (%) ; ,Number of organs involved,None,19,1,43,no,1:no,1:no,,0.818
1769,2364792,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of organs involved,20,0,2,no,1:no,1:no,,0.874
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?x, Number of organs involved,20,1,3,no,1:no,1:no,,0.709
1769,2364792,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of organs involved,21,0,2,no,1:no,1:no,,0.874
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?x, Number of organs involved,21,1,3,no,1:no,1:no,,0.709
1888,2376376,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1888,2376376,Table 1,BaselineCharacteristic,Epoetin ? (n=xxx),,,None,0,1,1,no,1:no,1:no,,0.735
1888,2376376,Table 1,BaselineCharacteristic,Control (n=xxx),,,None,0,2,1,no,1:no,1:no,,0.794
1888,2376376,Table 1,BaselineCharacteristic,"Sex, n (%)", ; ,None,None,1,0,24,no,1:no,1:no,,0.569
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,"Sex, n (%)",None,1,1,43,no,1:no,2:yes,+,0.539
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,"Sex, n (%)",None,1,2,43,no,1:no,1:no,,0.513
1888,2376376,Table 1,BaselineCharacteristic,Male, ; ,Male," Sex, n (%)",2,0,2,no,1:no,2:yes,+,0.576
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Male," Sex, n (%)",2,1,3,yes,2:yes,2:yes,,0.85
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Male," Sex, n (%)",2,2,3,yes,2:yes,2:yes,,0.815
1888,2376376,Table 1,BaselineCharacteristic,Female, ; ,Female," Sex, n (%)",3,0,2,no,1:no,2:yes,+,0.52
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Female," Sex, n (%)",3,1,3,yes,2:yes,2:yes,,0.859
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Female," Sex, n (%)",3,2,3,yes,2:yes,2:yes,,0.817
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no,1:no,1:no,,0.858
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,4,1,3,no,1:no,1:no,,0.731
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,4,2,3,no,1:no,1:no,,0.783
1888,2376376,Table 1,BaselineCharacteristic,Age (year), ; ,None,None,5,0,24,no,1:no,1:no,,0.867
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,Age (year),None,5,1,43,no,1:no,1:no,,0.826
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,Age (year),None,5,2,43,no,1:no,1:no,,0.846
1888,2376376,Table 1,BaselineCharacteristic,Median (range), ; ,Median (range), Age (year),6,0,2,no,1:no,1:no,,0.845
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,7,0,2,no,1:no,1:no,,0.869
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,7,1,3,no,1:no,1:no,,0.747
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,7,2,3,no,1:no,1:no,,0.786
1888,2376376,Table 1,BaselineCharacteristic,"WHO Performance Status, N (%)", ; ,None,None,8,0,24,no,1:no,1:no,,0.799
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,"WHO Performance Status, N (%)",None,8,1,43,no,1:no,1:no,,0.707
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,"WHO Performance Status, N (%)",None,8,2,43,no,1:no,1:no,,0.728
1888,2376376,Table 1,BaselineCharacteristic,x, ; ,x," WHO Performance Status, N (%)",9,0,2,no,1:no,1:no,,0.715
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,x," WHO Performance Status, N (%)",9,1,3,no,1:no,1:no,,0.541
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,x," WHO Performance Status, N (%)",9,2,3,no,1:no,1:no,,0.604
1888,2376376,Table 1,BaselineCharacteristic,x, ; ,x," WHO Performance Status, N (%)",10,0,2,no,1:no,1:no,,0.722
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,x," WHO Performance Status, N (%)",10,1,3,no,1:no,1:no,,0.553
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,x," WHO Performance Status, N (%)",10,2,3,no,1:no,1:no,,0.616
1888,2376376,Table 1,BaselineCharacteristic,x, ; ,x," WHO Performance Status, N (%)",11,0,2,no,1:no,1:no,,0.741
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,x," WHO Performance Status, N (%)",11,1,3,no,1:no,1:no,,0.574
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,x," WHO Performance Status, N (%)",11,2,3,no,1:no,1:no,,0.629
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,12,0,2,no,1:no,1:no,,0.892
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,12,1,3,no,1:no,1:no,,0.813
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,12,2,3,no,1:no,1:no,,0.836
1888,2376376,Table 1,BaselineCharacteristic,Time from diagnosis of anaemia of malignancy (months), ; ,None,None,13,0,24,no,1:no,1:no,,0.906
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,Time from diagnosis of anaemia of malignancy (months),None,13,1,43,no,1:no,1:no,,0.891
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,Time from diagnosis of anaemia of malignancy (months),None,13,2,43,no,1:no,1:no,,0.897
1888,2376376,Table 1,BaselineCharacteristic,Median (range), ; ,Median (range), Time from diagnosis of anaemia of malignancy (months),14,0,2,no,1:no,1:no,,0.917
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,15,0,2,no,1:no,1:no,,0.892
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,15,1,3,no,1:no,1:no,,0.807
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,15,2,3,no,1:no,1:no,,0.831
1888,2376376,Table 1,BaselineCharacteristic,"Underlying cancer type, N (%)", ; ,None,None,16,0,24,no,1:no,1:no,,0.671
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,"Underlying cancer type, N (%)",None,16,1,43,no,1:no,1:no,,0.57
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,"Underlying cancer type, N (%)",None,16,2,43,no,1:no,1:no,,0.6
1888,2376376,Table 1,BaselineCharacteristic,Lymphoid tumour, ; ,Lymphoid tumour," Underlying cancer type, N (%)",17,0,2,no,1:no,1:no,,0.717
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Lymphoid tumour," Underlying cancer type, N (%)",17,1,3,no,1:no,1:no,,0.511
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Lymphoid tumour," Underlying cancer type, N (%)",17,2,3,no,1:no,1:no,,0.543
1888,2376376,Table 1,BaselineCharacteristic,Multiple myeloma, ; ,Multiple myeloma," Underlying cancer type, N (%)",18,0,2,no,1:no,1:no,,0.699
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Multiple myeloma," Underlying cancer type, N (%)",18,1,3,no,1:no,2:yes,+,0.518
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Multiple myeloma," Underlying cancer type, N (%)",18,2,3,no,1:no,1:no,,0.521
1888,2376376,Table 1,BaselineCharacteristic,Non-Hodgkin\'s lymphoma, ; ,Non-Hodgkin\'s lymphoma," Underlying cancer type, N (%)",19,0,2,no,1:no,1:no,,0.7
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Non-Hodgkin\'s lymphoma," Underlying cancer type, N (%)",19,1,3,no,1:no,2:yes,+,0.512
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Non-Hodgkin\'s lymphoma," Underlying cancer type, N (%)",19,2,3,no,1:no,1:no,,0.526
1888,2376376,Table 1,BaselineCharacteristic,Chronic lymphocytic leukaemia, ; ,Chronic lymphocytic leukaemia," Underlying cancer type, N (%)",20,0,2,no,1:no,1:no,,0.7
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Chronic lymphocytic leukaemia," Underlying cancer type, N (%)",20,1,3,no,1:no,2:yes,+,0.512
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Chronic lymphocytic leukaemia," Underlying cancer type, N (%)",20,2,3,no,1:no,1:no,,0.527
1888,2376376,Table 1,BaselineCharacteristic,Other, ; ,Other," Underlying cancer type, N (%)",21,0,2,no,1:no,1:no,,0.701
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,Other," Underlying cancer type, N (%)",21,1,3,no,1:no,1:no,,0.564
1888,2376376,Table 1,BaselineCharacteristic,x (<x),Control (n=xxx) ; ,Other," Underlying cancer type, N (%)",21,2,3,no,1:no,1:no,,0.598
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,22,0,2,no,1:no,1:no,,0.904
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,22,1,3,no,1:no,1:no,,0.837
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,22,2,3,no,1:no,1:no,,0.857
1888,2376376,Table 1,BaselineCharacteristic,Solid tumour, ; ,Solid tumour," Underlying cancer type, N (%)",23,0,2,no,1:no,1:no,,0.735
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Solid tumour," Underlying cancer type, N (%)",23,1,3,no,1:no,1:no,,0.539
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Solid tumour," Underlying cancer type, N (%)",23,2,3,no,1:no,1:no,,0.571
1888,2376376,Table 1,BaselineCharacteristic,Ovarian, ; ,Ovarian," Underlying cancer type, N (%)",24,0,2,no,1:no,1:no,,0.704
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Ovarian," Underlying cancer type, N (%)",24,1,3,no,1:no,2:yes,+,0.503
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Ovarian," Underlying cancer type, N (%)",24,2,3,no,1:no,1:no,,0.535
1888,2376376,Table 1,BaselineCharacteristic,"Bone, connective tissue, skin and breast", ; ,"Bone, connective tissue, skin and breast"," Underlying cancer type, N (%)",25,0,2,no,1:no,1:no,,0.718
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,"Bone, connective tissue, skin and breast"," Underlying cancer type, N (%)",25,1,3,no,1:no,1:no,,0.589
1888,2376376,Table 1,BaselineCharacteristic,xx (x),Control (n=xxx) ; ,"Bone, connective tissue, skin and breast"," Underlying cancer type, N (%)",25,2,3,no,1:no,1:no,,0.577
1888,2376376,Table 1,BaselineCharacteristic,"Digestive organs, peritoneum", ; ,"Digestive organs, peritoneum"," Underlying cancer type, N (%)",26,0,2,no,1:no,1:no,,0.712
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,"Digestive organs, peritoneum"," Underlying cancer type, N (%)",26,1,3,no,1:no,1:no,,0.558
1888,2376376,Table 1,BaselineCharacteristic,x (x),Control (n=xxx) ; ,"Digestive organs, peritoneum"," Underlying cancer type, N (%)",26,2,3,no,1:no,1:no,,0.592
1888,2376376,Table 1,BaselineCharacteristic,Respiratory and intrathoracic organs, ; ,Respiratory and intrathoracic organs," Underlying cancer type, N (%)",27,0,2,no,1:no,1:no,,0.725
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,Respiratory and intrathoracic organs," Underlying cancer type, N (%)",27,1,3,no,1:no,1:no,,0.591
1888,2376376,Table 1,BaselineCharacteristic,x (x),Control (n=xxx) ; ,Respiratory and intrathoracic organs," Underlying cancer type, N (%)",27,2,3,no,1:no,1:no,,0.626
1888,2376376,Table 1,BaselineCharacteristic,Other, ; ,Other," Underlying cancer type, N (%)",28,0,2,no,1:no,1:no,,0.705
1888,2376376,Table 1,BaselineCharacteristic,xx (x),Epoetin ? (n=xxx) ; ,Other," Underlying cancer type, N (%)",28,1,3,no,1:no,1:no,,0.538
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Other," Underlying cancer type, N (%)",28,2,3,no,1:no,1:no,,0.563
1888,2376376,Table 1,BaselineCharacteristic,"Patients with chemotherapy before study, N (%)", ; ,"Patients with chemotherapy before study, N (%)"," Underlying cancer type, N (%)",29,0,2,no,1:no,1:no,,0.725
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,"Patients with chemotherapy before study, N (%)"," Underlying cancer type, N (%)",29,1,3,no,1:no,1:no,,0.543
1888,2376376,Table 1,BaselineCharacteristic,xxx (xx)*,Control (n=xxx) ; ,"Patients with chemotherapy before study, N (%)"," Underlying cancer type, N (%)",29,2,3,no,1:no,1:no,,0.552
1888,2376376,Table 1,BaselineCharacteristic,Chemotherapy, ; ,None,None,30,0,24,no,1:no,1:no,,0.896
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,Chemotherapy,None,30,1,43,no,1:no,1:no,,0.851
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,Chemotherapy,None,30,2,43,no,1:no,1:no,,0.87
1888,2376376,Table 1,BaselineCharacteristic,Alkylating agents, ; ,Alkylating agents, Chemotherapy,31,0,2,no,1:no,1:no,,0.902
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Alkylating agents, Chemotherapy,31,1,3,no,1:no,1:no,,0.794
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Alkylating agents, Chemotherapy,31,2,3,no,1:no,1:no,,0.809
1888,2376376,Table 1,BaselineCharacteristic,Antimetabolites, ; ,Antimetabolites, Chemotherapy,32,0,2,no,1:no,1:no,,0.902
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Antimetabolites, Chemotherapy,32,1,3,no,1:no,1:no,,0.794
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Antimetabolites, Chemotherapy,32,2,3,no,1:no,1:no,,0.809
1888,2376376,Table 1,BaselineCharacteristic,Plant alkaloids/other natural products, ; ,Plant alkaloids/other natural products, Chemotherapy,33,0,2,no,1:no,1:no,,0.902
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Plant alkaloids/other natural products, Chemotherapy,33,1,3,no,1:no,1:no,,0.794
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Plant alkaloids/other natural products, Chemotherapy,33,2,3,no,1:no,1:no,,0.809
1888,2376376,Table 1,BaselineCharacteristic,Cytotoxic antibiotics/related substances, ; ,Cytotoxic antibiotics/related substances, Chemotherapy,34,0,2,no,1:no,1:no,,0.902
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Cytotoxic antibiotics/related substances, Chemotherapy,34,1,3,no,1:no,1:no,,0.794
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Cytotoxic antibiotics/related substances, Chemotherapy,34,2,3,no,1:no,1:no,,0.809
1888,2376376,Table 1,BaselineCharacteristic,Other antineoplastic agents, ; ,Other antineoplastic agents, Chemotherapy,35,0,2,no,1:no,1:no,,0.905
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Other antineoplastic agents, Chemotherapy,35,1,3,no,1:no,1:no,,0.801
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Other antineoplastic agents, Chemotherapy,35,2,3,no,1:no,1:no,,0.816
1888,2376376,Table 1,BaselineCharacteristic,Other, ; ,Other, Chemotherapy,36,0,2,no,1:no,1:no,,0.905
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,Other, Chemotherapy,36,1,3,no,1:no,1:no,,0.825
1888,2376376,Table 1,BaselineCharacteristic,x (x),Control (n=xxx) ; ,Other, Chemotherapy,36,2,3,no,1:no,1:no,,0.841
1888,2376376,Table 1,BaselineCharacteristic,"Median haemoglobin level, g dl?x (range)", ; ,"Median haemoglobin level, g dl?x (range)", Chemotherapy,37,0,2,no,1:no,1:no,,0.895
1888,2376376,Table 1,BaselineCharacteristic,"Median serum erythropoietin level, mIU ml?x (range)", ; ,"Median serum erythropoietin level, mIU ml?x (range)", Chemotherapy,38,0,2,no,1:no,1:no,,0.912
1888,2376376,Table 1,BaselineCharacteristic,"Median serum iron level, ?g dl?x (range)", ; ,"Median serum iron level, ?g dl?x (range)", Chemotherapy,39,0,2,no,1:no,1:no,,0.903
1888,2376376,Table 1,BaselineCharacteristic,"Median transferrin saturation, % (range)", ; ,"Median transferrin saturation, % (range)", Chemotherapy,40,0,2,no,1:no,1:no,,0.878
1888,2376376,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1888,2376376,Table 2,BaselineCharacteristic,Epoetin ? (n=xxx),,,None,0,1,1,no,1:no,1:no,,0.735
1888,2376376,Table 2,BaselineCharacteristic,Control (n=xxx),,,None,0,2,1,no,1:no,1:no,,0.794
1888,2376376,Table 2,BaselineCharacteristic,Baseline quality-of-life score, ; ,None,None,1,0,2,no,1:no,1:no,,0.858
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,1,1,3,no,1:no,1:no,,0.705
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,1,2,3,no,1:no,1:no,,0.771
1888,2376376,Table 2,BaselineCharacteristic,SF-xx PCS, ; ,None,None,2,0,24,no,1:no,1:no,,0.81
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,SF-xx PCS,None,2,1,43,no,1:no,1:no,,0.731
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,SF-xx PCS,None,2,2,43,no,1:no,1:no,,0.787
1888,2376376,Table 2,BaselineCharacteristic,Mean (SD), ; ,Mean (SD), Baseline quality-of-life score SF-xx PCS,3,0,2,no,1:no,1:no,,0.85
1888,2376376,Table 2,BaselineCharacteristic,xx (x.x),Epoetin ? (n=xxx) ; ,Mean (SD), Baseline quality-of-life score SF-xx PCS,3,1,3,no,1:no,1:no,,0.689
1888,2376376,Table 2,BaselineCharacteristic,xx (x.x),Control (n=xxx) ; ,Mean (SD), Baseline quality-of-life score SF-xx PCS,3,2,3,no,1:no,1:no,,0.723
1888,2376376,Table 2,BaselineCharacteristic,Median, ; ,Median, Baseline quality-of-life score SF-xx PCS,4,0,2,no,1:no,1:no,,0.86
1888,2376376,Table 2,BaselineCharacteristic,xx,Epoetin ? (n=xxx) ; ,Median, Baseline quality-of-life score SF-xx PCS,4,1,3,no,1:no,1:no,,0.64
1888,2376376,Table 2,BaselineCharacteristic,xx,Control (n=xxx) ; ,Median, Baseline quality-of-life score SF-xx PCS,4,2,3,no,1:no,1:no,,0.669
1888,2376376,Table 2,BaselineCharacteristic,Range, ; ,Range, Baseline quality-of-life score SF-xx PCS,5,0,2,no,1:no,1:no,,0.822
1888,2376376,Table 2,BaselineCharacteristic,, ; ,None,None,6,0,2,no,1:no,1:no,,0.866
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,6,1,3,no,1:no,1:no,,0.749
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,6,2,3,no,1:no,1:no,,0.79
1888,2376376,Table 2,BaselineCharacteristic,FACT-F, ; ,None,None,7,0,24,no,1:no,1:no,,0.839
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,FACT-F,None,7,1,43,no,1:no,1:no,,0.766
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,FACT-F,None,7,2,43,no,1:no,1:no,,0.805
1888,2376376,Table 2,BaselineCharacteristic,Mean (SD), ; ,Mean (SD), Baseline quality-of-life score FACT-F,8,0,2,no,1:no,1:no,,0.861
1888,2376376,Table 2,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Mean (SD), Baseline quality-of-life score FACT-F,8,1,3,no,1:no,1:no,,0.694
1888,2376376,Table 2,BaselineCharacteristic,xx (xx)*,Control (n=xxx) ; ,Mean (SD), Baseline quality-of-life score FACT-F,8,2,3,no,1:no,1:no,,0.722
1888,2376376,Table 2,BaselineCharacteristic,Median, ; ,Median, Baseline quality-of-life score FACT-F,9,0,2,no,1:no,1:no,,0.881
1888,2376376,Table 2,BaselineCharacteristic,xx,Epoetin ? (n=xxx) ; ,Median, Baseline quality-of-life score FACT-F,9,1,3,no,1:no,1:no,,0.702
1888,2376376,Table 2,BaselineCharacteristic,xx,Control (n=xxx) ; ,Median, Baseline quality-of-life score FACT-F,9,2,3,no,1:no,1:no,,0.725
1888,2376376,Table 2,BaselineCharacteristic,Range, ; ,Range, Baseline quality-of-life score FACT-F,10,0,2,no,1:no,1:no,,0.886
1888,2376376,Table 2,BaselineCharacteristic,, ; ,None,None,11,0,2,no,1:no,1:no,,0.892
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,11,1,3,no,1:no,1:no,,0.813
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,11,2,3,no,1:no,1:no,,0.836
1888,2376376,Table 2,BaselineCharacteristic,FACT-An, ; ,None,None,12,0,24,no,1:no,1:no,,0.872
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,FACT-An,None,12,1,43,no,1:no,1:no,,0.815
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,FACT-An,None,12,2,43,no,1:no,1:no,,0.838
1888,2376376,Table 2,BaselineCharacteristic,Mean (SD), ; ,Mean (SD), Baseline quality-of-life score FACT-An,13,0,2,no,1:no,1:no,,0.884
1888,2376376,Table 2,BaselineCharacteristic,xx (x.x),Epoetin ? (n=xxx) ; ,Mean (SD), Baseline quality-of-life score FACT-An,13,1,3,no,1:no,1:no,,0.761
1888,2376376,Table 2,BaselineCharacteristic,xx (x.x),Control (n=xxx) ; ,Mean (SD), Baseline quality-of-life score FACT-An,13,2,3,no,1:no,1:no,,0.783
1888,2376376,Table 2,BaselineCharacteristic,Median, ; ,Median, Baseline quality-of-life score FACT-An,14,0,2,no,1:no,1:no,,0.898
1888,2376376,Table 2,BaselineCharacteristic,xx,Epoetin ? (n=xxx) ; ,Median, Baseline quality-of-life score FACT-An,14,1,3,no,1:no,1:no,,0.742
1888,2376376,Table 2,BaselineCharacteristic,xx,Control (n=xxx) ; ,Median, Baseline quality-of-life score FACT-An,14,2,3,no,1:no,1:no,,0.764
1888,2376376,Table 2,BaselineCharacteristic,Range, ; ,Range, Baseline quality-of-life score FACT-An,15,0,2,no,1:no,1:no,,0.898
1888,2376376,Table 2,BaselineCharacteristic,, ; ,None,None,16,0,2,no,1:no,1:no,,0.893
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,16,1,3,no,1:no,1:no,,0.808
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,16,2,3,no,1:no,1:no,,0.831
1888,2376376,Table 2,BaselineCharacteristic,VAS, ; ,None,None,17,0,24,no,1:no,1:no,,0.885
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,VAS,None,17,1,43,no,1:no,1:no,,0.833
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,VAS,None,17,2,43,no,1:no,1:no,,0.854
1888,2376376,Table 2,BaselineCharacteristic,Mean (SD), ; ,Mean (SD), Baseline quality-of-life score VAS,18,0,2,no,1:no,1:no,,0.893
1888,2376376,Table 2,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Mean (SD), Baseline quality-of-life score VAS,18,1,3,no,1:no,1:no,,0.774
1888,2376376,Table 2,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Mean (SD), Baseline quality-of-life score VAS,18,2,3,no,1:no,1:no,,0.797
1888,2376376,Table 2,BaselineCharacteristic,Median, ; ,Median, Baseline quality-of-life score VAS,19,0,2,no,1:no,1:no,,0.915
1888,2376376,Table 2,BaselineCharacteristic,xx,Epoetin ? (n=xxx) ; ,Median, Baseline quality-of-life score VAS,19,1,3,no,1:no,1:no,,0.786
1888,2376376,Table 2,BaselineCharacteristic,xx,Control (n=xxx) ; ,Median, Baseline quality-of-life score VAS,19,2,3,no,1:no,1:no,,0.808
1888,2376376,Table 2,BaselineCharacteristic,Range, ; ,Range, Baseline quality-of-life score VAS,20,0,2,no,1:no,1:no,,0.907
1906,2377091,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
1906,2377091,Table 1,BaselineCharacteristic,,,Characteristic,None,0,1,1,no,1:no,1:no,,0.749
1906,2377091,Table 1,BaselineCharacteristic,Mean age (range),Characteristic ; ,Mean age (range),None,1,0,2,no,1:no,1:no,,0.876
1906,2377091,Table 1,BaselineCharacteristic,Mean pretreatment PSA (range),Characteristic ; ,Mean pretreatment PSA (range),None,2,0,2,no,1:no,1:no,,0.848
1906,2377091,Table 1,BaselineCharacteristic,Gleason score for histology (range),Characteristic ; ,Gleason score for histology (range),None,3,0,2,no,1:no,1:no,,0.857
1906,2377091,Table 1,BaselineCharacteristic,Local stage (Tx/Tx),Characteristic ; ,Local stage (Tx/Tx),None,4,0,2,no,1:no,1:no,,0.897
1906,2377091,Table 1,BaselineCharacteristic,xx/x, ; ,Local stage (Tx/Tx),None,4,1,3,no,1:no,1:no,,0.791
1906,2377091,Table 1,BaselineCharacteristic,Bony metastases present,Characteristic ; ,Bony metastases present,None,5,0,2,no,1:no,1:no,,0.881
1906,2377091,Table 1,BaselineCharacteristic,xx (xx%), ; ,Bony metastases present,None,5,1,3,no,1:no,1:no,,0.625
1906,2377091,Table 1,BaselineCharacteristic,Concurrent LHRH analogue therapy,Characteristic ; ,Concurrent LHRH analogue therapy,None,6,0,2,no,1:no,1:no,,0.883
1906,2377091,Table 1,BaselineCharacteristic,xx (xx%), ; ,Concurrent LHRH analogue therapy,None,6,1,3,no,1:no,1:no,,0.649
1906,2377091,Table 1,BaselineCharacteristic,Previous bilateral subcapsular orchidectomy,Characteristic ; ,Previous bilateral subcapsular orchidectomy,None,7,0,2,no,1:no,1:no,,0.884
1906,2377091,Table 1,BaselineCharacteristic,x (xx%), ; ,Previous bilateral subcapsular orchidectomy,None,7,1,3,no,1:no,1:no,,0.717
1906,2377091,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1906,2377091,Table 2,BaselineCharacteristic,,,None,None,1,0,3,no,1:no,1:no,,0.792
1906,2377091,Table 2,BaselineCharacteristic,Time on study; mean (median), ; ,Time on study; mean (median),None,1,0,2,no,1:no,1:no,,0.865
1906,2377091,Table 2,BaselineCharacteristic,xx (xx) days,,Time on study; mean (median),None,1,1,3,no,1:no,1:no,,0.695
1906,2377091,Table 2,BaselineCharacteristic,Mean age (range), ; ,Mean age (range),None,2,0,2,no,1:no,1:no,,0.862
1906,2377091,Table 2,BaselineCharacteristic,Mean pretreatment PSA (range), ; ,Mean pretreatment PSA (range),None,3,0,2,no,1:no,1:no,,0.829
1906,2377091,Table 2,BaselineCharacteristic,Gleason score for histology (range), ; ,Gleason score for histology (range),None,4,0,2,no,1:no,1:no,,0.854
1906,2377091,Table 2,BaselineCharacteristic,Local stage (Tx/Tx), ; ,Local stage (Tx/Tx),None,5,0,2,no,1:no,1:no,,0.888
1906,2377091,Table 2,BaselineCharacteristic,x/x,,Local stage (Tx/Tx),None,5,1,3,no,1:no,1:no,,0.793
1906,2377091,Table 2,BaselineCharacteristic,Bony metastases present, ; ,Bony metastases present,None,6,0,2,no,1:no,1:no,,0.871
1906,2377091,Table 2,BaselineCharacteristic,x (xx%),,Bony metastases present,None,6,1,3,no,1:no,1:no,,0.707
1906,2377091,Table 2,BaselineCharacteristic,Concurrent LHRH analogue therapy, ; ,Concurrent LHRH analogue therapy,None,7,0,2,no,1:no,1:no,,0.878
1906,2377091,Table 2,BaselineCharacteristic,x (xx%),,Concurrent LHRH analogue therapy,None,7,1,3,no,1:no,1:no,,0.715
1906,2377091,Table 2,BaselineCharacteristic,Previous bilateral subcapsular orchidectomy, ; ,Previous bilateral subcapsular orchidectomy,None,8,0,2,no,1:no,1:no,,0.878
1906,2377091,Table 2,BaselineCharacteristic,x (xx%),,Previous bilateral subcapsular orchidectomy,None,8,1,3,no,1:no,1:no,,0.74
1911,2377146,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1911,2377146,Table 1,BaselineCharacteristic,Patients,,,None,0,1,1,no,1:no,1:no,,0.723
1911,2377146,Table 1,BaselineCharacteristic,Patients,,,None,0,2,1,no,1:no,1:no,,0.758
1911,2377146,Table 1,BaselineCharacteristic,Characteristics, ; ,None,None,1,0,12,no,1:no,1:no,,0.784
1911,2377146,Table 1,BaselineCharacteristic,n,Patients ; ,Characteristics,None,1,1,1,no,1:no,1:no,,0.646
1911,2377146,Table 1,BaselineCharacteristic,(%),Patients ; ,Characteristics,None,1,2,1,no,1:no,1:no,,0.715
1911,2377146,Table 1,BaselineCharacteristic,Number of patients, ; Characteristics ; ,Number of patients,,2,0,2,no,1:no,1:no,,0.74
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,Number of patients,,2,1,3,no,1:no,1:no,,0.517
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; (%) ; ,Number of patients,,2,2,3,no,1:no,2:yes,+,0.524
1911,2377146,Table 1,BaselineCharacteristic,Median age in years (range), ; Characteristics ; ,Median age in years (range),,3,0,2,no,1:no,1:no,,0.846
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,4,0,2,no,1:no,1:no,,0.845
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,4,1,3,no,1:no,1:no,,0.676
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,4,2,3,no,1:no,1:no,,0.71
1911,2377146,Table 1,BaselineCharacteristic,WHO performance status, ; Characteristics ; ,None,None,5,0,24,no,1:no,1:no,,0.851
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,WHO performance status,None,5,1,43,no,1:no,1:no,,0.716
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,WHO performance status,None,5,2,43,no,1:no,1:no,,0.765
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, WHO performance status,6,0,2,no,1:no,1:no,,0.814
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?x, WHO performance status,6,1,3,no,1:no,1:no,,0.587
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?x, WHO performance status,6,2,3,no,1:no,1:no,,0.535
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, WHO performance status,7,0,2,no,1:no,1:no,,0.822
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?x, WHO performance status,7,1,3,no,1:no,1:no,,0.589
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?x, WHO performance status,7,2,3,no,1:no,1:no,,0.542
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, WHO performance status,8,0,2,no,1:no,1:no,,0.825
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?x, WHO performance status,8,1,3,no,1:no,1:no,,0.674
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,?x, WHO performance status,8,2,3,no,1:no,1:no,,0.711
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,9,0,2,no,1:no,1:no,,0.855
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,9,1,3,no,1:no,1:no,,0.732
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,9,2,3,no,1:no,1:no,,0.746
1911,2377146,Table 1,BaselineCharacteristic,Number of organs involved, ; Characteristics ; ,None,None,10,0,24,no,1:no,1:no,,0.872
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,Number of organs involved,None,10,1,43,no,1:no,1:no,,0.795
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,Number of organs involved,None,10,2,43,no,1:no,1:no,,0.826
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, Number of organs involved,11,0,2,no,1:no,1:no,,0.835
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?x, Number of organs involved,11,1,3,no,1:no,1:no,,0.715
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?x, Number of organs involved,11,2,3,no,1:no,1:no,,0.677
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, Number of organs involved,12,0,2,no,1:no,1:no,,0.835
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?x, Number of organs involved,12,1,3,no,1:no,1:no,,0.718
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?x, Number of organs involved,12,2,3,no,1:no,1:no,,0.681
1911,2377146,Table 1,BaselineCharacteristic,??x, ; Characteristics ; ,??x, Number of organs involved,13,0,2,no,1:no,1:no,,0.835
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,??x, Number of organs involved,13,1,3,no,1:no,1:no,,0.751
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,??x, Number of organs involved,13,2,3,no,1:no,1:no,,0.768
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,14,0,2,no,1:no,1:no,,0.866
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,14,1,3,no,1:no,1:no,,0.755
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,14,2,3,no,1:no,1:no,,0.763
1911,2377146,Table 1,BaselineCharacteristic,Disease sites, ; Characteristics ; ,None,None,15,0,24,no,1:no,1:no,,0.834
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,Disease sites,None,15,1,43,no,1:no,1:no,,0.775
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,Disease sites,None,15,2,43,no,1:no,1:no,,0.782
1911,2377146,Table 1,BaselineCharacteristic,?Bone, ; Characteristics ; ,?Bone, Disease sites,16,0,2,no,1:no,1:no,,0.84
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Bone, Disease sites,16,1,3,no,1:no,1:no,,0.639
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Bone, Disease sites,16,2,3,no,1:no,1:no,,0.611
1911,2377146,Table 1,BaselineCharacteristic,?Liver, ; Characteristics ; ,?Liver, Disease sites,17,0,2,no,1:no,1:no,,0.874
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Liver, Disease sites,17,1,3,no,1:no,1:no,,0.69
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Liver, Disease sites,17,2,3,no,1:no,1:no,,0.667
1911,2377146,Table 1,BaselineCharacteristic,?Skin, ; Characteristics ; ,?Skin, Disease sites,18,0,2,no,1:no,1:no,,0.858
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Skin, Disease sites,18,1,3,no,1:no,1:no,,0.737
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Skin, Disease sites,18,2,3,no,1:no,1:no,,0.657
1911,2377146,Table 1,BaselineCharacteristic,?Lung, ; Characteristics ; ,?Lung, Disease sites,19,0,2,no,1:no,1:no,,0.858
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Lung, Disease sites,19,1,3,no,1:no,1:no,,0.682
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Lung, Disease sites,19,2,3,no,1:no,1:no,,0.657
1911,2377146,Table 1,BaselineCharacteristic,?Lymph node, ; Characteristics ; ,?Lymph node, Disease sites,20,0,2,no,1:no,1:no,,0.858
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Lymph node, Disease sites,20,1,3,no,1:no,1:no,,0.743
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Lymph node, Disease sites,20,2,3,no,1:no,1:no,,0.657
1911,2377146,Table 1,BaselineCharacteristic,?Other, ; Characteristics ; ,?Other, Disease sites,21,0,2,no,1:no,1:no,,0.861
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Other, Disease sites,21,1,3,no,1:no,1:no,,0.752
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Other, Disease sites,21,2,3,no,1:no,1:no,,0.657
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,22,0,2,no,1:no,1:no,,0.876
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,22,1,3,no,1:no,1:no,,0.787
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,22,2,3,no,1:no,1:no,,0.789
1911,2377146,Table 1,BaselineCharacteristic,Intent of previous chemotherapy, ; Characteristics ; ,None,None,23,0,24,no,1:no,1:no,,0.878
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,Intent of previous chemotherapy,None,23,1,43,no,1:no,1:no,,0.842
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,Intent of previous chemotherapy,None,23,2,43,no,1:no,1:no,,0.878
1911,2377146,Table 1,BaselineCharacteristic,?Neoadjuvant and adjuvant, ; Characteristics ; ,?Neoadjuvant and adjuvant, Intent of previous chemotherapy,24,0,2,no,1:no,1:no,,0.871
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Neoadjuvant and adjuvant, Intent of previous chemotherapy,24,1,3,no,1:no,1:no,,0.798
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Neoadjuvant and adjuvant, Intent of previous chemotherapy,24,2,3,no,1:no,1:no,,0.747
1911,2377146,Table 1,BaselineCharacteristic,?Neoadjuvant only, ; Characteristics ; ,?Neoadjuvant only, Intent of previous chemotherapy,25,0,2,no,1:no,1:no,,0.865
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Neoadjuvant only, Intent of previous chemotherapy,25,1,3,no,1:no,1:no,,0.772
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Neoadjuvant only, Intent of previous chemotherapy,25,2,3,no,1:no,1:no,,0.732
1911,2377146,Table 1,BaselineCharacteristic,?Adjuvant only, ; Characteristics ; ,?Adjuvant only, Intent of previous chemotherapy,26,0,2,no,1:no,1:no,,0.865
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Adjuvant only, Intent of previous chemotherapy,26,1,3,no,1:no,1:no,,0.738
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Adjuvant only, Intent of previous chemotherapy,26,2,3,no,1:no,1:no,,0.732
1911,2377146,Table 1,BaselineCharacteristic,?Neoadjuvant and adjuvant and metastatic, ; Characteristics ; ,?Neoadjuvant and adjuvant and metastatic, Intent of previous chemotherapy,27,0,2,no,1:no,1:no,,0.88
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Neoadjuvant and adjuvant and metastatic, Intent of previous chemotherapy,27,1,3,no,1:no,1:no,,0.819
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,?Neoadjuvant and adjuvant and metastatic, Intent of previous chemotherapy,27,2,3,no,1:no,1:no,,0.847
1911,2377146,Table 1,BaselineCharacteristic,?Adjuvant and metastatic, ; Characteristics ; ,?Adjuvant and metastatic, Intent of previous chemotherapy,28,0,2,no,1:no,1:no,,0.88
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Adjuvant and metastatic, Intent of previous chemotherapy,28,1,3,no,1:no,1:no,,0.819
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,?Adjuvant and metastatic, Intent of previous chemotherapy,28,2,3,no,1:no,1:no,,0.847
1911,2377146,Table 1,BaselineCharacteristic,?Metastatic, ; Characteristics ; ,?Metastatic, Intent of previous chemotherapy,29,0,2,no,1:no,1:no,,0.873
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Metastatic, Intent of previous chemotherapy,29,1,3,no,1:no,1:no,,0.764
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Metastatic, Intent of previous chemotherapy,29,2,3,no,1:no,1:no,,0.749
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,30,0,2,no,1:no,1:no,,0.877
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,30,1,3,no,1:no,1:no,,0.789
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,30,2,3,no,1:no,1:no,,0.794
1911,2377146,Table 1,BaselineCharacteristic,First-line metastatic, ; Characteristics ; ,First-line metastatic,,31,0,2,no,1:no,1:no,,0.872
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,First-line metastatic,,31,1,3,no,1:no,1:no,,0.701
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,First-line metastatic,,31,2,3,no,1:no,1:no,,0.677
1911,2377146,Table 1,BaselineCharacteristic,Second-line metastatic, ; Characteristics ; ,Second-line metastatic,,32,0,2,no,1:no,1:no,,0.872
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,Second-line metastatic,,32,1,3,no,1:no,1:no,,0.701
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,Second-line metastatic,,32,2,3,no,1:no,1:no,,0.677
1911,2377146,Table 1,BaselineCharacteristic,Anthracycline resistanta, ; Characteristics ; ,Anthracycline resistanta,,33,0,2,no,1:no,1:no,,0.866
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,Anthracycline resistanta,,33,1,3,no,1:no,1:no,,0.658
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,Anthracycline resistanta,,33,2,3,no,1:no,1:no,,0.623
1911,2377146,Table 1,BaselineCharacteristic,Anthracycline refractoryb, ; Characteristics ; ,Anthracycline refractoryb,,34,0,2,no,1:no,1:no,,0.866
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,Anthracycline refractoryb,,34,1,3,no,1:no,1:no,,0.729
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,Anthracycline refractoryb,,34,2,3,no,1:no,1:no,,0.756
1941,2394267,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
1941,2394267,Table 1,BaselineCharacteristic,No. of patients (%),,Characteristics,None,0,1,1,no,1:no,1:no,,0.751
1941,2394267,Table 1,BaselineCharacteristic,Gender,,None,None,1,0,12,no,1:no,1:no,,0.699
1941,2394267,Table 1,BaselineCharacteristic,,,Gender,None,1,1,1,no,1:no,1:no,,0.647
1941,2394267,Table 1,BaselineCharacteristic,?Male,,None,None,2,0,12,no,1:no,1:no,,0.652
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?Male,None,2,1,1,yes,2:yes,2:yes,,0.543
1941,2394267,Table 1,BaselineCharacteristic,?Female,,None,None,3,0,12,no,1:no,1:no,,0.686
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?Female,None,3,1,1,yes,2:yes,2:yes,,0.55
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,4,0,2,no,1:no,1:no,,0.858
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,4,1,3,no,1:no,1:no,,0.731
1941,2394267,Table 1,BaselineCharacteristic,Extent of disease,,None,None,5,0,24,no,1:no,1:no,,0.815
1941,2394267,Table 1,BaselineCharacteristic,,,Extent of disease,None,5,1,43,no,1:no,1:no,,0.782
1941,2394267,Table 1,BaselineCharacteristic,?Local,,?Local, Extent of disease,6,0,2,no,1:no,1:no,,0.796
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?Local, Extent of disease,6,1,3,no,1:no,1:no,,0.643
1941,2394267,Table 1,BaselineCharacteristic,?Metastatic,,?Metastatic, Extent of disease,7,0,24,no,1:no,1:no,,0.802
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?Metastatic, Extent of disease,7,1,43,no,1:no,1:no,,0.676
1941,2394267,Table 1,BaselineCharacteristic,??To lung/chest wall,,??To lung/chest wall, Extent of disease ?Metastatic,8,0,2,no,1:no,1:no,,0.844
1941,2394267,Table 1,BaselineCharacteristic,x,,??To lung/chest wall, Extent of disease ?Metastatic,8,1,3,no,1:no,1:no,,0.791
1941,2394267,Table 1,BaselineCharacteristic,"??To spleen, retroperitoneum, other abdomen",,"??To spleen, retroperitoneum, other abdomen", Extent of disease ?Metastatic,9,0,2,no,1:no,1:no,,0.851
1941,2394267,Table 1,BaselineCharacteristic,x,,"??To spleen, retroperitoneum, other abdomen", Extent of disease ?Metastatic,9,1,3,no,1:no,1:no,,0.802
1941,2394267,Table 1,BaselineCharacteristic,??To bone and abdomen,,??To bone and abdomen, Extent of disease ?Metastatic,10,0,2,no,1:no,1:no,,0.874
1941,2394267,Table 1,BaselineCharacteristic,x,,??To bone and abdomen, Extent of disease ?Metastatic,10,1,3,no,1:no,1:no,,0.838
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,11,0,2,no,1:no,1:no,,0.892
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,11,1,3,no,1:no,1:no,,0.813
1941,2394267,Table 1,BaselineCharacteristic,Previous treatmenta,,None,None,12,0,24,no,1:no,1:no,,0.877
1941,2394267,Table 1,BaselineCharacteristic,,,Previous treatmenta,None,12,1,43,no,1:no,1:no,,0.824
1941,2394267,Table 1,BaselineCharacteristic,?None,,?None, Previous treatmenta,13,0,2,no,1:no,1:no,,0.897
1941,2394267,Table 1,BaselineCharacteristic,xx,,?None, Previous treatmenta,13,1,3,no,1:no,1:no,,0.764
1941,2394267,Table 1,BaselineCharacteristic,?Surgery,,?Surgery, Previous treatmenta,14,0,2,no,1:no,1:no,,0.882
1941,2394267,Table 1,BaselineCharacteristic,xx,,?Surgery, Previous treatmenta,14,1,3,no,1:no,1:no,,0.716
1941,2394267,Table 1,BaselineCharacteristic,?Chemotherapy,,?Chemotherapy, Previous treatmenta,15,0,2,no,1:no,1:no,,0.886
1941,2394267,Table 1,BaselineCharacteristic,x,,?Chemotherapy, Previous treatmenta,15,1,3,no,1:no,1:no,,0.77
1941,2394267,Table 1,BaselineCharacteristic,?Hormone/immunotherapy,,?Hormone/immunotherapy, Previous treatmenta,16,0,2,no,1:no,1:no,,0.88
1941,2394267,Table 1,BaselineCharacteristic,x,,?Hormone/immunotherapy, Previous treatmenta,16,1,3,no,1:no,1:no,,0.763
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,17,0,2,no,1:no,1:no,,0.9
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,17,1,3,no,1:no,1:no,,0.826
1941,2394267,Table 1,BaselineCharacteristic,Performance status (WHO)b,,None,None,18,0,24,no,1:no,1:no,,0.861
1941,2394267,Table 1,BaselineCharacteristic,,,Performance status (WHO)b,None,18,1,43,no,1:no,1:no,,0.817
1941,2394267,Table 1,BaselineCharacteristic,?x,,?x, Performance status (WHO)b,19,0,2,no,1:no,1:no,,0.844
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?x, Performance status (WHO)b,19,1,3,no,1:no,1:no,,0.72
1941,2394267,Table 1,BaselineCharacteristic,?x,,?x, Performance status (WHO)b,20,0,2,no,1:no,1:no,,0.845
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?x, Performance status (WHO)b,20,1,3,no,1:no,1:no,,0.725
1941,2394267,Table 1,BaselineCharacteristic,?x,,?x, Performance status (WHO)b,21,0,2,no,1:no,1:no,,0.845
1941,2394267,Table 1,BaselineCharacteristic,x (xx.x),,?x, Performance status (WHO)b,21,1,3,no,1:no,1:no,,0.725
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,22,0,2,no,1:no,1:no,,0.904
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,22,1,3,no,1:no,1:no,,0.837
1941,2394267,Table 1,BaselineCharacteristic,"Age (years), median (range)",,"Age (years), median (range)",,23,0,2,no,1:no,1:no,,0.91
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,24,0,2,no,1:no,1:no,,0.905
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,24,1,3,no,1:no,1:no,,0.838
1941,2394267,Table 1,BaselineCharacteristic,"AFP (ng?ml?x), median (range)",,"AFP (ng?ml?x), median (range)",,25,0,2,no,1:no,1:no,,0.897
1976,2394470,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
1976,2394470,Table 1,BaselineCharacteristic,All patients (n=xx),,Characteristic,None,0,1,1,no,1:no,1:no,,0.637
1976,2394470,Table 1,BaselineCharacteristic,Age (years): mean (range),Characteristic ; ,Age (years): mean (range),,1,0,2,no,1:no,1:no,,0.833
1976,2394470,Table 1,BaselineCharacteristic,Male?:?female; n,Characteristic ; ,Male?:?female; n,,2,0,2,no,1:no,1:no,,0.654
1976,2394470,Table 1,BaselineCharacteristic,xx?:?xx,All patients (n=xx) ; ,Male?:?female; n,,2,1,3,yes,2:yes,2:yes,,0.791
1976,2394470,Table 1,BaselineCharacteristic,Caucasian: n,Characteristic ; ,Caucasian: n,,3,0,2,no,1:no,1:no,,0.802
1976,2394470,Table 1,BaselineCharacteristic,xx,All patients (n=xx) ; ,Caucasian: n,,3,1,3,no,1:no,2:yes,+,0.622
1976,2394470,Table 1,BaselineCharacteristic,Weight (kg): mean (range),Characteristic ; ,Weight (kg): mean (range),,4,0,2,no,1:no,1:no,,0.844
1976,2394470,Table 1,BaselineCharacteristic,Site of current cancer: n,Characteristic ; ,None,None,5,0,24,no,1:no,1:no,,0.817
1976,2394470,Table 1,BaselineCharacteristic,,All patients (n=xx) ; ,Site of current cancer: n,None,5,1,43,no,1:no,1:no,,0.606
1976,2394470,Table 1,BaselineCharacteristic,?Colorectal,Characteristic ; ,?Colorectal, Site of current cancer: n,6,0,2,no,1:no,1:no,,0.795
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Colorectal, Site of current cancer: n,6,1,3,no,1:no,1:no,,0.532
1976,2394470,Table 1,BaselineCharacteristic,?Ovary,Characteristic ; ,?Ovary, Site of current cancer: n,7,0,2,no,1:no,1:no,,0.795
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Ovary, Site of current cancer: n,7,1,3,no,1:no,1:no,,0.543
1976,2394470,Table 1,BaselineCharacteristic,?Mesothelioma,Characteristic ; ,?Mesothelioma, Site of current cancer: n,8,0,2,no,1:no,1:no,,0.792
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Mesothelioma, Site of current cancer: n,8,1,3,no,1:no,1:no,,0.555
1976,2394470,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?Lung, Site of current cancer: n,9,0,2,no,1:no,1:no,,0.809
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Lung, Site of current cancer: n,9,1,3,no,1:no,1:no,,0.563
1976,2394470,Table 1,BaselineCharacteristic,?Kidney,Characteristic ; ,?Kidney, Site of current cancer: n,10,0,2,no,1:no,1:no,,0.828
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Kidney, Site of current cancer: n,10,1,3,no,1:no,1:no,,0.579
1976,2394470,Table 1,BaselineCharacteristic,?Cervix,Characteristic ; ,?Cervix, Site of current cancer: n,11,0,2,no,1:no,1:no,,0.833
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Cervix, Site of current cancer: n,11,1,3,no,1:no,1:no,,0.589
1976,2394470,Table 1,BaselineCharacteristic,?Breast,Characteristic ; ,?Breast, Site of current cancer: n,12,0,2,no,1:no,1:no,,0.833
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Breast, Site of current cancer: n,12,1,3,no,1:no,1:no,,0.593
1976,2394470,Table 1,BaselineCharacteristic,?Skin,Characteristic ; ,?Skin, Site of current cancer: n,13,0,2,no,1:no,1:no,,0.833
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Skin, Site of current cancer: n,13,1,3,no,1:no,1:no,,0.593
1976,2394470,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other, Site of current cancer: n,14,0,2,no,1:no,1:no,,0.824
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Other, Site of current cancer: n,14,1,3,no,1:no,1:no,,0.601
1976,2394470,Table 1,BaselineCharacteristic,Prior anticancer treatment: na,Characteristic ; ,None,None,15,0,24,no,1:no,1:no,,0.883
1976,2394470,Table 1,BaselineCharacteristic,,All patients (n=xx) ; ,Prior anticancer treatment: na,None,15,1,43,no,1:no,1:no,,0.695
1976,2394470,Table 1,BaselineCharacteristic,?Chemotherapy,Characteristic ; ,?Chemotherapy, Prior anticancer treatment: na,16,0,2,no,1:no,1:no,,0.896
1976,2394470,Table 1,BaselineCharacteristic,xx,All patients (n=xx) ; ,?Chemotherapy, Prior anticancer treatment: na,16,1,3,no,1:no,1:no,,0.6
1976,2394470,Table 1,BaselineCharacteristic,?Radiation therapy,Characteristic ; ,?Radiation therapy, Prior anticancer treatment: na,17,0,2,no,1:no,1:no,,0.912
1976,2394470,Table 1,BaselineCharacteristic,xx,All patients (n=xx) ; ,?Radiation therapy, Prior anticancer treatment: na,17,1,3,no,1:no,1:no,,0.641
1976,2394470,Table 1,BaselineCharacteristic,?Surgery,Characteristic ; ,?Surgery, Prior anticancer treatment: na,18,0,2,no,1:no,1:no,,0.912
1976,2394470,Table 1,BaselineCharacteristic,xx,All patients (n=xx) ; ,?Surgery, Prior anticancer treatment: na,18,1,3,no,1:no,1:no,,0.619
1976,2394470,Table 1,BaselineCharacteristic,?Laser treatment,Characteristic ; ,?Laser treatment, Prior anticancer treatment: na,19,0,2,no,1:no,1:no,,0.908
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Laser treatment, Prior anticancer treatment: na,19,1,3,no,1:no,1:no,,0.663
1976,2394470,Table 1,BaselineCharacteristic,?Cryotherapy,Characteristic ; ,?Cryotherapy, Prior anticancer treatment: na,20,0,2,no,1:no,1:no,,0.908
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Cryotherapy, Prior anticancer treatment: na,20,1,3,no,1:no,1:no,,0.663
1988,2395326,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
1988,2395326,Table 2,BaselineCharacteristic,,,,None,0,1,1,no,1:no,1:no,,0.735
1988,2395326,Table 2,BaselineCharacteristic,Docetaxel/cisplatin,,,None,0,2,1,no,1:no,1:no,,0.775
1988,2395326,Table 2,BaselineCharacteristic,Docetaxel/irinotecan,,,None,0,3,1,no,1:no,1:no,,0.79
1988,2395326,Table 2,BaselineCharacteristic,?x text,,,None,0,4,1,no,1:no,1:no,,0.778
1988,2395326,Table 2,BaselineCharacteristic,No. of patients, ; ,No. of patients,None,1,0,2,no,1:no,1:no,,0.811
1988,2395326,Table 2,BaselineCharacteristic,, ; ,No. of patients,None,1,1,3,no,1:no,1:no,,0.746
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/cisplatin ; ,No. of patients,None,1,2,3,no,1:no,1:no,,0.625
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/irinotecan ; ,No. of patients,None,1,3,3,no,1:no,1:no,,0.638
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,No. of patients,None,1,4,3,no,1:no,1:no,,0.78
1988,2395326,Table 2,BaselineCharacteristic,Gender, ; ,Gender,None,2,0,2,no,1:no,1:no,,0.783
1988,2395326,Table 2,BaselineCharacteristic,Male/female, ; ,Gender,None,2,1,3,no,1:no,1:no,,0.614
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/cisplatin ; ,Gender,None,2,2,3,yes,2:yes,1:no,+,0.652
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/irinotecan ; ,Gender,None,2,3,3,yes,2:yes,1:no,+,0.668
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,Gender,None,2,4,3,no,1:no,1:no,,0.623
1988,2395326,Table 2,BaselineCharacteristic,Age (years), ; ,Age (years),None,3,0,2,no,1:no,1:no,,0.867
1988,2395326,Table 2,BaselineCharacteristic,Median, ; ,Age (years),None,3,1,3,no,1:no,1:no,,0.812
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/cisplatin ; ,Age (years),None,3,2,3,no,1:no,1:no,,0.748
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/irinotecan ; ,Age (years),None,3,3,3,no,1:no,1:no,,0.755
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,Age (years),None,3,4,3,no,1:no,1:no,,0.785
1988,2395326,Table 2,BaselineCharacteristic,, ; ,None,None,4,0,2,no,1:no,1:no,,0.858
1988,2395326,Table 2,BaselineCharacteristic,Range, ; ,None,None,4,1,3,no,1:no,1:no,,0.681
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,None,None,4,4,3,no,1:no,1:no,,0.756
1988,2395326,Table 2,BaselineCharacteristic,PS, ; ,PS,None,5,0,2,no,1:no,1:no,,0.883
1988,2395326,Table 2,BaselineCharacteristic,x/x, ; ,PS,None,5,1,3,no,1:no,1:no,,0.786
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/cisplatin ; ,PS,None,5,2,3,no,1:no,1:no,,0.811
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/irinotecan ; ,PS,None,5,3,3,no,1:no,1:no,,0.815
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,PS,None,5,4,3,no,1:no,1:no,,0.787
1988,2395326,Table 2,BaselineCharacteristic,Histology, ; ,Histology,None,6,0,2,no,1:no,1:no,,0.871
1988,2395326,Table 2,BaselineCharacteristic,Adenocarcinoma, ; ,Histology,None,6,1,3,no,1:no,1:no,,0.762
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/cisplatin ; ,Histology,None,6,2,3,no,1:no,1:no,,0.681
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/irinotecan ; ,Histology,None,6,3,3,no,1:no,1:no,,0.696
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,Histology,None,6,4,3,no,1:no,1:no,,0.775
1988,2395326,Table 2,BaselineCharacteristic,, ; ,None,None,7,0,2,no,1:no,1:no,,0.869
1988,2395326,Table 2,BaselineCharacteristic,Squamous cell carcinoma, ; ,None,None,7,1,3,no,1:no,1:no,,0.795
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/cisplatin ; ,None,None,7,2,3,no,1:no,1:no,,0.663
1988,2395326,Table 2,BaselineCharacteristic,x,Docetaxel/irinotecan ; ,None,None,7,3,3,no,1:no,1:no,,0.776
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,None,None,7,4,3,no,1:no,1:no,,0.777
1988,2395326,Table 2,BaselineCharacteristic,, ; ,None,None,8,0,2,no,1:no,1:no,,0.873
1988,2395326,Table 2,BaselineCharacteristic,Others, ; ,None,None,8,1,3,no,1:no,1:no,,0.774
1988,2395326,Table 2,BaselineCharacteristic,x,Docetaxel/cisplatin ; ,None,None,8,2,3,no,1:no,1:no,,0.772
1988,2395326,Table 2,BaselineCharacteristic,x,Docetaxel/irinotecan ; ,None,None,8,3,3,no,1:no,1:no,,0.79
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,None,None,8,4,3,no,1:no,1:no,,0.791
1988,2395326,Table 2,BaselineCharacteristic,Disease stage, ; ,Disease stage,None,9,0,2,no,1:no,1:no,,0.894
1988,2395326,Table 2,BaselineCharacteristic,Illb/IV, ; ,Disease stage,None,9,1,3,no,1:no,1:no,,0.826
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/cisplatin ; ,Disease stage,None,9,2,3,no,1:no,1:no,,0.831
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/irinotecan ; ,Disease stage,None,9,3,3,no,1:no,1:no,,0.844
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,Disease stage,None,9,4,3,no,1:no,1:no,,0.807
1988,2395326,Table 2,BaselineCharacteristic,Brain metastasis, ; ,Brain metastasis,None,10,0,2,no,1:no,1:no,,0.889
1988,2395326,Table 2,BaselineCharacteristic,(+)/(?), ; ,Brain metastasis,None,10,1,3,no,1:no,1:no,,0.801
1988,2395326,Table 2,BaselineCharacteristic,x/xx,Docetaxel/cisplatin ; ,Brain metastasis,None,10,2,3,no,1:no,1:no,,0.814
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/irinotecan ; ,Brain metastasis,None,10,3,3,no,1:no,1:no,,0.829
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,Brain metastasis,None,10,4,3,no,1:no,1:no,,0.799
2001,2409455,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
2001,2409455,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,no,1:no,1:no,,0.76
2001,2409455,Table 1,BaselineCharacteristic,%,,,None,0,2,1,no,1:no,1:no,,0.757
2001,2409455,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,1,0,24,no,1:no,1:no,,0.836
2001,2409455,Table 1,BaselineCharacteristic,Age (years),No. of patients ; ,Age (years),None,1,1,43,no,1:no,1:no,,0.812
2001,2409455,Table 1,BaselineCharacteristic,Age (years),% ; ,Age (years),None,1,2,43,no,1:no,1:no,,0.783
2001,2409455,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),2,0,2,no,1:no,1:no,,0.851
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Median, Age (years),2,1,3,no,1:no,1:no,,0.606
2001,2409455,Table 1,BaselineCharacteristic,xx,% ; ,?Median, Age (years),2,2,3,no,1:no,1:no,,0.608
2001,2409455,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),3,0,2,no,1:no,1:no,,0.824
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no,1:no,1:no,,0.858
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,4,1,3,no,1:no,1:no,,0.723
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,4,2,3,no,1:no,1:no,,0.701
2001,2409455,Table 1,BaselineCharacteristic,Sex, ; ,None,None,5,0,24,no,1:no,1:no,,0.605
2001,2409455,Table 1,BaselineCharacteristic,Sex,No. of patients ; ,Sex,None,5,1,43,no,1:no,1:no,,0.584
2001,2409455,Table 1,BaselineCharacteristic,Sex,% ; ,Sex,None,5,2,43,no,1:no,1:no,,0.532
2001,2409455,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Sex,6,0,2,no,1:no,2:yes,+,0.515
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Male, Sex,6,1,3,yes,2:yes,2:yes,,0.83
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Male, Sex,6,2,3,yes,2:yes,2:yes,,0.84
2001,2409455,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Sex,7,0,2,no,1:no,1:no,,0.524
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Female, Sex,7,1,3,yes,2:yes,2:yes,,0.748
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Female, Sex,7,2,3,yes,2:yes,2:yes,,0.838
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,8,0,2,no,1:no,1:no,,0.873
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,8,1,3,no,1:no,1:no,,0.813
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,8,2,3,no,1:no,1:no,,0.726
2001,2409455,Table 1,BaselineCharacteristic,Performance status, ; ,None,None,9,0,24,no,1:no,1:no,,0.887
2001,2409455,Table 1,BaselineCharacteristic,Performance status,No. of patients ; ,Performance status,None,9,1,43,no,1:no,1:no,,0.858
2001,2409455,Table 1,BaselineCharacteristic,Performance status,% ; ,Performance status,None,9,2,43,no,1:no,1:no,,0.791
2001,2409455,Table 1,BaselineCharacteristic,?ECOG x, ; ,?ECOG x, Performance status,10,0,2,no,1:no,1:no,,0.865
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?ECOG x, Performance status,10,1,3,no,1:no,1:no,,0.687
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?ECOG x, Performance status,10,2,3,no,1:no,1:no,,0.643
2001,2409455,Table 1,BaselineCharacteristic,?ECOG x, ; ,?ECOG x, Performance status,11,0,2,no,1:no,1:no,,0.866
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?ECOG x, Performance status,11,1,3,no,1:no,1:no,,0.702
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?ECOG x, Performance status,11,2,3,no,1:no,1:no,,0.656
2001,2409455,Table 1,BaselineCharacteristic,?ECOG x, ; ,?ECOG x, Performance status,12,0,2,no,1:no,1:no,,0.866
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?ECOG x, Performance status,12,1,3,no,1:no,1:no,,0.774
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?ECOG x, Performance status,12,2,3,no,1:no,1:no,,0.752
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,13,0,2,no,1:no,1:no,,0.892
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,13,1,3,no,1:no,1:no,,0.849
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,13,2,3,no,1:no,1:no,,0.76
2001,2409455,Table 1,BaselineCharacteristic,Histology, ; ,None,None,14,0,24,no,1:no,1:no,,0.878
2001,2409455,Table 1,BaselineCharacteristic,Histology,No. of patients ; ,Histology,None,14,1,43,no,1:no,1:no,,0.868
2001,2409455,Table 1,BaselineCharacteristic,Histology,% ; ,Histology,None,14,2,43,no,1:no,1:no,,0.785
2001,2409455,Table 1,BaselineCharacteristic,?WDA, ; ,?WDA, Histology,15,0,2,no,1:no,1:no,,0.883
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?WDA, Histology,15,1,3,no,1:no,1:no,,0.69
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?WDA, Histology,15,2,3,no,1:no,1:no,,0.593
2001,2409455,Table 1,BaselineCharacteristic,?PDC, ; ,?PDC, Histology,16,0,2,no,1:no,1:no,,0.883
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?PDC, Histology,16,1,3,no,1:no,1:no,,0.691
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?PDC, Histology,16,2,3,no,1:no,1:no,,0.599
2001,2409455,Table 1,BaselineCharacteristic,?SCC, ; ,?SCC, Histology,17,0,2,no,1:no,1:no,,0.896
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?SCC, Histology,17,1,3,no,1:no,1:no,,0.775
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?SCC, Histology,17,2,3,no,1:no,1:no,,0.754
2001,2409455,Table 1,BaselineCharacteristic,?UN, ; ,?UN, Histology,18,0,2,no,1:no,1:no,,0.9
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?UN, Histology,18,1,3,no,1:no,1:no,,0.718
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?UN, Histology,18,2,3,no,1:no,1:no,,0.769
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,19,0,2,no,1:no,1:no,,0.902
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,19,1,3,no,1:no,1:no,,0.862
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,19,2,3,no,1:no,1:no,,0.777
2001,2409455,Table 1,BaselineCharacteristic,Extension, ; ,None,None,20,0,24,no,1:no,1:no,,0.889
2001,2409455,Table 1,BaselineCharacteristic,Extension,No. of patients ; ,Extension,None,20,1,43,no,1:no,1:no,,0.872
2001,2409455,Table 1,BaselineCharacteristic,Extension,% ; ,Extension,None,20,2,43,no,1:no,1:no,,0.794
2001,2409455,Table 1,BaselineCharacteristic,?Locoregional, ; ,?Locoregional, Extension,21,0,2,no,1:no,1:no,,0.891
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Locoregional, Extension,21,1,3,no,1:no,1:no,,0.684
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Locoregional, Extension,21,2,3,no,1:no,1:no,,0.644
2001,2409455,Table 1,BaselineCharacteristic,?Disseminated, ; ,?Disseminated, Extension,22,0,2,no,1:no,1:no,,0.893
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Disseminated, Extension,22,1,3,no,1:no,1:no,,0.686
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Disseminated, Extension,22,2,3,no,1:no,1:no,,0.652
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,23,0,2,no,1:no,1:no,,0.905
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,23,1,3,no,1:no,1:no,,0.865
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,23,2,3,no,1:no,1:no,,0.79
2001,2409455,Table 1,BaselineCharacteristic,Topography, ; ,None,None,24,0,24,no,1:no,1:no,,0.891
2001,2409455,Table 1,BaselineCharacteristic,Topography,No. of patients ; ,Topography,None,24,1,43,no,1:no,1:no,,0.874
2001,2409455,Table 1,BaselineCharacteristic,Topography,% ; ,Topography,None,24,2,43,no,1:no,1:no,,0.805
2001,2409455,Table 1,BaselineCharacteristic,?Supradiaphragmatic, ; ,?Supradiaphragmatic, Topography,25,0,2,no,1:no,1:no,,0.895
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Supradiaphragmatic, Topography,25,1,3,no,1:no,1:no,,0.691
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Supradiaphragmatic, Topography,25,2,3,no,1:no,1:no,,0.663
2001,2409455,Table 1,BaselineCharacteristic,?Subdiaphragmatic, ; ,?Subdiaphragmatic, Topography,26,0,2,no,1:no,1:no,,0.895
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Subdiaphragmatic, Topography,26,1,3,no,1:no,1:no,,0.691
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Subdiaphragmatic, Topography,26,2,3,no,1:no,1:no,,0.663
2001,2409455,Table 1,BaselineCharacteristic,?Both sides, ; ,?Both sides, Topography,27,0,2,no,1:no,1:no,,0.895
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Both sides, Topography,27,1,3,no,1:no,1:no,,0.691
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Both sides, Topography,27,2,3,no,1:no,1:no,,0.663
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,28,0,2,no,1:no,1:no,,0.905
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,28,1,3,no,1:no,1:no,,0.865
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,28,2,3,no,1:no,1:no,,0.792
2001,2409455,Table 1,BaselineCharacteristic,Number of involved sites, ; ,None,None,29,0,24,no,1:no,1:no,,0.905
2001,2409455,Table 1,BaselineCharacteristic,Number of involved sites,No. of patients ; ,Number of involved sites,None,29,1,43,no,1:no,1:no,,0.898
2001,2409455,Table 1,BaselineCharacteristic,Number of involved sites,% ; ,Number of involved sites,None,29,2,43,no,1:no,1:no,,0.86
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of involved sites,30,0,2,no,1:no,1:no,,0.892
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of involved sites,30,1,3,no,1:no,1:no,,0.775
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of involved sites,30,2,3,no,1:no,1:no,,0.782
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of involved sites,31,0,2,no,1:no,1:no,,0.892
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of involved sites,31,1,3,no,1:no,1:no,,0.775
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of involved sites,31,2,3,no,1:no,1:no,,0.782
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of involved sites,32,0,2,no,1:no,1:no,,0.892
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of involved sites,32,1,3,no,1:no,1:no,,0.775
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of involved sites,32,2,3,no,1:no,1:no,,0.782
2001,2409455,Table 1,BaselineCharacteristic,??x, ; ,??x, Number of involved sites,33,0,2,no,1:no,1:no,,0.892
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,??x, Number of involved sites,33,1,3,no,1:no,1:no,,0.775
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,??x, Number of involved sites,33,2,3,no,1:no,1:no,,0.782
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,34,0,2,no,1:no,1:no,,0.905
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,34,1,3,no,1:no,1:no,,0.865
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,34,2,3,no,1:no,1:no,,0.792
2001,2409455,Table 1,BaselineCharacteristic,Number of metastases, ; ,None,None,35,0,24,no,1:no,1:no,,0.896
2001,2409455,Table 1,BaselineCharacteristic,Number of metastases,No. of patients ; ,Number of metastases,None,35,1,43,no,1:no,1:no,,0.873
2001,2409455,Table 1,BaselineCharacteristic,Number of metastases,% ; ,Number of metastases,None,35,2,43,no,1:no,1:no,,0.844
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of metastases,36,0,2,no,1:no,1:no,,0.869
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of metastases,36,1,3,no,1:no,1:no,,0.732
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of metastases,36,2,3,no,1:no,1:no,,0.729
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of metastases,37,0,2,no,1:no,1:no,,0.869
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Number of metastases,37,1,3,no,1:no,1:no,,0.781
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?x, Number of metastases,37,2,3,no,1:no,1:no,,0.803
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of metastases,38,0,2,no,1:no,1:no,,0.869
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of metastases,38,1,3,no,1:no,1:no,,0.732
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of metastases,38,2,3,no,1:no,1:no,,0.729
2001,2409455,Table 1,BaselineCharacteristic,??x, ; ,??x, Number of metastases,39,0,2,no,1:no,1:no,,0.869
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,??x, Number of metastases,39,1,3,no,1:no,1:no,,0.732
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,??x, Number of metastases,39,2,3,no,1:no,1:no,,0.729
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,40,0,2,no,1:no,1:no,,0.905
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,40,1,3,no,1:no,1:no,,0.865
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,40,2,3,no,1:no,1:no,,0.792
2001,2409455,Table 1,BaselineCharacteristic,Main involved sites, ; ,None,None,41,0,24,no,1:no,1:no,,0.91
2001,2409455,Table 1,BaselineCharacteristic,Main involved sites,No. of patients ; ,Main involved sites,None,41,1,43,no,1:no,1:no,,0.905
2001,2409455,Table 1,BaselineCharacteristic,Main involved sites,% ; ,Main involved sites,None,41,2,43,no,1:no,1:no,,0.833
2001,2409455,Table 1,BaselineCharacteristic,?Supraclavicular nodes, ; ,?Supraclavicular nodes, Main involved sites,42,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Supraclavicular nodes, Main involved sites,42,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Supraclavicular nodes, Main involved sites,42,2,3,no,1:no,1:no,,0.725
2001,2409455,Table 1,BaselineCharacteristic,?Hylomediastinal nodes, ; ,?Hylomediastinal nodes, Main involved sites,43,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Hylomediastinal nodes, Main involved sites,43,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Hylomediastinal nodes, Main involved sites,43,2,3,no,1:no,1:no,,0.725
2001,2409455,Table 1,BaselineCharacteristic,?Abdominal nodes, ; ,?Abdominal nodes, Main involved sites,44,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Abdominal nodes, Main involved sites,44,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Abdominal nodes, Main involved sites,44,2,3,no,1:no,1:no,,0.725
2001,2409455,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone, Main involved sites,45,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Bone, Main involved sites,45,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Bone, Main involved sites,45,2,3,no,1:no,1:no,,0.725
2001,2409455,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver, Main involved sites,46,0,2,no,1:no,1:no,,0.918
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Liver, Main involved sites,46,1,3,no,1:no,1:no,,0.758
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Liver, Main involved sites,46,2,3,no,1:no,1:no,,0.741
2001,2409455,Table 1,BaselineCharacteristic,?Lung, ; ,?Lung, Main involved sites,47,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Lung, Main involved sites,47,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Lung, Main involved sites,47,2,3,no,1:no,1:no,,0.725
2001,2409455,Table 1,BaselineCharacteristic,?Ascites, ; ,?Ascites, Main involved sites,48,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Ascites, Main involved sites,48,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Ascites, Main involved sites,48,2,3,no,1:no,1:no,,0.725
2001,2409455,Table 1,BaselineCharacteristic,?Pleural effusion, ; ,?Pleural effusion, Main involved sites,49,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Pleural effusion, Main involved sites,49,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?Pleural effusion, Main involved sites,49,2,3,no,1:no,1:no,,0.806
2001,2409455,Table 1,BaselineCharacteristic,?Nodes/soft tissues only, ; ,?Nodes/soft tissues only, Main involved sites,50,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Nodes/soft tissues only, Main involved sites,50,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Nodes/soft tissues only, Main involved sites,50,2,3,no,1:no,1:no,,0.725
2001,2409455,Table 1,BaselineCharacteristic,?Visceral/bone involvement, ; ,?Visceral/bone involvement, Main involved sites,51,0,2,no,1:no,1:no,,0.907
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Visceral/bone involvement, Main involved sites,51,1,3,no,1:no,1:no,,0.738
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Visceral/bone involvement, Main involved sites,51,2,3,no,1:no,1:no,,0.725
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,52,0,2,no,1:no,1:no,,0.905
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,52,1,3,no,1:no,1:no,,0.865
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,52,2,3,no,1:no,1:no,,0.792
2001,2409455,Table 1,BaselineCharacteristic,Main symptoms, ; ,None,None,53,0,24,no,1:no,1:no,,0.898
2001,2409455,Table 1,BaselineCharacteristic,Main symptoms,No. of patients ; ,Main symptoms,None,53,1,43,no,1:no,1:no,,0.881
2001,2409455,Table 1,BaselineCharacteristic,Main symptoms,% ; ,Main symptoms,None,53,2,43,no,1:no,1:no,,0.822
2001,2409455,Table 1,BaselineCharacteristic,?Pain, ; ,?Pain, Main symptoms,54,0,2,no,1:no,1:no,,0.898
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Pain, Main symptoms,54,1,3,no,1:no,1:no,,0.709
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Pain, Main symptoms,54,2,3,no,1:no,1:no,,0.675
2001,2409455,Table 1,BaselineCharacteristic,?Gastrointestinal, ; ,?Gastrointestinal, Main symptoms,55,0,2,no,1:no,1:no,,0.898
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Gastrointestinal, Main symptoms,55,1,3,no,1:no,1:no,,0.709
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Gastrointestinal, Main symptoms,55,2,3,no,1:no,1:no,,0.675
2001,2409455,Table 1,BaselineCharacteristic,?Respiratory, ; ,?Respiratory, Main symptoms,56,0,2,no,1:no,1:no,,0.898
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Respiratory, Main symptoms,56,1,3,no,1:no,1:no,,0.709
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Respiratory, Main symptoms,56,2,3,no,1:no,1:no,,0.675
2001,2409455,Table 1,BaselineCharacteristic,?Fever, ; ,?Fever, Main symptoms,57,0,2,no,1:no,1:no,,0.898
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Fever, Main symptoms,57,1,3,no,1:no,1:no,,0.709
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Fever, Main symptoms,57,2,3,no,1:no,1:no,,0.675
2001,2409455,Table 1,BaselineCharacteristic,?Weight loss >xx%, ; ,?Weight loss >xx%, Main symptoms,58,0,2,no,1:no,1:no,,0.903
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Weight loss >xx%, Main symptoms,58,1,3,no,1:no,1:no,,0.801
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?Weight loss >xx%, Main symptoms,58,2,3,no,1:no,1:no,,0.786
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,59,0,2,no,1:no,1:no,,0.905
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,59,1,3,no,1:no,1:no,,0.865
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,59,2,3,no,1:no,1:no,,0.792
2001,2409455,Table 1,BaselineCharacteristic,Laboratory parameters, ; ,None,None,60,0,24,no,1:no,1:no,,0.891
2001,2409455,Table 1,BaselineCharacteristic,Laboratory parameters,No. of patients ; ,Laboratory parameters,None,60,1,43,no,1:no,1:no,,0.874
2001,2409455,Table 1,BaselineCharacteristic,Laboratory parameters,% ; ,Laboratory parameters,None,60,2,43,no,1:no,1:no,,0.807
2001,2409455,Table 1,BaselineCharacteristic,?Hb <xx, ; ,?Hb <xx, Laboratory parameters,61,0,2,no,1:no,1:no,,0.896
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Hb <xx, Laboratory parameters,61,1,3,no,1:no,1:no,,0.692
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Hb <xx, Laboratory parameters,61,2,3,no,1:no,1:no,,0.663
2001,2409455,Table 1,BaselineCharacteristic,?CEA >x, ; ,?CEA >x, Laboratory parameters,65,0,2,no,1:no,1:no,,0.896
2001,2409455,Table 1,BaselineCharacteristic,xx/xx,No. of patients ; ,?CEA >x, Laboratory parameters,65,1,3,no,1:no,1:no,,0.778
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?CEA >x, Laboratory parameters,65,2,3,no,1:no,1:no,,0.663
2001,2409455,Table 1,BaselineCharacteristic,?CA xx.x>xx, ; ,?CA xx.x>xx, Laboratory parameters,66,0,2,no,1:no,1:no,,0.837
2001,2409455,Table 1,BaselineCharacteristic,xx/xx,No. of patients ; ,?CA xx.x>xx, Laboratory parameters,66,1,3,no,1:no,1:no,,0.692
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?CA xx.x>xx, Laboratory parameters,66,2,3,no,1:no,1:no,,0.663
2001,2409455,Table 1,BaselineCharacteristic,?CA xxx>xx, ; ,?CA xxx>xx, Laboratory parameters,67,0,2,no,1:no,1:no,,0.896
2001,2409455,Table 1,BaselineCharacteristic,xx/xx,No. of patients ; ,?CA xxx>xx, Laboratory parameters,67,1,3,no,1:no,1:no,,0.778
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?CA xxx>xx, Laboratory parameters,67,2,3,no,1:no,1:no,,0.663
2001,2409455,Table 1,BaselineCharacteristic,?Any epithelial marker abnormal, ; ,?Any epithelial marker abnormal, Laboratory parameters,68,0,2,no,1:no,1:no,,0.896
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Any epithelial marker abnormal, Laboratory parameters,68,1,3,no,1:no,1:no,,0.692
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Any epithelial marker abnormal, Laboratory parameters,68,2,3,no,1:no,1:no,,0.663
2001,2409455,Table 1,BaselineCharacteristic,?Any germ cell marker abnormal, ; ,?Any germ cell marker abnormal, Laboratory parameters,69,0,2,no,1:no,1:no,,0.902
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Any germ cell marker abnormal, Laboratory parameters,69,1,3,no,1:no,1:no,,0.78
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?Any germ cell marker abnormal, Laboratory parameters,69,2,3,no,1:no,1:no,,0.777
2011,2409510,Table 2,BaselineCharacteristic,No. of patients,,No. of patients,,0,0,2,no,1:no,1:no,,0.699
2011,2409510,Table 2,BaselineCharacteristic,,,No. of patients,,0,1,3,no,1:no,1:no,,0.591
2011,2409510,Table 2,BaselineCharacteristic,xx,,No. of patients,,0,2,3,no,1:no,2:yes,+,0.53
2011,2409510,Table 2,BaselineCharacteristic,"Age, years",,"Age, years",,1,0,24,no,1:no,1:no,,0.772
2011,2409510,Table 2,BaselineCharacteristic,Median,,"Age, years",,1,1,43,no,1:no,1:no,,0.769
2011,2409510,Table 2,BaselineCharacteristic,xx.x,,"Age, years",,1,2,43,no,1:no,1:no,,0.615
2011,2409510,Table 2,BaselineCharacteristic,,,,,2,0,2,no,1:no,1:no,,0.831
2011,2409510,Table 2,BaselineCharacteristic,Range,,,,2,1,3,no,1:no,1:no,,0.644
2011,2409510,Table 2,BaselineCharacteristic,Sex,,Sex,,3,0,2,no,1:no,1:no,,0.576
2011,2409510,Table 2,BaselineCharacteristic,Male/female,,Sex,,3,1,3,no,1:no,2:yes,+,0.625
2011,2409510,Table 2,BaselineCharacteristic,xx/x,,Sex,,3,2,3,yes,2:yes,2:yes,,0.608
2011,2409510,Table 2,BaselineCharacteristic,Performance status,,Performance status,,4,0,2,no,1:no,1:no,,0.867
2011,2409510,Table 2,BaselineCharacteristic,x/x,,Performance status,,4,1,3,no,1:no,1:no,,0.752
2011,2409510,Table 2,BaselineCharacteristic,x/xx,,Performance status,,4,2,3,no,1:no,1:no,,0.77
2011,2409510,Table 2,BaselineCharacteristic,Histology,,Histology,,5,0,2,no,1:no,1:no,,0.843
2011,2409510,Table 2,BaselineCharacteristic,Adeno/squamous,,Histology,,5,1,3,no,1:no,1:no,,0.736
2011,2409510,Table 2,BaselineCharacteristic,xx/x,,Histology,,5,2,3,no,1:no,1:no,,0.748
2011,2409510,Table 2,BaselineCharacteristic,Stage,,Stage,,6,0,2,no,1:no,1:no,,0.86
2011,2409510,Table 2,BaselineCharacteristic,IIIB/IV,,Stage,,6,1,3,no,1:no,1:no,,0.761
2011,2409510,Table 2,BaselineCharacteristic,x/xx,,Stage,,6,2,3,no,1:no,1:no,,0.783
2011,2409510,Table 2,BaselineCharacteristic,Prior therapy,,Prior therapy,,7,0,24,no,1:no,1:no,,0.794
2011,2409510,Table 2,BaselineCharacteristic,None,,Prior therapy,,7,1,43,no,1:no,1:no,,0.798
2011,2409510,Table 2,BaselineCharacteristic,x,,Prior therapy,,7,2,43,no,1:no,1:no,,0.739
2011,2409510,Table 2,BaselineCharacteristic,,,,,8,0,2,no,1:no,1:no,,0.837
2011,2409510,Table 2,BaselineCharacteristic,Surgery,,,,8,1,3,no,1:no,1:no,,0.743
2011,2409510,Table 2,BaselineCharacteristic,x,,,,8,2,3,no,1:no,1:no,,0.726
2011,2409510,Table 2,BaselineCharacteristic,,,,,9,0,2,no,1:no,1:no,,0.856
2011,2409510,Table 2,BaselineCharacteristic,Radiation,,,,9,1,3,no,1:no,1:no,,0.772
2011,2409510,Table 2,BaselineCharacteristic,x,,,,9,2,3,no,1:no,1:no,,0.749
2011,2409510,Table 2,BaselineCharacteristic,,,,,10,0,2,no,1:no,1:no,,0.863
2011,2409510,Table 2,BaselineCharacteristic,Chemotherapy,,,,10,1,3,no,1:no,1:no,,0.781
2011,2409510,Table 2,BaselineCharacteristic,xx,,,,10,2,3,no,1:no,1:no,,0.664
2011,2409510,Table 2,BaselineCharacteristic,,,,,11,0,2,no,1:no,1:no,,0.867
2011,2409510,Table 2,BaselineCharacteristic,?CDDP-based,,,,11,1,3,no,1:no,1:no,,0.776
2011,2409510,Table 2,BaselineCharacteristic,x,,,,11,2,3,no,1:no,1:no,,0.772
2011,2409510,Table 2,BaselineCharacteristic,,,,,12,0,2,no,1:no,1:no,,0.873
2011,2409510,Table 2,BaselineCharacteristic,?CBDCA-based,,,,12,1,3,no,1:no,1:no,,0.785
2011,2409510,Table 2,BaselineCharacteristic,x,,,,12,2,3,no,1:no,1:no,,0.776
2011,2409510,Table 2,BaselineCharacteristic,,,,,13,0,2,no,1:no,1:no,,0.873
2011,2409510,Table 2,BaselineCharacteristic,?Nonplatinum,,,,13,1,3,no,1:no,1:no,,0.785
2011,2409510,Table 2,BaselineCharacteristic,x,,,,13,2,3,no,1:no,1:no,,0.776
2011,2409510,Table 2,BaselineCharacteristic,,,,,14,0,2,no,1:no,1:no,,0.869
2011,2409510,Table 2,BaselineCharacteristic,?UFT,,,,14,1,3,no,1:no,1:no,,0.78
2011,2409510,Table 2,BaselineCharacteristic,x,,,,14,2,3,no,1:no,1:no,,0.764
2011,2409510,Table 2,BaselineCharacteristic,,,,,15,0,2,no,1:no,1:no,,0.874
2011,2409510,Table 2,BaselineCharacteristic,?Gefitinin,,,,15,1,3,no,1:no,1:no,,0.79
2011,2409510,Table 2,BaselineCharacteristic,x,,,,15,2,3,no,1:no,1:no,,0.77
2012,2409516,Table 1,BaselineCharacteristic,Patients entered,,None,None,0,0,12,no,1:no,1:no,,0.779
2012,2409516,Table 1,BaselineCharacteristic,x,,Patients entered,None,0,1,1,no,1:no,1:no,,0.738
2012,2409516,Table 1,BaselineCharacteristic,Male/female,,None,None,1,0,12,no,1:no,1:no,,0.792
2012,2409516,Table 1,BaselineCharacteristic,x/x,,Male/female,None,1,1,1,yes,2:yes,1:no,+,0.716
2012,2409516,Table 1,BaselineCharacteristic,"Median age, years (range)",,None,None,2,0,12,no,1:no,1:no,,0.837
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,3,0,2,no,1:no,1:no,,0.84
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,3,1,3,no,1:no,1:no,,0.711
2012,2409516,Table 1,BaselineCharacteristic,Performance status,,None,None,4,0,24,no,1:no,1:no,,0.851
2012,2409516,Table 1,BaselineCharacteristic,,,Performance status,None,4,1,43,no,1:no,1:no,,0.78
2012,2409516,Table 1,BaselineCharacteristic,?x,,?x, Performance status,5,0,2,no,1:no,1:no,,0.837
2012,2409516,Table 1,BaselineCharacteristic,x,,?x, Performance status,5,1,3,no,1:no,1:no,,0.75
2012,2409516,Table 1,BaselineCharacteristic,?x,,?x, Performance status,6,0,2,no,1:no,1:no,,0.837
2012,2409516,Table 1,BaselineCharacteristic,x,,?x, Performance status,6,1,3,no,1:no,1:no,,0.755
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,7,0,2,no,1:no,1:no,,0.869
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,7,1,3,no,1:no,1:no,,0.747
2012,2409516,Table 1,BaselineCharacteristic,Malignancy,,None,None,8,0,24,no,1:no,1:no,,0.852
2012,2409516,Table 1,BaselineCharacteristic,,,Malignancy,None,8,1,43,no,1:no,1:no,,0.786
2012,2409516,Table 1,BaselineCharacteristic,?Melanoma,,?Melanoma, Malignancy,9,0,2,no,1:no,1:no,,0.856
2012,2409516,Table 1,BaselineCharacteristic,x,,?Melanoma, Malignancy,9,1,3,no,1:no,1:no,,0.735
2012,2409516,Table 1,BaselineCharacteristic,?Non-small-cell lung cancer,,?Non-small-cell lung cancer, Malignancy,10,0,2,no,1:no,1:no,,0.87
2012,2409516,Table 1,BaselineCharacteristic,x,,?Non-small-cell lung cancer, Malignancy,10,1,3,no,1:no,1:no,,0.757
2012,2409516,Table 1,BaselineCharacteristic,?Sarcoma,,?Sarcoma, Malignancy,11,0,2,no,1:no,1:no,,0.867
2012,2409516,Table 1,BaselineCharacteristic,x,,?Sarcoma, Malignancy,11,1,3,no,1:no,1:no,,0.758
2012,2409516,Table 1,BaselineCharacteristic,?Renal cell carcinoma,,?Renal cell carcinoma, Malignancy,12,0,2,no,1:no,1:no,,0.895
2012,2409516,Table 1,BaselineCharacteristic,x,,?Renal cell carcinoma, Malignancy,12,1,3,no,1:no,1:no,,0.806
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,13,0,2,no,1:no,1:no,,0.892
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,13,1,3,no,1:no,1:no,,0.813
2012,2409516,Table 1,BaselineCharacteristic,Prior therapy,,None,None,14,0,24,no,1:no,1:no,,0.887
2012,2409516,Table 1,BaselineCharacteristic,,,Prior therapy,None,14,1,43,no,1:no,1:no,,0.838
2012,2409516,Table 1,BaselineCharacteristic,?Chemotherapy,,?Chemotherapy, Prior therapy,15,0,2,no,1:no,1:no,,0.889
2012,2409516,Table 1,BaselineCharacteristic,x,,?Chemotherapy, Prior therapy,15,1,3,no,1:no,1:no,,0.783
2012,2409516,Table 1,BaselineCharacteristic,?Radiotherapy,,?Radiotherapy, Prior therapy,16,0,2,no,1:no,1:no,,0.885
2012,2409516,Table 1,BaselineCharacteristic,x,,?Radiotherapy, Prior therapy,16,1,3,no,1:no,1:no,,0.777
2012,2409516,Table 1,BaselineCharacteristic,?Immunotherapy,,?Immunotherapy, Prior therapy,17,0,2,no,1:no,1:no,,0.898
2012,2409516,Table 1,BaselineCharacteristic,x,,?Immunotherapy, Prior therapy,17,1,3,no,1:no,1:no,,0.818
2012,2409516,Table 1,BaselineCharacteristic,?Hormonal therapy,,?Hormonal therapy, Prior therapy,18,0,2,no,1:no,1:no,,0.901
2012,2409516,Table 1,BaselineCharacteristic,x,,?Hormonal therapy, Prior therapy,18,1,3,no,1:no,1:no,,0.821
2062,2409820,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
2062,2409820,Table 2,BaselineCharacteristic,n,,,None,0,1,1,no,1:no,1:no,,0.703
2062,2409820,Table 2,BaselineCharacteristic,Entered/evaluable, ; ,Entered/evaluable,,1,0,2,no,1:no,1:no,,0.813
2062,2409820,Table 2,BaselineCharacteristic,xx/xx,n ; ,Entered/evaluable,,1,1,3,no,1:no,1:no,,0.619
2062,2409820,Table 2,BaselineCharacteristic,Male/female, ; ,Male/female,,2,0,2,no,1:no,1:no,,0.831
2062,2409820,Table 2,BaselineCharacteristic,xx/xx,n ; ,Male/female,,2,1,3,yes,2:yes,1:no,+,0.634
2062,2409820,Table 2,BaselineCharacteristic,Median age (range), ; ,Median age (range),,3,0,2,no,1:no,1:no,,0.844
2062,2409820,Table 2,BaselineCharacteristic,, ; ,None,None,4,0,2,no,1:no,1:no,,0.858
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,None,None,4,1,3,no,1:no,1:no,,0.668
2062,2409820,Table 2,BaselineCharacteristic,Performance status, ; ,None,None,5,0,24,no,1:no,1:no,,0.869
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,Performance status,None,5,1,43,no,1:no,1:no,,0.713
2062,2409820,Table 2,BaselineCharacteristic,?x, ; ,?x, Performance status,6,0,2,no,1:no,1:no,,0.837
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?x, Performance status,6,1,3,no,1:no,1:no,,0.611
2062,2409820,Table 2,BaselineCharacteristic,?x, ; ,?x, Performance status,7,0,2,no,1:no,1:no,,0.844
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?x, Performance status,7,1,3,no,1:no,1:no,,0.609
2062,2409820,Table 2,BaselineCharacteristic,, ; ,None,None,8,0,2,no,1:no,1:no,,0.873
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,None,None,8,1,3,no,1:no,1:no,,0.704
2062,2409820,Table 2,BaselineCharacteristic,Primary tumour site, ; ,None,None,9,0,24,no,1:no,1:no,,0.89
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,Primary tumour site,None,9,1,43,no,1:no,1:no,,0.77
2062,2409820,Table 2,BaselineCharacteristic,?Lung (NSCLC), ; ,?Lung (NSCLC), Primary tumour site,10,0,2,no,1:no,1:no,,0.887
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?Lung (NSCLC), Primary tumour site,10,1,3,no,1:no,1:no,,0.662
2062,2409820,Table 2,BaselineCharacteristic,?Colon, ; ,?Colon, Primary tumour site,11,0,2,no,1:no,1:no,,0.888
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Colon, Primary tumour site,11,1,3,no,1:no,1:no,,0.703
2062,2409820,Table 2,BaselineCharacteristic,?Gastric, ; ,?Gastric, Primary tumour site,12,0,2,no,1:no,1:no,,0.894
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Gastric, Primary tumour site,12,1,3,no,1:no,1:no,,0.707
2062,2409820,Table 2,BaselineCharacteristic,?Adenoidcystic, ; ,?Adenoidcystic, Primary tumour site,13,0,2,no,1:no,1:no,,0.894
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Adenoidcystic, Primary tumour site,13,1,3,no,1:no,1:no,,0.707
2062,2409820,Table 2,BaselineCharacteristic,?Melanoma, ; ,?Melanoma, Primary tumour site,14,0,2,no,1:no,1:no,,0.89
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Melanoma, Primary tumour site,14,1,3,no,1:no,1:no,,0.696
2062,2409820,Table 2,BaselineCharacteristic,?Mesothelioma, ; ,?Mesothelioma, Primary tumour site,15,0,2,no,1:no,1:no,,0.894
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Mesothelioma, Primary tumour site,15,1,3,no,1:no,1:no,,0.7
2062,2409820,Table 2,BaselineCharacteristic,?Biliary tract, ; ,?Biliary tract, Primary tumour site,16,0,2,no,1:no,1:no,,0.894
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Biliary tract, Primary tumour site,16,1,3,no,1:no,1:no,,0.7
2062,2409820,Table 2,BaselineCharacteristic,?Ovary, ; ,?Ovary, Primary tumour site,17,0,2,no,1:no,1:no,,0.907
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Ovary, Primary tumour site,17,1,3,no,1:no,1:no,,0.752
2062,2409820,Table 2,BaselineCharacteristic,?Pancreas, ; ,?Pancreas, Primary tumour site,18,0,2,no,1:no,1:no,,0.909
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Pancreas, Primary tumour site,18,1,3,no,1:no,1:no,,0.754
2062,2409820,Table 2,BaselineCharacteristic,?Peritoneal, ; ,?Peritoneal, Primary tumour site,19,0,2,no,1:no,1:no,,0.909
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Peritoneal, Primary tumour site,19,1,3,no,1:no,1:no,,0.76
2062,2409820,Table 2,BaselineCharacteristic,?Sarcoma, ; ,?Sarcoma, Primary tumour site,20,0,2,no,1:no,1:no,,0.91
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Sarcoma, Primary tumour site,20,1,3,no,1:no,1:no,,0.765
2062,2409820,Table 2,BaselineCharacteristic,, ; ,None,None,21,0,2,no,1:no,1:no,,0.902
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,None,None,21,1,3,no,1:no,1:no,,0.774
2062,2409820,Table 2,BaselineCharacteristic,Prior treatment, ; ,None,None,22,0,24,no,1:no,1:no,,0.89
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,Prior treatment,None,22,1,43,no,1:no,1:no,,0.817
2062,2409820,Table 2,BaselineCharacteristic,?Previous chemotherapy, ; ,?Previous chemotherapy, Prior treatment,23,0,2,no,1:no,1:no,,0.908
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?Previous chemotherapy, Prior treatment,23,1,3,no,1:no,1:no,,0.803
2062,2409820,Table 2,BaselineCharacteristic,?Previous radiation, ; ,?Previous radiation, Prior treatment,24,0,2,no,1:no,1:no,,0.909
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Previous radiation, Prior treatment,24,1,3,no,1:no,1:no,,0.805
2062,2409820,Table 2,BaselineCharacteristic,?Previous chemotherapy and radiation, ; ,?Previous chemotherapy and radiation, Prior treatment,25,0,2,no,1:no,1:no,,0.92
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Previous chemotherapy and radiation, Prior treatment,25,1,3,no,1:no,1:no,,0.831
2062,2409820,Table 2,BaselineCharacteristic,?No Previous chemotherapy or radiation, ; ,?No Previous chemotherapy or radiation, Prior treatment,26,0,2,no,1:no,1:no,,0.882
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?No Previous chemotherapy or radiation, Prior treatment,26,1,3,no,1:no,1:no,,0.784
2308,2570506,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
2308,2570506,Table 1,BaselineCharacteristic,"CAP Ile/Ile, N=xx (xx%)",,Characteristics,None,0,1,1,no,1:no,1:no,,0.681
2308,2570506,Table 1,BaselineCharacteristic,"Ile/Val, N=xx (xx%)",,Characteristics,None,0,2,1,no,1:no,1:no,,0.703
2308,2570506,Table 1,BaselineCharacteristic,"Val/Val, N=xx (xx%)",,Characteristics,None,0,3,1,no,1:no,1:no,,0.712
2308,2570506,Table 1,BaselineCharacteristic,"All patients, N=xxx",,Characteristics,None,0,4,1,no,1:no,1:no,,0.661
2308,2570506,Table 1,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,1,0,24,no,1:no,1:no,,0.826
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Age (years),None,1,1,43,no,1:no,1:no,,0.741
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Age (years),None,1,2,43,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Age (years),None,1,3,43,no,1:no,1:no,,0.769
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Age (years),None,1,4,43,no,1:no,1:no,,0.732
2308,2570506,Table 1,BaselineCharacteristic,?Median,Characteristics ; ,?Median, Age (years),2,0,2,no,1:no,1:no,,0.838
2308,2570506,Table 1,BaselineCharacteristic,xx,"CAP Ile/Ile, N=xx (xx%) ; ",?Median, Age (years),2,1,3,no,1:no,1:no,,0.656
2308,2570506,Table 1,BaselineCharacteristic,xx,"Ile/Val, N=xx (xx%) ; ",?Median, Age (years),2,2,3,no,1:no,1:no,,0.659
2308,2570506,Table 1,BaselineCharacteristic,xx,"Val/Val, N=xx (xx%) ; ",?Median, Age (years),2,3,3,no,1:no,1:no,,0.669
2308,2570506,Table 1,BaselineCharacteristic,xx.x,"All patients, N=xxx ; ",?Median, Age (years),2,4,3,no,1:no,1:no,,0.605
2308,2570506,Table 1,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),3,0,2,no,1:no,1:no,,0.813
2308,2570506,Table 1,BaselineCharacteristic,?>xx,Characteristics ; ,?>xx, Age (years),4,0,2,no,1:no,1:no,,0.811
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?>xx, Age (years),4,1,3,no,1:no,1:no,,0.596
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?>xx, Age (years),4,2,3,no,1:no,1:no,,0.617
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?>xx, Age (years),4,3,3,no,1:no,1:no,,0.621
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"All patients, N=xxx ; ",?>xx, Age (years),4,4,3,no,1:no,1:no,,0.633
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,5,0,2,no,1:no,1:no,,0.843
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,5,1,3,no,1:no,1:no,,0.673
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,5,2,3,no,1:no,1:no,,0.695
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,5,3,3,no,1:no,1:no,,0.706
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,5,4,3,no,1:no,1:no,,0.675
2308,2570506,Table 1,BaselineCharacteristic,Gender,Characteristics ; ,None,None,6,0,24,no,1:no,1:no,,0.737
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Gender,None,6,1,43,no,1:no,1:no,,0.596
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Gender,None,6,2,43,no,1:no,1:no,,0.615
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Gender,None,6,3,43,no,1:no,1:no,,0.625
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Gender,None,6,4,43,no,1:no,1:no,,0.591
2308,2570506,Table 1,BaselineCharacteristic,?Male (%),Characteristics ; ,?Male (%), Gender,7,0,2,no,1:no,1:no,,0.634
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Male (%), Gender,7,1,3,yes,2:yes,2:yes,,0.757
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Male (%), Gender,7,2,3,yes,2:yes,2:yes,,0.753
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Male (%), Gender,7,3,3,yes,2:yes,2:yes,,0.751
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Male (%), Gender,7,4,3,yes,2:yes,2:yes,,0.752
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,8,0,2,no,1:no,1:no,,0.847
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,8,1,3,no,1:no,1:no,,0.709
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,8,2,3,no,1:no,1:no,,0.716
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,8,3,3,no,1:no,1:no,,0.727
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,8,4,3,no,1:no,1:no,,0.699
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),Characteristics ; ,None,None,9,0,24,no,1:no,1:no,,0.876
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"CAP Ile/Ile, N=xx (xx%) ; ",WHO performance status (at start therapy),None,9,1,43,no,1:no,1:no,,0.798
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"Ile/Val, N=xx (xx%) ; ",WHO performance status (at start therapy),None,9,2,43,no,1:no,1:no,,0.806
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"Val/Val, N=xx (xx%) ; ",WHO performance status (at start therapy),None,9,3,43,no,1:no,1:no,,0.814
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"All patients, N=xxx ; ",WHO performance status (at start therapy),None,9,4,43,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, WHO performance status (at start therapy),11,0,2,no,1:no,1:no,,0.851
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"CAP Ile/Ile, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),11,1,3,no,1:no,1:no,,0.744
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Ile/Val, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),11,2,3,no,1:no,1:no,,0.75
2308,2570506,Table 1,BaselineCharacteristic,x,"Val/Val, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),11,3,3,no,1:no,1:no,,0.762
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"All patients, N=xxx ; ",?x, WHO performance status (at start therapy),11,4,3,no,1:no,1:no,,0.737
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,12,0,2,no,1:no,1:no,,0.866
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,12,1,3,no,1:no,1:no,,0.735
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,12,2,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,12,3,3,no,1:no,1:no,,0.756
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,12,4,3,no,1:no,1:no,,0.717
2308,2570506,Table 1,BaselineCharacteristic,Prior adjuvant therapy,Characteristics ; ,Prior adjuvant therapy,,13,0,2,no,1:no,1:no,,0.855
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",Prior adjuvant therapy,,13,1,3,no,1:no,1:no,,0.685
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Ile/Val, N=xx (xx%) ; ",Prior adjuvant therapy,,13,2,3,no,1:no,1:no,,0.702
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",Prior adjuvant therapy,,13,3,3,no,1:no,1:no,,0.713
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",Prior adjuvant therapy,,13,4,3,no,1:no,1:no,,0.581
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,14,0,2,no,1:no,1:no,,0.866
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,14,1,3,no,1:no,1:no,,0.735
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,14,2,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,14,3,3,no,1:no,1:no,,0.756
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,14,4,3,no,1:no,1:no,,0.717
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),Characteristics ; ,None,None,15,0,24,no,1:no,1:no,,0.874
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"CAP Ile/Ile, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,15,1,43,no,1:no,1:no,,0.802
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"Ile/Val, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,15,2,43,no,1:no,1:no,,0.803
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"Val/Val, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,15,3,43,no,1:no,1:no,,0.805
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"All patients, N=xxx ; ",Predominant localisation of metastases (at inclusion),None,15,4,43,no,1:no,1:no,,0.785
2308,2570506,Table 1,BaselineCharacteristic,?Liver,Characteristics ; ,?Liver, Predominant localisation of metastases (at inclusion),16,0,2,no,1:no,1:no,,0.878
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),16,1,3,no,1:no,1:no,,0.727
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),16,2,3,no,1:no,1:no,,0.727
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),16,3,3,no,1:no,1:no,,0.732
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Liver, Predominant localisation of metastases (at inclusion),16,4,3,no,1:no,1:no,,0.633
2308,2570506,Table 1,BaselineCharacteristic,?Extrahepatic,Characteristics ; ,?Extrahepatic, Predominant localisation of metastases (at inclusion),17,0,2,no,1:no,1:no,,0.866
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),17,1,3,no,1:no,1:no,,0.72
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),17,2,3,no,1:no,1:no,,0.721
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),17,3,3,no,1:no,1:no,,0.776
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),17,4,3,no,1:no,1:no,,0.613
2308,2570506,Table 1,BaselineCharacteristic,?Unknown,Characteristics ; ,?Unknown, Predominant localisation of metastases (at inclusion),18,0,2,no,1:no,1:no,,0.868
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"CAP Ile/Ile, N=xx (xx%) ; ",?Unknown, Predominant localisation of metastases (at inclusion),18,1,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Ile/Val, N=xx (xx%) ; ",?Unknown, Predominant localisation of metastases (at inclusion),18,2,3,no,1:no,1:no,,0.773
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"All patients, N=xxx ; ",?Unknown, Predominant localisation of metastases (at inclusion),18,4,3,no,1:no,1:no,,0.756
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,19,0,2,no,1:no,1:no,,0.875
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,19,1,3,no,1:no,1:no,,0.751
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,19,2,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,19,3,3,no,1:no,1:no,,0.766
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,19,4,3,no,1:no,1:no,,0.739
2308,2570506,Table 1,BaselineCharacteristic,Site of primary,Characteristics ; ,None,None,20,0,24,no,1:no,1:no,,0.876
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Site of primary,None,20,1,43,no,1:no,1:no,,0.802
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Site of primary,None,20,2,43,no,1:no,1:no,,0.802
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Site of primary,None,20,3,43,no,1:no,1:no,,0.804
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Site of primary,None,20,4,43,no,1:no,1:no,,0.79
2308,2570506,Table 1,BaselineCharacteristic,?Colon and sigmoid,Characteristics ; ,?Colon and sigmoid, Site of primary,21,0,2,no,1:no,1:no,,0.867
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,21,1,3,no,1:no,1:no,,0.738
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,21,2,3,no,1:no,1:no,,0.738
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,21,3,3,no,1:no,1:no,,0.744
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Colon and sigmoid, Site of primary,21,4,3,no,1:no,1:no,,0.633
2308,2570506,Table 1,BaselineCharacteristic,?Rectum,Characteristics ; ,?Rectum, Site of primary,22,0,2,no,1:no,1:no,,0.861
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Rectum, Site of primary,22,1,3,no,1:no,1:no,,0.719
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Rectum, Site of primary,22,2,3,no,1:no,1:no,,0.719
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Rectum, Site of primary,22,3,3,no,1:no,1:no,,0.767
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Rectum, Site of primary,22,4,3,no,1:no,1:no,,0.609
2308,2570506,Table 1,BaselineCharacteristic,?Multiple tumours,Characteristics ; ,?Multiple tumours, Site of primary,23,0,2,no,1:no,1:no,,0.862
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"CAP Ile/Ile, N=xx (xx%) ; ",?Multiple tumours, Site of primary,23,1,3,no,1:no,1:no,,0.777
2308,2570506,Table 1,BaselineCharacteristic,x (<x%),"All patients, N=xxx ; ",?Multiple tumours, Site of primary,23,4,3,no,1:no,1:no,,0.743
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,24,0,2,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,24,1,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,24,2,3,no,1:no,1:no,,0.764
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,24,3,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,24,4,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,Serum LDH,Characteristics ; ,None,None,25,0,24,no,1:no,1:no,,0.871
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Serum LDH,None,25,1,43,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Serum LDH,None,25,2,43,no,1:no,1:no,,0.778
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Serum LDH,None,25,3,43,no,1:no,1:no,,0.789
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Serum LDH,None,25,4,43,no,1:no,1:no,,0.765
2308,2570506,Table 1,BaselineCharacteristic,?Normal,Characteristics ; ,?Normal, Serum LDH,26,0,2,no,1:no,1:no,,0.872
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Normal, Serum LDH,26,1,3,no,1:no,1:no,,0.714
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Normal, Serum LDH,26,2,3,no,1:no,1:no,,0.723
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Normal, Serum LDH,26,3,3,no,1:no,1:no,,0.74
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Normal, Serum LDH,26,4,3,no,1:no,1:no,,0.609
2308,2570506,Table 1,BaselineCharacteristic,??ULN,Characteristics ; ,??ULN, Serum LDH,27,0,2,no,1:no,1:no,,0.872
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",??ULN, Serum LDH,27,1,3,no,1:no,1:no,,0.714
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",??ULN, Serum LDH,27,2,3,no,1:no,1:no,,0.723
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",??ULN, Serum LDH,27,3,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",??ULN, Serum LDH,27,4,3,no,1:no,1:no,,0.609
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,28,0,2,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,28,1,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,28,2,3,no,1:no,1:no,,0.764
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,28,3,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,28,4,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,Characteristics,Characteristics ; ,Characteristics,,29,0,2,no,1:no,1:no,,0.865
2308,2570506,Table 1,BaselineCharacteristic,"CAPIRI Ile/Ile, N=xx (xx%)","CAP Ile/Ile, N=xx (xx%) ; ",Characteristics,,29,1,3,no,1:no,1:no,,0.723
2308,2570506,Table 1,BaselineCharacteristic,"Ile/Val, N=xx (xx%)","Ile/Val, N=xx (xx%) ; ",Characteristics,,29,2,3,no,1:no,1:no,,0.735
2308,2570506,Table 1,BaselineCharacteristic,"Val/Val, N=xx (xx%)","Val/Val, N=xx (xx%) ; ",Characteristics,,29,3,3,no,1:no,1:no,,0.741
2308,2570506,Table 1,BaselineCharacteristic,"All patients, N=xxx","All patients, N=xxx ; ",Characteristics,,29,4,3,no,1:no,1:no,,0.678
2308,2570506,Table 1,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,30,0,24,no,1:no,1:no,,0.873
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Age (years),None,30,1,43,no,1:no,1:no,,0.815
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Age (years),None,30,2,43,no,1:no,1:no,,0.815
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Age (years),None,30,3,43,no,1:no,1:no,,0.817
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Age (years),None,30,4,43,no,1:no,1:no,,0.787
2308,2570506,Table 1,BaselineCharacteristic,?Median,Characteristics ; ,?Median, Age (years),31,0,2,no,1:no,1:no,,0.881
2308,2570506,Table 1,BaselineCharacteristic,xx.x,"CAP Ile/Ile, N=xx (xx%) ; ",?Median, Age (years),31,1,3,no,1:no,1:no,,0.726
2308,2570506,Table 1,BaselineCharacteristic,xx,"Ile/Val, N=xx (xx%) ; ",?Median, Age (years),31,2,3,no,1:no,1:no,,0.766
2308,2570506,Table 1,BaselineCharacteristic,xx,"Val/Val, N=xx (xx%) ; ",?Median, Age (years),31,3,3,no,1:no,1:no,,0.776
2308,2570506,Table 1,BaselineCharacteristic,xx,"All patients, N=xxx ; ",?Median, Age (years),31,4,3,no,1:no,1:no,,0.677
2308,2570506,Table 1,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),32,0,2,no,1:no,1:no,,0.892
2308,2570506,Table 1,BaselineCharacteristic,?>xx,Characteristics ; ,?>xx, Age (years),33,0,2,no,1:no,1:no,,0.867
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?>xx, Age (years),33,1,3,no,1:no,1:no,,0.75
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?>xx, Age (years),33,2,3,no,1:no,1:no,,0.753
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Val/Val, N=xx (xx%) ; ",?>xx, Age (years),33,3,3,no,1:no,1:no,,0.761
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?>xx, Age (years),33,4,3,no,1:no,1:no,,0.666
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,34,0,2,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,34,1,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,34,2,3,no,1:no,1:no,,0.764
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,34,3,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,34,4,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,Gender,Characteristics ; ,None,None,35,0,24,no,1:no,1:no,,0.795
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Gender,None,35,1,43,no,1:no,1:no,,0.701
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Gender,None,35,2,43,no,1:no,1:no,,0.717
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Gender,None,35,3,43,no,1:no,1:no,,0.725
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Gender,None,35,4,43,no,1:no,1:no,,0.692
2308,2570506,Table 1,BaselineCharacteristic,?Male (%),Characteristics ; ,?Male (%), Gender,36,0,2,no,1:no,1:no,,0.737
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Male (%), Gender,36,1,3,no,1:no,2:yes,+,0.603
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Male (%), Gender,36,2,3,no,1:no,2:yes,+,0.6
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Male (%), Gender,36,3,3,no,1:no,2:yes,+,0.531
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Male (%), Gender,36,4,3,no,1:no,2:yes,+,0.625
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,37,0,2,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,37,1,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,37,2,3,no,1:no,1:no,,0.764
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,37,3,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,37,4,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),Characteristics ; ,None,None,38,0,24,no,1:no,1:no,,0.892
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"CAP Ile/Ile, N=xx (xx%) ; ",WHO performance status (at start therapy),None,38,1,43,no,1:no,1:no,,0.816
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"Ile/Val, N=xx (xx%) ; ",WHO performance status (at start therapy),None,38,2,43,no,1:no,1:no,,0.823
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"Val/Val, N=xx (xx%) ; ",WHO performance status (at start therapy),None,38,3,43,no,1:no,1:no,,0.83
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"All patients, N=xxx ; ",WHO performance status (at start therapy),None,38,4,43,no,1:no,1:no,,0.796
2308,2570506,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, WHO performance status (at start therapy),40,0,2,no,1:no,1:no,,0.882
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"CAP Ile/Ile, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),40,1,3,no,1:no,1:no,,0.791
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Ile/Val, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),40,2,3,no,1:no,1:no,,0.797
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"All patients, N=xxx ; ",?x, WHO performance status (at start therapy),40,4,3,no,1:no,1:no,,0.778
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,41,0,2,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,41,1,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,41,2,3,no,1:no,1:no,,0.764
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,41,3,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,41,4,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,Prior adjuvant therapy,Characteristics ; ,Prior adjuvant therapy,,42,0,2,no,1:no,1:no,,0.878
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",Prior adjuvant therapy,,42,1,3,no,1:no,1:no,,0.731
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Ile/Val, N=xx (xx%) ; ",Prior adjuvant therapy,,42,2,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Val/Val, N=xx (xx%) ; ",Prior adjuvant therapy,,42,3,3,no,1:no,1:no,,0.778
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",Prior adjuvant therapy,,42,4,3,no,1:no,1:no,,0.63
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,43,0,2,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,43,1,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,43,2,3,no,1:no,1:no,,0.764
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,43,3,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,43,4,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),Characteristics ; ,None,None,44,0,24,no,1:no,1:no,,0.882
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"CAP Ile/Ile, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,44,1,43,no,1:no,1:no,,0.816
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"Ile/Val, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,44,2,43,no,1:no,1:no,,0.816
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"Val/Val, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,44,3,43,no,1:no,1:no,,0.818
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"All patients, N=xxx ; ",Predominant localisation of metastases (at inclusion),None,44,4,43,no,1:no,1:no,,0.793
2308,2570506,Table 1,BaselineCharacteristic,?Liver,Characteristics ; ,?Liver, Predominant localisation of metastases (at inclusion),45,0,2,no,1:no,1:no,,0.895
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),45,1,3,no,1:no,1:no,,0.765
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),45,2,3,no,1:no,1:no,,0.766
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),45,3,3,no,1:no,1:no,,0.771
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Liver, Predominant localisation of metastases (at inclusion),45,4,3,no,1:no,1:no,,0.67
2308,2570506,Table 1,BaselineCharacteristic,?Extrahepatic,Characteristics ; ,?Extrahepatic, Predominant localisation of metastases (at inclusion),46,0,2,no,1:no,1:no,,0.87
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),46,1,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),46,2,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),46,3,3,no,1:no,1:no,,0.797
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),46,4,3,no,1:no,1:no,,0.636
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,47,0,2,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,47,1,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,47,2,3,no,1:no,1:no,,0.764
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,47,3,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,47,4,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,Site of primary,Characteristics ; ,None,None,48,0,24,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Site of primary,None,48,1,43,no,1:no,1:no,,0.804
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Site of primary,None,48,2,43,no,1:no,1:no,,0.803
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Site of primary,None,48,3,43,no,1:no,1:no,,0.805
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Site of primary,None,48,4,43,no,1:no,1:no,,0.791
2308,2570506,Table 1,BaselineCharacteristic,?Colon and sigmoid,Characteristics ; ,?Colon and sigmoid, Site of primary,49,0,2,no,1:no,1:no,,0.87
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,49,1,3,no,1:no,1:no,,0.745
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,49,2,3,no,1:no,1:no,,0.745
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,49,3,3,no,1:no,1:no,,0.791
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Colon and sigmoid, Site of primary,49,4,3,no,1:no,1:no,,0.639
2308,2570506,Table 1,BaselineCharacteristic,?Rectum,Characteristics ; ,?Rectum, Site of primary,50,0,2,no,1:no,1:no,,0.863
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Rectum, Site of primary,50,1,3,no,1:no,1:no,,0.724
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Rectum, Site of primary,50,2,3,no,1:no,1:no,,0.725
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Rectum, Site of primary,50,3,3,no,1:no,1:no,,0.777
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Rectum, Site of primary,50,4,3,no,1:no,1:no,,0.614
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,51,0,2,no,1:no,1:no,,0.877
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,51,1,3,no,1:no,1:no,,0.758
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,51,2,3,no,1:no,1:no,,0.764
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,51,3,3,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,51,4,3,no,1:no,1:no,,0.742
2308,2570506,Table 1,BaselineCharacteristic,Serum LDH,Characteristics ; ,None,None,52,0,24,no,1:no,1:no,,0.871
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Serum LDH,None,52,1,43,no,1:no,1:no,,0.772
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Serum LDH,None,52,2,43,no,1:no,1:no,,0.778
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Serum LDH,None,52,3,43,no,1:no,1:no,,0.789
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Serum LDH,None,52,4,43,no,1:no,1:no,,0.765
2308,2570506,Table 1,BaselineCharacteristic,?Normal,Characteristics ; ,?Normal, Serum LDH,53,0,2,no,1:no,1:no,,0.873
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Normal, Serum LDH,53,1,3,no,1:no,1:no,,0.714
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Normal, Serum LDH,53,2,3,no,1:no,1:no,,0.723
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Normal, Serum LDH,53,3,3,no,1:no,1:no,,0.74
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Normal, Serum LDH,53,4,3,no,1:no,1:no,,0.609
2308,2570506,Table 1,BaselineCharacteristic,??ULN,Characteristics ; ,??ULN, Serum LDH,54,0,2,no,1:no,1:no,,0.873
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",??ULN, Serum LDH,54,1,3,no,1:no,1:no,,0.714
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",??ULN, Serum LDH,54,2,3,no,1:no,1:no,,0.723
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",??ULN, Serum LDH,54,3,3,no,1:no,1:no,,0.76
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",??ULN, Serum LDH,54,4,3,no,1:no,1:no,,0.609
2472,2653739,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
2472,2653739,Table 1,BaselineCharacteristic,%,,Characteristics,None,0,1,1,no,1:no,1:no,,0.723
2472,2653739,Table 1,BaselineCharacteristic,n,,Characteristics,None,0,2,1,no,1:no,1:no,,0.676
2472,2653739,Table 1,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,1,0,24,no,1:no,1:no,,0.826
2472,2653739,Table 1,BaselineCharacteristic,Age (years),% ; ,Age (years),None,1,1,43,no,1:no,1:no,,0.777
2472,2653739,Table 1,BaselineCharacteristic,Age (years),n ; ,Age (years),None,1,2,43,no,1:no,1:no,,0.746
2472,2653739,Table 1,BaselineCharacteristic,?Median,Characteristics ; ,?Median, Age (years),2,0,2,no,1:no,1:no,,0.838
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,?Median, Age (years),2,1,3,no,1:no,1:no,,0.724
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?Median, Age (years),2,2,3,no,1:no,1:no,,0.655
2472,2653739,Table 1,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),3,0,2,no,1:no,1:no,,0.813
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,?Range, Age (years),3,1,3,no,1:no,1:no,,0.708
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,4,0,2,no,1:no,1:no,,0.845
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,4,1,3,no,1:no,1:no,,0.682
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,4,2,3,no,1:no,1:no,,0.694
2472,2653739,Table 1,BaselineCharacteristic,Histological type,Characteristics ; ,None,None,5,0,24,no,1:no,1:no,,0.712
2472,2653739,Table 1,BaselineCharacteristic,Histological type,% ; ,Histological type,None,5,1,43,no,1:no,1:no,,0.633
2472,2653739,Table 1,BaselineCharacteristic,Histological type,n ; ,Histological type,None,5,2,43,no,1:no,1:no,,0.585
2472,2653739,Table 1,BaselineCharacteristic,?Serous,Characteristics ; ,?Serous, Histological type,6,0,2,no,1:no,1:no,,0.706
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?Serous, Histological type,6,1,3,no,1:no,2:yes,+,0.591
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?Serous, Histological type,6,2,3,no,1:no,2:yes,+,0.528
2472,2653739,Table 1,BaselineCharacteristic,?Endometrioid,Characteristics ; ,?Endometrioid, Histological type,7,0,2,no,1:no,1:no,,0.717
2472,2653739,Table 1,BaselineCharacteristic,x,% ; ,?Endometrioid, Histological type,7,1,3,no,1:no,1:no,,0.546
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?Endometrioid, Histological type,7,2,3,no,1:no,1:no,,0.543
2472,2653739,Table 1,BaselineCharacteristic,?Others,Characteristics ; ,?Others, Histological type,8,0,2,no,1:no,1:no,,0.713
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?Others, Histological type,8,1,3,no,1:no,2:yes,+,0.561
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?Others, Histological type,8,2,3,no,1:no,1:no,,0.556
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,9,0,2,no,1:no,1:no,,0.855
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,9,1,3,no,1:no,1:no,,0.731
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,9,2,3,no,1:no,1:no,,0.725
2472,2653739,Table 1,BaselineCharacteristic,Histological grade,Characteristics ; ,None,None,10,0,24,no,1:no,1:no,,0.848
2472,2653739,Table 1,BaselineCharacteristic,Histological grade,% ; ,Histological grade,None,10,1,43,no,1:no,1:no,,0.791
2472,2653739,Table 1,BaselineCharacteristic,Histological grade,n ; ,Histological grade,None,10,2,43,no,1:no,1:no,,0.764
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Histological grade,11,0,2,no,1:no,1:no,,0.818
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Histological grade,11,1,3,no,1:no,1:no,,0.617
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?x, Histological grade,11,2,3,no,1:no,1:no,,0.697
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Histological grade,12,0,2,no,1:no,1:no,,0.818
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Histological grade,12,1,3,no,1:no,1:no,,0.621
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Histological grade,12,2,3,no,1:no,1:no,,0.693
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Histological grade,13,0,2,no,1:no,1:no,,0.818
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Histological grade,13,1,3,no,1:no,1:no,,0.61
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Histological grade,13,2,3,no,1:no,1:no,,0.692
2472,2653739,Table 1,BaselineCharacteristic,?Unknown,Characteristics ; ,?Unknown, Histological grade,14,0,2,no,1:no,1:no,,0.841
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?Unknown, Histological grade,14,1,3,no,1:no,1:no,,0.627
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?Unknown, Histological grade,14,2,3,no,1:no,1:no,,0.651
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,15,0,2,no,1:no,1:no,,0.866
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,15,1,3,no,1:no,1:no,,0.739
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,15,2,3,no,1:no,1:no,,0.747
2472,2653739,Table 1,BaselineCharacteristic,Number of earlier chemotherapy regimens,Characteristics ; ,None,None,16,0,24,no,1:no,1:no,,0.881
2472,2653739,Table 1,BaselineCharacteristic,Number of earlier chemotherapy regimens,% ; ,Number of earlier chemotherapy regimens,None,16,1,43,no,1:no,1:no,,0.826
2472,2653739,Table 1,BaselineCharacteristic,Number of earlier chemotherapy regimens,n ; ,Number of earlier chemotherapy regimens,None,16,2,43,no,1:no,1:no,,0.801
2472,2653739,Table 1,BaselineCharacteristic,?One,Characteristics ; ,?One, Number of earlier chemotherapy regimens,17,0,2,no,1:no,1:no,,0.845
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?One, Number of earlier chemotherapy regimens,17,1,3,no,1:no,1:no,,0.716
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?One, Number of earlier chemotherapy regimens,17,2,3,no,1:no,1:no,,0.742
2472,2653739,Table 1,BaselineCharacteristic,?Two,Characteristics ; ,?Two, Number of earlier chemotherapy regimens,18,0,2,no,1:no,1:no,,0.847
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?Two, Number of earlier chemotherapy regimens,18,1,3,no,1:no,1:no,,0.727
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?Two, Number of earlier chemotherapy regimens,18,2,3,no,1:no,1:no,,0.773
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,19,0,2,no,1:no,1:no,,0.875
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,19,1,3,no,1:no,1:no,,0.769
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,19,2,3,no,1:no,1:no,,0.774
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,26,0,2,no,1:no,1:no,,0.877
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,26,1,3,no,1:no,1:no,,0.785
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,26,2,3,no,1:no,1:no,,0.782
2472,2653739,Table 1,BaselineCharacteristic,Performance status,Characteristics ; ,None,None,27,0,24,no,1:no,1:no,,0.885
2472,2653739,Table 1,BaselineCharacteristic,Performance status,% ; ,Performance status,None,27,1,43,no,1:no,1:no,,0.826
2472,2653739,Table 1,BaselineCharacteristic,Performance status,n ; ,Performance status,None,27,2,43,no,1:no,1:no,,0.806
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Performance status,28,0,2,no,1:no,1:no,,0.868
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Performance status,28,1,3,no,1:no,1:no,,0.707
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Performance status,28,2,3,no,1:no,1:no,,0.748
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Performance status,29,0,2,no,1:no,1:no,,0.868
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Performance status,29,1,3,no,1:no,1:no,,0.707
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Performance status,29,2,3,no,1:no,1:no,,0.748
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,30,0,2,no,1:no,1:no,,0.877
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,30,1,3,no,1:no,1:no,,0.785
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,30,2,3,no,1:no,1:no,,0.782
2472,2653739,Table 1,BaselineCharacteristic,Ascites,Characteristics ; ,Ascites,,31,0,2,no,1:no,1:no,,0.865
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,Ascites,,31,1,3,no,1:no,1:no,,0.654
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,Ascites,,31,2,3,no,1:no,1:no,,0.708
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,32,0,2,no,1:no,1:no,,0.877
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,32,1,3,no,1:no,1:no,,0.785
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,32,2,3,no,1:no,1:no,,0.782
2472,2653739,Table 1,BaselineCharacteristic,Measurable lesion,Characteristics ; ,None,None,33,0,24,no,1:no,1:no,,0.863
2472,2653739,Table 1,BaselineCharacteristic,Measurable lesion,% ; ,Measurable lesion,None,33,1,43,no,1:no,1:no,,0.8
2472,2653739,Table 1,BaselineCharacteristic,Measurable lesion,n ; ,Measurable lesion,None,33,2,43,no,1:no,1:no,,0.788
2472,2653739,Table 1,BaselineCharacteristic,?<x?cm,Characteristics ; ,?<x?cm, Measurable lesion,34,0,2,no,1:no,1:no,,0.866
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?<x?cm, Measurable lesion,34,1,3,no,1:no,1:no,,0.655
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?<x?cm, Measurable lesion,34,2,3,no,1:no,1:no,,0.711
2472,2653739,Table 1,BaselineCharacteristic,??x?cm,Characteristics ; ,??x?cm, Measurable lesion,35,0,2,no,1:no,1:no,,0.846
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,??x?cm, Measurable lesion,35,1,3,no,1:no,1:no,,0.645
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,??x?cm, Measurable lesion,35,2,3,no,1:no,1:no,,0.744
2472,2653739,Table 1,BaselineCharacteristic,?Not evaluable,Characteristics ; ,?Not evaluable, Measurable lesion,37,0,2,no,1:no,1:no,,0.868
2472,2653739,Table 1,BaselineCharacteristic,x,% ; ,?Not evaluable, Measurable lesion,37,1,3,no,1:no,1:no,,0.755
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?Not evaluable, Measurable lesion,37,2,3,no,1:no,1:no,,0.746
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,38,0,2,no,1:no,1:no,,0.877
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,38,1,3,no,1:no,1:no,,0.785
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,38,2,3,no,1:no,1:no,,0.782
2472,2653739,Table 1,BaselineCharacteristic,Number of disease sitesa,Characteristics ; ,None,None,39,0,24,no,1:no,1:no,,0.863
2472,2653739,Table 1,BaselineCharacteristic,Number of disease sitesa,% ; ,Number of disease sitesa,None,39,1,43,no,1:no,1:no,,0.821
2472,2653739,Table 1,BaselineCharacteristic,Number of disease sitesa,n ; ,Number of disease sitesa,None,39,2,43,no,1:no,1:no,,0.79
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Number of disease sitesa,40,0,2,no,1:no,1:no,,0.839
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Number of disease sitesa,40,1,3,no,1:no,1:no,,0.73
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Number of disease sitesa,40,2,3,no,1:no,1:no,,0.762
2472,2653739,Table 1,BaselineCharacteristic,?>x,Characteristics ; ,?>x, Number of disease sitesa,41,0,2,no,1:no,1:no,,0.841
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?>x, Number of disease sitesa,41,1,3,no,1:no,1:no,,0.708
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?>x, Number of disease sitesa,41,2,3,no,1:no,1:no,,0.734
2528,2674549,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
2528,2674549,Table 1,BaselineCharacteristic,Group x,,Characteristic,None,0,1,1,no,1:no,1:no,,0.759
2528,2674549,Table 1,BaselineCharacteristic,Group x,,Characteristic,None,0,2,1,no,1:no,1:no,,0.779
2528,2674549,Table 1,BaselineCharacteristic,Golimumab + methotrexate,,Characteristic,None,0,3,1,no,1:no,1:no,,0.8
2528,2674549,Table 1,BaselineCharacteristic,Golimumab + methotrexate,,Characteristic,None,0,4,1,no,1:no,1:no,,0.812
2528,2674549,Table 1,BaselineCharacteristic,Golimumab + methotrexate,,Characteristic,None,0,5,1,no,1:no,1:no,,0.806
2528,2674549,Table 1,BaselineCharacteristic,Characteristic,Characteristic ; ,None,None,1,0,12,no,1:no,1:no,,0.805
2528,2674549,Table 1,BaselineCharacteristic,Group x,Group x ; ,Characteristic,None,1,1,1,no,1:no,1:no,,0.747
2528,2674549,Table 1,BaselineCharacteristic,Group x,Group x ; ,Characteristic,None,1,2,1,no,1:no,1:no,,0.767
2528,2674549,Table 1,BaselineCharacteristic,Group x,Golimumab + methotrexate ; ,Characteristic,None,1,3,1,no,1:no,1:no,,0.781
2528,2674549,Table 1,BaselineCharacteristic,Group x,Golimumab + methotrexate ; ,Characteristic,None,1,4,1,no,1:no,1:no,,0.786
2528,2674549,Table 1,BaselineCharacteristic,Groups x and x combined,Golimumab + methotrexate ; ,Characteristic,None,1,5,1,no,1:no,1:no,,0.794
2528,2674549,Table 1,BaselineCharacteristic,Characteristic,Characteristic ; Characteristic ; ,None,None,2,0,12,no,1:no,1:no,,0.817
2528,2674549,Table 1,BaselineCharacteristic,Placebo + methotrexate,Group x ; Group x ; ,Characteristic,None,2,1,1,no,1:no,1:no,,0.629
2528,2674549,Table 1,BaselineCharacteristic,Golimumab xxx mg + placebo,Group x ; Group x ; ,Characteristic,None,2,2,1,no,1:no,1:no,,0.635
2528,2674549,Table 1,BaselineCharacteristic,xx mg,Golimumab + methotrexate ; Group x ; ,Characteristic,None,2,3,1,no,1:no,1:no,,0.683
2528,2674549,Table 1,BaselineCharacteristic,xxx mg,Golimumab + methotrexate ; Group x ; ,Characteristic,None,2,4,1,no,1:no,1:no,,0.767
2528,2674549,Table 1,BaselineCharacteristic,,Golimumab + methotrexate ; Groups x and x combined ; ,Characteristic,None,2,5,1,no,1:no,1:no,,0.798
2528,2674549,Table 1,BaselineCharacteristic,Patients randomly assigned,Characteristic ; Characteristic ; Characteristic ; ,Patients randomly assigned,,3,0,2,no,1:no,1:no,,0.814
2528,2674549,Table 1,BaselineCharacteristic,xxx,Group x ; Group x ; Placebo + methotrexate ; ,Patients randomly assigned,,3,1,3,no,1:no,1:no,,0.554
2528,2674549,Table 1,BaselineCharacteristic,xxx,Group x ; Group x ; Golimumab xxx mg + placebo ; ,Patients randomly assigned,,3,2,3,no,1:no,1:no,,0.544
2528,2674549,Table 1,BaselineCharacteristic,xx,Golimumab + methotrexate ; Group x ; xx mg ; ,Patients randomly assigned,,3,3,3,no,1:no,1:no,,0.578
2528,2674549,Table 1,BaselineCharacteristic,xx,Golimumab + methotrexate ; Group x ; xxx mg ; ,Patients randomly assigned,,3,4,3,no,1:no,1:no,,0.536
2528,2674549,Table 1,BaselineCharacteristic,xxx,Golimumab + methotrexate ; Groups x and x combined ;  ; ,Patients randomly assigned,,3,5,3,no,1:no,1:no,,0.713
2528,2674549,Table 1,BaselineCharacteristic,"Sex, n (%) women",Characteristic ; Characteristic ; Characteristic ; ,"Sex, n (%) women",,4,0,2,no,1:no,1:no,,0.537
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,"Sex, n (%) women",,4,1,3,yes,2:yes,2:yes,,0.76
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Sex, n (%) women",,4,2,3,yes,2:yes,2:yes,,0.745
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,"Sex, n (%) women",,4,3,3,yes,2:yes,2:yes,,0.739
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Sex, n (%) women",,4,4,3,yes,2:yes,2:yes,,0.726
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Sex, n (%) women",,4,5,3,yes,2:yes,2:yes,,0.688
2528,2674549,Table 1,BaselineCharacteristic,"Age, years",Characteristic ; Characteristic ; Characteristic ; ,"Age, years",,5,0,2,no,1:no,1:no,,0.835
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Group x ; Group x ; Placebo + methotrexate ; ,"Age, years",,5,1,3,no,1:no,1:no,,0.534
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Age, years",,5,2,3,no,1:no,2:yes,+,0.503
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Group x ; xx mg ; ,"Age, years",,5,3,3,no,1:no,1:no,,0.659
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Age, years",,5,4,3,no,1:no,1:no,,0.59
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Age, years",,5,5,3,no,1:no,1:no,,0.698
2528,2674549,Table 1,BaselineCharacteristic,"Disease duration, years",Characteristic ; Characteristic ; Characteristic ; ,"Disease duration, years",,6,0,2,no,1:no,1:no,,0.813
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Group x ; Group x ; Placebo + methotrexate ; ,"Disease duration, years",,6,1,3,no,1:no,1:no,,0.51
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Disease duration, years",,6,2,3,no,1:no,2:yes,+,0.514
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.x to x.x),Golimumab + methotrexate ; Group x ; xx mg ; ,"Disease duration, years",,6,3,3,no,1:no,1:no,,0.636
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.x to xx.x),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Disease duration, years",,6,4,3,no,1:no,1:no,,0.582
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Disease duration, years",,6,5,3,no,1:no,1:no,,0.676
2528,2674549,Table 1,BaselineCharacteristic,Anti-CCP antibodies,Characteristic ; Characteristic ; Characteristic ; ,Anti-CCP antibodies,,9,0,2,no,1:no,1:no,,0.872
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Anti-CCP antibodies,,9,1,3,no,1:no,1:no,,0.501
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Anti-CCP antibodies,,9,2,3,no,1:no,1:no,,0.507
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Anti-CCP antibodies,,9,3,3,no,1:no,1:no,,0.667
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Anti-CCP antibodies,,9,4,3,no,1:no,1:no,,0.625
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Anti-CCP antibodies,,9,5,3,no,1:no,1:no,,0.659
2528,2674549,Table 1,BaselineCharacteristic,Rheumatoid factor,Characteristic ; Characteristic ; Characteristic ; ,Rheumatoid factor,,10,0,2,no,1:no,1:no,,0.879
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Rheumatoid factor,,10,1,3,no,1:no,1:no,,0.505
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Rheumatoid factor,,10,2,3,no,1:no,1:no,,0.509
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Rheumatoid factor,,10,3,3,no,1:no,1:no,,0.672
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Rheumatoid factor,,10,4,3,no,1:no,1:no,,0.63
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Rheumatoid factor,,10,5,3,no,1:no,1:no,,0.664
2528,2674549,Table 1,BaselineCharacteristic,"CRP, mg/dl",Characteristic ; Characteristic ; Characteristic ; ,"CRP, mg/dl",,15,0,2,no,1:no,1:no,,0.891
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Group x ; Group x ; Placebo + methotrexate ; ,"CRP, mg/dl",,15,1,3,no,1:no,1:no,,0.553
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"CRP, mg/dl",,15,2,3,no,1:no,2:yes,+,0.518
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Golimumab + methotrexate ; Group x ; xx mg ; ,"CRP, mg/dl",,15,3,3,no,1:no,1:no,,0.702
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Golimumab + methotrexate ; Group x ; xxx mg ; ,"CRP, mg/dl",,15,4,3,no,1:no,1:no,,0.618
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"CRP, mg/dl",,15,5,3,no,1:no,1:no,,0.77
2528,2674549,Table 1,BaselineCharacteristic,DASxx using CRP,Characteristic ; Characteristic ; Characteristic ; ,DASxx using CRP,,16,0,2,no,1:no,1:no,,0.891
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Group x ; Group x ; Placebo + methotrexate ; ,DASxx using CRP,,16,1,3,no,1:no,1:no,,0.582
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Group x ; Group x ; Golimumab xxx mg + placebo ; ,DASxx using CRP,,16,2,3,no,1:no,1:no,,0.57
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Group x ; xx mg ; ,DASxx using CRP,,16,3,3,no,1:no,1:no,,0.611
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Group x ; xxx mg ; ,DASxx using CRP,,16,4,3,no,1:no,1:no,,0.721
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Groups x and x combined ;  ; ,DASxx using CRP,,16,5,3,no,1:no,1:no,,0.744
2528,2674549,Table 1,BaselineCharacteristic,DASxx using ESR,Characteristic ; Characteristic ; Characteristic ; ,DASxx using ESR,,17,0,2,no,1:no,1:no,,0.903
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Group x ; Group x ; Placebo + methotrexate ; ,DASxx using ESR,,17,1,3,no,1:no,1:no,,0.628
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Group x ; Group x ; Golimumab xxx mg + placebo ; ,DASxx using ESR,,17,2,3,no,1:no,1:no,,0.611
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Group x ; xx mg ; ,DASxx using ESR,,17,3,3,no,1:no,1:no,,0.645
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Group x ; xxx mg ; ,DASxx using ESR,,17,4,3,no,1:no,1:no,,0.755
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Groups x and x combined ;  ; ,DASxx using ESR,,17,5,3,no,1:no,1:no,,0.773
2528,2674549,Table 1,BaselineCharacteristic,"Methotrexate dose, mg/week",Characteristic ; Characteristic ; Characteristic ; ,"Methotrexate dose, mg/week",,18,0,2,no,1:no,1:no,,0.913
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Group x ; Group x ; Placebo + methotrexate ; ,"Methotrexate dose, mg/week",,18,1,3,no,1:no,1:no,,0.629
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Methotrexate dose, mg/week",,18,2,3,no,1:no,1:no,,0.559
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Group x ; xx mg ; ,"Methotrexate dose, mg/week",,18,3,3,no,1:no,1:no,,0.757
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Methotrexate dose, mg/week",,18,4,3,no,1:no,1:no,,0.686
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Methotrexate dose, mg/week",,18,5,3,no,1:no,1:no,,0.82
2528,2674549,Table 1,BaselineCharacteristic,"Duration of previous methotrexate use, years",Characteristic ; Characteristic ; Characteristic ; ,None,None,19,0,24,no,1:no,1:no,,0.901
2528,2674549,Table 1,BaselineCharacteristic,,Group x ; Group x ; Placebo + methotrexate ; ,"Duration of previous methotrexate use, years",None,19,1,43,no,1:no,1:no,,0.73
2528,2674549,Table 1,BaselineCharacteristic,,Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Duration of previous methotrexate use, years",None,19,2,43,no,1:no,1:no,,0.72
2528,2674549,Table 1,BaselineCharacteristic,,Golimumab + methotrexate ; Group x ; xx mg ; ,"Duration of previous methotrexate use, years",None,19,3,43,no,1:no,1:no,,0.785
2528,2674549,Table 1,BaselineCharacteristic,,Golimumab + methotrexate ; Group x ; xxx mg ; ,"Duration of previous methotrexate use, years",None,19,4,43,no,1:no,1:no,,0.84
2528,2674549,Table 1,BaselineCharacteristic,,Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Duration of previous methotrexate use, years",None,19,5,43,no,1:no,1:no,,0.883
2528,2674549,Table 1,BaselineCharacteristic,,Characteristic ; Characteristic ; Characteristic ; ,," Duration of previous methotrexate use, years",20,0,2,no,1:no,1:no,,0.887
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,," Duration of previous methotrexate use, years",20,1,3,no,1:no,1:no,,0.649
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,," Duration of previous methotrexate use, years",20,2,3,no,1:no,1:no,,0.636
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,," Duration of previous methotrexate use, years",20,3,3,no,1:no,1:no,,0.763
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,," Duration of previous methotrexate use, years",20,4,3,no,1:no,1:no,,0.742
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,," Duration of previous methotrexate use, years",20,5,3,no,1:no,1:no,,0.811
2528,2674549,Table 1,BaselineCharacteristic,,Characteristic ; Characteristic ; Characteristic ; ,," Duration of previous methotrexate use, years",21,0,2,no,1:no,1:no,,0.887
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,," Duration of previous methotrexate use, years",21,1,3,no,1:no,1:no,,0.649
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,," Duration of previous methotrexate use, years",21,2,3,no,1:no,1:no,,0.636
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,," Duration of previous methotrexate use, years",21,3,3,no,1:no,1:no,,0.763
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,," Duration of previous methotrexate use, years",21,4,3,no,1:no,1:no,,0.742
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,," Duration of previous methotrexate use, years",21,5,3,no,1:no,1:no,,0.811
2528,2674549,Table 1,BaselineCharacteristic,,Characteristic ; Characteristic ; Characteristic ; ,," Duration of previous methotrexate use, years",22,0,2,no,1:no,1:no,,0.888
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,," Duration of previous methotrexate use, years",22,1,3,no,1:no,1:no,,0.653
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,," Duration of previous methotrexate use, years",22,2,3,no,1:no,1:no,,0.64
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,," Duration of previous methotrexate use, years",22,3,3,no,1:no,1:no,,0.766
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,," Duration of previous methotrexate use, years",22,4,3,no,1:no,1:no,,0.745
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,," Duration of previous methotrexate use, years",22,5,3,no,1:no,1:no,,0.814
2528,2674549,Table 1,BaselineCharacteristic,Patients taking corticosteroids,Characteristic ; Characteristic ; Characteristic ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,0,2,no,1:no,1:no,,0.87
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,1,3,no,1:no,1:no,,0.642
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,2,3,no,1:no,1:no,,0.635
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,3,3,no,1:no,1:no,,0.749
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,4,3,no,1:no,1:no,,0.74
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,5,3,no,1:no,1:no,,0.779
2528,2674549,Table 1,BaselineCharacteristic,"Prednisone or equivalent dose, mg/day",Characteristic ; Characteristic ; Characteristic ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,0,2,no,1:no,1:no,,0.9
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Group x ; Group x ; Placebo + methotrexate ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,1,3,no,1:no,1:no,,0.7
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,2,3,no,1:no,1:no,,0.669
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Golimumab + methotrexate ; Group x ; xx mg ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,3,3,no,1:no,1:no,,0.818
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,4,3,no,1:no,1:no,,0.778
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,5,3,no,1:no,1:no,,0.861
2528,2674549,Table 1,BaselineCharacteristic,Patients with previous use of DMARD other than methotrexate,Characteristic ; Characteristic ; Characteristic ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,0,2,no,1:no,1:no,,0.871
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,1,3,no,1:no,1:no,,0.646
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,2,3,no,1:no,1:no,,0.644
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,3,3,no,1:no,1:no,,0.753
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,4,3,no,1:no,1:no,,0.749
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,5,3,no,1:no,1:no,,0.79
2528,2674549,Table 1,BaselineCharacteristic,Patients who required treatment for latent tuberculosis at baseline*,Characteristic ; Characteristic ; Characteristic ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,0,2,no,1:no,1:no,,0.887
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,1,3,no,1:no,1:no,,0.694
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,2,3,no,1:no,1:no,,0.698
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,3,3,no,1:no,1:no,,0.799
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,4,3,no,1:no,1:no,,0.801
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,5,3,no,1:no,1:no,,0.814
2529,2674556,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
2529,2674556,Table 1,BaselineCharacteristic,Placebo + MTX (n?=?xxx),,Characteristics,None,0,1,1,no,1:no,1:no,,0.521
2529,2674556,Table 1,BaselineCharacteristic,Certolizumab pegol xxx mg + MTX (n?=?xxx),,Characteristics,None,0,2,1,no,1:no,1:no,,0.607
2529,2674556,Table 1,BaselineCharacteristic,Certolizumab pegol xxx mg + MTX (n?=?xxx),,Characteristics,None,0,3,1,no,1:no,1:no,,0.616
2529,2674556,Table 1,BaselineCharacteristic,Demographics,Characteristics ; ,None,None,1,0,24,no,1:no,1:no,,0.789
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,Demographics,None,1,1,43,no,1:no,1:no,,0.519
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,Demographics,None,1,2,43,no,1:no,1:no,,0.584
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,Demographics,None,1,3,43,no,1:no,1:no,,0.594
2529,2674556,Table 1,BaselineCharacteristic,"Age (years), mean (SD)",Characteristics ; ,"Age (years), mean (SD)", Demographics,2,0,2,no,1:no,1:no,,0.792
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,"Age (years), mean (SD)", Demographics,2,1,3,no,1:no,2:yes,+,0.61
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Age (years), mean (SD)", Demographics,2,2,3,no,1:no,2:yes,+,0.525
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Age (years), mean (SD)", Demographics,2,3,3,no,1:no,2:yes,+,0.505
2529,2674556,Table 1,BaselineCharacteristic,"Female, n (%)",Characteristics ; ,"Female, n (%)", Demographics,3,0,2,no,1:no,1:no,,0.639
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Placebo + MTX (n?=?xxx) ; ,"Female, n (%)", Demographics,3,1,3,yes,2:yes,2:yes,,0.798
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Female, n (%)", Demographics,3,2,3,yes,2:yes,2:yes,,0.755
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Female, n (%)", Demographics,3,3,3,yes,2:yes,2:yes,,0.747
2529,2674556,Table 1,BaselineCharacteristic,"Disease duration (years), mean (SD)",Characteristics ; ,"Disease duration (years), mean (SD)", Demographics,4,0,2,no,1:no,1:no,,0.8
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Placebo + MTX (n?=?xxx) ; ,"Disease duration (years), mean (SD)", Demographics,4,1,3,no,1:no,2:yes,+,0.509
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Disease duration (years), mean (SD)", Demographics,4,2,3,no,1:no,1:no,,0.552
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Disease duration (years), mean (SD)", Demographics,4,3,3,no,1:no,1:no,,0.57
2529,2674556,Table 1,BaselineCharacteristic,"No of prior DMARDs (excluding MTX), mean (SD)",Characteristics ; ,"No of prior DMARDs (excluding MTX), mean (SD)", Demographics,5,0,2,no,1:no,1:no,,0.782
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Placebo + MTX (n?=?xxx) ; ,"No of prior DMARDs (excluding MTX), mean (SD)", Demographics,5,1,3,no,1:no,1:no,,0.537
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"No of prior DMARDs (excluding MTX), mean (SD)", Demographics,5,2,3,no,1:no,1:no,,0.613
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"No of prior DMARDs (excluding MTX), mean (SD)", Demographics,5,3,3,no,1:no,1:no,,0.624
2529,2674556,Table 1,BaselineCharacteristic,"MTX (mg/week), mean (SD)",Characteristics ; ,"MTX (mg/week), mean (SD)", Demographics,6,0,2,no,1:no,1:no,,0.816
2529,2674556,Table 1,BaselineCharacteristic,xx.x (x.x),Placebo + MTX (n?=?xxx) ; ,"MTX (mg/week), mean (SD)", Demographics,6,1,3,no,1:no,2:yes,+,0.586
2529,2674556,Table 1,BaselineCharacteristic,xx.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"MTX (mg/week), mean (SD)", Demographics,6,2,3,no,1:no,1:no,,0.519
2529,2674556,Table 1,BaselineCharacteristic,xx.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"MTX (mg/week), mean (SD)", Demographics,6,3,3,no,1:no,1:no,,0.535
2529,2674556,Table 1,BaselineCharacteristic,"Steroid use, n (%)",Characteristics ; ,"Steroid use, n (%)", Demographics,7,0,2,no,1:no,1:no,,0.688
2529,2674556,Table 1,BaselineCharacteristic,xx (xx.x),Placebo + MTX (n?=?xxx) ; ,"Steroid use, n (%)", Demographics,7,1,3,no,1:no,2:yes,+,0.708
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Steroid use, n (%)", Demographics,7,2,3,no,1:no,2:yes,+,0.652
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Steroid use, n (%)", Demographics,7,3,3,no,1:no,2:yes,+,0.642
2529,2674556,Table 1,BaselineCharacteristic,"Previous anti-TNF use, n (%)*",Characteristics ; ,"Previous anti-TNF use, n (%)*", Demographics,8,0,2,no,1:no,1:no,,0.71
2529,2674556,Table 1,BaselineCharacteristic,x (x.x),Placebo + MTX (n?=?xxx) ; ,"Previous anti-TNF use, n (%)*", Demographics,8,1,3,no,1:no,2:yes,+,0.56
2529,2674556,Table 1,BaselineCharacteristic,x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Previous anti-TNF use, n (%)*", Demographics,8,2,3,no,1:no,1:no,,0.501
2529,2674556,Table 1,BaselineCharacteristic,x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Previous anti-TNF use, n (%)*", Demographics,8,3,3,no,1:no,1:no,,0.504
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,9,0,2,no,1:no,1:no,,0.855
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,None,None,9,1,3,no,1:no,1:no,,0.552
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,9,2,3,no,1:no,1:no,,0.654
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,9,3,3,no,1:no,1:no,,0.667
2529,2674556,Table 1,BaselineCharacteristic,ACR core components,Characteristics ; ,None,None,10,0,24,no,1:no,1:no,,0.841
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,ACR core components,None,10,1,43,no,1:no,1:no,,0.561
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,ACR core components,None,10,2,43,no,1:no,1:no,,0.68
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,ACR core components,None,10,3,43,no,1:no,1:no,,0.688
2529,2674556,Table 1,BaselineCharacteristic,"ESR (mm/h), geometric mean (CV)",Characteristics ; ,"ESR (mm/h), geometric mean (CV)", ACR core components,17,0,2,no,1:no,1:no,,0.857
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,"ESR (mm/h), geometric mean (CV)", ACR core components,17,1,3,no,1:no,2:yes,+,0.548
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"ESR (mm/h), geometric mean (CV)", ACR core components,17,2,3,no,1:no,1:no,,0.57
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"ESR (mm/h), geometric mean (CV)", ACR core components,17,3,3,no,1:no,1:no,,0.587
2529,2674556,Table 1,BaselineCharacteristic,"HAQ-DI, mean (SD)",Characteristics ; ,"HAQ-DI, mean (SD)", ACR core components,18,0,2,no,1:no,1:no,,0.859
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Placebo + MTX (n?=?xxx) ; ,"HAQ-DI, mean (SD)", ACR core components,18,1,3,no,1:no,1:no,,0.585
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"HAQ-DI, mean (SD)", ACR core components,18,2,3,no,1:no,1:no,,0.688
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"HAQ-DI, mean (SD)", ACR core components,18,3,3,no,1:no,1:no,,0.704
2529,2674556,Table 1,BaselineCharacteristic,"Duration of morning stiffness (h), median (range)",Characteristics ; ,"Duration of morning stiffness (h), median (range)", ACR core components,19,0,2,no,1:no,1:no,,0.896
2529,2674556,Table 1,BaselineCharacteristic,x.x (x to xx.x),Placebo + MTX (n?=?xxx) ; ,"Duration of morning stiffness (h), median (range)", ACR core components,19,1,3,no,1:no,1:no,,0.59
2529,2674556,Table 1,BaselineCharacteristic,x.x (x to xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Duration of morning stiffness (h), median (range)", ACR core components,19,2,3,no,1:no,1:no,,0.688
2529,2674556,Table 1,BaselineCharacteristic,x.x (x to xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Duration of morning stiffness (h), median (range)", ACR core components,19,3,3,no,1:no,1:no,,0.69
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,20,0,2,no,1:no,1:no,,0.875
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,None,None,20,1,3,no,1:no,1:no,,0.615
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,20,2,3,no,1:no,1:no,,0.71
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,20,3,3,no,1:no,1:no,,0.714
2529,2674556,Table 1,BaselineCharacteristic,Rheumatoid factor,Characteristics ; ,None,None,21,0,24,no,1:no,1:no,,0.861
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,Rheumatoid factor,None,21,1,43,no,1:no,1:no,,0.624
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,Rheumatoid factor,None,21,2,43,no,1:no,1:no,,0.726
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,Rheumatoid factor,None,21,3,43,no,1:no,1:no,,0.73
2529,2674556,Table 1,BaselineCharacteristic,"RF positive (?xx IU/ml), n (%)",Characteristics ; ,"RF positive (?xx IU/ml), n (%)", Rheumatoid factor,22,0,2,no,1:no,1:no,,0.677
2529,2674556,Table 1,BaselineCharacteristic,xx (xx.x),Placebo + MTX (n?=?xxx) ; ,"RF positive (?xx IU/ml), n (%)", Rheumatoid factor,22,1,3,no,1:no,2:yes,+,0.571
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"RF positive (?xx IU/ml), n (%)", Rheumatoid factor,22,2,3,no,1:no,2:yes,+,0.516
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"RF positive (?xx IU/ml), n (%)", Rheumatoid factor,22,3,3,no,1:no,2:yes,+,0.51
2529,2674556,Table 1,BaselineCharacteristic,"RF plasma concentration (IU/ml), mean (SD)",Characteristics ; ,"RF plasma concentration (IU/ml), mean (SD)", Rheumatoid factor,23,0,2,no,1:no,1:no,,0.861
2529,2674556,Table 1,BaselineCharacteristic,xxx.x (xxx.x),Placebo + MTX (n?=?xxx) ; ,"RF plasma concentration (IU/ml), mean (SD)", Rheumatoid factor,23,1,3,no,1:no,1:no,,0.613
2529,2674556,Table 1,BaselineCharacteristic,xxx.x (xxx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"RF plasma concentration (IU/ml), mean (SD)", Rheumatoid factor,23,2,3,no,1:no,1:no,,0.707
2529,2674556,Table 1,BaselineCharacteristic,xxx.x (xxx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"RF plasma concentration (IU/ml), mean (SD)", Rheumatoid factor,23,3,3,no,1:no,1:no,,0.714
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,24,0,2,no,1:no,1:no,,0.877
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,None,None,24,1,3,no,1:no,1:no,,0.625
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,24,2,3,no,1:no,1:no,,0.72
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,24,3,3,no,1:no,1:no,,0.724
2529,2674556,Table 1,BaselineCharacteristic,x-Ray progression,Characteristics ; ,None,None,25,0,24,no,1:no,1:no,,0.863
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,x-Ray progression,None,25,1,43,no,1:no,1:no,,0.634
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,x-Ray progression,None,25,2,43,no,1:no,1:no,,0.736
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,x-Ray progression,None,25,3,43,no,1:no,1:no,,0.739
2529,2674556,Table 1,BaselineCharacteristic,"mTSS, mean (SD)",Characteristics ; ,"mTSS, mean (SD)", x-Ray progression,27,0,2,no,1:no,1:no,,0.862
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,"mTSS, mean (SD)", x-Ray progression,27,1,3,no,1:no,1:no,,0.547
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"mTSS, mean (SD)", x-Ray progression,27,2,3,no,1:no,1:no,,0.662
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"mTSS, mean (SD)", x-Ray progression,27,3,3,no,1:no,1:no,,0.671
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,, x-Ray progression,28,0,2,no,1:no,1:no,,0.865
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,, x-Ray progression,28,1,3,no,1:no,2:yes,+,0.535
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,, x-Ray progression,28,2,3,no,1:no,1:no,,0.59
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,, x-Ray progression,28,3,3,no,1:no,1:no,,0.599
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,, x-Ray progression,29,0,2,no,1:no,1:no,,0.865
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,, x-Ray progression,29,1,3,no,1:no,2:yes,+,0.535
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,, x-Ray progression,29,2,3,no,1:no,1:no,,0.59
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,, x-Ray progression,29,3,3,no,1:no,1:no,,0.599
2529,2674556,Table 1,BaselineCharacteristic,"Disease activity (DASxx (ESR)), mean (SD)",Characteristics ; ,"Disease activity (DASxx (ESR)), mean (SD)", x-Ray progression,30,0,2,no,1:no,1:no,,0.849
2529,2674556,Table 1,BaselineCharacteristic,x.xx (x.xx),Placebo + MTX (n?=?xxx) ; ,"Disease activity (DASxx (ESR)), mean (SD)", x-Ray progression,30,1,3,no,1:no,1:no,,0.546
2529,2674556,Table 1,BaselineCharacteristic,x.xx (x.xx),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Disease activity (DASxx (ESR)), mean (SD)", x-Ray progression,30,2,3,no,1:no,1:no,,0.655
2529,2674556,Table 1,BaselineCharacteristic,x.xx (x.xx),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Disease activity (DASxx (ESR)), mean (SD)", x-Ray progression,30,3,3,no,1:no,1:no,,0.664
2536,2678276,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
2536,2678276,Table 1,BaselineCharacteristic,XELIRI,,,None,0,1,1,no,1:no,1:no,,0.735
2536,2678276,Table 1,BaselineCharacteristic,FOLFIRI,,,None,0,2,1,no,1:no,1:no,,0.775
2536,2678276,Table 1,BaselineCharacteristic,,,,None,0,3,1,no,1:no,1:no,,0.79
2536,2678276,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no,1:no,1:no,,0.792
2536,2678276,Table 1,BaselineCharacteristic,n = xx,XELIRI ; ,,None,1,1,1,no,1:no,1:no,,0.578
2536,2678276,Table 1,BaselineCharacteristic,n = xx,FOLFIRI ; ,,None,1,2,1,no,1:no,1:no,,0.58
2536,2678276,Table 1,BaselineCharacteristic,p, ; ,,None,1,3,1,no,1:no,1:no,,0.791
2536,2678276,Table 1,BaselineCharacteristic,Median age-years, ;  ; ,Median age-years,,2,0,2,no,1:no,1:no,,0.849
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,Median age-years,,2,3,3,no,1:no,1:no,,0.679
2536,2678276,Table 1,BaselineCharacteristic,Gender, ;  ; ,None,None,3,0,24,no,1:no,1:no,,0.706
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Gender,None,3,1,43,no,1:no,2:yes,+,0.609
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Gender,None,3,2,43,no,1:no,2:yes,+,0.596
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Gender,None,3,3,43,no,1:no,1:no,,0.7
2536,2678276,Table 1,BaselineCharacteristic,?Male, ;  ; ,?Male, Gender,4,0,2,no,1:no,1:no,,0.694
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Male, Gender,4,1,3,yes,2:yes,2:yes,,0.739
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Male, Gender,4,2,3,yes,2:yes,2:yes,,0.738
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Male, Gender,4,3,3,no,1:no,2:yes,+,0.612
2536,2678276,Table 1,BaselineCharacteristic,?Female, ;  ; ,?Female, Gender,5,0,2,no,1:no,1:no,,0.7
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Female, Gender,5,1,3,no,1:no,2:yes,+,0.72
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Female, Gender,5,2,3,no,1:no,2:yes,+,0.714
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Female, Gender,5,3,3,no,1:no,2:yes,+,0.606
2536,2678276,Table 1,BaselineCharacteristic,WHO performance status, ;  ; ,None,None,6,0,24,no,1:no,1:no,,0.869
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,WHO performance status,None,6,1,43,no,1:no,1:no,,0.605
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,WHO performance status,None,6,2,43,no,1:no,1:no,,0.616
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,WHO performance status,None,6,3,43,no,1:no,1:no,,0.852
2536,2678276,Table 1,BaselineCharacteristic,?Performance status x, ;  ; ,?Performance status x, WHO performance status,7,0,2,no,1:no,1:no,,0.844
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Performance status x, WHO performance status,7,1,3,no,1:no,1:no,,0.572
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Performance status x, WHO performance status,7,2,3,no,1:no,1:no,,0.586
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Performance status x, WHO performance status,7,3,3,no,1:no,1:no,,0.736
2536,2678276,Table 1,BaselineCharacteristic,?Performance status x, ;  ; ,?Performance status x, WHO performance status,8,0,2,no,1:no,1:no,,0.847
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Performance status x, WHO performance status,8,1,3,no,1:no,1:no,,0.611
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Performance status x, WHO performance status,8,2,3,no,1:no,1:no,,0.626
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Performance status x, WHO performance status,8,3,3,no,1:no,1:no,,0.767
2536,2678276,Table 1,BaselineCharacteristic,Primary tumour, ;  ; ,None,None,9,0,24,no,1:no,1:no,,0.89
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Primary tumour,None,9,1,43,no,1:no,1:no,,0.662
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Primary tumour,None,9,2,43,no,1:no,1:no,,0.667
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Primary tumour,None,9,3,43,no,1:no,1:no,,0.865
2536,2678276,Table 1,BaselineCharacteristic,?Colon, ;  ; ,?Colon, Primary tumour,10,0,2,no,1:no,1:no,,0.887
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Colon, Primary tumour,10,1,3,no,1:no,1:no,,0.641
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Colon, Primary tumour,10,2,3,no,1:no,1:no,,0.65
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Colon, Primary tumour,10,3,3,no,1:no,1:no,,0.796
2536,2678276,Table 1,BaselineCharacteristic,?Rectum, ;  ; ,?Rectum, Primary tumour,11,0,2,no,1:no,1:no,,0.888
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Rectum, Primary tumour,11,1,3,no,1:no,1:no,,0.67
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),FOLFIRI ; n = xx ; ,?Rectum, Primary tumour,11,2,3,no,1:no,1:no,,0.692
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Rectum, Primary tumour,11,3,3,no,1:no,1:no,,0.804
2536,2678276,Table 1,BaselineCharacteristic,Initial stage of disease at diagnosis, ;  ; ,None,None,12,0,24,no,1:no,1:no,,0.903
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Initial stage of disease at diagnosis,None,12,1,43,no,1:no,1:no,,0.792
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Initial stage of disease at diagnosis,None,12,2,43,no,1:no,1:no,,0.787
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Initial stage of disease at diagnosis,None,12,3,43,no,1:no,1:no,,0.907
2536,2678276,Table 1,BaselineCharacteristic,?Stage x, ;  ; ,?Stage x, Initial stage of disease at diagnosis,13,0,2,no,1:no,1:no,,0.897
2536,2678276,Table 1,BaselineCharacteristic,x,XELIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,13,1,3,no,1:no,1:no,,0.761
2536,2678276,Table 1,BaselineCharacteristic,x (x%),FOLFIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,13,2,3,no,1:no,1:no,,0.751
2536,2678276,Table 1,BaselineCharacteristic,-, ; p ; ,?Stage x, Initial stage of disease at diagnosis,13,3,3,no,1:no,1:no,,0.857
2536,2678276,Table 1,BaselineCharacteristic,?Stage x, ;  ; ,?Stage x, Initial stage of disease at diagnosis,14,0,2,no,1:no,1:no,,0.886
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,14,1,3,no,1:no,1:no,,0.749
2536,2678276,Table 1,BaselineCharacteristic,x (x%),FOLFIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,14,2,3,no,1:no,1:no,,0.743
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Stage x, Initial stage of disease at diagnosis,14,3,3,no,1:no,1:no,,0.85
2536,2678276,Table 1,BaselineCharacteristic,?Stage x, ;  ; ,?Stage x, Initial stage of disease at diagnosis,15,0,2,no,1:no,1:no,,0.891
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,15,1,3,no,1:no,1:no,,0.75
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,15,2,3,no,1:no,1:no,,0.751
2536,2678276,Table 1,BaselineCharacteristic,"x,xx", ; p ; ,?Stage x, Initial stage of disease at diagnosis,15,3,3,no,1:no,1:no,,0.855
2536,2678276,Table 1,BaselineCharacteristic,?Stage x, ;  ; ,?Stage x, Initial stage of disease at diagnosis,16,0,2,no,1:no,1:no,,0.892
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,16,1,3,no,1:no,1:no,,0.751
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,16,2,3,no,1:no,1:no,,0.752
2536,2678276,Table 1,BaselineCharacteristic,x.x, ; p ; ,?Stage x, Initial stage of disease at diagnosis,16,3,3,no,1:no,1:no,,0.881
2536,2678276,Table 1,BaselineCharacteristic,Previous adjuvant treatment*, ;  ; ,None,None,17,0,24,no,1:no,1:no,,0.891
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Previous adjuvant treatment*,None,17,1,43,no,1:no,1:no,,0.735
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Previous adjuvant treatment*,None,17,2,43,no,1:no,1:no,,0.735
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Previous adjuvant treatment*,None,17,3,43,no,1:no,1:no,,0.874
2536,2678276,Table 1,BaselineCharacteristic,?Yes, ;  ; ,?Yes, Previous adjuvant treatment*,18,0,2,no,1:no,1:no,,0.898
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Yes, Previous adjuvant treatment*,18,1,3,no,1:no,1:no,,0.706
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Yes, Previous adjuvant treatment*,18,2,3,no,1:no,1:no,,0.719
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Yes, Previous adjuvant treatment*,18,3,3,no,1:no,1:no,,0.803
2536,2678276,Table 1,BaselineCharacteristic,?No, ;  ; ,?No, Previous adjuvant treatment*,19,0,2,no,1:no,1:no,,0.863
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?No, Previous adjuvant treatment*,19,1,3,no,1:no,1:no,,0.663
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?No, Previous adjuvant treatment*,19,2,3,no,1:no,1:no,,0.665
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?No, Previous adjuvant treatment*,19,3,3,no,1:no,1:no,,0.749
2536,2678276,Table 1,BaselineCharacteristic,Median time from diagnosis to randomisation (months), ;  ; ,Median time from diagnosis to randomisation (months),,20,0,2,no,1:no,1:no,,0.919
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,Median time from diagnosis to randomisation (months),,20,3,3,no,1:no,1:no,,0.848
2536,2678276,Table 1,BaselineCharacteristic,Number of liver metastases, ;  ; ,None,None,21,0,24,no,1:no,1:no,,0.905
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Number of liver metastases,None,21,1,43,no,1:no,1:no,,0.806
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Number of liver metastases,None,21,2,43,no,1:no,1:no,,0.809
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Number of liver metastases,None,21,3,43,no,1:no,1:no,,0.903
2536,2678276,Table 1,BaselineCharacteristic,?> xx, ;  ; ,?> xx, Number of liver metastases,24,0,2,no,1:no,1:no,,0.824
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?> xx, Number of liver metastases,24,1,3,no,1:no,1:no,,0.775
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?> xx, Number of liver metastases,24,2,3,no,1:no,1:no,,0.781
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?> xx, Number of liver metastases,24,3,3,no,1:no,1:no,,0.849
2536,2678276,Table 1,BaselineCharacteristic,Liver involvement (%), ;  ; ,None,None,25,0,24,no,1:no,1:no,,0.859
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Liver involvement (%),None,25,1,43,no,1:no,1:no,,0.643
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Liver involvement (%),None,25,2,43,no,1:no,1:no,,0.646
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Liver involvement (%),None,25,3,43,no,1:no,1:no,,0.843
2536,2678276,Table 1,BaselineCharacteristic,?< xx, ;  ; ,?< xx, Liver involvement (%),26,0,2,no,1:no,1:no,,0.781
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?< xx, Liver involvement (%),26,1,3,no,1:no,1:no,,0.596
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?< xx, Liver involvement (%),26,2,3,no,1:no,1:no,,0.605
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?< xx, Liver involvement (%),26,3,3,no,1:no,1:no,,0.731
2536,2678276,Table 1,BaselineCharacteristic,?> xx, ;  ; ,?> xx, Liver involvement (%),28,0,2,no,1:no,1:no,,0.781
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?> xx, Liver involvement (%),28,1,3,no,1:no,1:no,,0.596
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?> xx, Liver involvement (%),28,2,3,no,1:no,1:no,,0.605
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?> xx, Liver involvement (%),28,3,3,no,1:no,1:no,,0.732
2536,2678276,Table 1,BaselineCharacteristic,Median size of liver metastases (cm), ;  ; ,Median size of liver metastases (cm),,29,0,2,no,1:no,1:no,,0.929
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,Median size of liver metastases (cm),,29,3,3,no,1:no,1:no,,0.874
2536,2678276,Table 1,BaselineCharacteristic,"Bilateral liver metastases, n (%)", ;  ; ,"Bilateral liver metastases, n (%)",,30,0,2,no,1:no,1:no,,0.827
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,"Bilateral liver metastases, n (%)",,30,1,3,no,1:no,1:no,,0.615
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,"Bilateral liver metastases, n (%)",,30,2,3,no,1:no,1:no,,0.623
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,"Bilateral liver metastases, n (%)",,30,3,3,no,1:no,1:no,,0.689
2536,2678276,Table 1,BaselineCharacteristic,Baseline CEA, ;  ; ,None,None,31,0,24,no,1:no,1:no,,0.884
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Baseline CEA,None,31,1,43,no,1:no,1:no,,0.682
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Baseline CEA,None,31,2,43,no,1:no,1:no,,0.682
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Baseline CEA,None,31,3,43,no,1:no,1:no,,0.869
2536,2678276,Table 1,BaselineCharacteristic,?Normal, ;  ; ,?Normal, Baseline CEA,32,0,2,no,1:no,1:no,,0.891
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Normal, Baseline CEA,32,1,3,no,1:no,1:no,,0.65
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Normal, Baseline CEA,32,2,3,no,1:no,1:no,,0.664
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Normal, Baseline CEA,32,3,3,no,1:no,1:no,,0.782
2536,2678276,Table 1,BaselineCharacteristic,?> x.x ?g/l, ;  ; ,?> x.x ?g/l, Baseline CEA,33,0,2,no,1:no,1:no,,0.872
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?> x.x ?g/l, Baseline CEA,33,1,3,no,1:no,1:no,,0.65
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?> x.x ?g/l, Baseline CEA,33,2,3,no,1:no,1:no,,0.661
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?> x.x ?g/l, Baseline CEA,33,3,3,no,1:no,1:no,,0.782
2536,2678276,Table 1,BaselineCharacteristic,Baseline LDH, ;  ; ,None,None,34,0,24,no,1:no,1:no,,0.884
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Baseline LDH,None,34,1,43,no,1:no,1:no,,0.683
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Baseline LDH,None,34,2,43,no,1:no,1:no,,0.682
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Baseline LDH,None,34,3,43,no,1:no,1:no,,0.869
2536,2678276,Table 1,BaselineCharacteristic,?Normal, ;  ; ,?Normal, Baseline LDH,35,0,2,no,1:no,1:no,,0.891
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Normal, Baseline LDH,35,1,3,no,1:no,1:no,,0.656
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Normal, Baseline LDH,35,2,3,no,1:no,1:no,,0.665
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Normal, Baseline LDH,35,3,3,no,1:no,1:no,,0.782
2536,2678276,Table 1,BaselineCharacteristic,?> x.xx ?kat/l, ;  ; ,?> x.xx ?kat/l, Baseline LDH,36,0,2,no,1:no,1:no,,0.81
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?> x.xx ?kat/l, Baseline LDH,36,1,3,no,1:no,1:no,,0.651
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?> x.xx ?kat/l, Baseline LDH,36,2,3,no,1:no,1:no,,0.661
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?> x.xx ?kat/l, Baseline LDH,36,3,3,no,1:no,1:no,,0.782
2536,2678276,Table 1,BaselineCharacteristic,Reasons for initial unresectability, ;  ; ,None,None,37,0,24,no,1:no,1:no,,0.894
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Reasons for initial unresectability,None,37,1,43,no,1:no,1:no,,0.723
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Reasons for initial unresectability,None,37,2,43,no,1:no,1:no,,0.723
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Reasons for initial unresectability,None,37,3,43,no,1:no,1:no,,0.878
2536,2678276,Table 1,BaselineCharacteristic,?Location of metastases, ;  ; ,?Location of metastases, Reasons for initial unresectability,38,0,2,no,1:no,1:no,,0.897
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Location of metastases, Reasons for initial unresectability,38,1,3,no,1:no,1:no,,0.733
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),FOLFIRI ; n = xx ; ,?Location of metastases, Reasons for initial unresectability,38,2,3,no,1:no,1:no,,0.745
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Location of metastases, Reasons for initial unresectability,38,3,3,no,1:no,1:no,,0.841
2536,2678276,Table 1,BaselineCharacteristic,?Number of metastases, ;  ; ,?Number of metastases, Reasons for initial unresectability,39,0,2,no,1:no,1:no,,0.863
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Number of metastases, Reasons for initial unresectability,39,1,3,no,1:no,1:no,,0.757
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Number of metastases, Reasons for initial unresectability,39,2,3,no,1:no,1:no,,0.762
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Number of metastases, Reasons for initial unresectability,39,3,3,no,1:no,1:no,,0.832
2536,2678276,Table 1,BaselineCharacteristic,?Size of metastases, ;  ; ,?Size of metastases, Reasons for initial unresectability,40,0,2,no,1:no,1:no,,0.893
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Size of metastases, Reasons for initial unresectability,40,1,3,no,1:no,1:no,,0.717
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),FOLFIRI ; n = xx ; ,?Size of metastases, Reasons for initial unresectability,40,2,3,no,1:no,1:no,,0.728
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Size of metastases, Reasons for initial unresectability,40,3,3,no,1:no,1:no,,0.839
2602,2694271,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
2602,2694271,Table 1,BaselineCharacteristic,Gender, ; ,Gender,,1,0,24,no,1:no,1:no,,0.654
2602,2694271,Table 1,BaselineCharacteristic,, ; ,,,2,0,2,no,1:no,1:no,,0.831
2602,2694271,Table 1,BaselineCharacteristic,Country of birth, ; ,None,None,5,0,24,no,1:no,1:no,,0.838
2602,2694271,Table 1,BaselineCharacteristic,UK, ; ,UK, Country of birth,6,0,2,no,1:no,1:no,,0.804
2602,2694271,Table 1,BaselineCharacteristic,Africa, ; ,Africa, Country of birth,7,0,2,no,1:no,1:no,,0.823
2602,2694271,Table 1,BaselineCharacteristic,Other, ; ,Other, Country of birth,8,0,2,no,1:no,1:no,,0.833
2602,2694271,Table 1,BaselineCharacteristic,Healthcare worker, ; ,Healthcare worker, Country of birth,9,0,2,no,1:no,1:no,,0.846
2602,2694271,Table 1,BaselineCharacteristic,Significant travel history, ; ,Significant travel history, Country of birth,10,0,2,no,1:no,1:no,,0.86
2650,2705818,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
2650,2705818,Table 1,BaselineCharacteristic,Men,,,None,0,1,1,no,1:no,1:no,,0.735
2650,2705818,Table 1,BaselineCharacteristic,Women,,,None,0,2,1,no,1:no,1:no,,0.732
2650,2705818,Table 1,BaselineCharacteristic,Total,,,None,0,3,1,no,1:no,1:no,,0.691
2650,2705818,Table 1,BaselineCharacteristic,"Gender, n (%)", ; ,"Gender, n (%)",,1,0,2,no,1:no,1:no,,0.688
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Men ; ,"Gender, n (%)",,1,1,3,yes,2:yes,2:yes,,0.707
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Women ; ,"Gender, n (%)",,1,2,3,yes,2:yes,2:yes,,0.707
2650,2705818,Table 1,BaselineCharacteristic,xxx,Total ; ,"Gender, n (%)",,1,3,3,no,1:no,2:yes,+,0.579
2650,2705818,Table 1,BaselineCharacteristic,Range, ; ,Range,,3,0,2,no,1:no,1:no,,0.796
2650,2705818,Table 1,BaselineCharacteristic,"Race, n (%)", ; ,None,None,4,0,24,no,1:no,1:no,,0.736
2650,2705818,Table 1,BaselineCharacteristic,"Race, n (%)",Men ; ,"Race, n (%)",None,4,1,43,no,1:no,1:no,,0.643
2650,2705818,Table 1,BaselineCharacteristic,"Race, n (%)",Women ; ,"Race, n (%)",None,4,2,43,no,1:no,1:no,,0.617
2650,2705818,Table 1,BaselineCharacteristic,"Race, n (%)",Total ; ,"Race, n (%)",None,4,3,43,no,1:no,1:no,,0.595
2650,2705818,Table 1,BaselineCharacteristic,White, ; ,White," Race, n (%)",5,0,2,no,1:no,1:no,,0.703
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Men ; ,White," Race, n (%)",5,1,3,no,1:no,2:yes,+,0.617
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Women ; ,White," Race, n (%)",5,2,3,no,1:no,2:yes,+,0.636
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Total ; ,White," Race, n (%)",5,3,3,no,1:no,2:yes,+,0.625
2650,2705818,Table 1,BaselineCharacteristic,Black, ; ,Black," Race, n (%)",6,0,2,no,1:no,1:no,,0.703
2650,2705818,Table 1,BaselineCharacteristic,x (x),Men ; ,Black," Race, n (%)",6,1,3,no,1:no,2:yes,+,0.532
2650,2705818,Table 1,BaselineCharacteristic,x (x),Women ; ,Black," Race, n (%)",6,2,3,no,1:no,2:yes,+,0.533
2650,2705818,Table 1,BaselineCharacteristic,xx (x),Total ; ,Black," Race, n (%)",6,3,3,no,1:no,2:yes,+,0.635
2650,2705818,Table 1,BaselineCharacteristic,Asian, ; ,Asian," Race, n (%)",7,0,2,no,1:no,1:no,,0.703
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Men ; ,Asian," Race, n (%)",7,1,3,no,1:no,2:yes,+,0.617
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Women ; ,Asian," Race, n (%)",7,2,3,no,1:no,2:yes,+,0.633
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Total ; ,Asian," Race, n (%)",7,3,3,no,1:no,2:yes,+,0.615
2650,2705818,Table 1,BaselineCharacteristic,Other, ; ,Other," Race, n (%)",8,0,2,no,1:no,1:no,,0.718
2650,2705818,Table 1,BaselineCharacteristic,x,Men ; ,Other," Race, n (%)",8,1,3,no,1:no,1:no,,0.515
2650,2705818,Table 1,BaselineCharacteristic,xx (x),Women ; ,Other," Race, n (%)",8,2,3,no,1:no,2:yes,+,0.556
2650,2705818,Table 1,BaselineCharacteristic,xx (x),Total ; ,Other," Race, n (%)",8,3,3,no,1:no,2:yes,+,0.582
2650,2705818,Table 1,BaselineCharacteristic,"Postmenopausal,n (%)", ; ,"Postmenopausal,n (%)"," Race, n (%)",9,0,2,no,1:no,1:no,,0.729
2650,2705818,Table 1,BaselineCharacteristic,NA,Men ; ,"Postmenopausal,n (%)"," Race, n (%)",9,1,3,no,1:no,1:no,,0.593
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Women ; ,"Postmenopausal,n (%)"," Race, n (%)",9,2,3,no,1:no,2:yes,+,0.598
2650,2705818,Table 1,BaselineCharacteristic,NA,Total ; ,"Postmenopausal,n (%)"," Race, n (%)",9,3,3,no,1:no,1:no,,0.552
2650,2705818,Table 1,BaselineCharacteristic,"Past or presentBPH, n (%)", ; ,"Past or presentBPH, n (%)"," Race, n (%)",10,0,2,no,1:no,1:no,,0.742
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Men ; ,"Past or presentBPH, n (%)"," Race, n (%)",10,1,3,no,1:no,2:yes,+,0.508
2650,2705818,Table 1,BaselineCharacteristic,NA,Women ; ,"Past or presentBPH, n (%)"," Race, n (%)",10,2,3,no,1:no,1:no,,0.59
2650,2705818,Table 1,BaselineCharacteristic,NA,Total ; ,"Past or presentBPH, n (%)"," Race, n (%)",10,3,3,no,1:no,1:no,,0.58
2748,2736828,Table 1,BaselineCharacteristic,Parameter,,None,None,0,0,12,no,1:no,1:no,,0.799
2748,2736828,Table 1,BaselineCharacteristic,TMZ+IFN,,Parameter,None,0,1,1,no,1:no,1:no,,0.756
2748,2736828,Table 1,BaselineCharacteristic,TMZ+PEG,,Parameter,None,0,2,1,no,1:no,1:no,,0.796
2748,2736828,Table 1,BaselineCharacteristic,Number of patients,Parameter ; ,Number of patients,,1,0,2,no,1:no,1:no,,0.739
2748,2736828,Table 1,BaselineCharacteristic,xx,TMZ+IFN ; ,Number of patients,,1,1,3,no,1:no,1:no,,0.525
2748,2736828,Table 1,BaselineCharacteristic,xx,TMZ+PEG ; ,Number of patients,,1,2,3,no,1:no,1:no,,0.525
2748,2736828,Table 1,BaselineCharacteristic,Age: median (range),Parameter ; ,Age: median (range),,2,0,2,no,1:no,1:no,,0.862
2748,2736828,Table 1,BaselineCharacteristic,Gender: M/F (%),Parameter ; ,Gender: M/F (%),,3,0,2,no,1:no,1:no,,0.734
2748,2736828,Table 1,BaselineCharacteristic,xx?:?x (xx:xx),TMZ+IFN ; ,Gender: M/F (%),,3,1,3,yes,2:yes,2:yes,,0.681
2748,2736828,Table 1,BaselineCharacteristic,xx?:?xx (xx?:?xx),TMZ+PEG ; ,Gender: M/F (%),,3,2,3,yes,2:yes,2:yes,,0.634
2748,2736828,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,4,0,2,no,1:no,1:no,,0.863
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+IFN ; ,None,None,4,1,3,no,1:no,1:no,,0.731
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+PEG ; ,None,None,4,2,3,no,1:no,1:no,,0.768
2748,2736828,Table 1,BaselineCharacteristic,KPS,Parameter ; ,None,None,5,0,24,no,1:no,1:no,,0.842
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+IFN ; ,KPS,None,5,1,43,no,1:no,1:no,,0.758
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+PEG ; ,KPS,None,5,2,43,no,1:no,1:no,,0.787
2748,2736828,Table 1,BaselineCharacteristic,?Median,Parameter ; ,?Median, KPS,6,0,2,no,1:no,1:no,,0.863
2748,2736828,Table 1,BaselineCharacteristic,xx,TMZ+IFN ; ,?Median, KPS,6,1,3,no,1:no,1:no,,0.61
2748,2736828,Table 1,BaselineCharacteristic,xx,TMZ+PEG ; ,?Median, KPS,6,2,3,no,1:no,1:no,,0.624
2748,2736828,Table 1,BaselineCharacteristic,?xxx%,Parameter ; ,?xxx%, KPS,7,0,2,no,1:no,1:no,,0.846
2748,2736828,Table 1,BaselineCharacteristic,x (x%),TMZ+IFN ; ,?xxx%, KPS,7,1,3,no,1:no,1:no,,0.696
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?xxx%, KPS,7,2,3,no,1:no,1:no,,0.643
2748,2736828,Table 1,BaselineCharacteristic,?xx%,Parameter ; ,?xx%, KPS,8,0,2,no,1:no,1:no,,0.803
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+IFN ; ,?xx%, KPS,8,1,3,no,1:no,1:no,,0.657
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+PEG ; ,?xx%, KPS,8,2,3,no,1:no,1:no,,0.585
2748,2736828,Table 1,BaselineCharacteristic,?xx%,Parameter ; ,?xx%, KPS,9,0,2,no,1:no,1:no,,0.822
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+IFN ; ,?xx%, KPS,9,1,3,no,1:no,1:no,,0.604
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?xx%, KPS,9,2,3,no,1:no,1:no,,0.69
2748,2736828,Table 1,BaselineCharacteristic,?xx%,Parameter ; ,?xx%, KPS,10,0,2,no,1:no,1:no,,0.826
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+IFN ; ,?xx%, KPS,10,1,3,no,1:no,1:no,,0.69
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?xx%, KPS,10,2,3,no,1:no,1:no,,0.7
2748,2736828,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,11,0,2,no,1:no,1:no,,0.897
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+IFN ; ,None,None,11,1,3,no,1:no,1:no,,0.813
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+PEG ; ,None,None,11,2,3,no,1:no,1:no,,0.826
2748,2736828,Table 1,BaselineCharacteristic,Maximum prior resection,Parameter ; ,None,None,12,0,24,no,1:no,1:no,,0.885
2748,2736828,Table 1,BaselineCharacteristic,Maximum prior resection,TMZ+IFN ; ,Maximum prior resection,None,12,1,43,no,1:no,1:no,,0.833
2748,2736828,Table 1,BaselineCharacteristic,Maximum prior resection,TMZ+PEG ; ,Maximum prior resection,None,12,2,43,no,1:no,1:no,,0.846
2748,2736828,Table 1,BaselineCharacteristic,?Biopsy,Parameter ; ,?Biopsy, Maximum prior resection,13,0,2,no,1:no,1:no,,0.889
2748,2736828,Table 1,BaselineCharacteristic,x (x%),TMZ+IFN ; ,?Biopsy, Maximum prior resection,13,1,3,no,1:no,1:no,,0.761
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?Biopsy, Maximum prior resection,13,2,3,no,1:no,1:no,,0.738
2748,2736828,Table 1,BaselineCharacteristic,?Subtotal resection,Parameter ; ,?Subtotal resection, Maximum prior resection,14,0,2,no,1:no,1:no,,0.885
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+IFN ; ,?Subtotal resection, Maximum prior resection,14,1,3,no,1:no,1:no,,0.694
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?Subtotal resection, Maximum prior resection,14,2,3,no,1:no,1:no,,0.727
2748,2736828,Table 1,BaselineCharacteristic,?Gross total resection,Parameter ; ,?Gross total resection, Maximum prior resection,15,0,2,no,1:no,1:no,,0.832
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+IFN ; ,?Gross total resection, Maximum prior resection,15,1,3,no,1:no,1:no,,0.615
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+PEG ; ,?Gross total resection, Maximum prior resection,15,2,3,no,1:no,1:no,,0.616
2748,2736828,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,16,0,2,no,1:no,1:no,,0.897
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+IFN ; ,None,None,16,1,3,no,1:no,1:no,,0.808
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+PEG ; ,None,None,16,2,3,no,1:no,1:no,,0.821
2748,2736828,Table 1,BaselineCharacteristic,Number of prior chemotherapies,Parameter ; ,None,None,17,0,24,no,1:no,1:no,,0.9
2748,2736828,Table 1,BaselineCharacteristic,Number of prior chemotherapies,TMZ+IFN ; ,Number of prior chemotherapies,None,17,1,43,no,1:no,1:no,,0.873
2748,2736828,Table 1,BaselineCharacteristic,Number of prior chemotherapies,TMZ+PEG ; ,Number of prior chemotherapies,None,17,2,43,no,1:no,1:no,,0.873
2748,2736828,Table 1,BaselineCharacteristic,?x,Parameter ; ,?x, Number of prior chemotherapies,18,0,2,no,1:no,1:no,,0.862
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+IFN ; ,?x, Number of prior chemotherapies,18,1,3,no,1:no,1:no,,0.816
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+PEG ; ,?x, Number of prior chemotherapies,18,2,3,no,1:no,1:no,,0.772
2748,2736828,Table 1,BaselineCharacteristic,?x,Parameter ; ,?x, Number of prior chemotherapies,19,0,2,no,1:no,1:no,,0.867
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%)a,TMZ+IFN ; ,?x, Number of prior chemotherapies,19,1,3,no,1:no,1:no,,0.776
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%)b,TMZ+PEG ; ,?x, Number of prior chemotherapies,19,2,3,no,1:no,1:no,,0.735
2748,2736828,Table 1,BaselineCharacteristic,?x,Parameter ; ,?x, Number of prior chemotherapies,20,0,2,no,1:no,1:no,,0.867
2748,2736828,Table 1,BaselineCharacteristic,x (x%),TMZ+IFN ; ,?x, Number of prior chemotherapies,20,1,3,no,1:no,1:no,,0.839
2748,2736828,Table 1,BaselineCharacteristic,x (x%),TMZ+PEG ; ,?x, Number of prior chemotherapies,20,2,3,no,1:no,1:no,,0.839
2787,2747698,Table 2,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
2787,2747698,Table 2,BaselineCharacteristic,n,,Characteristic,None,0,1,1,no,1:no,1:no,,0.72
2787,2747698,Table 2,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,1,0,24,no,1:no,1:no,,0.845
2787,2747698,Table 2,BaselineCharacteristic,Age (years),n ; ,Age (years),None,1,1,43,no,1:no,1:no,,0.733
2787,2747698,Table 2,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),2,0,2,no,1:no,1:no,,0.858
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Median, Age (years),2,1,3,no,1:no,1:no,,0.652
2787,2747698,Table 2,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),3,0,2,no,1:no,1:no,,0.837
2787,2747698,Table 2,BaselineCharacteristic,WHO PS,Characteristic ; ,None,None,4,0,24,no,1:no,1:no,,0.849
2787,2747698,Table 2,BaselineCharacteristic,WHO PS,n ; ,WHO PS,None,4,1,43,no,1:no,1:no,,0.707
2787,2747698,Table 2,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO PS,5,0,2,no,1:no,1:no,,0.831
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?x, WHO PS,5,1,3,no,1:no,1:no,,0.631
2787,2747698,Table 2,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO PS,6,0,2,no,1:no,1:no,,0.83
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?x, WHO PS,6,1,3,no,1:no,1:no,,0.658
2787,2747698,Table 2,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO PS,7,0,2,no,1:no,1:no,,0.843
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?x, WHO PS,7,1,3,no,1:no,1:no,,0.662
2787,2747698,Table 2,BaselineCharacteristic,FIGO stage,Characteristic ; ,None,None,8,0,24,no,1:no,1:no,,0.884
2787,2747698,Table 2,BaselineCharacteristic,FIGO stage,n ; ,FIGO stage,None,8,1,43,no,1:no,1:no,,0.761
2787,2747698,Table 2,BaselineCharacteristic,?IVA,Characteristic ; ,?IVA, FIGO stage,9,0,2,no,1:no,1:no,,0.892
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?IVA, FIGO stage,9,1,3,no,1:no,1:no,,0.663
2787,2747698,Table 2,BaselineCharacteristic,?IVB,Characteristic ; ,?IVB, FIGO stage,10,0,2,no,1:no,1:no,,0.894
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?IVB, FIGO stage,10,1,3,no,1:no,1:no,,0.677
2787,2747698,Table 2,BaselineCharacteristic,?Recurrent,Characteristic ; ,?Recurrent, FIGO stage,11,0,2,no,1:no,1:no,,0.894
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Recurrent, FIGO stage,11,1,3,no,1:no,1:no,,0.685
2787,2747698,Table 2,BaselineCharacteristic,Site of recurrent,Characteristic ; ,None,None,12,0,24,no,1:no,1:no,,0.901
2787,2747698,Table 2,BaselineCharacteristic,Site of recurrent,n ; ,Site of recurrent,None,12,1,43,no,1:no,1:no,,0.791
2787,2747698,Table 2,BaselineCharacteristic,?Inside radiation field,Characteristic ; ,?Inside radiation field, Site of recurrent,13,0,2,no,1:no,1:no,,0.888
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Inside radiation field, Site of recurrent,13,1,3,no,1:no,1:no,,0.735
2787,2747698,Table 2,BaselineCharacteristic,?Outside radiation field,Characteristic ; ,?Outside radiation field, Site of recurrent,14,0,2,no,1:no,1:no,,0.884
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Outside radiation field, Site of recurrent,14,1,3,no,1:no,1:no,,0.688
2787,2747698,Table 2,BaselineCharacteristic,Histology,Characteristic ; ,None,None,15,0,24,no,1:no,1:no,,0.888
2787,2747698,Table 2,BaselineCharacteristic,Histology,n ; ,Histology,None,15,1,43,no,1:no,1:no,,0.755
2787,2747698,Table 2,BaselineCharacteristic,?Squamous cell carcinoma,Characteristic ; ,?Squamous cell carcinoma, Histology,16,0,2,no,1:no,1:no,,0.911
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Squamous cell carcinoma, Histology,16,1,3,no,1:no,1:no,,0.694
2787,2747698,Table 2,BaselineCharacteristic,?Adenosquamous cell carcinoma,Characteristic ; ,?Adenosquamous cell carcinoma, Histology,17,0,2,no,1:no,1:no,,0.918
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Adenosquamous cell carcinoma, Histology,17,1,3,no,1:no,1:no,,0.761
2787,2747698,Table 2,BaselineCharacteristic,?Adenocarcinoma,Characteristic ; ,?Adenocarcinoma, Histology,18,0,2,no,1:no,1:no,,0.91
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Adenocarcinoma, Histology,18,1,3,no,1:no,1:no,,0.732
2787,2747698,Table 2,BaselineCharacteristic,Prior therapy,Characteristic ; ,None,None,19,0,24,no,1:no,1:no,,0.909
2787,2747698,Table 2,BaselineCharacteristic,Prior therapy,n ; ,Prior therapy,None,19,1,43,no,1:no,1:no,,0.812
2787,2747698,Table 2,BaselineCharacteristic,?None,Characteristic ; ,?None, Prior therapy,20,0,2,no,1:no,1:no,,0.92
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?None, Prior therapy,20,1,3,no,1:no,1:no,,0.79
2787,2747698,Table 2,BaselineCharacteristic,?Chemoradiation,Characteristic ; ,?Chemoradiation, Prior therapy,21,0,2,no,1:no,1:no,,0.914
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Chemoradiation, Prior therapy,21,1,3,no,1:no,1:no,,0.755
2787,2747698,Table 2,BaselineCharacteristic,?Surgery,Characteristic ; ,?Surgery, Prior therapy,22,0,2,no,1:no,1:no,,0.919
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Surgery, Prior therapy,22,1,3,no,1:no,1:no,,0.77
2787,2747698,Table 2,BaselineCharacteristic,?Surgery plus chemoradiation,Characteristic ; ,?Surgery plus chemoradiation, Prior therapy,23,0,2,no,1:no,1:no,,0.92
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Surgery plus chemoradiation, Prior therapy,23,1,3,no,1:no,1:no,,0.755
2787,2747698,Table 6,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
2787,2747698,Table 6,BaselineCharacteristic,,,,None,0,1,1,no,1:no,1:no,,0.735
2787,2747698,Table 6,BaselineCharacteristic,Response,,,None,0,2,1,no,1:no,1:no,,0.775
2787,2747698,Table 6,BaselineCharacteristic,Response,,,None,0,3,1,no,1:no,1:no,,0.79
2787,2747698,Table 6,BaselineCharacteristic,Response,,,None,0,4,1,no,1:no,1:no,,0.802
2787,2747698,Table 6,BaselineCharacteristic,Response,,,None,0,5,1,no,1:no,1:no,,0.795
2787,2747698,Table 6,BaselineCharacteristic,,,,None,0,6,1,no,1:no,1:no,,0.796
2787,2747698,Table 6,BaselineCharacteristic,Characteristic, ; ,None,None,1,0,12,no,1:no,1:no,,0.805
2787,2747698,Table 6,BaselineCharacteristic,No. of Patients, ; ,Characteristic,None,1,1,1,no,1:no,1:no,,0.772
2787,2747698,Table 6,BaselineCharacteristic,CR,Response ; ,Characteristic,None,1,2,1,no,1:no,1:no,,0.769
2787,2747698,Table 6,BaselineCharacteristic,PR,Response ; ,Characteristic,None,1,3,1,no,1:no,1:no,,0.781
2787,2747698,Table 6,BaselineCharacteristic,NC,Response ; ,Characteristic,None,1,4,1,no,1:no,1:no,,0.793
2787,2747698,Table 6,BaselineCharacteristic,PD,Response ; ,Characteristic,None,1,5,1,no,1:no,1:no,,0.786
2787,2747698,Table 6,BaselineCharacteristic,Response rate (%) (xx% CI), ; ,Characteristic,None,1,6,1,no,1:no,1:no,,0.716
2787,2747698,Table 6,BaselineCharacteristic,Total, ; Characteristic ; ,Total,,2,0,2,no,1:no,1:no,,0.755
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,Total,,2,1,3,no,1:no,2:yes,+,0.601
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,Total,,2,2,3,no,1:no,1:no,,0.561
2787,2747698,Table 6,BaselineCharacteristic,xx,Response ; PR ; ,Total,,2,3,3,no,1:no,2:yes,+,0.546
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,Total,,2,4,3,no,1:no,1:no,,0.598
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,Total,,2,5,3,no,1:no,1:no,,0.612
2787,2747698,Table 6,BaselineCharacteristic,, ; Characteristic ; ,None,None,3,0,2,no,1:no,1:no,,0.85
2787,2747698,Table 6,BaselineCharacteristic,, ; No. of Patients ; ,None,None,3,1,3,no,1:no,1:no,,0.718
2787,2747698,Table 6,BaselineCharacteristic,,Response ; CR ; ,None,None,3,2,3,no,1:no,1:no,,0.753
2787,2747698,Table 6,BaselineCharacteristic,,Response ; PR ; ,None,None,3,3,3,no,1:no,1:no,,0.771
2787,2747698,Table 6,BaselineCharacteristic,,Response ; NC ; ,None,None,3,4,3,no,1:no,1:no,,0.781
2787,2747698,Table 6,BaselineCharacteristic,,Response ; PD ; ,None,None,3,5,3,no,1:no,1:no,,0.776
2787,2747698,Table 6,BaselineCharacteristic,, ; Response rate (%) (xx% CI) ; ,None,None,3,6,3,no,1:no,1:no,,0.629
2787,2747698,Table 6,BaselineCharacteristic,Stage, ; Characteristic ; ,None,None,4,0,24,no,1:no,1:no,,0.867
2787,2747698,Table 6,BaselineCharacteristic,Stage, ; No. of Patients ; ,Stage,None,4,1,43,no,1:no,1:no,,0.806
2787,2747698,Table 6,BaselineCharacteristic,Stage,Response ; CR ; ,Stage,None,4,2,43,no,1:no,1:no,,0.827
2787,2747698,Table 6,BaselineCharacteristic,Stage,Response ; PR ; ,Stage,None,4,3,43,no,1:no,1:no,,0.833
2787,2747698,Table 6,BaselineCharacteristic,Stage,Response ; NC ; ,Stage,None,4,4,43,no,1:no,1:no,,0.833
2787,2747698,Table 6,BaselineCharacteristic,Stage,Response ; PD ; ,Stage,None,4,5,43,no,1:no,1:no,,0.831
2787,2747698,Table 6,BaselineCharacteristic,Stage, ; Response rate (%) (xx% CI) ; ,Stage,None,4,6,43,no,1:no,1:no,,0.73
2787,2747698,Table 6,BaselineCharacteristic,?IV, ; Characteristic ; ,?IV, Stage,5,0,2,no,1:no,1:no,,0.878
2787,2747698,Table 6,BaselineCharacteristic,x, ; No. of Patients ; ,?IV, Stage,5,1,3,no,1:no,1:no,,0.663
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?IV, Stage,5,2,3,no,1:no,1:no,,0.749
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?IV, Stage,5,3,3,no,1:no,1:no,,0.762
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?IV, Stage,5,4,3,no,1:no,1:no,,0.772
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?IV, Stage,5,5,3,no,1:no,1:no,,0.782
2787,2747698,Table 6,BaselineCharacteristic,?Recurrent, ; Characteristic ; ,?Recurrent, Stage,6,0,2,no,1:no,1:no,,0.87
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?Recurrent, Stage,6,1,3,no,1:no,1:no,,0.583
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Recurrent, Stage,6,2,3,no,1:no,1:no,,0.731
2787,2747698,Table 6,BaselineCharacteristic,xx,Response ; PR ; ,?Recurrent, Stage,6,3,3,no,1:no,1:no,,0.666
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Recurrent, Stage,6,4,3,no,1:no,1:no,,0.761
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Recurrent, Stage,6,5,3,no,1:no,1:no,,0.771
2787,2747698,Table 6,BaselineCharacteristic,Histology, ; Characteristic ; ,None,None,7,0,24,no,1:no,1:no,,0.858
2787,2747698,Table 6,BaselineCharacteristic,Histology, ; No. of Patients ; ,Histology,None,7,1,43,no,1:no,1:no,,0.806
2787,2747698,Table 6,BaselineCharacteristic,Histology,Response ; CR ; ,Histology,None,7,2,43,no,1:no,1:no,,0.8
2787,2747698,Table 6,BaselineCharacteristic,Histology,Response ; PR ; ,Histology,None,7,3,43,no,1:no,1:no,,0.81
2787,2747698,Table 6,BaselineCharacteristic,Histology,Response ; NC ; ,Histology,None,7,4,43,no,1:no,1:no,,0.814
2787,2747698,Table 6,BaselineCharacteristic,Histology,Response ; PD ; ,Histology,None,7,5,43,no,1:no,1:no,,0.811
2787,2747698,Table 6,BaselineCharacteristic,Histology, ; Response rate (%) (xx% CI) ; ,Histology,None,7,6,43,no,1:no,1:no,,0.686
2787,2747698,Table 6,BaselineCharacteristic,?Squamous cell carcinoma, ; Characteristic ; ,?Squamous cell carcinoma, Histology,8,0,2,no,1:no,1:no,,0.881
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?Squamous cell carcinoma, Histology,8,1,3,no,1:no,1:no,,0.67
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Squamous cell carcinoma, Histology,8,2,3,no,1:no,1:no,,0.799
2787,2747698,Table 6,BaselineCharacteristic,xx,Response ; PR ; ,?Squamous cell carcinoma, Histology,8,3,3,no,1:no,1:no,,0.713
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Squamous cell carcinoma, Histology,8,4,3,no,1:no,1:no,,0.831
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Squamous cell carcinoma, Histology,8,5,3,no,1:no,1:no,,0.836
2787,2747698,Table 6,BaselineCharacteristic,?Nonsquamous cell carcinoma, ; Characteristic ; ,?Nonsquamous cell carcinoma, Histology,9,0,2,no,1:no,1:no,,0.891
2787,2747698,Table 6,BaselineCharacteristic,x, ; No. of Patients ; ,?Nonsquamous cell carcinoma, Histology,9,1,3,no,1:no,1:no,,0.739
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Nonsquamous cell carcinoma, Histology,9,2,3,no,1:no,1:no,,0.806
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?Nonsquamous cell carcinoma, Histology,9,3,3,no,1:no,1:no,,0.83
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Nonsquamous cell carcinoma, Histology,9,4,3,no,1:no,1:no,,0.841
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Nonsquamous cell carcinoma, Histology,9,5,3,no,1:no,1:no,,0.846
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy, ; Characteristic ; ,None,None,10,0,24,no,1:no,1:no,,0.891
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy, ; No. of Patients ; ,Prior therapy,None,10,1,43,no,1:no,1:no,,0.855
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy,Response ; CR ; ,Prior therapy,None,10,2,43,no,1:no,1:no,,0.848
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy,Response ; PR ; ,Prior therapy,None,10,3,43,no,1:no,1:no,,0.858
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy,Response ; NC ; ,Prior therapy,None,10,4,43,no,1:no,1:no,,0.866
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy,Response ; PD ; ,Prior therapy,None,10,5,43,no,1:no,1:no,,0.863
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy, ; Response rate (%) (xx% CI) ; ,Prior therapy,None,10,6,43,no,1:no,1:no,,0.764
2787,2747698,Table 6,BaselineCharacteristic,?No, ; Characteristic ; ,?No, Prior therapy,11,0,2,no,1:no,1:no,,0.856
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?No, Prior therapy,11,1,3,no,1:no,1:no,,0.653
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?No, Prior therapy,11,2,3,no,1:no,1:no,,0.703
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?No, Prior therapy,11,3,3,no,1:no,1:no,,0.736
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?No, Prior therapy,11,4,3,no,1:no,1:no,,0.738
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?No, Prior therapy,11,5,3,no,1:no,1:no,,0.746
2787,2747698,Table 6,BaselineCharacteristic,?Yes, ; Characteristic ; ,?Yes, Prior therapy,12,0,2,no,1:no,1:no,,0.9
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?Yes, Prior therapy,12,1,3,no,1:no,1:no,,0.7
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Yes, Prior therapy,12,2,3,no,1:no,1:no,,0.806
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?Yes, Prior therapy,12,3,3,no,1:no,1:no,,0.827
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Yes, Prior therapy,12,4,3,no,1:no,1:no,,0.829
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Yes, Prior therapy,12,5,3,no,1:no,1:no,,0.836
2787,2747698,Table 6,BaselineCharacteristic,Site, ; Characteristic ; ,None,None,13,0,24,no,1:no,1:no,,0.883
2787,2747698,Table 6,BaselineCharacteristic,Site, ; No. of Patients ; ,Site,None,13,1,43,no,1:no,1:no,,0.859
2787,2747698,Table 6,BaselineCharacteristic,Site,Response ; CR ; ,Site,None,13,2,43,no,1:no,1:no,,0.828
2787,2747698,Table 6,BaselineCharacteristic,Site,Response ; PR ; ,Site,None,13,3,43,no,1:no,1:no,,0.841
2787,2747698,Table 6,BaselineCharacteristic,Site,Response ; NC ; ,Site,None,13,4,43,no,1:no,1:no,,0.844
2787,2747698,Table 6,BaselineCharacteristic,Site,Response ; PD ; ,Site,None,13,5,43,no,1:no,1:no,,0.841
2787,2747698,Table 6,BaselineCharacteristic,Site, ; Response rate (%) (xx% CI) ; ,Site,None,13,6,43,no,1:no,1:no,,0.713
2787,2747698,Table 6,BaselineCharacteristic,?Inside radiation field, ; Characteristic ; ,?Inside radiation field, Site,14,0,2,no,1:no,1:no,,0.893
2787,2747698,Table 6,BaselineCharacteristic,x, ; No. of Patients ; ,?Inside radiation field, Site,14,1,3,no,1:no,1:no,,0.764
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Inside radiation field, Site,14,2,3,no,1:no,1:no,,0.806
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?Inside radiation field, Site,14,3,3,no,1:no,1:no,,0.824
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Inside radiation field, Site,14,4,3,no,1:no,1:no,,0.829
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Inside radiation field, Site,14,5,3,no,1:no,1:no,,0.835
2787,2747698,Table 6,BaselineCharacteristic,?Outside radiation field, ; Characteristic ; ,?Outside radiation field, Site,15,0,2,no,1:no,1:no,,0.899
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?Outside radiation field, Site,15,1,3,no,1:no,1:no,,0.685
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Outside radiation field, Site,15,2,3,no,1:no,1:no,,0.811
2787,2747698,Table 6,BaselineCharacteristic,xx,Response ; PR ; ,?Outside radiation field, Site,15,3,3,no,1:no,1:no,,0.758
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Outside radiation field, Site,15,4,3,no,1:no,1:no,,0.835
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Outside radiation field, Site,15,5,3,no,1:no,1:no,,0.841
2787,2747698,Table 6,BaselineCharacteristic,Age (years), ; Characteristic ; ,None,None,16,0,24,no,1:no,1:no,,0.882
2787,2747698,Table 6,BaselineCharacteristic,Age (years), ; No. of Patients ; ,Age (years),None,16,1,43,no,1:no,1:no,,0.863
2787,2747698,Table 6,BaselineCharacteristic,Age (years),Response ; CR ; ,Age (years),None,16,2,43,no,1:no,1:no,,0.854
2787,2747698,Table 6,BaselineCharacteristic,Age (years),Response ; PR ; ,Age (years),None,16,3,43,no,1:no,1:no,,0.862
2787,2747698,Table 6,BaselineCharacteristic,Age (years),Response ; NC ; ,Age (years),None,16,4,43,no,1:no,1:no,,0.863
2787,2747698,Table 6,BaselineCharacteristic,Age (years),Response ; PD ; ,Age (years),None,16,5,43,no,1:no,1:no,,0.86
2787,2747698,Table 6,BaselineCharacteristic,Age (years), ; Response rate (%) (xx% CI) ; ,Age (years),None,16,6,43,no,1:no,1:no,,0.756
2787,2747698,Table 6,BaselineCharacteristic,??xx, ; Characteristic ; ,??xx, Age (years),17,0,2,no,1:no,1:no,,0.828
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,??xx, Age (years),17,1,3,no,1:no,1:no,,0.732
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,??xx, Age (years),17,2,3,no,1:no,1:no,,0.743
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,??xx, Age (years),17,3,3,no,1:no,1:no,,0.764
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,??xx, Age (years),17,4,3,no,1:no,1:no,,0.767
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,??xx, Age (years),17,5,3,no,1:no,1:no,,0.77
2787,2747698,Table 6,BaselineCharacteristic,?>xx, ; Characteristic ; ,?>xx, Age (years),18,0,2,no,1:no,1:no,,0.887
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?>xx, Age (years),18,1,3,no,1:no,1:no,,0.739
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?>xx, Age (years),18,2,3,no,1:no,1:no,,0.795
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?>xx, Age (years),18,3,3,no,1:no,1:no,,0.815
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?>xx, Age (years),18,4,3,no,1:no,1:no,,0.817
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?>xx, Age (years),18,5,3,no,1:no,1:no,,0.823
2848,2768436,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
2848,2768436,Table 1,BaselineCharacteristic,No. xx,,,None,0,1,1,no,1:no,1:no,,0.626
2848,2768436,Table 1,BaselineCharacteristic,No. xx,,,None,0,2,1,no,1:no,1:no,,0.636
2848,2768436,Table 1,BaselineCharacteristic,Characteristics, ; ,None,None,1,0,12,no,1:no,1:no,,0.784
2848,2768436,Table 1,BaselineCharacteristic,No.,No. xx ; ,Characteristics,None,1,1,1,no,1:no,1:no,,0.596
2848,2768436,Table 1,BaselineCharacteristic,%,No. xx ; ,Characteristics,None,1,2,1,no,1:no,1:no,,0.577
2848,2768436,Table 1,BaselineCharacteristic,Sex, ; Characteristics ; ,None,None,2,0,24,no,1:no,1:no,,0.563
2848,2768436,Table 1,BaselineCharacteristic,Sex,No. xx ; No. ; ,Sex,None,2,1,43,no,1:no,2:yes,+,0.626
2848,2768436,Table 1,BaselineCharacteristic,Sex,No. xx ; % ; ,Sex,None,2,2,43,no,1:no,2:yes,+,0.603
2848,2768436,Table 1,BaselineCharacteristic,?Male, ; Characteristics ; ,?Male, Sex,3,0,2,no,1:no,2:yes,+,0.538
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Male, Sex,3,1,3,yes,2:yes,2:yes,,0.816
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Male, Sex,3,2,3,yes,2:yes,2:yes,,0.851
2848,2768436,Table 1,BaselineCharacteristic,?Female, ; Characteristics ; ,?Female, Sex,4,0,2,no,1:no,1:no,,0.509
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Female, Sex,4,1,3,yes,2:yes,2:yes,,0.794
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Female, Sex,4,2,3,yes,2:yes,2:yes,,0.825
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,5,0,2,no,1:no,1:no,,0.843
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,5,1,3,no,1:no,1:no,,0.569
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,5,2,3,no,1:no,2:yes,+,0.506
2848,2768436,Table 1,BaselineCharacteristic,"Age, years", ; Characteristics ; ,None,None,6,0,24,no,1:no,1:no,,0.84
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,"Age, years",None,6,1,43,no,1:no,1:no,,0.669
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,"Age, years",None,6,2,43,no,1:no,1:no,,0.629
2848,2768436,Table 1,BaselineCharacteristic,?Median, ; Characteristics ; ,?Median," Age, years",7,0,2,no,1:no,1:no,,0.835
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Median," Age, years",7,1,3,no,1:no,1:no,,0.637
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; % ; ,?Median," Age, years",7,2,3,no,1:no,1:no,,0.586
2848,2768436,Table 1,BaselineCharacteristic,?Range, ; Characteristics ; ,?Range," Age, years",8,0,2,no,1:no,1:no,,0.837
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,9,0,2,no,1:no,1:no,,0.855
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,9,1,3,no,1:no,1:no,,0.623
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,9,2,3,no,1:no,1:no,,0.577
2848,2768436,Table 1,BaselineCharacteristic,Karnofsky performance status, ; Characteristics ; ,None,None,10,0,24,no,1:no,1:no,,0.867
2848,2768436,Table 1,BaselineCharacteristic,Karnofsky performance status,No. xx ; No. ; ,Karnofsky performance status,None,10,1,43,no,1:no,1:no,,0.686
2848,2768436,Table 1,BaselineCharacteristic,Karnofsky performance status,No. xx ; % ; ,Karnofsky performance status,None,10,2,43,no,1:no,1:no,,0.666
2848,2768436,Table 1,BaselineCharacteristic,?xxx, ; Characteristics ; ,?xxx, Karnofsky performance status,11,0,2,no,1:no,1:no,,0.797
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?xxx, Karnofsky performance status,11,1,3,no,1:no,1:no,,0.557
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?xxx, Karnofsky performance status,11,2,3,no,1:no,1:no,,0.551
2848,2768436,Table 1,BaselineCharacteristic,?xx, ; Characteristics ; ,?xx, Karnofsky performance status,12,0,2,no,1:no,1:no,,0.783
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?xx, Karnofsky performance status,12,1,3,no,1:no,1:no,,0.699
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; % ; ,?xx, Karnofsky performance status,12,2,3,no,1:no,1:no,,0.651
2848,2768436,Table 1,BaselineCharacteristic,?xx, ; Characteristics ; ,?xx, Karnofsky performance status,13,0,2,no,1:no,1:no,,0.783
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?xx, Karnofsky performance status,13,1,3,no,1:no,1:no,,0.698
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; % ; ,?xx, Karnofsky performance status,13,2,3,no,1:no,1:no,,0.647
2848,2768436,Table 1,BaselineCharacteristic,?xx, ; Characteristics ; ,?xx, Karnofsky performance status,14,0,2,no,1:no,1:no,,0.777
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?xx, Karnofsky performance status,14,1,3,no,1:no,1:no,,0.685
2848,2768436,Table 1,BaselineCharacteristic,x.x,No. xx ; % ; ,?xx, Karnofsky performance status,14,2,3,no,1:no,1:no,,0.633
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,15,0,2,no,1:no,1:no,,0.866
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,15,1,3,no,1:no,1:no,,0.682
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,15,2,3,no,1:no,1:no,,0.617
2848,2768436,Table 1,BaselineCharacteristic,Primary tumour site, ; Characteristics ; ,None,None,16,0,24,no,1:no,1:no,,0.877
2848,2768436,Table 1,BaselineCharacteristic,Primary tumour site,No. xx ; No. ; ,Primary tumour site,None,16,1,43,no,1:no,1:no,,0.695
2848,2768436,Table 1,BaselineCharacteristic,Primary tumour site,No. xx ; % ; ,Primary tumour site,None,16,2,43,no,1:no,1:no,,0.661
2848,2768436,Table 1,BaselineCharacteristic,?Stomach, ; Characteristics ; ,?Stomach, Primary tumour site,17,0,2,no,1:no,1:no,,0.887
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Stomach, Primary tumour site,17,1,3,no,1:no,1:no,,0.722
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Stomach, Primary tumour site,17,2,3,no,1:no,1:no,,0.67
2848,2768436,Table 1,BaselineCharacteristic,?Gastro-oesophageal junction, ; Characteristics ; ,?Gastro-oesophageal junction, Primary tumour site,18,0,2,no,1:no,1:no,,0.89
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Gastro-oesophageal junction, Primary tumour site,18,1,3,no,1:no,1:no,,0.726
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Gastro-oesophageal junction, Primary tumour site,18,2,3,no,1:no,1:no,,0.675
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,19,0,2,no,1:no,1:no,,0.875
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,19,1,3,no,1:no,1:no,,0.707
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,19,2,3,no,1:no,1:no,,0.653
2848,2768436,Table 1,BaselineCharacteristic,Histotype, ; Characteristics ; ,None,None,20,0,24,no,1:no,1:no,,0.861
2848,2768436,Table 1,BaselineCharacteristic,Histotype,No. xx ; No. ; ,Histotype,None,20,1,43,no,1:no,1:no,,0.696
2848,2768436,Table 1,BaselineCharacteristic,Histotype,No. xx ; % ; ,Histotype,None,20,2,43,no,1:no,1:no,,0.662
2848,2768436,Table 1,BaselineCharacteristic,?Intestinal adenocarcinoma, ; Characteristics ; ,?Intestinal adenocarcinoma, Histotype,21,0,2,no,1:no,1:no,,0.862
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Intestinal adenocarcinoma, Histotype,21,1,3,no,1:no,1:no,,0.685
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Intestinal adenocarcinoma, Histotype,21,2,3,no,1:no,1:no,,0.635
2848,2768436,Table 1,BaselineCharacteristic,?Non-intestinal adenocarcinomaa, ; Characteristics ; ,?Non-intestinal adenocarcinomaa, Histotype,22,0,2,no,1:no,1:no,,0.863
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Non-intestinal adenocarcinomaa, Histotype,22,1,3,no,1:no,1:no,,0.691
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Non-intestinal adenocarcinomaa, Histotype,22,2,3,no,1:no,1:no,,0.642
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,23,0,2,no,1:no,1:no,,0.877
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,23,1,3,no,1:no,1:no,,0.721
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,23,2,3,no,1:no,1:no,,0.668
2848,2768436,Table 1,BaselineCharacteristic,State of disease, ; Characteristics ; ,None,None,24,0,24,no,1:no,1:no,,0.852
2848,2768436,Table 1,BaselineCharacteristic,State of disease,No. xx ; No. ; ,State of disease,None,24,1,43,no,1:no,1:no,,0.767
2848,2768436,Table 1,BaselineCharacteristic,State of disease,No. xx ; % ; ,State of disease,None,24,2,43,no,1:no,1:no,,0.721
2848,2768436,Table 1,BaselineCharacteristic,?Locally advanced, ; Characteristics ; ,?Locally advanced, State of disease,25,0,2,no,1:no,1:no,,0.849
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?Locally advanced, State of disease,25,1,3,no,1:no,1:no,,0.764
2848,2768436,Table 1,BaselineCharacteristic,x.x,No. xx ; % ; ,?Locally advanced, State of disease,25,2,3,no,1:no,1:no,,0.696
2848,2768436,Table 1,BaselineCharacteristic,?Metastatic, ; Characteristics ; ,?Metastatic, State of disease,26,0,2,no,1:no,1:no,,0.858
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Metastatic, State of disease,26,1,3,no,1:no,1:no,,0.764
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Metastatic, State of disease,26,2,3,no,1:no,1:no,,0.729
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,27,0,2,no,1:no,1:no,,0.877
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,27,1,3,no,1:no,1:no,,0.721
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,27,2,3,no,1:no,1:no,,0.668
2848,2768436,Table 1,BaselineCharacteristic,Prior surgery, ; Characteristics ; ,None,None,28,0,24,no,1:no,1:no,,0.885
2848,2768436,Table 1,BaselineCharacteristic,Prior surgery,No. xx ; No. ; ,Prior surgery,None,28,1,43,no,1:no,1:no,,0.754
2848,2768436,Table 1,BaselineCharacteristic,Prior surgery,No. xx ; % ; ,Prior surgery,None,28,2,43,no,1:no,1:no,,0.73
2848,2768436,Table 1,BaselineCharacteristic,?Total/partial gastrectomy, ; Characteristics ; ,?Total/partial gastrectomy, Prior surgery,29,0,2,no,1:no,1:no,,0.882
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Total/partial gastrectomy, Prior surgery,29,1,3,no,1:no,1:no,,0.752
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Total/partial gastrectomy, Prior surgery,29,2,3,no,1:no,1:no,,0.703
2848,2768436,Table 1,BaselineCharacteristic,?Protesis/anastomosis, ; Characteristics ; ,?Protesis/anastomosis, Prior surgery,30,0,2,no,1:no,1:no,,0.882
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?Protesis/anastomosis, Prior surgery,30,1,3,no,1:no,1:no,,0.752
2848,2768436,Table 1,BaselineCharacteristic,x.x,No. xx ; % ; ,?Protesis/anastomosis, Prior surgery,30,2,3,no,1:no,1:no,,0.703
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,31,0,2,no,1:no,1:no,,0.877
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,31,1,3,no,1:no,1:no,,0.721
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,31,2,3,no,1:no,1:no,,0.668
2848,2768436,Table 1,BaselineCharacteristic,Adjuvant chemotherapy, ; Characteristics ; ,Adjuvant chemotherapy,,32,0,24,no,1:no,1:no,,0.837
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,Adjuvant chemotherapy,,32,1,43,no,1:no,1:no,,0.704
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,Adjuvant chemotherapy,,32,2,43,no,1:no,1:no,,0.677
2848,2768436,Table 1,BaselineCharacteristic,?x-FU/AF regimens, ; Characteristics ; ,?x-FU/AF regimens, Adjuvant chemotherapy,33,0,2,no,1:no,1:no,,0.872
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?x-FU/AF regimens, Adjuvant chemotherapy,33,1,3,no,1:no,1:no,,0.727
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x-FU/AF regimens, Adjuvant chemotherapy,33,2,3,no,1:no,1:no,,0.682
2848,2768436,Table 1,BaselineCharacteristic,?x-FU/CDDP regimens, ; Characteristics ; ,?x-FU/CDDP regimens, Adjuvant chemotherapy,34,0,2,no,1:no,1:no,,0.872
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?x-FU/CDDP regimens, Adjuvant chemotherapy,34,1,3,no,1:no,1:no,,0.727
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x-FU/CDDP regimens, Adjuvant chemotherapy,34,2,3,no,1:no,1:no,,0.682
2848,2768436,Table 1,BaselineCharacteristic,?x-FU/CDDP/EPI regimens, ; Characteristics ; ,?x-FU/CDDP/EPI regimens, Adjuvant chemotherapy,35,0,2,no,1:no,1:no,,0.872
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?x-FU/CDDP/EPI regimens, Adjuvant chemotherapy,35,1,3,no,1:no,1:no,,0.727
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x-FU/CDDP/EPI regimens, Adjuvant chemotherapy,35,2,3,no,1:no,1:no,,0.682
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,36,0,2,no,1:no,1:no,,0.877
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,36,1,3,no,1:no,1:no,,0.721
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,36,2,3,no,1:no,1:no,,0.669
2848,2768436,Table 1,BaselineCharacteristic,Site of disease, ; Characteristics ; ,None,None,37,0,24,no,1:no,1:no,,0.852
2848,2768436,Table 1,BaselineCharacteristic,Site of disease,No. xx ; No. ; ,Site of disease,None,37,1,43,no,1:no,1:no,,0.768
2848,2768436,Table 1,BaselineCharacteristic,Site of disease,No. xx ; % ; ,Site of disease,None,37,2,43,no,1:no,1:no,,0.721
2848,2768436,Table 1,BaselineCharacteristic,?Primary, ; Characteristics ; ,?Primary, Site of disease,38,0,2,no,1:no,1:no,,0.852
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Primary, Site of disease,38,1,3,no,1:no,1:no,,0.75
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Primary, Site of disease,38,2,3,no,1:no,1:no,,0.701
2848,2768436,Table 1,BaselineCharacteristic,?Lymph nodes, ; Characteristics ; ,?Lymph nodes, Site of disease,39,0,2,no,1:no,1:no,,0.849
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Lymph nodes, Site of disease,39,1,3,no,1:no,1:no,,0.739
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Lymph nodes, Site of disease,39,2,3,no,1:no,1:no,,0.696
2848,2768436,Table 1,BaselineCharacteristic,?Liver, ; Characteristics ; ,?Liver, Site of disease,40,0,2,no,1:no,1:no,,0.874
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Liver, Site of disease,40,1,3,no,1:no,1:no,,0.772
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Liver, Site of disease,40,2,3,no,1:no,1:no,,0.716
2848,2768436,Table 1,BaselineCharacteristic,?Peritoneum/local recurrence, ; Characteristics ; ,?Peritoneum/local recurrence, Site of disease,41,0,2,no,1:no,1:no,,0.849
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Peritoneum/local recurrence, Site of disease,41,1,3,no,1:no,1:no,,0.739
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Peritoneum/local recurrence, Site of disease,41,2,3,no,1:no,1:no,,0.696
2848,2768436,Table 1,BaselineCharacteristic,?Other, ; Characteristics ; ,?Other, Site of disease,42,0,2,no,1:no,1:no,,0.852
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Other, Site of disease,42,1,3,no,1:no,1:no,,0.739
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Other, Site of disease,42,2,3,no,1:no,1:no,,0.696
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,43,0,2,no,1:no,1:no,,0.877
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,43,1,3,no,1:no,1:no,,0.721
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,43,2,3,no,1:no,1:no,,0.669
2848,2768436,Table 1,BaselineCharacteristic,No. of organs involved, ; Characteristics ; ,None,None,44,0,24,no,1:no,1:no,,0.873
2848,2768436,Table 1,BaselineCharacteristic,No. of organs involved,No. xx ; No. ; ,No. of organs involved,None,44,1,43,no,1:no,1:no,,0.794
2848,2768436,Table 1,BaselineCharacteristic,No. of organs involved,No. xx ; % ; ,No. of organs involved,None,44,2,43,no,1:no,1:no,,0.751
2848,2768436,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, No. of organs involved,45,0,2,no,1:no,1:no,,0.834
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?x, No. of organs involved,45,1,3,no,1:no,1:no,,0.777
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x, No. of organs involved,45,2,3,no,1:no,1:no,,0.714
2848,2768436,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, No. of organs involved,46,0,2,no,1:no,1:no,,0.834
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?x, No. of organs involved,46,1,3,no,1:no,1:no,,0.777
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x, No. of organs involved,46,2,3,no,1:no,1:no,,0.714
2848,2768436,Table 1,BaselineCharacteristic,?>x, ; Characteristics ; ,?>x, No. of organs involved,47,0,2,no,1:no,1:no,,0.863
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?>x, No. of organs involved,47,1,3,no,1:no,1:no,,0.748
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?>x, No. of organs involved,47,2,3,no,1:no,1:no,,0.714
2866,2775018,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,,no,1:no,1:no,,0.791
2866,2775018,Table 1,BaselineCharacteristic,,,None,None,0,1,,no,1:no,1:no,,0.714
2866,2775018,Table 1,BaselineCharacteristic,Acupuncture,,None,None,0,2,,no,1:no,1:no,,0.76
2866,2775018,Table 1,BaselineCharacteristic,Control,,None,None,0,3,,no,1:no,1:no,,0.796
2866,2775018,Table 1,BaselineCharacteristic,Total,,None,None,0,4,,no,1:no,1:no,,0.681
2866,2775018,Table 1,BaselineCharacteristic,Mean Age,Characteristics ; ,None,None,1,0,,no,1:no,1:no,,0.834
2866,2775018,Table 1,BaselineCharacteristic,, ; ,None,None,1,1,,no,1:no,1:no,,0.709
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Acupuncture ; ,None,None,1,2,,no,1:no,1:no,,0.624
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Control ; ,None,None,1,3,,no,1:no,1:no,,0.668
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Total ; ,None,None,1,4,,no,1:no,1:no,,0.555
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ; ,None,None,2,0,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,1,,no,1:no,1:no,,0.718
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ; ,None,None,2,2,,no,1:no,1:no,,0.626
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ; ,None,None,2,3,,no,1:no,1:no,,0.666
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ; ,None,None,2,4,,no,1:no,1:no,,0.554
2866,2775018,Table 1,BaselineCharacteristic,Female Sex (%),Characteristics ; Mean Age ;  ; ,None,None,3,0,,no,1:no,1:no,,0.537
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,3,1,,no,1:no,1:no,,0.713
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Acupuncture ; xx.x (x.x) ;  ; ,None,None,3,2,,yes,2:yes,1:no,+,0.631
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Control ; xx.x (x.x) ;  ; ,None,None,3,3,,yes,2:yes,1:no,+,0.67
2866,2775018,Table 1,BaselineCharacteristic,xx (xx),Total ; xx.x (x.x) ;  ; ,None,None,3,4,,yes,2:yes,1:no,+,0.554
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ; ,None,None,4,0,,no,1:no,1:no,,0.537
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ; ,None,None,4,1,,no,1:no,1:no,,0.733
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ; ,None,None,4,2,,no,1:no,1:no,,0.638
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ; ,None,None,4,3,,no,1:no,1:no,,0.677
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ; ,None,None,4,4,,no,1:no,1:no,,0.561
2866,2775018,Table 1,BaselineCharacteristic,Ethnicity (%),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; ,None,None,5,0,,no,1:no,1:no,,0.537
2866,2775018,Table 1,BaselineCharacteristic,White, ;  ;  ;  ;  ; ,None,None,5,1,,no,1:no,1:no,,0.747
2866,2775018,Table 1,BaselineCharacteristic,xx (xxx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; ,None,None,5,2,,no,1:no,1:no,,0.618
2866,2775018,Table 1,BaselineCharacteristic,xx(xxx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; ,None,None,5,3,,no,1:no,1:no,,0.674
2866,2775018,Table 1,BaselineCharacteristic,xx(xxx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; ,None,None,5,4,,no,1:no,1:no,,0.576
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ; ,None,None,6,0,,no,1:no,1:no,,0.537
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ; ,None,None,6,1,,no,1:no,1:no,,0.75
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ; ,None,None,6,2,,no,1:no,1:no,,0.627
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ; ,None,None,6,3,,no,1:no,1:no,,0.68
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ; ,None,None,6,4,,no,1:no,1:no,,0.575
2866,2775018,Table 1,BaselineCharacteristic,Employment History (%),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,7,0,,no,1:no,1:no,,0.547
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,7,1,,no,1:no,1:no,,0.749
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,7,2,,no,1:no,1:no,,0.631
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,7,3,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,7,4,,no,1:no,1:no,,0.585
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,8,0,,no,1:no,1:no,,0.548
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,8,1,,no,1:no,1:no,,0.772
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,8,2,,no,1:no,1:no,,0.652
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,8,3,,no,1:no,1:no,,0.703
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,8,4,,no,1:no,1:no,,0.607
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,9,0,,no,1:no,2:yes,+,0.503
2866,2775018,Table 1,BaselineCharacteristic,Employed part-time, ;  ;  ;  ;  ; White ;  ; ,,,9,1,,no,1:no,1:no,,0.757
2866,2775018,Table 1,BaselineCharacteristic,x (x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,9,2,,no,1:no,1:no,,0.574
2866,2775018,Table 1,BaselineCharacteristic,x (x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,9,3,,no,1:no,1:no,,0.626
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,9,4,,no,1:no,1:no,,0.526
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,10,0,,no,1:no,1:no,,0.567
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,10,1,,no,1:no,1:no,,0.799
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,10,2,,no,1:no,1:no,,0.689
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,10,3,,no,1:no,1:no,,0.738
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,10,4,,no,1:no,1:no,,0.633
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,11,0,,no,1:no,1:no,,0.503
2866,2775018,Table 1,BaselineCharacteristic,Employed full-time, ;  ;  ;  ;  ; White ;  ; ,,,11,1,,no,1:no,1:no,,0.786
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,11,2,,no,1:no,1:no,,0.604
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,11,3,,no,1:no,1:no,,0.651
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,11,4,,no,1:no,1:no,,0.542
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,12,0,,no,1:no,1:no,,0.573
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,12,1,,no,1:no,1:no,,0.814
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,12,2,,no,1:no,1:no,,0.702
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,12,3,,no,1:no,1:no,,0.747
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,12,4,,no,1:no,1:no,,0.634
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,13,0,,no,1:no,1:no,,0.503
2866,2775018,Table 1,BaselineCharacteristic,Self employed, ;  ;  ;  ;  ; White ;  ; ,,,13,1,,no,1:no,1:no,,0.795
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,13,2,,no,1:no,1:no,,0.603
2866,2775018,Table 1,BaselineCharacteristic,x (x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,13,3,,no,1:no,1:no,,0.65
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,13,4,,no,1:no,1:no,,0.541
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,14,0,,no,1:no,1:no,,0.572
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,14,1,,no,1:no,1:no,,0.814
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,14,2,,no,1:no,1:no,,0.692
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,14,3,,no,1:no,1:no,,0.739
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,14,4,,no,1:no,1:no,,0.632
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,15,0,,no,1:no,2:yes,+,0.504
2866,2775018,Table 1,BaselineCharacteristic,Retired, ;  ;  ;  ;  ; White ;  ; ,,,15,1,,no,1:no,1:no,,0.797
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,15,2,,no,1:no,1:no,,0.594
2866,2775018,Table 1,BaselineCharacteristic,xx (xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,15,3,,no,1:no,1:no,,0.642
2866,2775018,Table 1,BaselineCharacteristic,xx (xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,15,4,,no,1:no,1:no,,0.54
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,16,0,,no,1:no,1:no,,0.558
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,16,1,,no,1:no,1:no,,0.811
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,16,2,,no,1:no,1:no,,0.693
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,16,3,,no,1:no,1:no,,0.74
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,16,4,,no,1:no,1:no,,0.632
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,17,0,,no,1:no,1:no,,0.532
2866,2775018,Table 1,BaselineCharacteristic,Not employed but seeking work, ;  ;  ;  ;  ; White ;  ; ,,,17,1,,no,1:no,1:no,,0.83
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,17,2,,no,1:no,1:no,,0.635
2866,2775018,Table 1,BaselineCharacteristic,x (x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,17,3,,no,1:no,1:no,,0.682
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,17,4,,no,1:no,1:no,,0.585
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,18,0,,no,1:no,1:no,,0.598
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,18,1,,no,1:no,1:no,,0.833
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,18,2,,no,1:no,1:no,,0.721
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,18,3,,no,1:no,1:no,,0.766
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,18,4,,no,1:no,1:no,,0.666
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,19,0,,no,1:no,1:no,,0.536
2866,2775018,Table 1,BaselineCharacteristic,Not employed/not seeking work due to ill health, ;  ;  ;  ;  ; White ;  ; ,,,19,1,,no,1:no,1:no,,0.838
2866,2775018,Table 1,BaselineCharacteristic,x (x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,19,2,,no,1:no,1:no,,0.659
2866,2775018,Table 1,BaselineCharacteristic,x (x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,19,3,,no,1:no,1:no,,0.697
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,19,4,,no,1:no,1:no,,0.603
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,20,0,,no,1:no,1:no,,0.598
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,20,1,,no,1:no,1:no,,0.834
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,20,2,,no,1:no,1:no,,0.735
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,20,3,,no,1:no,1:no,,0.772
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,20,4,,no,1:no,1:no,,0.669
2866,2775018,Table 1,BaselineCharacteristic,Education,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,21,0,,no,1:no,1:no,,0.598
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,21,1,,no,1:no,1:no,,0.834
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,21,2,,no,1:no,1:no,,0.735
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,21,3,,no,1:no,1:no,,0.772
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,21,4,,no,1:no,1:no,,0.669
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,22,0,,no,1:no,1:no,,0.599
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,22,1,,no,1:no,1:no,,0.838
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,22,2,,no,1:no,1:no,,0.742
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,22,3,,no,1:no,1:no,,0.78
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,22,4,,no,1:no,1:no,,0.673
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,23,0,,no,1:no,1:no,,0.539
2866,2775018,Table 1,BaselineCharacteristic,Not in full time education (%), ;  ;  ;  ;  ; White ;  ; ,,,23,1,,no,1:no,1:no,,0.792
2866,2775018,Table 1,BaselineCharacteristic,xx (xxx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,23,2,,no,1:no,1:no,,0.671
2866,2775018,Table 1,BaselineCharacteristic,xx (xxx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,23,3,,no,1:no,1:no,,0.709
2866,2775018,Table 1,BaselineCharacteristic,xx (xxx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,23,4,,no,1:no,1:no,,0.612
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,24,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,24,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,24,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,24,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,24,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,25,0,,no,1:no,1:no,,0.54
2866,2775018,Table 1,BaselineCharacteristic,Age when leaving full time education (SD), ;  ;  ;  ;  ; White ;  ; ,,,25,1,,no,1:no,1:no,,0.837
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,25,2,,no,1:no,1:no,,0.688
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,25,3,,no,1:no,1:no,,0.726
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,25,4,,no,1:no,1:no,,0.625
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,26,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,26,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,26,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,26,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,26,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,27,0,,no,1:no,1:no,,0.54
2866,2775018,Table 1,BaselineCharacteristic,Since leaving school/college/uni have had more part-time further/higher education (%), ;  ;  ;  ;  ; White ;  ; ,,,27,1,,no,1:no,1:no,,0.782
2866,2775018,Table 1,BaselineCharacteristic,x (xx%),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,27,2,,no,1:no,1:no,,0.673
2866,2775018,Table 1,BaselineCharacteristic,x (xx%),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,27,3,,no,1:no,1:no,,0.723
2866,2775018,Table 1,BaselineCharacteristic,xx (xx%),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,27,4,,no,1:no,1:no,,0.623
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,28,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,28,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,28,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,28,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,28,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,Mean OKS (SD),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,29,0,,no,1:no,1:no,,0.608
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (x.xx), ;  ;  ;  ;  ; White ;  ; ,None,None,29,1,,no,1:no,1:no,,0.799
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,29,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (x.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,29,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,29,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,30,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,30,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,30,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,30,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,30,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,31,0,,no,1:no,1:no,,0.608
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD), ;  ;  ;  ;  ; White ;  ; ,None,None,31,1,,no,1:no,1:no,,0.859
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,31,2,,no,1:no,1:no,,0.802
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,31,3,,no,1:no,1:no,,0.838
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,31,4,,no,1:no,1:no,,0.74
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,32,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,32,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,32,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,32,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,32,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean WOMAC Scores (SD),33,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Pain x-xx, ;  ;  ;  ;  ; White ;  ; ,, Mean WOMAC Scores (SD),33,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean WOMAC Scores (SD),33,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),33,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),33,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,34,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,34,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,34,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,34,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,34,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean WOMAC Scores (SD),35,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Stiffness x-x, ;  ;  ;  ;  ; White ;  ; ,, Mean WOMAC Scores (SD),35,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean WOMAC Scores (SD),35,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,x.x (x.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),35,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),35,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,36,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,36,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,36,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,36,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,36,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean WOMAC Scores (SD),37,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Function x-xx, ;  ;  ;  ;  ; White ;  ; ,, Mean WOMAC Scores (SD),37,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean WOMAC Scores (SD),37,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),37,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.x (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),37,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,38,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,38,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,38,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,38,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,38,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean WOMAC Scores (SD),39,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Global x-xxx = best health, ;  ;  ;  ;  ; White ;  ; ,, Mean WOMAC Scores (SD),39,1,,no,1:no,1:no,,0.795
2866,2775018,Table 1,BaselineCharacteristic,xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean WOMAC Scores (SD),39,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),39,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),39,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,40,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,40,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,40,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,40,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,40,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,41,0,,no,1:no,1:no,,0.608
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD), ;  ;  ;  ;  ; White ;  ; ,None,None,41,1,,no,1:no,1:no,,0.859
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,41,2,,no,1:no,1:no,,0.802
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,41,3,,no,1:no,1:no,,0.838
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,41,4,,no,1:no,1:no,,0.74
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,42,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,42,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,42,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,42,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,42,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),43,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Physical Functioning, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),43,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),43,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),43,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),43,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,44,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,44,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,44,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,44,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,44,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),45,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Social Functioning, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),45,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),45,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),45,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),45,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,46,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,46,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,46,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,46,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,46,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),47,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Role Physical Functioning, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),47,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx.x (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),47,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),47,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),47,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,48,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,48,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,48,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,48,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,48,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),49,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Role Mental Functioning, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),49,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),49,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),49,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),49,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,50,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,50,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,50,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,50,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,50,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),51,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Mental Health, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),51,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),51,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),51,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),51,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,52,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,52,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,52,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,52,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,52,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),53,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Vitality, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),53,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),53,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),53,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),53,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,54,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,54,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,54,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,54,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,54,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),55,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,Pain, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),55,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),55,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),55,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),55,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,56,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,56,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,56,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,56,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,56,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),57,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,General Health, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),57,1,,no,1:no,1:no,,0.85
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),57,2,,no,1:no,1:no,,0.752
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),57,3,,no,1:no,1:no,,0.787
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),57,4,,no,1:no,1:no,,0.695
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,58,0,,no,1:no,1:no,,0.601
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,58,1,,no,1:no,1:no,,0.839
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,58,2,,no,1:no,1:no,,0.753
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,58,3,,no,1:no,1:no,,0.79
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,58,4,,no,1:no,1:no,,0.683
2866,2775018,Table 1,BaselineCharacteristic,EQxD (SD),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,EQxD (SD),,59,0,,no,1:no,1:no,,0.562
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,EQxD (SD),,59,1,,no,1:no,1:no,,0.852
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,EQxD (SD),,59,2,,no,1:no,1:no,,0.732
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,EQxD (SD),,59,3,,no,1:no,1:no,,0.767
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,EQxD (SD),,59,4,,no,1:no,1:no,,0.672
2880,2778527,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
2880,2778527,Table 1,BaselineCharacteristic,Sunitinib (N=xx),,,None,0,1,1,no,1:no,1:no,,0.709
2880,2778527,Table 1,BaselineCharacteristic,"Age in years, median (range)", ; ,"Age in years, median (range)",,1,0,2,no,1:no,1:no,,0.844
2880,2778527,Table 1,BaselineCharacteristic,"Male/female, n (%)", ; ,"Male/female, n (%)",,2,0,2,no,1:no,1:no,,0.715
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x),Sunitinib (N=xx) ; ,"Male/female, n (%)",,2,1,3,yes,2:yes,2:yes,,0.65
2880,2778527,Table 1,BaselineCharacteristic,"ECOG PS x/x, n (%)", ; ,"ECOG PS x/x, n (%)",,3,0,2,no,1:no,1:no,,0.752
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x)a,Sunitinib (N=xx) ; ,"ECOG PS x/x, n (%)",,3,1,3,no,1:no,2:yes,+,0.552
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no,1:no,1:no,,0.858
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,4,1,3,no,1:no,1:no,,0.703
2880,2778527,Table 1,BaselineCharacteristic,"Smoking status, n (%)", ; ,None,None,5,0,24,no,1:no,1:no,,0.769
2880,2778527,Table 1,BaselineCharacteristic,"Smoking status, n (%)",Sunitinib (N=xx) ; ,"Smoking status, n (%)",None,5,1,43,no,1:no,1:no,,0.648
2880,2778527,Table 1,BaselineCharacteristic,?Ever smoked, ; ,?Ever smoked," Smoking status, n (%)",6,0,2,no,1:no,1:no,,0.757
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Ever smoked," Smoking status, n (%)",6,1,3,no,1:no,2:yes,+,0.531
2880,2778527,Table 1,BaselineCharacteristic,?Never smoked, ; ,?Never smoked," Smoking status, n (%)",7,0,2,no,1:no,1:no,,0.757
2880,2778527,Table 1,BaselineCharacteristic,x (xx.x),Sunitinib (N=xx) ; ,?Never smoked," Smoking status, n (%)",7,1,3,no,1:no,2:yes,+,0.531
2880,2778527,Table 1,BaselineCharacteristic,?Not known, ; ,?Not known," Smoking status, n (%)",8,0,2,no,1:no,1:no,,0.777
2880,2778527,Table 1,BaselineCharacteristic,x (x.x),Sunitinib (N=xx) ; ,?Not known," Smoking status, n (%)",8,1,3,no,1:no,1:no,,0.541
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,9,0,2,no,1:no,1:no,,0.881
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,9,1,3,no,1:no,1:no,,0.76
2880,2778527,Table 1,BaselineCharacteristic,"NSCLC histology, n (%)", ; ,None,None,10,0,24,no,1:no,1:no,,0.794
2880,2778527,Table 1,BaselineCharacteristic,"NSCLC histology, n (%)",Sunitinib (N=xx) ; ,"NSCLC histology, n (%)",None,10,1,43,no,1:no,1:no,,0.67
2880,2778527,Table 1,BaselineCharacteristic,?Adenocarcinoma, ; ,?Adenocarcinoma," NSCLC histology, n (%)",11,0,2,no,1:no,1:no,,0.77
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Adenocarcinoma," NSCLC histology, n (%)",11,1,3,no,1:no,1:no,,0.502
2880,2778527,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ; ,?Squamous cell carcinoma," NSCLC histology, n (%)",12,0,2,no,1:no,1:no,,0.812
2880,2778527,Table 1,BaselineCharacteristic,x (xx.x),Sunitinib (N=xx) ; ,?Squamous cell carcinoma," NSCLC histology, n (%)",12,1,3,no,1:no,1:no,,0.577
2880,2778527,Table 1,BaselineCharacteristic,?Large cell carcinoma, ; ,?Large cell carcinoma," NSCLC histology, n (%)",13,0,2,no,1:no,1:no,,0.803
2880,2778527,Table 1,BaselineCharacteristic,x (x.x),Sunitinib (N=xx) ; ,?Large cell carcinoma," NSCLC histology, n (%)",13,1,3,no,1:no,1:no,,0.597
2880,2778527,Table 1,BaselineCharacteristic,?Bronchioloalveolar, ; ,?Bronchioloalveolar," NSCLC histology, n (%)",14,0,2,no,1:no,1:no,,0.755
2880,2778527,Table 1,BaselineCharacteristic,x (x.x),Sunitinib (N=xx) ; ,?Bronchioloalveolar," NSCLC histology, n (%)",14,1,3,no,1:no,1:no,,0.523
2880,2778527,Table 1,BaselineCharacteristic,?Other, ; ,?Other," NSCLC histology, n (%)",15,0,2,no,1:no,1:no,,0.761
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Other," NSCLC histology, n (%)",15,1,3,no,1:no,1:no,,0.52
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,16,0,2,no,1:no,1:no,,0.893
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,16,1,3,no,1:no,1:no,,0.78
2880,2778527,Table 1,BaselineCharacteristic,"Disease stage, n (%)", ; ,None,None,17,0,24,no,1:no,1:no,,0.819
2880,2778527,Table 1,BaselineCharacteristic,"Disease stage, n (%)",Sunitinib (N=xx) ; ,"Disease stage, n (%)",None,17,1,43,no,1:no,1:no,,0.734
2880,2778527,Table 1,BaselineCharacteristic,?IIIB, ; ,?IIIB," Disease stage, n (%)",18,0,2,no,1:no,1:no,,0.822
2880,2778527,Table 1,BaselineCharacteristic,x (xx.x),Sunitinib (N=xx) ; ,?IIIB," Disease stage, n (%)",18,1,3,no,1:no,1:no,,0.608
2880,2778527,Table 1,BaselineCharacteristic,?IV, ; ,?IV," Disease stage, n (%)",19,0,2,no,1:no,1:no,,0.833
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?IV," Disease stage, n (%)",19,1,3,no,1:no,1:no,,0.616
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,20,0,2,no,1:no,1:no,,0.902
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,20,1,3,no,1:no,1:no,,0.8
2880,2778527,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)", ; ,None,None,21,0,24,no,1:no,1:no,,0.843
2880,2778527,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)",Sunitinib (N=xx) ; ,"Metastatic sites, n (%)",None,21,1,43,no,1:no,1:no,,0.753
2880,2778527,Table 1,BaselineCharacteristic,?Lung, ; ,?Lung," Metastatic sites, n (%)",22,0,2,no,1:no,1:no,,0.831
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Lung," Metastatic sites, n (%)",22,1,3,no,1:no,1:no,,0.631
2880,2778527,Table 1,BaselineCharacteristic,?Lymph nodes, ; ,?Lymph nodes," Metastatic sites, n (%)",23,0,2,no,1:no,1:no,,0.833
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Lymph nodes," Metastatic sites, n (%)",23,1,3,no,1:no,1:no,,0.635
2880,2778527,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone," Metastatic sites, n (%)",24,0,2,no,1:no,1:no,,0.833
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Bone," Metastatic sites, n (%)",24,1,3,no,1:no,1:no,,0.635
2880,2778527,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver," Metastatic sites, n (%)",25,0,2,no,1:no,1:no,,0.845
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Liver," Metastatic sites, n (%)",25,1,3,no,1:no,1:no,,0.661
2880,2778527,Table 1,BaselineCharacteristic,?Otherb, ; ,?Otherb," Metastatic sites, n (%)",26,0,2,no,1:no,1:no,,0.834
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Otherb," Metastatic sites, n (%)",26,1,3,no,1:no,1:no,,0.636
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,27,0,2,no,1:no,1:no,,0.905
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,27,1,3,no,1:no,1:no,,0.806
2880,2778527,Table 1,BaselineCharacteristic,"Previous chemotherapy, n (%)", ; ,"Previous chemotherapy, n (%)",,28,0,24,no,1:no,1:no,,0.816
2880,2778527,Table 1,BaselineCharacteristic,xx (xxx),Sunitinib (N=xx) ; ,"Previous chemotherapy, n (%)",,28,1,43,no,1:no,1:no,,0.634
2880,2778527,Table 1,BaselineCharacteristic,?Carboplatin, ; ,?Carboplatin," Previous chemotherapy, n (%)",29,0,2,no,1:no,1:no,,0.831
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Carboplatin," Previous chemotherapy, n (%)",29,1,3,no,1:no,1:no,,0.632
2880,2778527,Table 1,BaselineCharacteristic,?Cisplatin, ; ,?Cisplatin," Previous chemotherapy, n (%)",30,0,2,no,1:no,1:no,,0.831
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Cisplatin," Previous chemotherapy, n (%)",30,1,3,no,1:no,1:no,,0.632
2880,2778527,Table 1,BaselineCharacteristic,?Gemcitabine, ; ,?Gemcitabine," Previous chemotherapy, n (%)",31,0,2,no,1:no,1:no,,0.831
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Gemcitabine," Previous chemotherapy, n (%)",31,1,3,no,1:no,1:no,,0.632
2880,2778527,Table 1,BaselineCharacteristic,?Docetaxel, ; ,?Docetaxel," Previous chemotherapy, n (%)",32,0,2,no,1:no,1:no,,0.844
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Docetaxel," Previous chemotherapy, n (%)",32,1,3,no,1:no,1:no,,0.681
2880,2778527,Table 1,BaselineCharacteristic,?Paclitaxel, ; ,?Paclitaxel," Previous chemotherapy, n (%)",33,0,2,no,1:no,1:no,,0.831
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Paclitaxel," Previous chemotherapy, n (%)",33,1,3,no,1:no,1:no,,0.632
2880,2778527,Table 1,BaselineCharacteristic,?Pemetrexed, ; ,?Pemetrexed," Previous chemotherapy, n (%)",34,0,2,no,1:no,1:no,,0.831
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Pemetrexed," Previous chemotherapy, n (%)",34,1,3,no,1:no,1:no,,0.632
2880,2778527,Table 1,BaselineCharacteristic,?Other, ; ,?Other," Previous chemotherapy, n (%)",35,0,2,no,1:no,1:no,,0.832
2880,2778527,Table 1,BaselineCharacteristic,x (xx.x),Sunitinib (N=xx) ; ,?Other," Previous chemotherapy, n (%)",35,1,3,no,1:no,1:no,,0.652
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,36,0,2,no,1:no,1:no,,0.905
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,36,1,3,no,1:no,1:no,,0.806
2880,2778527,Table 1,BaselineCharacteristic,"Maximum number of previous regimens, n (%)", ; ,None,None,37,0,24,no,1:no,1:no,,0.837
2880,2778527,Table 1,BaselineCharacteristic,"Maximum number of previous regimens, n (%)",Sunitinib (N=xx) ; ,"Maximum number of previous regimens, n (%)",None,37,1,43,no,1:no,1:no,,0.756
2880,2778527,Table 1,BaselineCharacteristic,?Chemotherapy x/x/>x (%), ; ,?Chemotherapy x/x/>x (%)," Maximum number of previous regimens, n (%)",38,0,2,no,1:no,1:no,,0.819
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x)/x (x.x),Sunitinib (N=xx) ; ,?Chemotherapy x/x/>x (%)," Maximum number of previous regimens, n (%)",38,1,3,no,1:no,1:no,,0.676
2880,2778527,Table 1,BaselineCharacteristic,?EGFR inhibitorc x/x (%), ; ,?EGFR inhibitorc x/x (%)," Maximum number of previous regimens, n (%)",39,0,2,no,1:no,1:no,,0.805
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/x (x.x),Sunitinib (N=xx) ; ,?EGFR inhibitorc x/x (%)," Maximum number of previous regimens, n (%)",39,1,3,no,1:no,1:no,,0.647
2880,2778527,Table 1,BaselineCharacteristic,?Total x/x/>x (%), ; ,?Total x/x/>x (%)," Maximum number of previous regimens, n (%)",40,0,2,no,1:no,1:no,,0.762
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x)/xx (xx.x),Sunitinib (N=xx) ; ,?Total x/x/>x (%)," Maximum number of previous regimens, n (%)",40,1,3,no,1:no,1:no,,0.593
2995,2813746,Table 1,BaselineCharacteristic,Number of patients,,None,None,0,0,12,no,1:no,1:no,,0.783
2995,2813746,Table 1,BaselineCharacteristic,(n=xx),,Number of patients,None,0,1,1,no,1:no,1:no,,0.732
2995,2813746,Table 1,BaselineCharacteristic,"Median age, years",,None,None,1,0,12,no,1:no,1:no,,0.847
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,2,0,2,no,1:no,1:no,,0.842
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,2,1,3,no,1:no,1:no,,0.719
2995,2813746,Table 1,BaselineCharacteristic,Gender,,Gender,,3,0,24,no,1:no,1:no,,0.663
2995,2813746,Table 1,BaselineCharacteristic,n (%),,Gender,,3,1,43,no,1:no,2:yes,+,0.515
2995,2813746,Table 1,BaselineCharacteristic,?Male,,?Male, Gender,4,0,2,no,1:no,1:no,,0.694
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Male, Gender,4,1,3,yes,2:yes,2:yes,,0.697
2995,2813746,Table 1,BaselineCharacteristic,?Female,,?Female, Gender,5,0,2,no,1:no,1:no,,0.7
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Female, Gender,5,1,3,yes,2:yes,2:yes,,0.671
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,6,0,2,no,1:no,1:no,,0.866
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,6,1,3,no,1:no,1:no,,0.749
2995,2813746,Table 1,BaselineCharacteristic,ECOG performance status,,None,None,7,0,24,no,1:no,1:no,,0.873
2995,2813746,Table 1,BaselineCharacteristic,ECOG performance status,,ECOG performance status,None,7,1,43,no,1:no,1:no,,0.807
2995,2813746,Table 1,BaselineCharacteristic,?ECOG x,,?ECOG x, ECOG performance status,8,0,2,no,1:no,1:no,,0.847
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?ECOG x, ECOG performance status,8,1,3,no,1:no,1:no,,0.692
2995,2813746,Table 1,BaselineCharacteristic,?ECOG x,,?ECOG x, ECOG performance status,9,0,2,no,1:no,1:no,,0.858
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?ECOG x, ECOG performance status,9,1,3,no,1:no,1:no,,0.712
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,10,0,2,no,1:no,1:no,,0.888
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,10,1,3,no,1:no,1:no,,0.798
2995,2813746,Table 1,BaselineCharacteristic,Site,,None,None,11,0,24,no,1:no,1:no,,0.871
2995,2813746,Table 1,BaselineCharacteristic,Site,,Site,None,11,1,43,no,1:no,1:no,,0.815
2995,2813746,Table 1,BaselineCharacteristic,?Gallbladder,,?Gallbladder, Site,12,0,2,no,1:no,1:no,,0.873
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Gallbladder, Site,12,1,3,no,1:no,1:no,,0.7
2995,2813746,Table 1,BaselineCharacteristic,?Extrahepatic,,?Extrahepatic, Site,13,0,2,no,1:no,1:no,,0.873
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,?Extrahepatic, Site,13,1,3,no,1:no,1:no,,0.703
2995,2813746,Table 1,BaselineCharacteristic,?Intrahepatic,,?Intrahepatic, Site,14,0,2,no,1:no,1:no,,0.869
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Intrahepatic, Site,14,1,3,no,1:no,1:no,,0.69
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,15,0,2,no,1:no,1:no,,0.892
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,15,1,3,no,1:no,1:no,,0.807
2995,2813746,Table 1,BaselineCharacteristic,TNM stage,,None,None,16,0,24,no,1:no,1:no,,0.886
2995,2813746,Table 1,BaselineCharacteristic,TNM stage,,TNM stage,None,16,1,43,no,1:no,1:no,,0.847
2995,2813746,Table 1,BaselineCharacteristic,?II,,?II, TNM stage,17,0,2,no,1:no,1:no,,0.903
2995,2813746,Table 1,BaselineCharacteristic,x (x),,?II, TNM stage,17,1,3,no,1:no,1:no,,0.812
2995,2813746,Table 1,BaselineCharacteristic,?III,,?III, TNM stage,18,0,2,no,1:no,1:no,,0.905
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,?III, TNM stage,18,1,3,no,1:no,1:no,,0.758
2995,2813746,Table 1,BaselineCharacteristic,?IV,,?IV, TNM stage,19,0,2,no,1:no,1:no,,0.911
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?IV, TNM stage,19,1,3,no,1:no,1:no,,0.802
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,20,0,2,no,1:no,1:no,,0.902
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,20,1,3,no,1:no,1:no,,0.832
2995,2813746,Table 1,BaselineCharacteristic,Previous treatments,,None,None,21,0,24,no,1:no,1:no,,0.894
2995,2813746,Table 1,BaselineCharacteristic,Previous treatments,,Previous treatments,None,21,1,43,no,1:no,1:no,,0.85
2995,2813746,Table 1,BaselineCharacteristic,?Surgery,,?Surgery, Previous treatments,22,0,24,no,1:no,1:no,,0.872
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Surgery, Previous treatments,22,1,43,no,1:no,1:no,,0.759
2995,2813746,Table 1,BaselineCharacteristic,??Radical,,??Radical, Previous treatments ?Surgery,23,0,2,no,1:no,1:no,,0.902
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,??Radical, Previous treatments ?Surgery,23,1,3,no,1:no,1:no,,0.778
2995,2813746,Table 1,BaselineCharacteristic,??Palliative/biopsy,,??Palliative/biopsy, Previous treatments ?Surgery,24,0,2,no,1:no,1:no,,0.902
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,??Palliative/biopsy, Previous treatments ?Surgery,24,1,3,no,1:no,1:no,,0.768
2995,2813746,Table 1,BaselineCharacteristic,?Chemotherapy lines,,?Chemotherapy lines, Previous treatments,25,0,24,no,1:no,1:no,,0.88
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Chemotherapy lines, Previous treatments,25,1,43,no,1:no,1:no,,0.788
2995,2813746,Table 1,BaselineCharacteristic,??x,,??x, Previous treatments ?Chemotherapy lines,26,0,2,no,1:no,1:no,,0.884
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,??x, Previous treatments ?Chemotherapy lines,26,1,3,no,1:no,1:no,,0.784
2995,2813746,Table 1,BaselineCharacteristic,??x,,??x, Previous treatments ?Chemotherapy lines,27,0,2,no,1:no,1:no,,0.884
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,??x, Previous treatments ?Chemotherapy lines,27,1,3,no,1:no,1:no,,0.784
2995,2813746,Table 1,BaselineCharacteristic,??x,,??x, Previous treatments ?Chemotherapy lines,28,0,2,no,1:no,1:no,,0.884
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,??x, Previous treatments ?Chemotherapy lines,28,1,3,no,1:no,1:no,,0.784
2995,2813746,Table 1,BaselineCharacteristic,??>x,,??>x, Previous treatments ?Chemotherapy lines,29,0,2,no,1:no,1:no,,0.906
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??>x, Previous treatments ?Chemotherapy lines,29,1,3,no,1:no,1:no,,0.828
2995,2813746,Table 1,BaselineCharacteristic,?Radiotherapy,,?Radiotherapy, Previous treatments,30,0,24,no,1:no,1:no,,0.872
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,?Radiotherapy, Previous treatments,30,1,43,no,1:no,1:no,,0.742
2995,2813746,Table 1,BaselineCharacteristic,??Stereotactic,,??Stereotactic, Previous treatments ?Radiotherapy,31,0,2,no,1:no,1:no,,0.899
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??Stereotactic, Previous treatments ?Radiotherapy,31,1,3,no,1:no,1:no,,0.824
2995,2813746,Table 1,BaselineCharacteristic,??Palliative,,??Palliative, Previous treatments ?Radiotherapy,32,0,2,no,1:no,1:no,,0.9
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??Palliative, Previous treatments ?Radiotherapy,32,1,3,no,1:no,1:no,,0.824
2995,2813746,Table 1,BaselineCharacteristic,?Local treatments,,?Local treatments, Previous treatments,33,0,24,no,1:no,1:no,,0.873
2995,2813746,Table 1,BaselineCharacteristic,x (x),,?Local treatments, Previous treatments,33,1,43,no,1:no,1:no,,0.817
2995,2813746,Table 1,BaselineCharacteristic,??Hyperthermy,,??Hyperthermy, Previous treatments ?Local treatments,34,0,2,no,1:no,1:no,,0.9
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??Hyperthermy, Previous treatments ?Local treatments,34,1,3,no,1:no,1:no,,0.824
2995,2813746,Table 1,BaselineCharacteristic,??RF,,??RF, Previous treatments ?Local treatments,35,0,2,no,1:no,1:no,,0.9
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??RF, Previous treatments ?Local treatments,35,1,3,no,1:no,1:no,,0.824
2995,2813746,Table 1,BaselineCharacteristic,??TACE/RF,,??TACE/RF, Previous treatments ?Local treatments,36,0,2,no,1:no,1:no,,0.9
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??TACE/RF, Previous treatments ?Local treatments,36,1,3,no,1:no,1:no,,0.824
3036,2820465,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
3036,2820465,Table 1,BaselineCharacteristic,Anti-IL-xx,,,None,0,1,1,no,1:no,1:no,,0.735
3036,2820465,Table 1,BaselineCharacteristic,Anti-IL-xx,,,None,0,2,1,no,1:no,1:no,,0.775
3036,2820465,Table 1,BaselineCharacteristic,Anti-IL-xx,,,None,0,3,1,no,1:no,1:no,,0.79
3036,2820465,Table 1,BaselineCharacteristic,,,,None,0,4,1,no,1:no,1:no,,0.802
3036,2820465,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no,1:no,1:no,,0.792
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ; ,,None,1,1,1,no,1:no,1:no,,0.716
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ; ,,None,1,2,1,no,1:no,1:no,,0.756
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ; ,,None,1,3,1,no,1:no,1:no,,0.77
3036,2820465,Table 1,BaselineCharacteristic,, ; ,,None,1,4,1,no,1:no,1:no,,0.782
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,0,12,no,1:no,1:no,,0.805
3036,2820465,Table 1,BaselineCharacteristic,x mg/kg (n = x),Anti-IL-xx ;  ; ,,None,2,1,1,no,1:no,1:no,,0.581
3036,2820465,Table 1,BaselineCharacteristic,x mg/kg (n = x),Anti-IL-xx ;  ; ,,None,2,2,1,no,1:no,1:no,,0.602
3036,2820465,Table 1,BaselineCharacteristic,xx mg/kg (n = x),Anti-IL-xx ;  ; ,,None,2,3,1,no,1:no,1:no,,0.519
3036,2820465,Table 1,BaselineCharacteristic,Placebo (n = x), ;  ; ,,None,2,4,1,no,1:no,2:yes,+,0.574
3036,2820465,Table 1,BaselineCharacteristic,"Randomised, n", ;  ;  ; ,"Randomised, n",,3,0,2,no,1:no,1:no,,0.791
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Randomised, n",,3,1,3,no,1:no,1:no,,0.509
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Randomised, n",,3,2,3,no,1:no,1:no,,0.517
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Randomised, n",,3,3,3,no,1:no,2:yes,+,0.515
3036,2820465,Table 1,BaselineCharacteristic,x, ;  ; Placebo (n = x) ; ,"Randomised, n",,3,4,3,no,1:no,2:yes,+,0.605
3036,2820465,Table 1,BaselineCharacteristic,"Completed study, n (%)", ;  ;  ; ,"Completed study, n (%)",,4,0,2,no,1:no,1:no,,0.706
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Completed study, n (%)",,4,1,3,no,1:no,2:yes,+,0.663
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Completed study, n (%)",,4,2,3,no,1:no,2:yes,+,0.641
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Completed study, n (%)",,4,3,3,no,1:no,2:yes,+,0.645
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x), ;  ; Placebo (n = x) ; ,"Completed study, n (%)",,4,4,3,no,1:no,2:yes,+,0.737
3036,2820465,Table 1,BaselineCharacteristic,"Sex, n (%)", ;  ;  ; ,None,None,5,0,24,no,1:no,1:no,,0.57
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Sex, n (%)",None,5,1,43,no,1:no,2:yes,+,0.609
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Sex, n (%)",None,5,2,43,no,1:no,2:yes,+,0.602
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Sex, n (%)",None,5,3,43,no,1:no,2:yes,+,0.7
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"Sex, n (%)",None,5,4,43,no,1:no,2:yes,+,0.672
3036,2820465,Table 1,BaselineCharacteristic,?Male, ;  ;  ; ,?Male," Sex, n (%)",6,0,2,no,1:no,2:yes,+,0.58
3036,2820465,Table 1,BaselineCharacteristic,x (xxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Male," Sex, n (%)",6,1,3,yes,2:yes,2:yes,,0.784
3036,2820465,Table 1,BaselineCharacteristic,x (xxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Male," Sex, n (%)",6,2,3,yes,2:yes,2:yes,,0.787
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Male," Sex, n (%)",6,3,3,yes,2:yes,2:yes,,0.819
3036,2820465,Table 1,BaselineCharacteristic,x (xxx), ;  ; Placebo (n = x) ; ,?Male," Sex, n (%)",6,4,3,yes,2:yes,2:yes,,0.816
3036,2820465,Table 1,BaselineCharacteristic,?Female, ;  ;  ; ,?Female," Sex, n (%)",7,0,2,no,1:no,2:yes,+,0.523
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Female," Sex, n (%)",7,1,3,yes,2:yes,2:yes,,0.765
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Female," Sex, n (%)",7,2,3,yes,2:yes,2:yes,,0.759
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Female," Sex, n (%)",7,3,3,yes,2:yes,2:yes,,0.811
3036,2820465,Table 1,BaselineCharacteristic,x, ;  ; Placebo (n = x) ; ,?Female," Sex, n (%)",7,4,3,yes,2:yes,2:yes,,0.81
3036,2820465,Table 1,BaselineCharacteristic,"Age, years", ;  ;  ; ,None,None,8,0,24,no,1:no,1:no,,0.859
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Age, years",None,8,1,43,no,1:no,1:no,,0.7
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Age, years",None,8,2,43,no,1:no,1:no,,0.702
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Age, years",None,8,3,43,no,1:no,1:no,,0.665
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"Age, years",None,8,4,43,no,1:no,1:no,,0.568
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD)," Age, years",9,0,2,no,1:no,1:no,,0.812
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," Age, years",9,1,3,no,1:no,1:no,,0.592
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," Age, years",9,2,3,no,1:no,1:no,,0.617
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD)," Age, years",9,3,3,no,1:no,1:no,,0.633
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x), ;  ; Placebo (n = x) ; ,?Mean (SD)," Age, years",9,4,3,no,1:no,1:no,,0.52
3036,2820465,Table 1,BaselineCharacteristic,?Range, ;  ;  ; ,?Range," Age, years",10,0,2,no,1:no,1:no,,0.884
3036,2820465,Table 1,BaselineCharacteristic,xx-xx,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Range," Age, years",10,1,3,no,1:no,1:no,,0.666
3036,2820465,Table 1,BaselineCharacteristic,xx-xx,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Range," Age, years",10,2,3,no,1:no,1:no,,0.677
3036,2820465,Table 1,BaselineCharacteristic,xx-xx,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Range," Age, years",10,3,3,no,1:no,1:no,,0.659
3036,2820465,Table 1,BaselineCharacteristic,xx-xx, ;  ; Placebo (n = x) ; ,?Range," Age, years",10,4,3,no,1:no,1:no,,0.576
3036,2820465,Table 1,BaselineCharacteristic,"Race, n (%)", ;  ;  ; ,None,None,11,0,24,no,1:no,1:no,,0.791
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Race, n (%)",None,11,1,43,no,1:no,1:no,,0.627
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Race, n (%)",None,11,2,43,no,1:no,1:no,,0.637
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Race, n (%)",None,11,3,43,no,1:no,1:no,,0.566
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"Race, n (%)",None,11,4,43,no,1:no,2:yes,+,0.513
3036,2820465,Table 1,BaselineCharacteristic,?White, ;  ;  ; ,?White," Race, n (%)",12,0,2,no,1:no,1:no,,0.755
3036,2820465,Table 1,BaselineCharacteristic,x (xxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?White," Race, n (%)",12,1,3,no,1:no,1:no,,0.508
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?White," Race, n (%)",12,2,3,no,1:no,1:no,,0.526
3036,2820465,Table 1,BaselineCharacteristic,x (xxx),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?White," Race, n (%)",12,3,3,no,1:no,2:yes,+,0.521
3036,2820465,Table 1,BaselineCharacteristic,x (xxx), ;  ; Placebo (n = x) ; ,?White," Race, n (%)",12,4,3,no,1:no,2:yes,+,0.587
3036,2820465,Table 1,BaselineCharacteristic,?Black, ;  ;  ; ,?Black," Race, n (%)",13,0,2,no,1:no,1:no,,0.751
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Black," Race, n (%)",13,1,3,no,1:no,1:no,,0.54
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Black," Race, n (%)",13,2,3,no,1:no,1:no,,0.522
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Black," Race, n (%)",13,3,3,no,1:no,1:no,,0.519
3036,2820465,Table 1,BaselineCharacteristic,x, ;  ; Placebo (n = x) ; ,?Black," Race, n (%)",13,4,3,no,1:no,2:yes,+,0.588
3036,2820465,Table 1,BaselineCharacteristic,"Weight, kg", ;  ;  ; ,None,None,14,0,24,no,1:no,1:no,,0.891
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Weight, kg",None,14,1,43,no,1:no,1:no,,0.726
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Weight, kg",None,14,2,43,no,1:no,1:no,,0.732
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Weight, kg",None,14,3,43,no,1:no,1:no,,0.707
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"Weight, kg",None,14,4,43,no,1:no,1:no,,0.557
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD)," Weight, kg",15,0,2,no,1:no,1:no,,0.879
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," Weight, kg",15,1,3,no,1:no,1:no,,0.715
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," Weight, kg",15,2,3,no,1:no,1:no,,0.733
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD)," Weight, kg",15,3,3,no,1:no,1:no,,0.738
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x), ;  ; Placebo (n = x) ; ,?Mean (SD)," Weight, kg",15,4,3,no,1:no,1:no,,0.568
3036,2820465,Table 1,BaselineCharacteristic,"BMI, kg/mx", ;  ;  ; ,None,None,16,0,24,no,1:no,1:no,,0.872
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"BMI, kg/mx",None,16,1,43,no,1:no,1:no,,0.698
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"BMI, kg/mx",None,16,2,43,no,1:no,1:no,,0.704
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"BMI, kg/mx",None,16,3,43,no,1:no,1:no,,0.665
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"BMI, kg/mx",None,16,4,43,no,1:no,1:no,,0.532
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD)," BMI, kg/mx",17,0,2,no,1:no,1:no,,0.878
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," BMI, kg/mx",17,1,3,no,1:no,1:no,,0.691
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," BMI, kg/mx",17,2,3,no,1:no,1:no,,0.712
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD)," BMI, kg/mx",17,3,3,no,1:no,1:no,,0.717
3036,2820465,Table 1,BaselineCharacteristic,xx (x.x), ;  ; Placebo (n = x) ; ,?Mean (SD)," BMI, kg/mx",17,4,3,no,1:no,1:no,,0.548
3036,2820465,Table 1,BaselineCharacteristic,% predicted FEVx, ;  ;  ; ,None,None,18,0,24,no,1:no,1:no,,0.841
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,% predicted FEVx,None,18,1,43,no,1:no,1:no,,0.658
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,% predicted FEVx,None,18,2,43,no,1:no,1:no,,0.669
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,% predicted FEVx,None,18,3,43,no,1:no,1:no,,0.6
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,% predicted FEVx,None,18,4,43,no,1:no,1:no,,0.518
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD), % predicted FEVx,19,0,2,no,1:no,1:no,,0.856
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD), % predicted FEVx,19,1,3,no,1:no,1:no,,0.601
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD), % predicted FEVx,19,2,3,no,1:no,1:no,,0.618
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD), % predicted FEVx,19,3,3,no,1:no,1:no,,0.619
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x), ;  ; Placebo (n = x) ; ,?Mean (SD), % predicted FEVx,19,4,3,no,1:no,2:yes,+,0.502
3036,2820465,Table 1,BaselineCharacteristic,FEVx, ;  ;  ; ,None,None,20,0,24,no,1:no,1:no,,0.89
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,FEVx,None,20,1,43,no,1:no,1:no,,0.73
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,FEVx,None,20,2,43,no,1:no,1:no,,0.735
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,FEVx,None,20,3,43,no,1:no,1:no,,0.696
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,FEVx,None,20,4,43,no,1:no,1:no,,0.563
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD), FEVx,21,0,2,no,1:no,1:no,,0.883
3036,2820465,Table 1,BaselineCharacteristic,x.xx (x.xx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD), FEVx,21,1,3,no,1:no,1:no,,0.707
3036,2820465,Table 1,BaselineCharacteristic,x.xx (x.xx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD), FEVx,21,2,3,no,1:no,1:no,,0.723
3036,2820465,Table 1,BaselineCharacteristic,x.xx (x.xx),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD), FEVx,21,3,3,no,1:no,1:no,,0.728
3036,2820465,Table 1,BaselineCharacteristic,x.xx (x.xx), ;  ; Placebo (n = x) ; ,?Mean (SD), FEVx,21,4,3,no,1:no,1:no,,0.559
3036,2820465,Table 1,BaselineCharacteristic,"ICS dose, ?g/d", ;  ;  ; ,None,None,22,0,24,no,1:no,1:no,,0.9
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"ICS dose, ?g/d",None,22,1,43,no,1:no,1:no,,0.755
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"ICS dose, ?g/d",None,22,2,43,no,1:no,1:no,,0.76
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"ICS dose, ?g/d",None,22,3,43,no,1:no,1:no,,0.734
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"ICS dose, ?g/d",None,22,4,43,no,1:no,1:no,,0.606
3036,2820465,Table 1,BaselineCharacteristic,?Median (range), ;  ;  ; ,?Median (range)," ICS dose, ?g/d",23,0,2,no,1:no,1:no,,0.919
3036,2820465,Table 1,BaselineCharacteristic,xxx (xxx-xxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Median (range)," ICS dose, ?g/d",23,1,3,no,1:no,1:no,,0.758
3036,2820465,Table 1,BaselineCharacteristic,xxx (xxx-xxxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Median (range)," ICS dose, ?g/d",23,2,3,no,1:no,1:no,,0.763
3036,2820465,Table 1,BaselineCharacteristic,xxx (xxx-xxx),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Median (range)," ICS dose, ?g/d",23,3,3,no,1:no,1:no,,0.712
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,?Median (range)," ICS dose, ?g/d",23,4,3,no,1:no,1:no,,0.628
3304,2905291,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
3304,2905291,Table 1,BaselineCharacteristic,No. of patients,,Characteristic,None,0,1,1,no,1:no,1:no,,0.787
3304,2905291,Table 1,BaselineCharacteristic,Total,Characteristic ; ,Total,,1,0,2,no,1:no,1:no,,0.741
3304,2905291,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Total,,1,1,3,no,1:no,2:yes,+,0.603
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,0,2,no,1:no,1:no,,0.852
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,2,1,3,no,1:no,1:no,,0.736
3304,2905291,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,3,0,24,no,1:no,1:no,,0.845
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,Age (years),None,3,1,43,no,1:no,1:no,,0.781
3304,2905291,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),4,0,2,no,1:no,1:no,,0.85
3304,2905291,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Median, Age (years),4,1,3,no,1:no,1:no,,0.587
3304,2905291,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),5,0,2,no,1:no,1:no,,0.836
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,0,2,no,1:no,1:no,,0.876
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,6,1,3,no,1:no,1:no,,0.756
3304,2905291,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,7,0,24,no,1:no,1:no,,0.637
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,Sex,None,7,1,43,no,1:no,1:no,,0.603
3304,2905291,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Sex,8,0,2,no,1:no,1:no,,0.539
3304,2905291,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Male, Sex,8,1,3,yes,2:yes,2:yes,,0.787
3304,2905291,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Sex,9,0,2,no,1:no,1:no,,0.556
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Female, Sex,9,1,3,yes,2:yes,2:yes,,0.64
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,10,0,2,no,1:no,1:no,,0.898
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,10,1,3,no,1:no,1:no,,0.825
3304,2905291,Table 1,BaselineCharacteristic,ECOG performance status,Characteristic ; ,None,None,11,0,24,no,1:no,1:no,,0.902
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,ECOG performance status,None,11,1,43,no,1:no,1:no,,0.87
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,12,0,2,no,1:no,1:no,,0.876
3304,2905291,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, ECOG performance status,12,1,3,no,1:no,1:no,,0.721
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,13,0,2,no,1:no,1:no,,0.876
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, ECOG performance status,13,1,3,no,1:no,1:no,,0.774
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,14,0,2,no,1:no,1:no,,0.864
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, ECOG performance status,14,1,3,no,1:no,1:no,,0.772
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,15,0,2,no,1:no,1:no,,0.902
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,15,1,3,no,1:no,1:no,,0.849
3304,2905291,Table 1,BaselineCharacteristic,Previous anti-tumour regimens,Characteristic ; ,None,None,16,0,24,no,1:no,1:no,,0.889
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,Previous anti-tumour regimens,None,16,1,43,no,1:no,1:no,,0.863
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,17,0,2,no,1:no,1:no,,0.882
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,17,1,3,no,1:no,1:no,,0.761
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,18,0,2,no,1:no,1:no,,0.886
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,18,1,3,no,1:no,1:no,,0.764
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,19,0,2,no,1:no,1:no,,0.886
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,19,1,3,no,1:no,1:no,,0.764
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,20,0,2,no,1:no,1:no,,0.886
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,20,1,3,no,1:no,1:no,,0.765
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,21,0,2,no,1:no,1:no,,0.886
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,21,1,3,no,1:no,1:no,,0.765
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,22,0,2,no,1:no,1:no,,0.913
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,22,1,3,no,1:no,1:no,,0.863
3304,2905291,Table 1,BaselineCharacteristic,Primary tumour type,Characteristic ; ,None,None,23,0,24,no,1:no,1:no,,0.806
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,Primary tumour type,None,23,1,43,no,1:no,1:no,,0.772
3304,2905291,Table 1,BaselineCharacteristic,?Pancreatic carcinoma,Characteristic ; ,?Pancreatic carcinoma, Primary tumour type,24,0,2,no,1:no,1:no,,0.82
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Pancreatic carcinoma, Primary tumour type,24,1,3,no,1:no,1:no,,0.718
3304,2905291,Table 1,BaselineCharacteristic,?Osteo/chondrosarcoma,Characteristic ; ,?Osteo/chondrosarcoma, Primary tumour type,25,0,2,no,1:no,1:no,,0.817
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Osteo/chondrosarcoma, Primary tumour type,25,1,3,no,1:no,1:no,,0.703
3304,2905291,Table 1,BaselineCharacteristic,?Soft tissue sarcoma,Characteristic ; ,?Soft tissue sarcoma, Primary tumour type,26,0,2,no,1:no,1:no,,0.817
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Soft tissue sarcoma, Primary tumour type,26,1,3,no,1:no,1:no,,0.703
3304,2905291,Table 1,BaselineCharacteristic,?Rectal carcinoma,Characteristic ; ,?Rectal carcinoma, Primary tumour type,27,0,2,no,1:no,1:no,,0.821
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Rectal carcinoma, Primary tumour type,27,1,3,no,1:no,1:no,,0.719
3304,2905291,Table 1,BaselineCharacteristic,?Gastric carcinoma,Characteristic ; ,?Gastric carcinoma, Primary tumour type,28,0,2,no,1:no,1:no,,0.821
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Gastric carcinoma, Primary tumour type,28,1,3,no,1:no,1:no,,0.719
3304,2905291,Table 1,BaselineCharacteristic,?Carcinoma of unknown primary,Characteristic ; ,?Carcinoma of unknown primary, Primary tumour type,29,0,2,no,1:no,1:no,,0.811
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Carcinoma of unknown primary, Primary tumour type,29,1,3,no,1:no,1:no,,0.719
3304,2905291,Table 1,BaselineCharacteristic,?Ovarian carcinoma,Characteristic ; ,?Ovarian carcinoma, Primary tumour type,30,0,2,no,1:no,1:no,,0.821
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Ovarian carcinoma, Primary tumour type,30,1,3,no,1:no,1:no,,0.719
3304,2905291,Table 1,BaselineCharacteristic,?Malignant melanoma,Characteristic ; ,?Malignant melanoma, Primary tumour type,31,0,2,no,1:no,1:no,,0.817
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Malignant melanoma, Primary tumour type,31,1,3,no,1:no,1:no,,0.703
3304,2905291,Table 1,BaselineCharacteristic,?Mesothelioma,Characteristic ; ,?Mesothelioma, Primary tumour type,32,0,2,no,1:no,1:no,,0.817
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Mesothelioma, Primary tumour type,32,1,3,no,1:no,1:no,,0.703
3304,2905291,Table 1,BaselineCharacteristic,?Bladder carcinoma,Characteristic ; ,?Bladder carcinoma, Primary tumour type,33,0,2,no,1:no,1:no,,0.821
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Bladder carcinoma, Primary tumour type,33,1,3,no,1:no,1:no,,0.719
3304,2905291,Table 1,BaselineCharacteristic,?Hepatocellular carcinoma,Characteristic ; ,?Hepatocellular carcinoma, Primary tumour type,34,0,2,no,1:no,1:no,,0.821
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Hepatocellular carcinoma, Primary tumour type,34,1,3,no,1:no,1:no,,0.719
3304,2905291,Table 1,BaselineCharacteristic,?Cholangiocarcinoma,Characteristic ; ,?Cholangiocarcinoma, Primary tumour type,35,0,2,no,1:no,1:no,,0.817
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Cholangiocarcinoma, Primary tumour type,35,1,3,no,1:no,1:no,,0.703
3424,2941791,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
3424,2941791,Table 1,BaselineCharacteristic,Data available,,,None,0,1,1,no,1:no,1:no,,0.735
3424,2941791,Table 1,BaselineCharacteristic,n,,,None,0,2,1,no,1:no,1:no,,0.727
3424,2941791,Table 1,BaselineCharacteristic,Value,,,None,0,3,1,no,1:no,1:no,,0.79
3424,2941791,Table 1,BaselineCharacteristic,Female (%), ; ,Female (%),,3,0,2,no,1:no,1:no,,0.64
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,Female (%),,3,1,3,yes,2:yes,2:yes,,0.543
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,Female (%),,3,2,3,yes,2:yes,2:yes,,0.572
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,Female (%),,3,3,3,yes,2:yes,2:yes,,0.726
3424,2941791,Table 1,BaselineCharacteristic,Waist circumference, ; ,None,None,6,0,24,no,1:no,1:no,,0.836
3424,2941791,Table 1,BaselineCharacteristic,,Data available ; ,Waist circumference,None,6,1,43,no,1:no,1:no,,0.761
3424,2941791,Table 1,BaselineCharacteristic,,n ; ,Waist circumference,None,6,2,43,no,1:no,1:no,,0.701
3424,2941791,Table 1,BaselineCharacteristic,,Value ; ,Waist circumference,None,6,3,43,no,1:no,1:no,,0.799
3424,2941791,Table 1,BaselineCharacteristic,??Men (% ? xxx cm), ; ,??Men (% ? xxx cm), Waist circumference ,7,0,2,no,1:no,1:no,,0.682
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,??Men (% ? xxx cm), Waist circumference ,7,1,3,no,1:no,1:no,,0.578
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,??Men (% ? xxx cm), Waist circumference ,7,2,3,no,1:no,1:no,,0.539
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,??Men (% ? xxx cm), Waist circumference ,7,3,3,no,1:no,2:yes,+,0.559
3424,2941791,Table 1,BaselineCharacteristic,??Women (% ? xx cm), ; ,??Women (% ? xx cm), Waist circumference ,8,0,2,no,1:no,1:no,,0.585
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,??Women (% ? xx cm), Waist circumference ,8,1,3,no,1:no,2:yes,+,0.576
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,??Women (% ? xx cm), Waist circumference ,8,2,3,no,1:no,2:yes,+,0.601
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,??Women (% ? xx cm), Waist circumference ,8,3,3,no,1:no,2:yes,+,0.531
3424,2941791,Table 1,BaselineCharacteristic,Hypertension (%), ; ,Hypertension (%),,9,0,24,no,1:no,1:no,,0.757
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,Hypertension (%),,9,1,43,no,1:no,1:no,,0.707
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,Hypertension (%),,9,2,43,no,1:no,1:no,,0.632
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,Hypertension (%),,9,3,43,no,1:no,1:no,,0.579
3424,2941791,Table 1,BaselineCharacteristic,??>x years (%), ; ,??>x years (%), Hypertension (%) ,10,0,2,no,1:no,1:no,,0.788
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,??>x years (%), Hypertension (%) ,10,1,3,no,1:no,1:no,,0.72
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,??>x years (%), Hypertension (%) ,10,2,3,no,1:no,1:no,,0.631
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,??>x years (%), Hypertension (%) ,10,3,3,no,1:no,1:no,,0.598
3490,2964613,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
3490,2964613,Table 1,BaselineCharacteristic,Patients (N = xxx),,Characteristics,None,0,1,1,no,1:no,1:no,,0.651
3490,2964613,Table 1,BaselineCharacteristic,"Age (years), mean (SD)",Characteristics ; ,"Age (years), mean (SD)",None,1,0,2,no,1:no,1:no,,0.826
3490,2964613,Table 1,BaselineCharacteristic,xx.x (x.xx),Patients (N = xxx) ; ,"Age (years), mean (SD)",None,1,1,3,no,1:no,1:no,,0.52
3490,2964613,Table 1,BaselineCharacteristic,"Sex, n (%)",Characteristics ; ,"Sex, n (%)",None,2,0,2,no,1:no,1:no,,0.601
3490,2964613,Table 1,BaselineCharacteristic,,Patients (N = xxx) ; ,"Sex, n (%)",None,2,1,3,no,1:no,2:yes,+,0.596
3490,2964613,Table 1,BaselineCharacteristic,Male,Characteristics ; ,Male,None,3,0,2,no,1:no,1:no,,0.716
3490,2964613,Table 1,BaselineCharacteristic,xxx (xx.x),Patients (N = xxx) ; ,Male,None,3,1,3,yes,2:yes,2:yes,,0.668
3490,2964613,Table 1,BaselineCharacteristic,Female,Characteristics ; ,Female,None,4,0,2,no,1:no,1:no,,0.731
3490,2964613,Table 1,BaselineCharacteristic,xx (xx.x),Patients (N = xxx) ; ,Female,None,4,1,3,yes,2:yes,2:yes,,0.664
3490,2964613,Table 1,BaselineCharacteristic,"Race, n (%)",Characteristics ; ,"Race, n (%)",None,5,0,2,no,1:no,1:no,,0.754
3490,2964613,Table 1,BaselineCharacteristic,,Patients (N = xxx) ; ,"Race, n (%)",None,5,1,3,no,1:no,1:no,,0.551
3490,2964613,Table 1,BaselineCharacteristic,Caucasian,Characteristics ; ,Caucasian,None,6,0,2,no,1:no,1:no,,0.843
3490,2964613,Table 1,BaselineCharacteristic,xxx (xx.x),Patients (N = xxx) ; ,Caucasian,None,6,1,3,no,1:no,2:yes,+,0.526
3490,2964613,Table 1,BaselineCharacteristic,Others,Characteristics ; ,Others,None,7,0,2,no,1:no,1:no,,0.843
3490,2964613,Table 1,BaselineCharacteristic,x (x.x),Patients (N = xxx) ; ,Others,None,7,1,3,no,1:no,1:no,,0.636
3490,2964613,Table 1,BaselineCharacteristic,"BMI (kg/mx), mean (SD)",Characteristics ; ,"BMI (kg/mx), mean (SD)",None,8,0,2,no,1:no,1:no,,0.86
3490,2964613,Table 1,BaselineCharacteristic,xx.x (x.xx),Patients (N = xxx) ; ,"BMI (kg/mx), mean (SD)",None,8,1,3,no,1:no,1:no,,0.62
3490,2964613,Table 1,BaselineCharacteristic,"Duration of COPD (years), mean (SD)",Characteristics ; ,"Duration of COPD (years), mean (SD)",None,9,0,2,no,1:no,1:no,,0.875
3490,2964613,Table 1,BaselineCharacteristic,x.x (x.xx),Patients (N = xxx) ; ,"Duration of COPD (years), mean (SD)",None,9,1,3,no,1:no,1:no,,0.681
3490,2964613,Table 1,BaselineCharacteristic,"Smoking history, n (%)",Characteristics ; ,"Smoking history, n (%)",None,10,0,2,no,1:no,1:no,,0.792
3490,2964613,Table 1,BaselineCharacteristic,,Patients (N = xxx) ; ,"Smoking history, n (%)",None,10,1,3,no,1:no,1:no,,0.682
3490,2964613,Table 1,BaselineCharacteristic,Ex-smoker,Characteristics ; ,Ex-smoker,None,11,0,2,no,1:no,1:no,,0.866
3490,2964613,Table 1,BaselineCharacteristic,xx (xx.x),Patients (N = xxx) ; ,Ex-smoker,None,11,1,3,no,1:no,1:no,,0.608
3490,2964613,Table 1,BaselineCharacteristic,Current smoker,Characteristics ; ,Current smoker,None,12,0,2,no,1:no,1:no,,0.866
3490,2964613,Table 1,BaselineCharacteristic,xx (xx.x),Patients (N = xxx) ; ,Current smoker,None,12,1,3,no,1:no,1:no,,0.608
3490,2964613,Table 1,BaselineCharacteristic,"Number of pack-years, mean (SD)",Characteristics ; ,"Number of pack-years, mean (SD)",None,13,0,2,no,1:no,1:no,,0.871
3490,2964613,Table 1,BaselineCharacteristic,xx.x (xx.xx),Patients (N = xxx) ; ,"Number of pack-years, mean (SD)",None,13,1,3,no,1:no,1:no,,0.721
3490,2964613,Table 1,BaselineCharacteristic,"Post-bronchodilator FEVx (% predicted), mean (SD)",Characteristics ; ,"Post-bronchodilator FEVx (% predicted), mean (SD)",None,14,0,2,no,1:no,1:no,,0.841
3490,2964613,Table 1,BaselineCharacteristic,xx.x (xx.xx),Patients (N = xxx) ; ,"Post-bronchodilator FEVx (% predicted), mean (SD)",None,14,1,3,no,1:no,1:no,,0.584
3490,2964613,Table 1,BaselineCharacteristic,"Post-bronchodilator FEVx/FVC (%), mean (SD)",Characteristics ; ,"Post-bronchodilator FEVx/FVC (%), mean (SD)",None,15,0,2,no,1:no,1:no,,0.831
3490,2964613,Table 1,BaselineCharacteristic,xx.x (xx.xx),Patients (N = xxx) ; ,"Post-bronchodilator FEVx/FVC (%), mean (SD)",None,15,1,3,no,1:no,1:no,,0.582
3490,2964613,Table 1,BaselineCharacteristic,"FEVx reversibility (% increase), mean (SD)",Characteristics ; ,"FEVx reversibility (% increase), mean (SD)",None,16,0,2,no,1:no,1:no,,0.84
3490,2964613,Table 1,BaselineCharacteristic,xx.x (xx.xx),Patients (N = xxx) ; ,"FEVx reversibility (% increase), mean (SD)",None,16,1,3,no,1:no,1:no,,0.584
3496,2965867,Table 1,BaselineCharacteristic,Parameter/dose level,,None,None,0,0,12,no,1:no,1:no,,0.803
3496,2965867,Table 1,BaselineCharacteristic,xxx?IU?m?x,,Parameter/dose level,None,0,1,1,no,1:no,1:no,,0.729
3496,2965867,Table 1,BaselineCharacteristic,xxx?IU?m?x,,Parameter/dose level,None,0,2,1,no,1:no,1:no,,0.744
3496,2965867,Table 1,BaselineCharacteristic,Overall,,Parameter/dose level,None,0,3,1,no,1:no,1:no,,0.817
3496,2965867,Table 1,BaselineCharacteristic,"Case, number",Parameter/dose level ; ,"Case, number",,1,0,2,no,1:no,1:no,,0.763
3496,2965867,Table 1,BaselineCharacteristic,xx,xxx?IU?m?x ; ,"Case, number",,1,1,3,no,1:no,2:yes,+,0.567
3496,2965867,Table 1,BaselineCharacteristic,xx,xxx?IU?m?x ; ,"Case, number",,1,2,3,no,1:no,2:yes,+,0.566
3496,2965867,Table 1,BaselineCharacteristic,xx,Overall ; ,"Case, number",,1,3,3,no,1:no,1:no,,0.548
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,2,0,2,no,1:no,1:no,,0.85
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,2,1,3,no,1:no,1:no,,0.715
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,2,2,3,no,1:no,1:no,,0.729
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,2,3,3,no,1:no,1:no,,0.8
3496,2965867,Table 1,BaselineCharacteristic,Gender,Parameter/dose level ; ,None,None,3,0,24,no,1:no,1:no,,0.734
3496,2965867,Table 1,BaselineCharacteristic,Gender,xxx?IU?m?x ; ,Gender,None,3,1,43,no,1:no,1:no,,0.631
3496,2965867,Table 1,BaselineCharacteristic,Gender,xxx?IU?m?x ; ,Gender,None,3,2,43,no,1:no,1:no,,0.65
3496,2965867,Table 1,BaselineCharacteristic,Gender,Overall ; ,Gender,None,3,3,43,no,1:no,1:no,,0.74
3496,2965867,Table 1,BaselineCharacteristic,?Male,Parameter/dose level ; ,?Male, Gender,4,0,2,no,1:no,1:no,,0.73
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Male, Gender,4,1,3,yes,2:yes,2:yes,,0.668
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Male, Gender,4,2,3,yes,2:yes,2:yes,,0.667
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Male, Gender,4,3,3,yes,2:yes,2:yes,,0.668
3496,2965867,Table 1,BaselineCharacteristic,?Female,Parameter/dose level ; ,?Female, Gender,5,0,2,no,1:no,1:no,,0.729
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Female, Gender,5,1,3,yes,2:yes,2:yes,,0.675
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Female, Gender,5,2,3,yes,2:yes,2:yes,,0.664
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Female, Gender,5,3,3,yes,2:yes,2:yes,,0.646
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,6,0,2,no,1:no,1:no,,0.878
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,6,1,3,no,1:no,1:no,,0.74
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,6,2,3,no,1:no,1:no,,0.755
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,6,3,3,no,1:no,1:no,,0.809
3496,2965867,Table 1,BaselineCharacteristic,Age,Parameter/dose level ; ,None,None,7,0,24,no,1:no,1:no,,0.876
3496,2965867,Table 1,BaselineCharacteristic,Age,xxx?IU?m?x ; ,Age,None,7,1,43,no,1:no,1:no,,0.767
3496,2965867,Table 1,BaselineCharacteristic,Age,xxx?IU?m?x ; ,Age,None,7,2,43,no,1:no,1:no,,0.781
3496,2965867,Table 1,BaselineCharacteristic,Age,Overall ; ,Age,None,7,3,43,no,1:no,1:no,,0.878
3496,2965867,Table 1,BaselineCharacteristic,?Median,Parameter/dose level ; ,?Median, Age,8,0,2,no,1:no,1:no,,0.882
3496,2965867,Table 1,BaselineCharacteristic,xx,xxx?IU?m?x ; ,?Median, Age,8,1,3,no,1:no,1:no,,0.612
3496,2965867,Table 1,BaselineCharacteristic,xx,xxx?IU?m?x ; ,?Median, Age,8,2,3,no,1:no,1:no,,0.616
3496,2965867,Table 1,BaselineCharacteristic,xx,Overall ; ,?Median, Age,8,3,3,no,1:no,1:no,,0.709
3496,2965867,Table 1,BaselineCharacteristic,?Range,Parameter/dose level ; ,?Range, Age,9,0,2,no,1:no,1:no,,0.881
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,10,0,2,no,1:no,1:no,,0.894
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,10,1,3,no,1:no,1:no,,0.755
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,10,2,3,no,1:no,1:no,,0.774
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,10,3,3,no,1:no,1:no,,0.836
3496,2965867,Table 1,BaselineCharacteristic,Karnofsky performance status,Parameter/dose level ; ,None,None,11,0,24,no,1:no,1:no,,0.901
3496,2965867,Table 1,BaselineCharacteristic,Karnofsky performance status,xxx?IU?m?x ; ,Karnofsky performance status,None,11,1,43,no,1:no,1:no,,0.787
3496,2965867,Table 1,BaselineCharacteristic,Karnofsky performance status,xxx?IU?m?x ; ,Karnofsky performance status,None,11,2,43,no,1:no,1:no,,0.806
3496,2965867,Table 1,BaselineCharacteristic,Karnofsky performance status,Overall ; ,Karnofsky performance status,None,11,3,43,no,1:no,1:no,,0.887
3496,2965867,Table 1,BaselineCharacteristic,?xxx,Parameter/dose level ; ,?xxx, Karnofsky performance status,12,0,2,no,1:no,1:no,,0.839
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?xxx, Karnofsky performance status,12,1,3,no,1:no,1:no,,0.678
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?xxx, Karnofsky performance status,12,2,3,no,1:no,1:no,,0.694
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?xxx, Karnofsky performance status,12,3,3,no,1:no,1:no,,0.643
3496,2965867,Table 1,BaselineCharacteristic,?xx,Parameter/dose level ; ,?xx, Karnofsky performance status,13,0,2,no,1:no,1:no,,0.834
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?xx, Karnofsky performance status,13,1,3,no,1:no,1:no,,0.677
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?xx, Karnofsky performance status,13,2,3,no,1:no,1:no,,0.693
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?xx, Karnofsky performance status,13,3,3,no,1:no,1:no,,0.711
3496,2965867,Table 1,BaselineCharacteristic,?xx,Parameter/dose level ; ,?xx, Karnofsky performance status,14,0,2,no,1:no,1:no,,0.828
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?xx, Karnofsky performance status,14,1,3,no,1:no,1:no,,0.669
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?xx, Karnofsky performance status,14,2,3,no,1:no,1:no,,0.685
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?xx, Karnofsky performance status,14,3,3,no,1:no,1:no,,0.705
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,15,0,2,no,1:no,1:no,,0.898
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,15,1,3,no,1:no,1:no,,0.76
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,15,2,3,no,1:no,1:no,,0.779
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,15,3,3,no,1:no,1:no,,0.839
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,19,0,2,no,1:no,1:no,,0.908
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,19,1,3,no,1:no,1:no,,0.806
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,19,2,3,no,1:no,1:no,,0.813
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,19,3,3,no,1:no,1:no,,0.846
3496,2965867,Table 1,BaselineCharacteristic,HbsAg,Parameter/dose level ; ,None,None,20,0,24,no,1:no,1:no,,0.895
3496,2965867,Table 1,BaselineCharacteristic,HbsAg,xxx?IU?m?x ; ,HbsAg,None,20,1,43,no,1:no,1:no,,0.806
3496,2965867,Table 1,BaselineCharacteristic,HbsAg,xxx?IU?m?x ; ,HbsAg,None,20,2,43,no,1:no,1:no,,0.814
3496,2965867,Table 1,BaselineCharacteristic,HbsAg,Overall ; ,HbsAg,None,20,3,43,no,1:no,1:no,,0.876
3496,2965867,Table 1,BaselineCharacteristic,?Positive,Parameter/dose level ; ,?Positive, HbsAg,21,0,2,no,1:no,1:no,,0.898
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Positive, HbsAg,21,1,3,no,1:no,1:no,,0.667
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Positive, HbsAg,21,2,3,no,1:no,1:no,,0.68
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Positive, HbsAg,21,3,3,no,1:no,1:no,,0.706
3496,2965867,Table 1,BaselineCharacteristic,?Negative,Parameter/dose level ; ,?Negative, HbsAg,22,0,2,no,1:no,1:no,,0.9
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Negative, HbsAg,22,1,3,no,1:no,1:no,,0.675
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Negative, HbsAg,22,2,3,no,1:no,1:no,,0.688
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Negative, HbsAg,22,3,3,no,1:no,1:no,,0.711
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,23,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,23,1,3,no,1:no,1:no,,0.814
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,23,2,3,no,1:no,1:no,,0.821
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,23,3,3,no,1:no,1:no,,0.853
3496,2965867,Table 1,BaselineCharacteristic,Anti-HCV antibody,Parameter/dose level ; ,None,None,24,0,24,no,1:no,1:no,,0.897
3496,2965867,Table 1,BaselineCharacteristic,Anti-HCV antibody,xxx?IU?m?x ; ,Anti-HCV antibody,None,24,1,43,no,1:no,1:no,,0.814
3496,2965867,Table 1,BaselineCharacteristic,Anti-HCV antibody,xxx?IU?m?x ; ,Anti-HCV antibody,None,24,2,43,no,1:no,1:no,,0.828
3496,2965867,Table 1,BaselineCharacteristic,Anti-HCV antibody,Overall ; ,Anti-HCV antibody,None,24,3,43,no,1:no,1:no,,0.879
3496,2965867,Table 1,BaselineCharacteristic,?Positive,Parameter/dose level ; ,?Positive, Anti-HCV antibody,25,0,2,no,1:no,1:no,,0.902
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Positive, Anti-HCV antibody,25,1,3,no,1:no,1:no,,0.689
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Positive, Anti-HCV antibody,25,2,3,no,1:no,1:no,,0.708
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Positive, Anti-HCV antibody,25,3,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,?Negative,Parameter/dose level ; ,?Negative, Anti-HCV antibody,26,0,2,no,1:no,1:no,,0.902
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Negative, Anti-HCV antibody,26,1,3,no,1:no,1:no,,0.689
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Negative, Anti-HCV antibody,26,2,3,no,1:no,1:no,,0.708
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Negative, Anti-HCV antibody,26,3,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,?Unknown,Parameter/dose level ; ,?Unknown, Anti-HCV antibody,27,0,2,no,1:no,1:no,,0.902
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),xxx?IU?m?x ; ,?Unknown, Anti-HCV antibody,27,1,3,no,1:no,1:no,,0.773
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),xxx?IU?m?x ; ,?Unknown, Anti-HCV antibody,27,2,3,no,1:no,1:no,,0.781
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),Overall ; ,?Unknown, Anti-HCV antibody,27,3,3,no,1:no,1:no,,0.798
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,28,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,28,1,3,no,1:no,1:no,,0.815
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,28,2,3,no,1:no,1:no,,0.829
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,28,3,3,no,1:no,1:no,,0.862
3496,2965867,Table 1,BaselineCharacteristic,Vascular invasion,Parameter/dose level ; ,None,None,29,0,24,no,1:no,1:no,,0.897
3496,2965867,Table 1,BaselineCharacteristic,Vascular invasion,xxx?IU?m?x ; ,Vascular invasion,None,29,1,43,no,1:no,1:no,,0.814
3496,2965867,Table 1,BaselineCharacteristic,Vascular invasion,xxx?IU?m?x ; ,Vascular invasion,None,29,2,43,no,1:no,1:no,,0.828
3496,2965867,Table 1,BaselineCharacteristic,Vascular invasion,Overall ; ,Vascular invasion,None,29,3,43,no,1:no,1:no,,0.879
3496,2965867,Table 1,BaselineCharacteristic,?Absent,Parameter/dose level ; ,?Absent, Vascular invasion,30,0,2,no,1:no,1:no,,0.902
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Absent, Vascular invasion,30,1,3,no,1:no,1:no,,0.689
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Absent, Vascular invasion,30,2,3,no,1:no,1:no,,0.709
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Absent, Vascular invasion,30,3,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,?Present,Parameter/dose level ; ,?Present, Vascular invasion,31,0,2,no,1:no,1:no,,0.902
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Present, Vascular invasion,31,1,3,no,1:no,1:no,,0.689
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Present, Vascular invasion,31,2,3,no,1:no,1:no,,0.709
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Present, Vascular invasion,31,3,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,32,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,32,1,3,no,1:no,1:no,,0.815
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,32,2,3,no,1:no,1:no,,0.829
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,32,3,3,no,1:no,1:no,,0.862
3496,2965867,Table 1,BaselineCharacteristic,Extrahepatic metastases,Parameter/dose level ; ,None,None,33,0,24,no,1:no,1:no,,0.902
3496,2965867,Table 1,BaselineCharacteristic,Extrahepatic metastases,xxx?IU?m?x ; ,Extrahepatic metastases,None,33,1,43,no,1:no,1:no,,0.824
3496,2965867,Table 1,BaselineCharacteristic,Extrahepatic metastases,xxx?IU?m?x ; ,Extrahepatic metastases,None,33,2,43,no,1:no,1:no,,0.832
3496,2965867,Table 1,BaselineCharacteristic,Extrahepatic metastases,Overall ; ,Extrahepatic metastases,None,33,3,43,no,1:no,1:no,,0.883
3496,2965867,Table 1,BaselineCharacteristic,?Absent,Parameter/dose level ; ,?Absent, Extrahepatic metastases,34,0,2,no,1:no,1:no,,0.908
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Absent, Extrahepatic metastases,34,1,3,no,1:no,1:no,,0.7
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Absent, Extrahepatic metastases,34,2,3,no,1:no,1:no,,0.719
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Absent, Extrahepatic metastases,34,3,3,no,1:no,1:no,,0.731
3496,2965867,Table 1,BaselineCharacteristic,?Present,Parameter/dose level ; ,?Present, Extrahepatic metastases,35,0,2,no,1:no,1:no,,0.908
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Present, Extrahepatic metastases,35,1,3,no,1:no,1:no,,0.7
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Present, Extrahepatic metastases,35,2,3,no,1:no,1:no,,0.719
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Present, Extrahepatic metastases,35,3,3,no,1:no,1:no,,0.731
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,36,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,36,1,3,no,1:no,1:no,,0.815
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,36,2,3,no,1:no,1:no,,0.829
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,36,3,3,no,1:no,1:no,,0.862
3496,2965867,Table 1,BaselineCharacteristic,Prior therapy,Parameter/dose level ; ,None,None,37,0,24,no,1:no,1:no,,0.909
3496,2965867,Table 1,BaselineCharacteristic,Prior therapy,xxx?IU?m?x ; ,Prior therapy,None,37,1,43,no,1:no,1:no,,0.837
3496,2965867,Table 1,BaselineCharacteristic,Prior therapy,xxx?IU?m?x ; ,Prior therapy,None,37,2,43,no,1:no,1:no,,0.851
3496,2965867,Table 1,BaselineCharacteristic,Prior therapy,Overall ; ,Prior therapy,None,37,3,43,no,1:no,1:no,,0.897
3496,2965867,Table 1,BaselineCharacteristic,?Hepatic resection,Parameter/dose level ; ,?Hepatic resection, Prior therapy,38,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Hepatic resection, Prior therapy,38,1,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Hepatic resection, Prior therapy,38,2,3,no,1:no,1:no,,0.734
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Hepatic resection, Prior therapy,38,3,3,no,1:no,1:no,,0.751
3496,2965867,Table 1,BaselineCharacteristic,?Transcatheter arterial chemoembolization,Parameter/dose level ; ,?Transcatheter arterial chemoembolization, Prior therapy,39,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Transcatheter arterial chemoembolization, Prior therapy,39,1,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Transcatheter arterial chemoembolization, Prior therapy,39,2,3,no,1:no,1:no,,0.734
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Transcatheter arterial chemoembolization, Prior therapy,39,3,3,no,1:no,1:no,,0.751
3496,2965867,Table 1,BaselineCharacteristic,?Radiotherapy,Parameter/dose level ; ,?Radiotherapy, Prior therapy,40,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Radiotherapy, Prior therapy,40,1,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Radiotherapy, Prior therapy,40,2,3,no,1:no,1:no,,0.734
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Radiotherapy, Prior therapy,40,3,3,no,1:no,1:no,,0.751
3496,2965867,Table 1,BaselineCharacteristic,?Systemic therapy,Parameter/dose level ; ,?Systemic therapy, Prior therapy,41,0,24,no,1:no,1:no,,0.883
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Systemic therapy, Prior therapy,41,1,43,no,1:no,1:no,,0.719
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Systemic therapy, Prior therapy,41,2,43,no,1:no,1:no,,0.728
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Systemic therapy, Prior therapy,41,3,43,no,1:no,1:no,,0.753
3496,2965867,Table 1,BaselineCharacteristic,??Thalidomide alone,Parameter/dose level ; ,??Thalidomide alone, Prior therapy ?Systemic therapy,42,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Thalidomide alone, Prior therapy ?Systemic therapy,42,1,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),xxx?IU?m?x ; ,??Thalidomide alone, Prior therapy ?Systemic therapy,42,2,3,no,1:no,1:no,,0.8
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),Overall ; ,??Thalidomide alone, Prior therapy ?Systemic therapy,42,3,3,no,1:no,1:no,,0.821
3496,2965867,Table 1,BaselineCharacteristic,??Chemotherapy with/without thalidomide,Parameter/dose level ; ,??Chemotherapy with/without thalidomide, Prior therapy ?Systemic therapy,43,0,2,no,1:no,1:no,,0.914
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Chemotherapy with/without thalidomide, Prior therapy ?Systemic therapy,43,1,3,no,1:no,1:no,,0.734
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Chemotherapy with/without thalidomide, Prior therapy ?Systemic therapy,43,2,3,no,1:no,1:no,,0.743
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,??Chemotherapy with/without thalidomide, Prior therapy ?Systemic therapy,43,3,3,no,1:no,1:no,,0.774
3496,2965867,Table 1,BaselineCharacteristic,??Anti-angiogenic therapya,Parameter/dose level ; ,??Anti-angiogenic therapya, Prior therapy ?Systemic therapy,44,0,2,no,1:no,1:no,,0.91
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Anti-angiogenic therapya, Prior therapy ?Systemic therapy,44,1,3,no,1:no,1:no,,0.724
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Anti-angiogenic therapya, Prior therapy ?Systemic therapy,44,2,3,no,1:no,1:no,,0.734
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),Overall ; ,??Anti-angiogenic therapya, Prior therapy ?Systemic therapy,44,3,3,no,1:no,1:no,,0.77
3503,2967062,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
3503,2967062,Table 1,BaselineCharacteristic,Number (%),,Characteristic,None,0,1,1,no,1:no,1:no,,0.749
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,1,1,3,no,1:no,1:no,,0.684
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,0,2,no,1:no,1:no,,0.852
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,2,1,3,no,1:no,1:no,,0.689
3503,2967062,Table 1,BaselineCharacteristic,Performance status,Characteristic ; ,None,None,3,0,24,no,1:no,1:no,,0.84
3503,2967062,Table 1,BaselineCharacteristic,Performance status,Number (%) ; ,Performance status,None,3,1,43,no,1:no,1:no,,0.737
3503,2967062,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,4,0,2,no,1:no,1:no,,0.838
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?x, Performance status,4,1,3,no,1:no,2:yes,+,0.512
3503,2967062,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,5,0,2,no,1:no,1:no,,0.847
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?x, Performance status,5,1,3,no,1:no,2:yes,+,0.504
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,0,2,no,1:no,1:no,,0.876
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,6,1,3,no,1:no,1:no,,0.709
3503,2967062,Table 1,BaselineCharacteristic,Gender,Characteristic ; ,None,None,7,0,24,no,1:no,1:no,,0.765
3503,2967062,Table 1,BaselineCharacteristic,Gender,Number (%) ; ,Gender,None,7,1,43,no,1:no,1:no,,0.622
3503,2967062,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Gender,8,0,2,no,1:no,1:no,,0.754
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Male, Gender,8,1,3,yes,2:yes,2:yes,,0.685
3503,2967062,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Gender,9,0,2,no,1:no,1:no,,0.752
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Female, Gender,9,1,3,yes,2:yes,2:yes,,0.692
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,10,0,2,no,1:no,1:no,,0.898
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,10,1,3,no,1:no,1:no,,0.759
3503,2967062,Table 1,BaselineCharacteristic,Histology,Characteristic ; ,None,None,11,0,24,no,1:no,1:no,,0.888
3503,2967062,Table 1,BaselineCharacteristic,Histology,Number (%) ; ,Histology,None,11,1,43,no,1:no,1:no,,0.788
3503,2967062,Table 1,BaselineCharacteristic,?Clear cell,Characteristic ; ,?Clear cell, Histology,12,0,2,no,1:no,1:no,,0.901
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Clear cell, Histology,12,1,3,no,1:no,1:no,,0.647
3503,2967062,Table 1,BaselineCharacteristic,?Clear cell/sarcomatoid,Characteristic ; ,?Clear cell/sarcomatoid, Histology,13,0,2,no,1:no,1:no,,0.894
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Clear cell/sarcomatoid, Histology,13,1,3,no,1:no,1:no,,0.7
3503,2967062,Table 1,BaselineCharacteristic,?Clear cell/papillary,Characteristic ; ,?Clear cell/papillary, Histology,14,0,2,no,1:no,1:no,,0.89
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Clear cell/papillary, Histology,14,1,3,no,1:no,1:no,,0.687
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,15,0,2,no,1:no,1:no,,0.902
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,15,1,3,no,1:no,1:no,,0.767
3503,2967062,Table 1,BaselineCharacteristic,Grade,Characteristic ; ,None,None,16,0,24,no,1:no,1:no,,0.883
3503,2967062,Table 1,BaselineCharacteristic,Grade,Number (%) ; ,Grade,None,16,1,43,no,1:no,1:no,,0.791
3503,2967062,Table 1,BaselineCharacteristic,?Gx,Characteristic ; ,?Gx, Grade,17,0,2,no,1:no,1:no,,0.903
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Gx, Grade,17,1,3,no,1:no,1:no,,0.628
3503,2967062,Table 1,BaselineCharacteristic,?Gx,Characteristic ; ,?Gx, Grade,18,0,2,no,1:no,1:no,,0.906
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Gx, Grade,18,1,3,no,1:no,1:no,,0.646
3503,2967062,Table 1,BaselineCharacteristic,?Gx,Characteristic ; ,?Gx, Grade,19,0,2,no,1:no,1:no,,0.906
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Gx, Grade,19,1,3,no,1:no,1:no,,0.646
3503,2967062,Table 1,BaselineCharacteristic,?GX,Characteristic ; ,?GX, Grade,20,0,2,no,1:no,1:no,,0.907
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?GX, Grade,20,1,3,no,1:no,1:no,,0.744
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,21,0,2,no,1:no,1:no,,0.911
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,21,1,3,no,1:no,1:no,,0.81
3503,2967062,Table 1,BaselineCharacteristic,Disease status at study entry,Characteristic ; ,None,None,22,0,24,no,1:no,1:no,,0.885
3503,2967062,Table 1,BaselineCharacteristic,Disease status at study entry,Number (%) ; ,Disease status at study entry,None,22,1,43,no,1:no,1:no,,0.818
3503,2967062,Table 1,BaselineCharacteristic,?Progressive disease,Characteristic ; ,?Progressive disease, Disease status at study entry,23,0,2,no,1:no,1:no,,0.905
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Progressive disease, Disease status at study entry,23,1,3,no,1:no,1:no,,0.71
3503,2967062,Table 1,BaselineCharacteristic,?Stable disease,Characteristic ; ,?Stable disease, Disease status at study entry,24,0,2,no,1:no,1:no,,0.905
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Stable disease, Disease status at study entry,24,1,3,no,1:no,1:no,,0.792
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,25,0,2,no,1:no,1:no,,0.913
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,25,1,3,no,1:no,1:no,,0.822
3503,2967062,Table 1,BaselineCharacteristic,MSKCC risk group,Characteristic ; ,None,None,26,0,24,no,1:no,1:no,,0.882
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,MSKCC risk group,None,26,1,43,no,1:no,1:no,,0.802
3503,2967062,Table 1,BaselineCharacteristic,?High,Characteristic ; ,?High, MSKCC risk group,27,0,2,no,1:no,1:no,,0.893
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?High, MSKCC risk group,27,1,3,no,1:no,1:no,,0.786
3503,2967062,Table 1,BaselineCharacteristic,?Intermediate,Characteristic ; ,?Intermediate, MSKCC risk group,28,0,2,no,1:no,1:no,,0.893
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Intermediate, MSKCC risk group,28,1,3,no,1:no,1:no,,0.663
3503,2967062,Table 1,BaselineCharacteristic,?Low,Characteristic ; ,?Low, MSKCC risk group,29,0,2,no,1:no,1:no,,0.893
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Low, MSKCC risk group,29,1,3,no,1:no,1:no,,0.657
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,30,0,2,no,1:no,1:no,,0.913
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,30,1,3,no,1:no,1:no,,0.822
3503,2967062,Table 1,BaselineCharacteristic,Previous nephrectomy,Characteristic ; ,None,None,31,0,24,no,1:no,1:no,,0.906
3503,2967062,Table 1,BaselineCharacteristic,Previous nephrectomy,Number (%) ; ,Previous nephrectomy,None,31,1,43,no,1:no,1:no,,0.833
3503,2967062,Table 1,BaselineCharacteristic,?Yes,Characteristic ; ,?Yes, Previous nephrectomy,32,0,2,no,1:no,1:no,,0.917
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Yes, Previous nephrectomy,32,1,3,no,1:no,1:no,,0.709
3503,2967062,Table 1,BaselineCharacteristic,?No,Characteristic ; ,?No, Previous nephrectomy,33,0,2,no,1:no,1:no,,0.889
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?No, Previous nephrectomy,33,1,3,no,1:no,1:no,,0.69
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,34,0,2,no,1:no,1:no,,0.913
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,34,1,3,no,1:no,1:no,,0.823
3503,2967062,Table 1,BaselineCharacteristic,Previous systemic treatment,Characteristic ; ,None,None,35,0,24,no,1:no,1:no,,0.897
3503,2967062,Table 1,BaselineCharacteristic,Previous systemic treatment,Number (%) ; ,Previous systemic treatment,None,35,1,43,no,1:no,1:no,,0.82
3503,2967062,Table 1,BaselineCharacteristic,?Cytokine,Characteristic ; ,?Cytokine, Previous systemic treatment,36,0,2,no,1:no,1:no,,0.912
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Cytokine, Previous systemic treatment,36,1,3,no,1:no,1:no,,0.7
3503,2967062,Table 1,BaselineCharacteristic,?Nil,Characteristic ; ,?Nil, Previous systemic treatment,37,0,2,no,1:no,1:no,,0.912
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Nil, Previous systemic treatment,37,1,3,no,1:no,1:no,,0.706
3559,2990596,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
3559,2990596,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,no,1:no,1:no,,0.76
3559,2990596,Table 1,BaselineCharacteristic,Total, ; ,Total,,1,0,2,no,1:no,1:no,,0.721
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Total,,1,1,3,no,1:no,2:yes,+,0.603
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,2,0,2,no,1:no,1:no,,0.842
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,2,1,3,no,1:no,1:no,,0.736
3559,2990596,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,3,0,24,no,1:no,1:no,,0.836
3559,2990596,Table 1,BaselineCharacteristic,Age (years),No. of patients ; ,Age (years),None,3,1,43,no,1:no,1:no,,0.781
3559,2990596,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),4,0,2,no,1:no,1:no,,0.844
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Median, Age (years),4,1,3,no,1:no,1:no,,0.587
3559,2990596,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),5,0,2,no,1:no,1:no,,0.823
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,6,0,2,no,1:no,1:no,,0.866
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,6,1,3,no,1:no,1:no,,0.756
3559,2990596,Table 1,BaselineCharacteristic,Gender, ; ,None,None,7,0,24,no,1:no,1:no,,0.739
3559,2990596,Table 1,BaselineCharacteristic,Gender,No. of patients ; ,Gender,None,7,1,43,no,1:no,1:no,,0.681
3559,2990596,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Gender,8,0,2,no,1:no,1:no,,0.734
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Male, Gender,8,1,3,yes,2:yes,2:yes,,0.715
3559,2990596,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Gender,9,0,2,no,1:no,1:no,,0.723
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Female, Gender,9,1,3,yes,2:yes,2:yes,,0.633
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,2,no,1:no,1:no,,0.888
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,10,1,3,no,1:no,1:no,,0.825
3559,2990596,Table 1,BaselineCharacteristic,PS (ECOG), ; ,None,None,11,0,24,no,1:no,1:no,,0.89
3559,2990596,Table 1,BaselineCharacteristic,PS (ECOG),No. of patients ; ,PS (ECOG),None,11,1,43,no,1:no,1:no,,0.862
3559,2990596,Table 1,BaselineCharacteristic,?x, ; ,?x, PS (ECOG),12,0,2,no,1:no,1:no,,0.869
3559,2990596,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, PS (ECOG),12,1,3,no,1:no,1:no,,0.748
3559,2990596,Table 1,BaselineCharacteristic,?x, ; ,?x, PS (ECOG),13,0,2,no,1:no,1:no,,0.869
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, PS (ECOG),13,1,3,no,1:no,1:no,,0.711
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,14,0,2,no,1:no,1:no,,0.892
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,14,1,3,no,1:no,1:no,,0.849
3559,2990596,Table 1,BaselineCharacteristic,Pathology, ; ,None,None,15,0,24,no,1:no,1:no,,0.871
3559,2990596,Table 1,BaselineCharacteristic,Pathology,No. of patients ; ,Pathology,None,15,1,43,no,1:no,1:no,,0.859
3559,2990596,Table 1,BaselineCharacteristic,?Adenocarcinoma, ; ,?Adenocarcinoma, Pathology,16,0,2,no,1:no,1:no,,0.875
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Adenocarcinoma, Pathology,16,1,3,no,1:no,1:no,,0.655
3559,2990596,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ; ,?Squamous cell carcinoma, Pathology,17,0,2,no,1:no,1:no,,0.909
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Squamous cell carcinoma, Pathology,17,1,3,no,1:no,1:no,,0.747
3559,2990596,Table 1,BaselineCharacteristic,?Others, ; ,?Others, Pathology,18,0,2,no,1:no,1:no,,0.891
3559,2990596,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Others, Pathology,18,1,3,no,1:no,1:no,,0.753
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,19,0,2,no,1:no,1:no,,0.902
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,19,1,3,no,1:no,1:no,,0.862
3559,2990596,Table 1,BaselineCharacteristic,Clinical stage, ; ,None,None,20,0,24,no,1:no,1:no,,0.9
3559,2990596,Table 1,BaselineCharacteristic,Clinical stage,No. of patients ; ,Clinical stage,None,20,1,43,no,1:no,1:no,,0.891
3559,2990596,Table 1,BaselineCharacteristic,?IIIA, ; ,?IIIA, Clinical stage,21,0,2,no,1:no,1:no,,0.906
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?IIIA, Clinical stage,21,1,3,no,1:no,1:no,,0.731
3559,2990596,Table 1,BaselineCharacteristic,?IIIB, ; ,?IIIB, Clinical stage,22,0,2,no,1:no,1:no,,0.908
3559,2990596,Table 1,BaselineCharacteristic,x,No. of patients ; ,?IIIB, Clinical stage,22,1,3,no,1:no,1:no,,0.774
3566,2991028,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
3566,2991028,Table 1,BaselineCharacteristic,,,,None,0,1,1,no,1:no,1:no,,0.735
3566,2991028,Table 1,BaselineCharacteristic,AMG xxx,,,None,0,2,1,no,1:no,1:no,,0.74
3566,2991028,Table 1,BaselineCharacteristic,AMG xxx,,,None,0,3,1,no,1:no,1:no,,0.75
3566,2991028,Table 1,BaselineCharacteristic,AMG xxx,,,None,0,4,1,no,1:no,1:no,,0.756
3566,2991028,Table 1,BaselineCharacteristic,AMG xxx,,,None,0,5,1,no,1:no,1:no,,0.753
3566,2991028,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no,1:no,1:no,,0.792
3566,2991028,Table 1,BaselineCharacteristic,, ; ,,None,1,1,1,no,1:no,1:no,,0.716
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ; ,,None,1,2,1,no,1:no,1:no,,0.735
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ; ,,None,1,3,1,no,1:no,1:no,,0.745
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ; ,,None,1,4,1,no,1:no,1:no,,0.751
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ; ,,None,1,5,1,no,1:no,1:no,,0.748
3566,2991028,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,0,12,no,1:no,1:no,,0.805
3566,2991028,Table 1,BaselineCharacteristic,Placebo(n = xxx), ;  ; ,,None,2,1,1,no,1:no,1:no,,0.562
3566,2991028,Table 1,BaselineCharacteristic,xx mg(n = xxx),AMG xxx ;  ; ,,None,2,2,1,no,1:no,1:no,,0.595
3566,2991028,Table 1,BaselineCharacteristic,xxx mg(n = xxx),AMG xxx ;  ; ,,None,2,3,1,no,1:no,1:no,,0.687
3566,2991028,Table 1,BaselineCharacteristic,xxx mg(n = xxx),AMG xxx ;  ; ,,None,2,4,1,no,1:no,1:no,,0.696
3566,2991028,Table 1,BaselineCharacteristic,Total(n = xxx),AMG xxx ;  ; ,,None,2,5,1,no,1:no,1:no,,0.661
3566,2991028,Table 1,BaselineCharacteristic,Mean age (years), ;  ;  ; ,Mean age (years),,3,0,2,no,1:no,1:no,,0.817
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean age (years),,3,1,3,no,1:no,2:yes,+,0.619
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean age (years),,3,2,3,no,1:no,2:yes,+,0.552
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean age (years),,3,3,3,no,1:no,2:yes,+,0.532
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean age (years),,3,4,3,no,1:no,2:yes,+,0.516
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean age (years),,3,5,3,no,1:no,2:yes,+,0.534
3566,2991028,Table 1,BaselineCharacteristic,"Age group, n (%)", ;  ;  ; ,None,None,4,0,24,no,1:no,1:no,,0.753
3566,2991028,Table 1,BaselineCharacteristic,, ;  ; Placebo(n = xxx) ; ,"Age group, n (%)",None,4,1,43,no,1:no,2:yes,+,0.501
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xx mg(n = xxx) ; ,"Age group, n (%)",None,4,2,43,no,1:no,2:yes,+,0.51
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,"Age group, n (%)",None,4,3,43,no,1:no,1:no,,0.572
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,"Age group, n (%)",None,4,4,43,no,1:no,1:no,,0.587
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; Total(n = xxx) ; ,"Age group, n (%)",None,4,5,43,no,1:no,1:no,,0.595
3566,2991028,Table 1,BaselineCharacteristic,?< xx years, ;  ;  ; ,?< xx years," Age group, n (%)",5,0,2,no,1:no,1:no,,0.706
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x), ;  ; Placebo(n = xxx) ; ,?< xx years," Age group, n (%)",5,1,3,no,1:no,2:yes,+,0.611
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,?< xx years," Age group, n (%)",5,2,3,no,1:no,2:yes,+,0.563
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?< xx years," Age group, n (%)",5,3,3,no,1:no,2:yes,+,0.55
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?< xx years," Age group, n (%)",5,4,3,no,1:no,2:yes,+,0.543
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; Total(n = xxx) ; ,?< xx years," Age group, n (%)",5,5,3,no,1:no,2:yes,+,0.537
3566,2991028,Table 1,BaselineCharacteristic,??xx years, ;  ;  ; ,??xx years," Age group, n (%)",6,0,2,no,1:no,1:no,,0.706
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x), ;  ; Placebo(n = xxx) ; ,??xx years," Age group, n (%)",6,1,3,no,1:no,2:yes,+,0.605
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,??xx years," Age group, n (%)",6,2,3,no,1:no,2:yes,+,0.557
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,??xx years," Age group, n (%)",6,3,3,no,1:no,2:yes,+,0.543
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,??xx years," Age group, n (%)",6,4,3,no,1:no,2:yes,+,0.537
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x),AMG xxx ;  ; Total(n = xxx) ; ,??xx years," Age group, n (%)",6,5,3,no,1:no,2:yes,+,0.521
3566,2991028,Table 1,BaselineCharacteristic,"Female, n (%)", ;  ;  ; ,"Female, n (%)",,7,0,2,no,1:no,1:no,,0.628
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x), ;  ; Placebo(n = xxx) ; ,"Female, n (%)",,7,1,3,yes,2:yes,2:yes,,0.784
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,"Female, n (%)",,7,2,3,yes,2:yes,2:yes,,0.736
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,"Female, n (%)",,7,3,3,yes,2:yes,2:yes,,0.728
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,"Female, n (%)",,7,4,3,yes,2:yes,2:yes,,0.718
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; Total(n = xxx) ; ,"Female, n (%)",,7,5,3,yes,2:yes,2:yes,,0.714
3566,2991028,Table 1,BaselineCharacteristic,"Ethnicity, n (%)", ;  ;  ; ,None,None,8,0,24,no,1:no,1:no,,0.756
3566,2991028,Table 1,BaselineCharacteristic,, ;  ; Placebo(n = xxx) ; ,"Ethnicity, n (%)",None,8,1,43,no,1:no,2:yes,+,0.503
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xx mg(n = xxx) ; ,"Ethnicity, n (%)",None,8,2,43,no,1:no,2:yes,+,0.542
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,"Ethnicity, n (%)",None,8,3,43,no,1:no,1:no,,0.57
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,"Ethnicity, n (%)",None,8,4,43,no,1:no,1:no,,0.587
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; Total(n = xxx) ; ,"Ethnicity, n (%)",None,8,5,43,no,1:no,1:no,,0.611
3566,2991028,Table 1,BaselineCharacteristic,?White, ;  ;  ; ,?White," Ethnicity, n (%)",9,0,2,no,1:no,1:no,,0.729
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x), ;  ; Placebo(n = xxx) ; ,?White," Ethnicity, n (%)",9,1,3,no,1:no,2:yes,+,0.691
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,?White," Ethnicity, n (%)",9,2,3,no,1:no,2:yes,+,0.619
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?White," Ethnicity, n (%)",9,3,3,no,1:no,2:yes,+,0.61
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?White," Ethnicity, n (%)",9,4,3,no,1:no,2:yes,+,0.599
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; Total(n = xxx) ; ,?White," Ethnicity, n (%)",9,5,3,no,1:no,2:yes,+,0.556
3566,2991028,Table 1,BaselineCharacteristic,?Hispanic, ;  ;  ; ,?Hispanic," Ethnicity, n (%)",10,0,2,no,1:no,1:no,,0.739
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x), ;  ; Placebo(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,1,3,no,1:no,2:yes,+,0.686
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,2,3,no,1:no,2:yes,+,0.611
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,3,3,no,1:no,2:yes,+,0.602
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,4,3,no,1:no,2:yes,+,0.591
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; Total(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,5,3,no,1:no,2:yes,+,0.548
3566,2991028,Table 1,BaselineCharacteristic,?Othera, ;  ;  ; ,?Othera," Ethnicity, n (%)",11,0,2,no,1:no,1:no,,0.755
3566,2991028,Table 1,BaselineCharacteristic,x (x.x), ;  ; Placebo(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,1,3,no,1:no,2:yes,+,0.592
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; xx mg(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,2,3,no,1:no,2:yes,+,0.572
3566,2991028,Table 1,BaselineCharacteristic,x (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,3,3,no,1:no,2:yes,+,0.516
3566,2991028,Table 1,BaselineCharacteristic,x (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,4,3,no,1:no,2:yes,+,0.504
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; Total(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,5,3,no,1:no,2:yes,+,0.518
3566,2991028,Table 1,BaselineCharacteristic,Mean weight (kg), ;  ;  ; ,Mean weight (kg),,12,0,2,no,1:no,1:no,,0.885
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean weight (kg),,12,1,3,no,1:no,2:yes,+,0.521
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean weight (kg),,12,2,3,no,1:no,1:no,,0.602
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean weight (kg),,12,3,3,no,1:no,1:no,,0.62
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean weight (kg),,12,4,3,no,1:no,1:no,,0.627
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean weight (kg),,12,5,3,no,1:no,1:no,,0.602
3566,2991028,Table 1,BaselineCharacteristic,Mean height (cm), ;  ;  ; ,Mean height (cm),,13,0,2,no,1:no,1:no,,0.878
3566,2991028,Table 1,BaselineCharacteristic,xxx.x, ;  ; Placebo(n = xxx) ; ,Mean height (cm),,13,1,3,no,1:no,2:yes,+,0.505
3566,2991028,Table 1,BaselineCharacteristic,xxx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean height (cm),,13,2,3,no,1:no,1:no,,0.539
3566,2991028,Table 1,BaselineCharacteristic,xxx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean height (cm),,13,3,3,no,1:no,1:no,,0.612
3566,2991028,Table 1,BaselineCharacteristic,xxx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean height (cm),,13,4,3,no,1:no,1:no,,0.62
3566,2991028,Table 1,BaselineCharacteristic,xxx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean height (cm),,13,5,3,no,1:no,1:no,,0.6
3566,2991028,Table 1,BaselineCharacteristic,Mean body mass index (kg/mx), ;  ;  ; ,Mean body mass index (kg/mx),,14,0,2,no,1:no,1:no,,0.874
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean body mass index (kg/mx),,14,1,3,no,1:no,2:yes,+,0.591
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean body mass index (kg/mx),,14,2,3,no,1:no,1:no,,0.531
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean body mass index (kg/mx),,14,3,3,no,1:no,1:no,,0.548
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean body mass index (kg/mx),,14,4,3,no,1:no,1:no,,0.556
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean body mass index (kg/mx),,14,5,3,no,1:no,1:no,,0.546
3566,2991028,Table 1,BaselineCharacteristic,Mean duration of RA (years), ;  ;  ; ,Mean duration of RA (years),,15,0,2,no,1:no,1:no,,0.877
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,Mean duration of RA (years),,15,1,3,no,1:no,1:no,,0.559
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean duration of RA (years),,15,2,3,no,1:no,1:no,,0.602
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean duration of RA (years),,15,3,3,no,1:no,1:no,,0.652
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean duration of RA (years),,15,4,3,no,1:no,1:no,,0.659
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean duration of RA (years),,15,5,3,no,1:no,1:no,,0.642
3566,2991028,Table 1,BaselineCharacteristic,Subcomponent of ACR (mean), ;  ;  ; ,None,None,16,0,24,no,1:no,1:no,,0.898
3566,2991028,Table 1,BaselineCharacteristic,, ;  ; Placebo(n = xxx) ; ,Subcomponent of ACR (mean),None,16,1,43,no,1:no,1:no,,0.632
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xx mg(n = xxx) ; ,Subcomponent of ACR (mean),None,16,2,43,no,1:no,1:no,,0.652
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,Subcomponent of ACR (mean),None,16,3,43,no,1:no,1:no,,0.71
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,Subcomponent of ACR (mean),None,16,4,43,no,1:no,1:no,,0.715
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; Total(n = xxx) ; ,Subcomponent of ACR (mean),None,16,5,43,no,1:no,1:no,,0.727
3566,2991028,Table 1,BaselineCharacteristic,?Tender joint count, ;  ;  ; ,?Tender joint count, Subcomponent of ACR (mean),17,0,2,no,1:no,1:no,,0.886
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,1,3,no,1:no,1:no,,0.513
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,2,3,no,1:no,1:no,,0.616
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,3,3,no,1:no,1:no,,0.622
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,4,3,no,1:no,1:no,,0.631
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,5,3,no,1:no,1:no,,0.611
3566,2991028,Table 1,BaselineCharacteristic,?Swollen joint count, ;  ;  ; ,?Swollen joint count, Subcomponent of ACR (mean),18,0,2,no,1:no,1:no,,0.889
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,1,3,no,1:no,1:no,,0.521
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,2,3,no,1:no,1:no,,0.619
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,3,3,no,1:no,1:no,,0.625
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,4,3,no,1:no,1:no,,0.634
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,5,3,no,1:no,1:no,,0.619
3566,2991028,Table 1,BaselineCharacteristic,?Patient global assessment, ;  ;  ; ,?Patient global assessment, Subcomponent of ACR (mean),19,0,2,no,1:no,1:no,,0.884
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,1,3,no,1:no,1:no,,0.643
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,2,3,no,1:no,1:no,,0.66
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,3,3,no,1:no,1:no,,0.707
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,4,3,no,1:no,1:no,,0.716
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,5,3,no,1:no,1:no,,0.677
3566,2991028,Table 1,BaselineCharacteristic,?Physician global assessment, ;  ;  ; ,?Physician global assessment, Subcomponent of ACR (mean),20,0,2,no,1:no,1:no,,0.889
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,1,3,no,1:no,1:no,,0.602
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,2,3,no,1:no,1:no,,0.628
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,3,3,no,1:no,1:no,,0.673
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,4,3,no,1:no,1:no,,0.681
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,5,3,no,1:no,1:no,,0.663
3566,2991028,Table 1,BaselineCharacteristic,?Patient pain assessment, ;  ;  ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,0,2,no,1:no,1:no,,0.884
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,1,3,no,1:no,1:no,,0.584
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,2,3,no,1:no,1:no,,0.66
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,3,3,no,1:no,1:no,,0.662
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,4,3,no,1:no,1:no,,0.671
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,5,3,no,1:no,1:no,,0.632
3566,2991028,Table 1,BaselineCharacteristic,HAQ Disability Index, ;  ;  ; ,HAQ Disability Index,,22,0,2,no,1:no,1:no,,0.893
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,HAQ Disability Index,,22,1,3,no,1:no,1:no,,0.55
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,HAQ Disability Index,,22,2,3,no,1:no,1:no,,0.578
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,HAQ Disability Index,,22,3,3,no,1:no,1:no,,0.661
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,HAQ Disability Index,,22,4,3,no,1:no,1:no,,0.669
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,HAQ Disability Index,,22,5,3,no,1:no,1:no,,0.64
3566,2991028,Table 1,BaselineCharacteristic,C-reactive protein (mg/dl), ;  ;  ; ,C-reactive protein (mg/dl),,23,0,2,no,1:no,1:no,,0.894
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,C-reactive protein (mg/dl),,23,1,3,no,1:no,1:no,,0.554
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,C-reactive protein (mg/dl),,23,2,3,no,1:no,1:no,,0.581
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,C-reactive protein (mg/dl),,23,3,3,no,1:no,1:no,,0.664
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,C-reactive protein (mg/dl),,23,4,3,no,1:no,1:no,,0.672
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,C-reactive protein (mg/dl),,23,5,3,no,1:no,1:no,,0.643
3566,2991028,Table 1,BaselineCharacteristic,ESR (mm/hour), ;  ;  ; ,ESR (mm/hour),,24,0,2,no,1:no,1:no,,0.894
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,ESR (mm/hour),,24,1,3,no,1:no,2:yes,+,0.536
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,ESR (mm/hour),,24,2,3,no,1:no,1:no,,0.589
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,ESR (mm/hour),,24,3,3,no,1:no,1:no,,0.598
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,ESR (mm/hour),,24,4,3,no,1:no,1:no,,0.606
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,ESR (mm/hour),,24,5,3,no,1:no,1:no,,0.598
3566,2991028,Table 1,BaselineCharacteristic,Mean DASxx CRP, ;  ;  ; ,Mean DASxx CRP,,25,0,2,no,1:no,1:no,,0.893
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,Mean DASxx CRP,,25,1,3,no,1:no,1:no,,0.59
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean DASxx CRP,,25,2,3,no,1:no,1:no,,0.601
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean DASxx CRP,,25,3,3,no,1:no,1:no,,0.679
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean DASxx CRP,,25,4,3,no,1:no,1:no,,0.687
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean DASxx CRP,,25,5,3,no,1:no,1:no,,0.665
3566,2991028,Table 1,BaselineCharacteristic,Mean DASxx ESR, ;  ;  ; ,Mean DASxx ESR,,26,0,2,no,1:no,1:no,,0.893
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,Mean DASxx ESR,,26,1,3,no,1:no,1:no,,0.59
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean DASxx ESR,,26,2,3,no,1:no,1:no,,0.601
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean DASxx ESR,,26,3,3,no,1:no,1:no,,0.679
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean DASxx ESR,,26,4,3,no,1:no,1:no,,0.687
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean DASxx ESR,,26,5,3,no,1:no,1:no,,0.665
3566,2991028,Table 1,BaselineCharacteristic,Mean tender joint count (xx joints), ;  ;  ; ,Mean tender joint count (xx joints),,27,0,2,no,1:no,1:no,,0.836
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean tender joint count (xx joints),,27,1,3,no,1:no,2:yes,+,0.502
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean tender joint count (xx joints),,27,2,3,no,1:no,1:no,,0.601
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean tender joint count (xx joints),,27,3,3,no,1:no,1:no,,0.61
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean tender joint count (xx joints),,27,4,3,no,1:no,1:no,,0.618
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean tender joint count (xx joints),,27,5,3,no,1:no,1:no,,0.611
3566,2991028,Table 1,BaselineCharacteristic,Mean swollen joint count (xx joints), ;  ;  ; ,Mean swollen joint count (xx joints),,28,0,2,no,1:no,1:no,,0.837
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean swollen joint count (xx joints),,28,1,3,no,1:no,2:yes,+,0.502
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean swollen joint count (xx joints),,28,2,3,no,1:no,1:no,,0.601
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean swollen joint count (xx joints),,28,3,3,no,1:no,1:no,,0.61
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean swollen joint count (xx joints),,28,4,3,no,1:no,1:no,,0.618
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean swollen joint count (xx joints),,28,5,3,no,1:no,1:no,,0.611
3596,3001966,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
3596,3001966,Table 1,BaselineCharacteristic,Celecoxib group (n = xxx),,Characteristic,None,0,1,1,no,1:no,1:no,,0.693
3596,3001966,Table 1,BaselineCharacteristic,Placebo group (n = xxx),,Characteristic,None,0,2,1,no,1:no,1:no,,0.556
3596,3001966,Table 1,BaselineCharacteristic,P*,,Characteristic,None,0,3,1,no,1:no,1:no,,0.8
3596,3001966,Table 1,BaselineCharacteristic,"Age, y",Characteristic ; ,None,None,1,0,24,no,1:no,1:no,,0.862
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Age, y",None,1,1,43,no,1:no,1:no,,0.639
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Age, y",None,1,2,43,no,1:no,1:no,,0.537
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Age, y",None,1,3,43,no,1:no,1:no,,0.854
3596,3001966,Table 1,BaselineCharacteristic,????Mean (SD),Characteristic ; ,????Mean (SD)," Age, y   ",2,0,2,no,1:no,1:no,,0.836
3596,3001966,Table 1,BaselineCharacteristic,xx.x (x.x),Celecoxib group (n = xxx) ; ,????Mean (SD)," Age, y   ",2,1,3,no,1:no,1:no,,0.534
3596,3001966,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo group (n = xxx) ; ,????Mean (SD)," Age, y   ",2,2,3,no,1:no,2:yes,+,0.531
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Mean (SD)," Age, y   ",2,3,3,no,1:no,1:no,,0.677
3596,3001966,Table 1,BaselineCharacteristic,????Median (range),Characteristic ; ,????Median (range)," Age, y   ",3,0,2,no,1:no,1:no,,0.86
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Median (range)," Age, y   ",3,3,3,no,1:no,1:no,,0.772
3596,3001966,Table 1,BaselineCharacteristic,"Sex, No. (%)",Characteristic ; ,None,None,4,0,24,no,1:no,1:no,,0.647
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Sex, No. (%)",None,4,1,43,no,1:no,2:yes,+,0.57
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Sex, No. (%)",None,4,2,43,no,1:no,2:yes,+,0.625
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Sex, No. (%)",None,4,3,43,no,1:no,1:no,,0.549
3596,3001966,Table 1,BaselineCharacteristic,????Male,Characteristic ; ,????Male," Sex, No. (%)   ",5,0,2,no,1:no,2:yes,+,0.509
3596,3001966,Table 1,BaselineCharacteristic,xxx (xx),Celecoxib group (n = xxx) ; ,????Male," Sex, No. (%)   ",5,1,3,yes,2:yes,2:yes,,0.823
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????Male," Sex, No. (%)   ",5,2,3,yes,2:yes,2:yes,,0.852
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Male," Sex, No. (%)   ",5,3,3,no,1:no,2:yes,+,0.839
3596,3001966,Table 1,BaselineCharacteristic,????Female,Characteristic ; ,????Female," Sex, No. (%)   ",6,0,2,no,1:no,1:no,,0.505
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????Female," Sex, No. (%)   ",6,1,3,yes,2:yes,2:yes,,0.81
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????Female," Sex, No. (%)   ",6,2,3,yes,2:yes,2:yes,,0.834
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Female," Sex, No. (%)   ",6,3,3,no,1:no,2:yes,+,0.714
3596,3001966,Table 1,BaselineCharacteristic,"Race, No. (%)",Characteristic ; ,None,None,7,0,24,no,1:no,1:no,,0.806
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Race, No. (%)",None,7,1,43,no,1:no,1:no,,0.567
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Race, No. (%)",None,7,2,43,no,1:no,2:yes,+,0.51
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Race, No. (%)",None,7,3,43,no,1:no,1:no,,0.724
3596,3001966,Table 1,BaselineCharacteristic,????White,Characteristic ; ,????White," Race, No. (%)   ",8,0,2,no,1:no,1:no,,0.784
3596,3001966,Table 1,BaselineCharacteristic,xxx (xx),Celecoxib group (n = xxx) ; ,????White," Race, No. (%)   ",8,1,3,no,1:no,2:yes,+,0.612
3596,3001966,Table 1,BaselineCharacteristic,xxx (xxx),Placebo group (n = xxx) ; ,????White," Race, No. (%)   ",8,2,3,no,1:no,2:yes,+,0.597
3596,3001966,Table 1,BaselineCharacteristic,x.xx,P* ; ,????White," Race, No. (%)   ",8,3,3,no,1:no,2:yes,+,0.522
3596,3001966,Table 1,BaselineCharacteristic,????Other,Characteristic ; ,????Other," Race, No. (%)   ",9,0,2,no,1:no,1:no,,0.786
3596,3001966,Table 1,BaselineCharacteristic,x ( x),Celecoxib group (n = xxx) ; ,????Other," Race, No. (%)   ",9,1,3,no,1:no,2:yes,+,0.521
3596,3001966,Table 1,BaselineCharacteristic,x (x),Placebo group (n = xxx) ; ,????Other," Race, No. (%)   ",9,2,3,no,1:no,2:yes,+,0.586
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Other," Race, No. (%)   ",9,3,3,no,1:no,1:no,,0.643
3596,3001966,Table 1,BaselineCharacteristic,"Fitzpatrick skin type, No. (%)",Characteristic ; ,None,None,10,0,24,no,1:no,1:no,,0.741
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Fitzpatrick skin type, No. (%)",None,10,1,43,no,1:no,2:yes,+,0.509
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Fitzpatrick skin type, No. (%)",None,10,2,43,no,1:no,2:yes,+,0.571
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Fitzpatrick skin type, No. (%)",None,10,3,43,no,1:no,1:no,,0.639
3596,3001966,Table 1,BaselineCharacteristic,????I,Characteristic ; ,????I," Fitzpatrick skin type, No. (%)   ",11,0,2,no,1:no,1:no,,0.725
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????I," Fitzpatrick skin type, No. (%)   ",11,1,3,no,1:no,2:yes,+,0.59
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????I," Fitzpatrick skin type, No. (%)   ",11,2,3,no,1:no,2:yes,+,0.643
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????I," Fitzpatrick skin type, No. (%)   ",11,3,3,no,1:no,2:yes,+,0.512
3596,3001966,Table 1,BaselineCharacteristic,????II,Characteristic ; ,????II," Fitzpatrick skin type, No. (%)   ",12,0,2,no,1:no,1:no,,0.728
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????II," Fitzpatrick skin type, No. (%)   ",12,1,3,no,1:no,2:yes,+,0.6
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????II," Fitzpatrick skin type, No. (%)   ",12,2,3,no,1:no,2:yes,+,0.657
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????II," Fitzpatrick skin type, No. (%)   ",12,3,3,no,1:no,1:no,,0.594
3596,3001966,Table 1,BaselineCharacteristic,????III,Characteristic ; ,????III," Fitzpatrick skin type, No. (%)   ",13,0,2,no,1:no,1:no,,0.723
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????III," Fitzpatrick skin type, No. (%)   ",13,1,3,no,1:no,2:yes,+,0.61
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????III," Fitzpatrick skin type, No. (%)   ",13,2,3,no,1:no,2:yes,+,0.668
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????III," Fitzpatrick skin type, No. (%)   ",13,3,3,no,1:no,1:no,,0.584
3596,3001966,Table 1,BaselineCharacteristic,Number of actinic keratoses at screening,Characteristic ; ,None,None,14,0,24,no,1:no,1:no,,0.891
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,Number of actinic keratoses at screening,None,14,1,43,no,1:no,1:no,,0.705
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,Number of actinic keratoses at screening,None,14,2,43,no,1:no,1:no,,0.602
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,Number of actinic keratoses at screening,None,14,3,43,no,1:no,1:no,,0.86
3596,3001966,Table 1,BaselineCharacteristic,????Mean (SD),Characteristic ; ,????Mean (SD), Number of actinic keratoses at screening   ,15,0,2,no,1:no,1:no,,0.865
3596,3001966,Table 1,BaselineCharacteristic,xx.x (x.x),Celecoxib group (n = xxx) ; ,????Mean (SD), Number of actinic keratoses at screening   ,15,1,3,no,1:no,1:no,,0.676
3596,3001966,Table 1,BaselineCharacteristic,xx.x (x.x),Placebo group (n = xxx) ; ,????Mean (SD), Number of actinic keratoses at screening   ,15,2,3,no,1:no,1:no,,0.555
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Mean (SD), Number of actinic keratoses at screening   ,15,3,3,no,1:no,1:no,,0.753
3596,3001966,Table 1,BaselineCharacteristic,????Median (range),Characteristic ; ,????Median (range), Number of actinic keratoses at screening   ,16,0,2,no,1:no,1:no,,0.901
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Median (range), Number of actinic keratoses at screening   ,16,3,3,no,1:no,1:no,,0.879
3596,3001966,Table 1,BaselineCharacteristic,"History of skin cancer, No. (%)",Characteristic ; ,None,None,17,0,24,no,1:no,1:no,,0.887
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"History of skin cancer, No. (%)",None,17,1,43,no,1:no,1:no,,0.704
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"History of skin cancer, No. (%)",None,17,2,43,no,1:no,1:no,,0.627
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"History of skin cancer, No. (%)",None,17,3,43,no,1:no,1:no,,0.833
3596,3001966,Table 1,BaselineCharacteristic,????Yes,Characteristic ; ,????Yes," History of skin cancer, No. (%)   ",18,0,2,no,1:no,1:no,,0.876
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????Yes," History of skin cancer, No. (%)   ",18,1,3,no,1:no,1:no,,0.57
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????Yes," History of skin cancer, No. (%)   ",18,2,3,no,1:no,1:no,,0.506
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Yes," History of skin cancer, No. (%)   ",18,3,3,no,1:no,1:no,,0.694
3596,3001966,Table 1,BaselineCharacteristic,????No,Characteristic ; ,????No," History of skin cancer, No. (%)   ",19,0,2,no,1:no,1:no,,0.869
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????No," History of skin cancer, No. (%)   ",19,1,3,no,1:no,1:no,,0.571
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????No," History of skin cancer, No. (%)   ",19,2,3,no,1:no,1:no,,0.506
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????No," History of skin cancer, No. (%)   ",19,3,3,no,1:no,1:no,,0.769
3596,3001966,Table 1,BaselineCharacteristic,"Total number of skin cancer diagnoses per patient before screening, No. (%)",Characteristic ; ,None,None,20,0,24,no,1:no,1:no,,0.799
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,1,20,43,no,1:no,1:no,,0.585
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,2,20,43,no,1:no,1:no,,0.521
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,3,20,43,no,1:no,1:no,,0.639
3596,3001966,Table 1,BaselineCharacteristic,????x,Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",21,0,2,no,1:no,1:no,,0.755
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",21,1,3,no,1:no,1:no,,0.554
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",21,2,3,no,1:no,2:yes,+,0.516
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",21,3,3,no,1:no,1:no,,0.574
3596,3001966,Table 1,BaselineCharacteristic,????x,Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,0,2,no,1:no,1:no,,0.756
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,1,3,no,1:no,1:no,,0.556
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,2,3,no,1:no,2:yes,+,0.513
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,3,3,no,1:no,1:no,,0.615
3596,3001966,Table 1,BaselineCharacteristic,????x,Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,0,2,no,1:no,1:no,,0.758
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,1,3,no,1:no,1:no,,0.56
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,2,3,no,1:no,2:yes,+,0.509
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,3,3,no,1:no,1:no,,0.619
3596,3001966,Table 1,BaselineCharacteristic,????>x,Characteristic ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,0,2,no,1:no,1:no,,0.796
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,1,3,no,1:no,1:no,,0.589
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,2,3,no,1:no,1:no,,0.506
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,3,3,no,1:no,1:no,,0.667
3596,3001966,Table 1,BaselineCharacteristic,????Mean (SD),Characteristic ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,0,2,no,1:no,1:no,,0.804
3596,3001966,Table 1,BaselineCharacteristic,x.x (x.x),Celecoxib group (n = xxx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,1,3,no,1:no,1:no,,0.633
3596,3001966,Table 1,BaselineCharacteristic,x.x (x.x),Placebo group (n = xxx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,2,3,no,1:no,1:no,,0.547
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,3,3,no,1:no,1:no,,0.639
3596,3001966,Table 1,BaselineCharacteristic,????Median (range),Characteristic ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,0,2,no,1:no,1:no,,0.839
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,3,3,no,1:no,1:no,,0.728
3596,3001966,Table 4,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
3596,3001966,Table 4,BaselineCharacteristic,Celecoxib group,,,None,0,1,1,no,1:no,1:no,,0.735
3596,3001966,Table 4,BaselineCharacteristic,Celecoxib group,,,None,0,2,1,no,1:no,1:no,,0.759
3596,3001966,Table 4,BaselineCharacteristic,Celecoxib group,,,None,0,3,1,no,1:no,1:no,,0.785
3596,3001966,Table 4,BaselineCharacteristic,Placebo group,,,None,0,4,1,no,1:no,1:no,,0.676
3596,3001966,Table 4,BaselineCharacteristic,Placebo group,,,None,0,5,1,no,1:no,1:no,,0.671
3596,3001966,Table 4,BaselineCharacteristic,Placebo group,,,None,0,6,1,no,1:no,1:no,,0.672
3596,3001966,Table 4,BaselineCharacteristic,Characteristic, ; ,None,None,1,0,12,no,1:no,1:no,,0.805
3596,3001966,Table 4,BaselineCharacteristic,Withdrew (n = xx),Celecoxib group ; ,Characteristic,None,1,1,1,no,1:no,1:no,,0.63
3596,3001966,Table 4,BaselineCharacteristic,Completed (n = xx),Celecoxib group ; ,Characteristic,None,1,2,1,no,1:no,1:no,,0.634
3596,3001966,Table 4,BaselineCharacteristic,P,Celecoxib group ; ,Characteristic,None,1,3,1,no,1:no,1:no,,0.809
3596,3001966,Table 4,BaselineCharacteristic,Withdrew (n = xx),Placebo group ; ,Characteristic,None,1,4,1,no,1:no,2:yes,+,0.514
3596,3001966,Table 4,BaselineCharacteristic,Completed (n = xx),Placebo group ; ,Characteristic,None,1,5,1,no,1:no,2:yes,+,0.51
3596,3001966,Table 4,BaselineCharacteristic,P,Placebo group ; ,Characteristic,None,1,6,1,no,1:no,1:no,,0.704
3596,3001966,Table 4,BaselineCharacteristic,"Age, y", ; Characteristic ; ,None,None,2,0,24,no,1:no,1:no,,0.869
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Age, y",None,2,1,43,no,1:no,1:no,,0.622
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Age, y",None,2,2,43,no,1:no,1:no,,0.631
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Age, y",None,2,3,43,no,1:no,1:no,,0.84
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"Age, y",None,2,4,43,no,1:no,1:no,,0.522
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"Age, y",None,2,5,43,no,1:no,1:no,,0.526
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"Age, y",None,2,6,43,no,1:no,1:no,,0.748
3596,3001966,Table 4,BaselineCharacteristic,????Mean (SD), ; Characteristic ; ,????Mean (SD)," Age, y   ",3,0,2,no,1:no,1:no,,0.826
3596,3001966,Table 4,BaselineCharacteristic,xx.x (xx.x),Celecoxib group ; Withdrew (n = xx) ; ,????Mean (SD)," Age, y   ",3,1,3,no,1:no,1:no,,0.569
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Celecoxib group ; Completed (n = xx) ; ,????Mean (SD)," Age, y   ",3,2,3,no,1:no,1:no,,0.598
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Mean (SD)," Age, y   ",3,3,3,no,1:no,1:no,,0.714
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Placebo group ; Withdrew (n = xx) ; ,????Mean (SD)," Age, y   ",3,4,3,no,1:no,2:yes,+,0.5
3596,3001966,Table 4,BaselineCharacteristic,xx.x (xx.x),Placebo group ; Completed (n = xx) ; ,????Mean (SD)," Age, y   ",3,5,3,no,1:no,1:no,,0.503
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????Mean (SD)," Age, y   ",3,6,3,no,1:no,1:no,,0.636
3596,3001966,Table 4,BaselineCharacteristic,????Median (range), ; Characteristic ; ,????Median (range)," Age, y   ",4,0,2,no,1:no,1:no,,0.862
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Median (range)," Age, y   ",4,3,3,no,1:no,1:no,,0.81
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Median (range)," Age, y   ",4,6,3,no,1:no,1:no,,0.748
3596,3001966,Table 4,BaselineCharacteristic,"Sex, No. (%)", ; Characteristic ; ,None,None,5,0,24,no,1:no,1:no,,0.657
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Sex, No. (%)",None,5,1,43,no,1:no,2:yes,+,0.648
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Sex, No. (%)",None,5,2,43,no,1:no,2:yes,+,0.643
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Sex, No. (%)",None,5,3,43,no,1:no,1:no,,0.573
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"Sex, No. (%)",None,5,4,43,no,1:no,2:yes,+,0.704
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"Sex, No. (%)",None,5,5,43,no,1:no,2:yes,+,0.7
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"Sex, No. (%)",None,5,6,43,no,1:no,1:no,,0.51
3596,3001966,Table 4,BaselineCharacteristic,????Male, ; Characteristic ; ,????Male," Sex, No. (%)   ",6,0,2,no,1:no,2:yes,+,0.509
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????Male," Sex, No. (%)   ",6,1,3,yes,2:yes,2:yes,,0.809
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????Male," Sex, No. (%)   ",6,2,3,yes,2:yes,2:yes,,0.805
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Male," Sex, No. (%)   ",6,3,3,no,1:no,2:yes,+,0.753
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Withdrew (n = xx) ; ,????Male," Sex, No. (%)   ",6,4,3,yes,2:yes,2:yes,,0.829
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????Male," Sex, No. (%)   ",6,5,3,yes,2:yes,2:yes,,0.819
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????Male," Sex, No. (%)   ",6,6,3,no,1:no,2:yes,+,0.771
3596,3001966,Table 4,BaselineCharacteristic,????Female, ; Characteristic ; ,????Female," Sex, No. (%)   ",7,0,2,yes,2:yes,1:no,+,0.505
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????Female," Sex, No. (%)   ",7,1,3,yes,2:yes,2:yes,,0.797
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????Female," Sex, No. (%)   ",7,2,3,no,1:no,2:yes,+,0.797
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Female," Sex, No. (%)   ",7,3,3,yes,2:yes,2:yes,,0.675
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????Female," Sex, No. (%)   ",7,4,3,yes,2:yes,2:yes,,0.83
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????Female," Sex, No. (%)   ",7,5,3,no,1:no,2:yes,+,0.819
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Female," Sex, No. (%)   ",7,6,3,no,1:no,2:yes,+,0.714
3596,3001966,Table 4,BaselineCharacteristic,"Race, No. (%)", ; Characteristic ; ,None,None,8,0,24,no,1:no,1:no,,0.811
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Race, No. (%)",None,8,1,43,no,1:no,2:yes,+,0.536
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Race, No. (%)",None,8,2,43,no,1:no,2:yes,+,0.528
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Race, No. (%)",None,8,3,43,no,1:no,1:no,,0.706
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"Race, No. (%)",None,8,4,43,no,1:no,2:yes,+,0.623
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"Race, No. (%)",None,8,5,43,no,1:no,2:yes,+,0.619
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"Race, No. (%)",None,8,6,43,no,1:no,1:no,,0.622
3596,3001966,Table 4,BaselineCharacteristic,????White, ; Characteristic ; ,????White," Race, No. (%)   ",9,0,2,no,1:no,1:no,,0.786
3596,3001966,Table 4,BaselineCharacteristic,xx (xxx),Celecoxib group ; Withdrew (n = xx) ; ,????White," Race, No. (%)   ",9,1,3,no,1:no,2:yes,+,0.6
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????White," Race, No. (%)   ",9,2,3,no,1:no,2:yes,+,0.575
3596,3001966,Table 4,BaselineCharacteristic,x.xx,Celecoxib group ; P ; ,????White," Race, No. (%)   ",9,3,3,no,1:no,1:no,,0.509
3596,3001966,Table 4,BaselineCharacteristic,xx (xxx),Placebo group ; Withdrew (n = xx) ; ,????White," Race, No. (%)   ",9,4,3,no,1:no,2:yes,+,0.653
3596,3001966,Table 4,BaselineCharacteristic,xx (xxx),Placebo group ; Completed (n = xx) ; ,????White," Race, No. (%)   ",9,5,3,no,1:no,2:yes,+,0.647
3596,3001966,Table 4,BaselineCharacteristic,????Other, ; Characteristic ; ,????Other," Race, No. (%)   ",10,0,2,no,1:no,1:no,,0.799
3596,3001966,Table 4,BaselineCharacteristic,x,Celecoxib group ; Withdrew (n = xx) ; ,????Other," Race, No. (%)   ",10,1,3,no,1:no,2:yes,+,0.566
3596,3001966,Table 4,BaselineCharacteristic,x (x),Celecoxib group ; Completed (n = xx) ; ,????Other," Race, No. (%)   ",10,2,3,no,1:no,2:yes,+,0.55
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Other," Race, No. (%)   ",10,3,3,no,1:no,1:no,,0.648
3596,3001966,Table 4,BaselineCharacteristic,x,Placebo group ; Withdrew (n = xx) ; ,????Other," Race, No. (%)   ",10,4,3,no,1:no,2:yes,+,0.64
3596,3001966,Table 4,BaselineCharacteristic,x,Placebo group ; Completed (n = xx) ; ,????Other," Race, No. (%)   ",10,5,3,no,1:no,2:yes,+,0.633
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Other," Race, No. (%)   ",10,6,3,no,1:no,1:no,,0.587
3596,3001966,Table 4,BaselineCharacteristic,"Fitzpatrick skin type, No. (%)", ; Characteristic ; ,"Fitzpatrick skin type, No. (%)",,11,0,24,no,1:no,1:no,,0.695
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Fitzpatrick skin type, No. (%)",,11,1,43,no,1:no,2:yes,+,0.605
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Fitzpatrick skin type, No. (%)",,11,2,43,no,1:no,2:yes,+,0.592
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Fitzpatrick skin type, No. (%)",,11,3,43,no,1:no,1:no,,0.575
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,"Fitzpatrick skin type, No. (%)",,11,4,43,no,1:no,2:yes,+,0.655
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,"Fitzpatrick skin type, No. (%)",,11,5,43,no,1:no,2:yes,+,0.64
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,"Fitzpatrick skin type, No. (%)",,11,6,43,no,1:no,2:yes,+,0.546
3596,3001966,Table 4,BaselineCharacteristic,????I, ; Characteristic ; ,????I," Fitzpatrick skin type, No. (%)   ",12,0,2,no,1:no,1:no,,0.731
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????I," Fitzpatrick skin type, No. (%)   ",12,1,3,no,1:no,2:yes,+,0.579
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????I," Fitzpatrick skin type, No. (%)   ",12,2,3,no,1:no,2:yes,+,0.568
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????I," Fitzpatrick skin type, No. (%)   ",12,3,3,no,1:no,2:yes,+,0.507
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Withdrew (n = xx) ; ,????I," Fitzpatrick skin type, No. (%)   ",12,4,3,no,1:no,2:yes,+,0.628
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????I," Fitzpatrick skin type, No. (%)   ",12,5,3,no,1:no,2:yes,+,0.619
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????I," Fitzpatrick skin type, No. (%)   ",12,6,3,no,1:no,1:no,,0.548
3596,3001966,Table 4,BaselineCharacteristic,????II, ; Characteristic ; ,????II," Fitzpatrick skin type, No. (%)   ",13,0,2,no,1:no,1:no,,0.724
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????II," Fitzpatrick skin type, No. (%)   ",13,1,3,no,1:no,2:yes,+,0.596
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????II," Fitzpatrick skin type, No. (%)   ",13,2,3,no,1:no,2:yes,+,0.583
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????II," Fitzpatrick skin type, No. (%)   ",13,3,3,no,1:no,1:no,,0.587
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????II," Fitzpatrick skin type, No. (%)   ",13,4,3,no,1:no,2:yes,+,0.662
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????II," Fitzpatrick skin type, No. (%)   ",13,5,3,no,1:no,2:yes,+,0.64
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????II," Fitzpatrick skin type, No. (%)   ",13,6,3,no,1:no,1:no,,0.541
3596,3001966,Table 4,BaselineCharacteristic,????III, ; Characteristic ; ,????III," Fitzpatrick skin type, No. (%)   ",14,0,2,no,1:no,1:no,,0.729
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????III," Fitzpatrick skin type, No. (%)   ",14,1,3,no,1:no,2:yes,+,0.598
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????III," Fitzpatrick skin type, No. (%)   ",14,2,3,no,1:no,2:yes,+,0.592
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????III," Fitzpatrick skin type, No. (%)   ",14,3,3,no,1:no,1:no,,0.584
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,????III," Fitzpatrick skin type, No. (%)   ",14,4,3,no,1:no,2:yes,+,0.657
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,????III," Fitzpatrick skin type, No. (%)   ",14,5,3,no,1:no,2:yes,+,0.647
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????III," Fitzpatrick skin type, No. (%)   ",14,6,3,no,1:no,1:no,,0.54
3596,3001966,Table 4,BaselineCharacteristic,No. of actinic keratoses at screening, ; Characteristic ; ,None,None,15,0,24,no,1:no,1:no,,0.891
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,No. of actinic keratoses at screening,None,1,15,43,no,1:no,1:no,,0.643
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,No. of actinic keratoses at screening,None,2,15,43,no,1:no,1:no,,0.655
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,No. of actinic keratoses at screening,None,3,15,43,no,1:no,1:no,,0.807
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,No. of actinic keratoses at screening,None,4,15,43,no,1:no,1:no,,0.51
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,No. of actinic keratoses at screening,None,5,15,43,no,1:no,1:no,,0.521
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,No. of actinic keratoses at screening,None,6,15,43,no,1:no,1:no,,0.741
3596,3001966,Table 4,BaselineCharacteristic,????Mean (SD), ; Characteristic ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,0,2,no,1:no,1:no,,0.869
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Celecoxib group ; Withdrew (n = xx) ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,1,3,no,1:no,1:no,,0.656
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Celecoxib group ; Completed (n = xx) ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,2,3,no,1:no,1:no,,0.663
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,3,3,no,1:no,1:no,,0.732
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Placebo group ; Withdrew (n = xx) ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,4,3,no,1:no,1:no,,0.55
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Placebo group ; Completed (n = xx) ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,5,3,no,1:no,1:no,,0.554
3596,3001966,Table 4,BaselineCharacteristic,x.xx,Placebo group ; P ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,6,3,no,1:no,1:no,,0.674
3596,3001966,Table 4,BaselineCharacteristic,????Median (range), ; Characteristic ; ,????Median (range), No. of actinic keratoses at screening   ,17,0,2,no,1:no,1:no,,0.892
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Median (range), No. of actinic keratoses at screening   ,17,3,3,no,1:no,1:no,,0.84
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Median (range), No. of actinic keratoses at screening   ,17,6,3,no,1:no,1:no,,0.751
3596,3001966,Table 4,BaselineCharacteristic,"History of skin cancer, No. (%)", ; Characteristic ; ,None,None,18,0,24,no,1:no,1:no,,0.89
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"History of skin cancer, No. (%)",None,18,1,43,no,1:no,1:no,,0.625
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"History of skin cancer, No. (%)",None,18,2,43,no,1:no,1:no,,0.636
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"History of skin cancer, No. (%)",None,18,3,43,no,1:no,1:no,,0.809
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"History of skin cancer, No. (%)",None,18,4,43,no,1:no,1:no,,0.555
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"History of skin cancer, No. (%)",None,18,5,43,no,1:no,1:no,,0.559
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"History of skin cancer, No. (%)",None,18,6,43,no,1:no,1:no,,0.725
3596,3001966,Table 4,BaselineCharacteristic,????Yes, ; Characteristic ; ,????Yes," History of skin cancer, No. (%)   ",19,0,2,no,1:no,1:no,,0.876
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????Yes," History of skin cancer, No. (%)   ",19,1,3,no,1:no,1:no,,0.58
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????Yes," History of skin cancer, No. (%)   ",19,2,3,no,1:no,1:no,,0.587
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Yes," History of skin cancer, No. (%)   ",19,3,3,no,1:no,1:no,,0.671
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Withdrew (n = xx) ; ,????Yes," History of skin cancer, No. (%)   ",19,4,3,no,1:no,1:no,,0.521
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????Yes," History of skin cancer, No. (%)   ",19,5,3,no,1:no,1:no,,0.526
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????Yes," History of skin cancer, No. (%)   ",19,6,3,no,1:no,1:no,,0.616
3596,3001966,Table 4,BaselineCharacteristic,????No, ; Characteristic ; ,????No," History of skin cancer, No. (%)   ",20,0,2,no,1:no,1:no,,0.87
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????No," History of skin cancer, No. (%)   ",20,1,3,no,1:no,1:no,,0.568
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????No," History of skin cancer, No. (%)   ",20,2,3,no,1:no,1:no,,0.578
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????No," History of skin cancer, No. (%)   ",20,3,3,no,1:no,1:no,,0.762
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????No," History of skin cancer, No. (%)   ",20,4,3,no,1:no,1:no,,0.508
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????No," History of skin cancer, No. (%)   ",20,5,3,no,1:no,1:no,,0.517
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????No," History of skin cancer, No. (%)   ",20,6,3,no,1:no,1:no,,0.69
3596,3001966,Table 4,BaselineCharacteristic,"Total number of skin cancer diagnoses per patient before screening, No. (%)", ; Characteristic ; ,None,None,21,0,24,no,1:no,1:no,,0.799
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,1,21,43,no,1:no,1:no,,0.534
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,2,21,43,no,1:no,1:no,,0.538
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,3,21,43,no,1:no,1:no,,0.646
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,4,21,43,no,1:no,2:yes,+,0.53
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,5,21,43,no,1:no,2:yes,+,0.523
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,6,21,43,no,1:no,1:no,,0.602
3596,3001966,Table 4,BaselineCharacteristic,????x, ; Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,0,2,no,1:no,1:no,,0.756
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,1,3,no,1:no,1:no,,0.57
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,2,3,no,1:no,1:no,,0.571
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,3,3,no,1:no,1:no,,0.582
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,4,3,no,1:no,2:yes,+,0.516
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,5,3,no,1:no,2:yes,+,0.516
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,6,3,no,1:no,1:no,,0.536
3596,3001966,Table 4,BaselineCharacteristic,????x, ; Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,0,2,no,1:no,1:no,,0.758
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,1,3,no,1:no,1:no,,0.574
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,2,3,no,1:no,1:no,,0.575
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,3,3,no,1:no,1:no,,0.64
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,4,3,no,1:no,2:yes,+,0.512
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,5,3,no,1:no,2:yes,+,0.512
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,6,3,no,1:no,1:no,,0.584
3596,3001966,Table 4,BaselineCharacteristic,????x, ; Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,0,2,no,1:no,1:no,,0.758
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,1,3,no,1:no,1:no,,0.574
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,2,3,no,1:no,1:no,,0.575
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,3,3,no,1:no,1:no,,0.64
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,4,3,no,1:no,2:yes,+,0.512
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,5,3,no,1:no,2:yes,+,0.512
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,6,3,no,1:no,1:no,,0.584
3596,3001966,Table 4,BaselineCharacteristic,????>x, ; Characteristic ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,0,2,no,1:no,1:no,,0.796
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,1,3,no,1:no,1:no,,0.574
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,2,3,no,1:no,1:no,,0.595
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,3,3,no,1:no,1:no,,0.686
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,4,3,no,1:no,2:yes,+,0.512
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,5,3,no,1:no,1:no,,0.506
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,6,3,no,1:no,1:no,,0.625
3596,3001966,Table 4,BaselineCharacteristic,????Mean (SD), ; Characteristic ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,0,2,no,1:no,1:no,,0.804
3596,3001966,Table 4,BaselineCharacteristic,x.x (x.x),Celecoxib group ; Withdrew (n = xx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,1,3,no,1:no,1:no,,0.62
3596,3001966,Table 4,BaselineCharacteristic,x.x (x.x),Celecoxib group ; Completed (n = xx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,2,3,no,1:no,1:no,,0.621
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,3,3,no,1:no,1:no,,0.639
3596,3001966,Table 4,BaselineCharacteristic,x.x (x.x),Placebo group ; Withdrew (n = xx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,4,3,no,1:no,1:no,,0.535
3596,3001966,Table 4,BaselineCharacteristic,x.x (x.x),Placebo group ; Completed (n = xx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,5,3,no,1:no,1:no,,0.535
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,6,3,no,1:no,1:no,,0.586
3596,3001966,Table 4,BaselineCharacteristic,????Median (range), ; Characteristic ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",27,0,2,no,1:no,1:no,,0.839
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",27,3,3,no,1:no,1:no,,0.749
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",27,6,3,no,1:no,1:no,,0.684
3654,3015435,Table 1.,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
3654,3015435,Table 1.,BaselineCharacteristic,Ondansetron,,,None,0,1,1,no,1:no,1:no,,0.735
3654,3015435,Table 1.,BaselineCharacteristic,Droperidol,,,None,0,2,1,no,1:no,1:no,,0.775
3654,3015435,Table 1.,BaselineCharacteristic,Metoclopramide,,,None,0,3,1,no,1:no,1:no,,0.79
3654,3015435,Table 1.,BaselineCharacteristic,N, ; ,N,,1,0,2,no,1:no,1:no,,0.777
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,N,,1,1,3,no,1:no,1:no,,0.501
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,N,,1,2,3,no,1:no,1:no,,0.517
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,N,,1,3,3,no,1:no,1:no,,0.537
3654,3015435,Table 1.,BaselineCharacteristic,Sex: Female, ; ,Sex: Female,,2,0,24,no,1:no,2:yes,+,0.562
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,Sex: Female,,2,1,43,yes,2:yes,2:yes,,0.774
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,Sex: Female,,2,2,43,yes,2:yes,2:yes,,0.777
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,Sex: Female,,2,3,43,yes,2:yes,2:yes,,0.766
3654,3015435,Table 1.,BaselineCharacteristic,????Male, ; ,????Male, Sex: Female   ,3,0,2,no,1:no,2:yes,+,0.564
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,????Male, Sex: Female   ,3,1,3,yes,2:yes,2:yes,,0.844
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,????Male, Sex: Female   ,3,2,3,yes,2:yes,2:yes,,0.847
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,????Male, Sex: Female   ,3,3,3,yes,2:yes,2:yes,,0.835
3654,3015435,Table 1.,BaselineCharacteristic,Weight: Female, ; ,Weight: Female,,4,0,24,no,1:no,1:no,,0.687
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Ondansetron ; ,Weight: Female,,4,1,43,no,1:no,2:yes,+,0.585
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Droperidol ; ,Weight: Female,,4,2,43,no,1:no,2:yes,+,0.574
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Metoclopramide ; ,Weight: Female,,4,3,43,no,1:no,2:yes,+,0.563
3654,3015435,Table 1.,BaselineCharacteristic,????Male, ; ,????Male, Weight: Female   ,5,0,2,no,1:no,1:no,,0.637
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Ondansetron ; ,????Male, Weight: Female   ,5,1,3,no,1:no,2:yes,+,0.676
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Droperidol ; ,????Male, Weight: Female   ,5,2,3,no,1:no,2:yes,+,0.68
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Metoclopramide ; ,????Male, Weight: Female   ,5,3,3,no,1:no,2:yes,+,0.668
3654,3015435,Table 1.,BaselineCharacteristic,Motion Sickness, ; ,Motion Sickness,,6,0,2,no,1:no,1:no,,0.826
3654,3015435,Table 1.,BaselineCharacteristic,x,Ondansetron ; ,Motion Sickness,,6,1,3,no,1:no,1:no,,0.681
3654,3015435,Table 1.,BaselineCharacteristic,x,Droperidol ; ,Motion Sickness,,6,2,3,no,1:no,1:no,,0.695
3654,3015435,Table 1.,BaselineCharacteristic,x,Metoclopramide ; ,Motion Sickness,,6,3,3,no,1:no,1:no,,0.717
3654,3015435,Table 1.,BaselineCharacteristic,PONV, ; ,PONV,,7,0,2,no,1:no,1:no,,0.836
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,PONV,,7,1,3,no,1:no,1:no,,0.554
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,PONV,,7,2,3,no,1:no,1:no,,0.568
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,PONV,,7,3,3,no,1:no,1:no,,0.592
3654,3015435,Table 1.,BaselineCharacteristic,Diabetic, ; ,Diabetic,,8,0,2,no,1:no,1:no,,0.837
3654,3015435,Table 1.,BaselineCharacteristic,x,Ondansetron ; ,Diabetic,,8,1,3,no,1:no,1:no,,0.712
3654,3015435,Table 1.,BaselineCharacteristic,x,Droperidol ; ,Diabetic,,8,2,3,no,1:no,1:no,,0.726
3654,3015435,Table 1.,BaselineCharacteristic,x,Metoclopramide ; ,Diabetic,,8,3,3,no,1:no,1:no,,0.753
3654,3015435,Table 1.,BaselineCharacteristic,Age, ; ,Age,,9,0,2,no,1:no,1:no,,0.873
3654,3015435,Table 1.,BaselineCharacteristic,xx +/? xx.x,Ondansetron ; ,Age,,9,1,3,no,1:no,1:no,,0.692
3654,3015435,Table 1.,BaselineCharacteristic,xx +/? xx.x,Droperidol ; ,Age,,9,2,3,no,1:no,1:no,,0.713
3654,3015435,Table 1.,BaselineCharacteristic,xx +/? xx.x,Metoclopramide ; ,Age,,9,3,3,no,1:no,1:no,,0.73
3654,3015435,Table 1.,BaselineCharacteristic,Duration of Operation, ; ,Duration of Operation,,10,0,2,no,1:no,1:no,,0.877
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Ondansetron ; ,Duration of Operation,,10,1,3,no,1:no,1:no,,0.757
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Droperidol ; ,Duration of Operation,,10,2,3,no,1:no,1:no,,0.772
3654,3015435,Table 1.,BaselineCharacteristic,xx +/? xx.x,Metoclopramide ; ,Duration of Operation,,10,3,3,no,1:no,1:no,,0.771
3654,3015435,Table 1.,BaselineCharacteristic,Laparoscopic Cholecystectomy, ; ,Laparoscopic Cholecystectomy,,11,0,2,no,1:no,1:no,,0.867
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,Laparoscopic Cholecystectomy,,11,1,3,no,1:no,1:no,,0.687
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,Laparoscopic Cholecystectomy,,11,2,3,no,1:no,1:no,,0.697
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,Laparoscopic Cholecystectomy,,11,3,3,no,1:no,1:no,,0.71
3654,3015435,Table 1.,BaselineCharacteristic,Laparoscopic Herniorrhaphy, ; ,Laparoscopic Herniorrhaphy,,12,0,2,no,1:no,1:no,,0.873
3654,3015435,Table 1.,BaselineCharacteristic,x,Ondansetron ; ,Laparoscopic Herniorrhaphy,,12,1,3,no,1:no,1:no,,0.762
3654,3015435,Table 1.,BaselineCharacteristic,x,Droperidol ; ,Laparoscopic Herniorrhaphy,,12,2,3,no,1:no,1:no,,0.776
3654,3015435,Table 1.,BaselineCharacteristic,x,Metoclopramide ; ,Laparoscopic Herniorrhaphy,,12,3,3,no,1:no,1:no,,0.797
3654,3015435,Table 1.,BaselineCharacteristic,Laparoscopic Appendectomy, ; ,Laparoscopic Appendectomy,,13,0,2,no,1:no,1:no,,0.873
3654,3015435,Table 1.,BaselineCharacteristic,x,Ondansetron ; ,Laparoscopic Appendectomy,,13,1,3,no,1:no,1:no,,0.762
3654,3015435,Table 1.,BaselineCharacteristic,x,Droperidol ; ,Laparoscopic Appendectomy,,13,2,3,no,1:no,1:no,,0.776
3654,3015435,Table 1.,BaselineCharacteristic,x,Metoclopramide ; ,Laparoscopic Appendectomy,,13,3,3,no,1:no,1:no,,0.797
3654,3015435,Table 1.,BaselineCharacteristic,Diagnostic Laparoscopy, ; ,Diagnostic Laparoscopy,,14,0,2,no,1:no,1:no,,0.869
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,Diagnostic Laparoscopy,,14,1,3,no,1:no,1:no,,0.69
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,Diagnostic Laparoscopy,,14,2,3,no,1:no,1:no,,0.7
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,Diagnostic Laparoscopy,,14,3,3,no,1:no,1:no,,0.714
3713,3031899,Table 2,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
3713,3031899,Table 2,BaselineCharacteristic,Number (n=xx),,Characteristics,None,0,1,1,no,1:no,1:no,,0.693
3713,3031899,Table 2,BaselineCharacteristic,%,,Characteristics,None,0,2,1,no,1:no,1:no,,0.738
3713,3031899,Table 2,BaselineCharacteristic,Sex,Characteristics ; ,None,None,1,0,24,no,1:no,1:no,,0.556
3713,3031899,Table 2,BaselineCharacteristic,Sex,Number (n=xx) ; ,Sex,None,1,1,43,no,1:no,2:yes,+,0.538
3713,3031899,Table 2,BaselineCharacteristic,Sex,% ; ,Sex,None,1,2,43,no,1:no,1:no,,0.529
3713,3031899,Table 2,BaselineCharacteristic,?Male: female,Characteristics ; ,?Male: female, Sex,2,0,2,no,1:no,2:yes,+,0.571
3713,3031899,Table 2,BaselineCharacteristic,xx?:?x,Number (n=xx) ; ,?Male: female, Sex,2,1,3,yes,2:yes,2:yes,,0.839
3713,3031899,Table 2,BaselineCharacteristic,xx?:?x,% ; ,?Male: female, Sex,2,2,3,yes,2:yes,2:yes,,0.88
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,3,0,2,no,1:no,1:no,,0.831
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,3,1,3,no,1:no,1:no,,0.668
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,3,2,3,no,1:no,1:no,,0.682
3713,3031899,Table 2,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,4,0,24,no,1:no,1:no,,0.831
3713,3031899,Table 2,BaselineCharacteristic,Age (years),Number (n=xx) ; ,Age (years),None,4,1,43,no,1:no,1:no,,0.769
3713,3031899,Table 2,BaselineCharacteristic,Age (years),% ; ,Age (years),None,4,2,43,no,1:no,1:no,,0.781
3713,3031899,Table 2,BaselineCharacteristic,?Median,Characteristics ; ,?Median, Age (years),5,0,2,no,1:no,1:no,,0.832
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?Median, Age (years),5,1,3,no,1:no,1:no,,0.643
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,?Median, Age (years),5,2,3,no,1:no,1:no,,0.743
3713,3031899,Table 2,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),6,0,2,no,1:no,1:no,,0.815
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,?Range, Age (years),6,2,3,no,1:no,1:no,,0.734
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,7,0,2,no,1:no,1:no,,0.843
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,7,1,3,no,1:no,1:no,,0.685
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,7,2,3,no,1:no,1:no,,0.711
3713,3031899,Table 2,BaselineCharacteristic,ECOG performance status,Characteristics ; ,None,None,8,0,24,no,1:no,1:no,,0.861
3713,3031899,Table 2,BaselineCharacteristic,ECOG performance status,Number (n=xx) ; ,ECOG performance status,None,8,1,43,no,1:no,1:no,,0.768
3713,3031899,Table 2,BaselineCharacteristic,ECOG performance status,% ; ,ECOG performance status,None,8,2,43,no,1:no,1:no,,0.78
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, ECOG performance status,9,0,2,no,1:no,1:no,,0.835
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, ECOG performance status,9,1,3,no,1:no,1:no,,0.688
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,9,2,3,no,1:no,1:no,,0.632
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, ECOG performance status,10,0,2,no,1:no,1:no,,0.837
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?x, ECOG performance status,10,1,3,no,1:no,1:no,,0.683
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,10,2,3,no,1:no,1:no,,0.643
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,11,0,2,no,1:no,1:no,,0.866
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,11,1,3,no,1:no,1:no,,0.786
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,11,2,3,no,1:no,1:no,,0.759
3713,3031899,Table 2,BaselineCharacteristic,Histology,Characteristics ; ,None,None,12,0,24,no,1:no,1:no,,0.852
3713,3031899,Table 2,BaselineCharacteristic,Histology,Number (n=xx) ; ,Histology,None,12,1,43,no,1:no,1:no,,0.793
3713,3031899,Table 2,BaselineCharacteristic,Histology,% ; ,Histology,None,12,2,43,no,1:no,1:no,,0.786
3713,3031899,Table 2,BaselineCharacteristic,?Squamous,Characteristics ; ,?Squamous, Histology,13,0,2,no,1:no,1:no,,0.855
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?Squamous, Histology,13,1,3,no,1:no,1:no,,0.676
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Squamous, Histology,13,2,3,no,1:no,1:no,,0.629
3713,3031899,Table 2,BaselineCharacteristic,?Adenocarcinoma,Characteristics ; ,?Adenocarcinoma, Histology,14,0,2,no,1:no,1:no,,0.847
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?Adenocarcinoma, Histology,14,1,3,no,1:no,1:no,,0.659
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Adenocarcinoma, Histology,14,2,3,no,1:no,1:no,,0.588
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,15,0,2,no,1:no,1:no,,0.866
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,15,1,3,no,1:no,1:no,,0.79
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,15,2,3,no,1:no,1:no,,0.749
3713,3031899,Table 2,BaselineCharacteristic,Tumour location,Characteristics ; ,None,None,16,0,24,no,1:no,1:no,,0.873
3713,3031899,Table 2,BaselineCharacteristic,Tumour location,Number (n=xx) ; ,Tumour location,None,16,1,43,no,1:no,1:no,,0.824
3713,3031899,Table 2,BaselineCharacteristic,Tumour location,% ; ,Tumour location,None,16,2,43,no,1:no,1:no,,0.795
3713,3031899,Table 2,BaselineCharacteristic,?Upper third,Characteristics ; ,?Upper third, Tumour location,17,0,2,no,1:no,1:no,,0.887
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?Upper third, Tumour location,17,1,3,no,1:no,1:no,,0.783
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Upper third, Tumour location,17,2,3,no,1:no,1:no,,0.674
3713,3031899,Table 2,BaselineCharacteristic,?Middle third,Characteristics ; ,?Middle third, Tumour location,18,0,2,no,1:no,1:no,,0.889
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?Middle third, Tumour location,18,1,3,no,1:no,1:no,,0.786
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Middle third, Tumour location,18,2,3,no,1:no,1:no,,0.691
3713,3031899,Table 2,BaselineCharacteristic,?Lower third,Characteristics ; ,?Lower third, Tumour location,19,0,2,no,1:no,1:no,,0.889
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?Lower third, Tumour location,19,1,3,no,1:no,1:no,,0.755
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Lower third, Tumour location,19,2,3,no,1:no,1:no,,0.691
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,20,0,2,no,1:no,1:no,,0.875
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,20,1,3,no,1:no,1:no,,0.823
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,20,2,3,no,1:no,1:no,,0.777
3713,3031899,Table 2,BaselineCharacteristic,T stage,Characteristics ; ,None,None,21,0,24,no,1:no,1:no,,0.873
3713,3031899,Table 2,BaselineCharacteristic,T stage,Number (n=xx) ; ,T stage,None,21,1,43,no,1:no,1:no,,0.843
3713,3031899,Table 2,BaselineCharacteristic,T stage,% ; ,T stage,None,21,2,43,no,1:no,1:no,,0.836
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, T stage,22,0,2,no,1:no,1:no,,0.851
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, T stage,22,1,3,no,1:no,1:no,,0.785
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, T stage,22,2,3,no,1:no,1:no,,0.708
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, T stage,23,0,2,no,1:no,1:no,,0.852
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, T stage,23,1,3,no,1:no,1:no,,0.789
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, T stage,23,2,3,no,1:no,1:no,,0.713
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, T stage,24,0,2,no,1:no,1:no,,0.852
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?x, T stage,24,1,3,no,1:no,1:no,,0.741
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, T stage,24,2,3,no,1:no,1:no,,0.713
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, T stage,25,0,2,no,1:no,1:no,,0.853
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, T stage,25,1,3,no,1:no,1:no,,0.798
3713,3031899,Table 2,BaselineCharacteristic,x.x,% ; ,?x, T stage,25,2,3,no,1:no,1:no,,0.795
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,26,0,2,no,1:no,1:no,,0.877
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,26,1,3,no,1:no,1:no,,0.826
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,26,2,3,no,1:no,1:no,,0.792
3713,3031899,Table 2,BaselineCharacteristic,N stage,Characteristics ; ,None,None,27,0,24,no,1:no,1:no,,0.809
3713,3031899,Table 2,BaselineCharacteristic,N stage,Number (n=xx) ; ,N stage,None,27,1,43,no,1:no,1:no,,0.793
3713,3031899,Table 2,BaselineCharacteristic,N stage,% ; ,N stage,None,27,2,43,no,1:no,1:no,,0.789
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, N stage,28,0,2,no,1:no,1:no,,0.769
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, N stage,28,1,3,no,1:no,1:no,,0.74
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, N stage,28,2,3,no,1:no,1:no,,0.664
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, N stage,29,0,2,no,1:no,1:no,,0.769
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?x, N stage,29,1,3,no,1:no,1:no,,0.728
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, N stage,29,2,3,no,1:no,1:no,,0.664
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,30,0,2,no,1:no,1:no,,0.877
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,30,1,3,no,1:no,1:no,,0.826
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,30,2,3,no,1:no,1:no,,0.792
3713,3031899,Table 2,BaselineCharacteristic,Stage grouping,Characteristics ; ,None,None,31,0,24,no,1:no,1:no,,0.874
3713,3031899,Table 2,BaselineCharacteristic,Stage grouping,Number (n=xx) ; ,Stage grouping,None,31,1,43,no,1:no,1:no,,0.845
3713,3031899,Table 2,BaselineCharacteristic,Stage grouping,% ; ,Stage grouping,None,31,2,43,no,1:no,1:no,,0.841
3713,3031899,Table 2,BaselineCharacteristic,?I,Characteristics ; ,?I, Stage grouping,32,0,2,no,1:no,1:no,,0.88
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?I, Stage grouping,32,1,3,no,1:no,1:no,,0.811
3713,3031899,Table 2,BaselineCharacteristic,x.x,% ; ,?I, Stage grouping,32,2,3,no,1:no,1:no,,0.809
3713,3031899,Table 2,BaselineCharacteristic,?IIa,Characteristics ; ,?IIa, Stage grouping,33,0,2,no,1:no,1:no,,0.879
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?IIa, Stage grouping,33,1,3,no,1:no,1:no,,0.801
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?IIa, Stage grouping,33,2,3,no,1:no,1:no,,0.719
3713,3031899,Table 2,BaselineCharacteristic,?IIb,Characteristics ; ,?IIb, Stage grouping,34,0,2,no,1:no,1:no,,0.879
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?IIb, Stage grouping,34,1,3,no,1:no,1:no,,0.801
3713,3031899,Table 2,BaselineCharacteristic,x.x,% ; ,?IIb, Stage grouping,34,2,3,no,1:no,1:no,,0.798
3713,3031899,Table 2,BaselineCharacteristic,?III,Characteristics ; ,?III, Stage grouping,35,0,2,no,1:no,1:no,,0.879
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?III, Stage grouping,35,1,3,no,1:no,1:no,,0.761
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?III, Stage grouping,35,2,3,no,1:no,1:no,,0.719
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,36,0,2,no,1:no,1:no,,0.877
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,36,1,3,no,1:no,1:no,,0.826
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,36,2,3,no,1:no,1:no,,0.792
3713,3031899,Table 2,BaselineCharacteristic,Previous surgery,Characteristics ; ,None,None,37,0,24,no,1:no,1:no,,0.881
3713,3031899,Table 2,BaselineCharacteristic,Previous surgery,Number (n=xx) ; ,Previous surgery,None,37,1,43,no,1:no,1:no,,0.849
3713,3031899,Table 2,BaselineCharacteristic,Previous surgery,% ; ,Previous surgery,None,37,2,43,no,1:no,1:no,,0.825
3713,3031899,Table 2,BaselineCharacteristic,?Yes,Characteristics ; ,?Yes, Previous surgery,38,0,2,no,1:no,1:no,,0.886
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?Yes, Previous surgery,38,1,3,no,1:no,1:no,,0.809
3713,3031899,Table 2,BaselineCharacteristic,x.x,% ; ,?Yes, Previous surgery,38,2,3,no,1:no,1:no,,0.784
3713,3031899,Table 2,BaselineCharacteristic,?No,Characteristics ; ,?No, Previous surgery,39,0,2,no,1:no,1:no,,0.866
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?No, Previous surgery,39,1,3,no,1:no,1:no,,0.732
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?No, Previous surgery,39,2,3,no,1:no,1:no,,0.684
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,40,0,2,no,1:no,1:no,,0.877
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,40,1,3,no,1:no,1:no,,0.826
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,40,2,3,no,1:no,1:no,,0.792
3713,3031899,Table 2,BaselineCharacteristic,Weight loss over previous x months,Characteristics ; ,None,None,41,0,24,no,1:no,1:no,,0.864
3713,3031899,Table 2,BaselineCharacteristic,Weight loss over previous x months,Number (n=xx) ; ,Weight loss over previous x months,None,41,1,43,no,1:no,1:no,,0.835
3713,3031899,Table 2,BaselineCharacteristic,Weight loss over previous x months,% ; ,Weight loss over previous x months,None,41,2,43,no,1:no,1:no,,0.815
3713,3031899,Table 2,BaselineCharacteristic,?None,Characteristics ; ,?None, Weight loss over previous x months,42,0,2,no,1:no,1:no,,0.882
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?None, Weight loss over previous x months,42,1,3,no,1:no,1:no,,0.835
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?None, Weight loss over previous x months,42,2,3,no,1:no,1:no,,0.754
3713,3031899,Table 2,BaselineCharacteristic,??xx%,Characteristics ; ,??xx%, Weight loss over previous x months,43,0,2,no,1:no,1:no,,0.839
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,??xx%, Weight loss over previous x months,43,1,3,no,1:no,1:no,,0.734
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,??xx%, Weight loss over previous x months,43,2,3,no,1:no,1:no,,0.65
3713,3031899,Table 2,BaselineCharacteristic,?>xx%,Characteristics ; ,?>xx%, Weight loss over previous x months,44,0,2,no,1:no,1:no,,0.873
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?>xx%, Weight loss over previous x months,44,1,3,no,1:no,1:no,,0.813
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?>xx%, Weight loss over previous x months,44,2,3,no,1:no,1:no,,0.709
3716,3032760,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
3716,3032760,Table 1,BaselineCharacteristic,Everolimus x mg/day(n = xx),,Characteristic,None,0,1,1,no,1:no,1:no,,0.547
3716,3032760,Table 1,BaselineCharacteristic,Everolimus xx mg/day(n = xx),,Characteristic,None,0,2,1,no,1:no,1:no,,0.63
3716,3032760,Table 1,BaselineCharacteristic,"Median (range) age, y",Characteristic ; ,"Median (range) age, y",,1,0,2,no,1:no,1:no,,0.857
3716,3032760,Table 1,BaselineCharacteristic,xx (xx-xx),Everolimus x mg/day(n = xx) ; ,"Median (range) age, y",,1,1,3,no,1:no,1:no,,0.564
3716,3032760,Table 1,BaselineCharacteristic,xx (xx-xx),Everolimus xx mg/day(n = xx) ; ,"Median (range) age, y",,1,2,3,no,1:no,1:no,,0.581
3716,3032760,Table 1,BaselineCharacteristic,"Sex, n (%)",Characteristic ; ,None,None,2,0,24,no,1:no,1:no,,0.604
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus x mg/day(n = xx) ; ,"Sex, n (%)",None,2,1,43,no,1:no,2:yes,+,0.711
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus xx mg/day(n = xx) ; ,"Sex, n (%)",None,2,2,43,no,1:no,2:yes,+,0.686
3716,3032760,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male," Sex, n (%)",3,0,2,no,1:no,2:yes,+,0.515
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Male," Sex, n (%)",3,1,3,yes,2:yes,2:yes,,0.845
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Male," Sex, n (%)",3,2,3,yes,2:yes,2:yes,,0.843
3716,3032760,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female," Sex, n (%)",4,0,2,no,1:no,1:no,,0.509
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Female," Sex, n (%)",4,1,3,yes,2:yes,2:yes,,0.859
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Female," Sex, n (%)",4,2,3,yes,2:yes,2:yes,,0.853
3716,3032760,Table 1,BaselineCharacteristic,"WHO performance status, n (%)",Characteristic ; ,None,None,5,0,24,no,1:no,1:no,,0.799
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus x mg/day(n = xx) ; ,"WHO performance status, n (%)",None,5,1,43,no,1:no,1:no,,0.503
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus xx mg/day(n = xx) ; ,"WHO performance status, n (%)",None,5,2,43,no,1:no,1:no,,0.516
3716,3032760,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," WHO performance status, n (%)",6,0,2,no,1:no,1:no,,0.725
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?x," WHO performance status, n (%)",6,1,3,no,1:no,2:yes,+,0.526
3716,3032760,Table 1,BaselineCharacteristic,x (x.x),Everolimus xx mg/day(n = xx) ; ,?x," WHO performance status, n (%)",6,2,3,no,1:no,2:yes,+,0.503
3716,3032760,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," WHO performance status, n (%)",7,0,2,no,1:no,1:no,,0.727
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?x," WHO performance status, n (%)",7,1,3,no,1:no,2:yes,+,0.513
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?x," WHO performance status, n (%)",7,2,3,no,1:no,1:no,,0.51
3716,3032760,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," WHO performance status, n (%)",8,0,2,no,1:no,1:no,,0.737
3716,3032760,Table 1,BaselineCharacteristic,x,Everolimus x mg/day(n = xx) ; ,?x," WHO performance status, n (%)",8,1,3,no,1:no,1:no,,0.51
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?x," WHO performance status, n (%)",8,2,3,no,1:no,1:no,,0.532
3716,3032760,Table 1,BaselineCharacteristic,"Prior antineoplastic therapy, n (%)",Characteristic ; ,None,None,9,0,24,no,1:no,1:no,,0.835
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus x mg/day(n = xx) ; ,"Prior antineoplastic therapy, n (%)",None,9,1,43,no,1:no,1:no,,0.667
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus xx mg/day(n = xx) ; ,"Prior antineoplastic therapy, n (%)",None,9,2,43,no,1:no,1:no,,0.645
3716,3032760,Table 1,BaselineCharacteristic,?Surgery,Characteristic ; ,?Surgery," Prior antineoplastic therapy, n (%)",10,0,2,no,1:no,1:no,,0.827
3716,3032760,Table 1,BaselineCharacteristic,xx (xx.x),Everolimus x mg/day(n = xx) ; ,?Surgery," Prior antineoplastic therapy, n (%)",10,1,3,no,1:no,1:no,,0.621
3716,3032760,Table 1,BaselineCharacteristic,xx (xx.x),Everolimus xx mg/day(n = xx) ; ,?Surgery," Prior antineoplastic therapy, n (%)",10,2,3,no,1:no,1:no,,0.625
3716,3032760,Table 1,BaselineCharacteristic,?Radiotherapy,Characteristic ; ,?Radiotherapy," Prior antineoplastic therapy, n (%)",11,0,2,no,1:no,1:no,,0.829
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Radiotherapy," Prior antineoplastic therapy, n (%)",11,1,3,no,1:no,1:no,,0.638
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Radiotherapy," Prior antineoplastic therapy, n (%)",11,2,3,no,1:no,1:no,,0.643
3716,3032760,Table 1,BaselineCharacteristic,?Chemotherapy,Characteristic ; ,?Chemotherapy," Prior antineoplastic therapy, n (%)",12,0,2,no,1:no,1:no,,0.84
3716,3032760,Table 1,BaselineCharacteristic,xx (xx.x),Everolimus x mg/day(n = xx) ; ,?Chemotherapy," Prior antineoplastic therapy, n (%)",12,1,3,no,1:no,1:no,,0.657
3716,3032760,Table 1,BaselineCharacteristic,xx (xx.x),Everolimus xx mg/day(n = xx) ; ,?Chemotherapy," Prior antineoplastic therapy, n (%)",12,2,3,no,1:no,1:no,,0.66
3716,3032760,Table 1,BaselineCharacteristic,?Targeted therapy,Characteristic ; ,?Targeted therapy," Prior antineoplastic therapy, n (%)",13,0,2,no,1:no,1:no,,0.829
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Targeted therapy," Prior antineoplastic therapy, n (%)",13,1,3,no,1:no,1:no,,0.641
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Targeted therapy," Prior antineoplastic therapy, n (%)",13,2,3,no,1:no,1:no,,0.646
3716,3032760,Table 1,BaselineCharacteristic,?Immunotherapy,Characteristic ; ,?Immunotherapy," Prior antineoplastic therapy, n (%)",14,0,2,no,1:no,1:no,,0.822
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Immunotherapy," Prior antineoplastic therapy, n (%)",14,1,3,no,1:no,1:no,,0.629
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Immunotherapy," Prior antineoplastic therapy, n (%)",14,2,3,no,1:no,1:no,,0.634
3716,3032760,Table 1,BaselineCharacteristic,?Hormonal therapy,Characteristic ; ,?Hormonal therapy," Prior antineoplastic therapy, n (%)",15,0,2,no,1:no,1:no,,0.825
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Hormonal therapy," Prior antineoplastic therapy, n (%)",15,1,3,no,1:no,1:no,,0.63
3716,3032760,Table 1,BaselineCharacteristic,x,Everolimus xx mg/day(n = xx) ; ,?Hormonal therapy," Prior antineoplastic therapy, n (%)",15,2,3,no,1:no,1:no,,0.635
3777,3048218,Table 1,BaselineCharacteristic,Number of patients,,None,None,0,0,12,no,1:no,1:no,,0.783
3777,3048218,Table 1,BaselineCharacteristic,xx,,Number of patients,None,0,1,1,no,1:no,1:no,,0.649
3777,3048218,Table 1,BaselineCharacteristic,"Mean age, years (range)",,None,None,1,0,12,no,1:no,1:no,,0.82
3777,3048218,Table 1,BaselineCharacteristic,Gender (male/female),,None,None,2,0,12,no,1:no,1:no,,0.71
3777,3048218,Table 1,BaselineCharacteristic,xx/xx,,Gender (male/female),None,2,1,1,yes,2:yes,1:no,+,0.651
3777,3048218,Table 1,BaselineCharacteristic,Performance status (x/x/x),,None,None,3,0,12,no,1:no,1:no,,0.83
3777,3048218,Table 1,BaselineCharacteristic,xx/xx/x,,Performance status (x/x/x),None,3,1,1,no,1:no,1:no,,0.763
3777,3048218,Table 1,BaselineCharacteristic,,,None,None,4,0,2,no,1:no,1:no,,0.858
3777,3048218,Table 1,BaselineCharacteristic,,,None,None,4,1,3,no,1:no,1:no,,0.731
3777,3048218,Table 1,BaselineCharacteristic,Tumour type (n),,None,None,5,0,24,no,1:no,1:no,,0.691
3777,3048218,Table 1,BaselineCharacteristic,Tumour type (n),,Tumour type (n),None,5,1,43,no,1:no,1:no,,0.579
3777,3048218,Table 1,BaselineCharacteristic,?Melanoma,,?Melanoma, Tumour type (n),6,0,2,no,1:no,1:no,,0.715
3777,3048218,Table 1,BaselineCharacteristic,xx,,?Melanoma, Tumour type (n),6,1,3,no,1:no,2:yes,+,0.515
3777,3048218,Table 1,BaselineCharacteristic,?Colorectal,,?Colorectal, Tumour type (n),7,0,2,no,1:no,1:no,,0.715
3777,3048218,Table 1,BaselineCharacteristic,x,,?Colorectal, Tumour type (n),7,1,3,no,1:no,1:no,,0.54
3777,3048218,Table 1,BaselineCharacteristic,?Transitional cell carcinoma bladder,,?Transitional cell carcinoma bladder, Tumour type (n),8,0,2,no,1:no,1:no,,0.725
3777,3048218,Table 1,BaselineCharacteristic,x,,?Transitional cell carcinoma bladder, Tumour type (n),8,1,3,no,1:no,1:no,,0.578
3777,3048218,Table 1,BaselineCharacteristic,?Squamous cell carcinoma vulva,,?Squamous cell carcinoma vulva, Tumour type (n),9,0,2,no,1:no,1:no,,0.757
3777,3048218,Table 1,BaselineCharacteristic,x,,?Squamous cell carcinoma vulva, Tumour type (n),9,1,3,no,1:no,1:no,,0.621
3777,3048218,Table 1,BaselineCharacteristic,?Haemangioblastoma,,?Haemangioblastoma, Tumour type (n),10,0,2,no,1:no,1:no,,0.742
3777,3048218,Table 1,BaselineCharacteristic,x,,?Haemangioblastoma, Tumour type (n),10,1,3,no,1:no,1:no,,0.578
3777,3048218,Table 1,BaselineCharacteristic,?Merkel cell carcinoma,,?Merkel cell carcinoma, Tumour type (n),11,0,2,no,1:no,1:no,,0.754
3777,3048218,Table 1,BaselineCharacteristic,x,,?Merkel cell carcinoma, Tumour type (n),11,1,3,no,1:no,1:no,,0.62
3777,3048218,Table 1,BaselineCharacteristic,?Adenocarcinoma lung,,?Adenocarcinoma lung, Tumour type (n),12,0,2,no,1:no,1:no,,0.743
3777,3048218,Table 1,BaselineCharacteristic,x,,?Adenocarcinoma lung, Tumour type (n),12,1,3,no,1:no,1:no,,0.601
3777,3048218,Table 1,BaselineCharacteristic,,,None,None,13,0,2,no,1:no,1:no,,0.892
3777,3048218,Table 1,BaselineCharacteristic,,,None,None,13,1,3,no,1:no,1:no,,0.813
3777,3048218,Table 1,BaselineCharacteristic,Previous chemotherapy regimens (n),,None,None,14,0,24,no,1:no,1:no,,0.844
3777,3048218,Table 1,BaselineCharacteristic,Previous chemotherapy regimens (n),,Previous chemotherapy regimens (n),None,14,1,43,no,1:no,1:no,,0.768
3777,3048218,Table 1,BaselineCharacteristic,?x,,?x, Previous chemotherapy regimens (n),15,0,2,no,1:no,1:no,,0.777
3777,3048218,Table 1,BaselineCharacteristic,xx,,?x, Previous chemotherapy regimens (n),15,1,3,no,1:no,1:no,,0.674
3777,3048218,Table 1,BaselineCharacteristic,?x,,?x, Previous chemotherapy regimens (n),16,0,2,no,1:no,1:no,,0.777
3777,3048218,Table 1,BaselineCharacteristic,x,,?x, Previous chemotherapy regimens (n),16,1,3,no,1:no,1:no,,0.684
3777,3048218,Table 1,BaselineCharacteristic,?x,,?x, Previous chemotherapy regimens (n),17,0,2,no,1:no,1:no,,0.811
3777,3048218,Table 1,BaselineCharacteristic,x,,?x, Previous chemotherapy regimens (n),17,1,3,no,1:no,1:no,,0.736
3777,3048218,Table 1,BaselineCharacteristic,??x,,??x, Previous chemotherapy regimens (n),18,0,2,no,1:no,1:no,,0.814
3777,3048218,Table 1,BaselineCharacteristic,x,,??x, Previous chemotherapy regimens (n),18,1,3,no,1:no,1:no,,0.74
3781,3049578,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
3781,3049578,Table 1,BaselineCharacteristic,No. of patients=xx (xxx%),,,None,0,1,1,no,1:no,1:no,,0.795
3781,3049578,Table 1,BaselineCharacteristic,Age, ; ,None,None,1,0,24,no,1:no,1:no,,0.847
3781,3049578,Table 1,BaselineCharacteristic,Age,No. of patients=xx (xxx%) ; ,Age,None,1,1,43,no,1:no,1:no,,0.808
3781,3049578,Table 1,BaselineCharacteristic,?Median/range, ; ,?Median/range, Age,2,0,2,no,1:no,1:no,,0.853
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,3,0,2,no,1:no,1:no,,0.84
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,3,1,3,no,1:no,1:no,,0.725
3781,3049578,Table 1,BaselineCharacteristic,Sex, ; ,None,None,4,0,24,no,1:no,1:no,,0.586
3781,3049578,Table 1,BaselineCharacteristic,Sex,No. of patients=xx (xxx%) ; ,Sex,None,4,1,43,no,1:no,1:no,,0.563
3781,3049578,Table 1,BaselineCharacteristic,?Male/female, ; ,?Male/female, Sex,5,0,2,no,1:no,1:no,,0.585
3781,3049578,Table 1,BaselineCharacteristic,xx/xx (xx/xx),No. of patients=xx (xxx%) ; ,?Male/female, Sex,5,1,3,yes,2:yes,2:yes,,0.569
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,6,0,2,no,1:no,1:no,,0.866
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,6,1,3,no,1:no,1:no,,0.774
3781,3049578,Table 1,BaselineCharacteristic,Performance status, ; ,None,None,7,0,24,no,1:no,1:no,,0.873
3781,3049578,Table 1,BaselineCharacteristic,Performance status,No. of patients=xx (xxx%) ; ,Performance status,None,7,1,43,no,1:no,1:no,,0.838
3781,3049578,Table 1,BaselineCharacteristic,?x/x, ; ,?x/x, Performance status,8,0,2,no,1:no,1:no,,0.873
3781,3049578,Table 1,BaselineCharacteristic,xx/x (xx/xx),No. of patients=xx (xxx%) ; ,?x/x, Performance status,8,1,3,no,1:no,1:no,,0.757
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,9,0,2,no,1:no,1:no,,0.881
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,9,1,3,no,1:no,1:no,,0.806
3781,3049578,Table 1,BaselineCharacteristic,Dysphagia, ; ,None,None,10,0,24,no,1:no,1:no,,0.868
3781,3049578,Table 1,BaselineCharacteristic,Dysphagia,No. of patients=xx (xxx%) ; ,Dysphagia,None,10,1,43,no,1:no,1:no,,0.821
3781,3049578,Table 1,BaselineCharacteristic,?Absent/moderate, ; ,?Absent/moderate, Dysphagia,11,0,2,no,1:no,1:no,,0.867
3781,3049578,Table 1,BaselineCharacteristic,x/x (xx/xx),No. of patients=xx (xxx%) ; ,?Absent/moderate, Dysphagia,11,1,3,no,1:no,1:no,,0.736
3781,3049578,Table 1,BaselineCharacteristic,?Severe, ; ,?Severe, Dysphagia,12,0,2,no,1:no,1:no,,0.873
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Severe, Dysphagia,12,1,3,no,1:no,1:no,,0.68
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,13,0,2,no,1:no,1:no,,0.892
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,13,1,3,no,1:no,1:no,,0.845
3781,3049578,Table 1,BaselineCharacteristic,Tumor location, ; ,None,None,14,0,24,no,1:no,1:no,,0.891
3781,3049578,Table 1,BaselineCharacteristic,Tumor location,No. of patients=xx (xxx%) ; ,Tumor location,None,14,1,43,no,1:no,1:no,,0.859
3781,3049578,Table 1,BaselineCharacteristic,?Upper third, ; ,?Upper third, Tumor location,15,0,2,no,1:no,1:no,,0.883
3781,3049578,Table 1,BaselineCharacteristic,x (xx),No. of patients=xx (xxx%) ; ,?Upper third, Tumor location,15,1,3,no,1:no,1:no,,0.725
3781,3049578,Table 1,BaselineCharacteristic,?Middle third, ; ,?Middle third, Tumor location,16,0,2,no,1:no,1:no,,0.884
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Middle third, Tumor location,16,1,3,no,1:no,1:no,,0.712
3781,3049578,Table 1,BaselineCharacteristic,?Lower third, ; ,?Lower third, Tumor location,17,0,2,no,1:no,1:no,,0.896
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Lower third, Tumor location,17,1,3,no,1:no,1:no,,0.738
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,18,0,2,no,1:no,1:no,,0.902
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,18,1,3,no,1:no,1:no,,0.857
3781,3049578,Table 1,BaselineCharacteristic,Histology, ; ,None,None,19,0,24,no,1:no,1:no,,0.894
3781,3049578,Table 1,BaselineCharacteristic,Histology,No. of patients=xx (xxx%) ; ,Histology,None,19,1,43,no,1:no,1:no,,0.879
3781,3049578,Table 1,BaselineCharacteristic,?Adenocarcinoma, ; ,?Adenocarcinoma, Histology,20,0,2,no,1:no,1:no,,0.9
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Adenocarcinoma, Histology,20,1,3,no,1:no,1:no,,0.763
3781,3049578,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ; ,?Squamous cell carcinoma, Histology,21,0,2,no,1:no,1:no,,0.916
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Squamous cell carcinoma, Histology,21,1,3,no,1:no,1:no,,0.813
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,22,0,2,no,1:no,1:no,,0.904
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,22,1,3,no,1:no,1:no,,0.859
3781,3049578,Table 1,BaselineCharacteristic,EUS T stagea, ; ,None,None,23,0,24,no,1:no,1:no,,0.891
3781,3049578,Table 1,BaselineCharacteristic,EUS T stagea,No. of patients=xx (xxx%) ; ,EUS T stagea,None,23,1,43,no,1:no,1:no,,0.862
3781,3049578,Table 1,BaselineCharacteristic,?x, ; ,?x, EUS T stagea,24,0,2,no,1:no,1:no,,0.872
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?x, EUS T stagea,24,1,3,no,1:no,1:no,,0.752
3781,3049578,Table 1,BaselineCharacteristic,?x, ; ,?x, EUS T stagea,25,0,2,no,1:no,1:no,,0.873
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?x, EUS T stagea,25,1,3,no,1:no,1:no,,0.755
3781,3049578,Table 1,BaselineCharacteristic,?x, ; ,?x, EUS T stagea,26,0,2,no,1:no,1:no,,0.873
3781,3049578,Table 1,BaselineCharacteristic,x (x),No. of patients=xx (xxx%) ; ,?x, EUS T stagea,26,1,3,no,1:no,1:no,,0.765
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,27,0,2,no,1:no,1:no,,0.905
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,27,1,3,no,1:no,1:no,,0.861
3781,3049578,Table 1,BaselineCharacteristic,EUS N stagea, ; ,None,None,28,0,24,no,1:no,1:no,,0.858
3781,3049578,Table 1,BaselineCharacteristic,EUS N stagea,No. of patients=xx (xxx%) ; ,EUS N stagea,None,28,1,43,no,1:no,1:no,,0.799
3781,3049578,Table 1,BaselineCharacteristic,?x, ; ,?x, EUS N stagea,29,0,2,no,1:no,1:no,,0.802
3781,3049578,Table 1,BaselineCharacteristic,x (xx),No. of patients=xx (xxx%) ; ,?x, EUS N stagea,29,1,3,no,1:no,1:no,,0.694
3781,3049578,Table 1,BaselineCharacteristic,?x/Mxa, ; ,?x/Mxa, EUS N stagea,30,0,2,no,1:no,1:no,,0.845
3781,3049578,Table 1,BaselineCharacteristic,xx/x (xx/xx),No. of patients=xx (xxx%) ; ,?x/Mxa, EUS N stagea,30,1,3,no,1:no,1:no,,0.714
3787,3049870,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
3787,3049870,Table 1,BaselineCharacteristic,Number (%),,Characteristic,None,0,1,1,no,1:no,1:no,,0.749
3787,3049870,Table 1,BaselineCharacteristic,"Age, years",Characteristic ; ,None,None,1,0,24,no,1:no,1:no,,0.845
3787,3049870,Table 1,BaselineCharacteristic,"Age, years",Number (%) ; ,"Age, years",None,1,1,43,no,1:no,1:no,,0.785
3787,3049870,Table 1,BaselineCharacteristic,"?Median, range",Characteristic ; ,"?Median, range"," Age, years",2,0,2,no,1:no,1:no,,0.859
3787,3049870,Table 1,BaselineCharacteristic,"xx (xx, xx)",Number (%) ; ,"?Median, range"," Age, years",2,1,3,no,1:no,1:no,,0.584
3787,3049870,Table 1,BaselineCharacteristic,"?Sex, male",Characteristic ; ,"?Sex, male"," Age, years",3,0,2,no,1:no,1:no,,0.579
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,"?Sex, male"," Age, years",3,1,3,no,1:no,2:yes,+,0.642
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,no,1:no,1:no,,0.869
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,4,1,3,no,1:no,1:no,,0.705
3787,3049870,Table 1,BaselineCharacteristic,Performance status,Characteristic ; ,None,None,5,0,24,no,1:no,1:no,,0.877
3787,3049870,Table 1,BaselineCharacteristic,Performance status,Number (%) ; ,Performance status,None,5,1,43,no,1:no,1:no,,0.757
3787,3049870,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,6,0,2,no,1:no,1:no,,0.847
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?x, Performance status,6,1,3,no,1:no,1:no,,0.505
3787,3049870,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,7,0,2,no,1:no,1:no,,0.854
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?x, Performance status,7,1,3,no,1:no,1:no,,0.513
3787,3049870,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,8,0,2,no,1:no,1:no,,0.857
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?x, Performance status,8,1,3,no,1:no,1:no,,0.533
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,9,0,2,no,1:no,1:no,,0.891
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,9,1,3,no,1:no,1:no,,0.743
3787,3049870,Table 1,BaselineCharacteristic,Lymphoma stage at study entry,Characteristic ; ,None,None,10,0,24,no,1:no,1:no,,0.901
3787,3049870,Table 1,BaselineCharacteristic,Lymphoma stage at study entry,Number (%) ; ,Lymphoma stage at study entry,None,10,1,43,no,1:no,1:no,,0.828
3787,3049870,Table 1,BaselineCharacteristic,"?x, x",Characteristic ; ,"?x, x", Lymphoma stage at study entry,11,0,2,no,1:no,1:no,,0.883
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,"?x, x", Lymphoma stage at study entry,11,1,3,no,1:no,1:no,,0.666
3787,3049870,Table 1,BaselineCharacteristic,"?x, x",Characteristic ; ,"?x, x", Lymphoma stage at study entry,12,0,2,no,1:no,1:no,,0.883
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,"?x, x", Lymphoma stage at study entry,12,1,3,no,1:no,1:no,,0.67
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,13,0,2,no,1:no,1:no,,0.902
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,13,1,3,no,1:no,1:no,,0.769
3787,3049870,Table 1,BaselineCharacteristic,Disease type,Characteristic ; ,None,None,14,0,24,no,1:no,1:no,,0.754
3787,3049870,Table 1,BaselineCharacteristic,Disease type,Number (%) ; ,Disease type,None,14,1,43,no,1:no,1:no,,0.647
3787,3049870,Table 1,BaselineCharacteristic,?DLBCL,Characteristic ; ,?DLBCL, Disease type,15,0,2,no,1:no,1:no,,0.779
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?DLBCL, Disease type,15,1,3,no,1:no,1:no,,0.501
3787,3049870,Table 1,BaselineCharacteristic,?MCL,Characteristic ; ,?MCL, Disease type,16,0,2,no,1:no,1:no,,0.78
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?MCL, Disease type,16,1,3,no,1:no,1:no,,0.522
3787,3049870,Table 1,BaselineCharacteristic,?FL-III,Characteristic ; ,?FL-III, Disease type,17,0,2,no,1:no,1:no,,0.786
3787,3049870,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?FL-III, Disease type,17,1,3,no,1:no,1:no,,0.564
3787,3049870,Table 1,BaselineCharacteristic,?TL,Characteristic ; ,?TL, Disease type,18,0,2,no,1:no,1:no,,0.789
3787,3049870,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?TL, Disease type,18,1,3,no,1:no,1:no,,0.642
3787,3049870,Table 1,BaselineCharacteristic,?Precursor T-lymphoblastic leukemia/lymphoma,Characteristic ; ,?Precursor T-lymphoblastic leukemia/lymphoma, Disease type,19,0,2,no,1:no,1:no,,0.79
3787,3049870,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Precursor T-lymphoblastic leukemia/lymphoma, Disease type,19,1,3,no,1:no,1:no,,0.642
3787,3049870,Table 1,BaselineCharacteristic,?Unspecified high-grade B-cell lymphoma,Characteristic ; ,?Unspecified high-grade B-cell lymphoma, Disease type,20,0,2,no,1:no,1:no,,0.79
3787,3049870,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Unspecified high-grade B-cell lymphoma, Disease type,20,1,3,no,1:no,1:no,,0.643
3787,3049870,Table 1,BaselineCharacteristic,Previous stem cell transplant,Characteristic ; ,Previous stem cell transplant,,21,0,2,no,1:no,1:no,,0.917
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,Previous stem cell transplant,,21,1,3,no,1:no,1:no,,0.692
3787,3049870,Table 1,BaselineCharacteristic,Presence of B symptoms,Characteristic ; ,Presence of B symptoms,,22,0,2,no,1:no,1:no,,0.855
3787,3049870,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,Presence of B symptoms,,22,1,3,no,1:no,1:no,,0.739
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,23,0,2,no,1:no,1:no,,0.913
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,23,1,3,no,1:no,1:no,,0.82
3787,3049870,Table 1,BaselineCharacteristic,Number of previous therapy treatments,Characteristic ; ,None,None,24,0,24,no,1:no,1:no,,0.905
3787,3049870,Table 1,BaselineCharacteristic,Number of previous therapy treatments,Number (%) ; ,Number of previous therapy treatments,None,24,1,43,no,1:no,1:no,,0.857
3787,3049870,Table 1,BaselineCharacteristic,"?Median, range",Characteristic ; ,"?Median, range", Number of previous therapy treatments,25,0,2,no,1:no,1:no,,0.912
3787,3049870,Table 1,BaselineCharacteristic,"x (x, xx)",Number (%) ; ,"?Median, range", Number of previous therapy treatments,25,1,3,no,1:no,1:no,,0.811
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,26,0,2,no,1:no,1:no,,0.913
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,26,1,3,no,1:no,1:no,,0.822
3787,3049870,Table 1,BaselineCharacteristic,Type of previous therapy,Characteristic ; ,None,None,27,0,24,no,1:no,1:no,,0.803
3787,3049870,Table 1,BaselineCharacteristic,Type of previous therapy,Number (%) ; ,Type of previous therapy,None,27,1,43,no,1:no,1:no,,0.741
3787,3049870,Table 1,BaselineCharacteristic,?Rituximab,Characteristic ; ,?Rituximab, Type of previous therapy,28,0,2,no,1:no,1:no,,0.8
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Rituximab, Type of previous therapy,28,1,3,no,1:no,1:no,,0.647
3787,3049870,Table 1,BaselineCharacteristic,?Anthracycline,Characteristic ; ,?Anthracycline, Type of previous therapy,29,0,2,no,1:no,1:no,,0.8
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Anthracycline, Type of previous therapy,29,1,3,no,1:no,1:no,,0.647
3950,3080287,Table 1,BaselineCharacteristic,site,,None,None,0,0,12,no,1:no,1:no,,0.793
3950,3080287,Table 1,BaselineCharacteristic,maxillary sinus,,site,None,0,1,1,no,1:no,1:no,,0.735
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,site,None,0,2,1,no,1:no,1:no,,0.671
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,1,0,12,no,1:no,1:no,,0.792
3950,3080287,Table 1,BaselineCharacteristic,nasal cavity,,,None,1,1,1,no,1:no,1:no,,0.716
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,1,2,1,no,1:no,1:no,,0.753
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,2,0,12,no,1:no,1:no,,0.805
3950,3080287,Table 1,BaselineCharacteristic,ethmoid sinus,,,None,2,1,1,no,1:no,1:no,,0.717
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,2,2,1,no,1:no,1:no,,0.758
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,3,0,12,no,1:no,1:no,,0.798
3950,3080287,Table 1,BaselineCharacteristic,sphenoid sinus,,,None,3,1,1,no,1:no,1:no,,0.718
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,None,3,2,1,no,1:no,1:no,,0.754
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,4,0,12,no,1:no,1:no,,0.817
3950,3080287,Table 1,BaselineCharacteristic,pansinus,,,None,4,1,1,no,1:no,1:no,,0.738
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,4,2,1,no,1:no,1:no,,0.764
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,0,2,no,1:no,1:no,,0.866
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,1,3,no,1:no,1:no,,0.746
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,2,3,no,1:no,1:no,,0.775
3950,3080287,Table 1,BaselineCharacteristic,histology,,histology,,6,0,24,no,1:no,1:no,,0.796
3950,3080287,Table 1,BaselineCharacteristic,adenoidcystic carcinoma,,histology,,6,1,43,no,1:no,1:no,,0.759
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,histology,,6,2,43,no,1:no,1:no,,0.581
3950,3080287,Table 1,BaselineCharacteristic,,,,,7,0,2,no,1:no,1:no,,0.836
3950,3080287,Table 1,BaselineCharacteristic,malignant melanoma,,,,7,1,3,no,1:no,1:no,,0.705
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,7,2,3,no,1:no,1:no,,0.703
3950,3080287,Table 1,BaselineCharacteristic,,,,,8,0,2,no,1:no,1:no,,0.837
3950,3080287,Table 1,BaselineCharacteristic,undifferentiated carcinoma,,,,8,1,3,no,1:no,1:no,,0.755
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,8,2,3,no,1:no,1:no,,0.726
3950,3080287,Table 1,BaselineCharacteristic,,,,,9,0,2,no,1:no,1:no,,0.856
3950,3080287,Table 1,BaselineCharacteristic,chordoma,,,,9,1,3,no,1:no,1:no,,0.752
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,9,2,3,no,1:no,1:no,,0.749
3950,3080287,Table 1,BaselineCharacteristic,,,,,10,0,2,no,1:no,1:no,,0.863
3950,3080287,Table 1,BaselineCharacteristic,chondrosarcoma,,,,10,1,3,no,1:no,1:no,,0.766
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,10,2,3,no,1:no,1:no,,0.762
3950,3080287,Table 1,BaselineCharacteristic,,,,,11,0,2,no,1:no,1:no,,0.867
3950,3080287,Table 1,BaselineCharacteristic,osteosarcoma,,,,11,1,3,no,1:no,1:no,,0.776
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,11,2,3,no,1:no,1:no,,0.772
3950,3080287,Table 1,BaselineCharacteristic,,,,,12,0,2,no,1:no,1:no,,0.873
3950,3080287,Table 1,BaselineCharacteristic,ameloblastic carcinoma,,,,12,1,3,no,1:no,1:no,,0.809
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,12,2,3,no,1:no,1:no,,0.776
3950,3080287,Table 1,BaselineCharacteristic,,,,,13,0,2,no,1:no,1:no,,0.873
3950,3080287,Table 1,BaselineCharacteristic,malignant peripheral nerve sheath tumour,,,,13,1,3,no,1:no,1:no,,0.812
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,13,2,3,no,1:no,1:no,,0.776
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,0,2,no,1:no,1:no,,0.892
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,1,3,no,1:no,1:no,,0.813
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,2,3,no,1:no,1:no,,0.826
3950,3080287,Table 1,BaselineCharacteristic,stage,,stage,,15,0,24,no,1:no,1:no,,0.861
3950,3080287,Table 1,BaselineCharacteristic,Tx,,stage,,15,1,43,no,1:no,1:no,,0.84
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,stage,,15,2,43,no,1:no,1:no,,0.741
3950,3080287,Table 1,BaselineCharacteristic,,,,,16,0,2,no,1:no,1:no,,0.875
3950,3080287,Table 1,BaselineCharacteristic,Tx,,,,16,1,3,no,1:no,1:no,,0.809
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,16,2,3,no,1:no,1:no,,0.77
3950,3080287,Table 1,BaselineCharacteristic,,,,,17,0,2,no,1:no,1:no,,0.888
3950,3080287,Table 1,BaselineCharacteristic,Tx,,,,17,1,3,no,1:no,1:no,,0.825
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,17,2,3,no,1:no,1:no,,0.808
3950,3080287,Table 1,BaselineCharacteristic,,,,,18,0,2,no,1:no,1:no,,0.891
3950,3080287,Table 1,BaselineCharacteristic,N+,,,,18,1,3,no,1:no,1:no,,0.826
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,18,2,3,no,1:no,1:no,,0.812
3950,3080287,Table 1,BaselineCharacteristic,,,,,19,0,2,no,1:no,1:no,,0.891
3950,3080287,Table 1,BaselineCharacteristic,not applicable,,,,19,1,3,no,1:no,1:no,,0.833
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,19,2,3,no,1:no,1:no,,0.812
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,0,2,no,1:no,1:no,,0.902
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,1,3,no,1:no,1:no,,0.832
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,2,3,no,1:no,1:no,,0.843
3950,3080287,Table 1,BaselineCharacteristic,therapy,,therapy,,21,0,24,no,1:no,1:no,,0.865
3950,3080287,Table 1,BaselineCharacteristic,primary,,therapy,,21,1,43,no,1:no,1:no,,0.836
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,therapy,,21,2,43,no,1:no,1:no,,0.747
3950,3080287,Table 1,BaselineCharacteristic,,,,,22,0,2,no,1:no,1:no,,0.893
3950,3080287,Table 1,BaselineCharacteristic,local relapse,,,,22,1,3,no,1:no,1:no,,0.829
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,22,2,3,no,1:no,1:no,,0.817
3950,3080287,Table 1,BaselineCharacteristic,,,,,23,0,2,no,1:no,1:no,,0.894
3950,3080287,Table 1,BaselineCharacteristic,reirradiation,,,,23,1,3,no,1:no,1:no,,0.831
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,23,2,3,no,1:no,1:no,,0.821
3950,3080287,Table 1,BaselineCharacteristic,,,,,24,0,2,no,1:no,1:no,,0.894
3950,3080287,Table 1,BaselineCharacteristic,Rx-resected,,,,24,1,3,no,1:no,1:no,,0.831
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,,,24,2,3,no,1:no,1:no,,0.765
3950,3080287,Table 1,BaselineCharacteristic,,,,,25,0,2,no,1:no,1:no,,0.895
3950,3080287,Table 1,BaselineCharacteristic,Rx-resected/definitive RT,,,,25,1,3,no,1:no,1:no,,0.834
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,,,25,2,3,no,1:no,1:no,,0.769
3950,3080287,Table 1,BaselineCharacteristic,,,,,26,0,2,no,1:no,1:no,,0.895
3950,3080287,Table 1,BaselineCharacteristic,orbital exenteration,,,,26,1,3,no,1:no,1:no,,0.834
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,26,2,3,no,1:no,1:no,,0.825
3950,3080287,Table 1,BaselineCharacteristic,,,,,27,0,2,no,1:no,1:no,,0.895
3950,3080287,Table 1,BaselineCharacteristic,post-induction,,,,27,1,3,no,1:no,1:no,,0.834
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,27,2,3,no,1:no,1:no,,0.825
3950,3080287,Table 1,BaselineCharacteristic,,,,,28,0,2,no,1:no,1:no,,0.895
3950,3080287,Table 1,BaselineCharacteristic,comb. Radioimmunotherapy,,,,28,1,3,no,1:no,1:no,,0.834
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,28,2,3,no,1:no,1:no,,0.825
3950,3080287,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
3950,3080287,Table 2,BaselineCharacteristic,median dose/GyE or Gy,,,None,0,1,1,no,1:no,1:no,,0.771
3950,3080287,Table 2,BaselineCharacteristic,range/GyE or Gy,,,None,0,2,1,no,1:no,1:no,,0.782
3950,3080287,Table 2,BaselineCharacteristic,Cxx, ; ,Cxx,,1,0,2,no,1:no,1:no,,0.813
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,Cxx,,1,1,3,no,1:no,1:no,,0.605
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,Cxx,,1,2,3,no,1:no,1:no,,0.57
3950,3080287,Table 2,BaselineCharacteristic,IMRT, ; ,IMRT,,2,0,2,no,1:no,1:no,,0.831
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,IMRT,,2,1,3,no,1:no,1:no,,0.61
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,IMRT,,2,2,3,no,1:no,1:no,,0.576
3950,3080287,Table 2,BaselineCharacteristic,total, ; ,total,,3,0,24,no,1:no,1:no,,0.67
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,total,,3,1,43,no,1:no,1:no,,0.534
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,total,,3,2,43,no,1:no,2:yes,+,0.504
3950,3080287,Table 2,BaselineCharacteristic,, ; ,,,4,0,2,no,1:no,1:no,,0.826
3950,3080287,Table 2,BaselineCharacteristic,median volume/cc,median dose/GyE or Gy ; ,,,4,1,3,no,1:no,1:no,,0.746
3950,3080287,Table 2,BaselineCharacteristic,range/cc,range/GyE or Gy ; ,,,4,2,3,no,1:no,1:no,,0.714
3950,3080287,Table 2,BaselineCharacteristic,CTVx, ; ,CTVx,,5,0,2,no,1:no,1:no,,0.828
3950,3080287,Table 2,BaselineCharacteristic,xxx.x,median dose/GyE or Gy ; ,CTVx,,5,1,3,no,1:no,1:no,,0.665
3950,3080287,Table 2,BaselineCharacteristic,xx.x - xxx.x,range/GyE or Gy ; ,CTVx,,5,2,3,no,1:no,1:no,,0.518
3950,3080287,Table 2,BaselineCharacteristic,CTVx, ; ,CTVx,,6,0,2,no,1:no,1:no,,0.826
3950,3080287,Table 2,BaselineCharacteristic,xxx.x,median dose/GyE or Gy ; ,CTVx,,6,1,3,no,1:no,1:no,,0.671
3950,3080287,Table 2,BaselineCharacteristic,xxx.x - xxxx.x,range/GyE or Gy ; ,CTVx,,6,2,3,no,1:no,1:no,,0.622
3950,3080287,Table 2,BaselineCharacteristic,, ; ,None,None,7,0,2,no,1:no,1:no,,0.869
3950,3080287,Table 2,BaselineCharacteristic,,median dose/GyE or Gy ; ,None,None,7,1,3,no,1:no,1:no,,0.797
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,None,None,7,2,3,no,1:no,1:no,,0.784
3950,3080287,Table 2,BaselineCharacteristic,combined treatment, ; ,combined treatment,,8,0,2,no,1:no,1:no,,0.837
3950,3080287,Table 2,BaselineCharacteristic,xx pts,median dose/GyE or Gy ; ,combined treatment,,8,1,3,no,1:no,1:no,,0.667
3950,3080287,Table 2,BaselineCharacteristic,(x fractions Cxx),range/GyE or Gy ; ,combined treatment,,8,2,3,no,1:no,1:no,,0.741
3950,3080287,Table 2,BaselineCharacteristic,step& shoot IMRT, ; ,step& shoot IMRT,,9,0,2,no,1:no,1:no,,0.856
3950,3080287,Table 2,BaselineCharacteristic,xx pts,median dose/GyE or Gy ; ,step& shoot IMRT,,9,1,3,no,1:no,1:no,,0.674
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,step& shoot IMRT,,9,2,3,no,1:no,1:no,,0.771
3950,3080287,Table 2,BaselineCharacteristic,tomotherapy, ; ,tomotherapy,,10,0,2,no,1:no,1:no,,0.863
3950,3080287,Table 2,BaselineCharacteristic,x pts,median dose/GyE or Gy ; ,tomotherapy,,10,1,3,no,1:no,1:no,,0.789
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,tomotherapy,,10,2,3,no,1:no,1:no,,0.784
3950,3080287,Table 2,BaselineCharacteristic,Cxx only, ; ,Cxx only,,11,0,2,no,1:no,1:no,,0.867
3950,3080287,Table 2,BaselineCharacteristic,x pts,median dose/GyE or Gy ; ,Cxx only,,11,1,3,no,1:no,1:no,,0.794
3950,3080287,Table 2,BaselineCharacteristic,(xx-xx fractions),range/GyE or Gy ; ,Cxx only,,11,2,3,no,1:no,1:no,,0.794
4000,3095543,Table 1,BaselineCharacteristic,Clinical characterisitics,,None,None,0,0,,no,1:no,1:no,,0.799
4000,3095543,Table 1,BaselineCharacteristic,Mean (SD),,None,None,0,1,,no,1:no,1:no,,0.766
4000,3095543,Table 1,BaselineCharacteristic,"Age, y",Clinical characterisitics ; ,None,None,1,0,,no,1:no,1:no,,0.854
4000,3095543,Table 1,BaselineCharacteristic,x.xx (x.xx),Mean (SD) ; ,None,None,1,1,,no,1:no,1:no,,0.676
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ; ",None,None,2,0,,no,1:no,1:no,,0.859
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ; ,None,None,2,1,,no,1:no,1:no,,0.682
4000,3095543,Table 1,BaselineCharacteristic,IQ (WISC-III Full Scale),"Clinical characterisitics ; Age, y ;  ; ",None,None,3,0,,no,1:no,1:no,,0.848
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; ,None,None,3,1,,no,1:no,1:no,,0.682
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ; ",None,None,4,0,,no,1:no,1:no,,0.866
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ; ,None,None,4,1,,no,1:no,1:no,,0.688
4000,3095543,Table 1,BaselineCharacteristic,"Mother's age, y","Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; ",None,None,5,0,,no,1:no,1:no,,0.873
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (x.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; ,None,None,5,1,,no,1:no,1:no,,0.712
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ; ",None,None,6,0,,no,1:no,1:no,,0.873
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ; ,None,None,6,1,,no,1:no,1:no,,0.716
4000,3095543,Table 1,BaselineCharacteristic,"Mother's education, y","Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; ",None,None,7,0,,no,1:no,1:no,,0.871
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (x.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,7,1,,no,1:no,1:no,,0.716
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ; ",None,None,8,0,,no,1:no,1:no,,0.879
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ; ,None,None,8,1,,no,1:no,1:no,,0.735
4000,3095543,Table 1,BaselineCharacteristic,CBCL scales,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,9,0,,no,1:no,1:no,,0.889
4000,3095543,Table 1,BaselineCharacteristic,CBCL scales,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,9,1,,no,1:no,1:no,,0.755
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,10,0,,no,1:no,1:no,,0.893
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,10,1,,no,1:no,1:no,,0.768
4000,3095543,Table 1,BaselineCharacteristic,Aggression,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Aggression, CBCL scales,11,0,,no,1:no,1:no,,0.859
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Aggression, CBCL scales,11,1,,no,1:no,1:no,,0.737
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,12,0,,no,1:no,1:no,,0.898
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,12,1,,no,1:no,1:no,,0.79
4000,3095543,Table 1,BaselineCharacteristic,Attention Problems,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Attention Problems, CBCL scales,13,0,,no,1:no,1:no,,0.868
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (x.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Attention Problems, CBCL scales,13,1,,no,1:no,1:no,,0.737
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,14,0,,no,1:no,1:no,,0.898
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,14,1,,no,1:no,1:no,,0.78
4000,3095543,Table 1,BaselineCharacteristic,CPRS scales,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,15,0,,no,1:no,1:no,,0.898
4000,3095543,Table 1,BaselineCharacteristic,CPRS scales,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,15,1,,no,1:no,1:no,,0.78
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,16,0,,no,1:no,1:no,,0.898
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,16,1,,no,1:no,1:no,,0.78
4000,3095543,Table 1,BaselineCharacteristic,Restless-Impulsive,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Restless-Impulsive, CPRS scales,17,0,,no,1:no,1:no,,0.885
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (x.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Restless-Impulsive, CPRS scales,17,1,,no,1:no,1:no,,0.749
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,18,0,,no,1:no,1:no,,0.912
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,18,1,,no,1:no,1:no,,0.805
4000,3095543,Table 1,BaselineCharacteristic,Emotional Lability,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Emotional Lability, CPRS scales,19,0,,no,1:no,1:no,,0.889
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Emotional Lability, CPRS scales,19,1,,no,1:no,1:no,,0.755
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,20,0,,no,1:no,1:no,,0.913
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,20,1,,no,1:no,1:no,,0.812
4000,3095543,Table 1,BaselineCharacteristic,CTRS scales,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,21,0,,no,1:no,1:no,,0.913
4000,3095543,Table 1,BaselineCharacteristic,CTRS scales,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,21,1,,no,1:no,1:no,,0.812
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,22,0,,no,1:no,1:no,,0.914
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,22,1,,no,1:no,1:no,,0.819
4000,3095543,Table 1,BaselineCharacteristic,Restless-Impulsive,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Restless-Impulsive, CTRS scales,23,0,,no,1:no,1:no,,0.891
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Restless-Impulsive, CTRS scales,23,1,,no,1:no,1:no,,0.772
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,24,0,,no,1:no,1:no,,0.915
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,24,1,,no,1:no,1:no,,0.823
4000,3095543,Table 1,BaselineCharacteristic,Emotional Lability,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Emotional Lability, CTRS scales,25,0,,no,1:no,1:no,,0.892
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Emotional Lability, CTRS scales,25,1,,no,1:no,1:no,,0.775
4021,3101364,Table 1.,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
4021,3101364,Table 1.,BaselineCharacteristic,No. of patients,,Characteristic,None,0,1,1,no,1:no,1:no,,0.787
4021,3101364,Table 1.,BaselineCharacteristic,No. of patients entered,Characteristic ; ,No. of patients entered,,1,0,2,no,1:no,1:no,,0.731
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,No. of patients entered,,1,1,3,no,1:no,2:yes,+,0.535
4021,3101364,Table 1.,BaselineCharacteristic,No. of patients eligible,Characteristic ; ,No. of patients eligible,,2,0,2,no,1:no,1:no,,0.739
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,No. of patients eligible,,2,1,3,no,1:no,2:yes,+,0.534
4021,3101364,Table 1.,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,3,0,24,no,1:no,1:no,,0.845
4021,3101364,Table 1.,BaselineCharacteristic,Age (years),No. of patients ; ,Age (years),None,3,1,43,no,1:no,1:no,,0.781
4021,3101364,Table 1.,BaselineCharacteristic,????Median,Characteristic ; ,????Median, Age (years)   ,4,0,2,no,1:no,1:no,,0.85
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Median, Age (years)   ,4,1,3,no,1:no,1:no,,0.587
4021,3101364,Table 1.,BaselineCharacteristic,????Range,Characteristic ; ,????Range, Age (years)   ,5,0,2,no,1:no,1:no,,0.836
4021,3101364,Table 1.,BaselineCharacteristic,Performance status,Characteristic ; ,None,None,6,0,24,no,1:no,1:no,,0.877
4021,3101364,Table 1.,BaselineCharacteristic,Performance status,No. of patients ; ,Performance status,None,6,1,43,no,1:no,1:no,,0.824
4021,3101364,Table 1.,BaselineCharacteristic,????x,Characteristic ; ,????x, Performance status   ,7,0,2,no,1:no,1:no,,0.854
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????x, Performance status   ,7,1,3,no,1:no,1:no,,0.625
4021,3101364,Table 1.,BaselineCharacteristic,????x,Characteristic ; ,????x, Performance status   ,8,0,2,no,1:no,1:no,,0.857
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????x, Performance status   ,8,1,3,no,1:no,1:no,,0.668
4021,3101364,Table 1.,BaselineCharacteristic,Histology,Characteristic ; ,None,None,9,0,24,no,1:no,1:no,,0.877
4021,3101364,Table 1.,BaselineCharacteristic,Histology,No. of patients ; ,Histology,None,9,1,43,no,1:no,1:no,,0.825
4021,3101364,Table 1.,BaselineCharacteristic,????Squamous cell carcinoma,Characteristic ; ,????Squamous cell carcinoma, Histology   ,10,0,2,no,1:no,1:no,,0.9
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Squamous cell carcinoma, Histology   ,10,1,3,no,1:no,1:no,,0.679
4021,3101364,Table 1.,BaselineCharacteristic,????Adenocarcinoma,Characteristic ; ,????Adenocarcinoma, Histology   ,11,0,2,no,1:no,1:no,,0.888
4021,3101364,Table 1.,BaselineCharacteristic,x,No. of patients ; ,????Adenocarcinoma, Histology   ,11,1,3,no,1:no,1:no,,0.731
4021,3101364,Table 1.,BaselineCharacteristic,????Adenosquamous,Characteristic ; ,????Adenosquamous, Histology   ,12,0,2,no,1:no,1:no,,0.894
4021,3101364,Table 1.,BaselineCharacteristic,x,No. of patients ; ,????Adenosquamous, Histology   ,12,1,3,no,1:no,1:no,,0.75
4021,3101364,Table 1.,BaselineCharacteristic,????Small cell carcinoma,Characteristic ; ,????Small cell carcinoma, Histology   ,13,0,2,no,1:no,1:no,,0.906
4021,3101364,Table 1.,BaselineCharacteristic,x,No. of patients ; ,????Small cell carcinoma, Histology   ,13,1,3,no,1:no,1:no,,0.794
4021,3101364,Table 1.,BaselineCharacteristic,Site of disease,Characteristic ; ,None,None,14,0,24,no,1:no,1:no,,0.88
4021,3101364,Table 1.,BaselineCharacteristic,Site of disease,No. of patients ; ,Site of disease,None,14,1,43,no,1:no,1:no,,0.837
4021,3101364,Table 1.,BaselineCharacteristic,????Pelvic,Characteristic ; ,????Pelvic, Site of disease   ,15,0,2,no,1:no,1:no,,0.87
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Pelvic, Site of disease   ,15,1,3,no,1:no,1:no,,0.657
4021,3101364,Table 1.,BaselineCharacteristic,????Distant,Characteristic ; ,????Distant, Site of disease   ,16,0,2,no,1:no,1:no,,0.871
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Distant, Site of disease   ,16,1,3,no,1:no,1:no,,0.658
4021,3101364,Table 1.,BaselineCharacteristic,????Both,Characteristic ; ,????Both, Site of disease   ,17,0,2,no,1:no,1:no,,0.883
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Both, Site of disease   ,17,1,3,no,1:no,1:no,,0.678
4021,3101364,Table 1.,BaselineCharacteristic,Prior therapy,Characteristic ; ,None,None,18,0,24,no,1:no,1:no,,0.909
4021,3101364,Table 1.,BaselineCharacteristic,Prior therapy,No. of patients ; ,Prior therapy,None,18,1,43,no,1:no,1:no,,0.89
4021,3101364,Table 1.,BaselineCharacteristic,????Prior radiotherapy,Characteristic ; ,????Prior radiotherapy, Prior therapy   ,19,0,2,no,1:no,1:no,,0.914
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Prior radiotherapy, Prior therapy   ,19,1,3,no,1:no,1:no,,0.716
4021,3101364,Table 1.,BaselineCharacteristic,?Prior chemotherapya,Characteristic ; ,?Prior chemotherapya, Prior therapy,20,0,24,no,1:no,1:no,,0.886
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,?Prior chemotherapya, Prior therapy,20,1,43,no,1:no,1:no,,0.711
4021,3101364,Table 1.,BaselineCharacteristic,????Prior chemoradiotherapy,Characteristic ; ,????Prior chemoradiotherapy, Prior therapy ?Prior chemotherapya  ,21,0,2,no,1:no,1:no,,0.914
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Prior chemoradiotherapy, Prior therapy ?Prior chemotherapya  ,21,1,3,no,1:no,1:no,,0.717
4021,3101364,Table 1.,BaselineCharacteristic,????Prior platinum therapy,Characteristic ; ,????Prior platinum therapy, Prior therapy ?Prior chemotherapya  ,22,0,2,no,1:no,1:no,,0.916
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Prior platinum therapy, Prior therapy ?Prior chemotherapya  ,22,1,3,no,1:no,1:no,,0.719
4021,3101364,Table 2.,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
4021,3101364,Table 2.,BaselineCharacteristic,n,,,None,0,1,1,no,1:no,1:no,,0.703
4021,3101364,Table 2.,BaselineCharacteristic,CR,,,None,0,2,1,no,1:no,1:no,,0.775
4021,3101364,Table 2.,BaselineCharacteristic,PR,,,None,0,3,1,no,1:no,1:no,,0.79
4021,3101364,Table 2.,BaselineCharacteristic,SD,,,None,0,4,1,no,1:no,1:no,,0.804
4021,3101364,Table 2.,BaselineCharacteristic,PD,,,None,0,5,1,no,1:no,1:no,,0.795
4021,3101364,Table 2.,BaselineCharacteristic,Response rate (xx% CI),,,None,0,6,1,no,1:no,1:no,,0.753
4021,3101364,Table 2.,BaselineCharacteristic,Overall, ; ,Overall,,1,0,2,no,1:no,1:no,,0.796
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,Overall,,1,1,3,no,1:no,1:no,,0.535
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,Overall,,1,2,3,no,1:no,1:no,,0.65
4021,3101364,Table 2.,BaselineCharacteristic,xx,PR ; ,Overall,,1,3,3,no,1:no,1:no,,0.59
4021,3101364,Table 2.,BaselineCharacteristic,xx,SD ; ,Overall,,1,4,3,no,1:no,1:no,,0.65
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,Overall,,1,5,3,no,1:no,1:no,,0.68
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy, ; ,None,None,2,0,24,no,1:no,1:no,,0.83
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,n ; ,Prior therapy,None,2,1,43,no,1:no,1:no,,0.71
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,CR ; ,Prior therapy,None,2,2,43,no,1:no,1:no,,0.806
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,PR ; ,Prior therapy,None,2,3,43,no,1:no,1:no,,0.823
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,SD ; ,Prior therapy,None,2,4,43,no,1:no,1:no,,0.844
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,PD ; ,Prior therapy,None,2,5,43,no,1:no,1:no,,0.829
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,Response rate (xx% CI) ; ,Prior therapy,None,2,6,43,no,1:no,1:no,,0.78
4021,3101364,Table 2.,BaselineCharacteristic,????Chemotherapy, ; ,????Chemotherapy, Prior therapy   ,3,0,2,no,1:no,1:no,,0.846
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,????Chemotherapy, Prior therapy   ,3,1,3,no,1:no,1:no,,0.642
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,????Chemotherapy, Prior therapy   ,3,2,3,no,1:no,1:no,,0.718
4021,3101364,Table 2.,BaselineCharacteristic,x,PR ; ,????Chemotherapy, Prior therapy   ,3,3,3,no,1:no,1:no,,0.739
4021,3101364,Table 2.,BaselineCharacteristic,x,SD ; ,????Chemotherapy, Prior therapy   ,3,4,3,no,1:no,1:no,,0.76
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,????Chemotherapy, Prior therapy   ,3,5,3,no,1:no,1:no,,0.752
4021,3101364,Table 2.,BaselineCharacteristic,????Chemoradiotherapy, ; ,????Chemoradiotherapy, Prior therapy   ,4,0,2,no,1:no,1:no,,0.839
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,????Chemoradiotherapy, Prior therapy   ,4,1,3,no,1:no,1:no,,0.61
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,????Chemoradiotherapy, Prior therapy   ,4,2,3,no,1:no,1:no,,0.708
4021,3101364,Table 2.,BaselineCharacteristic,x,PR ; ,????Chemoradiotherapy, Prior therapy   ,4,3,3,no,1:no,1:no,,0.727
4021,3101364,Table 2.,BaselineCharacteristic,x,SD ; ,????Chemoradiotherapy, Prior therapy   ,4,4,3,no,1:no,1:no,,0.755
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,????Chemoradiotherapy, Prior therapy   ,4,5,3,no,1:no,1:no,,0.74
4021,3101364,Table 2.,BaselineCharacteristic,????Platinum therapy, ; ,????Platinum therapy, Prior therapy   ,5,0,2,no,1:no,1:no,,0.841
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,????Platinum therapy, Prior therapy   ,5,1,3,no,1:no,1:no,,0.618
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,????Platinum therapy, Prior therapy   ,5,2,3,no,1:no,1:no,,0.724
4021,3101364,Table 2.,BaselineCharacteristic,x,PR ; ,????Platinum therapy, Prior therapy   ,5,3,3,no,1:no,1:no,,0.747
4021,3101364,Table 2.,BaselineCharacteristic,xx,SD ; ,????Platinum therapy, Prior therapy   ,5,4,3,no,1:no,1:no,,0.702
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,????Platinum therapy, Prior therapy   ,5,5,3,no,1:no,1:no,,0.758
4021,3101364,Table 2.,BaselineCharacteristic,????No platinum therapy, ; ,????No platinum therapy, Prior therapy   ,6,0,2,no,1:no,1:no,,0.787
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,????No platinum therapy, Prior therapy   ,6,1,3,no,1:no,1:no,,0.588
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,????No platinum therapy, Prior therapy   ,6,2,3,no,1:no,1:no,,0.618
4021,3101364,Table 2.,BaselineCharacteristic,x,PR ; ,????No platinum therapy, Prior therapy   ,6,3,3,no,1:no,1:no,,0.651
4021,3101364,Table 2.,BaselineCharacteristic,x,SD ; ,????No platinum therapy, Prior therapy   ,6,4,3,no,1:no,1:no,,0.706
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,????No platinum therapy, Prior therapy   ,6,5,3,no,1:no,1:no,,0.678
4275,3170974,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
4275,3170974,Table 1,BaselineCharacteristic,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d.,,,None,0,1,1,no,1:no,1:no,,0.605
4275,3170974,Table 1,BaselineCharacteristic,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d.,,,None,0,2,1,no,1:no,1:no,,0.598
4275,3170974,Table 1,BaselineCharacteristic,"Median age (range), years", ; ,"Median age (range), years",,1,0,2,no,1:no,1:no,,0.835
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,2,0,2,no,1:no,1:no,,0.842
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,2,1,3,no,1:no,1:no,,0.56
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,2,2,3,no,1:no,1:no,,0.587
4275,3170974,Table 1,BaselineCharacteristic,"Sex, n (%)", ; ,None,None,3,0,24,no,1:no,1:no,,0.568
4275,3170974,Table 1,BaselineCharacteristic,"Sex, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Sex, n (%)",None,3,1,43,no,1:no,2:yes,+,0.632
4275,3170974,Table 1,BaselineCharacteristic,"Sex, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Sex, n (%)",None,3,2,43,no,1:no,2:yes,+,0.605
4275,3170974,Table 1,BaselineCharacteristic,?Male, ; ,?Male," Sex, n (%)",4,0,2,no,1:no,2:yes,+,0.58
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Male," Sex, n (%)",4,1,3,yes,2:yes,2:yes,,0.753
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Male," Sex, n (%)",4,2,3,yes,2:yes,2:yes,,0.733
4275,3170974,Table 1,BaselineCharacteristic,?Female, ; ,?Female," Sex, n (%)",5,0,2,no,1:no,2:yes,+,0.523
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Female," Sex, n (%)",5,1,3,yes,2:yes,2:yes,,0.757
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Female," Sex, n (%)",5,2,3,yes,2:yes,2:yes,,0.737
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,6,0,2,no,1:no,1:no,,0.866
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,6,1,3,no,1:no,1:no,,0.577
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,6,2,3,no,1:no,1:no,,0.607
4275,3170974,Table 1,BaselineCharacteristic,"Tumor-related symptoms, n (%)", ; ,"Tumor-related symptoms, n (%)",,7,0,24,no,1:no,1:no,,0.666
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Tumor-related symptoms, n (%)",,7,1,43,no,1:no,1:no,,0.507
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Tumor-related symptoms, n (%)",,7,2,43,no,1:no,1:no,,0.525
4275,3170974,Table 1,BaselineCharacteristic,?Appetite loss, ; ,?Appetite loss," Tumor-related symptoms, n (%)",8,0,2,no,1:no,1:no,,0.733
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Appetite loss," Tumor-related symptoms, n (%)",8,1,3,no,1:no,1:no,,0.506
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Appetite loss," Tumor-related symptoms, n (%)",8,2,3,no,1:no,1:no,,0.539
4275,3170974,Table 1,BaselineCharacteristic,?Nausea/vomiting, ; ,?Nausea/vomiting," Tumor-related symptoms, n (%)",9,0,2,no,1:no,1:no,,0.731
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Nausea/vomiting," Tumor-related symptoms, n (%)",9,1,3,no,1:no,1:no,,0.519
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Nausea/vomiting," Tumor-related symptoms, n (%)",9,2,3,no,1:no,1:no,,0.538
4275,3170974,Table 1,BaselineCharacteristic,?Weight loss, ; ,?Weight loss," Tumor-related symptoms, n (%)",10,0,2,no,1:no,1:no,,0.762
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Weight loss," Tumor-related symptoms, n (%)",10,1,3,no,1:no,1:no,,0.547
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Weight loss," Tumor-related symptoms, n (%)",10,2,3,no,1:no,1:no,,0.561
4275,3170974,Table 1,BaselineCharacteristic,?Pain, ; ,?Pain," Tumor-related symptoms, n (%)",11,0,2,no,1:no,1:no,,0.757
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Pain," Tumor-related symptoms, n (%)",11,1,3,no,1:no,1:no,,0.534
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Pain," Tumor-related symptoms, n (%)",11,2,3,no,1:no,1:no,,0.539
4275,3170974,Table 1,BaselineCharacteristic,?Dysphagia, ; ,?Dysphagia," Tumor-related symptoms, n (%)",12,0,2,no,1:no,1:no,,0.757
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Dysphagia," Tumor-related symptoms, n (%)",12,1,3,no,1:no,1:no,,0.538
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Dysphagia," Tumor-related symptoms, n (%)",12,2,3,no,1:no,1:no,,0.539
4275,3170974,Table 1,BaselineCharacteristic,?Other, ; ,?Other," Tumor-related symptoms, n (%)",13,0,2,no,1:no,1:no,,0.757
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Other," Tumor-related symptoms, n (%)",13,1,3,no,1:no,1:no,,0.55
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Other," Tumor-related symptoms, n (%)",13,2,3,no,1:no,1:no,,0.551
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,14,0,2,no,1:no,1:no,,0.892
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,14,1,3,no,1:no,1:no,,0.632
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,14,2,3,no,1:no,1:no,,0.644
4275,3170974,Table 1,BaselineCharacteristic,"ECOG performance status, n (%)", ; ,None,None,15,0,24,no,1:no,1:no,,0.817
4275,3170974,Table 1,BaselineCharacteristic,"ECOG performance status, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"ECOG performance status, n (%)",None,15,1,43,no,1:no,1:no,,0.578
4275,3170974,Table 1,BaselineCharacteristic,"ECOG performance status, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"ECOG performance status, n (%)",None,15,2,43,no,1:no,1:no,,0.577
4275,3170974,Table 1,BaselineCharacteristic,?x, ; ,?x," ECOG performance status, n (%)",16,0,2,no,1:no,1:no,,0.728
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",16,1,3,no,1:no,1:no,,0.569
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",16,2,3,no,1:no,1:no,,0.549
4275,3170974,Table 1,BaselineCharacteristic,?x, ; ,?x," ECOG performance status, n (%)",17,0,2,no,1:no,1:no,,0.768
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",17,1,3,no,1:no,1:no,,0.603
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",17,2,3,no,1:no,1:no,,0.584
4275,3170974,Table 1,BaselineCharacteristic,?x, ; ,?x," ECOG performance status, n (%)",18,0,2,no,1:no,1:no,,0.777
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",18,1,3,no,1:no,1:no,,0.608
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",18,2,3,no,1:no,1:no,,0.589
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,19,0,2,no,1:no,1:no,,0.902
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,19,1,3,no,1:no,1:no,,0.655
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,19,2,3,no,1:no,1:no,,0.671
4275,3170974,Table 1,BaselineCharacteristic,"Primary tumor, n (%)", ; ,None,None,20,0,24,no,1:no,1:no,,0.841
4275,3170974,Table 1,BaselineCharacteristic,"Primary tumor, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Primary tumor, n (%)",None,20,1,43,no,1:no,1:no,,0.631
4275,3170974,Table 1,BaselineCharacteristic,"Primary tumor, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Primary tumor, n (%)",None,20,2,43,no,1:no,1:no,,0.646
4275,3170974,Table 1,BaselineCharacteristic,?Gastro-esophageal junction, ; ,?Gastro-esophageal junction," Primary tumor, n (%)",21,0,2,no,1:no,1:no,,0.818
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Gastro-esophageal junction," Primary tumor, n (%)",21,1,3,no,1:no,1:no,,0.625
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Gastro-esophageal junction," Primary tumor, n (%)",21,2,3,no,1:no,1:no,,0.636
4275,3170974,Table 1,BaselineCharacteristic,?Gastric body, ; ,?Gastric body," Primary tumor, n (%)",22,0,2,no,1:no,1:no,,0.819
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Gastric body," Primary tumor, n (%)",22,1,3,no,1:no,1:no,,0.629
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Gastric body," Primary tumor, n (%)",22,2,3,no,1:no,1:no,,0.64
4275,3170974,Table 1,BaselineCharacteristic,?Not specified, ; ,?Not specified," Primary tumor, n (%)",23,0,2,no,1:no,1:no,,0.824
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Not specified," Primary tumor, n (%)",23,1,3,no,1:no,1:no,,0.635
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Not specified," Primary tumor, n (%)",23,2,3,no,1:no,1:no,,0.644
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,24,0,2,no,1:no,1:no,,0.905
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,24,1,3,no,1:no,1:no,,0.667
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,24,2,3,no,1:no,1:no,,0.69
4275,3170974,Table 1,BaselineCharacteristic,"Extent of disease, n (%)", ; ,None,None,25,0,24,no,1:no,1:no,,0.811
4275,3170974,Table 1,BaselineCharacteristic,"Extent of disease, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Extent of disease, n (%)",None,25,1,43,no,1:no,1:no,,0.6
4275,3170974,Table 1,BaselineCharacteristic,"Extent of disease, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Extent of disease, n (%)",None,25,2,43,no,1:no,1:no,,0.62
4275,3170974,Table 1,BaselineCharacteristic,?Metastatic, ; ,?Metastatic," Extent of disease, n (%)",26,0,2,no,1:no,1:no,,0.806
4275,3170974,Table 1,BaselineCharacteristic,xx (xxx),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Metastatic," Extent of disease, n (%)",26,1,3,no,1:no,1:no,,0.591
4275,3170974,Table 1,BaselineCharacteristic,xx (xxx),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Metastatic," Extent of disease, n (%)",26,2,3,no,1:no,1:no,,0.623
4275,3170974,Table 1,BaselineCharacteristic,?Locally advanced, ; ,?Locally advanced," Extent of disease, n (%)",27,0,2,no,1:no,1:no,,0.79
4275,3170974,Table 1,BaselineCharacteristic,x (x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Locally advanced," Extent of disease, n (%)",27,1,3,no,1:no,1:no,,0.581
4275,3170974,Table 1,BaselineCharacteristic,x (x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Locally advanced," Extent of disease, n (%)",27,2,3,no,1:no,1:no,,0.609
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,28,0,2,no,1:no,1:no,,0.905
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,28,1,3,no,1:no,1:no,,0.667
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,28,2,3,no,1:no,1:no,,0.69
4275,3170974,Table 1,BaselineCharacteristic,Histological type, ; ,None,None,29,0,24,no,1:no,1:no,,0.775
4275,3170974,Table 1,BaselineCharacteristic,Histological type,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,Histological type,None,29,1,43,no,1:no,1:no,,0.611
4275,3170974,Table 1,BaselineCharacteristic,Histological type,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,Histological type,None,29,2,43,no,1:no,1:no,,0.646
4275,3170974,Table 1,BaselineCharacteristic,?Intestinal, ; ,?Intestinal, Histological type,30,0,2,no,1:no,1:no,,0.787
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Intestinal, Histological type,30,1,3,no,1:no,1:no,,0.607
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Intestinal, Histological type,30,2,3,no,1:no,1:no,,0.62
4275,3170974,Table 1,BaselineCharacteristic,?Diffuse, ; ,?Diffuse, Histological type,31,0,2,no,1:no,1:no,,0.787
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Diffuse, Histological type,31,1,3,no,1:no,1:no,,0.607
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Diffuse, Histological type,31,2,3,no,1:no,1:no,,0.62
4275,3170974,Table 1,BaselineCharacteristic,?Not specified, ; ,?Not specified, Histological type,32,0,2,no,1:no,1:no,,0.788
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Not specified, Histological type,32,1,3,no,1:no,1:no,,0.61
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Not specified, Histological type,32,2,3,no,1:no,1:no,,0.621
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,33,0,2,no,1:no,1:no,,0.905
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,33,1,3,no,1:no,1:no,,0.667
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,33,2,3,no,1:no,1:no,,0.69
4275,3170974,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)", ; ,None,None,34,0,24,no,1:no,1:no,,0.846
4275,3170974,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Metastatic sites, n (%)",None,34,1,43,no,1:no,1:no,,0.619
4275,3170974,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Metastatic sites, n (%)",None,34,2,43,no,1:no,1:no,,0.627
4275,3170974,Table 1,BaselineCharacteristic,??x, ; ,??x," Metastatic sites, n (%)",35,0,2,no,1:no,1:no,,0.8
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,??x," Metastatic sites, n (%)",35,1,3,no,1:no,1:no,,0.63
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,??x," Metastatic sites, n (%)",35,2,3,no,1:no,1:no,,0.63
4275,3170974,Table 1,BaselineCharacteristic,?>x, ; ,?>x," Metastatic sites, n (%)",36,0,2,no,1:no,1:no,,0.835
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?>x," Metastatic sites, n (%)",36,1,3,no,1:no,1:no,,0.63
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?>x," Metastatic sites, n (%)",36,2,3,no,1:no,1:no,,0.63
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,37,0,2,no,1:no,1:no,,0.905
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,37,1,3,no,1:no,1:no,,0.667
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,37,2,3,no,1:no,1:no,,0.69
4275,3170974,Table 1,BaselineCharacteristic,"Organs involved by metastases, n (%)", ; ,None,None,38,0,24,no,1:no,1:no,,0.831
4275,3170974,Table 1,BaselineCharacteristic,"Organs involved by metastases, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Organs involved by metastases, n (%)",None,38,1,43,no,1:no,1:no,,0.609
4275,3170974,Table 1,BaselineCharacteristic,"Organs involved by metastases, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Organs involved by metastases, n (%)",None,38,2,43,no,1:no,1:no,,0.637
4275,3170974,Table 1,BaselineCharacteristic,?Peritoneal carcinomatosis, ; ,?Peritoneal carcinomatosis," Organs involved by metastases, n (%)",39,0,2,no,1:no,1:no,,0.82
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Peritoneal carcinomatosis," Organs involved by metastases, n (%)",39,1,3,no,1:no,1:no,,0.608
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Peritoneal carcinomatosis," Organs involved by metastases, n (%)",39,2,3,no,1:no,1:no,,0.636
4275,3170974,Table 1,BaselineCharacteristic,?Lung, ; ,?Lung," Organs involved by metastases, n (%)",40,0,2,no,1:no,1:no,,0.82
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Lung," Organs involved by metastases, n (%)",40,1,3,no,1:no,1:no,,0.608
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Lung," Organs involved by metastases, n (%)",40,2,3,no,1:no,1:no,,0.636
4275,3170974,Table 1,BaselineCharacteristic,?Lymphnode, ; ,?Lymphnode," Organs involved by metastases, n (%)",41,0,2,no,1:no,1:no,,0.82
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Lymphnode," Organs involved by metastases, n (%)",41,1,3,no,1:no,1:no,,0.608
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Lymphnode," Organs involved by metastases, n (%)",41,2,3,no,1:no,1:no,,0.636
4275,3170974,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver," Organs involved by metastases, n (%)",42,0,2,no,1:no,1:no,,0.837
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Liver," Organs involved by metastases, n (%)",42,1,3,no,1:no,1:no,,0.624
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Liver," Organs involved by metastases, n (%)",42,2,3,no,1:no,1:no,,0.646
4275,3170974,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone," Organs involved by metastases, n (%)",43,0,2,no,1:no,1:no,,0.82
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Bone," Organs involved by metastases, n (%)",43,1,3,no,1:no,1:no,,0.608
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Bone," Organs involved by metastases, n (%)",43,2,3,no,1:no,1:no,,0.636
4275,3170974,Table 1,BaselineCharacteristic,?Intra-abdominal massa, ; ,?Intra-abdominal massa," Organs involved by metastases, n (%)",44,0,2,no,1:no,1:no,,0.82
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Intra-abdominal massa," Organs involved by metastases, n (%)",44,1,3,no,1:no,1:no,,0.608
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Intra-abdominal massa," Organs involved by metastases, n (%)",44,2,3,no,1:no,1:no,,0.636
4275,3170974,Table 1,BaselineCharacteristic,?Abdominal wall, ; ,?Abdominal wall," Organs involved by metastases, n (%)",45,0,2,no,1:no,1:no,,0.82
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Abdominal wall," Organs involved by metastases, n (%)",45,1,3,no,1:no,1:no,,0.608
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Abdominal wall," Organs involved by metastases, n (%)",45,2,3,no,1:no,1:no,,0.636
4275,3170974,Table 1,BaselineCharacteristic,?Otherb, ; ,?Otherb," Organs involved by metastases, n (%)",46,0,2,no,1:no,1:no,,0.82
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Otherb," Organs involved by metastases, n (%)",46,1,3,no,1:no,1:no,,0.608
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Otherb," Organs involved by metastases, n (%)",46,2,3,no,1:no,1:no,,0.636
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,47,0,2,no,1:no,1:no,,0.905
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,47,1,3,no,1:no,1:no,,0.667
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,47,2,3,no,1:no,1:no,,0.69
4275,3170974,Table 1,BaselineCharacteristic,"Surgery for primary tumor, n (%)", ; ,None,None,48,0,24,no,1:no,1:no,,0.857
4275,3170974,Table 1,BaselineCharacteristic,"Surgery for primary tumor, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Surgery for primary tumor, n (%)",None,48,1,43,no,1:no,1:no,,0.656
4275,3170974,Table 1,BaselineCharacteristic,"Surgery for primary tumor, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Surgery for primary tumor, n (%)",None,48,2,43,no,1:no,1:no,,0.67
4275,3170974,Table 1,BaselineCharacteristic,?Yes, ; ,?Yes," Surgery for primary tumor, n (%)",49,0,2,no,1:no,1:no,,0.843
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Yes," Surgery for primary tumor, n (%)",49,1,3,no,1:no,1:no,,0.66
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Yes," Surgery for primary tumor, n (%)",49,2,3,no,1:no,1:no,,0.67
4275,3170974,Table 1,BaselineCharacteristic,?No, ; ,?No," Surgery for primary tumor, n (%)",50,0,2,no,1:no,1:no,,0.844
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?No," Surgery for primary tumor, n (%)",50,1,3,no,1:no,1:no,,0.642
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?No," Surgery for primary tumor, n (%)",50,2,3,no,1:no,1:no,,0.646
4275,3170974,Table 1,BaselineCharacteristic,?Not known, ; ,?Not known," Surgery for primary tumor, n (%)",51,0,2,no,1:no,1:no,,0.844
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Not known," Surgery for primary tumor, n (%)",51,2,3,no,1:no,1:no,,0.667
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,52,0,2,no,1:no,1:no,,0.905
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,52,1,3,no,1:no,1:no,,0.667
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,52,2,3,no,1:no,1:no,,0.69
4275,3170974,Table 1,BaselineCharacteristic,"Measurable disease, n (%)", ; ,"Measurable disease, n (%)",,53,0,2,no,1:no,1:no,,0.794
4275,3170974,Table 1,BaselineCharacteristic,xx (xxx),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Measurable disease, n (%)",,53,1,3,no,1:no,1:no,,0.58
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Measurable disease, n (%)",,53,2,3,no,1:no,1:no,,0.615
4321,3179720,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
4321,3179720,Table 1,BaselineCharacteristic,Patients (n = xx),,Characteristics,None,0,1,1,no,1:no,1:no,,0.537
4321,3179720,Table 1,BaselineCharacteristic,"Median age, years (range)",Characteristics ; ,"Median age, years (range)",,1,0,2,no,1:no,1:no,,0.823
4321,3179720,Table 1,BaselineCharacteristic,xx (xx-xx),Patients (n = xx) ; ,"Median age, years (range)",,1,1,3,no,1:no,1:no,,0.562
4321,3179720,Table 1,BaselineCharacteristic,"Gender, n (%):",Characteristics ; ,None,None,2,0,24,no,1:no,1:no,,0.609
4321,3179720,Table 1,BaselineCharacteristic,,Patients (n = xx) ; ,"Gender, n (%):",None,2,1,43,no,1:no,2:yes,+,0.655
4321,3179720,Table 1,BaselineCharacteristic,?Male,Characteristics ; ,?Male," Gender, n (%):",3,0,2,no,1:no,1:no,,0.546
4321,3179720,Table 1,BaselineCharacteristic,xx (xx),Patients (n = xx) ; ,?Male," Gender, n (%):",3,1,3,yes,2:yes,2:yes,,0.801
4321,3179720,Table 1,BaselineCharacteristic,?Female,Characteristics ; ,?Female," Gender, n (%):",4,0,2,no,1:no,1:no,,0.609
4321,3179720,Table 1,BaselineCharacteristic,xx (xx),Patients (n = xx) ; ,?Female," Gender, n (%):",4,1,3,yes,2:yes,2:yes,,0.793
4321,3179720,Table 1,BaselineCharacteristic,"WHO performance status, n (%)",Characteristics ; ,None,None,5,0,24,no,1:no,1:no,,0.736
4321,3179720,Table 1,BaselineCharacteristic,,Patients (n = xx) ; ,"WHO performance status, n (%)",None,5,1,43,no,1:no,1:no,,0.52
4321,3179720,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x," WHO performance status, n (%)",6,0,2,no,1:no,1:no,,0.672
4321,3179720,Table 1,BaselineCharacteristic,xx (xx),Patients (n = xx) ; ,?x," WHO performance status, n (%)",6,1,3,no,1:no,2:yes,+,0.528
4321,3179720,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x," WHO performance status, n (%)",7,0,2,no,1:no,1:no,,0.675
4321,3179720,Table 1,BaselineCharacteristic,x (xx),Patients (n = xx) ; ,?x," WHO performance status, n (%)",7,1,3,no,1:no,2:yes,+,0.514
4321,3179720,Table 1,BaselineCharacteristic,"TN clinical stage, n (%)",Characteristics ; ,None,None,8,0,24,no,1:no,1:no,,0.737
4321,3179720,Table 1,BaselineCharacteristic,,Patients (n = xx) ; ,"TN clinical stage, n (%)",None,8,1,43,no,1:no,1:no,,0.573
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",9,0,2,no,1:no,1:no,,0.746
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",9,1,3,no,1:no,1:no,,0.529
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",10,0,2,no,1:no,1:no,,0.746
4321,3179720,Table 1,BaselineCharacteristic,x (x.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",10,1,3,no,1:no,1:no,,0.537
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",11,0,2,no,1:no,1:no,,0.754
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",11,1,3,no,1:no,1:no,,0.563
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",12,0,2,no,1:no,1:no,,0.754
4321,3179720,Table 1,BaselineCharacteristic,x (x.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",12,1,3,no,1:no,1:no,,0.567
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",13,0,2,no,1:no,1:no,,0.754
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",13,1,3,no,1:no,1:no,,0.566
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",14,0,2,no,1:no,1:no,,0.743
4321,3179720,Table 1,BaselineCharacteristic,x (x.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",14,1,3,no,1:no,1:no,,0.554
4321,3179720,Table 1,BaselineCharacteristic,"Median clinical tumour size per MRI, cm (range)",Characteristics ; ,"Median clinical tumour size per MRI, cm (range)",,15,0,2,no,1:no,1:no,,0.893
4321,3179720,Table 1,BaselineCharacteristic,x (x-xx),Patients (n = xx) ; ,"Median clinical tumour size per MRI, cm (range)",,15,1,3,no,1:no,1:no,,0.692
4321,3179720,Table 1,BaselineCharacteristic,"Median tumour distance from anal verge, cm (range)",Characteristics ; ,"Median tumour distance from anal verge, cm (range)",,16,0,2,no,1:no,1:no,,0.893
4321,3179720,Table 1,BaselineCharacteristic,x (x-xx),Patients (n = xx) ; ,"Median tumour distance from anal verge, cm (range)",,16,1,3,no,1:no,1:no,,0.692
4321,3179720,Table 1,BaselineCharacteristic,"Type of surgerya, n (%)",Characteristics ; ,None,None,17,0,24,no,1:no,1:no,,0.648
4321,3179720,Table 1,BaselineCharacteristic,,Patients (n = xx) ; ,"Type of surgerya, n (%)",None,17,1,43,no,1:no,1:no,,0.536
4321,3179720,Table 1,BaselineCharacteristic,?Low anterior resection,Characteristics ; ,?Low anterior resection," Type of surgerya, n (%)",18,0,2,no,1:no,1:no,,0.664
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?Low anterior resection," Type of surgerya, n (%)",18,1,3,no,1:no,2:yes,+,0.509
4321,3179720,Table 1,BaselineCharacteristic,?Coloanal reconstruction,Characteristics ; ,?Coloanal reconstruction," Type of surgerya, n (%)",19,0,2,no,1:no,1:no,,0.664
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?Coloanal reconstruction," Type of surgerya, n (%)",19,1,3,no,1:no,2:yes,+,0.503
4321,3179720,Table 1,BaselineCharacteristic,?Abdominoperineal resection,Characteristics ; ,?Abdominoperineal resection," Type of surgerya, n (%)",20,0,2,no,1:no,1:no,,0.664
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?Abdominoperineal resection," Type of surgerya, n (%)",20,1,3,no,1:no,2:yes,+,0.503
4321,3179720,Table 1,BaselineCharacteristic,?Pelvic exenteration,Characteristics ; ,?Pelvic exenteration," Type of surgerya, n (%)",21,0,2,no,1:no,1:no,,0.664
4321,3179720,Table 1,BaselineCharacteristic,x (x.x),Patients (n = xx) ; ,?Pelvic exenteration," Type of surgerya, n (%)",21,1,3,no,1:no,2:yes,+,0.503
4604,3251866,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
4604,3251866,Table 1,BaselineCharacteristic,N=xx,,Characteristic,None,0,1,1,no,1:no,1:no,,0.73
4604,3251866,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,1,0,24,no,1:no,1:no,,0.845
4604,3251866,Table 1,BaselineCharacteristic,Age (years),N=xx ; ,Age (years),None,1,1,43,no,1:no,1:no,,0.78
4604,3251866,Table 1,BaselineCharacteristic,?Age (range),Characteristic ; ,?Age (range), Age (years),3,0,2,no,1:no,1:no,,0.837
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,no,1:no,1:no,,0.869
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,4,1,3,no,1:no,1:no,,0.703
4604,3251866,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,5,0,24,no,1:no,1:no,,0.633
4604,3251866,Table 1,BaselineCharacteristic,Sex,N=xx ; ,Sex,None,5,1,43,no,1:no,2:yes,+,0.516
4604,3251866,Table 1,BaselineCharacteristic,?Male (%),Characteristic ; ,?Male (%), Sex,6,0,2,no,1:no,1:no,,0.508
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Male (%), Sex,6,1,3,yes,2:yes,2:yes,,0.852
4604,3251866,Table 1,BaselineCharacteristic,?Female (%),Characteristic ; ,?Female (%), Sex,7,0,2,no,1:no,2:yes,+,0.502
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Female (%), Sex,7,1,3,yes,2:yes,2:yes,,0.846
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,8,0,2,no,1:no,1:no,,0.883
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,8,1,3,no,1:no,1:no,,0.746
4604,3251866,Table 1,BaselineCharacteristic,ECOG performance status,Characteristic ; ,None,None,9,0,24,no,1:no,1:no,,0.895
4604,3251866,Table 1,BaselineCharacteristic,ECOG performance status,N=xx ; ,ECOG performance status,None,9,1,43,no,1:no,1:no,,0.808
4604,3251866,Table 1,BaselineCharacteristic,?x (%),Characteristic ; ,?x (%), ECOG performance status,10,0,2,no,1:no,1:no,,0.826
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?x (%), ECOG performance status,10,1,3,no,1:no,1:no,,0.591
4604,3251866,Table 1,BaselineCharacteristic,?x (%),Characteristic ; ,?x (%), ECOG performance status,11,0,2,no,1:no,1:no,,0.833
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?x (%), ECOG performance status,11,1,3,no,1:no,1:no,,0.598
4604,3251866,Table 1,BaselineCharacteristic,?x (%),Characteristic ; ,?x (%), ECOG performance status,12,0,2,no,1:no,1:no,,0.833
4604,3251866,Table 1,BaselineCharacteristic,x (x.x),N=xx ; ,?x (%), ECOG performance status,12,1,3,no,1:no,1:no,,0.693
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,13,0,2,no,1:no,1:no,,0.902
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,13,1,3,no,1:no,1:no,,0.785
4604,3251866,Table 1,BaselineCharacteristic,Primary site,Characteristic ; ,None,None,14,0,24,no,1:no,1:no,,0.889
4604,3251866,Table 1,BaselineCharacteristic,Primary site,N=xx ; ,Primary site,None,14,1,43,no,1:no,1:no,,0.793
4604,3251866,Table 1,BaselineCharacteristic,?Head of pancreas (%),Characteristic ; ,?Head of pancreas (%), Primary site,15,0,2,no,1:no,1:no,,0.845
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Head of pancreas (%), Primary site,15,1,3,no,1:no,1:no,,0.594
4604,3251866,Table 1,BaselineCharacteristic,?Body of pancreas (%),Characteristic ; ,?Body of pancreas (%), Primary site,16,0,2,no,1:no,1:no,,0.845
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Body of pancreas (%), Primary site,16,1,3,no,1:no,1:no,,0.596
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,17,0,2,no,1:no,1:no,,0.909
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,17,1,3,no,1:no,1:no,,0.794
4604,3251866,Table 1,BaselineCharacteristic,T stage,Characteristic ; ,None,None,18,0,24,no,1:no,1:no,,0.906
4604,3251866,Table 1,BaselineCharacteristic,T stage,N=xx ; ,T stage,None,18,1,43,no,1:no,1:no,,0.831
4604,3251866,Table 1,BaselineCharacteristic,?Tx (%),Characteristic ; ,?Tx (%), T stage,19,0,2,no,1:no,1:no,,0.887
4604,3251866,Table 1,BaselineCharacteristic,x (x.x),N=xx ; ,?Tx (%), T stage,19,1,3,no,1:no,1:no,,0.731
4604,3251866,Table 1,BaselineCharacteristic,?Tx (%),Characteristic ; ,?Tx (%), T stage,20,0,2,no,1:no,1:no,,0.888
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Tx (%), T stage,20,1,3,no,1:no,1:no,,0.655
4604,3251866,Table 1,BaselineCharacteristic,?Tx (%),Characteristic ; ,?Tx (%), T stage,21,0,2,no,1:no,1:no,,0.888
4604,3251866,Table 1,BaselineCharacteristic,x (xx.x),N=xx ; ,?Tx (%), T stage,21,1,3,no,1:no,1:no,,0.655
4604,3251866,Table 1,BaselineCharacteristic,?Tx (%),Characteristic ; ,?Tx (%), T stage,22,0,2,no,1:no,1:no,,0.889
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Tx (%), T stage,22,1,3,no,1:no,1:no,,0.663
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,23,0,2,no,1:no,1:no,,0.913
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,23,1,3,no,1:no,1:no,,0.806
4604,3251866,Table 1,BaselineCharacteristic,N stage,Characteristic ; ,None,None,24,0,24,no,1:no,1:no,,0.875
4604,3251866,Table 1,BaselineCharacteristic,N stage,N=xx ; ,N stage,None,24,1,43,no,1:no,1:no,,0.786
4604,3251866,Table 1,BaselineCharacteristic,?Nx (%),Characteristic ; ,?Nx (%), N stage,25,0,2,no,1:no,1:no,,0.852
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Nx (%), N stage,25,1,3,no,1:no,1:no,,0.612
4604,3251866,Table 1,BaselineCharacteristic,?Nx (%),Characteristic ; ,?Nx (%), N stage,26,0,2,no,1:no,1:no,,0.852
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Nx (%), N stage,26,1,3,no,1:no,1:no,,0.612
4604,3251866,Table 4,BaselineCharacteristic,Component,,None,None,0,0,12,no,1:no,1:no,,0.793
4604,3251866,Table 4,BaselineCharacteristic,Confounder,,Component,None,0,1,1,no,1:no,1:no,,0.735
4604,3251866,Table 4,BaselineCharacteristic,Gem,,Component,None,0,2,1,no,1:no,1:no,,0.775
4604,3251866,Table 4,BaselineCharacteristic,GemOx,,Component,None,0,3,1,no,1:no,1:no,,0.79
4604,3251866,Table 4,BaselineCharacteristic,Favours,,Component,None,0,4,1,no,1:no,1:no,,0.802
4604,3251866,Table 4,BaselineCharacteristic,Inclusion criteria,Component ; ,Inclusion criteria,,1,0,24,no,1:no,1:no,,0.746
4604,3251866,Table 4,BaselineCharacteristic,Liver function tests,Confounder ; ,Inclusion criteria,,1,1,43,no,1:no,1:no,,0.725
4604,3251866,Table 4,BaselineCharacteristic,No limit,Gem ; ,Inclusion criteria,,1,2,43,no,1:no,1:no,,0.597
4604,3251866,Table 4,BaselineCharacteristic,GemOx,Favours ; ,Inclusion criteria,,1,4,43,no,1:no,1:no,,0.706
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,2,0,2,no,1:no,1:no,,0.831
4604,3251866,Table 4,BaselineCharacteristic,Operability,Confounder ; ,,,2,1,3,no,1:no,1:no,,0.681
4604,3251866,Table 4,BaselineCharacteristic,Inoperable only,Gem ; ,,,2,2,3,no,1:no,1:no,,0.699
4604,3251866,Table 4,BaselineCharacteristic,Included patients strongly declining surgery,GemOx ; ,,,2,3,3,no,1:no,1:no,,0.706
4604,3251866,Table 4,BaselineCharacteristic,Gem,Favours ; ,,,2,4,3,no,1:no,1:no,,0.714
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,None,None,3,0,2,no,1:no,1:no,,0.84
4604,3251866,Table 4,BaselineCharacteristic,,Confounder ; ,None,None,3,1,3,no,1:no,1:no,,0.711
4604,3251866,Table 4,BaselineCharacteristic,,Gem ; ,None,None,3,2,3,no,1:no,1:no,,0.753
4604,3251866,Table 4,BaselineCharacteristic,,GemOx ; ,None,None,3,3,3,no,1:no,1:no,,0.771
4604,3251866,Table 4,BaselineCharacteristic,,Favours ; ,None,None,3,4,3,no,1:no,1:no,,0.781
4604,3251866,Table 4,BaselineCharacteristic,Baseline characteristics,Component ; ,Baseline characteristics,,4,0,24,no,1:no,1:no,,0.724
4604,3251866,Table 4,BaselineCharacteristic,Male (%),Confounder ; ,Baseline characteristics,,4,1,43,no,1:no,2:yes,+,0.543
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,Baseline characteristics,,4,2,43,no,1:no,1:no,,0.53
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,Baseline characteristics,,4,3,43,no,1:no,1:no,,0.541
4604,3251866,Table 4,BaselineCharacteristic,Unknown,Favours ; ,Baseline characteristics,,4,4,43,no,1:no,1:no,,0.685
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,5,0,2,no,1:no,1:no,,0.828
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,,,5,2,3,no,1:no,1:no,,0.569
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,,,5,3,3,no,1:no,1:no,,0.588
4604,3251866,Table 4,BaselineCharacteristic,Neither,Favours ; ,,,5,4,3,no,1:no,1:no,,0.738
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,6,0,2,no,1:no,1:no,,0.826
4604,3251866,Table 4,BaselineCharacteristic,Tx (%),Confounder ; ,,,6,1,3,no,1:no,1:no,,0.676
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,,,6,2,3,no,1:no,1:no,,0.566
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,,,6,3,3,no,1:no,1:no,,0.586
4604,3251866,Table 4,BaselineCharacteristic,Gem,Favours ; ,,,6,4,3,no,1:no,1:no,,0.74
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,7,0,2,no,1:no,1:no,,0.836
4604,3251866,Table 4,BaselineCharacteristic,Nx (%),Confounder ; ,,,7,1,3,no,1:no,1:no,,0.652
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,,,7,2,3,no,1:no,1:no,,0.568
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,,,7,3,3,no,1:no,1:no,,0.592
4604,3251866,Table 4,BaselineCharacteristic,Gem,Favours ; ,,,7,4,3,no,1:no,1:no,,0.748
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,8,0,2,no,1:no,1:no,,0.837
4604,3251866,Table 4,BaselineCharacteristic,Age (minimum),Confounder ; ,,,8,1,3,no,1:no,1:no,,0.77
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,,,8,2,3,no,1:no,1:no,,0.605
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,,,8,3,3,no,1:no,1:no,,0.624
4604,3251866,Table 4,BaselineCharacteristic,Gem,Favours ; ,,,8,4,3,no,1:no,1:no,,0.757
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,None,None,9,0,2,no,1:no,1:no,,0.881
4604,3251866,Table 4,BaselineCharacteristic,,Confounder ; ,None,None,9,1,3,no,1:no,1:no,,0.788
4604,3251866,Table 4,BaselineCharacteristic,,Gem ; ,None,None,9,2,3,no,1:no,1:no,,0.801
4604,3251866,Table 4,BaselineCharacteristic,,GemOx ; ,None,None,9,3,3,no,1:no,1:no,,0.816
4604,3251866,Table 4,BaselineCharacteristic,,Favours ; ,None,None,9,4,3,no,1:no,1:no,,0.827
4604,3251866,Table 4,BaselineCharacteristic,Treatment,Component ; ,Treatment,,10,0,2,no,1:no,1:no,,0.861
4604,3251866,Table 4,BaselineCharacteristic,Schedule,Confounder ; ,Treatment,,10,1,3,no,1:no,1:no,,0.769
4604,3251866,Table 4,BaselineCharacteristic,Gem dx dx dxx,Gem ; ,Treatment,,10,2,3,no,1:no,1:no,,0.781
4604,3251866,Table 4,BaselineCharacteristic,GemOx dx dxx,GemOx ; ,Treatment,,10,3,3,no,1:no,1:no,,0.79
4604,3251866,Table 4,BaselineCharacteristic,N/A,Favours ; ,Treatment,,10,4,3,no,1:no,1:no,,0.801
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,None,None,11,0,2,no,1:no,1:no,,0.892
4604,3251866,Table 4,BaselineCharacteristic,,Confounder ; ,None,None,11,1,3,no,1:no,1:no,,0.813
4604,3251866,Table 4,BaselineCharacteristic,,Gem ; ,None,None,11,2,3,no,1:no,1:no,,0.826
4604,3251866,Table 4,BaselineCharacteristic,,GemOx ; ,None,None,11,3,3,no,1:no,1:no,,0.836
4604,3251866,Table 4,BaselineCharacteristic,,Favours ; ,None,None,11,4,3,no,1:no,1:no,,0.838
4604,3251866,Table 4,BaselineCharacteristic,Assessment,Component ; ,Assessment,,12,0,24,no,1:no,1:no,,0.828
4604,3251866,Table 4,BaselineCharacteristic,Tumour assessment,Confounder ; ,Assessment,,12,1,43,no,1:no,1:no,,0.806
4604,3251866,Table 4,BaselineCharacteristic,WHO,Gem ; ,Assessment,,12,2,43,no,1:no,1:no,,0.792
4604,3251866,Table 4,BaselineCharacteristic,RECIST,GemOx ; ,Assessment,,12,3,43,no,1:no,1:no,,0.799
4604,3251866,Table 4,BaselineCharacteristic,Unknown,Favours ; ,Assessment,,12,4,43,no,1:no,1:no,,0.802
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,13,0,2,no,1:no,1:no,,0.873
4604,3251866,Table 4,BaselineCharacteristic,CT scans during Rx,Confounder ; ,,,13,1,3,no,1:no,1:no,,0.785
4604,3251866,Table 4,BaselineCharacteristic,>x weeks apart,Gem ; ,,,13,2,3,no,1:no,1:no,,0.798
4604,3251866,Table 4,BaselineCharacteristic,"Weeks x, xx, xx",GemOx ; ,,,13,3,3,no,1:no,1:no,,0.742
4604,3251866,Table 4,BaselineCharacteristic,Unknown,Favours ; ,,,13,4,3,no,1:no,1:no,,0.805
4680,3273358,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
4680,3273358,Table 1,BaselineCharacteristic,Olaparib dose (mg b.i.d.),,,None,0,1,1,no,1:no,1:no,,0.697
4680,3273358,Table 1,BaselineCharacteristic,Olaparib dose (mg b.i.d.),,,None,0,2,1,no,1:no,1:no,,0.736
4680,3273358,Table 1,BaselineCharacteristic,Olaparib dose (mg b.i.d.),,,None,0,3,1,no,1:no,1:no,,0.746
4680,3273358,Table 1,BaselineCharacteristic,Olaparib dose (mg b.i.d.),,,None,0,4,1,no,1:no,1:no,,0.762
4680,3273358,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no,1:no,1:no,,0.792
4680,3273358,Table 1,BaselineCharacteristic,xxx (n=x),Olaparib dose (mg b.i.d.) ; ,,None,1,1,1,no,1:no,1:no,,0.687
4680,3273358,Table 1,BaselineCharacteristic,xxx (n=x),Olaparib dose (mg b.i.d.) ; ,,None,1,2,1,no,1:no,1:no,,0.704
4680,3273358,Table 1,BaselineCharacteristic,xxx (n=x),Olaparib dose (mg b.i.d.) ; ,,None,1,3,1,no,1:no,1:no,,0.71
4680,3273358,Table 1,BaselineCharacteristic,All patients (n=xx),Olaparib dose (mg b.i.d.) ; ,,None,1,4,1,no,1:no,1:no,,0.632
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)", ;  ; ,None,None,2,0,24,no,1:no,1:no,,0.569
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Sex, n (%)",None,2,1,43,no,1:no,2:yes,+,0.539
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Sex, n (%)",None,2,2,43,no,1:no,2:yes,+,0.514
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Sex, n (%)",None,2,3,43,no,1:no,2:yes,+,0.509
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)",Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,"Sex, n (%)",None,2,4,43,no,1:no,2:yes,+,0.581
4680,3273358,Table 1,BaselineCharacteristic,?Male, ;  ; ,?Male," Sex, n (%)",3,0,2,no,1:no,2:yes,+,0.576
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Male," Sex, n (%)",3,1,3,yes,2:yes,2:yes,,0.701
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Male," Sex, n (%)",3,2,3,yes,2:yes,2:yes,,0.697
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Male," Sex, n (%)",3,3,3,yes,2:yes,2:yes,,0.699
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Male," Sex, n (%)",3,4,3,yes,2:yes,2:yes,,0.764
4680,3273358,Table 1,BaselineCharacteristic,?Female, ;  ; ,?Female," Sex, n (%)",4,0,2,no,1:no,2:yes,+,0.523
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Female," Sex, n (%)",4,1,3,yes,2:yes,2:yes,,0.725
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Female," Sex, n (%)",4,2,3,yes,2:yes,2:yes,,0.718
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Female," Sex, n (%)",4,3,3,yes,2:yes,2:yes,,0.712
4680,3273358,Table 1,BaselineCharacteristic,xx (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Female," Sex, n (%)",4,4,3,yes,2:yes,2:yes,,0.786
4680,3273358,Table 1,BaselineCharacteristic,?Median age (range), ;  ; ,?Median age (range)," Sex, n (%)",5,0,2,no,1:no,1:no,,0.61
4680,3273358,Table 1,BaselineCharacteristic,, ;  ; ,None,None,6,0,2,no,1:no,1:no,,0.866
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,6,1,3,no,1:no,1:no,,0.719
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,6,2,3,no,1:no,1:no,,0.735
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,6,3,3,no,1:no,1:no,,0.744
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,None,None,6,4,3,no,1:no,1:no,,0.663
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)", ;  ; ,None,None,7,0,24,no,1:no,1:no,,0.737
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Race, n (%)",None,7,1,43,no,1:no,1:no,,0.617
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Race, n (%)",None,7,2,43,no,1:no,1:no,,0.636
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Race, n (%)",None,7,3,43,no,1:no,1:no,,0.641
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)",Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,"Race, n (%)",None,7,4,43,no,1:no,1:no,,0.556
4680,3273358,Table 1,BaselineCharacteristic,?Caucasian, ;  ; ,?Caucasian," Race, n (%)",8,0,2,no,1:no,1:no,,0.714
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Caucasian," Race, n (%)",8,1,3,no,1:no,1:no,,0.522
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Caucasian," Race, n (%)",8,2,3,no,1:no,1:no,,0.539
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Caucasian," Race, n (%)",8,3,3,no,1:no,1:no,,0.544
4680,3273358,Table 1,BaselineCharacteristic,xx (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Caucasian," Race, n (%)",8,4,3,no,1:no,2:yes,+,0.562
4680,3273358,Table 1,BaselineCharacteristic,?Oriental, ;  ; ,?Oriental," Race, n (%)",9,0,2,no,1:no,1:no,,0.729
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Oriental," Race, n (%)",9,1,3,no,1:no,1:no,,0.528
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Oriental," Race, n (%)",9,2,3,no,1:no,1:no,,0.54
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Oriental," Race, n (%)",9,3,3,no,1:no,1:no,,0.545
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Oriental," Race, n (%)",9,4,3,no,1:no,2:yes,+,0.512
4680,3273358,Table 1,BaselineCharacteristic,, ;  ; ,None,None,10,0,2,no,1:no,1:no,,0.888
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,10,1,3,no,1:no,1:no,,0.708
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,10,2,3,no,1:no,1:no,,0.732
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,10,3,3,no,1:no,1:no,,0.742
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,None,None,10,4,3,no,1:no,1:no,,0.682
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)", ;  ; ,None,None,11,0,24,no,1:no,1:no,,0.824
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"ECOG PS at screening, n (%)",None,11,1,43,no,1:no,1:no,,0.702
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"ECOG PS at screening, n (%)",None,11,2,43,no,1:no,1:no,,0.717
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"ECOG PS at screening, n (%)",None,11,3,43,no,1:no,1:no,,0.715
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)",Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,"ECOG PS at screening, n (%)",None,11,4,43,no,1:no,1:no,,0.622
4680,3273358,Table 1,BaselineCharacteristic,?x, ;  ; ,?x," ECOG PS at screening, n (%)",12,0,2,no,1:no,1:no,,0.756
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",12,1,3,no,1:no,1:no,,0.619
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",12,2,3,no,1:no,1:no,,0.624
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",12,3,3,no,1:no,1:no,,0.626
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?x," ECOG PS at screening, n (%)",12,4,3,no,1:no,1:no,,0.544
4680,3273358,Table 1,BaselineCharacteristic,?x, ;  ; ,?x," ECOG PS at screening, n (%)",13,0,2,no,1:no,1:no,,0.756
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",13,1,3,no,1:no,1:no,,0.619
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",13,2,3,no,1:no,1:no,,0.624
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",13,3,3,no,1:no,1:no,,0.626
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?x," ECOG PS at screening, n (%)",13,4,3,no,1:no,1:no,,0.544
4680,3273358,Table 1,BaselineCharacteristic,, ;  ; ,None,None,14,0,2,no,1:no,1:no,,0.892
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,14,1,3,no,1:no,1:no,,0.72
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,14,2,3,no,1:no,1:no,,0.745
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,14,3,3,no,1:no,1:no,,0.754
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,None,None,14,4,3,no,1:no,1:no,,0.683
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a, ;  ; ,None,None,15,0,24,no,1:no,1:no,,0.78
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,Previous therapy n (%)a,None,15,1,43,no,1:no,1:no,,0.657
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,Previous therapy n (%)a,None,15,2,43,no,1:no,1:no,,0.667
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,Previous therapy n (%)a,None,15,3,43,no,1:no,1:no,,0.665
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,Previous therapy n (%)a,None,15,4,43,no,1:no,1:no,,0.58
4680,3273358,Table 1,BaselineCharacteristic,?Radiotherapy, ;  ; ,?Radiotherapy, Previous therapy n (%)a,16,0,2,no,1:no,1:no,,0.747
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Radiotherapy, Previous therapy n (%)a,16,1,3,no,1:no,1:no,,0.574
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Radiotherapy, Previous therapy n (%)a,16,2,3,no,1:no,1:no,,0.585
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Radiotherapy, Previous therapy n (%)a,16,3,3,no,1:no,1:no,,0.586
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Radiotherapy, Previous therapy n (%)a,16,4,3,no,1:no,2:yes,+,0.513
4680,3273358,Table 1,BaselineCharacteristic,?Chemotherapy, ;  ; ,?Chemotherapy, Previous therapy n (%)a,17,0,2,no,1:no,1:no,,0.792
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Chemotherapy, Previous therapy n (%)a,17,1,3,no,1:no,1:no,,0.639
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Chemotherapy, Previous therapy n (%)a,17,2,3,no,1:no,1:no,,0.646
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Chemotherapy, Previous therapy n (%)a,17,3,3,no,1:no,1:no,,0.651
4680,3273358,Table 1,BaselineCharacteristic,xx (xxx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Chemotherapy, Previous therapy n (%)a,17,4,3,no,1:no,1:no,,0.546
4680,3273358,Table 1,BaselineCharacteristic,?Immunotherapy/hormone therapy, ;  ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,0,2,no,1:no,1:no,,0.788
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,1,3,no,1:no,1:no,,0.641
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,2,3,no,1:no,1:no,,0.653
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,3,3,no,1:no,1:no,,0.653
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,4,3,no,1:no,1:no,,0.543
4680,3273358,Table 1,BaselineCharacteristic,?Other systemic cancer therapyb, ;  ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,0,2,no,1:no,1:no,,0.798
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,1,3,no,1:no,1:no,,0.66
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,2,3,no,1:no,1:no,,0.672
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,3,3,no,1:no,1:no,,0.668
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,4,3,no,1:no,1:no,,0.559
4680,3273358,Table 1,BaselineCharacteristic,?Surgeryc, ;  ; ,?Surgeryc, Previous therapy n (%)a,20,0,2,no,1:no,1:no,,0.801
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Surgeryc, Previous therapy n (%)a,20,1,3,no,1:no,1:no,,0.651
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Surgeryc, Previous therapy n (%)a,20,2,3,no,1:no,1:no,,0.663
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Surgeryc, Previous therapy n (%)a,20,3,3,no,1:no,1:no,,0.659
4680,3273358,Table 1,BaselineCharacteristic,xx (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Surgeryc, Previous therapy n (%)a,20,4,3,no,1:no,1:no,,0.543
4680,3273358,Table 1,BaselineCharacteristic,, ;  ; ,None,None,21,0,2,no,1:no,1:no,,0.902
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,21,1,3,no,1:no,1:no,,0.761
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,21,2,3,no,1:no,1:no,,0.777
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,21,3,3,no,1:no,1:no,,0.778
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,None,None,21,4,3,no,1:no,1:no,,0.706
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)", ;  ; ,None,None,22,0,24,no,1:no,1:no,,0.84
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Primary tumour site, n (%)",None,22,1,43,no,1:no,1:no,,0.738
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Primary tumour site, n (%)",None,22,2,43,no,1:no,1:no,,0.746
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Primary tumour site, n (%)",None,22,3,43,no,1:no,1:no,,0.74
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)",Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,"Primary tumour site, n (%)",None,22,4,43,no,1:no,1:no,,0.666
4680,3273358,Table 1,BaselineCharacteristic,?Colorectal, ;  ; ,?Colorectal," Primary tumour site, n (%)",23,0,2,no,1:no,1:no,,0.837
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Colorectal," Primary tumour site, n (%)",23,1,3,no,1:no,1:no,,0.686
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Colorectal," Primary tumour site, n (%)",23,2,3,no,1:no,1:no,,0.695
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Colorectal," Primary tumour site, n (%)",23,3,3,no,1:no,1:no,,0.693
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Colorectal," Primary tumour site, n (%)",23,4,3,no,1:no,1:no,,0.572
4680,3273358,Table 1,BaselineCharacteristic,?Breast, ;  ; ,?Breast," Primary tumour site, n (%)",24,0,2,no,1:no,1:no,,0.837
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Breast," Primary tumour site, n (%)",24,1,3,no,1:no,1:no,,0.693
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Breast," Primary tumour site, n (%)",24,2,3,no,1:no,1:no,,0.709
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Breast," Primary tumour site, n (%)",24,3,3,no,1:no,1:no,,0.707
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Breast," Primary tumour site, n (%)",24,4,3,no,1:no,1:no,,0.572
4680,3273358,Table 1,BaselineCharacteristic,?Pleura, ;  ; ,?Pleura," Primary tumour site, n (%)",25,0,2,no,1:no,1:no,,0.838
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pleura," Primary tumour site, n (%)",25,1,3,no,1:no,1:no,,0.696
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pleura," Primary tumour site, n (%)",25,2,3,no,1:no,1:no,,0.712
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pleura," Primary tumour site, n (%)",25,3,3,no,1:no,1:no,,0.711
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Pleura," Primary tumour site, n (%)",25,4,3,no,1:no,1:no,,0.616
4680,3273358,Table 1,BaselineCharacteristic,?Skin/soft tissue, ;  ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,0,2,no,1:no,1:no,,0.838
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,1,3,no,1:no,1:no,,0.696
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,2,3,no,1:no,1:no,,0.712
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,3,3,no,1:no,1:no,,0.711
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,4,3,no,1:no,1:no,,0.616
4680,3273358,Table 1,BaselineCharacteristic,?Cervix, ;  ; ,?Cervix," Primary tumour site, n (%)",27,0,2,no,1:no,1:no,,0.838
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Cervix," Primary tumour site, n (%)",27,1,3,no,1:no,1:no,,0.696
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Cervix," Primary tumour site, n (%)",27,2,3,no,1:no,1:no,,0.712
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Cervix," Primary tumour site, n (%)",27,3,3,no,1:no,1:no,,0.711
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Cervix," Primary tumour site, n (%)",27,4,3,no,1:no,1:no,,0.616
4680,3273358,Table 1,BaselineCharacteristic,?Pseudomyxoma peritonei, ;  ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,0,2,no,1:no,1:no,,0.838
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,1,3,no,1:no,1:no,,0.696
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,2,3,no,1:no,1:no,,0.712
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,3,3,no,1:no,1:no,,0.711
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,4,3,no,1:no,1:no,,0.616
4680,3273358,Table 1,BaselineCharacteristic,?Upper GI, ;  ; ,?Upper GI," Primary tumour site, n (%)",29,0,2,no,1:no,1:no,,0.838
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Upper GI," Primary tumour site, n (%)",29,1,3,no,1:no,1:no,,0.696
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Upper GI," Primary tumour site, n (%)",29,2,3,no,1:no,1:no,,0.712
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Upper GI," Primary tumour site, n (%)",29,3,3,no,1:no,1:no,,0.711
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Upper GI," Primary tumour site, n (%)",29,4,3,no,1:no,1:no,,0.616
4688,3276256,Table 2,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no,1:no,1:no,,0.785
4688,3276256,Table 2,BaselineCharacteristic,MF/F xxx/xx ?g bid (n = xxx),,Characteristics,None,0,1,1,no,1:no,1:no,,0.628
4688,3276256,Table 2,BaselineCharacteristic,MF/F xxx/xx ?g bid (n = xxx),,Characteristics,None,0,2,1,no,1:no,1:no,,0.618
4688,3276256,Table 2,BaselineCharacteristic,MF xxx ?g bid (n = xxx),,Characteristics,None,0,3,1,no,1:no,1:no,,0.626
4688,3276256,Table 2,BaselineCharacteristic,F xx ?g bid (n = xxx),,Characteristics,None,0,4,1,no,1:no,1:no,,0.541
4688,3276256,Table 2,BaselineCharacteristic,Placebo (n = xxx),,Characteristics,None,0,5,1,no,1:no,1:no,,0.502
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",Characteristics ; ,None,None,1,0,24,no,1:no,1:no,,0.531
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Sex, n (%)",None,1,1,43,no,1:no,2:yes,+,0.599
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Sex, n (%)",None,1,2,43,no,1:no,2:yes,+,0.596
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",MF xxx ?g bid (n = xxx) ; ,"Sex, n (%)",None,1,3,43,no,1:no,2:yes,+,0.588
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",F xx ?g bid (n = xxx) ; ,"Sex, n (%)",None,1,4,43,no,1:no,2:yes,+,0.659
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",Placebo (n = xxx) ; ,"Sex, n (%)",None,1,5,43,no,1:no,2:yes,+,0.645
4688,3276256,Table 2,BaselineCharacteristic,?Female,Characteristics ; ,?Female," Sex, n (%)",2,0,2,no,1:no,2:yes,+,0.508
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Female," Sex, n (%)",2,1,3,yes,2:yes,2:yes,,0.824
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Female," Sex, n (%)",2,2,3,yes,2:yes,2:yes,,0.823
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF xxx ?g bid (n = xxx) ; ,?Female," Sex, n (%)",2,3,3,yes,2:yes,2:yes,,0.808
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),F xx ?g bid (n = xxx) ; ,?Female," Sex, n (%)",2,4,3,yes,2:yes,2:yes,,0.796
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),Placebo (n = xxx) ; ,?Female," Sex, n (%)",2,5,3,yes,2:yes,2:yes,,0.833
4688,3276256,Table 2,BaselineCharacteristic,?Male,Characteristics ; ,?Male," Sex, n (%)",3,0,2,no,1:no,2:yes,+,0.575
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Male," Sex, n (%)",3,1,3,yes,2:yes,2:yes,,0.832
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Male," Sex, n (%)",3,2,3,yes,2:yes,2:yes,,0.83
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF xxx ?g bid (n = xxx) ; ,?Male," Sex, n (%)",3,3,3,yes,2:yes,2:yes,,0.824
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),F xx ?g bid (n = xxx) ; ,?Male," Sex, n (%)",3,4,3,yes,2:yes,2:yes,,0.813
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,?Male," Sex, n (%)",3,5,3,yes,2:yes,2:yes,,0.839
4688,3276256,Table 2,BaselineCharacteristic,"Age, mean, years (SD)",Characteristics ; ,"Age, mean, years (SD)",,4,0,2,no,1:no,1:no,,0.784
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),MF/F xxx/xx ?g bid (n = xxx) ; ,"Age, mean, years (SD)",,4,1,3,no,1:no,2:yes,+,0.557
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),MF/F xxx/xx ?g bid (n = xxx) ; ,"Age, mean, years (SD)",,4,2,3,no,1:no,2:yes,+,0.538
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),MF xxx ?g bid (n = xxx) ; ,"Age, mean, years (SD)",,4,3,3,no,1:no,2:yes,+,0.511
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),F xx ?g bid (n = xxx) ; ,"Age, mean, years (SD)",,4,4,3,no,1:no,1:no,,0.51
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),Placebo (n = xxx) ; ,"Age, mean, years (SD)",,4,5,3,no,1:no,2:yes,+,0.578
4688,3276256,Table 2,BaselineCharacteristic,"Weight, mean kg (SD)",Characteristics ; ,"Weight, mean kg (SD)",,5,0,2,no,1:no,1:no,,0.828
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF/F xxx/xx ?g bid (n = xxx) ; ,"Weight, mean kg (SD)",,5,1,3,no,1:no,1:no,,0.554
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF/F xxx/xx ?g bid (n = xxx) ; ,"Weight, mean kg (SD)",,5,2,3,no,1:no,1:no,,0.557
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF xxx ?g bid (n = xxx) ; ,"Weight, mean kg (SD)",,5,3,3,no,1:no,1:no,,0.574
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),F xx ?g bid (n = xxx) ; ,"Weight, mean kg (SD)",,5,4,3,no,1:no,1:no,,0.609
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),Placebo (n = xxx) ; ,"Weight, mean kg (SD)",,5,5,3,no,1:no,1:no,,0.519
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",Characteristics ; ,None,None,6,0,24,no,1:no,1:no,,0.69
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Race, n (%)",None,6,1,43,no,1:no,1:no,,0.561
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Race, n (%)",None,6,2,43,no,1:no,1:no,,0.579
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",MF xxx ?g bid (n = xxx) ; ,"Race, n (%)",None,6,3,43,no,1:no,1:no,,0.587
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",F xx ?g bid (n = xxx) ; ,"Race, n (%)",None,6,4,43,no,1:no,2:yes,+,0.512
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",Placebo (n = xxx) ; ,"Race, n (%)",None,6,5,43,no,1:no,1:no,,0.505
4688,3276256,Table 2,BaselineCharacteristic,?White,Characteristics ; ,?White," Race, n (%)",7,0,2,no,1:no,1:no,,0.688
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?White," Race, n (%)",7,1,3,no,1:no,2:yes,+,0.632
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?White," Race, n (%)",7,2,3,no,1:no,2:yes,+,0.619
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF xxx ?g bid (n = xxx) ; ,?White," Race, n (%)",7,3,3,no,1:no,2:yes,+,0.599
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),F xx ?g bid (n = xxx) ; ,?White," Race, n (%)",7,4,3,no,1:no,2:yes,+,0.589
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,?White," Race, n (%)",7,5,3,no,1:no,2:yes,+,0.654
4688,3276256,Table 2,BaselineCharacteristic,?Black or African American,Characteristics ; ,?Black or African American," Race, n (%)",8,0,2,no,1:no,1:no,,0.705
4688,3276256,Table 2,BaselineCharacteristic,x (<x),MF/F xxx/xx ?g bid (n = xxx) ; ,?Black or African American," Race, n (%)",8,1,3,no,1:no,2:yes,+,0.543
4688,3276256,Table 2,BaselineCharacteristic,x,MF/F xxx/xx ?g bid (n = xxx) ; ,?Black or African American," Race, n (%)",8,2,3,no,1:no,2:yes,+,0.529
4688,3276256,Table 2,BaselineCharacteristic,x (x),MF xxx ?g bid (n = xxx) ; ,?Black or African American," Race, n (%)",8,3,3,no,1:no,2:yes,+,0.525
4688,3276256,Table 2,BaselineCharacteristic,x (x),F xx ?g bid (n = xxx) ; ,?Black or African American," Race, n (%)",8,4,3,no,1:no,2:yes,+,0.569
4688,3276256,Table 2,BaselineCharacteristic,x (x),Placebo (n = xxx) ; ,?Black or African American," Race, n (%)",8,5,3,no,1:no,2:yes,+,0.573
4688,3276256,Table 2,BaselineCharacteristic,?Asian,Characteristics ; ,?Asian," Race, n (%)",9,0,2,no,1:no,1:no,,0.714
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Asian," Race, n (%)",9,1,3,no,1:no,2:yes,+,0.61
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Asian," Race, n (%)",9,2,3,no,1:no,2:yes,+,0.597
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF xxx ?g bid (n = xxx) ; ,?Asian," Race, n (%)",9,3,3,no,1:no,2:yes,+,0.576
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),F xx ?g bid (n = xxx) ; ,?Asian," Race, n (%)",9,4,3,no,1:no,2:yes,+,0.566
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),Placebo (n = xxx) ; ,?Asian," Race, n (%)",9,5,3,no,1:no,2:yes,+,0.646
4688,3276256,Table 2,BaselineCharacteristic,?Multiracial,Characteristics ; ,?Multiracial," Race, n (%)",10,0,2,no,1:no,1:no,,0.717
4688,3276256,Table 2,BaselineCharacteristic,x (x),MF/F xxx/xx ?g bid (n = xxx) ; ,?Multiracial," Race, n (%)",10,1,3,no,1:no,2:yes,+,0.554
4688,3276256,Table 2,BaselineCharacteristic,x (x),MF/F xxx/xx ?g bid (n = xxx) ; ,?Multiracial," Race, n (%)",10,2,3,no,1:no,2:yes,+,0.54
4688,3276256,Table 2,BaselineCharacteristic,x (x),MF xxx ?g bid (n = xxx) ; ,?Multiracial," Race, n (%)",10,3,3,no,1:no,2:yes,+,0.536
4688,3276256,Table 2,BaselineCharacteristic,x (x),F xx ?g bid (n = xxx) ; ,?Multiracial," Race, n (%)",10,4,3,no,1:no,2:yes,+,0.572
4688,3276256,Table 2,BaselineCharacteristic,x (x),Placebo (n = xxx) ; ,?Multiracial," Race, n (%)",10,5,3,no,1:no,2:yes,+,0.595
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",Characteristics ; ,None,None,11,0,24,no,1:no,1:no,,0.756
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Smoking status, n (%)",None,11,1,43,no,1:no,1:no,,0.653
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Smoking status, n (%)",None,11,2,43,no,1:no,1:no,,0.672
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",MF xxx ?g bid (n = xxx) ; ,"Smoking status, n (%)",None,11,3,43,no,1:no,1:no,,0.671
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",F xx ?g bid (n = xxx) ; ,"Smoking status, n (%)",None,11,4,43,no,1:no,1:no,,0.634
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",Placebo (n = xxx) ; ,"Smoking status, n (%)",None,11,5,43,no,1:no,1:no,,0.593
4688,3276256,Table 2,BaselineCharacteristic,?Current smokers,Characteristics ; ,?Current smokers," Smoking status, n (%)",12,0,2,no,1:no,1:no,,0.777
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,1,3,no,1:no,1:no,,0.543
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,2,3,no,1:no,1:no,,0.554
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF xxx ?g bid (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,3,3,no,1:no,1:no,,0.561
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),F xx ?g bid (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,4,3,no,1:no,1:no,,0.572
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),Placebo (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,5,3,no,1:no,2:yes,+,0.514
4688,3276256,Table 2,BaselineCharacteristic,?Ex-smokers,Characteristics ; ,?Ex-smokers," Smoking status, n (%)",13,0,2,no,1:no,1:no,,0.777
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,1,3,no,1:no,1:no,,0.548
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,2,3,no,1:no,1:no,,0.559
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF xxx ?g bid (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,3,3,no,1:no,1:no,,0.567
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),F xx ?g bid (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,4,3,no,1:no,1:no,,0.577
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,5,3,no,1:no,2:yes,+,0.509
4688,3276256,Table 2,BaselineCharacteristic,"Smoking history, mean pack-years (SD)",Characteristics ; ,"Smoking history, mean pack-years (SD)",,14,0,2,no,1:no,1:no,,0.858
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF/F xxx/xx ?g bid (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,1,3,no,1:no,1:no,,0.666
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF/F xxx/xx ?g bid (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,2,3,no,1:no,1:no,,0.67
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF xxx ?g bid (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,3,3,no,1:no,1:no,,0.676
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),F xx ?g bid (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,4,3,no,1:no,1:no,,0.685
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),Placebo (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,5,3,no,1:no,1:no,,0.593
4689,3276257,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
4689,3276257,Table 1,BaselineCharacteristic,MF/F xxx/xx ?g BID (n = xxx),,,None,0,1,1,no,1:no,1:no,,0.666
4689,3276257,Table 1,BaselineCharacteristic,MF/F xxx/xx ?g BID (n = xxx),,,None,0,2,1,no,1:no,1:no,,0.665
4689,3276257,Table 1,BaselineCharacteristic,MF xxx ?g BID (n = xxx),,,None,0,3,1,no,1:no,1:no,,0.673
4689,3276257,Table 1,BaselineCharacteristic,F xx ?g BID (n = xxx),,,None,0,4,1,no,1:no,1:no,,0.599
4689,3276257,Table 1,BaselineCharacteristic,Placebo (n = xxx),,,None,0,5,1,no,1:no,1:no,,0.539
4689,3276257,Table 1,BaselineCharacteristic,"Males, n (%)", ; ,"Males, n (%)",None,1,0,2,no,1:no,1:no,,0.782
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Males, n (%)",None,1,1,3,yes,2:yes,2:yes,,0.606
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Males, n (%)",None,1,2,3,yes,2:yes,2:yes,,0.601
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF xxx ?g BID (n = xxx) ; ,"Males, n (%)",None,1,3,3,yes,2:yes,2:yes,,0.573
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),F xx ?g BID (n = xxx) ; ,"Males, n (%)",None,1,4,3,yes,2:yes,2:yes,,0.555
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,"Males, n (%)",None,1,5,3,yes,2:yes,2:yes,,0.651
4689,3276257,Table 1,BaselineCharacteristic,"White, n (%)", ; ,"White, n (%)",None,4,0,2,no,1:no,1:no,,0.793
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"White, n (%)",None,4,1,3,no,1:no,2:yes,+,0.589
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"White, n (%)",None,4,2,3,no,1:no,2:yes,+,0.572
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF xxx ?g BID (n = xxx) ; ,"White, n (%)",None,4,3,3,no,1:no,2:yes,+,0.547
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),F xx ?g BID (n = xxx) ; ,"White, n (%)",None,4,4,3,no,1:no,2:yes,+,0.529
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,"White, n (%)",None,4,5,3,no,1:no,2:yes,+,0.622
4689,3276257,Table 1,BaselineCharacteristic,"Black or African American, n (%)", ; ,"Black or African American, n (%)",None,5,0,2,no,1:no,1:no,,0.792
4689,3276257,Table 1,BaselineCharacteristic,x (x),MF/F xxx/xx ?g BID (n = xxx) ; ,"Black or African American, n (%)",None,5,1,3,no,1:no,2:yes,+,0.5
4689,3276257,Table 1,BaselineCharacteristic,xx (x),MF/F xxx/xx ?g BID (n = xxx) ; ,"Black or African American, n (%)",None,5,2,3,no,1:no,2:yes,+,0.572
4689,3276257,Table 1,BaselineCharacteristic,x (x),MF xxx ?g BID (n = xxx) ; ,"Black or African American, n (%)",None,5,3,3,no,1:no,1:no,,0.524
4689,3276257,Table 1,BaselineCharacteristic,x (x),F xx ?g BID (n = xxx) ; ,"Black or African American, n (%)",None,5,4,3,no,1:no,2:yes,+,0.559
4689,3276257,Table 1,BaselineCharacteristic,x (x),Placebo (n = xxx) ; ,"Black or African American, n (%)",None,5,5,3,no,1:no,2:yes,+,0.553
4689,3276257,Table 1,BaselineCharacteristic,"Asian, n (%)", ; ,"Asian, n (%)",None,6,0,2,no,1:no,1:no,,0.79
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Asian, n (%)",None,6,1,3,no,1:no,2:yes,+,0.581
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Asian, n (%)",None,6,2,3,no,1:no,2:yes,+,0.564
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),MF xxx ?g BID (n = xxx) ; ,"Asian, n (%)",None,6,3,3,no,1:no,2:yes,+,0.539
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),F xx ?g BID (n = xxx) ; ,"Asian, n (%)",None,6,4,3,no,1:no,2:yes,+,0.521
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),Placebo (n = xxx) ; ,"Asian, n (%)",None,6,5,3,no,1:no,2:yes,+,0.611
4689,3276257,Table 1,BaselineCharacteristic,"Current smokers, n (%)", ; ,"Current smokers, n (%)",None,7,0,2,no,1:no,1:no,,0.79
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Current smokers, n (%)",None,7,1,3,no,1:no,2:yes,+,0.566
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Current smokers, n (%)",None,7,2,3,no,1:no,2:yes,+,0.549
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF xxx ?g BID (n = xxx) ; ,"Current smokers, n (%)",None,7,3,3,no,1:no,2:yes,+,0.523
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),F xx ?g BID (n = xxx) ; ,"Current smokers, n (%)",None,7,4,3,no,1:no,2:yes,+,0.509
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,"Current smokers, n (%)",None,7,5,3,no,1:no,2:yes,+,0.606
4689,3276257,Table 1,BaselineCharacteristic,"Ex-smokers, n (%)", ; ,"Ex-smokers, n (%)",None,8,0,2,no,1:no,1:no,,0.796
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Ex-smokers, n (%)",None,8,1,3,no,1:no,2:yes,+,0.544
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Ex-smokers, n (%)",None,8,2,3,no,1:no,2:yes,+,0.527
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF xxx ?g BID (n = xxx) ; ,"Ex-smokers, n (%)",None,8,3,3,no,1:no,2:yes,+,0.502
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),F xx ?g BID (n = xxx) ; ,"Ex-smokers, n (%)",None,8,4,3,no,1:no,1:no,,0.513
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,"Ex-smokers, n (%)",None,8,5,3,no,1:no,2:yes,+,0.593
4928,3342898,Table 1,BaselineCharacteristic,characteristic,,None,None,0,0,,no,1:no,1:no,,0.811
4928,3342898,Table 1,BaselineCharacteristic,,,None,None,0,1,,no,1:no,1:no,,0.714
4928,3342898,Table 1,BaselineCharacteristic,range,,None,None,0,2,,no,1:no,1:no,,0.713
4928,3342898,Table 1,BaselineCharacteristic,"median age (years), n = xx",characteristic ; ,None,None,1,0,,no,1:no,1:no,,0.737
4928,3342898,Table 1,BaselineCharacteristic,xx, ; ,None,None,1,1,,no,1:no,1:no,,0.609
4928,3342898,Table 1,BaselineCharacteristic,xx - xx,range ; ,None,None,1,2,,no,1:no,1:no,,0.601
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ; ",None,None,2,0,,no,1:no,1:no,,0.747
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ; ,None,None,2,1,,no,1:no,1:no,,0.618
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ; ,None,None,2,2,,no,1:no,1:no,,0.603
4928,3342898,Table 1,BaselineCharacteristic,"median follow-up (months), n = xx excluding pts under treatment","characteristic ; median age (years), n = xx ;  ; ",None,None,3,0,,no,1:no,1:no,,0.755
4928,3342898,Table 1,BaselineCharacteristic,xx.x, ; xx ;  ; ,None,None,3,1,,no,1:no,1:no,,0.615
4928,3342898,Table 1,BaselineCharacteristic,x.x - xx,range ; xx - xx ;  ; ,None,None,3,2,,no,1:no,1:no,,0.558
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ; ",None,None,4,0,,no,1:no,1:no,,0.755
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ; ,None,None,4,1,,no,1:no,1:no,,0.622
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ; ,None,None,4,2,,no,1:no,1:no,,0.567
4928,3342898,Table 1,BaselineCharacteristic,deceased (pts),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; ",None,None,5,0,,no,1:no,1:no,,0.755
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; ,None,None,5,1,,no,1:no,1:no,,0.646
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ; ,None,None,5,2,,no,1:no,1:no,,0.576
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ; ",None,None,6,0,,no,1:no,1:no,,0.755
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ; ,None,None,6,1,,no,1:no,1:no,,0.655
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ; ,None,None,6,2,,no,1:no,1:no,,0.58
4928,3342898,Table 1,BaselineCharacteristic,male (pts),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; ",None,None,7,0,,no,1:no,1:no,,0.686
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; ,None,None,7,1,,no,1:no,1:no,,0.656
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ; ,None,None,7,2,,no,1:no,1:no,,0.579
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ; ",None,None,8,0,,no,1:no,1:no,,0.699
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ; ,None,None,8,1,,no,1:no,1:no,,0.69
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ; ,None,None,8,2,,no,1:no,1:no,,0.623
4928,3342898,Table 1,BaselineCharacteristic,female (pts),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; ",None,None,9,0,,no,1:no,1:no,,0.636
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; ,None,None,9,1,,no,1:no,1:no,,0.714
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ; ,None,None,9,2,,no,1:no,1:no,,0.649
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ; ",None,None,10,0,,no,1:no,1:no,,0.637
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ; ,None,None,10,1,,no,1:no,1:no,,0.736
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ; ,None,None,10,2,,no,1:no,1:no,,0.715
4928,3342898,Table 1,BaselineCharacteristic,Site (n = xx),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,11,0,,no,1:no,1:no,,0.654
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,11,1,,no,1:no,1:no,,0.757
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,11,2,,no,1:no,1:no,,0.733
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,12,0,,no,1:no,1:no,,0.654
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,12,1,,no,1:no,1:no,,0.757
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,12,2,,no,1:no,1:no,,0.733
4928,3342898,Table 1,BaselineCharacteristic,palate (pts),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",palate (pts),,13,0,,no,1:no,1:no,,0.623
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,palate (pts),,13,1,,no,1:no,1:no,,0.7
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,palate (pts),,13,2,,no,1:no,1:no,,0.709
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,14,0,,no,1:no,1:no,,0.653
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,14,1,,no,1:no,1:no,,0.747
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,14,2,,no,1:no,1:no,,0.73
4928,3342898,Table 1,BaselineCharacteristic,oropharynx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",oropharynx,,15,0,,no,1:no,1:no,,0.618
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,oropharynx,,15,1,,no,1:no,1:no,,0.689
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,oropharynx,,15,2,,no,1:no,1:no,,0.706
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,16,0,,no,1:no,1:no,,0.653
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,16,1,,no,1:no,1:no,,0.748
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,16,2,,no,1:no,1:no,,0.733
4928,3342898,Table 1,BaselineCharacteristic,hypopharynx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",hypopharynx,,17,0,,no,1:no,1:no,,0.645
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,hypopharynx,,17,1,,no,1:no,1:no,,0.724
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,hypopharynx,,17,2,,no,1:no,1:no,,0.73
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,18,0,,no,1:no,1:no,,0.682
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,18,1,,no,1:no,1:no,,0.781
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,18,2,,no,1:no,1:no,,0.755
4928,3342898,Table 1,BaselineCharacteristic,larynx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",larynx,,19,0,,no,1:no,1:no,,0.648
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,larynx,,19,1,,no,1:no,1:no,,0.731
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,larynx,,19,2,,no,1:no,1:no,,0.736
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,20,0,,no,1:no,1:no,,0.683
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,20,1,,no,1:no,1:no,,0.787
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,20,2,,no,1:no,1:no,,0.761
4928,3342898,Table 1,BaselineCharacteristic,Stage (n = xx),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,21,0,,no,1:no,1:no,,0.695
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,21,1,,no,1:no,1:no,,0.787
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,21,2,,no,1:no,1:no,,0.761
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,22,0,,no,1:no,1:no,,0.684
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,22,1,,no,1:no,1:no,,0.795
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,22,2,,no,1:no,1:no,,0.769
4928,3342898,Table 1,BaselineCharacteristic,Tx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Tx,,23,0,,no,1:no,1:no,,0.657
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Tx,,23,1,,no,1:no,1:no,,0.762
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Tx,,23,2,,no,1:no,1:no,,0.765
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,24,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,24,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,24,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,Tx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Tx,,25,0,,no,1:no,1:no,,0.658
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Tx,,25,1,,no,1:no,1:no,,0.765
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Tx,,25,2,,no,1:no,1:no,,0.768
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,26,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,26,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,26,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,Tx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Tx,,27,0,,no,1:no,1:no,,0.658
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Tx,,27,1,,no,1:no,1:no,,0.765
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Tx,,27,2,,no,1:no,1:no,,0.768
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,28,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,28,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,28,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,Nx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Nx,,29,0,,no,1:no,1:no,,0.651
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Nx,,29,1,,no,1:no,1:no,,0.752
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Nx,,29,2,,no,1:no,1:no,,0.756
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,30,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,30,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,30,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,Nxb,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Nxb,,31,0,,no,1:no,1:no,,0.651
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Nxb,,31,1,,no,1:no,1:no,,0.752
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Nxb,,31,2,,no,1:no,1:no,,0.756
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,32,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,32,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,32,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,Nxc,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Nxc,,33,0,,no,1:no,1:no,,0.651
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Nxc,,33,1,,no,1:no,1:no,,0.752
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Nxc,,33,2,,no,1:no,1:no,,0.756
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,34,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,34,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,34,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,Nx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Nx,,35,0,,no,1:no,1:no,,0.651
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Nx,,35,1,,no,1:no,1:no,,0.752
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Nx,,35,2,,no,1:no,1:no,,0.756
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,36,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,36,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,36,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,therapy (n = xx),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,37,0,,no,1:no,1:no,,0.686
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,37,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,37,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,38,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,38,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,38,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,median dose (cervical lymph nodes)/Gy,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",median dose (cervical lymph nodes)/Gy,,39,0,,no,1:no,1:no,,0.672
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,median dose (cervical lymph nodes)/Gy,,39,1,,no,1:no,1:no,,0.805
4928,3342898,Table 1,BaselineCharacteristic,xx - xx,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,median dose (cervical lymph nodes)/Gy,,39,2,,no,1:no,1:no,,0.791
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,40,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,40,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,40,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,median dose (primary and involved nodes)/Gy,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",median dose (primary and involved nodes)/Gy,,41,0,,no,1:no,1:no,,0.719
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,median dose (primary and involved nodes)/Gy,,41,1,,no,1:no,1:no,,0.838
4928,3342898,Table 1,BaselineCharacteristic,xx - xx,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,median dose (primary and involved nodes)/Gy,,41,2,,no,1:no,1:no,,0.831
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,42,0,,no,1:no,1:no,,0.685
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,42,1,,no,1:no,1:no,,0.799
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,42,2,,no,1:no,1:no,,0.773
4928,3342898,Table 1,BaselineCharacteristic,median total dose/Gy,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",median total dose/Gy,,43,0,,no,1:no,1:no,,0.642
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,median total dose/Gy,,43,1,,no,1:no,1:no,,0.701
4928,3342898,Table 1,BaselineCharacteristic,xx - xx,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,median total dose/Gy,,43,2,,no,1:no,1:no,,0.71
5127,3389237,Table I,BaselineCharacteristic,Parameter,,None,None,0,0,12,no,1:no,1:no,,0.799
5127,3389237,Table I,BaselineCharacteristic,Total (N?=?xx),,Parameter,None,0,1,1,no,1:no,1:no,,0.569
5127,3389237,Table I,BaselineCharacteristic,Gender,Parameter ; ,None,None,1,0,24,no,1:no,1:no,,0.719
5127,3389237,Table I,BaselineCharacteristic,Gender,Total (N?=?xx) ; ,Gender,None,1,1,43,no,1:no,2:yes,+,0.648
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Gender,2,0,2,no,1:no,1:no,,0.795
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Gender,2,1,3,yes,2:yes,2:yes,,0.718
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Gender,3,0,2,no,1:no,1:no,,0.792
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Gender,3,1,3,yes,2:yes,2:yes,,0.718
5127,3389237,Table I,BaselineCharacteristic,Age (yr),Parameter ; ,None,None,4,0,24,no,1:no,1:no,,0.862
5127,3389237,Table I,BaselineCharacteristic,Age (yr),Total (N?=?xx) ; ,Age (yr),None,4,1,43,no,1:no,1:no,,0.555
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age (yr),5,0,2,no,1:no,1:no,,0.853
5127,3389237,Table I,BaselineCharacteristic,xx.x (xx.xx),Total (N?=?xx) ; ,, Age (yr),5,1,3,no,1:no,2:yes,+,0.509
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age (yr),6,0,2,no,1:no,1:no,,0.851
5127,3389237,Table I,BaselineCharacteristic,xx.x,Total (N?=?xx) ; ,, Age (yr),6,1,3,no,1:no,1:no,,0.52
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age (yr),7,0,2,no,1:no,1:no,,0.856
5127,3389237,Table I,BaselineCharacteristic,"x, xx",Total (N?=?xx) ; ,, Age (yr),7,1,3,no,1:no,1:no,,0.524
5127,3389237,Table I,BaselineCharacteristic,Age group,Parameter ; ,None,None,8,0,24,no,1:no,1:no,,0.855
5127,3389237,Table I,BaselineCharacteristic,Age group,Total (N?=?xx) ; ,Age group,None,8,1,43,no,1:no,1:no,,0.594
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age group,9,0,2,no,1:no,1:no,,0.854
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Age group,9,1,3,no,1:no,1:no,,0.512
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age group,10,0,2,no,1:no,1:no,,0.855
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Age group,10,1,3,no,1:no,1:no,,0.518
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age group,11,0,2,no,1:no,1:no,,0.863
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Age group,11,1,3,no,1:no,1:no,,0.534
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age group,12,0,2,no,1:no,1:no,,0.869
5127,3389237,Table I,BaselineCharacteristic,x (xx.x%),Total (N?=?xx) ; ,, Age group,12,1,3,no,1:no,1:no,,0.554
5127,3389237,Table I,BaselineCharacteristic,Race,Parameter ; ,None,None,13,0,24,no,1:no,1:no,,0.876
5127,3389237,Table I,BaselineCharacteristic,Race,Total (N?=?xx) ; ,Race,None,13,1,43,no,1:no,1:no,,0.622
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Race,14,0,2,no,1:no,1:no,,0.878
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Race,14,1,3,no,1:no,1:no,,0.515
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Race,15,0,2,no,1:no,1:no,,0.883
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Race,15,1,3,no,1:no,1:no,,0.537
5127,3389237,Table I,BaselineCharacteristic,Primary diagnosis,Parameter ; ,None,None,16,0,24,no,1:no,1:no,,0.898
5127,3389237,Table I,BaselineCharacteristic,Primary diagnosis,Total (N?=?xx) ; ,Primary diagnosis,None,16,1,43,no,1:no,1:no,,0.697
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,17,0,2,no,1:no,1:no,,0.911
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Primary diagnosis,17,1,3,no,1:no,1:no,,0.643
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,18,0,2,no,1:no,1:no,,0.914
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Primary diagnosis,18,1,3,no,1:no,1:no,,0.64
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,19,0,2,no,1:no,1:no,,0.914
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Primary diagnosis,19,1,3,no,1:no,1:no,,0.651
5127,3389237,Table I,BaselineCharacteristic,SBI history,Parameter ; ,SBI history, Primary diagnosis,20,0,2,no,1:no,1:no,,0.915
5127,3389237,Table I,BaselineCharacteristic,x (xx.x%),Total (N?=?xx) ; ,SBI history, Primary diagnosis,20,1,3,no,1:no,1:no,,0.687
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,21,0,2,no,1:no,1:no,,0.914
5127,3389237,Table I,BaselineCharacteristic,x (xx.x%),Total (N?=?xx) ; ,, Primary diagnosis,21,1,3,no,1:no,1:no,,0.651
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,22,0,2,no,1:no,1:no,,0.916
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Primary diagnosis,22,1,3,no,1:no,1:no,,0.654
5153,3396277,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xx U/kg)(n = x),,,None,0,1,1,no,1:no,2:yes,+,0.503
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xxx U/kg)(n = x),,,None,0,2,1,no,1:no,1:no,,0.566
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xxx/xx U/kg) (n = xx),,,None,0,3,1,no,1:no,2:yes,+,0.504
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx),,,None,0,4,1,no,1:no,2:yes,+,0.517
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xxx/xxx U/kg)(n = x),,,None,0,5,1,no,1:no,1:no,,0.552
5153,3396277,Table 2,BaselineCharacteristic,Placebo (n = xx),,,None,0,6,1,no,1:no,2:yes,+,0.568
5153,3396277,Table 2,BaselineCharacteristic,Total(n = xx),,,None,0,7,1,no,1:no,1:no,,0.572
5153,3396277,Table 2,BaselineCharacteristic,"Male:female, n", ; ,"Male:female, n",,2,0,2,no,1:no,1:no,,0.618
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Male:female, n",,2,1,3,yes,2:yes,2:yes,,0.753
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Male:female, n",,2,2,3,yes,2:yes,2:yes,,0.69
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Male:female, n",,2,3,3,yes,2:yes,2:yes,,0.751
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Male:female, n",,2,4,3,yes,2:yes,2:yes,,0.739
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Male:female, n",,2,5,3,yes,2:yes,2:yes,,0.666
5153,3396277,Table 2,BaselineCharacteristic,xx:xx,Placebo (n = xx) ; ,"Male:female, n",,2,6,3,yes,2:yes,2:yes,,0.796
5153,3396277,Table 2,BaselineCharacteristic,xx:xx,Total(n = xx) ; ,"Male:female, n",,2,7,3,yes,2:yes,2:yes,,0.739
5153,3396277,Table 2,BaselineCharacteristic,"Race, n (%)", ; ,None,None,3,0,24,no,1:no,1:no,,0.719
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Race, n (%)",None,3,1,43,no,1:no,2:yes,+,0.628
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Race, n (%)",None,3,2,43,no,1:no,2:yes,+,0.501
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Race, n (%)",None,3,3,43,no,1:no,2:yes,+,0.628
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Race, n (%)",None,3,4,43,no,1:no,2:yes,+,0.651
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Race, n (%)",None,3,5,43,no,1:no,2:yes,+,0.546
5153,3396277,Table 2,BaselineCharacteristic,,Placebo (n = xx) ; ,"Race, n (%)",None,3,6,43,no,1:no,2:yes,+,0.652
5153,3396277,Table 2,BaselineCharacteristic,,Total(n = xx) ; ,"Race, n (%)",None,3,7,43,no,1:no,2:yes,+,0.569
5153,3396277,Table 2,BaselineCharacteristic,?Caucasian/white, ; ,?Caucasian/white," Race, n (%)",4,0,2,no,1:no,1:no,,0.706
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Caucasian/white," Race, n (%)",4,1,3,no,1:no,2:yes,+,0.683
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Caucasian/white," Race, n (%)",4,2,3,no,1:no,2:yes,+,0.675
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Caucasian/white," Race, n (%)",4,3,3,no,1:no,2:yes,+,0.67
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Caucasian/white," Race, n (%)",4,4,3,no,1:no,2:yes,+,0.706
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Caucasian/white," Race, n (%)",4,5,3,no,1:no,2:yes,+,0.692
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,?Caucasian/white," Race, n (%)",4,6,3,no,1:no,2:yes,+,0.719
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?Caucasian/white," Race, n (%)",4,7,3,no,1:no,2:yes,+,0.627
5153,3396277,Table 2,BaselineCharacteristic,?Black/African American, ; ,?Black/African American," Race, n (%)",5,0,2,no,1:no,1:no,,0.703
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Black/African American," Race, n (%)",5,1,3,no,1:no,2:yes,+,0.65
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Black/African American," Race, n (%)",5,2,3,no,1:no,2:yes,+,0.647
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Black/African American," Race, n (%)",5,3,3,no,1:no,2:yes,+,0.638
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Black/African American," Race, n (%)",5,4,3,no,1:no,2:yes,+,0.673
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Black/African American," Race, n (%)",5,5,3,no,1:no,2:yes,+,0.659
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Placebo (n = xx) ; ,?Black/African American," Race, n (%)",5,6,3,no,1:no,2:yes,+,0.692
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Total(n = xx) ; ,?Black/African American," Race, n (%)",5,7,3,no,1:no,2:yes,+,0.605
5153,3396277,Table 2,BaselineCharacteristic,?Other, ; ,?Other," Race, n (%)",6,0,2,no,1:no,1:no,,0.707
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Other," Race, n (%)",6,1,3,no,1:no,2:yes,+,0.6
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Other," Race, n (%)",6,2,3,no,1:no,2:yes,+,0.534
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Other," Race, n (%)",6,3,3,no,1:no,2:yes,+,0.595
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Other," Race, n (%)",6,4,3,no,1:no,2:yes,+,0.629
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Other," Race, n (%)",6,5,3,no,1:no,2:yes,+,0.564
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Placebo (n = xx) ; ,?Other," Race, n (%)",6,6,3,no,1:no,2:yes,+,0.647
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Total(n = xx) ; ,?Other," Race, n (%)",6,7,3,no,1:no,2:yes,+,0.555
5153,3396277,Table 2,BaselineCharacteristic,"Shock, n (%)", ; ,None,None,7,0,24,no,1:no,1:no,,0.737
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Shock, n (%)",None,7,1,43,no,1:no,2:yes,+,0.56
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Shock, n (%)",None,7,2,43,no,1:no,1:no,,0.551
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Shock, n (%)",None,7,3,43,no,1:no,2:yes,+,0.563
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Shock, n (%)",None,7,4,43,no,1:no,2:yes,+,0.593
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Shock, n (%)",None,7,5,43,no,1:no,1:no,,0.503
5153,3396277,Table 2,BaselineCharacteristic,,Placebo (n = xx) ; ,"Shock, n (%)",None,7,6,43,no,1:no,2:yes,+,0.623
5153,3396277,Table 2,BaselineCharacteristic,,Total(n = xx) ; ,"Shock, n (%)",None,7,7,43,no,1:no,2:yes,+,0.522
5153,3396277,Table 2,BaselineCharacteristic,?Yes, ; ,?Yes," Shock, n (%)",8,0,2,no,1:no,1:no,,0.721
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Yes," Shock, n (%)",8,1,3,no,1:no,2:yes,+,0.579
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Yes," Shock, n (%)",8,2,3,no,1:no,2:yes,+,0.604
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Yes," Shock, n (%)",8,3,3,no,1:no,2:yes,+,0.569
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Yes," Shock, n (%)",8,4,3,no,1:no,2:yes,+,0.604
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Yes," Shock, n (%)",8,5,3,no,1:no,2:yes,+,0.593
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,?Yes," Shock, n (%)",8,6,3,no,1:no,2:yes,+,0.641
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?Yes," Shock, n (%)",8,7,3,no,1:no,2:yes,+,0.526
5153,3396277,Table 2,BaselineCharacteristic,?No, ; ,?No," Shock, n (%)",9,0,2,no,1:no,1:no,,0.726
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?No," Shock, n (%)",9,1,3,no,1:no,2:yes,+,0.587
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?No," Shock, n (%)",9,2,3,no,1:no,2:yes,+,0.602
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?No," Shock, n (%)",9,3,3,no,1:no,2:yes,+,0.58
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?No," Shock, n (%)",9,4,3,no,1:no,2:yes,+,0.619
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?No," Shock, n (%)",9,5,3,no,1:no,2:yes,+,0.616
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?No," Shock, n (%)",9,6,3,no,1:no,2:yes,+,0.641
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?No," Shock, n (%)",9,7,3,no,1:no,2:yes,+,0.552
5153,3396277,Table 2,BaselineCharacteristic,"On ventilator, n (%)*", ; ,None,None,10,0,24,no,1:no,1:no,,0.788
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"On ventilator, n (%)*",None,10,1,43,no,1:no,1:no,,0.51
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"On ventilator, n (%)*",None,10,2,43,no,1:no,1:no,,0.578
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"On ventilator, n (%)*",None,10,3,43,no,1:no,1:no,,0.507
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"On ventilator, n (%)*",None,10,4,43,no,1:no,2:yes,+,0.529
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"On ventilator, n (%)*",None,10,5,43,no,1:no,1:no,,0.551
5153,3396277,Table 2,BaselineCharacteristic,,Placebo (n = xx) ; ,"On ventilator, n (%)*",None,10,6,43,no,1:no,2:yes,+,0.564
5153,3396277,Table 2,BaselineCharacteristic,,Total(n = xx) ; ,"On ventilator, n (%)*",None,10,7,43,no,1:no,1:no,,0.56
5153,3396277,Table 2,BaselineCharacteristic,?Yes, ; ,?Yes," On ventilator, n (%)*",11,0,2,no,1:no,1:no,,0.762
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Yes," On ventilator, n (%)*",11,1,3,no,1:no,2:yes,+,0.504
5153,3396277,Table 2,BaselineCharacteristic,x (xxx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Yes," On ventilator, n (%)*",11,2,3,no,1:no,1:no,,0.522
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Yes," On ventilator, n (%)*",11,3,3,no,1:no,1:no,,0.508
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Yes," On ventilator, n (%)*",11,4,3,no,1:no,2:yes,+,0.531
5153,3396277,Table 2,BaselineCharacteristic,x (xxx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Yes," On ventilator, n (%)*",11,5,3,no,1:no,2:yes,+,0.511
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,?Yes," On ventilator, n (%)*",11,6,3,no,1:no,2:yes,+,0.58
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?Yes," On ventilator, n (%)*",11,7,3,no,1:no,1:no,,0.542
5153,3396277,Table 2,BaselineCharacteristic,?No, ; ,?No," On ventilator, n (%)*",12,0,2,no,1:no,1:no,,0.763
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?No," On ventilator, n (%)*",12,1,3,no,1:no,2:yes,+,0.514
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?No," On ventilator, n (%)*",12,2,3,no,1:no,1:no,,0.525
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?No," On ventilator, n (%)*",12,3,3,no,1:no,2:yes,+,0.505
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?No," On ventilator, n (%)*",12,4,3,no,1:no,2:yes,+,0.545
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?No," On ventilator, n (%)*",12,5,3,no,1:no,2:yes,+,0.504
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?No," On ventilator, n (%)*",12,6,3,no,1:no,2:yes,+,0.581
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Total(n = xx) ; ,?No," On ventilator, n (%)*",12,7,3,no,1:no,1:no,,0.517
5153,3396277,Table 2,BaselineCharacteristic,?Missing, ; ,?Missing," On ventilator, n (%)*",13,0,2,no,1:no,1:no,,0.751
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Missing," On ventilator, n (%)*",13,1,3,no,1:no,2:yes,+,0.517
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Missing," On ventilator, n (%)*",13,2,3,no,1:no,1:no,,0.514
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Missing," On ventilator, n (%)*",13,3,3,no,1:no,2:yes,+,0.503
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Missing," On ventilator, n (%)*",13,4,3,no,1:no,2:yes,+,0.547
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Missing," On ventilator, n (%)*",13,5,3,no,1:no,1:no,,0.506
5153,3396277,Table 2,BaselineCharacteristic,x,Placebo (n = xx) ; ,?Missing," On ventilator, n (%)*",13,6,3,no,1:no,2:yes,+,0.594
5153,3396277,Table 2,BaselineCharacteristic,x,Total(n = xx) ; ,?Missing," On ventilator, n (%)*",13,7,3,no,1:no,1:no,,0.535
5153,3396277,Table 2,BaselineCharacteristic,"Shock + ventilator, n (%)*", ; ,"Shock + ventilator, n (%)*",,14,0,2,no,1:no,1:no,,0.739
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Shock + ventilator, n (%)*",,14,1,3,no,1:no,2:yes,+,0.539
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Shock + ventilator, n (%)*",,14,2,3,no,1:no,2:yes,+,0.558
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Shock + ventilator, n (%)*",,14,3,3,no,1:no,2:yes,+,0.525
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Shock + ventilator, n (%)*",,14,4,3,no,1:no,2:yes,+,0.568
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Shock + ventilator, n (%)*",,14,5,3,no,1:no,2:yes,+,0.558
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,"Shock + ventilator, n (%)*",,14,6,3,no,1:no,2:yes,+,0.622
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,"Shock + ventilator, n (%)*",,14,7,3,no,1:no,1:no,,0.521
5153,3396277,Table 2,BaselineCharacteristic,"Organ failures, n (%)**", ; ,None,None,15,0,24,no,1:no,1:no,,0.782
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Organ failures, n (%)**",None,15,1,43,no,1:no,1:no,,0.511
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Organ failures, n (%)**",None,15,2,43,no,1:no,1:no,,0.587
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Organ failures, n (%)**",None,15,3,43,no,1:no,1:no,,0.509
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Organ failures, n (%)**",None,15,4,43,no,1:no,2:yes,+,0.526
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Organ failures, n (%)**",None,15,5,43,no,1:no,1:no,,0.55
5153,3396277,Table 2,BaselineCharacteristic,,Placebo (n = xx) ; ,"Organ failures, n (%)**",None,15,6,43,no,1:no,2:yes,+,0.566
5153,3396277,Table 2,BaselineCharacteristic,,Total(n = xx) ; ,"Organ failures, n (%)**",None,15,7,43,no,1:no,1:no,,0.556
5153,3396277,Table 2,BaselineCharacteristic,?x, ; ,?x," Organ failures, n (%)**",16,0,2,no,1:no,1:no,,0.672
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",16,1,3,no,1:no,2:yes,+,0.534
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",16,2,3,no,1:no,1:no,,0.503
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",16,3,3,no,1:no,2:yes,+,0.52
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",16,4,3,no,1:no,2:yes,+,0.562
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",16,5,3,no,1:no,2:yes,+,0.51
5153,3396277,Table 2,BaselineCharacteristic,x,Placebo (n = xx) ; ,?x," Organ failures, n (%)**",16,6,3,no,1:no,2:yes,+,0.616
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Total(n = xx) ; ,?x," Organ failures, n (%)**",16,7,3,no,1:no,1:no,,0.522
5153,3396277,Table 2,BaselineCharacteristic,?x, ; ,?x," Organ failures, n (%)**",17,0,2,no,1:no,1:no,,0.716
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",17,1,3,no,1:no,1:no,,0.525
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",17,2,3,no,1:no,1:no,,0.562
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",17,3,3,no,1:no,1:no,,0.536
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",17,4,3,no,1:no,2:yes,+,0.501
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",17,5,3,no,1:no,1:no,,0.504
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Placebo (n = xx) ; ,?x," Organ failures, n (%)**",17,6,3,no,1:no,2:yes,+,0.559
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Total(n = xx) ; ,?x," Organ failures, n (%)**",17,7,3,no,1:no,1:no,,0.57
5153,3396277,Table 2,BaselineCharacteristic,?x, ; ,?x," Organ failures, n (%)**",18,0,2,no,1:no,1:no,,0.73
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",18,1,3,no,1:no,1:no,,0.534
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",18,2,3,no,1:no,1:no,,0.506
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",18,3,3,no,1:no,1:no,,0.545
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",18,4,3,no,1:no,1:no,,0.504
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",18,5,3,no,1:no,1:no,,0.509
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?x," Organ failures, n (%)**",18,6,3,no,1:no,2:yes,+,0.549
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?x," Organ failures, n (%)**",18,7,3,no,1:no,1:no,,0.574
5153,3396277,Table 2,BaselineCharacteristic,?x, ; ,?x," Organ failures, n (%)**",19,0,2,no,1:no,1:no,,0.73
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",19,1,3,no,1:no,1:no,,0.54
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",19,2,3,no,1:no,1:no,,0.52
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",19,3,3,no,1:no,1:no,,0.551
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",19,4,3,no,1:no,1:no,,0.509
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",19,5,3,no,1:no,1:no,,0.515
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?x," Organ failures, n (%)**",19,6,3,no,1:no,2:yes,+,0.544
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?x," Organ failures, n (%)**",19,7,3,no,1:no,1:no,,0.574
5153,3396277,Table 2,BaselineCharacteristic,?? x, ; ,?? x," Organ failures, n (%)**",20,0,2,no,1:no,1:no,,0.735
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?? x," Organ failures, n (%)**",20,1,3,no,1:no,1:no,,0.54
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?? x," Organ failures, n (%)**",20,2,3,no,1:no,1:no,,0.52
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?? x," Organ failures, n (%)**",20,3,3,no,1:no,1:no,,0.551
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?? x," Organ failures, n (%)**",20,4,3,no,1:no,1:no,,0.509
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?? x," Organ failures, n (%)**",20,5,3,no,1:no,1:no,,0.515
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?? x," Organ failures, n (%)**",20,6,3,no,1:no,2:yes,+,0.544
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?? x," Organ failures, n (%)**",20,7,3,no,1:no,1:no,,0.574
5153,3396277,Table 2,BaselineCharacteristic,APACHE II score, ; ,APACHE II score,,21,0,24,no,1:no,1:no,,0.888
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,APACHE II score,,21,1,43,no,1:no,1:no,,0.67
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,APACHE II score,,21,2,43,no,1:no,1:no,,0.694
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,APACHE II score,,21,3,43,no,1:no,1:no,,0.682
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,APACHE II score,,21,4,43,no,1:no,1:no,,0.664
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,APACHE II score,,21,5,43,no,1:no,1:no,,0.687
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,APACHE II score,,21,6,43,no,1:no,1:no,,0.55
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,APACHE II score,,21,7,43,no,1:no,1:no,,0.683
5153,3396277,Table 2,BaselineCharacteristic,SOFA score, ; ,SOFA score,,23,0,24,no,1:no,1:no,,0.888
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,SOFA score,,23,1,43,no,1:no,1:no,,0.675
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,SOFA score,,23,2,43,no,1:no,1:no,,0.699
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,SOFA score,,23,3,43,no,1:no,1:no,,0.687
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,SOFA score,,23,4,43,no,1:no,1:no,,0.669
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,SOFA score,,23,5,43,no,1:no,1:no,,0.692
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,SOFA score,,23,6,43,no,1:no,1:no,,0.551
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,SOFA score,,23,7,43,no,1:no,1:no,,0.683
5153,3396277,Table 2,BaselineCharacteristic,"TNF-? concentration, pg/mL", ; ,"TNF-? concentration, pg/mL",,25,0,24,no,1:no,1:no,,0.879
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"TNF-? concentration, pg/mL",,25,1,43,no,1:no,1:no,,0.681
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"TNF-? concentration, pg/mL",,25,2,43,no,1:no,1:no,,0.695
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"TNF-? concentration, pg/mL",,25,3,43,no,1:no,1:no,,0.695
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"TNF-? concentration, pg/mL",,25,4,43,no,1:no,1:no,,0.677
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"TNF-? concentration, pg/mL",,25,5,43,no,1:no,1:no,,0.689
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,"TNF-? concentration, pg/mL",,25,6,43,no,1:no,1:no,,0.553
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,"TNF-? concentration, pg/mL",,25,7,43,no,1:no,1:no,,0.663
5153,3396277,Table 2,BaselineCharacteristic,?Median (range), ; ,?Median (range)," TNF-? concentration, pg/mL",26,0,2,no,1:no,1:no,,0.914
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Median (range)," TNF-? concentration, pg/mL",26,1,3,no,1:no,1:no,,0.717
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Median (range)," TNF-? concentration, pg/mL",26,2,3,no,1:no,1:no,,0.677
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Median (range)," TNF-? concentration, pg/mL",26,3,3,no,1:no,1:no,,0.718
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to x.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Median (range)," TNF-? concentration, pg/mL",26,4,3,no,1:no,1:no,,0.707
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Median (range)," TNF-? concentration, pg/mL",26,5,3,no,1:no,1:no,,0.708
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),Placebo (n = xx) ; ,?Median (range)," TNF-? concentration, pg/mL",26,6,3,no,1:no,1:no,,0.585
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),Total(n = xx) ; ,?Median (range)," TNF-? concentration, pg/mL",26,7,3,no,1:no,1:no,,0.717
5153,3396277,Table 2,BaselineCharacteristic,"IL-x concentration, pg/mL", ; ,"IL-x concentration, pg/mL",,27,0,24,no,1:no,1:no,,0.879
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"IL-x concentration, pg/mL",,27,1,43,no,1:no,1:no,,0.681
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"IL-x concentration, pg/mL",,27,2,43,no,1:no,1:no,,0.695
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"IL-x concentration, pg/mL",,27,3,43,no,1:no,1:no,,0.695
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"IL-x concentration, pg/mL",,27,4,43,no,1:no,1:no,,0.677
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"IL-x concentration, pg/mL",,27,5,43,no,1:no,1:no,,0.689
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,"IL-x concentration, pg/mL",,27,6,43,no,1:no,1:no,,0.553
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,"IL-x concentration, pg/mL",,27,7,43,no,1:no,1:no,,0.663
5153,3396277,Table 2,BaselineCharacteristic,?Median (range), ; ,?Median (range)," IL-x concentration, pg/mL",28,0,2,no,1:no,1:no,,0.914
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xx,xxx)",AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Median (range)," IL-x concentration, pg/mL",28,1,3,no,1:no,1:no,,0.676
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xx,xxx)",AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Median (range)," IL-x concentration, pg/mL",28,2,3,no,1:no,1:no,,0.677
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xx,xxx)",AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Median (range)," IL-x concentration, pg/mL",28,3,3,no,1:no,1:no,,0.682
5153,3396277,Table 2,BaselineCharacteristic,"xxxx(xxx to xx,xxx)",AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Median (range)," IL-x concentration, pg/mL",28,4,3,no,1:no,1:no,,0.659
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xxx to xx,xxx)",AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Median (range)," IL-x concentration, pg/mL",28,5,3,no,1:no,1:no,,0.656
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xxx,xxx)",Placebo (n = xx) ; ,?Median (range)," IL-x concentration, pg/mL",28,6,3,no,1:no,1:no,,0.598
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xxx,xxx)",Total(n = xx) ; ,?Median (range)," IL-x concentration, pg/mL",28,7,3,no,1:no,1:no,,0.689
5153,3396277,Table 2,BaselineCharacteristic,"Procalcitonin level, ng/mL", ; ,"Procalcitonin level, ng/mL",,29,0,24,no,1:no,1:no,,0.888
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Procalcitonin level, ng/mL",,29,1,43,no,1:no,1:no,,0.696
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Procalcitonin level, ng/mL",,29,2,43,no,1:no,1:no,,0.729
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Procalcitonin level, ng/mL",,29,3,43,no,1:no,1:no,,0.707
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Procalcitonin level, ng/mL",,29,4,43,no,1:no,1:no,,0.686
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Procalcitonin level, ng/mL",,29,5,43,no,1:no,1:no,,0.712
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,"Procalcitonin level, ng/mL",,29,6,43,no,1:no,1:no,,0.593
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,"Procalcitonin level, ng/mL",,29,7,43,no,1:no,1:no,,0.697
5153,3396277,Table 2,BaselineCharacteristic,?Median (range), ; ,?Median (range)," Procalcitonin level, ng/mL",30,0,2,no,1:no,1:no,,0.926
5153,3396277,Table 2,BaselineCharacteristic,xx.x (x.x to xxx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Median (range)," Procalcitonin level, ng/mL",30,1,3,no,1:no,1:no,,0.706
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xxx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Median (range)," Procalcitonin level, ng/mL",30,2,3,no,1:no,1:no,,0.756
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xxx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Median (range)," Procalcitonin level, ng/mL",30,3,3,no,1:no,1:no,,0.714
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Median (range)," Procalcitonin level, ng/mL",30,4,3,no,1:no,1:no,,0.715
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Median (range)," Procalcitonin level, ng/mL",30,5,3,no,1:no,1:no,,0.716
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),Placebo (n = xx) ; ,?Median (range)," Procalcitonin level, ng/mL",30,6,3,no,1:no,1:no,,0.589
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),Total(n = xx) ; ,?Median (range)," Procalcitonin level, ng/mL",30,7,3,no,1:no,1:no,,0.685
5153,3396277,Table 2,BaselineCharacteristic,"?> x.x ng/mL, n (%)", ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,0,2,no,1:no,1:no,,0.793
5153,3396277,Table 2,BaselineCharacteristic,x (xxx),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,1,3,no,1:no,1:no,,0.581
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,2,3,no,1:no,1:no,,0.588
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,3,3,no,1:no,1:no,,0.609
5153,3396277,Table 2,BaselineCharacteristic,xx (xxx),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,4,3,no,1:no,1:no,,0.542
5153,3396277,Table 2,BaselineCharacteristic,x (xxx),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,5,3,no,1:no,1:no,,0.608
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,6,3,no,1:no,1:no,,0.509
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,7,3,no,1:no,1:no,,0.628
5153,3396277,Table 2,BaselineCharacteristic,"Total fluid volume in xx h prior to randomization, mL/kg", ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,0,24,no,1:no,1:no,,0.765
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,1,43,no,1:no,1:no,,0.659
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,2,43,no,1:no,1:no,,0.629
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,3,43,no,1:no,1:no,,0.66
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,4,43,no,1:no,1:no,,0.649
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,5,43,no,1:no,1:no,,0.65
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,6,43,no,1:no,1:no,,0.58
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,7,43,no,1:no,1:no,,0.695
5153,3396277,Table 2,BaselineCharacteristic,?Median (range), ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,0,2,no,1:no,1:no,,0.846
5153,3396277,Table 2,BaselineCharacteristic,xx.x(xx.x to xxx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,1,3,no,1:no,1:no,,0.674
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,2,3,no,1:no,1:no,,0.668
5153,3396277,Table 2,BaselineCharacteristic,xx.x(xx.x to xxx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,3,3,no,1:no,1:no,,0.668
5153,3396277,Table 2,BaselineCharacteristic,xx.x(xx.x to xxx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,4,3,no,1:no,1:no,,0.653
5153,3396277,Table 2,BaselineCharacteristic,xx.x(xx.x to xxx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,5,3,no,1:no,1:no,,0.649
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),Placebo (n = xx) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,6,3,no,1:no,1:no,,0.601
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),Total(n = xx) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,7,3,no,1:no,1:no,,0.703
5225,3405220,Table 1,BaselineCharacteristic,Operating characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
5225,3405220,Table 1,BaselineCharacteristic,Standard treatment alone,,Operating characteristic,None,0,1,1,no,1:no,1:no,,0.737
5225,3405220,Table 1,BaselineCharacteristic,Standard treatment + huachansu,,Operating characteristic,None,0,2,1,no,1:no,1:no,,0.775
5225,3405220,Table 1,BaselineCharacteristic,True overall response rate,Operating characteristic ; ,True overall response rate,None,1,0,2,no,1:no,1:no,,0.853
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment alone ; ,True overall response rate,None,1,1,3,no,1:no,1:no,,0.724
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment + huachansu ; ,True overall response rate,None,1,2,3,no,1:no,1:no,,0.76
5225,3405220,Table 1,BaselineCharacteristic,Average number of patients,Operating characteristic ; ,Average number of patients,None,2,0,2,no,1:no,1:no,,0.827
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment alone ; ,Average number of patients,None,2,1,3,no,1:no,1:no,,0.613
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment + huachansu ; ,Average number of patients,None,2,2,3,no,1:no,1:no,,0.614
5225,3405220,Table 1,BaselineCharacteristic,Probability of selection as best,Operating characteristic ; ,Probability of selection as best,None,3,0,2,no,1:no,1:no,,0.856
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of selection as best,None,3,1,3,no,1:no,1:no,,0.724
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of selection as best,None,3,2,3,no,1:no,1:no,,0.732
5225,3405220,Table 1,BaselineCharacteristic,Probability of early selection,Operating characteristic ; ,Probability of early selection,None,4,0,2,no,1:no,1:no,,0.867
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of early selection,None,4,1,3,no,1:no,1:no,,0.73
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of early selection,None,4,2,3,no,1:no,1:no,,0.739
5225,3405220,Table 1,BaselineCharacteristic,,Operating characteristic ; ,None,None,5,0,2,no,1:no,1:no,,0.876
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment alone ; ,None,None,5,1,3,no,1:no,1:no,,0.742
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment + huachansu ; ,None,None,5,2,3,no,1:no,1:no,,0.766
5225,3405220,Table 1,BaselineCharacteristic,True overall response rate,Operating characteristic ; ,True overall response rate,None,6,0,2,no,1:no,1:no,,0.873
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment alone ; ,True overall response rate,None,6,1,3,no,1:no,1:no,,0.745
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment + huachansu ; ,True overall response rate,None,6,2,3,no,1:no,1:no,,0.767
5225,3405220,Table 1,BaselineCharacteristic,Average number of patients,Operating characteristic ; ,Average number of patients,None,7,0,2,no,1:no,1:no,,0.841
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment alone ; ,Average number of patients,None,7,1,3,no,1:no,1:no,,0.628
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment + huachansu ; ,Average number of patients,None,7,2,3,no,1:no,1:no,,0.63
5225,3405220,Table 1,BaselineCharacteristic,Probability of selection as best,Operating characteristic ; ,Probability of selection as best,None,8,0,2,no,1:no,1:no,,0.894
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of selection as best,None,8,1,3,no,1:no,1:no,,0.764
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of selection as best,None,8,2,3,no,1:no,1:no,,0.769
5225,3405220,Table 1,BaselineCharacteristic,Probability of early selection,Operating characteristic ; ,Probability of early selection,None,9,0,2,no,1:no,1:no,,0.9
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of early selection,None,9,1,3,no,1:no,1:no,,0.776
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of early selection,None,9,2,3,no,1:no,1:no,,0.781
5225,3405220,Table 1,BaselineCharacteristic,,Operating characteristic ; ,None,None,10,0,2,no,1:no,1:no,,0.898
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment alone ; ,None,None,10,1,3,no,1:no,1:no,,0.793
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment + huachansu ; ,None,None,10,2,3,no,1:no,1:no,,0.802
5225,3405220,Table 1,BaselineCharacteristic,True overall response rate,Operating characteristic ; ,True overall response rate,None,11,0,2,no,1:no,1:no,,0.894
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment alone ; ,True overall response rate,None,11,1,3,no,1:no,1:no,,0.793
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment + huachansu ; ,True overall response rate,None,11,2,3,no,1:no,1:no,,0.799
5225,3405220,Table 1,BaselineCharacteristic,Average number of patients,Operating characteristic ; ,Average number of patients,None,12,0,2,no,1:no,1:no,,0.888
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment alone ; ,Average number of patients,None,12,1,3,no,1:no,1:no,,0.76
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment + huachansu ; ,Average number of patients,None,12,2,3,no,1:no,1:no,,0.762
5225,3405220,Table 1,BaselineCharacteristic,Probability of selection as best,Operating characteristic ; ,Probability of selection as best,None,13,0,2,no,1:no,1:no,,0.911
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of selection as best,None,13,1,3,no,1:no,1:no,,0.783
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of selection as best,None,13,2,3,no,1:no,1:no,,0.796
5225,3405220,Table 1,BaselineCharacteristic,Probability of early selection,Operating characteristic ; ,Probability of early selection,None,14,0,2,no,1:no,1:no,,0.911
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of early selection,None,14,1,3,no,1:no,1:no,,0.782
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of early selection,None,14,2,3,no,1:no,1:no,,0.795
5225,3405220,Table 1,BaselineCharacteristic,,Operating characteristic ; ,None,None,15,0,2,no,1:no,1:no,,0.902
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment alone ; ,None,None,15,1,3,no,1:no,1:no,,0.802
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment + huachansu ; ,None,None,15,2,3,no,1:no,1:no,,0.811
5225,3405220,Table 1,BaselineCharacteristic,True overall response rate,Operating characteristic ; ,True overall response rate,None,16,0,2,no,1:no,1:no,,0.893
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment alone ; ,True overall response rate,None,16,1,3,no,1:no,1:no,,0.786
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment + huachansu ; ,True overall response rate,None,16,2,3,no,1:no,1:no,,0.793
5225,3405220,Table 1,BaselineCharacteristic,Average number of patients,Operating characteristic ; ,Average number of patients,None,17,0,2,no,1:no,1:no,,0.9
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment alone ; ,Average number of patients,None,17,1,3,no,1:no,1:no,,0.798
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment + huachansu ; ,Average number of patients,None,17,2,3,no,1:no,1:no,,0.799
5225,3405220,Table 1,BaselineCharacteristic,Probability of selection as best,Operating characteristic ; ,Probability of selection as best,None,18,0,2,no,1:no,1:no,,0.917
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of selection as best,None,18,1,3,no,1:no,1:no,,0.811
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of selection as best,None,18,2,3,no,1:no,1:no,,0.816
5225,3405220,Table 1,BaselineCharacteristic,Probability of early selection,Operating characteristic ; ,Probability of early selection,None,19,0,2,no,1:no,1:no,,0.917
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of early selection,None,19,1,3,no,1:no,1:no,,0.823
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of early selection,None,19,2,3,no,1:no,1:no,,0.825
5225,3405220,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
5225,3405220,Table 2,BaselineCharacteristic,Treatment arm,,,None,0,1,1,no,1:no,1:no,,0.688
5225,3405220,Table 2,BaselineCharacteristic,Treatment arm,,,None,0,2,1,no,1:no,1:no,,0.726
5225,3405220,Table 2,BaselineCharacteristic,Treatment arm,,,None,0,3,1,no,1:no,1:no,,0.738
5225,3405220,Table 2,BaselineCharacteristic,Treatment arm,,,None,0,4,1,no,1:no,1:no,,0.75
5225,3405220,Table 2,BaselineCharacteristic,,,,None,0,5,1,no,1:no,1:no,,0.795
5225,3405220,Table 2,BaselineCharacteristic,,,,None,0,6,1,no,1:no,1:no,,0.796
5225,3405220,Table 2,BaselineCharacteristic,,,,None,0,7,1,no,1:no,1:no,,0.798
5225,3405220,Table 2,BaselineCharacteristic,, ; ,None,None,1,0,12,no,1:no,1:no,,0.792
5225,3405220,Table 2,BaselineCharacteristic,Gemcitabine + huachansu,Treatment arm ; ,,None,1,1,1,no,1:no,1:no,,0.669
5225,3405220,Table 2,BaselineCharacteristic,Gemcitabine + huachansu,Treatment arm ; ,,None,1,2,1,no,1:no,1:no,,0.708
5225,3405220,Table 2,BaselineCharacteristic,Gemcitabine + placebo,Treatment arm ; ,,None,1,3,1,no,1:no,1:no,,0.605
5225,3405220,Table 2,BaselineCharacteristic,Gemcitabine + placebo,Treatment arm ; ,,None,1,4,1,no,1:no,1:no,,0.61
5225,3405220,Table 2,BaselineCharacteristic,Total, ; ,,None,1,5,1,no,1:no,1:no,,0.68
5225,3405220,Table 2,BaselineCharacteristic,Total, ; ,,None,1,6,1,no,1:no,1:no,,0.681
5225,3405220,Table 2,BaselineCharacteristic,, ; ,,None,1,7,1,no,1:no,1:no,,0.779
5225,3405220,Table 2,BaselineCharacteristic,Characteristic, ;  ; ,None,None,2,0,12,no,1:no,1:no,,0.817
5225,3405220,Table 2,BaselineCharacteristic,No. of patients,Treatment arm ; Gemcitabine + huachansu ; ,Characteristic,None,2,1,1,no,1:no,1:no,,0.75
5225,3405220,Table 2,BaselineCharacteristic,%,Treatment arm ; Gemcitabine + huachansu ; ,Characteristic,None,2,2,1,no,1:no,1:no,,0.705
5225,3405220,Table 2,BaselineCharacteristic,No. of patients,Treatment arm ; Gemcitabine + placebo ; ,Characteristic,None,2,3,1,no,1:no,1:no,,0.686
5225,3405220,Table 2,BaselineCharacteristic,%,Treatment arm ; Gemcitabine + placebo ; ,Characteristic,None,2,4,1,no,1:no,1:no,,0.614
5225,3405220,Table 2,BaselineCharacteristic,No. of patients, ; Total ; ,Characteristic,None,2,5,1,no,1:no,1:no,,0.683
5225,3405220,Table 2,BaselineCharacteristic,%, ; Total ; ,Characteristic,None,2,6,1,no,1:no,1:no,,0.664
5225,3405220,Table 2,BaselineCharacteristic,Pa, ;  ; ,Characteristic,None,2,7,1,no,1:no,1:no,,0.791
5225,3405220,Table 2,BaselineCharacteristic,Gender, ;  ; Characteristic ; ,None,None,3,0,24,no,1:no,1:no,,0.732
5225,3405220,Table 2,BaselineCharacteristic,Gender,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Gender,None,3,1,43,no,1:no,1:no,,0.65
5225,3405220,Table 2,BaselineCharacteristic,Gender,Treatment arm ; Gemcitabine + huachansu ; % ; ,Gender,None,3,2,43,no,1:no,1:no,,0.597
5225,3405220,Table 2,BaselineCharacteristic,Gender,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Gender,None,3,3,43,no,1:no,1:no,,0.601
5225,3405220,Table 2,BaselineCharacteristic,Gender,Treatment arm ; Gemcitabine + placebo ; % ; ,Gender,None,3,4,43,no,1:no,1:no,,0.54
5225,3405220,Table 2,BaselineCharacteristic,Gender, ; Total ; No. of patients ; ,Gender,None,3,5,43,no,1:no,1:no,,0.584
5225,3405220,Table 2,BaselineCharacteristic,Gender, ; Total ; % ; ,Gender,None,3,6,43,no,1:no,1:no,,0.548
5225,3405220,Table 2,BaselineCharacteristic,Gender, ;  ; Pa ; ,Gender,None,3,7,43,no,1:no,1:no,,0.675
5225,3405220,Table 2,BaselineCharacteristic,?Male, ;  ; Characteristic ; ,?Male, Gender,4,0,2,no,1:no,1:no,,0.73
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Male, Gender,4,1,3,yes,2:yes,2:yes,,0.72
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Male, Gender,4,2,3,yes,2:yes,2:yes,,0.717
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Male, Gender,4,3,3,yes,2:yes,2:yes,,0.746
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Male, Gender,4,4,3,yes,2:yes,2:yes,,0.751
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Male, Gender,4,5,3,yes,2:yes,2:yes,,0.766
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Male, Gender,4,6,3,yes,2:yes,2:yes,,0.763
5225,3405220,Table 2,BaselineCharacteristic,x.xxx, ;  ; Pa ; ,?Male, Gender,4,7,3,yes,2:yes,2:yes,,0.562
5225,3405220,Table 2,BaselineCharacteristic,?Female, ;  ; Characteristic ; ,?Female, Gender,5,0,2,no,1:no,1:no,,0.729
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Female, Gender,5,1,3,yes,2:yes,2:yes,,0.649
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Female, Gender,5,2,3,yes,2:yes,2:yes,,0.726
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Female, Gender,5,3,3,yes,2:yes,2:yes,,0.665
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Female, Gender,5,4,3,yes,2:yes,2:yes,,0.743
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Female, Gender,5,5,3,yes,2:yes,2:yes,,0.696
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Female, Gender,5,6,3,yes,2:yes,2:yes,,0.752
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?Female, Gender,5,7,3,no,1:no,1:no,,0.535
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,6,0,2,no,1:no,1:no,,0.876
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,6,1,3,no,1:no,1:no,,0.747
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,6,2,3,no,1:no,1:no,,0.662
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,6,3,3,no,1:no,1:no,,0.688
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,6,4,3,no,1:no,1:no,,0.593
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,6,5,3,no,1:no,1:no,,0.652
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,6,6,3,no,1:no,1:no,,0.59
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,6,7,3,no,1:no,1:no,,0.799
5225,3405220,Table 2,BaselineCharacteristic,Stage, ;  ; Characteristic ; ,None,None,7,0,24,no,1:no,1:no,,0.873
5225,3405220,Table 2,BaselineCharacteristic,Stage,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Stage,None,7,1,43,no,1:no,1:no,,0.829
5225,3405220,Table 2,BaselineCharacteristic,Stage,Treatment arm ; Gemcitabine + huachansu ; % ; ,Stage,None,7,2,43,no,1:no,1:no,,0.747
5225,3405220,Table 2,BaselineCharacteristic,Stage,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Stage,None,7,3,43,no,1:no,1:no,,0.757
5225,3405220,Table 2,BaselineCharacteristic,Stage,Treatment arm ; Gemcitabine + placebo ; % ; ,Stage,None,7,4,43,no,1:no,1:no,,0.675
5225,3405220,Table 2,BaselineCharacteristic,Stage, ; Total ; No. of patients ; ,Stage,None,7,5,43,no,1:no,1:no,,0.73
5225,3405220,Table 2,BaselineCharacteristic,Stage, ; Total ; % ; ,Stage,None,7,6,43,no,1:no,1:no,,0.684
5225,3405220,Table 2,BaselineCharacteristic,Stage, ;  ; Pa ; ,Stage,None,7,7,43,no,1:no,1:no,,0.84
5225,3405220,Table 2,BaselineCharacteristic,?Metastatic, ;  ; Characteristic ; ,?Metastatic, Stage,8,0,2,no,1:no,1:no,,0.892
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Metastatic, Stage,8,1,3,no,1:no,1:no,,0.679
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Metastatic, Stage,8,2,3,no,1:no,1:no,,0.635
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Metastatic, Stage,8,3,3,no,1:no,1:no,,0.603
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Metastatic, Stage,8,4,3,no,1:no,1:no,,0.563
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Metastatic, Stage,8,5,3,no,1:no,1:no,,0.617
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Metastatic, Stage,8,6,3,no,1:no,1:no,,0.6
5225,3405220,Table 2,BaselineCharacteristic,x.xxx, ;  ; Pa ; ,?Metastatic, Stage,8,7,3,no,1:no,1:no,,0.778
5225,3405220,Table 2,BaselineCharacteristic,?Locally advanced, ;  ; Characteristic ; ,?Locally advanced, Stage,9,0,2,no,1:no,1:no,,0.892
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Locally advanced, Stage,9,1,3,no,1:no,1:no,,0.66
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Locally advanced, Stage,9,2,3,no,1:no,1:no,,0.629
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Locally advanced, Stage,9,3,3,no,1:no,1:no,,0.627
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Locally advanced, Stage,9,4,3,no,1:no,1:no,,0.551
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Locally advanced, Stage,9,5,3,no,1:no,1:no,,0.578
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Locally advanced, Stage,9,6,3,no,1:no,1:no,,0.58
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?Locally advanced, Stage,9,7,3,no,1:no,1:no,,0.829
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,10,0,2,no,1:no,1:no,,0.898
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,10,1,3,no,1:no,1:no,,0.809
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,10,2,3,no,1:no,1:no,,0.694
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,10,3,3,no,1:no,1:no,,0.725
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,10,4,3,no,1:no,1:no,,0.612
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,10,5,3,no,1:no,1:no,,0.718
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,10,6,3,no,1:no,1:no,,0.623
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,10,7,3,no,1:no,1:no,,0.835
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas, ;  ; Characteristic ; ,None,None,11,0,24,no,1:no,1:no,,0.921
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Location of the tumour in the pancreas,None,11,1,43,no,1:no,1:no,,0.862
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas,Treatment arm ; Gemcitabine + huachansu ; % ; ,Location of the tumour in the pancreas,None,11,2,43,no,1:no,1:no,,0.824
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Location of the tumour in the pancreas,None,11,3,43,no,1:no,1:no,,0.791
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas,Treatment arm ; Gemcitabine + placebo ; % ; ,Location of the tumour in the pancreas,None,11,4,43,no,1:no,1:no,,0.748
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas, ; Total ; No. of patients ; ,Location of the tumour in the pancreas,None,11,5,43,no,1:no,1:no,,0.775
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas, ; Total ; % ; ,Location of the tumour in the pancreas,None,11,6,43,no,1:no,1:no,,0.75
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas, ;  ; Pa ; ,Location of the tumour in the pancreas,None,11,7,43,no,1:no,1:no,,0.914
5225,3405220,Table 2,BaselineCharacteristic,?Head, ;  ; Characteristic ; ,?Head, Location of the tumour in the pancreas,12,0,2,no,1:no,1:no,,0.909
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Head, Location of the tumour in the pancreas,12,1,3,no,1:no,1:no,,0.748
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Head, Location of the tumour in the pancreas,12,2,3,no,1:no,1:no,,0.752
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Head, Location of the tumour in the pancreas,12,3,3,no,1:no,1:no,,0.673
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Head, Location of the tumour in the pancreas,12,4,3,no,1:no,1:no,,0.682
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Head, Location of the tumour in the pancreas,12,5,3,no,1:no,1:no,,0.687
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Head, Location of the tumour in the pancreas,12,6,3,no,1:no,1:no,,0.686
5225,3405220,Table 2,BaselineCharacteristic,x.xxx, ;  ; Pa ; ,?Head, Location of the tumour in the pancreas,12,7,3,no,1:no,1:no,,0.848
5225,3405220,Table 2,BaselineCharacteristic,?Body, ;  ; Characteristic ; ,?Body, Location of the tumour in the pancreas,13,0,2,no,1:no,1:no,,0.909
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Body, Location of the tumour in the pancreas,13,1,3,no,1:no,1:no,,0.794
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Body, Location of the tumour in the pancreas,13,2,3,no,1:no,1:no,,0.751
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Body, Location of the tumour in the pancreas,13,3,3,no,1:no,1:no,,0.72
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Body, Location of the tumour in the pancreas,13,4,3,no,1:no,1:no,,0.682
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Body, Location of the tumour in the pancreas,13,5,3,no,1:no,1:no,,0.686
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Body, Location of the tumour in the pancreas,13,6,3,no,1:no,1:no,,0.682
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?Body, Location of the tumour in the pancreas,13,7,3,no,1:no,1:no,,0.877
5225,3405220,Table 2,BaselineCharacteristic,?Tail, ;  ; Characteristic ; ,?Tail, Location of the tumour in the pancreas,14,0,2,no,1:no,1:no,,0.905
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Tail, Location of the tumour in the pancreas,14,1,3,no,1:no,1:no,,0.752
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Tail, Location of the tumour in the pancreas,14,2,3,no,1:no,1:no,,0.747
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Tail, Location of the tumour in the pancreas,14,3,3,no,1:no,1:no,,0.678
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Tail, Location of the tumour in the pancreas,14,4,3,no,1:no,1:no,,0.68
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Tail, Location of the tumour in the pancreas,14,5,3,no,1:no,1:no,,0.686
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Tail, Location of the tumour in the pancreas,14,6,3,no,1:no,1:no,,0.68
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?Tail, Location of the tumour in the pancreas,14,7,3,no,1:no,1:no,,0.874
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,15,0,2,no,1:no,1:no,,0.902
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,15,1,3,no,1:no,1:no,,0.828
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,15,2,3,no,1:no,1:no,,0.695
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,15,3,3,no,1:no,1:no,,0.74
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,15,4,3,no,1:no,1:no,,0.604
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,15,5,3,no,1:no,1:no,,0.732
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,15,6,3,no,1:no,1:no,,0.632
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,15,7,3,no,1:no,1:no,,0.837
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery, ;  ; Characteristic ; ,None,None,16,0,24,no,1:no,1:no,,0.898
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Prior surgery,None,16,1,43,no,1:no,1:no,,0.859
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery,Treatment arm ; Gemcitabine + huachansu ; % ; ,Prior surgery,None,16,2,43,no,1:no,1:no,,0.753
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Prior surgery,None,16,3,43,no,1:no,1:no,,0.775
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery,Treatment arm ; Gemcitabine + placebo ; % ; ,Prior surgery,None,16,4,43,no,1:no,1:no,,0.678
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery, ; Total ; No. of patients ; ,Prior surgery,None,16,5,43,no,1:no,1:no,,0.768
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery, ; Total ; % ; ,Prior surgery,None,16,6,43,no,1:no,1:no,,0.695
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery, ;  ; Pa ; ,Prior surgery,None,16,7,43,no,1:no,1:no,,0.872
5225,3405220,Table 2,BaselineCharacteristic,?Yes, ;  ; Characteristic ; ,?Yes, Prior surgery,17,0,2,no,1:no,1:no,,0.915
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Yes, Prior surgery,17,1,3,no,1:no,1:no,,0.784
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Yes, Prior surgery,17,2,3,no,1:no,1:no,,0.699
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Yes, Prior surgery,17,3,3,no,1:no,1:no,,0.694
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Yes, Prior surgery,17,4,3,no,1:no,1:no,,0.625
5225,3405220,Table 2,BaselineCharacteristic,x, ; Total ; No. of patients ; ,?Yes, Prior surgery,17,5,3,no,1:no,1:no,,0.73
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Yes, Prior surgery,17,6,3,no,1:no,1:no,,0.613
5225,3405220,Table 2,BaselineCharacteristic,x.xxxb, ;  ; Pa ; ,?Yes, Prior surgery,17,7,3,no,1:no,1:no,,0.864
5225,3405220,Table 2,BaselineCharacteristic,?No, ;  ; Characteristic ; ,?No, Prior surgery,18,0,2,no,1:no,1:no,,0.894
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?No, Prior surgery,18,1,3,no,1:no,1:no,,0.733
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?No, Prior surgery,18,2,3,no,1:no,1:no,,0.676
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?No, Prior surgery,18,3,3,no,1:no,1:no,,0.646
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?No, Prior surgery,18,4,3,no,1:no,1:no,,0.603
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?No, Prior surgery,18,5,3,no,1:no,1:no,,0.648
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?No, Prior surgery,18,6,3,no,1:no,1:no,,0.568
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?No, Prior surgery,18,7,3,no,1:no,1:no,,0.824
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,19,0,2,no,1:no,1:no,,0.911
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,19,1,3,no,1:no,1:no,,0.84
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,19,2,3,no,1:no,1:no,,0.723
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,19,3,3,no,1:no,1:no,,0.746
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,19,4,3,no,1:no,1:no,,0.63
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,19,5,3,no,1:no,1:no,,0.738
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,19,6,3,no,1:no,1:no,,0.663
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,19,7,3,no,1:no,1:no,,0.856
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy, ;  ; Characteristic ; ,None,None,20,0,24,no,1:no,1:no,,0.91
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Prior chemotherapy,None,20,1,43,no,1:no,1:no,,0.876
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy,Treatment arm ; Gemcitabine + huachansu ; % ; ,Prior chemotherapy,None,20,2,43,no,1:no,1:no,,0.781
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Prior chemotherapy,None,20,3,43,no,1:no,1:no,,0.788
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy,Treatment arm ; Gemcitabine + placebo ; % ; ,Prior chemotherapy,None,20,4,43,no,1:no,1:no,,0.703
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy, ; Total ; No. of patients ; ,Prior chemotherapy,None,20,5,43,no,1:no,1:no,,0.775
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy, ; Total ; % ; ,Prior chemotherapy,None,20,6,43,no,1:no,1:no,,0.716
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy, ;  ; Pa ; ,Prior chemotherapy,None,20,7,43,no,1:no,1:no,,0.886
5225,3405220,Table 2,BaselineCharacteristic,?Yes, ;  ; Characteristic ; ,?Yes, Prior chemotherapy,21,0,2,no,1:no,1:no,,0.916
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Yes, Prior chemotherapy,21,1,3,no,1:no,1:no,,0.769
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Yes, Prior chemotherapy,21,2,3,no,1:no,1:no,,0.73
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Yes, Prior chemotherapy,21,3,3,no,1:no,1:no,,0.675
5225,3405220,Table 2,BaselineCharacteristic,x.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Yes, Prior chemotherapy,21,4,3,no,1:no,1:no,,0.61
5225,3405220,Table 2,BaselineCharacteristic,x, ; Total ; No. of patients ; ,?Yes, Prior chemotherapy,21,5,3,no,1:no,1:no,,0.717
5225,3405220,Table 2,BaselineCharacteristic,x.xx, ; Total ; % ; ,?Yes, Prior chemotherapy,21,6,3,no,1:no,1:no,,0.646
5225,3405220,Table 2,BaselineCharacteristic,x.xxxb, ;  ; Pa ; ,?Yes, Prior chemotherapy,21,7,3,no,1:no,1:no,,0.865
5225,3405220,Table 2,BaselineCharacteristic,?No, ;  ; Characteristic ; ,?No, Prior chemotherapy,22,0,2,no,1:no,1:no,,0.889
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?No, Prior chemotherapy,22,1,3,no,1:no,1:no,,0.738
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?No, Prior chemotherapy,22,2,3,no,1:no,1:no,,0.696
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?No, Prior chemotherapy,22,3,3,no,1:no,1:no,,0.651
5225,3405220,Table 2,BaselineCharacteristic,xxx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?No, Prior chemotherapy,22,4,3,no,1:no,1:no,,0.577
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?No, Prior chemotherapy,22,5,3,no,1:no,1:no,,0.647
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?No, Prior chemotherapy,22,6,3,no,1:no,1:no,,0.582
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?No, Prior chemotherapy,22,7,3,no,1:no,1:no,,0.825
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,23,0,2,no,1:no,1:no,,0.913
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,23,1,3,no,1:no,1:no,,0.844
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,23,2,3,no,1:no,1:no,,0.733
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,23,3,3,no,1:no,1:no,,0.749
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,23,4,3,no,1:no,1:no,,0.634
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,23,5,3,no,1:no,1:no,,0.741
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,23,6,3,no,1:no,1:no,,0.667
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,23,7,3,no,1:no,1:no,,0.863
5225,3405220,Table 2,BaselineCharacteristic,Age (years), ;  ; Characteristic ; ,Age (years),,24,0,2,no,1:no,1:no,,0.889
5225,3405220,Table 2,BaselineCharacteristic,x.xxxc, ;  ; Pa ; ,Age (years),,24,7,3,no,1:no,1:no,,0.836
5225,3405220,Table 2,BaselineCharacteristic,Karnofsky performance status, ;  ; Characteristic ; ,Karnofsky performance status,,25,0,2,no,1:no,1:no,,0.924
5225,3405220,Table 2,BaselineCharacteristic,x.xxxd, ;  ; Pa ; ,Karnofsky performance status,,25,7,3,no,1:no,1:no,,0.881
5228,3405224,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
5228,3405224,Table 1,BaselineCharacteristic,n,,,None,0,1,1,no,1:no,1:no,,0.703
5228,3405224,Table 1,BaselineCharacteristic,%,,,None,0,2,1,no,1:no,1:no,,0.757
5228,3405224,Table 1,BaselineCharacteristic,Gender: male/female, ; ,Gender: male/female,,1,0,2,no,1:no,1:no,,0.759
5228,3405224,Table 1,BaselineCharacteristic,xx/xx,n ; ,Gender: male/female,,1,1,3,yes,2:yes,1:no,+,0.515
5228,3405224,Table 1,BaselineCharacteristic,xx/xx,% ; ,Gender: male/female,,1,2,3,yes,2:yes,1:no,+,0.552
5228,3405224,Table 1,BaselineCharacteristic,"Median age (range, in years)", ; ,"Median age (range, in years)",,2,0,2,no,1:no,1:no,,0.857
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,"Median age (range, in years)",,2,2,3,no,1:no,1:no,,0.764
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,3,0,2,no,1:no,1:no,,0.84
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,3,1,3,no,1:no,1:no,,0.645
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,3,2,3,no,1:no,1:no,,0.682
5228,3405224,Table 1,BaselineCharacteristic,Primary melanoma, ; ,None,None,4,0,24,no,1:no,1:no,,0.833
5228,3405224,Table 1,BaselineCharacteristic,Primary melanoma,n ; ,Primary melanoma,None,4,1,43,no,1:no,1:no,,0.698
5228,3405224,Table 1,BaselineCharacteristic,Primary melanoma,% ; ,Primary melanoma,None,4,2,43,no,1:no,1:no,,0.739
5228,3405224,Table 1,BaselineCharacteristic,?SSM, ; ,?SSM, Primary melanoma,5,0,2,no,1:no,1:no,,0.838
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?SSM, Primary melanoma,5,1,3,no,1:no,1:no,,0.545
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?SSM, Primary melanoma,5,2,3,no,1:no,2:yes,+,0.541
5228,3405224,Table 1,BaselineCharacteristic,?Nodular, ; ,?Nodular, Primary melanoma,6,0,2,no,1:no,1:no,,0.836
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Nodular, Primary melanoma,6,1,3,no,1:no,1:no,,0.61
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Nodular, Primary melanoma,6,2,3,no,1:no,2:yes,+,0.538
5228,3405224,Table 1,BaselineCharacteristic,?Uveal, ; ,?Uveal, Primary melanoma,7,0,2,no,1:no,1:no,,0.846
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Uveal, Primary melanoma,7,1,3,no,1:no,1:no,,0.612
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Uveal, Primary melanoma,7,2,3,no,1:no,2:yes,+,0.538
5228,3405224,Table 1,BaselineCharacteristic,?Unknown primary, ; ,?Unknown primary, Primary melanoma,8,0,2,no,1:no,1:no,,0.848
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Unknown primary, Primary melanoma,8,1,3,no,1:no,1:no,,0.627
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Unknown primary, Primary melanoma,8,2,3,no,1:no,1:no,,0.502
5228,3405224,Table 1,BaselineCharacteristic,?Others, ; ,?Others, Primary melanoma,9,0,2,no,1:no,1:no,,0.866
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Others, Primary melanoma,9,1,3,no,1:no,1:no,,0.645
5228,3405224,Table 1,BaselineCharacteristic,x,% ; ,?Others, Primary melanoma,9,2,3,no,1:no,1:no,,0.685
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,2,no,1:no,1:no,,0.888
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,10,1,3,no,1:no,1:no,,0.738
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,10,2,3,no,1:no,1:no,,0.749
5228,3405224,Table 1,BaselineCharacteristic,AJCC stage IV, ; ,None,None,11,0,24,no,1:no,1:no,,0.893
5228,3405224,Table 1,BaselineCharacteristic,AJCC stage IV,n ; ,AJCC stage IV,None,11,1,43,no,1:no,1:no,,0.809
5228,3405224,Table 1,BaselineCharacteristic,AJCC stage IV,% ; ,AJCC stage IV,None,11,2,43,no,1:no,1:no,,0.83
5228,3405224,Table 1,BaselineCharacteristic,?Mxa, ; ,?Mxa, AJCC stage IV,12,0,2,no,1:no,1:no,,0.896
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Mxa, AJCC stage IV,12,1,3,no,1:no,1:no,,0.718
5228,3405224,Table 1,BaselineCharacteristic,x,% ; ,?Mxa, AJCC stage IV,12,2,3,no,1:no,1:no,,0.763
5228,3405224,Table 1,BaselineCharacteristic,?Mxb, ; ,?Mxb, AJCC stage IV,13,0,2,no,1:no,1:no,,0.896
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Mxb, AJCC stage IV,13,1,3,no,1:no,1:no,,0.718
5228,3405224,Table 1,BaselineCharacteristic,x,% ; ,?Mxb, AJCC stage IV,13,2,3,no,1:no,1:no,,0.759
5228,3405224,Table 1,BaselineCharacteristic,?Mxc, ; ,?Mxc, AJCC stage IV,14,0,2,no,1:no,1:no,,0.892
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?Mxc, AJCC stage IV,14,1,3,no,1:no,1:no,,0.696
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Mxc, AJCC stage IV,14,2,3,no,1:no,1:no,,0.674
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,15,0,2,no,1:no,1:no,,0.892
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,15,1,3,no,1:no,1:no,,0.739
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,15,2,3,no,1:no,1:no,,0.749
5228,3405224,Table 1,BaselineCharacteristic,>x Metastatic sites, ; ,>x Metastatic sites,,16,0,24,no,1:no,1:no,,0.864
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,>x Metastatic sites,,16,1,43,no,1:no,1:no,,0.712
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,>x Metastatic sites,,16,2,43,no,1:no,1:no,,0.685
5228,3405224,Table 1,BaselineCharacteristic,?Lung metastases, ; ,?Lung metastases, >x Metastatic sites,17,0,2,no,1:no,1:no,,0.905
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?Lung metastases, >x Metastatic sites,17,1,3,no,1:no,1:no,,0.741
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Lung metastases, >x Metastatic sites,17,2,3,no,1:no,1:no,,0.724
5228,3405224,Table 1,BaselineCharacteristic,?Liver metastases, ; ,?Liver metastases, >x Metastatic sites,18,0,2,no,1:no,1:no,,0.921
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?Liver metastases, >x Metastatic sites,18,1,3,no,1:no,1:no,,0.766
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Liver metastases, >x Metastatic sites,18,2,3,no,1:no,1:no,,0.754
5228,3405224,Table 1,BaselineCharacteristic,?Brain metastases, ; ,?Brain metastases, >x Metastatic sites,19,0,2,no,1:no,1:no,,0.909
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?Brain metastases, >x Metastatic sites,19,1,3,no,1:no,1:no,,0.755
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Brain metastases, >x Metastatic sites,19,2,3,no,1:no,1:no,,0.736
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,20,0,2,no,1:no,1:no,,0.902
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,20,1,3,no,1:no,1:no,,0.774
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,20,2,3,no,1:no,1:no,,0.777
5228,3405224,Table 1,BaselineCharacteristic,LDH>N, ; ,LDH>N,,21,0,2,no,1:no,1:no,,0.891
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,LDH>N,,21,1,3,no,1:no,1:no,,0.689
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,LDH>N,,21,2,3,no,1:no,1:no,,0.651
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,22,0,2,no,1:no,1:no,,0.904
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,22,1,3,no,1:no,1:no,,0.776
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,22,2,3,no,1:no,1:no,,0.787
5228,3405224,Table 1,BaselineCharacteristic,Previous chemotherapy, ; ,Previous chemotherapy,,23,0,24,no,1:no,1:no,,0.877
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,Previous chemotherapy,,23,1,43,no,1:no,1:no,,0.733
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,Previous chemotherapy,,23,2,43,no,1:no,1:no,,0.719
5228,3405224,Table 1,BaselineCharacteristic,??x Lines of chemotherapy, ; ,??x Lines of chemotherapy, Previous chemotherapy,24,0,2,no,1:no,1:no,,0.888
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,??x Lines of chemotherapy, Previous chemotherapy,24,1,3,no,1:no,1:no,,0.752
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,??x Lines of chemotherapy, Previous chemotherapy,24,2,3,no,1:no,1:no,,0.748
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,25,0,2,no,1:no,1:no,,0.905
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,25,1,3,no,1:no,1:no,,0.778
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,25,2,3,no,1:no,1:no,,0.792
5228,3405224,Table 1,BaselineCharacteristic,Performance Status (WHO), ; ,None,None,26,0,24,no,1:no,1:no,,0.91
5228,3405224,Table 1,BaselineCharacteristic,Performance Status (WHO),n ; ,Performance Status (WHO),None,26,1,43,no,1:no,1:no,,0.801
5228,3405224,Table 1,BaselineCharacteristic,Performance Status (WHO),% ; ,Performance Status (WHO),None,26,2,43,no,1:no,1:no,,0.834
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,29,0,2,no,1:no,1:no,,0.905
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,29,1,3,no,1:no,1:no,,0.778
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,29,2,3,no,1:no,1:no,,0.792
5228,3405224,Table 1,BaselineCharacteristic,"Median time from first metastasis (range, in months)", ; ,"Median time from first metastasis (range, in months)",,30,0,2,no,1:no,1:no,,0.924
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,"Median time from first metastasis (range, in months)",,30,2,3,no,1:no,1:no,,0.841
5354,3419963,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no,1:no,1:no,,0.793
5354,3419963,Table 1,BaselineCharacteristic,"Patients (n=xx), n (%)",,,None,0,1,1,no,1:no,1:no,,0.658
5354,3419963,Table 1,BaselineCharacteristic,"Age, years", ; ,None,None,1,0,24,no,1:no,1:no,,0.836
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ","Age, years",None,1,1,43,no,1:no,1:no,,0.685
5354,3419963,Table 1,BaselineCharacteristic,?Median, ; ,?Median," Age, years",2,0,2,no,1:no,1:no,,0.851
5354,3419963,Table 1,BaselineCharacteristic,xx,"Patients (n=xx), n (%) ; ",?Median," Age, years",2,1,3,no,1:no,1:no,,0.547
5354,3419963,Table 1,BaselineCharacteristic,?Range, ; ,?Range," Age, years",3,0,2,no,1:no,1:no,,0.824
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no,1:no,1:no,,0.858
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,4,1,3,no,1:no,1:no,,0.594
5354,3419963,Table 1,BaselineCharacteristic,Gender, ; ,None,None,5,0,24,no,1:no,1:no,,0.729
5354,3419963,Table 1,BaselineCharacteristic,Gender,"Patients (n=xx), n (%) ; ",Gender,None,5,1,43,no,1:no,1:no,,0.501
5354,3419963,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Gender,6,0,2,no,1:no,1:no,,0.701
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Male, Gender,6,1,3,yes,2:yes,2:yes,,0.811
5354,3419963,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Gender,7,0,2,no,1:no,1:no,,0.71
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Female, Gender,7,1,3,yes,2:yes,2:yes,,0.777
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,8,0,2,no,1:no,1:no,,0.873
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,8,1,3,no,1:no,1:no,,0.621
5354,3419963,Table 1,BaselineCharacteristic,ECOG PS, ; ,None,None,9,0,24,no,1:no,1:no,,0.88
5354,3419963,Table 1,BaselineCharacteristic,ECOG PS,"Patients (n=xx), n (%) ; ",ECOG PS,None,9,1,43,no,1:no,1:no,,0.675
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, ECOG PS,10,0,2,no,1:no,1:no,,0.868
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?x, ECOG PS,10,1,3,no,1:no,1:no,,0.527
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, ECOG PS,11,0,2,no,1:no,1:no,,0.869
5354,3419963,Table 1,BaselineCharacteristic,xx (xx),"Patients (n=xx), n (%) ; ",?x, ECOG PS,11,1,3,no,1:no,1:no,,0.536
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,12,0,2,no,1:no,1:no,,0.892
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,12,1,3,no,1:no,1:no,,0.665
5354,3419963,Table 1,BaselineCharacteristic,Type of tumour, ; ,None,None,13,0,24,no,1:no,1:no,,0.781
5354,3419963,Table 1,BaselineCharacteristic,Type of tumour,"Patients (n=xx), n (%) ; ",Type of tumour,None,13,1,43,no,1:no,1:no,,0.617
5354,3419963,Table 1,BaselineCharacteristic,?Mesothelioma, ; ,?Mesothelioma, Type of tumour,14,0,2,no,1:no,1:no,,0.772
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Mesothelioma, Type of tumour,14,1,3,no,1:no,2:yes,+,0.526
5354,3419963,Table 1,BaselineCharacteristic,?Non-small-cell lung cancer, ; ,?Non-small-cell lung cancer, Type of tumour,15,0,2,no,1:no,1:no,,0.784
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Non-small-cell lung cancer, Type of tumour,15,1,3,no,1:no,2:yes,+,0.512
5354,3419963,Table 1,BaselineCharacteristic,?Angiosarcoma, ; ,?Angiosarcoma, Type of tumour,16,0,2,no,1:no,1:no,,0.777
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Angiosarcoma, Type of tumour,16,1,3,no,1:no,1:no,,0.533
5354,3419963,Table 1,BaselineCharacteristic,?Breast cancer, ; ,?Breast cancer, Type of tumour,17,0,2,no,1:no,1:no,,0.787
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Breast cancer, Type of tumour,17,1,3,no,1:no,1:no,,0.564
5354,3419963,Table 1,BaselineCharacteristic,?Cholangiocarcinoma, ; ,?Cholangiocarcinoma, Type of tumour,18,0,2,no,1:no,1:no,,0.783
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Cholangiocarcinoma, Type of tumour,18,1,3,no,1:no,1:no,,0.566
5354,3419963,Table 1,BaselineCharacteristic,?Endometrial stromal sarcoma, ; ,?Endometrial stromal sarcoma, Type of tumour,19,0,2,no,1:no,1:no,,0.784
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Endometrial stromal sarcoma, Type of tumour,19,1,3,no,1:no,1:no,,0.572
5354,3419963,Table 1,BaselineCharacteristic,?Appendiceal adenocarcinoma, ; ,?Appendiceal adenocarcinoma, Type of tumour,20,0,2,no,1:no,1:no,,0.784
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Appendiceal adenocarcinoma, Type of tumour,20,1,3,no,1:no,1:no,,0.572
5354,3419963,Table 1,BaselineCharacteristic,?Carcinoma of unknown origin, ; ,?Carcinoma of unknown origin, Type of tumour,21,0,2,no,1:no,1:no,,0.794
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Carcinoma of unknown origin, Type of tumour,21,1,3,no,1:no,1:no,,0.593
5354,3419963,Table 1,BaselineCharacteristic,?Rectal cancer, ; ,?Rectal cancer, Type of tumour,22,0,2,no,1:no,1:no,,0.791
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Rectal cancer, Type of tumour,22,1,3,no,1:no,1:no,,0.579
5354,3419963,Table 1,BaselineCharacteristic,?Thyroid poorly differentiated carcinoma, ; ,?Thyroid poorly differentiated carcinoma, Type of tumour,23,0,2,no,1:no,1:no,,0.796
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Thyroid poorly differentiated carcinoma, Type of tumour,23,1,3,no,1:no,1:no,,0.599
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,24,0,2,no,1:no,1:no,,0.905
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,24,1,3,no,1:no,1:no,,0.692
5354,3419963,Table 1,BaselineCharacteristic,Prior treatment, ; ,None,None,25,0,24,no,1:no,1:no,,0.89
5354,3419963,Table 1,BaselineCharacteristic,Prior treatment,"Patients (n=xx), n (%) ; ",Prior treatment,None,25,1,43,no,1:no,1:no,,0.756
5354,3419963,Table 1,BaselineCharacteristic,?Surgery, ; ,?Surgery, Prior treatment,26,0,2,no,1:no,1:no,,0.905
5354,3419963,Table 1,BaselineCharacteristic,xx (xx),"Patients (n=xx), n (%) ; ",?Surgery, Prior treatment,26,1,3,no,1:no,1:no,,0.674
5354,3419963,Table 1,BaselineCharacteristic,?Chemotherapy, ; ,?Chemotherapy, Prior treatment,27,0,2,no,1:no,1:no,,0.905
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Chemotherapy, Prior treatment,27,1,3,no,1:no,1:no,,0.65
5354,3419963,Table 1,BaselineCharacteristic,?Radiotherapy, ; ,?Radiotherapy, Prior treatment,28,0,2,no,1:no,1:no,,0.901
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Radiotherapy, Prior treatment,28,1,3,no,1:no,1:no,,0.62
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,29,0,2,no,1:no,1:no,,0.905
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,29,1,3,no,1:no,1:no,,0.692
5354,3419963,Table 1,BaselineCharacteristic,No. of prior chemotherapy regimens, ; ,None,None,30,0,24,no,1:no,1:no,,0.902
5354,3419963,Table 1,BaselineCharacteristic,No. of prior chemotherapy regimens,"Patients (n=xx), n (%) ; ",No. of prior chemotherapy regimens,None,30,1,43,no,1:no,1:no,,0.789
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,31,0,2,no,1:no,1:no,,0.843
5354,3419963,Table 1,BaselineCharacteristic,xx,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,31,1,3,no,1:no,1:no,,0.633
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,32,0,2,no,1:no,1:no,,0.843
5354,3419963,Table 1,BaselineCharacteristic,x,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,32,1,3,no,1:no,1:no,,0.662
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,33,0,2,no,1:no,1:no,,0.843
5354,3419963,Table 1,BaselineCharacteristic,x,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,33,1,3,no,1:no,1:no,,0.662
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,34,0,2,no,1:no,1:no,,0.843
5354,3419963,Table 1,BaselineCharacteristic,x,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,34,1,3,no,1:no,1:no,,0.662
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,35,0,2,no,1:no,1:no,,0.843
5354,3419963,Table 1,BaselineCharacteristic,x,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,35,1,3,no,1:no,1:no,,0.662
5767,3504074,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no,1:no,1:no,,0.806
5767,3504074,Table 1,BaselineCharacteristic,Etanercept + placebo (n = xxx),,Characteristic,None,0,1,1,no,1:no,1:no,,0.582
5767,3504074,Table 1,BaselineCharacteristic,Etanercept + methotrexate (n = xxx),,Characteristic,None,0,2,1,no,1:no,1:no,,0.71
5767,3504074,Table 1,BaselineCharacteristic,"Male sex, n (%)",Characteristic ; ,"Male sex, n (%)",,1,0,2,no,1:no,2:yes,+,0.519
5767,3504074,Table 1,BaselineCharacteristic,"Race, n (%)",Characteristic ; ,None,None,2,0,24,no,1:no,1:no,,0.74
5767,3504074,Table 1,BaselineCharacteristic,"Race, n (%)",Etanercept + placebo (n = xxx) ; ,"Race, n (%)",None,2,1,43,no,1:no,2:yes,+,0.539
5767,3504074,Table 1,BaselineCharacteristic,"Race, n (%)",Etanercept + methotrexate (n = xxx) ; ,"Race, n (%)",None,2,2,43,no,1:no,1:no,,0.562
5767,3504074,Table 1,BaselineCharacteristic,?White,Characteristic ; ,?White," Race, n (%)",3,0,2,no,1:no,1:no,,0.738
5767,3504074,Table 1,BaselineCharacteristic,?Black,Characteristic ; ,?Black," Race, n (%)",4,0,2,no,1:no,1:no,,0.735
5767,3504074,Table 1,BaselineCharacteristic,?Hispanic,Characteristic ; ,?Hispanic," Race, n (%)",5,0,2,no,1:no,1:no,,0.732
5767,3504074,Table 1,BaselineCharacteristic,?Asian,Characteristic ; ,?Asian," Race, n (%)",6,0,2,no,1:no,1:no,,0.732
5767,3504074,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other," Race, n (%)",7,0,2,no,1:no,1:no,,0.736
5767,3504074,Table 1,BaselineCharacteristic,"Age (years), mean (SD)",Characteristic ; ,"Age (years), mean (SD)",,8,0,24,no,1:no,1:no,,0.796
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Age (years), mean (SD)",9,0,2,no,1:no,1:no,,0.83
5767,3504074,Table 1,BaselineCharacteristic,"Weight (kg), mean (SD)",Characteristic ; ,"Weight (kg), mean (SD)",,10,0,24,no,1:no,1:no,,0.867
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Weight (kg), mean (SD)",11,0,2,no,1:no,1:no,,0.885
5767,3504074,Table 1,BaselineCharacteristic,"Height (cm), mean (SD)",Characteristic ; ,"Height (cm), mean (SD)",,12,0,24,no,1:no,1:no,,0.857
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Height (cm), mean (SD)",13,0,2,no,1:no,1:no,,0.886
5767,3504074,Table 1,BaselineCharacteristic,"BMI (kg m?x), mean (SD)",Characteristic ; ,"BMI (kg m?x), mean (SD)",,14,0,24,no,1:no,1:no,,0.853
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," BMI (kg m?x), mean (SD)",15,0,2,no,1:no,1:no,,0.894
5767,3504074,Table 1,BaselineCharacteristic,"?? xx kg m?x, n (%)",Characteristic ; ,"?? xx kg m?x, n (%)"," BMI (kg m?x), mean (SD)",16,0,2,no,1:no,1:no,,0.757
5767,3504074,Table 1,BaselineCharacteristic,"?> xx kg m?x, n (%)",Characteristic ; ,"?> xx kg m?x, n (%)"," BMI (kg m?x), mean (SD)",17,0,2,no,1:no,1:no,,0.769
5767,3504074,Table 1,BaselineCharacteristic,"Psoriasis BSA affected, %, mean (SD)",Characteristic ; ,"Psoriasis BSA affected, %, mean (SD)",,18,0,24,no,1:no,1:no,,0.853
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Psoriasis BSA affected, %, mean (SD)",19,0,2,no,1:no,1:no,,0.88
5767,3504074,Table 1,BaselineCharacteristic,"PASI, mean (SD)",Characteristic ; ,"PASI, mean (SD)",,20,0,24,no,1:no,1:no,,0.88
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," PASI, mean (SD)",21,0,2,no,1:no,1:no,,0.896
5767,3504074,Table 1,BaselineCharacteristic,"sPGA, n (%)",Characteristic ; ,None,None,22,0,24,no,1:no,1:no,,0.834
5767,3504074,Table 1,BaselineCharacteristic,"sPGA, n (%)",Etanercept + placebo (n = xxx) ; ,"sPGA, n (%)",None,22,1,43,no,1:no,1:no,,0.565
5767,3504074,Table 1,BaselineCharacteristic,"sPGA, n (%)",Etanercept + methotrexate (n = xxx) ; ,"sPGA, n (%)",None,22,2,43,no,1:no,1:no,,0.687
5767,3504074,Table 1,BaselineCharacteristic,?Unknown,Characteristic ; ,?Unknown," sPGA, n (%)",23,0,2,no,1:no,1:no,,0.825
5767,3504074,Table 1,BaselineCharacteristic,x (x),Etanercept + methotrexate (n = xxx) ; ,?Unknown," sPGA, n (%)",23,2,3,no,1:no,1:no,,0.62
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",24,0,2,no,1:no,1:no,,0.77
5767,3504074,Table 1,BaselineCharacteristic,x (x),Etanercept + placebo (n = xxx) ; ,?x," sPGA, n (%)",24,1,3,no,1:no,1:no,,0.522
5767,3504074,Table 1,BaselineCharacteristic,x (x),Etanercept + methotrexate (n = xxx) ; ,?x," sPGA, n (%)",24,2,3,no,1:no,1:no,,0.628
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",25,0,2,no,1:no,1:no,,0.771
5767,3504074,Table 1,BaselineCharacteristic,x (x),Etanercept + methotrexate (n = xxx) ; ,?x," sPGA, n (%)",25,2,3,no,1:no,1:no,,0.629
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",26,0,2,no,1:no,1:no,,0.771
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",27,0,2,no,1:no,1:no,,0.771
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",28,0,2,no,1:no,1:no,,0.771
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",29,0,2,no,1:no,1:no,,0.771
5767,3504074,Table 1,BaselineCharacteristic,"Duration of psoriasis, years, mean (SD)",Characteristic ; ,"Duration of psoriasis, years, mean (SD)",,30,0,24,no,1:no,1:no,,0.875
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Duration of psoriasis, years, mean (SD)",31,0,2,no,1:no,1:no,,0.885
5767,3504074,Table 1,BaselineCharacteristic,"History of psoriatic arthritis, n (%)",Characteristic ; ,"History of psoriatic arthritis, n (%)",,32,0,2,no,1:no,1:no,,0.833
5767,3504074,Table 1,BaselineCharacteristic,"Prior psoriasis therapy, n (%)",Characteristic ; ,"Prior psoriasis therapy, n (%)",,33,0,2,no,1:no,1:no,,0.869
5767,3504074,Table 1,BaselineCharacteristic,"Prior systemic therapy, n (%)",Characteristic ; ,"Prior systemic therapy, n (%)",,34,0,24,no,1:no,1:no,,0.844
5767,3504074,Table 1,BaselineCharacteristic,?Methotrexate,Characteristic ; ,?Methotrexate," Prior systemic therapy, n (%)",35,0,2,no,1:no,1:no,,0.869
5767,3504074,Table 1,BaselineCharacteristic,?Oral retinoids,Characteristic ; ,?Oral retinoids," Prior systemic therapy, n (%)",36,0,2,no,1:no,1:no,,0.869
5767,3504074,Table 1,BaselineCharacteristic,?Steroids,Characteristic ; ,?Steroids," Prior systemic therapy, n (%)",37,0,2,no,1:no,1:no,,0.869
5767,3504074,Table 1,BaselineCharacteristic,"Prior TNF-blocker therapy, n (%)",Characteristic ; ,"Prior TNF-blocker therapy, n (%)",,38,0,24,no,1:no,1:no,,0.844
5767,3504074,Table 1,BaselineCharacteristic,?Etanercept,Characteristic ; ,?Etanercept," Prior TNF-blocker therapy, n (%)",39,0,2,no,1:no,1:no,,0.869
5767,3504074,Table 1,BaselineCharacteristic,?Adalimumab,Characteristic ; ,?Adalimumab," Prior TNF-blocker therapy, n (%)",40,0,2,no,1:no,1:no,,0.869
5767,3504074,Table 1,BaselineCharacteristic,"Prior phototherapy, n (%)",Characteristic ; ,"Prior phototherapy, n (%)",,41,0,24,no,1:no,1:no,,0.827
5767,3504074,Table 1,BaselineCharacteristic,?UVB,Characteristic ; ,?UVB," Prior phototherapy, n (%)",42,0,2,no,1:no,1:no,,0.851
5767,3504074,Table 1,BaselineCharacteristic,?PUVA,Characteristic ; ,?PUVA," Prior phototherapy, n (%)",43,0,2,no,1:no,1:no,,0.851
5767,3504074,Table 1,BaselineCharacteristic,"Prior topical nonsteroid use, n (%)",Characteristic ; ,"Prior topical nonsteroid use, n (%)",,44,0,24,no,1:no,1:no,,0.827
5767,3504074,Table 1,BaselineCharacteristic,?Vitamin D analogues,Characteristic ; ,?Vitamin D analogues," Prior topical nonsteroid use, n (%)",45,0,2,no,1:no,1:no,,0.851
5767,3504074,Table 1,BaselineCharacteristic,?Tar compounds,Characteristic ; ,?Tar compounds," Prior topical nonsteroid use, n (%)",46,0,2,no,1:no,1:no,,0.851
5767,3504074,Table 1,BaselineCharacteristic,"Prior topical steroid use, n (%)",Characteristic ; ,"Prior topical steroid use, n (%)",,47,0,24,no,1:no,1:no,,0.827
5767,3504074,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other," Prior topical steroid use, n (%)",48,0,2,no,1:no,1:no,,0.852
6312,3600662,Table 1,BaselineCharacteristic,Patient characteristic,,None,None,0,0,12,no,1:no,1:no,,0.812
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,1,1,no,1:no,1:no,,0.769
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,2,1,no,1:no,1:no,,0.785
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,3,1,no,1:no,1:no,,0.791
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,4,1,no,1:no,1:no,,0.798
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,5,1,no,1:no,1:no,,0.793
6312,3600662,Table 1,BaselineCharacteristic,Total (N = xx),,Patient characteristic,None,0,6,1,no,1:no,1:no,,0.648
6312,3600662,Table 1,BaselineCharacteristic,Patient characteristic,Patient characteristic ; ,None,None,1,0,12,no,1:no,1:no,,0.812
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,1,1,no,1:no,1:no,,0.736
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,2,1,no,1:no,1:no,,0.741
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,3,1,no,1:no,1:no,,0.746
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,4,1,no,1:no,1:no,,0.749
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,5,1,no,1:no,1:no,,0.75
6312,3600662,Table 1,BaselineCharacteristic,Total (N = xx),Total (N = xx) ; ,Patient characteristic,None,1,6,1,no,1:no,1:no,,0.631
6312,3600662,Table 1,BaselineCharacteristic,Patient characteristic,Patient characteristic ; Patient characteristic ; ,None,None,2,0,12,no,1:no,1:no,,0.82
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,1,1,no,1:no,1:no,,0.607
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,2,1,no,1:no,1:no,,0.624
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,3,1,no,1:no,1:no,,0.609
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,4,1,no,1:no,1:no,,0.614
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,5,1,no,1:no,1:no,,0.614
6312,3600662,Table 1,BaselineCharacteristic,Total (N = xx),Total (N = xx) ; Total (N = xx) ; ,Patient characteristic,None,2,6,1,no,1:no,1:no,,0.634
6312,3600662,Table 1,BaselineCharacteristic,"Age, years",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,None,None,3,0,24,no,1:no,1:no,,0.846
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,1,43,no,1:no,1:no,,0.586
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,2,43,no,1:no,1:no,,0.593
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,3,43,no,1:no,1:no,,0.595
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,4,43,no,1:no,1:no,,0.601
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,5,43,no,1:no,1:no,,0.604
6312,3600662,Table 1,BaselineCharacteristic,,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Age, years",None,3,6,43,no,1:no,1:no,,0.588
6312,3600662,Table 1,BaselineCharacteristic,?Median,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?Median," Age, years",4,0,2,no,1:no,1:no,,0.855
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,1,3,no,1:no,1:no,,0.514
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,2,3,no,1:no,1:no,,0.524
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,3,3,no,1:no,1:no,,0.537
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,4,3,no,1:no,1:no,,0.553
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,5,3,no,1:no,1:no,,0.558
6312,3600662,Table 1,BaselineCharacteristic,xx,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?Median," Age, years",4,6,3,no,1:no,1:no,,0.585
6312,3600662,Table 1,BaselineCharacteristic,?Range,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?Range," Age, years",5,0,2,no,1:no,1:no,,0.845
6312,3600662,Table 1,BaselineCharacteristic,"Sex, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,None,None,6,0,24,no,1:no,1:no,,0.632
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,1,43,no,1:no,2:yes,+,0.605
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,2,43,no,1:no,2:yes,+,0.597
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,3,43,no,1:no,2:yes,+,0.61
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,4,43,no,1:no,2:yes,+,0.611
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,5,43,no,1:no,2:yes,+,0.601
6312,3600662,Table 1,BaselineCharacteristic,,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Sex, n (%)",None,6,6,43,no,1:no,2:yes,+,0.67
6312,3600662,Table 1,BaselineCharacteristic,?Men,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?Men," Sex, n (%)",7,0,2,no,1:no,1:no,,0.603
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,1,3,yes,2:yes,2:yes,,0.692
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,2,3,yes,2:yes,2:yes,,0.73
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,3,3,yes,2:yes,2:yes,,0.743
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,4,3,yes,2:yes,2:yes,,0.741
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,5,3,yes,2:yes,2:yes,,0.725
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?Men," Sex, n (%)",7,6,3,yes,2:yes,2:yes,,0.711
6312,3600662,Table 1,BaselineCharacteristic,?Women,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?Women," Sex, n (%)",8,0,24,no,1:no,1:no,,0.51
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,1,43,yes,2:yes,2:yes,,0.662
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,2,43,yes,2:yes,2:yes,,0.675
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,3,43,yes,2:yes,2:yes,,0.684
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,4,43,yes,2:yes,2:yes,,0.683
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,5,43,yes,2:yes,2:yes,,0.667
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?Women," Sex, n (%)",8,6,43,yes,2:yes,2:yes,,0.685
6312,3600662,Table 1,BaselineCharacteristic,"Tumor type, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,None,None,9,0,2,no,1:no,1:no,,0.747
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,1,3,no,1:no,1:no,,0.62
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,2,3,no,1:no,1:no,,0.628
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,3,3,no,1:no,1:no,,0.628
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,4,3,no,1:no,1:no,,0.639
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,5,3,no,1:no,1:no,,0.642
6312,3600662,Table 1,BaselineCharacteristic,,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,None,None,9,6,3,no,1:no,1:no,,0.593
6312,3600662,Table 1,BaselineCharacteristic,??Ovarian carcinoma,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Ovarian carcinoma," Tumor type, n (%) ?Women",10,0,2,no,1:no,1:no,,0.707
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,1,3,no,1:no,2:yes,+,0.539
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,2,3,no,1:no,2:yes,+,0.58
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,3,3,no,1:no,2:yes,+,0.574
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,4,3,no,1:no,2:yes,+,0.567
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,5,3,no,1:no,2:yes,+,0.558
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Ovarian carcinoma," Tumor type, n (%) ?Women",10,6,3,no,1:no,2:yes,+,0.519
6312,3600662,Table 1,BaselineCharacteristic,??Lung carcinoma,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Lung carcinoma," Tumor type, n (%) ?Women",11,0,2,no,1:no,1:no,,0.714
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,1,3,no,1:no,2:yes,+,0.516
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,2,3,no,1:no,2:yes,+,0.506
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,3,3,no,1:no,2:yes,+,0.506
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,4,3,no,1:no,2:yes,+,0.526
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,5,3,no,1:no,2:yes,+,0.518
6312,3600662,Table 1,BaselineCharacteristic,x (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Lung carcinoma," Tumor type, n (%) ?Women",11,6,3,no,1:no,1:no,,0.502
6312,3600662,Table 1,BaselineCharacteristic,??Colon,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Colon," Tumor type, n (%) ?Women",12,0,2,no,1:no,1:no,,0.706
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,1,3,no,1:no,2:yes,+,0.526
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,2,3,no,1:no,2:yes,+,0.548
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,3,3,no,1:no,2:yes,+,0.542
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,4,3,no,1:no,2:yes,+,0.507
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,5,3,no,1:no,1:no,,0.504
6312,3600662,Table 1,BaselineCharacteristic,x (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Colon," Tumor type, n (%) ?Women",12,6,3,no,1:no,2:yes,+,0.508
6312,3600662,Table 1,BaselineCharacteristic,??Prostate,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Prostate," Tumor type, n (%) ?Women",13,0,2,no,1:no,1:no,,0.708
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,1,3,no,1:no,2:yes,+,0.526
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,2,3,no,1:no,2:yes,+,0.515
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,3,3,no,1:no,2:yes,+,0.543
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,4,3,no,1:no,2:yes,+,0.507
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,5,3,no,1:no,2:yes,+,0.528
6312,3600662,Table 1,BaselineCharacteristic,x (x),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Prostate," Tumor type, n (%) ?Women",13,6,3,no,1:no,2:yes,+,0.509
6312,3600662,Table 1,BaselineCharacteristic,??Othera,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Othera," Tumor type, n (%) ?Women",14,0,2,no,1:no,1:no,,0.708
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,1,3,no,1:no,2:yes,+,0.532
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,2,3,no,1:no,2:yes,+,0.522
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,3,3,no,1:no,2:yes,+,0.552
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,4,3,no,1:no,2:yes,+,0.514
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,5,3,no,1:no,2:yes,+,0.536
6312,3600662,Table 1,BaselineCharacteristic,x (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Othera," Tumor type, n (%) ?Women",14,6,3,no,1:no,2:yes,+,0.51
6312,3600662,Table 1,BaselineCharacteristic,"Tumor stage, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,None,None,15,0,24,no,1:no,1:no,,0.865
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,1,43,no,1:no,1:no,,0.653
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,2,43,no,1:no,1:no,,0.654
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,3,43,no,1:no,1:no,,0.646
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,4,43,no,1:no,1:no,,0.656
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,5,43,no,1:no,1:no,,0.665
6312,3600662,Table 1,BaselineCharacteristic,,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Tumor stage, n (%)",None,15,6,43,no,1:no,1:no,,0.709
6312,3600662,Table 1,BaselineCharacteristic,??I,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??I," Tumor stage, n (%) ?Women",16,0,2,no,1:no,1:no,,0.835
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,1,3,no,1:no,1:no,,0.603
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,2,3,no,1:no,1:no,,0.609
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,3,3,no,1:no,1:no,,0.588
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,4,3,no,1:no,1:no,,0.618
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,5,3,no,1:no,1:no,,0.607
6312,3600662,Table 1,BaselineCharacteristic,x (x),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??I," Tumor stage, n (%) ?Women",16,6,3,no,1:no,1:no,,0.644
6312,3600662,Table 1,BaselineCharacteristic,?II,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?II," Tumor stage, n (%)",17,0,2,no,1:no,1:no,,0.863
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,1,3,no,1:no,1:no,,0.66
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,2,3,no,1:no,1:no,,0.645
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,3,3,no,1:no,1:no,,0.659
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,4,3,no,1:no,1:no,,0.672
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,5,3,no,1:no,1:no,,0.677
6312,3600662,Table 1,BaselineCharacteristic,x (x),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?II," Tumor stage, n (%)",17,6,3,no,1:no,1:no,,0.685
6312,3600662,Table 1,BaselineCharacteristic,?III,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?III," Tumor stage, n (%)",18,0,2,no,1:no,1:no,,0.871
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,1,3,no,1:no,1:no,,0.649
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,2,3,no,1:no,1:no,,0.641
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,3,3,no,1:no,1:no,,0.645
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,4,3,no,1:no,1:no,,0.657
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,5,3,no,1:no,1:no,,0.66
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?III," Tumor stage, n (%)",18,6,3,no,1:no,1:no,,0.736
6312,3600662,Table 1,BaselineCharacteristic,?IV,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?IV," Tumor stage, n (%)",19,0,2,no,1:no,1:no,,0.879
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,1,3,no,1:no,1:no,,0.675
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,2,3,no,1:no,1:no,,0.677
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,3,3,no,1:no,1:no,,0.651
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,4,3,no,1:no,1:no,,0.662
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,5,3,no,1:no,1:no,,0.666
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?IV," Tumor stage, n (%)",19,6,3,no,1:no,1:no,,0.744
6312,3600662,Table 1,BaselineCharacteristic,"Prior chemotherapy, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,"Prior chemotherapy, n (%)",,20,0,2,no,1:no,1:no,,0.873
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,1,3,no,1:no,1:no,,0.654
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,2,3,no,1:no,1:no,,0.653
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,3,3,no,1:no,1:no,,0.65
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,4,3,no,1:no,1:no,,0.65
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,5,3,no,1:no,1:no,,0.65
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Prior chemotherapy, n (%)",,20,6,3,no,1:no,1:no,,0.674
6312,3600662,Table 1,BaselineCharacteristic,"Prior radiotherapy, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,"Prior radiotherapy, n (%)",,21,0,2,no,1:no,1:no,,0.867
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,1,3,no,1:no,1:no,,0.654
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,2,3,no,1:no,1:no,,0.637
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,3,3,no,1:no,1:no,,0.633
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,4,3,no,1:no,1:no,,0.633
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,5,3,no,1:no,1:no,,0.635
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Prior radiotherapy, n (%)",,21,6,3,no,1:no,1:no,,0.64
6425,493270,Table 1,BaselineCharacteristic,Characteristics*,,None,None,0,0,12,no,1:no,1:no,,0.793
6425,493270,Table 1,BaselineCharacteristic,Phase I (n = xx),,Characteristics*,None,0,1,1,no,1:no,1:no,,0.571
6425,493270,Table 1,BaselineCharacteristic,Phase II (n = xx),,Characteristics*,None,0,2,1,no,1:no,1:no,,0.551
6425,493270,Table 1,BaselineCharacteristic,Eligible,Characteristics* ; ,Eligible,,1,0,2,no,1:no,1:no,,0.813
6425,493270,Table 1,BaselineCharacteristic,xx (xxx%),Phase I (n = xx) ; ,Eligible,,1,1,3,no,1:no,2:yes,+,0.526
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,Eligible,,1,2,3,no,1:no,2:yes,+,0.582
6425,493270,Table 1,BaselineCharacteristic,Evaluable,Characteristics* ; ,Evaluable,,2,0,2,no,1:no,1:no,,0.831
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase I (n = xx) ; ,Evaluable,,2,1,3,no,1:no,2:yes,+,0.558
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,Evaluable,,2,2,3,no,1:no,2:yes,+,0.581
6425,493270,Table 1,BaselineCharacteristic,Median age (range) years,Characteristics* ; ,Median age (range) years,,3,0,2,no,1:no,1:no,,0.838
6425,493270,Table 1,BaselineCharacteristic,Sex,Characteristics* ; ,None,None,4,0,24,no,1:no,1:no,,0.586
6425,493270,Table 1,BaselineCharacteristic,Sex,Phase I (n = xx) ; ,Sex,None,4,1,43,no,1:no,2:yes,+,0.641
6425,493270,Table 1,BaselineCharacteristic,Sex,Phase II (n = xx) ; ,Sex,None,4,2,43,no,1:no,2:yes,+,0.657
6425,493270,Table 1,BaselineCharacteristic,?Male,Characteristics* ; ,?Male, Sex,5,0,2,no,1:no,2:yes,+,0.515
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Male, Sex,5,1,3,yes,2:yes,2:yes,,0.776
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Male, Sex,5,2,3,yes,2:yes,2:yes,,0.793
6425,493270,Table 1,BaselineCharacteristic,?Female,Characteristics* ; ,?Female, Sex,6,0,2,no,1:no,1:no,,0.519
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Female, Sex,6,1,3,yes,2:yes,2:yes,,0.76
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Female, Sex,6,2,3,yes,2:yes,2:yes,,0.773
6425,493270,Table 1,BaselineCharacteristic,WHO performance status,Characteristics* ; ,None,None,7,0,24,no,1:no,1:no,,0.873
6425,493270,Table 1,BaselineCharacteristic,WHO performance status,Phase I (n = xx) ; ,WHO performance status,None,7,1,43,no,1:no,1:no,,0.591
6425,493270,Table 1,BaselineCharacteristic,WHO performance status,Phase II (n = xx) ; ,WHO performance status,None,7,2,43,no,1:no,1:no,,0.576
6425,493270,Table 1,BaselineCharacteristic,?x,Characteristics* ; ,?x, WHO performance status,8,0,2,no,1:no,1:no,,0.847
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?x, WHO performance status,8,1,3,no,1:no,1:no,,0.558
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?x, WHO performance status,8,2,3,no,1:no,1:no,,0.545
6425,493270,Table 1,BaselineCharacteristic,?x,Characteristics* ; ,?x, WHO performance status,9,0,2,no,1:no,1:no,,0.858
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase I (n = xx) ; ,?x, WHO performance status,9,1,3,no,1:no,1:no,,0.571
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?x, WHO performance status,9,2,3,no,1:no,1:no,,0.558
6425,493270,Table 1,BaselineCharacteristic,?x,Characteristics* ; ,?x, WHO performance status,10,0,2,no,1:no,1:no,,0.865
6425,493270,Table 1,BaselineCharacteristic,x,Phase I (n = xx) ; ,?x, WHO performance status,10,1,3,no,1:no,1:no,,0.591
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase II (n = xx) ; ,?x, WHO performance status,10,2,3,no,1:no,1:no,,0.581
6425,493270,Table 1,BaselineCharacteristic,Primary tumour site,Characteristics* ; ,None,None,11,0,24,no,1:no,1:no,,0.894
6425,493270,Table 1,BaselineCharacteristic,Primary tumour site,Phase I (n = xx) ; ,Primary tumour site,None,11,1,43,no,1:no,1:no,,0.681
6425,493270,Table 1,BaselineCharacteristic,Primary tumour site,Phase II (n = xx) ; ,Primary tumour site,None,11,2,43,no,1:no,1:no,,0.668
6425,493270,Table 1,BaselineCharacteristic,?Colon,Characteristics* ; ,?Colon, Primary tumour site,12,0,2,no,1:no,1:no,,0.894
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Colon, Primary tumour site,12,1,3,no,1:no,1:no,,0.631
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Colon, Primary tumour site,12,2,3,no,1:no,1:no,,0.628
6425,493270,Table 1,BaselineCharacteristic,?Rectum,Characteristics* ; ,?Rectum, Primary tumour site,13,0,2,no,1:no,1:no,,0.894
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Rectum, Primary tumour site,13,1,3,no,1:no,1:no,,0.631
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Rectum, Primary tumour site,13,2,3,no,1:no,1:no,,0.633
6425,493270,Table 1,BaselineCharacteristic,?Colon rectosigmoid,Characteristics* ; ,?Colon rectosigmoid, Primary tumour site,14,0,2,no,1:no,1:no,,0.89
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase I (n = xx) ; ,?Colon rectosigmoid, Primary tumour site,14,1,3,no,1:no,1:no,,0.628
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Colon rectosigmoid, Primary tumour site,14,2,3,no,1:no,1:no,,0.631
6425,493270,Table 1,BaselineCharacteristic,Organ involved,Characteristics* ; ,None,None,15,0,24,no,1:no,1:no,,0.88
6425,493270,Table 1,BaselineCharacteristic,Organ involved,Phase I (n = xx) ; ,Organ involved,None,15,1,43,no,1:no,1:no,,0.66
6425,493270,Table 1,BaselineCharacteristic,Organ involved,Phase II (n = xx) ; ,Organ involved,None,15,2,43,no,1:no,1:no,,0.639
6425,493270,Table 1,BaselineCharacteristic,?Median number,Characteristics* ; ,?Median number, Organ involved,16,0,2,no,1:no,1:no,,0.861
6425,493270,Table 1,BaselineCharacteristic,?Liver,Characteristics* ; ,?Liver, Organ involved,17,0,2,no,1:no,1:no,,0.906
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase I (n = xx) ; ,?Liver, Organ involved,17,1,3,no,1:no,1:no,,0.678
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Liver, Organ involved,17,2,3,no,1:no,1:no,,0.652
6425,493270,Table 1,BaselineCharacteristic,?Lung,Characteristics* ; ,?Lung, Organ involved,18,0,2,no,1:no,1:no,,0.897
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Lung, Organ involved,18,1,3,no,1:no,1:no,,0.649
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Lung, Organ involved,18,2,3,no,1:no,1:no,,0.637
6425,493270,Table 1,BaselineCharacteristic,?Lymph node,Characteristics* ; ,?Lymph node, Organ involved,19,0,2,no,1:no,1:no,,0.897
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase I (n = xx) ; ,?Lymph node, Organ involved,19,1,3,no,1:no,1:no,,0.658
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Lymph node, Organ involved,19,2,3,no,1:no,1:no,,0.638
6425,493270,Table 1,BaselineCharacteristic,?Other soft tissue,Characteristics* ; ,?Other soft tissue, Organ involved,20,0,2,no,1:no,1:no,,0.901
6425,493270,Table 1,BaselineCharacteristic,x,Phase I (n = xx) ; ,?Other soft tissue, Organ involved,20,1,3,no,1:no,1:no,,0.666
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Other soft tissue, Organ involved,20,2,3,no,1:no,1:no,,0.643
6425,493270,Table 1,BaselineCharacteristic,?Abdominal cavity,Characteristics* ; ,?Abdominal cavity, Organ involved,21,0,2,no,1:no,1:no,,0.897
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Abdominal cavity, Organ involved,21,1,3,no,1:no,1:no,,0.649
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase II (n = xx) ; ,?Abdominal cavity, Organ involved,21,2,3,no,1:no,1:no,,0.643
6425,493270,Table 1,BaselineCharacteristic,?Peritoneum,Characteristics* ; ,?Peritoneum, Organ involved,22,0,2,no,1:no,1:no,,0.899
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase I (n = xx) ; ,?Peritoneum, Organ involved,22,1,3,no,1:no,1:no,,0.661
6425,493270,Table 1,BaselineCharacteristic,x,Phase II (n = xx) ; ,?Peritoneum, Organ involved,22,2,3,no,1:no,1:no,,0.645
6425,493270,Table 1,BaselineCharacteristic,?Bone,Characteristics* ; ,?Bone, Organ involved,23,0,2,no,1:no,1:no,,0.899
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase I (n = xx) ; ,?Bone, Organ involved,23,1,3,no,1:no,1:no,,0.665
6425,493270,Table 1,BaselineCharacteristic,x,Phase II (n = xx) ; ,?Bone, Organ involved,23,2,3,no,1:no,1:no,,0.65
6425,493270,Table 1,BaselineCharacteristic,?Skin,Characteristics* ; ,?Skin, Organ involved,24,0,2,no,1:no,1:no,,0.899
6425,493270,Table 1,BaselineCharacteristic,x,Phase I (n = xx) ; ,?Skin, Organ involved,24,1,3,no,1:no,1:no,,0.663
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase II (n = xx) ; ,?Skin, Organ involved,24,2,3,no,1:no,1:no,,0.65
6425,493270,Table 1,BaselineCharacteristic,?Other,Characteristics* ; ,?Other, Organ involved,25,0,2,no,1:no,1:no,,0.904
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Other, Organ involved,25,1,3,no,1:no,1:no,,0.667
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase II (n = xx) ; ,?Other, Organ involved,25,2,3,no,1:no,1:no,,0.65
6425,493270,Table 1,BaselineCharacteristic,Prior therapy,Characteristics* ; ,None,None,26,0,24,no,1:no,1:no,,0.905
6425,493270,Table 1,BaselineCharacteristic,Prior therapy,Phase I (n = xx) ; ,Prior therapy,None,26,1,43,no,1:no,1:no,,0.726
6425,493270,Table 1,BaselineCharacteristic,Prior therapy,Phase II (n = xx) ; ,Prior therapy,None,26,2,43,no,1:no,1:no,,0.713
6425,493270,Table 1,BaselineCharacteristic,?Surgery,Characteristics* ; ,?Surgery, Prior therapy,27,0,2,no,1:no,1:no,,0.908
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase I (n = xx) ; ,?Surgery, Prior therapy,27,1,3,no,1:no,1:no,,0.703
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Surgery, Prior therapy,27,2,3,no,1:no,1:no,,0.683
6425,493270,Table 1,BaselineCharacteristic,?Radiotherapy,Characteristics* ; ,?Radiotherapy, Prior therapy,28,0,2,no,1:no,1:no,,0.905
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Radiotherapy, Prior therapy,28,1,3,no,1:no,1:no,,0.684
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Radiotherapy, Prior therapy,28,2,3,no,1:no,1:no,,0.675
6425,493270,Table 1,BaselineCharacteristic,?Adjuvant chemotherapy,Characteristics* ; ,?Adjuvant chemotherapy, Prior therapy,29,0,2,no,1:no,1:no,,0.909
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Adjuvant chemotherapy, Prior therapy,29,1,3,no,1:no,1:no,,0.704
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Adjuvant chemotherapy, Prior therapy,29,2,3,no,1:no,1:no,,0.713
6425,493270,Table 1,BaselineCharacteristic,?Surgery + radiotherapy,Characteristics* ; ,?Surgery + radiotherapy, Prior therapy,30,0,2,no,1:no,1:no,,0.908
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Surgery + radiotherapy, Prior therapy,30,1,3,no,1:no,1:no,,0.708
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Surgery + radiotherapy, Prior therapy,30,2,3,no,1:no,1:no,,0.683
6425,493270,Table 1,BaselineCharacteristic,?Surgery + chemotherapy,Characteristics* ; ,?Surgery + chemotherapy, Prior therapy,31,0,2,no,1:no,1:no,,0.912
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Surgery + chemotherapy, Prior therapy,31,1,3,no,1:no,1:no,,0.727
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Surgery + chemotherapy, Prior therapy,31,2,3,no,1:no,1:no,,0.721
6425,493270,Table 1,BaselineCharacteristic,?Radiotherapy + chemotherapy,Characteristics* ; ,?Radiotherapy + chemotherapy, Prior therapy,32,0,2,no,1:no,1:no,,0.909
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Radiotherapy + chemotherapy, Prior therapy,32,1,3,no,1:no,1:no,,0.704
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase II (n = xx) ; ,?Radiotherapy + chemotherapy, Prior therapy,32,2,3,no,1:no,1:no,,0.686
6425,493270,Table 1,BaselineCharacteristic,?Surgery + radiotherapy + chemotherapy,Characteristics* ; ,?Surgery + radiotherapy + chemotherapy, Prior therapy,33,0,2,no,1:no,1:no,,0.912
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Surgery + radiotherapy + chemotherapy, Prior therapy,33,1,3,no,1:no,1:no,,0.727
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase II (n = xx) ; ,?Surgery + radiotherapy + chemotherapy, Prior therapy,33,2,3,no,1:no,1:no,,0.709
